TransporterID	Gene_name	MOA	Drug_Name	Highest_status	IC50 (microM)	Ki50 (microM)	Description	Inhibitor used drug_substrate	Cell System
DTD0008	SLCO1B1	Inhibition	Telaprevir	Approved Drug	0.0022	.	Telaprevir inhibits the activity of SLCO1B1 (IC50 = 0.0022 microM)	.	.
DTD0015	ABCC4	Inhibition	Diclofenac	Approved Drug	0.006	.	Diclofenac inhibits the transportation of Methotrexate by ABCC4 (IC50 = 0.006 microM)	Methotrexate	Human embryonic kidney 293 cells (HEK293)-MRP4
DTD0006	SLC22A2	Inhibition	Telaprevir	Approved Drug	0.0064	.	Telaprevir inhibits the activity of SLC22A2 (IC50 = 0.0064 microM)	.	.
DTD0030	SLCO1B3	Inhibition	Telaprevir	Approved Drug	0.0068	.	Telaprevir inhibits the activity of SLCO1B3 (IC50 = 0.0068 microM)	.	.
DTD0025	SLC22A8	Inhibition	Rhein	Natural Product	0.008	.	Rhubarb inhibits the transportation of Estrone sulfate by SLC22A8 in a competitive manner (IC50 = 0.008 microM)	Estrone sulfate	Human embryonic kidney 293 cells (HEK293)-OAT3
DTD0010	SLC22A1	Inhibition	Benzyl alcohol	Approved Drug	0.018	.	Benzyl alcohol inhibits the transportation of Tetraethylammonium by SLC22A1 (IC50 = 0.018 microM)	Tetraethylammonium	.
DTD0452	SLC6A2	Inhibition	alpha-Pyrrolidinopentiophenone	Approved Drug	0.02	.	alpha-Pyrrolidinopentiophenone inhibits the transportation of Norepinephrine by SLC6A2 (IC50 = 0.02 microM)	Norepinephrine	Human embryonic kidney 293 cells (HEK293)-NET
DTD0003	ABCB1	Inhibition	Valspodar	Discontinued Drug	0.0222	.	Valspodar inhibits the transportation of Digoxin by ABCB1 (IC50 = 0.0222 microM)	Digoxin	LLC-PK1 vesicles-MDR1
DTD0007	SLC47A1	Inhibition	Telaprevir	Approved Drug	0.023	.	Telaprevir inhibits the activity of SLC47A1 (IC50 = 0.023 microM)	.	.
DTD0003	ABCB1	Inhibition	Elacridar	Discontinued Drug	0.027	.	Elacridar inhibits the transportation of Colchicine by ABCB1 (IC50 = 0.027 microM)	Colchicine	Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DTD0025	SLC22A8	Inhibition	Olmesartan medoxomil	Approved Drug	0.027	.	Olmesartan medoxomil inhibits the transportation of Uric acid by SLC22A8 (IC50 = 0.027 microM)	Uric acid	Human embryonic kidney 293 cells (HEK293)-OAT3
DTD0008	SLCO1B1	Inhibition	Paclitaxel	Approved Drug	0.03	.	Paclitaxel inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (IC50 = 0.03 microM)	Estradiol-17beta-glucuronide	Chinese hamster ovary (CHO) cells-OATP1B1
DTD0452	SLC6A2	Inhibition	Methylenedioxypyrovalerone (MDPV)	Investigative Drug	0.04	.	Methylenedioxypyrovalerone (MDPV) inhibits the transportation of Norepinephrine by SLC6A2 (IC50 = 0.04 microM)	Norepinephrine	Human embryonic kidney 293 cells (HEK293)-NET
DTD0455	SLC6A3	Inhibition	alpha-Pyrrolidinopentiophenone	Approved Drug	0.04	.	alpha-Pyrrolidinopentiophenone inhibits the transportation of Serotonin by SLC6A3 (IC50 = 0.04 microM)	Serotonin	Human embryonic kidney 293 cells (HEK293)-DAT1
DTD0003	ABCB1	Inhibition	Elacridar	Discontinued Drug	0.043	.	Elacridar inhibits the transportation of Vinblastine by ABCB1 (IC50 = 0.043 microM)	Vinblastine	Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DTD0452	SLC6A2	Inhibition	Pyrovalerone	Investigative Drug	0.05	.	Pyrovalerone inhibits the transportation of Norepinephrine by SLC6A2 (IC50 = 0.05 microM)	Norepinephrine	Human embryonic kidney 293 cells (HEK293)-NET
DTD0455	SLC6A3	Inhibition	Methylenedioxypyrovalerone (MDPV)	Investigative Drug	0.05	.	Methylenedioxypyrovalerone (MDPV) inhibits the transportation of Serotonin by SLC6A3 (IC50 = 0.05 microM)	Serotonin	Human embryonic kidney 293 cells (HEK293)-DAT1
DTD0003	ABCB1	Inhibition	Elacridar	Discontinued Drug	0.055	.	Elacridar inhibits the transportation of Digoxin by ABCB1 (IC50 = 0.055 microM)	Digoxin	Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DTD0002	ABCC2	Inhibition	Indomethacin	Approved Drug	0.06	.	Indomethacin inhibits the transportation of Methotrexate by ABCC2 (IC50 = 0.06 microM)	Methotrexate	Human embryonic kidney 293 cells (HEK293)-MRP2
DTD0030	SLCO1B3	Inhibition	Cyclosporine	Approved Drug	0.06	.	Cyclosporine inhibits the transportation of Rosuvastatin by SLCO1B3 (IC50 = 0.06 microM)	Rosuvastatin	Human cervical cancer cell line (Hela)-OATP1B3
DTD0004	ABCG2	Inhibition	Coumestrol	Investigative Drug	0.063	.	Coumestrol inhibits the transportation of Methotrexate by ABCG2 (IC50 = 0.063 microM)	Methotrexate	.
DTD0452	SLC6A2	Inhibition	Amphetamine	Approved Drug	0.07	.	Amphetamine inhibits the transportation of Norepinephrine by SLC6A2 (IC50 = 0.07 microM)	Norepinephrine	Human embryonic kidney 293 cells (HEK293)-NET
DTD0031	SLCO2B1	Inhibition	Cyclosporine	Approved Drug	0.07	.	Cyclosporine inhibits the transportation of Rosuvastatin by SLCO2B1 (IC50 = 0.07 microM)	Rosuvastatin	Human embryonic kidney 293 cells (HEK293)-OATP2B1
DTD0455	SLC6A3	Inhibition	Pyrovalerone	Investigative Drug	0.07	.	Pyrovalerone inhibits the transportation of Serotonin by SLC6A3 (IC50 = 0.07 microM)	Serotonin	Human embryonic kidney 293 cells (HEK293)-DAT1
DTD0024	SLC22A6	Inhibition	Rhein	Natural Product	0.072	.	Rhubarb inhibits the transportation of P-aminohippuric acid by SLC22A6 in a competitive manner (IC50 = 0.072 microM)	P-aminohippuric acid	Chinese hamster ovary (CHO) cells-OAT1
DTD0008	SLCO1B1	Inhibition	Bromsulphthalein	Investigative Drug	0.08	.	Bromsulphthalein inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (IC50 = 0.08 microM)	Estradiol-17beta-glucuronide	Human cervical cancer cell line (Hela)-OATP1B1
DTD0025	SLC22A8	Inhibition	Pratosartan	Drug in Phase 3 Trial	0.095	.	Pratosartan inhibits the transportation of Uric acid by SLC22A8 (IC50 = 0.095 microM)	Uric acid	Human embryonic kidney 293 cells (HEK293)-OAT3
DTD0106	SLC16A2	Inhibition	Silychristin	Natural Product	0.1	.	Silychristin inhibits the transportation of Thyroid hormones by SLC16A2 (IC50 = 0.1 microM)	Thyroid hormones	Madin darby canine kidney strain cell line (MDCK)-SLC16A2
DTD0003	ABCB1	Inhibition	Valspodar	Discontinued Drug	0.11	.	Valspodar inhibits the transportation of Digoxin by ABCB1 (IC50 = 0.11 microM)	Digoxin	Human enterocyte-like 2 cell (Caco-2)-MDR1
DTD0452	SLC6A2	Inhibition	Naphyrone	Drug Withdrawn	0.11	.	Naphyrone inhibits the transportation of Norepinephrine by SLC6A2 (IC50 = 0.11 microM)	Norepinephrine	Human embryonic kidney 293 cells (HEK293)-NET
DTD0455	SLC6A3	Inhibition	3',4'-Methylenedioxy-alpha-pyrrolidinobutyrophenone (MDPBP)	Investigative Drug	0.11	.	3',4'-Methylenedioxy-alpha-pyrrolidinobutyrophenone (MDPBP) inhibits the transportation of Serotonin by SLC6A3 (IC50 = 0.11 microM)	Serotonin	Human embryonic kidney 293 cells (HEK293)-DAT1
DTD0452	SLC6A2	Inhibition	Methcathinone	Investigative Drug	0.12	.	Methcathinone inhibits the transportation of Norepinephrine by SLC6A2 (IC50 = 0.12 microM)	Norepinephrine	Human embryonic kidney 293 cells (HEK293)-NET
DTD0004	ABCG2	Inhibition	Erlotinib	Approved Drug	0.13	0.15	Erlotinib inhibits the transportation of Estrone sulfate by ABCG2 (IC50 = 0.13 microM; Ki = 0.15 microM)	Estrone sulfate	Myelogenous leukemia cell line (K562)-BCRP
DTD0027	SLC22A12	Inhibition	Benzbromarone	Approved Drug	0.13	.	Benzbromarone inhibits the transportation of Uric acid by SLC22A12 (IC50 = 0.13 microM)	Uric acid	Human embryonic kidney 293 cells (HEK293)-URAT1
DTD0452	SLC6A2	Inhibition	Methamphetamine	Approved Drug	0.14	.	Methamphetamine inhibits the transportation of Norepinephrine by SLC6A2 (IC50 = 0.14 microM)	Norepinephrine	Human embryonic kidney 293 cells (HEK293)-NET
DTD0452	SLC6A2	Inhibition	3',4'-Methylenedioxy-alpha-pyrrolidinobutyrophenone (MDPBP)	Investigative Drug	0.16	.	3',4'-Methylenedioxy-alpha-pyrrolidinobutyrophenone (MDPBP) inhibits the transportation of Norepinephrine by SLC6A2 (IC50 = 0.16 microM)	Norepinephrine	Human embryonic kidney 293 cells (HEK293)-NET
DTD0003	ABCB1	Inhibition	Dihydromyricetin	Approved Drug	0.172	.	Dihydromyricetin inhibits the transporation of adriamycin by ABCB1 through ERK/Akt signaling pathways (IC50 = 0.172 microM)	Adriamycin	Human myelogenous leukemia cell line (K562)
DTD0003	ABCB1	Inhibition	Elacridar	Discontinued Drug	0.18	.	Elacridar inhibits the transportation of Digoxin by ABCB1 (IC50 = 0.18 microM)	Digoxin	Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DTD0031	SLCO2B1	Inhibition	MK-571	Discontinued Drug	0.2	.	MK-571 inhibits the transportation of Bromsulphthalein by SLCO2B1 (IC50 = 0.2 microM)	Bromsulphthalein	Madin Darby canine kidney strain II (MDCKII) cells-OATP2B1
DTD0231	SLC26A3	Inhibition	Dimethylcoumarin DRAinh-A250	Investigative Drug	0.2	.	The dimethylcoumarin DRAinh-A250 inhibits the transportation of Chloride ion by SLC26A3 (IC50 = 0.2 microM)	Chloride ion	Fischer rat thyroid (FRT) cells
DTD0452	SLC6A2	Inhibition	4-Fluoroamphetamine	Approved Drug	0.2	.	4-Fluoroamphetamine inhibits the transportation of Norepinephrine by SLC6A2 (IC50 = 0.2 microM)	Norepinephrine	Human embryonic kidney 293 cells (HEK293)-NET
DTD0025	SLC22A8	Inhibition	Valsartan	Approved Drug	0.2	.	Valsartan inhibits the transportation of Uric acid by SLC22A8 (IC50 = 0.2 microM)	Uric acid	Human embryonic kidney 293 cells (HEK293)-OAT3
DTD0003	ABCB1	Inhibition	Verapamil	Approved Drug	0.2	.	Verapamil inhibits the transportation of Vincristine by ABCB1 (IC50 = 0.2 microM)	Vincristine	Myelogenous leukemia cell line (K562)-MDR1
DTD0452	SLC6A2	Inhibition	4-Fluoromethamphetamine	Approved Drug	0.22	.	4-Fluoromethamphetamine inhibits the transportation of Norepinephrine by SLC6A2 (IC50 = 0.22 microM)	Norepinephrine	Human embryonic kidney 293 cells (HEK293)-NET
DTD0455	SLC6A3	Inhibition	Naphyrone	Drug Withdrawn	0.22	.	Naphyrone inhibits the transportation of Serotonin by SLC6A3 (IC50 = 0.22 microM)	Serotonin	Human embryonic kidney 293 cells (HEK293)-DAT1
DTD0004	ABCG2	Inhibition	Atovaquone	Approved Drug	0.23	.	Atovaquone inhibits the transportation of Estrone sulphate by ABCG2 (IC50 = 0.23 microM)	Estrone sulphate	Human embryonic kidney 293 cells (HEK293)-BCRP
DTD0024	SLC22A6	Inhibition	Olmesartan medoxomil	Approved Drug	0.28	.	Olmesartan medoxomil inhibits the transportation of Uric acid by SLC22A6 (IC50 = 0.28 microM)	Uric acid	Human embryonic kidney 293 cells (HEK293)-OAT1
DTD0003	ABCB1	Inhibition	Valspodar	Discontinued Drug	0.291	.	Valspodar inhibits the transportation of Doxorubicin by ABCB1 (IC50 = 0.291 microM)	Doxorubicin	LLC-PK1 vesicles-MDR1
DTD0030	SLCO1B3	Inhibition	Cyclosporine	Approved Drug	0.3	.	Cyclosporine inhibits the transportation of Amantinin by SLCO1B3 (IC50 = 0.3 microM)	Amantinin	Madin Darby canine kidney strain II (MDCKII) cells-OATP1B3
DTD0008	SLCO1B1	Inhibition	Cyclosporine	Approved Drug	0.3	.	Cyclosporine inhibits the transportation of Bosentan by SLCO1B1 (IC50 = 0.3 microM)	Bosentan	Chinese hamster ovary (CHO) cells-OATP1B1
DTD0030	SLCO1B3	Inhibition	Cyclosporine	Approved Drug	0.3	.	Cyclosporine inhibits the transportation of Bromsulphthalein by SLCO1B3 (IC50 = 0.3 microM)	Bromsulphthalein	Madin Darby canine kidney strain II (MDCKII) cells-OATP1B3
DTD0030	SLCO1B3	Inhibition	MK-571	Discontinued Drug	0.3	.	MK-571 inhibits the transportation of Bromsulphthalein by SLCO1B3 (IC50 = 0.3 microM)	Bromsulphthalein	Madin Darby canine kidney strain II (MDCKII) cells-OATP1B3
DTD0008	SLCO1B1	Inhibition	MK-571	Discontinued Drug	0.3	.	MK-571 inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (IC50 = 0.3 microM)	Estradiol-17beta-glucuronide	Human embryonic kidney 293 cells (HEK293)-OATP1B1
DTD0024	SLC22A6	Inhibition	Morin	Investigative Drug	0.3	.	Morin inhibits the transportation of Para-aminohippuric acid by SLC22A6 (IC50 = 0.3 microM)	Para-aminohippuric acid	.
DTD0025	SLC22A8	Inhibition	Candesartan	Approved Drug	0.3	.	Candesartan inhibits the transportation of Uric acid by SLC22A8 (IC50 = 0.3 microM)	Uric acid	Human embryonic kidney 293 cells (HEK293)-OAT3
DTD0004	ABCG2	Inhibition	Elacridar	Discontinued Drug	0.31	.	Elacridar inhibits the transportation of Mitoxantrone by ABCG2 (IC50 = 0.31 microM)	Mitoxantrone	Human embryonic kidney 293 cells (HEK293)-BCRP
DTD0008	SLCO1B1	Inhibition	Cyclosporine	Approved Drug	0.31	.	Cyclosporine inhibits the transportation of Rosuvastatin by SLCO1B1 (IC50 = 0.31 microM)	Rosuvastatin	Human cervical cancer cell line (Hela)-OATP1B1
DTD0452	SLC6A2	Inhibition	Ephedrine	Approved Drug	0.32	.	Ephedrine inhibits the transportation of Norepinephrine by SLC6A2 (IC50 = 0.32 microM)	Norepinephrine	Human embryonic kidney 293 cells (HEK293)-NET
DTD0008	SLCO1B1	Inhibition	Cyclosporine	Approved Drug	0.37	.	Cyclosporine inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (IC50 = 0.37 microM)	Estradiol-17beta-glucuronide	Human cervical cancer cell line (Hela)-OATP1B1
DTD0019	SLC10A1	Inhibition	Cyclosporine	Approved Drug	0.37	.	Cyclosporine inhibits the transportation of Rosuvastatin by SLC10A1 (IC50 = 0.37 microM)	Rosuvastatin	Human cervical cancer cell line (Hela)-NTCP
DTD0031	SLCO2B1	Inhibition	Atorvastatin	Approved Drug	0.4	.	Atorvastatin inhibits the transportation of Estrone sulfate by SLCO2B1 (IC50 = 0.4 microM)	Estrone sulfate	Madin Darby canine kidney strain II (MDCKII) cells-OATP2B1
DTD0004	ABCG2	Inhibition	Gefitinib	Approved Drug	0.4	.	Gefitinib inhibits the transportation of Hoechst 33342 by ABCG2 (IC50 = 0.4 microM)	Hoechst 33342	Spodoptera frugiperda (Sf9) cells-BCRP
DTD0025	SLC22A8	Inhibition	Quercetin-3-O-glucuronide	Natural Product	0.43	.	Quercetin-3-O-glucuronide inhibits the transportation of 5-carboxyfluorescein by SLC22A8 (IC50 = 0.43 microM)	5-carboxyfluorescein	Human embryonic kidney 293 cells (HEK293)-OAT3
DTD0024	SLC22A6	Inhibition	Telmisartan	Approved Drug	0.46	.	Telmisartan inhibits the transportation of Uric acid by SLC22A6 (IC50 = 0.46 microM)	Uric acid	Human embryonic kidney 293 cells (HEK293)-OAT1
DTD0024	SLC22A6	Inhibition	Luteolin	Natural Product	0.47	.	Luteolin inhibits the transportation of Para-aminohippuric acid by SLC22A6 (IC50 = 0.47 microM)	Para-aminohippuric acid	.
DTD0030	SLCO1B3	Inhibition	MK-571	Discontinued Drug	0.5	0.2	MK-571 inhibits the transportation of Amantinin by SLCO1B3 (IC50 = 0.5 microM; Ki = 0.2 microM)	Amantinin	Madin Darby canine kidney strain II (MDCKII) cells-OATP1B3
DTD0030	SLCO1B3	Inhibition	Montelukast	Approved Drug	0.5	.	Montelukast inhibits the transportation of Bromsulphthalein by SLCO1B3 (IC50 = 0.5 microM)	Bromsulphthalein	Madin Darby canine kidney strain II (MDCKII) cells-OATP1B3
DTD0008	SLCO1B1	Inhibition	Lopinavir	Approved Drug	0.5	0.5	Lopinavir inhibits the transportation of Cholyl-glycylamido-fluorescein by SLCO1B1 (IC50 = 0.5 microM; Ki = 0.5 microM)	Cholyl-glycylamido-fluorescein	Chinese hamster ovary (CHO) cells-OATP1B1
DTD0030	SLCO1B3	Inhibition	Paclitaxel	Approved Drug	0.5	.	Paclitaxel inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B3 (IC50 = 0.5 microM)	Estradiol-17beta-glucuronide	Chinese hamster ovary (CHO) cells-OATP1B3
DTD0455	SLC6A3	Inhibition	3',4'-Methylenedioxy-alpha-pyrrolidinopropiophenone (MDPPP)	Investigative Drug	0.53	.	3',4'-Methylenedioxy-alpha-pyrrolidinopropiophenone (MDPPP) inhibits the transportation of Serotonin by SLC6A3 (IC50 = 0.53 microM)	Serotonin	Human embryonic kidney 293 cells (HEK293)-DAT1
DTD0025	SLC22A8	Inhibition	Ethacrynic Acid	Approved Drug	0.58	.	Ethacrynic acid inhibits the transportation of Estrone sulfate by SLC22A8 (IC50 = 0.58 microM)	Estrone sulfate	The Proximal Tubule (S2) Cells-OAT3
DTD0001	ABCC1	Inhibition	MK-571	Discontinued Drug	0.6	.	MK-571 inhibits the transportation of Leukotriene C4 by ABCC1 (IC50 = 0.6 microM)	Leukotriene C4	Human cervical cancer cell line (Hela)-MRP1
DTD0025	SLC22A8	Inhibition	Indomethacin	Approved Drug	0.61	.	Indomethacin inhibits the transportation of Estrone sulfate by SLC22A8 (IC50 = 0.61 microM)	Estrone sulfate	The Proximal Tubule (S2) Cells-OAT3
DTD0010	SLC22A1	Inhibition	Verapamil	Approved Drug	0.62	.	Verapamil inhibits the transportation of Metformin by SLC22A1 (IC50 = 0.62 microM)	Metformin	Human embryonic kidney 293 cells (HEK293)-OCT1
DTD0010	SLC22A1	Inhibition	Zearalenone	Mycotoxins	0.62	.	Zearalenone inhibits the transportation of Organic cation by SLC22A1 (IC50 = 0.62 microM)	Organic cation	The Proximal Tubule (S2) Cells-OCT1
DTD0008	SLCO1B1	Inhibition	Bromsulphthalein	Investigative Drug	0.7	0.6	Bromsulphthalein inhibits the transportation of Cholyl-glycylamido-fluorescein by SLCO1B1 (IC50 = 0.7 microM; Ki = 0.6 microM)	Cholyl-glycylamido-fluorescein	Chinese hamster ovary (CHO) cells-OATP1B1
DTD0008	SLCO1B1	Inhibition	Lithocholic Acid	Investigative Drug	0.7	.	Lithocholate inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (IC50 = 0.7 microM)	Estradiol-17beta-glucuronide	Chinese hamster ovary (CHO) cells-OATP1B1
DTD0014	ABCB11	Inhibition	Valinomycin	Investigative Drug	0.7	.	Valinomycin inhibits the transportation of Sodium taurocholate by ABCB11 (IC50 = 0.7 microM)	Sodium taurocholate	Spodoptera frugiperda (Sf9) cells-BSEP
DTD0003	ABCB1	Inhibition	6,7-epoxybergamottin	Natural Product	0.7	.	6,7-epoxybergamottin inhibits the transportation of Talinolol by ABCB1 (IC50 = 0.7 microM)	Talinolol	Human enterocyte-like 2 cell (Caco-2)-MDR1
DTD0008	SLCO1B1	Inhibition	Ritonavir	Approved Drug	0.71	.	Ritonavir inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (IC50 = 0.71 microM)	Estradiol-17beta-glucuronide	Human cervical cancer cell line (Hela)-OATP1B1
DTD0004	ABCG2	Inhibition	Sulfasalazine	Approved Drug	0.73	.	Sulfasalazine inhibits the transportation of Estrone sulfate by ABCG2 (IC50 = 0.73 microM)	Estrone sulfate	Oocytes-BCRP
DTD0025	SLC22A8	Inhibition	Quercetin-3-O-sulfate	Natural Product	0.75	.	Quercetin-3-O-sulfate inhibits the transportation of 5-carboxyfluorescein by SLC22A8 (IC50 = 0.75 microM)	5-carboxyfluorescein	Human embryonic kidney 293 cells (HEK293)-OAT3
DTD0025	SLC22A8	Inhibition	Bumetanide	Approved Drug	0.75	.	Bumetanide inhibits the transportation of Estrone sulfate by SLC22A8 (IC50 = 0.75 microM)	Estrone sulfate	The Proximal Tubule (S2) Cells-OAT3
DTD0025	SLC22A8	Inhibition	Mefenamic Acid	Approved Drug	0.78	.	Mefenamic acid inhibits the transportation of Estrone sulfate by SLC22A8 (IC50 = 0.78 microM)	Estrone sulfate	The Proximal Tubule (S2) Cells-OAT3
DTD0008	SLCO1B1	Inhibition	Estrone sulfate	Investigative Drug	0.79	.	Estrone sulfate inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (IC50 = 0.79 microM)	Estradiol-17beta-glucuronide	Human embryonic kidney 293 cells (HEK293)-OATP1B1
DTD0030	SLCO1B3	Inhibition	Rifampicin	Approved Drug	0.8	.	Rifampicin inhibits the transportation of Amantinin by SLCO1B3 (IC50 = 0.8 microM)	Amantinin	Madin Darby canine kidney strain II (MDCKII) cells-OATP1B3
DTD0030	SLCO1B3	Inhibition	Cyclosporine	Approved Drug	0.8	.	Cyclosporine inhibits the transportation of Bosentan by SLCO1B3 (IC50 = 0.8 microM)	Bosentan	Chinese hamster ovary (CHO) cells-OATP1B1
DTD0003	ABCB1	Inhibition	Cyclosporine	Approved Drug	0.8	.	Cyclosporine inhibits the transportation of Calcein AM by ABCB1 (IC50 = 0.8 microM)	Calcein AM	LLC-PK1 vesicles-MDR1
DTD0456	SLC6A4	Inhibition	Naphyrone	Drug Withdrawn	0.8	.	Naphyrone inhibits the transportation of Dopamine by SLC6A4 (IC50 = 0.8 microM)	Dopamine	Human embryonic kidney 293 cells (HEK293)-SERT
DTD0031	SLCO2B1	Inhibition	Silybin B	Natural Product	0.8	.	Silybin B inhibits the transportation of Estrone sulfate by SLCO2B1 (IC50 = 0.8 microM)	Estrone sulfate	Human embryonic kidney 293 cells (HEK293)-OATP2B1
DTD0008	SLCO1B1	Inhibition	Hyperforin	Investigative Drug	0.82	.	Hyperforin inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (IC50 = 0.82 microM)	Estradiol-17beta-glucuronide	Human cervical cancer cell line (Hela)-OATP1B1
DTD0024	SLC22A6	Inhibition	Mefenamic Acid	Approved Drug	0.83	.	Mefenamic acid inhibits the transportation of Aminohippuric acid by SLC22A6 (IC50 = 0.83 microM)	Aminohippuric acid	The Proximal Tubule (S2) Cells-OAT1
DTD0024	SLC22A6	Inhibition	Diflunisal	Approved Drug	0.85	.	Diflunisal inhibits the transportation of Adefovir by SLC22A6 (IC50 = 0.85 microM)	Adefovir	Chinese hamster ovary (CHO) cells-OAT1
DTD0024	SLC22A6	Inhibition	Adefovir	Approved Drug	0.9	.	Adefovir inhibits the transportation of Ketoprofen by SLC22A6 (IC50 = 0.9 microM)	Ketoprofen	Chinese hamster ovary (CHO) cells-OAT1
DTD0010	SLC22A1	Inhibition	Dieldrin	Natural Product	0.9	.	Dieldrin inhibits the transportation of Tetraethylammonium by SLC22A1 (IC50 = 0.9 microM)	Tetraethylammonium	Human hepatoma HepaRG cells-OCT1
DTD0008	SLCO1B1	Inhibition	Nelfinavir	Approved Drug	0.93	.	Nelfinavir inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (IC50 = 0.93 microM)	Estradiol-17beta-glucuronide	Human cervical cancer cell line (Hela)-OATP1B1
DTD0014	ABCB11	Inhibition	Cyclosporine	Approved Drug	0.93	.	Cyclosporine inhibits the transportation of Glycocholate by ABCB11 (IC50 = 0.93 microM)	Glycocholate	Spodoptera frugiperda (Sf9) cells-BSEP
DTD0008	SLCO1B1	Inhibition	Rifampicin	Approved Drug	0.94	.	Rifampicin inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (IC50 = 0.94 microM)	Estradiol-17beta-glucuronide	Human cervical cancer cell line (Hela)-OATP1B1
DTD0014	ABCB11	Inhibition	Cyclosporine	Approved Drug	0.94	.	Cyclosporine inhibits the transportation of Taurochenodeoxycholate by ABCB11 (IC50 = 0.94 microM)	Taurochenodeoxycholate	Spodoptera frugiperda (Sf9) cells-BSEP
DTD0003	ABCB1	Inhibition	Itraconazole	Approved Drug	0.95	.	Itraconazole inhibits the transportation of Digoxin by ABCB1 (IC50 = 0.95 microM)	Digoxin	Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DTD0452	SLC6A2	Inhibition	3',4'-Methylenedioxy-alpha-pyrrolidinopropiophenone (MDPPP)	Investigative Drug	0.97	.	3',4'-Methylenedioxy-alpha-pyrrolidinopropiophenone (MDPPP) inhibits the transportation of Norepinephrine by SLC6A2 (IC50 = 0.97 microM)	Norepinephrine	Human embryonic kidney 293 cells (HEK293)-NET
DTD0031	SLCO2B1	Inhibition	Silibinin dihemisuccinate	Natural Product	1	.	Silibinin dihemisuccinate inhibits the transportation of Bromosulfophthalein by SLCO2B1 (IC50 = 1 microM)	Bromosulfophthalein	Madin darby canine kidney strain II cell line (MDCKII)-OATP2B1
DTD0031	SLCO2B1	Inhibition	Montelukast	Approved Drug	1	.	Montelukast inhibits the transportation of Bromsulphthalein by SLCO2B1 (IC50 = 1 microM)	Bromsulphthalein	Madin Darby canine kidney strain II (MDCKII) cells-OATP2B1
DTD0030	SLCO1B3	Inhibition	Digoxin	Approved Drug	1	0.7	Digoxin inhibits the transportation of Cholyl-glycylamido-fluorescein by SLCO1B3 (IC50 = 1 microM; Ki = 0.7 microM)	Cholyl-glycylamido-fluorescein	Chinese hamster ovary (CHO) cells-OATP1B3
DTD0030	SLCO1B3	Inhibition	Silibinin dihemisuccinate	Natural Product	1	2.1	Silibinin dihemisuccinate inhibits the transportation of H-amanitin by SLCO1B3 (IC50 = 1 microM; Ki = 2.1 microM)	H-amanitin	Madin darby canine kidney strain II cell line (MDCKII)-OATP1B3
DTD0111	SLC16A7	Inhibition	AR-C155858	Investigative Drug	1	.	AR-C155858 inhibits the transportation of Ketone bodies and L-lactate by SLC16A7 (IC50 = 1 microM)	Ketone bodies and L-lactate	Breast cancer cell lines-MCT2
DTD0019	SLC10A1	Inhibition	Cyclosporine	Approved Drug	1	.	Cyclosporine inhibits the transportation of Sodium taurocholate by SLC10A1 (IC50 = 1 microM)	Sodium taurocholate	Human cervical cancer cell line (Hela)-NTCP
DTD0003	ABCB1	Inhibition	Valspodar	Discontinued Drug	1.06	.	Valspodar inhibits the transportation of Vinblastine by ABCB1 (IC50 = 1.06 microM)	Vinblastine	LLC-PK1 vesicles-MDR1
DTD0455	SLC6A3	Inhibition	Methamphetamine	Approved Drug	1.1	.	Methamphetamine inhibits the transportation of Serotonin by SLC6A3 (IC50 = 1.1 microM)	Serotonin	Human embryonic kidney 293 cells (HEK293)-DAT1
DTD0008	SLCO1B1	Inhibition	Troglitazone	Approved Drug	1.2	.	Troglitazone inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (IC50 = 1.2 microM)	Estradiol-17beta-glucuronide	Chinese hamster ovary (CHO) cells-OATP1B1
DTD0010	SLC22A1	Inhibition	Atropine	Approved Drug	1.2	.	Atropine inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 1.2 microM)	N-methylpyridinium	Human embryonic kidney 293 cells (HEK293)-OCT1
DTD0024	SLC22A6	Inhibition	Gallic Acid	Natural Product	1.2	.	Gallic acid inhibits the transportation of P-aminohippuric acid by SLC22A6 (IC50 = 1.2 microM)	P-aminohippuric acid	Chinese hamster ovary (CHO) cells-OAT1
DTD0026	SLC22A11	Inhibition	Telmisartan	Approved Drug	1.2	.	Telmisartan inhibits the transportation of Uric acid by SLC22A11 (IC50 = 1.2 microM)	Uric acid	Human embryonic kidney 293 cells (HEK293)-OAT4
DTD0024	SLC22A6	Inhibition	Quercetin-3-O-sulfate	Natural Product	1.22	.	Quercetin-3-O-sulfate inhibits the transportation of Para-aminohippuric acid by SLC22A6 (IC50 = 1.22 microM)	Para-aminohippuric acid	.
DTD0008	SLCO1B1	Inhibition	Saquinavir	Approved Drug	1.23	.	Saquinavir inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (IC50 = 1.23 microM)	Estradiol-17beta-glucuronide	Human cervical cancer cell line (Hela)-OATP1B1
DTD0010	SLC22A1	Inhibition	Verapamil	Approved Drug	1.23	.	Verapamil inhibits the transportation of YM155 by SLC22A1 (IC50 = 1.23 microM)	YM155	Human embryonic kidney 293 cells (HEK293)-OCT1
DTD0024	SLC22A6	Inhibition	Ketoprofen	Approved Drug	1.3	.	Ketoprofen inhibits the transportation of Adefovir by SLC22A6 (IC50 = 1.3 microM)	Adefovir	Chinese hamster ovary (CHO) cells-OAT1
DTD0030	SLCO1B3	Inhibition	Rifampicin	Approved Drug	1.3	0.9	Rifampicin inhibits the transportation of Cholyl-glycylamido-fluorescein by SLCO1B3 (IC50 = 1.3 microM; Ki = 0.9 microM)	Cholyl-glycylamido-fluorescein	Chinese hamster ovary (CHO) cells-OATP1B3
DTD0003	ABCB1	Inhibition	Cyclosporine	Approved Drug	1.3	.	Cyclosporine inhibits the transportation of Digoxin by ABCB1 (IC50 = 1.3 microM)	Digoxin	Human enterocyte-like 2 cell (Caco-2)-MDR1
DTD0455	SLC6A3	Inhibition	Amphetamine	Approved Drug	1.3	.	Amphetamine inhibits the transportation of Serotonin by SLC6A3 (IC50 = 1.3 microM)	Serotonin	Human embryonic kidney 293 cells (HEK293)-DAT1
DTD0025	SLC22A8	Inhibition	Quercetin-3-O-glucuronide	Natural Product	1.31	.	Quercetin-3-O-glucuronide inhibits the transportation of 5-carboxyfluorescein by SLC22A8 (IC50 = 1.31 microM)	5-carboxyfluorescein	Human embryonic kidney 293 cells (HEK293)-OAT3
DTD0031	SLCO2B1	Inhibition	Phloretin	Investigative Drug	1.31	.	Phloretin inhibits the transportation of Estrone sulfate by SLCO2B1 (IC50 = 1.31 microM)	Estrone sulfate	Xenopus laevis oocytes-OATP2B1
DTD0003	ABCB1	Inhibition	Ketoconazole	Approved Drug	1.34	.	Ketoconazole inhibits the transportation of Digoxin by ABCB1 (IC50 = 1.34 microM)	Digoxin	Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DTD0003	ABCB1	Inhibition	Cyclosporine	Approved Drug	1.36	.	Cyclosporine inhibits the transportation of Colchicine by ABCB1 (IC50 = 1.36 microM)	Colchicine	Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DTD0193	SLC25A31	Inhibition	2,2'-Methanediylbis (4-nitrophenol)	Investigative Drug	1.4	.	2,2'-Methanediylbis(4-nitrophenol) inhibits the activity of SLC25A31 (IC50 = 1.4 microM)	.	Meiotic germ cells
DTD0024	SLC22A6	Inhibition	Ketoprofen	Approved Drug	1.4	.	Ketoprofen inhibits the transportation of 6-Carboxyfluorescein by SLC22A6 (IC50 = 1.4 microM)	6-Carboxyfluorescein	Chinese hamster ovary (CHO) cells-OAT1
DTD0030	SLCO1B3	Inhibition	Bromsulphthalein	Investigative Drug	1.4	1	Bromsulphthalein inhibits the transportation of Cholyl-glycylamido-fluorescein by SLCO1B3 (IC50 = 1.4 microM; Ki = 1 microM)	Cholyl-glycylamido-fluorescein	Chinese hamster ovary (CHO) cells-OATP1B3
DTD0003	ABCB1	Inhibition	Cyclosporine	Approved Drug	1.4	.	Cyclosporine inhibits the transportation of Daunorubicin by ABCB1 (IC50 = 1.4 microM)	Daunorubicin	NIH-3T3-G185-MDR1
DTD0002	ABCC2	Inhibition	Ketoprofen	Approved Drug	1.4	.	Ketoprofen inhibits the transportation of Methotrexate by ABCC2 (IC50 = 1.4 microM)	Methotrexate	Human embryonic kidney 293 cells (HEK293)-MRP2
DTD0003	ABCB1	Inhibition	Cyclosporine	Approved Drug	1.4	.	Cyclosporine inhibits the transportation of Rhodamine 123 by ABCB1 (IC50 = 1.4 microM)	Rhodamine 123	NIH-3T3-G185-MDR1
DTD0024	SLC22A6	Inhibition	Flurbiprofen	Approved Drug	1.5	.	Flurbiprofen inhibits the transportation of Adefovir by SLC22A6 (IC50 = 1.5 microM)	Adefovir	Chinese hamster ovary (CHO) cells-OAT1
DTD0008	SLCO1B1	Inhibition	Sildenafil	Approved Drug	1.5	.	Sildenafil inhibits the transportation of Bosentan by SLCO1B1 (IC50 = 1.5 microM)	Bosentan	Chinese hamster ovary (CHO) cells-OATP1B1
DTD0030	SLCO1B3	Inhibition	Rifampicin	Approved Drug	1.5	.	Rifampicin inhibits the transportation of Bromsulphthalein by SLCO1B3 (IC50 = 1.5 microM)	Bromsulphthalein	Madin Darby canine kidney strain II (MDCKII) cells-OATP1B3
DTD0008	SLCO1B1	Inhibition	Rifampicin	Approved Drug	1.5	.	Rifampicin inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (IC50 = 1.5 microM)	Estradiol-17beta-glucuronide	Chinese hamster ovary (CHO) cells-OATP1B1
DTD0024	SLC22A6	Inhibition	Adefovir	Approved Drug	1.5	.	Adefovir inhibits the transportation of Ibuprofen by SLC22A6 (IC50 = 1.5 microM)	Ibuprofen	Chinese hamster ovary (CHO) cells-OAT1
DTD0024	SLC22A6	Inhibition	Pratosartan	Drug in Phase 3 Trial	1.5	.	Pratosartan inhibits the transportation of Uric acid by SLC22A6 (IC50 = 1.5 microM)	Uric acid	Human embryonic kidney 293 cells (HEK293)-OAT1
DTD0015	ABCC4	Inhibition	Losartan	Approved Drug	1.5	.	Losartan inhibits the transportation of Uric acid by ABCC4 (IC50 = 1.5 microM)	Uric acid	Spodoptera frugiperda (Sf9) cells-MRP4
DTD0003	ABCB1	Inhibition	Endosulfan	Natural Product	1.5	.	Endosulfan inhibits the transportation of Verapamil by ABCB1 (IC50 = 1.5 microM)	Verapamil	NIH 3T3 cells-MDR1
DTD0003	ABCB1	Inhibition	Phosalone	Natural Product	1.5	.	Phosalone inhibits the transportation of Verapamil by ABCB1 (IC50 = 1.5 microM)	Verapamil	NIH 3T3 cells-MDR1
DTD0003	ABCB1	Inhibition	Propiconazole	Natural Product	1.5	.	Propiconazole inhibits the transportation of Verapamil by ABCB1 (IC50 = 1.5 microM)	Verapamil	NIH 3T3 cells-MDR1
DTD0010	SLC22A1	Inhibition	Lindane	Approved Drug	1.52	.	Lindane inhibits the transportation of Tetraethylammonium by SLC22A1 (IC50 = 1.52 microM)	Tetraethylammonium	Human hepatoma HepaRG cells-OCT1
DTD0010	SLC22A1	Inhibition	Prazosin	Approved Drug	1.56	.	Prazosin inhibits the transportation of YM155 by SLC22A1 (IC50 = 1.56 microM)	YM155	Human embryonic kidney 293 cells (HEK293)-OCT1
DTD0030	SLCO1B3	Inhibition	Rifampicin	Approved Drug	1.6	.	Rifampicin inhibits the transportation of Bosentan by SLCO1B3 (IC50 = 1.6 microM)	Bosentan	Chinese hamster ovary (CHO) cells-OATP1B1
DTD0008	SLCO1B1	Inhibition	Ritonavir	Approved Drug	1.6	1.4	Ritonavir inhibits the transportation of Cholyl-glycylamido-fluorescein by SLCO1B1 (IC50 = 1.6 microM; Ki = 1.4 microM)	Cholyl-glycylamido-fluorescein	Chinese hamster ovary (CHO) cells-OATP1B1
DTD0003	ABCB1	Inhibition	Cyclosporine	Approved Drug	1.6	.	Cyclosporine inhibits the transportation of Digoxin by ABCB1 (IC50 = 1.6 microM)	Digoxin	Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DTD0004	ABCG2	Inhibition	SN-38	Drug in Phase 2 Trial	1.6	.	SN-38 inhibits the transportation of Estrone sulfate by ABCG2 (IC50 = 1.6 microM)	Estrone sulfate	Mouse lymphoma (P388) cells-BCRP
DTD0010	SLC22A1	Inhibition	Repaglinide	Approved Drug	1.6	.	Repaglinide inhibits the transportation of Metformin by SLC22A1 (IC50 = 1.6 microM)	Metformin	Madin Darby canine kidney strain II (MDCKII) cells-OCT1
DTD0025	SLC22A8	Inhibition	Losartan	Approved Drug	1.6	.	Losartan inhibits the transportation of Uric acid by SLC22A8 (IC50 = 1.6 microM)	Uric acid	Human embryonic kidney 293 cells (HEK293)-OAT3
DTD0025	SLC22A8	Inhibition	Telmisartan	Approved Drug	1.6	.	Telmisartan inhibits the transportation of Uric acid by SLC22A8 (IC50 = 1.6 microM)	Uric acid	Human embryonic kidney 293 cells (HEK293)-OAT3
DTD0003	ABCB1	Inhibition	Cyclosporine	Approved Drug	1.7	.	Cyclosporine inhibits the transportation of Calcein AM by ABCB1 (IC50 = 1.7 microM)	Calcein AM	NIH-3T3-G185-MDR1
DTD0008	SLCO1B1	Inhibition	Atazanavir	Approved Drug	1.7	1.5	Atazanavir inhibits the transportation of Cholyl-glycylamido-fluorescein by SLCO1B1 (IC50 = 1.7 microM; Ki = 1.5 microM)	Cholyl-glycylamido-fluorescein	Chinese hamster ovary (CHO) cells-OATP1B1
DTD0008	SLCO1B1	Inhibition	Bromsulphthalein	Investigative Drug	1.7	.	Bromsulphthalein inhibits the transportation of Estrone sulfate by SLCO1B1 (IC50 = 1.7 microM)	Estrone sulfate	Monkey kidney tissue Fibroblast-like cell lines (COS1)-OATP2B1
DTD0031	SLCO2B1	Inhibition	Bromsulphthalein	Investigative Drug	1.7	.	Bromsulphthalein inhibits the transportation of Estrone sulfate by SLCO2B1 (IC50 = 1.7 microM)	Estrone sulfate	Monkey kidney tissue Fibroblast-like cell lines (COS1)-OATP2B1
DTD0010	SLC22A1	Inhibition	Alpha-zearalenol	Mycotoxins	1.7	.	Alpha-zearalenol inhibits the transportation of Organic cation by SLC22A1 (IC50 = 1.7 microM)	Organic cation	The Proximal Tubule (S2) Cells-OCT1
DTD0003	ABCB1	Inhibition	Cyclosporine	Approved Drug	1.7	.	Cyclosporine inhibits the transportation of Rhodamine 123 by ABCB1 (IC50 = 1.7 microM)	Rhodamine 123	NIH-3T3-G185-MDR1
DTD0025	SLC22A8	Inhibition	Furosemide	Approved Drug	1.7	.	Furosemide inhibits the transportation of Sitagliptin by SLC22A8 (IC50 = 1.7 microM)	Sitagliptin	Chinese hamster ovary (CHO) cells-OAT3
DTD0008	SLCO1B1	Inhibition	Rifampicin	Approved Drug	1.8	1.6	Rifampicin inhibits the transportation of Cholyl-glycylamido-fluorescein by SLCO1B1 (IC50 = 1.8 microM; Ki = 1.6 microM)	Cholyl-glycylamido-fluorescein	Chinese hamster ovary (CHO) cells-OATP1B1
DTD0003	ABCB1	Inhibition	Telithromycin	Approved Drug	1.8	.	Telithromycin inhibits the transportation of Digoxin by ABCB1 (IC50 = 1.8 microM)	Digoxin	Human enterocyte-like 2 cell (Caco-2)-MDR1
DTD0003	ABCB1	Inhibition	Cyclosporine	Approved Drug	1.8	.	Cyclosporine inhibits the transportation of LDS-751 by ABCB1 (IC50 = 1.8 microM)	LDS-751	NIH-3T3-G185-MDR1
DTD0024	SLC22A6	Inhibition	Adefovir	Approved Drug	1.8	.	Adefovir inhibits the transportation of Naproxen by SLC22A6 (IC50 = 1.8 microM)	Naproxen	Chinese hamster ovary (CHO) cells-OAT1
DTD0010	SLC22A1	Inhibition	Repaglinide	Approved Drug	1.8	.	Repaglinide inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 1.8 microM)	N-methylpyridinium	Madin Darby canine kidney strain II (MDCKII) cells-OCT1
DTD0007	SLC47A1	Inhibition	Quinine	Approved Drug	1.9	.	Quinine inhibits the transportation of 1-methyl-4-phenylpyridinium by SLC47A1 (IC50 = 1.9 microM)	1-methyl-4-phenylpyridinium	Chinese hamster ovary (CHO) cells-MATE1
DTD0025	SLC22A8	Inhibition	Cyclopiazonic acid	Natural Product	1.9	.	Cyclopiazonic acid inhibits the transportation of Organic anion by SLC22A8 (IC50 = 1.9 microM)	Organic anion	The Proximal Tubule (S2) Cells-OAT3
DTD0025	SLC22A8	Inhibition	Cyclopiazonic acid	Mycotoxins	1.9	.	Cyclopiazonic acid inhibits the transportation of Organic anion by SLC22A8 (IC50 = 1.9 microM)	Organic anion	The Proximal Tubule (S2) Cells-OAT3
DTD0031	SLCO2B1	Inhibition	Hesperetin	Approved Drug	1.92	.	Hesperetin inhibits the transportation of Estrone sulfate by SLCO2B1 (IC50 = 1.92 microM)	Estrone sulfate	Xenopus laevis oocytes-OATP2B1
DTD0015	ABCC4	Inhibition	Dipyridamole	Approved Drug	2	.	Dipyridamole inhibits the transportation of 9-(2-Phosphonomethoxyethyl)adenine by ABCC4 (IC50 = 2 microM)	9-(2-Phosphonomethoxyethyl)adenine	Human embryonic kidney 293 cells (HEK293)-MRP4
DTD0030	SLCO1B3	Inhibition	Paclitaxel	Approved Drug	2	.	Paclitaxel inhibits the transportation of Amantinin by SLCO1B3 (IC50 = 2 microM)	Amantinin	Madin Darby canine kidney strain II (MDCKII) cells-OATP1B3
DTD0030	SLCO1B3	Inhibition	Lopinavir	Approved Drug	2	1.4	Lopinavir inhibits the transportation of Cholyl-glycylamido-fluorescein by SLCO1B3 (IC50 = 2 microM; Ki = 1.4 microM)	Cholyl-glycylamido-fluorescein	Chinese hamster ovary (CHO) cells-OATP1B3
DTD0015	ABCC4	Inhibition	MK-571	Discontinued Drug	2	.	MK-571 inhibits the transportation of Cholyltaurine by ABCC4 (IC50 = 2 microM)	Cholyltaurine	Chinese hamster lung fibroblasts V79 cells (V79)-MRP4
DTD0003	ABCB1	Inhibition	Itraconazole	Approved Drug	2	.	Itraconazole inhibits the transportation of Digoxin by ABCB1 (IC50 = 2 microM)	Digoxin	Human enterocyte-like 2 cell (Caco-2)-MDR1
DTD0031	SLCO2B1	Inhibition	Bromsulphthalein	Investigative Drug	2	1.5	Bromsulphthalein inhibits the transportation of Estrone sulfate by SLCO2B1 (IC50 = 2 microM; Ki = 1.5 microM)	Estrone sulfate	Human enterocyte-like 2 cell (Caco-2)-OATP2B1
DTD0027	SLC22A12	Inhibition	Morin	Investigative Drug	2	.	Morin inhibits the transportation of Uric acid by SLC22A12 (IC50 = 2 microM)	Uric acid	Human embryonic kidney 293 cells (HEK293)-URAT1
DTD0003	ABCB1	Inhibition	Erlotinib	Approved Drug	2	.	Erlotinib inhibits the transportation of Vincristine by ABCB1 (IC50 = 2 microM)	Vincristine	Myelogenous leukemia cell line (K562)-MDR1
DTD0008	SLCO1B1	Inhibition	Saquinavir	Approved Drug	2.1	1.8	Saquinavir inhibits the transportation of Cholyl-glycylamido-fluorescein by SLCO1B1 (IC50 = 2.1 microM; Ki = 1.8 microM)	Cholyl-glycylamido-fluorescein	Chinese hamster ovary (CHO) cells-OATP1B1
DTD0031	SLCO2B1	Inhibition	Rifampicin	Approved Drug	2.1	1.6	Rifampicin inhibits the transportation of Estrone sulfate by SLCO2B1 (IC50 = 2.1 microM; Ki = 1.6 microM)	Estrone sulfate	Human enterocyte-like 2 cell (Caco-2)-OATP2B1
DTD0003	ABCB1	Inhibition	Cyclosporine	Approved Drug	2.1	.	Cyclosporine inhibits the transportation of Tetramethylrosamine by ABCB1 (IC50 = 2.1 microM)	Tetramethylrosamine	NIH-3T3-G185-MDR1
DTD0015	ABCC4	Inhibition	Sulindac	Approved Drug	2.11	.	Sulindac inhibits the transportation of Methotrexate by ABCC4 (IC50 = 2.11 microM)	Methotrexate	Human embryonic kidney 293 cells (HEK293)-MRP4
DTD0008	SLCO1B1	Inhibition	Repaglinide	Approved Drug	2.2	.	Repaglinide inhibits the transportation of Bromsulphthalein by SLCO1B1 (IC50 = 2.2 microM)	Bromsulphthalein	Human embryonic kidney 293 cells (HEK293)-OATP1B1
DTD0008	SLCO1B1	Inhibition	Cyclosporine	Approved Drug	2.2	.	Cyclosporine inhibits the transportation of Rosuvastatin by SLCO1B1 (IC50 = 2.2 microM)	Rosuvastatin	Oocytes-OATP1B1
DTD0025	SLC22A8	Inhibition	Fenofibric acid	Approved Drug	2.2	.	Fenofibric acid inhibits the transportation of Sitagliptin by SLC22A8 (IC50 = 2.2 microM)	Sitagliptin	Chinese hamster ovary (CHO) cells-OAT3
DTD0003	ABCB1	Inhibition	Verapamil	Approved Drug	2.21	.	Verapamil inhibits the transportation of Paclitaxel by ABCB1 (IC50 = 2.21 microM)	Paclitaxel	.
DTD0014	ABCB11	Inhibition	Clofazimine	Approved Drug	2.3	.	Clofazimine inhibits the transportation of Sodium taurocholate by ABCB11 (IC50 = 2.3 microM)	Sodium taurocholate	Spodoptera frugiperda (Sf9) cells-BSEP
DTD0003	ABCB1	Inhibition	Cyclosporine	Approved Drug	2.4	.	Cyclosporine inhibits the transportation of Fluo-3-AM by ABCB1 (IC50 = 2.4 microM)	Fluo-3-AM	NIH-3T3-G185-MDR1
DTD0455	SLC6A3	Inhibition	Methcathinone	Investigative Drug	2.4	.	Methcathinone inhibits the transportation of Serotonin by SLC6A3 (IC50 = 2.4 microM)	Serotonin	Human embryonic kidney 293 cells (HEK293)-DAT1
DTD0031	SLCO2B1	Inhibition	Estrone	Approved Drug	2.5	1.9	Estrone inhibits the transportation of Estrone sulfate by SLCO2B1 (IC50 = 2.5 microM; Ki = 1.9 microM)	Estrone sulfate	Human enterocyte-like 2 cell (Caco-2)-OATP2B1
DTD0007	SLC47A1	Inhibition	Chloroquine	Approved Drug	2.5	.	Chloroquine inhibits the transportation of Metformin by SLC47A1 (IC50 = 2.5 microM)	Metformin	Human embryonic kidney 293 cells (HEK293)-MATE1
DTD0025	SLC22A8	Inhibition	Piroxicam	Approved Drug	2.52	.	Piroxicam inhibits the transportation of Estrone sulfate by SLC22A8 (IC50 = 2.52 microM)	Estrone sulfate	The Proximal Tubule (S2) Cells-OAT3
DTD0030	SLCO1B3	Inhibition	Rifampicin	Approved Drug	2.6	.	Rifampicin inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B3 (IC50 = 2.6 microM)	Estradiol-17beta-glucuronide	Chinese hamster ovary (CHO) cells-OATP1B3
DTD0029	SLCO1A2	Inhibition	Verapamil	Approved Drug	2.6	.	Verapamil inhibits the transportation of Fexofenadine by SLCO1A2 (IC50 = 2.6 microM)	Fexofenadine	Human cervical cancer cell line (Hela)-OATP1A2
DTD0010	SLC22A1	Inhibition	Allethrin	Natural Product	2.6	.	Allethrin inhibits the transportation of Verapamil by SLC22A1 (IC50 = 2.6 microM)	Verapamil	Human embryonic kidney 293 cells (HEK293)-OCT1
DTD0031	SLCO2B1	Inhibition	Orange juice	Dietary Constituent	2.7	.	Orange juice inhibits the transportation of Aliskiren by SLCO2B1 (IC50 = 2.7 microM)	Aliskiren	Healthy people
DTD0030	SLCO1B3	Inhibition	Silybin A	Natural Product	2.7	.	Silybin A inhibits the transportation of Estradiol-17-glucuronide by SLCO1B3 (IC50 = 2.7 microM)	Estradiol-17-glucuronide	Human embryonic kidney 293 cells (HEK293)-OATP1B3
DTD0029	SLCO1A2	Inhibition	Hesperidin	Approved Drug	2.7	.	Hesperidin inhibits the transportation of Fexofenadine by SLCO1A2 (IC50 = 2.7 microM)	Fexofenadine	Human cervical cancer cell line (Hela)-OATP1A2
DTD0010	SLC22A1	Inhibition	Phenoxybenzamine	Approved Drug	2.72	.	Phenoxybenzamine inhibits the transportation of 1-Methyl-4-phenylpyridinium by SLC22A1 (IC50 = 2.72 microM)	1-Methyl-4-phenylpyridinium	Human embryonic kidney 293 cells (HEK293)-OCT1
DTD0003	ABCB1	Inhibition	Astemizole	Drug Withdrawn	2.73	.	Astemizole inhibits the transportation of Digoxin by ABCB1 (IC50 = 2.73 microM)	Digoxin	Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DTD0006	SLC22A2	Inhibition	Fenamiphos	Natural Product	2.8	.	Fenamiphos inhibits the transportation of Dopamine by SLC22A2 (IC50 = 2.8 microM)	Dopamine	Human embryonic kidney 293 cells (HEK293)-OCT2
DTD0014	ABCB11	Inhibition	Reserpine	Approved Drug	2.8	.	Reserpine inhibits the transportation of Sodium taurocholate by ABCB11 (IC50 = 2.8 microM)	Sodium taurocholate	Spodoptera frugiperda (Sf9) cells-BSEP
DTD0009	SLC22A3	Inhibition	Estradiol	Approved Drug	2.88	.	Estradiol inhibits the transportation of 1-Methyl-4-phenylpyridinium by SLC22A3 (IC50 = 2.88 microM)	1-Methyl-4-phenylpyridinium	Human embryonic kidney 293 cells (HEK293)-OCT3
DTD0003	ABCB1	Inhibition	Pimozide	Approved Drug	2.9	.	Pimozide inhibits the transportation of Calcein AM by ABCB1 (IC50 = 2.9 microM)	Calcein AM	LLC-PK1 vesicles-MDR1
DTD0006	SLC22A2	Inhibition	Testosterone	Approved Drug	3	.	Testosterone inhibits the activity of SLC22A2 (IC50 = 3 microM)	.	.
DTD0024	SLC22A6	Inhibition	Indomethacin	Approved Drug	3	.	Indomethacin inhibits the transportation of Adefovir by SLC22A6 (IC50 = 3 microM)	Adefovir	Chinese hamster ovary (CHO) cells-OAT1
DTD0030	SLCO1B3	Inhibition	Bromsulphthalein	Investigative Drug	3	.	Bromsulphthalein inhibits the transportation of Amantinin by SLCO1B3 (IC50 = 3 microM)	Amantinin	Madin Darby canine kidney strain II (MDCKII) cells-OATP1B3
DTD0030	SLCO1B3	Inhibition	Atazanavir	Approved Drug	3	2	Atazanavir inhibits the transportation of Cholyl-glycylamido-fluorescein by SLCO1B3 (IC50 = 3 microM; Ki = 2 microM)	Cholyl-glycylamido-fluorescein	Chinese hamster ovary (CHO) cells-OATP1B3
DTD0031	SLCO2B1	Inhibition	Rifamycin SV	Approved Drug	3	2.3	Rifamycin SV inhibits the transportation of Estrone sulfate by SLCO2B1 (IC50 = 3 microM; Ki = 2.3 microM)	Estrone sulfate	Human enterocyte-like 2 cell (Caco-2)-OATP2B1
DTD0025	SLC22A8	Inhibition	Sulfasalazine	Approved Drug	3	.	Sulfasalazine inhibits the transportation of Methotrexate by SLC22A8 (IC50 = 3 microM)	Methotrexate	Oocytes-OAT3
DTD0004	ABCG2	Inhibition	p,p'-tetrachlorodiphenylethane (DDD)	Environmental toxicant	3	.	p,p'-DDD inhibits the transportation of Sulfasalazine by ABCG2 (IC50 = 3 microM)	Sulfasalazine	Spodoptera frugiperda (Sf9) cells-BCRP
DTD0010	SLC22A1	Inhibition	Progesterone	Approved Drug	3.05	.	Progesterone inhibits the transportation of 1-Methyl-4-phenylpyridinium by SLC22A1 (IC50 = 3.05 microM)	1-Methyl-4-phenylpyridinium	Human embryonic kidney 293 cells (HEK293)-OCT1
DTD0003	ABCB1	Inhibition	Ketoconazole	Approved Drug	3.07	.	Ketoconazole inhibits the transportation of Digoxin by ABCB1 (IC50 = 3.07 microM)	Digoxin	Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DTD0007	SLC47A1	Inhibition	Ritonavir	Approved Drug	3.1	.	Ritonavir inhibits the activity of SLC47A1 (IC50 = 3.1 microM)	.	.
DTD0025	SLC22A8	Inhibition	Probenecid	Approved Drug	3.1	.	Probenecid inhibits the transportation of Cimetidine by SLC22A8 (IC50 = 3.1 microM)	Cimetidine	Chinese hamster ovary (CHO) cells-OAT3
DTD0028	SLC47A2	Inhibition	Cobicistat	Approved Drug	3.2	.	Cobicistat inhibits the activity of SLC47A2 (IC50 = 3.2 microM)	.	.
DTD0008	SLCO1B1	Inhibition	Rifampicin	Approved Drug	3.2	.	Rifampicin inhibits the transportation of Bosentan by SLCO1B1 (IC50 = 3.2 microM)	Bosentan	Chinese hamster ovary (CHO) cells-OATP1B1
DTD0008	SLCO1B1	Inhibition	Rifampicin	Approved Drug	3.25	3.08	Rifampicin inhibits the transportation of Atorvastatin by SLCO1B1 (IC50 = 3.25 microM; Ki = 3.08 microM)	Atorvastatin	Human embryonic kidney 293 cells (HEK293)-OATP1B1
DTD0007	SLC47A1	Inhibition	Sirolimus	Approved Drug	3.27	.	Rapamycin inhibits the transportation of Metformin by SLC47A1 (IC50 = 3.27 microM)	Metformin	Human cervical cancer cell line (Hela)-MATE1
DTD0024	SLC22A6	Inhibition	Glutarate	Investigative Drug	3.3	.	Glutarate inhibits the transportation of Aminohippuric acid by SLC22A6 (IC50 = 3.3 microM)	Aminohippuric acid	Human embryonic kidney 293 cells (HEK293)-OAT1
DTD0008	SLCO1B1	Inhibition	Mifepristone	Approved Drug	3.3	.	Mifepristone inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (IC50 = 3.3 microM)	Estradiol-17beta-glucuronide	Chinese hamster ovary (CHO) cells-OATP1B1
DTD0010	SLC22A1	Inhibition	Diphenhydramine	Approved Drug	3.4	.	Diphenhydramine inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 3.4 microM)	N-methylpyridinium	Human embryonic kidney 293 cells (HEK293)-OCT1
DTD0003	ABCB1	Inhibition	Cyclosporine	Approved Drug	3.41	.	Cyclosporine inhibits the transportation of Calcein AM by ABCB1 (IC50 = 3.41 microM)	Calcein AM	CEM/VLB100 drug-resistant cells-MDR1
DTD0001	ABCC1	Inhibition	MK-571	Discontinued Drug	3.5	.	MK-571 inhibits the transportation of 2',7'-Bis-(3-carboxy-propyl)-5-(and-6)-carboxyfluorescein (BCPCF) by ABCC1 (IC50 = 3.5 microM)	2',7'-Bis-(3-carboxy-propyl)-5-(and-6)-carboxyfluorescein (BCPCF)	Human erythrocytes-MRP1
DTD0008	SLCO1B1	Inhibition	Cyclosporine	Approved Drug	3.5	.	Cyclosporine inhibits the transportation of Bromsulphthalein by SLCO1B1 (IC50 = 3.5 microM)	Bromsulphthalein	Madin Darby canine kidney strain II (MDCKII) cells-OATP1B1
DTD0003	ABCB1	Inhibition	Miconazole	Approved Drug	3.5	.	Miconazole inhibits the transportation of Calcein AM by ABCB1 (IC50 = 3.5 microM)	Calcein AM	LLC-PK1 vesicles-MDR1
DTD0008	SLCO1B1	Inhibition	Darunavir	Approved Drug	3.5	3.1	Darunavir inhibits the transportation of Cholyl-glycylamido-fluorescein by SLCO1B1 (IC50 = 3.5 microM; Ki = 3.1 microM)	Cholyl-glycylamido-fluorescein	Chinese hamster ovary (CHO) cells-OATP1B1
DTD0007	SLC47A1	Inhibition	Sirolimus	Approved Drug	3.51	.	Rapamycin inhibits the transportation of Tetraethylammonium by SLC47A1 (IC50 = 3.51 microM)	Tetraethylammonium	Human cervical cancer cell line (Hela)-MATE1
DTD0006	SLC22A2	Inhibition	Carvedilol	Approved Drug	3.6	.	Carvedilol inhibits the activity of SLC22A2 (IC50 = 3.6 microM)	.	Human embryonic kidney 293 cells (HEK293)-OCT2
DTD0030	SLCO1B3	Inhibition	Ritonavir	Approved Drug	3.6	2.5	Ritonavir inhibits the transportation of Cholyl-glycylamido-fluorescein by SLCO1B3 (IC50 = 3.6 microM; Ki = 2.5 microM)	Cholyl-glycylamido-fluorescein	Chinese hamster ovary (CHO) cells-OATP1B3
DTD0006	SLC22A2	Inhibition	Phosmet	Natural Product	3.6	.	Phosmet inhibits the transportation of Dopamine by SLC22A2 (IC50 = 3.6 microM)	Dopamine	Human embryonic kidney 293 cells (HEK293)-OCT2
DTD0031	SLCO2B1	Inhibition	Silychristin	Natural Product	3.6	.	Silychristin inhibits the transportation of Estrone sulfate by SLCO2B1 (IC50 = 3.6 microM)	Estrone sulfate	Human embryonic kidney 293 cells (HEK293)-OATP2B1
DTD0029	SLCO1A2	Inhibition	Naringin	Investigative Drug	3.6	.	Naringin inhibits the transportation of Fexofenadine by SLCO1A2 (IC50 = 3.6 microM)	Fexofenadine	Human cervical cancer cell line (Hela)-OATP1A2
DTD0019	SLC10A1	Inhibition	Chenodeoxycholic acid	Approved Drug	3.6	.	Chenodeoxycholic acid inhibits the transportation of Sodium taurocholate by SLC10A1 (IC50 = 3.6 microM)	Sodium taurocholate	Human cervical cancer cell line (Hela)-NTCP
DTD0025	SLC22A8	Inhibition	Sulindac	Approved Drug	3.62	.	Sulindac inhibits the transportation of Estrone sulfate by SLC22A8 (IC50 = 3.62 microM)	Estrone sulfate	The Proximal Tubule (S2) Cells-OAT3
DTD0003	ABCB1	Inhibition	Cyclosporine	Approved Drug	3.66	.	Cyclosporine inhibits the transportation of Doxorubicin by ABCB1 (IC50 = 3.66 microM)	Doxorubicin	LLC-PK1 vesicles-MDR1
DTD0008	SLCO1B1	Inhibition	Tacrolimus	Approved Drug	3.7	.	Tacrolimus inhibits the transportation of Phalloidin by SLCO1B1 (IC50 = 3.7 microM)	Phalloidin	Human embryonic kidney 293 cells (HEK293)-OATP1B1
DTD0455	SLC6A3	Inhibition	4-Fluoroamphetamine	Approved Drug	3.7	.	4-Fluoroamphetamine inhibits the transportation of Serotonin by SLC6A3 (IC50 = 3.7 microM)	Serotonin	Human embryonic kidney 293 cells (HEK293)-DAT1
DTD0025	SLC22A8	Inhibition	Ibuprofen	Approved Drug	3.7	.	Ibuprofen inhibits the transportation of Sitagliptin by SLC22A8 (IC50 = 3.7 microM)	Sitagliptin	Chinese hamster ovary (CHO) cells-OAT3
DTD0006	SLC22A2	Inhibition	Piperine	Natural Product	3.727	.	Piperine inhibits the transportation of Metformin by SLC22A2 (IC50 = 3.727 microM)	Metformin	Madin darby canine kidney strain cell line (MDCK)-OCT2
DTD0029	SLCO1A2	Inhibition	Bromsulphthalein	Investigative Drug	3.75	.	Bromsulphthalein inhibits the transportation of Estrone sulfate by SLCO1A2 (IC50 = 3.75 microM)	Estrone sulfate	Monkey kidney tissue Fibroblast-like cell lines (COS1)-OATP1A2
DTD0024	SLC22A6	Inhibition	Chlorothiazide	Approved Drug	3.78	.	Chlorothiazide inhibits the transportation of Aminohippuric acid by SLC22A6 (IC50 = 3.78 microM)	Aminohippuric acid	The Proximal Tubule (S2) Cells-OAT1
DTD0003	ABCB1	Inhibition	Ritonavir	Approved Drug	3.8	.	Ritonavir inhibits the transportation of Digoxin by ABCB1 (IC50 = 3.8 microM)	Digoxin	Human enterocyte-like 2 cell (Caco-2)-MDR1
DTD0003	ABCB1	Inhibition	p,p'-dichlorodiphenyltrichloroethane (DDT)	Environmental toxicant	3.8	.	p,p'-DDT inhibits the transportation of Verapamil by ABCB1 (IC50 = 3.8 microM)	Verapamil	Spodoptera frugiperda (Sf9) cells-MDR1
DTD0024	SLC22A6	Inhibition	Indomethacin	Approved Drug	3.83	.	Indomethacin inhibits the transportation of Aminohippuric acid by SLC22A6 (IC50 = 3.83 microM)	Aminohippuric acid	The Proximal Tubule (S2) Cells-OAT1
DTD0024	SLC22A6	Inhibition	Probenecid	Approved Drug	3.9	.	Probenecid inhibits the transportation of Cidofovir by SLC22A6 (IC50 = 3.9 microM)	Cidofovir	Chinese hamster ovary (CHO) cells-OAT1
DTD0008	SLCO1B1	Inhibition	Estradiol	Approved Drug	3.9	.	Estradiol inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (IC50 = 3.9 microM)	Estradiol-17beta-glucuronide	Chinese hamster ovary (CHO) cells-OATP1B1
DTD0031	SLCO2B1	Inhibition	Indinavir	Approved Drug	3.9	3	Indinavir inhibits the transportation of Estrone sulfate by SLCO2B1 (IC50 = 3.9 microM; Ki = 3 microM)	Estrone sulfate	Human enterocyte-like 2 cell (Caco-2)-OATP2B1
DTD0024	SLC22A6	Inhibition	Diclofenac	Approved Drug	4	.	Diclofenac inhibits the transportation of Adefovir by SLC22A6 (IC50 = 4 microM)	Adefovir	Chinese hamster ovary (CHO) cells-OAT1
DTD0030	SLCO1B3	Inhibition	Sildenafil	Approved Drug	4	.	Sildenafil inhibits the transportation of Bosentan by SLCO1B3 (IC50 = 4 microM)	Bosentan	Chinese hamster ovary (CHO) cells-OATP1B1
DTD0030	SLCO1B3	Inhibition	Paclitaxel	Approved Drug	4	.	Paclitaxel inhibits the transportation of Bromsulphthalein by SLCO1B3 (IC50 = 4 microM)	Bromsulphthalein	Madin Darby canine kidney strain II (MDCKII) cells-OATP1B3
DTD0002	ABCC2	Inhibition	MK-571	Discontinued Drug	4	.	MK-571 inhibits the transportation of Ethacrynic acid glutathione by ABCC2 (IC50 = 4 microM)	Ethacrynic acid glutathione	Spodoptera frugiperda (Sf9) cells-MRP2
DTD0004	ABCG2	Inhibition	p,p'-dichlorodiphenyldichloroethane (DDE)	Environmental toxicant	4	.	p,p'-DDE inhibits the transportation of Sulfasalazine by ABCG2 (IC50 = 4 microM)	Sulfasalazine	Spodoptera frugiperda (Sf9) cells-BCRP
DTD0030	SLCO1B3	Inhibition	Saquinavir	Approved Drug	4.1	2.8	Saquinavir inhibits the transportation of Cholyl-glycylamido-fluorescein by SLCO1B3 (IC50 = 4.1 microM; Ki = 2.8 microM)	Cholyl-glycylamido-fluorescein	Chinese hamster ovary (CHO) cells-OATP1B3
DTD0003	ABCB1	Inhibition	Clarithromycin	Approved Drug	4.1	.	Clarithromycin inhibits the transportation of Digoxin by ABCB1 (IC50 = 4.1 microM)	Digoxin	Human enterocyte-like 2 cell (Caco-2)-MDR1
DTD0023	SLC22A5	Inhibition	Emetine	Approved Drug	4.2	.	Emetine inhibits the transportation of L-carnitine by SLC22A5 (IC50 = 4.2 microM)	L-carnitine	Oocytes-OCTN2
DTD0003	ABCB1	Inhibition	Verapamil	Approved Drug	4.2	.	Verapamil inhibits the transportation of Rhodamine 123 by ABCB1 (IC50 = 4.2 microM)	Rhodamine 123	NIH-3T3-G185-MDR1
DTD0009	SLC22A3	Inhibition	Progesterone	Approved Drug	4.28	.	Progesterone inhibits the transportation of 1-Methyl-4-phenylpyridinium by SLC22A3 (IC50 = 4.28 microM)	1-Methyl-4-phenylpyridinium	Human embryonic kidney 293 cells (HEK293)-OCT3
DTD0503	SLCO4C1	Inhibition	Saquinavir	Approved Drug	4.3	.	Saquinavir inhibits the activity of SLCO4C1 (IC50 = 4.3 microM)	.	.
DTD0024	SLC22A6	Inhibition	Ketoprofen	Approved Drug	4.34	.	Ketoprofen inhibits the transportation of Aminohippuric acid by SLC22A6 (IC50 = 4.34 microM)	Aminohippuric acid	The Proximal Tubule (S2) Cells-OAT1
DTD0007	SLC47A1	Inhibition	Cobicistat	Approved Drug	4.4	.	Cobicistat inhibits the activity of SLC47A1 (IC50 = 4.4 microM)	.	.
DTD0007	SLC47A1	Inhibition	Mitoxantrone	Approved Drug	4.4	.	Mitoxantrone inhibits the transportation of Metformin by SLC47A1 (IC50 = 4.4 microM)	Metformin	Human cervical cancer cell line (Hela)-MATE1
DTD0026	SLC22A11	Inhibition	Olmesartan medoxomil	Approved Drug	4.4	.	Olmesartan medoxomil inhibits the transportation of Uric acid by SLC22A11 (IC50 = 4.4 microM)	Uric acid	Human embryonic kidney 293 cells (HEK293)-OAT4
DTD0006	SLC22A2	Inhibition	N-methylpyridinium	Drug in Preclinical Test	4.42	.	N-methylpyridinium inhibits the transportation of YM155 by SLC22A2 (IC50 = 4.42 microM)	YM155	Human embryonic kidney 293 cells (HEK293)-OCT2
DTD0024	SLC22A6	Inhibition	Diclofenac	Approved Drug	4.46	.	Diclofenac inhibits the transportation of Aminohippuric acid by SLC22A6 (IC50 = 4.46 microM)	Aminohippuric acid	The Proximal Tubule (S2) Cells-OAT1
DTD0003	ABCB1	Inhibition	Sufentanil	Approved Drug	4.5	.	Sufentanil inhibits the transportation of Digoxin by ABCB1 (IC50 = 4.5 microM)	Digoxin	Human enterocyte-like 2 cell (Caco-2)-MDR1
DTD0031	SLCO2B1	Inhibition	Silybin A	Natural Product	4.5	.	Silybin A inhibits the transportation of Estrone sulfate by SLCO2B1 (IC50 = 4.5 microM)	Estrone sulfate	Human embryonic kidney 293 cells (HEK293)-OATP2B1
DTD0452	SLC6A2	Inhibition	4-Fluoroephedrine	Natural Product	4.5	.	4-Fluoroephedrine inhibits the transportation of Norepinephrine by SLC6A2 (IC50 = 4.5 microM)	Norepinephrine	Human embryonic kidney 293 cells (HEK293)-NET
DTD0025	SLC22A8	Inhibition	Alpha-zearalenol	Mycotoxins	4.55	.	Alpha-zearalenol inhibits the transportation of Organic anion by SLC22A8 (IC50 = 4.55 microM)	Organic anion	The Proximal Tubule (S2) Cells-OAT3
DTD0024	SLC22A6	Inhibition	Sulfasalazine	Approved Drug	4.6	.	Sulfasalazine inhibits the transportation of Methotrexate by SLC22A6 (IC50 = 4.6 microM)	Methotrexate	Oocytes-OAT1
DTD0031	SLCO2B1	Inhibition	Naringin	Investigative Drug	4.63	.	Naringin inhibits the transportation of Estrone sulfate by SLCO2B1 (IC50 = 4.63 microM)	Estrone sulfate	Xenopus laevis oocytes-OATP2B1
DTD0025	SLC22A8	Inhibition	Naproxen	Approved Drug	4.67	.	Naproxen inhibits the transportation of Estrone sulfate by SLC22A8 (IC50 = 4.67 microM)	Estrone sulfate	The Proximal Tubule (S2) Cells-OAT3
DTD0006	SLC22A2	Inducer	Vorinostat	Approved Drug	4.69	.	Vorinostat inhibits histone deacetylase, which then enhances Oxaliplatin's transportation via increasing the histone acethylation level of SLC22A2 (IC50 = 4.69 microM)	Oxaliplatin	Human renal cell carcinoma cells (RCC)
DTD0024	SLC22A6	Inhibition	Alpha-ketoglutaric acid	Investigative Drug	4.7	.	Alpha-ketoglutaric acid inhibits the transportation of Aminohippuric acid by SLC22A6 (IC50 = 4.7 microM)	Aminohippuric acid	Human embryonic kidney 293 cells (HEK293)-OAT1
DTD0003	ABCB1	Inhibition	Nefazodone	Approved Drug	4.7	.	Nefazodone inhibits the transportation of Rhodamine 123 by ABCB1 (IC50 = 4.7 microM)	Rhodamine 123	Human enterocyte-like 2 cell (Caco-2)-MDR1
DTD0003	ABCB1	Inhibition	Verapamil	Approved Drug	4.78	.	Verapamil inhibits the transportation of Paclitaxel by ABCB1 (IC50 = 4.78 microM)	Paclitaxel	Human uterine cancer cells (MES-SA/Dx5)
DTD0030	SLCO1B3	Inhibition	Darunavir	Approved Drug	4.8	3.3	Darunavir inhibits the transportation of Cholyl-glycylamido-fluorescein by SLCO1B3 (IC50 = 4.8 microM; Ki = 3.3 microM)	Cholyl-glycylamido-fluorescein	Chinese hamster ovary (CHO) cells-OATP1B3
DTD0030	SLCO1B3	Inhibition	Boceprevir	Approved Drug	4.9	.	Boceprevir inhibits the activity of SLCO1B3 (IC50 = 4.9 microM)	.	.
DTD0006	SLC22A2	Inhibition	Phenoxybenzamine	Approved Drug	4.9	.	Phenoxybenzamine inhibits the transportation of 1-Methyl-4-phenylpyridinium by SLC22A2 (IC50 = 4.9 microM)	1-Methyl-4-phenylpyridinium	Human embryonic kidney 293 cells (HEK293)-OCT2
DTD0024	SLC22A6	Inhibition	Glutarate	Investigative Drug	4.9	.	Glutarate inhibits the transportation of 6-Carboxyfluorescein by SLC22A6 (IC50 = 4.9 microM)	6-Carboxyfluorescein	Chinese hamster ovary (CHO) cells-OAT1
DTD0010	SLC22A1	Inhibition	Tetramethrin	Natural Product	4.9	.	Tetramethrin inhibits the transportation of Verapamil by SLC22A1 (IC50 = 4.9 microM)	Verapamil	Human embryonic kidney 293 cells (HEK293)-OCT1
DTD0025	SLC22A8	Inhibition	Novobiocin	Approved Drug	4.99	4.77	Novobiocin inhibits the transportation of Estrone sulfate by SLC22A8 (IC50 = 4.99 microM; Ki = 4.77 microM)	Estrone sulfate	Monkey kidney tissue Fibroblast-like cell lines (COS)7-OAT3
DTD0002	ABCC2	Inhibition	Curcumin	Drug in Phase 3 Trial	5	.	Curcumin inhibits the activity of ABCC2 (IC50 = 5 microM)	.	Madin Darby canine kidney strain II (MDCKII) cells-MRP2
DTD0008	SLCO1B1	Inhibition	MK-571	Discontinued Drug	5	.	MK-571 inhibits the transportation of Bromsulphthalein by SLCO1B1 (IC50 = 5 microM)	Bromsulphthalein	Madin Darby canine kidney strain II (MDCKII) cells-OATP1B1
DTD0001	ABCC1	Inhibition	MK-571	Discontinued Drug	5	.	MK-571 inhibits the transportation of Calcein AM by ABCC1 (IC50 = 5 microM)	Calcein AM	Madin Darby canine kidney strain II (MDCKII) cells-MRP1
DTD0003	ABCB1	Inhibition	Ritonavir	Approved Drug	5	.	Ritonavir inhibits the transportation of Digoxin by ABCB1 (IC50 = 5 microM)	Digoxin	Human enterocyte-like 2 cell (Caco-2)-MDR1
DTD0030	SLCO1B3	Inhibition	Silybin B	Natural Product	5	.	Silybin B inhibits the transportation of Estradiol-17-glucuronide by SLCO1B3 (IC50 = 5 microM)	Estradiol-17-glucuronide	Human embryonic kidney 293 cells (HEK293)-OATP1B3
DTD0002	ABCC2	Inhibition	Curcumin	Drug in Phase 3 Trial	5	.	Curcumin inhibits the transportation of Ethacrynic acid glutathione by ABCC2 (IC50 = 5 microM)	Ethacrynic acid glutathione	Spodoptera frugiperda (Sf9) cells-MRP2
DTD0001	ABCC1	Inhibition	Cyclosporine	Approved Drug	5	.	Cyclosporine inhibits the transportation of Leukotriene C4 by ABCC1 (IC50 = 5 microM)	Leukotriene C4	Human cervical cancer cell line (Hela)-MRP1
DTD0004	ABCG2	Inhibition	p,p'-dichlorodiphenyltrichloroethane (DDT)	Environmental toxicant	5	.	p,p'-DDT inhibits the transportation of Sulfasalazine by ABCG2 (IC50 = 5 microM)	Sulfasalazine	Spodoptera frugiperda (Sf9) cells-BCRP
DTD0010	SLC22A1	Inhibition	Ritonavir	Approved Drug	5.18	.	Ritonavir inhibits the transportation of Tetraethylammonium by SLC22A1 (IC50 = 5.18 microM)	Tetraethylammonium	Human cervical cancer cell line (Hela)-OCT1
DTD0031	SLCO2B1	Inhibition	Repaglinide	Approved Drug	5.2	.	Repaglinide inhibits the transportation of Bromsulphthalein by SLCO2B1 (IC50 = 5.2 microM)	Bromsulphthalein	Human embryonic kidney 293 cells (HEK293)-OATP2B1
DTD0007	SLC47A1	Inhibition	Mitoxantrone	Approved Drug	5.2	.	Mitoxantrone inhibits the transportation of Tetraethylammonium by SLC47A1 (IC50 = 5.2 microM)	Tetraethylammonium	Human cervical cancer cell line (Hela)-MATE1
DTD0030	SLCO1B3	Inhibition	Mifepristone	Approved Drug	5.3	.	Mifepristone inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B3 (IC50 = 5.3 microM)	Estradiol-17beta-glucuronide	Chinese hamster ovary (CHO) cells-OATP1B3
DTD0031	SLCO2B1	Inhibition	Saquinavir	Approved Drug	5.3	4	Saquinavir inhibits the transportation of Estrone sulfate by SLCO2B1 (IC50 = 5.3 microM; Ki = 4 microM)	Estrone sulfate	Human enterocyte-like 2 cell (Caco-2)-OATP2B1
DTD0006	SLC22A2	Inhibition	Corticosterone	Investigative Drug	5.35	.	Corticosterone inhibits the transportation of YM155 by SLC22A2 (IC50 = 5.35 microM)	YM155	Human embryonic kidney 293 cells (HEK293)-OCT2
DTD0025	SLC22A8	Inhibition	Bumetanide	Approved Drug	5.4	.	Bumetanide inhibits the transportation of Methotrexate by SLC22A8 (IC50 = 5.4 microM)	Methotrexate	Oocytes-OAT3
DTD0006	SLC22A2	Inhibition	Piperine	Natural Product	5.4	.	Piperine inhibits the transportation of Serotonin by SLC22A2 (IC50 = 5.4 microM)	Serotonin	Madin darby canine kidney strain cell line (MDCK)-OCT2
DTD0003	ABCB1	Inhibition	Amiodarone	Approved Drug	5.48	.	Amiodarone inhibits the transportation of Digoxin by ABCB1 (IC50 = 5.48 microM)	Digoxin	LLC-PK1 vesicles-MDR1
DTD0003	ABCB1	Inhibition	Ketoconazole	Approved Drug	5.49	.	Ketoconazole inhibits the transportation of Colchicine by ABCB1 (IC50 = 5.49 microM)	Colchicine	Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DTD0019	SLC10A1	Inhibition	Propranolol	Approved Drug	5.5	.	Propranolol inhibits the transportation of Sodium taurocholate by SLC10A1 (IC50 = 5.5 microM)	Sodium taurocholate	Human cervical cancer cell line (Hela)-NTCP
DTD0030	SLCO1B3	Inhibition	Repaglinide	Approved Drug	5.6	.	Repaglinide inhibits the transportation of Bromsulphthalein by SLCO1B3 (IC50 = 5.6 microM)	Bromsulphthalein	Human embryonic kidney 293 cells (HEK293)-OATP1B3
DTD0003	ABCB1	Inhibition	Ketoconazole	Approved Drug	5.6	.	Ketoconazole inhibits the transportation of Rhodamine 123 by ABCB1 (IC50 = 5.6 microM)	Rhodamine 123	NIH-3T3-G185-MDR1
DTD0025	SLC22A8	Inhibition	Probenecid	Approved Drug	5.6	.	Probenecid inhibits the transportation of Sitagliptin by SLC22A8 (IC50 = 5.6 microM)	Sitagliptin	Chinese hamster ovary (CHO) cells-OAT3
DTD0004	ABCG2	Inhibition	Resmethrin	Natural Product	5.6	.	Resmethrin inhibits the transportation of Sulfasalazine by ABCG2 (IC50 = 5.6 microM)	Sulfasalazine	Spodoptera frugiperda (Sf9) cells-BCRP
DTD0024	SLC22A6	Inhibition	Naproxen	Approved Drug	5.67	.	Naproxen inhibits the transportation of Aminohippuric acid by SLC22A6 (IC50 = 5.67 microM)	Aminohippuric acid	The Proximal Tubule (S2) Cells-OAT1
DTD0008	SLCO1B1	Inhibition	Tetramethrin	Natural Product	5.7	.	Tetramethrin inhibits the transportation of Fluorescein by SLCO1B1 (IC50 = 5.7 microM)	Fluorescein	Chinese hamster ovary (CHO) cells-OATP1B1
DTD0003	ABCB1	Inhibition	Fluphenazine	Approved Drug	5.7	.	Fluphenazine inhibits the transportation of LDS-751 by ABCB1 (IC50 = 5.7 microM)	LDS-751	NIH-3T3-G185-MDR1
DTD0010	SLC22A1	Inhibition	Quinine	Approved Drug	5.7	.	Quinine inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 5.7 microM)	N-methylpyridinium	Chinese hamster ovary (CHO) cells-OCT1
DTD0010	SLC22A1	Inhibition	Estradiol	Approved Drug	5.73	.	Estradiol inhibits the transportation of 1-Methyl-4-phenylpyridinium by SLC22A1 (IC50 = 5.73 microM)	1-Methyl-4-phenylpyridinium	Human embryonic kidney 293 cells (HEK293)-OCT1
DTD0025	SLC22A8	Inhibition	Fluvastatin	Approved Drug	5.79	.	Fluvastatin inhibits the transportation of Estrone sulfate by SLC22A8 (IC50 = 5.79 microM)	Estrone sulfate	The Proximal Tubule (S2) Cells-OAT3
DTD0024	SLC22A6	Inhibition	Naproxen	Approved Drug	5.8	.	Naproxen inhibits the transportation of Adefovir by SLC22A6 (IC50 = 5.8 microM)	Adefovir	Chinese hamster ovary (CHO) cells-OAT1
DTD0008	SLCO1B1	Inhibition	Indinavir	Approved Drug	5.84	.	Indinavir inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (IC50 = 5.84 microM)	Estradiol-17beta-glucuronide	Human cervical cancer cell line (Hela)-OATP1B1
DTD0025	SLC22A8	Inhibition	Ketoprofen	Approved Drug	5.98	.	Ketoprofen inhibits the transportation of Estrone sulfate by SLC22A8 (IC50 = 5.98 microM)	Estrone sulfate	The Proximal Tubule (S2) Cells-OAT3
DTD0024	SLC22A6	Inhibition	Betamipron	Approved Drug	6	.	Betamipron inhibits the transportation of Adefovir by SLC22A6 (IC50 = 6 microM)	Adefovir	Chinese hamster ovary (CHO) cells-OAT1
DTD0025	SLC22A8	Inhibition	Ibuprofen	Approved Drug	6	.	Ibuprofen inhibits the transportation of Estrone sulfate by SLC22A8 (IC50 = 6 microM)	Estrone sulfate	The Proximal Tubule (S2) Cells-OAT3
DTD0006	SLC22A2	Inhibition	Imipramine	Approved Drug	6	.	Imipramine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 6 microM)	N-methylpyridinium	Human embryonic kidney 293 cells (HEK293)-OCT2
DTD0007	SLC47A1	Inhibition	Cigarette smoke condensate	Natural Product	6.1	.	Cigarette smoke condensate inhibits the activity of SLC47A1 (IC50 = 6.1 microM)	.	Human embryonic kidney 293 cells (HEK293)-MATE1
DTD0008	SLCO1B1	Inhibition	Lovastatin	Approved Drug	6.1	.	Lovastatin inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (IC50 = 6.1 microM)	Estradiol-17beta-glucuronide	Chinese hamster ovary (CHO) cells-OATP1B1
DTD0015	ABCC4	Inhibition	Indomethacin	Approved Drug	6.1	.	Indomethacin inhibits the transportation of Methotrexate by ABCC4 (IC50 = 6.1 microM)	Methotrexate	Human embryonic kidney 293 cells (HEK293)-MRP4
DTD0007	SLC47A1	Inhibition	Cigarette smoke condensate	Natural Product	6.1	.	Cigarette smoke condensate inhibits the transportation of Verapamil by repressing mRNA expression of SLC47A1 (IC50 = 6.1 microM)	Verapamil	Human hepatoma HepaRG cells-MATE1
DTD0009	SLC22A3	Inhibition	Phenoxybenzamine	Approved Drug	6.13	.	Phenoxybenzamine inhibits the transportation of 1-Methyl-4-phenylpyridinium by SLC22A3 (IC50 = 6.13 microM)	1-Methyl-4-phenylpyridinium	Human embryonic kidney 293 cells (HEK293)-OCT3
DTD0003	ABCB1	Inhibition	Cyclosporine	Approved Drug	6.18	.	Cyclosporine inhibits the transportation of Vinblastine by ABCB1 (IC50 = 6.18 microM)	Vinblastine	Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DTD0014	ABCB11	Inhibition	Candesartan cilexetil	Approved Drug	6.2	.	Candesartan cilexetil inhibits the activity of ABCB11 (IC50 = 6.2 microM)	.	Human hepatocytes-BSEP
DTD0024	SLC22A6	Inhibition	Adipate	Investigative Drug	6.2	.	Adipate inhibits the transportation of Aminohippuric acid by SLC22A6 (IC50 = 6.2 microM)	Aminohippuric acid	Human embryonic kidney 293 cells (HEK293)-OAT1
DTD0025	SLC22A8	Inhibition	Quinapril	Approved Drug	6.2	.	Quinapril inhibits the transportation of Sitagliptin by SLC22A8 (IC50 = 6.2 microM)	Sitagliptin	Chinese hamster ovary (CHO) cells-OAT3
DTD0024	SLC22A6	Inhibition	Probenecid	Approved Drug	6.3	.	Probenecid inhibits the transportation of 6-Carboxyfluorescein by SLC22A6 (IC50 = 6.3 microM)	6-Carboxyfluorescein	Chinese hamster ovary (CHO) cells-OAT1
DTD0031	SLCO2B1	Inhibition	Ritonavir	Approved Drug	6.3	4.8	Ritonavir inhibits the transportation of Estrone sulfate by SLCO2B1 (IC50 = 6.3 microM; Ki = 4.8 microM)	Estrone sulfate	Human enterocyte-like 2 cell (Caco-2)-OATP2B1
DTD0003	ABCB1	Inhibition	Trifluoperazine	Approved Drug	6.3	.	Trifluoperazine inhibits the transportation of LDS-751 by ABCB1 (IC50 = 6.3 microM)	LDS-751	NIH-3T3-G185-MDR1
DTD0003	ABCB1	Inhibition	Ketoconazole	Approved Drug	6.34	.	Ketoconazole inhibits the transportation of Vinblastine by ABCB1 (IC50 = 6.34 microM)	Vinblastine	Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DTD0028	SLC47A2	Inhibition	Quinine	Approved Drug	6.4	.	Quinine inhibits the transportation of 1-methyl-4-phenylpyridinium by SLC47A2 (IC50 = 6.4 microM)	1-methyl-4-phenylpyridinium	Chinese hamster ovary (CHO) cells-MATE2
DTD0024	SLC22A6	Inhibition	Probenecid	Approved Drug	6.5	.	Probenecid inhibits the transportation of Aminohippuric acid by SLC22A6 (IC50 = 6.5 microM)	Aminohippuric acid	Chinese hamster ovary (CHO) cells-OAT1
DTD0003	ABCB1	Inhibition	Fluphenazine	Approved Drug	6.5	.	Fluphenazine inhibits the transportation of Daunorubicin by ABCB1 (IC50 = 6.5 microM)	Daunorubicin	NIH-3T3-G185-MDR1
DTD0003	ABCB1	Inhibition	Fentanyl	Approved Drug	6.5	.	Fentanyl inhibits the transportation of Digoxin by ABCB1 (IC50 = 6.5 microM)	Digoxin	Human enterocyte-like 2 cell (Caco-2)-MDR1
DTD0010	SLC22A1	Inhibition	Clonidine	Approved Drug	6.5	.	Clonidine inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 6.5 microM)	N-methylpyridinium	Human embryonic kidney 293 cells (HEK293)-OCT1
DTD0024	SLC22A6	Inhibition	Cyclopiazonic acid	Natural Product	6.59	.	Cyclopiazonic acid inhibits the transportation of Organic anion by SLC22A6 (IC50 = 6.59 microM)	Organic anion	The Proximal Tubule (S2) Cells-OAT1
DTD0024	SLC22A6	Inhibition	Cyclopiazonic acid	Mycotoxins	6.59	.	Cyclopiazonic acid inhibits the transportation of Organic anion by SLC22A6 (IC50 = 6.59 microM)	Organic anion	The Proximal Tubule (S2) Cells-OAT1
DTD0025	SLC22A8	Inhibition	Citreoverdine	Natural Product	6.63	.	Citreoverdine inhibits the transportation of Organic anion by SLC22A8 (IC50 = 6.63 microM)	Organic anion	The Proximal Tubule (S2) Cells-OAT3
DTD0025	SLC22A8	Inhibition	Citrioveridine	Mycotoxins	6.63	.	Citrioveridine inhibits the transportation of Organic anion by SLC22A8 (IC50 = 6.63 microM)	Organic anion	The Proximal Tubule (S2) Cells-OAT3
DTD0010	SLC22A1	Inhibition	Citreoverdine	Natural Product	6.63	.	Citreoverdine inhibits the transportation of Organic cation by SLC22A1 (IC50 = 6.63 microM)	Organic cation	The Proximal Tubule (S2) Cells-OCT1
DTD0010	SLC22A1	Inhibition	Citrioveridine	Mycotoxins	6.63	.	Citrioveridine inhibits the transportation of Organic cation by SLC22A1 (IC50 = 6.63 microM)	Organic cation	The Proximal Tubule (S2) Cells-OCT1
DTD0010	SLC22A1	Inhibition	Quinine	Approved Drug	6.7	.	Quinine inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 6.7 microM)	N-methylpyridinium	Oocytes-OCT1
DTD0009	SLC22A3	Inhibition	Famotidine	Approved Drug	6.7	.	Famotidine inhibits the transportation of N-methylpyridinium by SLC22A3 (IC50 = 6.7 microM)	N-methylpyridinium	Oocytes-OCT3
DTD0025	SLC22A8	Inhibition	Zearalenone	Mycotoxins	6.71	.	Zearalenone inhibits the transportation of Organic anion by SLC22A8 (IC50 = 6.71 microM)	Organic anion	The Proximal Tubule (S2) Cells-OAT3
DTD0030	SLCO1B3	Inhibition	Lithocholic Acid	Investigative Drug	6.8	.	Lithocholate inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B3 (IC50 = 6.8 microM)	Estradiol-17beta-glucuronide	Chinese hamster ovary (CHO) cells-OATP1B3
DTD0003	ABCB1	Inhibition	Atovaquone	Approved Drug	6.8	.	Atovaquone inhibits the transportation of N-methyl quinidine by ABCB1 (IC50 = 6.8 microM)	N-methyl quinidine	Human embryonic kidney 293 cells (HEK293)-MDR1
DTD0025	SLC22A8	Inhibition	Gemfibrozil	Approved Drug	6.8	.	Gemfibrozil inhibits the transportation of Pravastatin by SLC22A8 (IC50 = 6.8 microM)	Pravastatin	The Proximal Tubule (S2) Cells-OAT3
DTD0006	SLC22A2	Inhibition	Fenamiphos	Natural Product	6.9	.	Fenamiphos inhibits the transportation of Rhodamine 123 by SLC22A2 (IC50 = 6.9 microM)	Rhodamine 123	Human embryonic kidney 293 cells (HEK293)-OCT2
DTD0010	SLC22A1	Inhibition	Amitriptyline	Approved Drug	6.99	.	Amitriptyline inhibits the transportation of Metformin by SLC22A1 (IC50 = 6.99 microM)	Metformin	Human embryonic kidney 293 cells (HEK293)-OCT1
DTD0001	ABCC1	Inhibition	Indomethacin	Approved Drug	7	.	Indomethacin inhibits the transportation of 2',7'-Bis-(3-carboxy-propyl)-5-(and-6)-carboxyfluorescein (BCPCF) by ABCC1 (IC50 = 7 microM)	2',7'-Bis-(3-carboxy-propyl)-5-(and-6)-carboxyfluorescein (BCPCF)	Human erythrocytes-MRP1
DTD0004	ABCG2	Inhibition	Anidulafungin	Approved Drug	7	.	Anidulafungin inhibits the transportation of Fluorescent protein by ABCG2 (IC50 = 7 microM)	Fluorescent protein	Human embryonic kidney 293 cells (HEK293)-BCRP
DTD0004	ABCG2	Inhibition	Permethrin	Approved Drug	7	.	Permethrin inhibits the transportation of Sulfasalazine by ABCG2 (IC50 = 7 microM)	Sulfasalazine	Spodoptera frugiperda (Sf9) cells-BCRP
DTD0010	SLC22A1	Inhibition	Phosmet	Natural Product	7.1	.	Phosmet inhibits the transportation of Dopamine by SLC22A1 (IC50 = 7.1 microM)	Dopamine	Human embryonic kidney 293 cells (HEK293)-OCT1
DTD0003	ABCB1	Inhibition	Tamoxifen	Approved Drug	7.1	.	Tamoxifen inhibits the transportation of Rhodamine 123 by ABCB1 (IC50 = 7.1 microM)	Rhodamine 123	NIH-3T3-G185-MDR1
DTD0010	SLC22A1	Inhibition	Quinine	Approved Drug	7.11	.	Quinine inhibits the transportation of YM155 by SLC22A1 (IC50 = 7.11 microM)	YM155	Human embryonic kidney 293 cells (HEK293)-OCT1
DTD0008	SLCO1B1	Inhibition	Cigarette smoke condensate	Natural Product	7.2	.	Cigarette smoke condensate inhibits the activity of SLCO1B1 (IC50 = 7.2 microM)	.	Human embryonic kidney 293 cells (HEK293)-OATP1B1
DTD0003	ABCB1	Inhibition	Trifluoperazine	Approved Drug	7.2	.	Trifluoperazine inhibits the transportation of Daunorubicin by ABCB1 (IC50 = 7.2 microM)	Daunorubicin	NIH-3T3-G185-MDR1
DTD0008	SLCO1B1	Inhibition	Cigarette smoke condensate	Natural Product	7.2	.	Cigarette smoke condensate inhibits the transportation of Estrone sulfate by by repressing mRNA expression of SLCO1B1 (IC50 = 7.2 microM)	Estrone sulfate	Human hepatoma HepaRG cells-OATP1B1
DTD0019	SLC10A1	Inhibition	Bromsulphthalein	Investigative Drug	7.3	.	Bromsulphthalein inhibits the transportation of Sodium taurocholate by SLC10A1 (IC50 = 7.3 microM)	Sodium taurocholate	Human cervical cancer cell line (Hela)-NTCP
DTD0025	SLC22A8	Inhibition	Furosemide	Approved Drug	7.31	.	Furosemide inhibits the transportation of Estrone sulfate by SLC22A8 (IC50 = 7.31 microM)	Estrone sulfate	The Proximal Tubule (S2) Cells-OAT3
DTD0024	SLC22A6	Inhibition	Probenecid	Approved Drug	7.4	.	Probenecid inhibits the transportation of Adefovir by SLC22A6 (IC50 = 7.4 microM)	Adefovir	Chinese hamster ovary (CHO) cells-OAT1
DTD0010	SLC22A1	Inhibition	Antiparasitics	Discontinued Drug	7.4	.	Antiparasitics inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 7.4 microM)	N-methylpyridinium	Chinese hamster ovary (CHO) cells-OCT1
DTD0014	ABCB11	Inhibition	Cyclosporine	Approved Drug	7.5	.	Cyclosporine inhibits the transportation of Bodipy by ABCB11 (IC50 = 7.5 microM)	Bodipy	.
DTD0014	ABCB11	Inhibition	Cyanidin	Natural Product	7.6	.	Cyanidin inhibits the activity of ABCB11 (IC50 = 7.6 microM)	.	Human breast adenocarcinoma cell line (MCF-7)-BSEP
DTD0030	SLCO1B3	Inhibition	Cigarette smoke condensate	Natural Product	7.6	.	Cigarette smoke condensate inhibits the activity of SLCO1B3 (IC50 = 7.6 microM)	.	Human embryonic kidney 293 cells (HEK293)-OATP1B3
DTD0024	SLC22A6	Inhibition	Bumetanide	Approved Drug	7.6	.	Bumetanide inhibits the transportation of Aminohippuric acid by SLC22A6 (IC50 = 7.6 microM)	Aminohippuric acid	The Proximal Tubule (S2) Cells-OAT1
DTD0030	SLCO1B3	Inhibition	Cigarette smoke condensate	Natural Product	7.6	.	Cigarette smoke condensate inhibits the transportation of Cholecystokinin octapeptide sulphated by SLCO1B3 (IC50 = 7.6 microM)	Cholecystokinin octapeptide sulphated	Human hepatoma HepaRG cells-OATP1B3
DTD0004	ABCG2	Inhibition	Lopinavir	Approved Drug	7.66	.	Lopinavir inhibits the transportation of Pheophorbide A by ABCG2 (IC50 = 7.66 microM)	Pheophorbide A	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
DTD0455	SLC6A3	Inhibition	4-Fluoromethamphetamine	Approved Drug	7.7	.	4-Fluoromethamphetamine inhibits the transportation of Serotonin by SLC6A3 (IC50 = 7.7 microM)	Serotonin	Human embryonic kidney 293 cells (HEK293)-DAT1
DTD0025	SLC22A8	Inhibition	Diclofenac	Approved Drug	7.78	.	Diclofenac inhibits the transportation of Estrone sulfate by SLC22A8 (IC50 = 7.78 microM)	Estrone sulfate	The Proximal Tubule (S2) Cells-OAT3
DTD0004	ABCG2	Inhibition	Berry anthocyanins	Natural Product	7.8	.	Berry anthocyanins inhibits the activity of ABCG2 (IC50 = 7.8 microM)	.	Human breast adenocarcinoma cell line (MCF-7)-BCRP
DTD0014	ABCB11	Inhibition	Cyclosporine	Approved Drug	7.8	.	Cyclosporine inhibits the transportation of Dihydrofluorescein by ABCB11 (IC50 = 7.8 microM)	Dihydrofluorescein	.
DTD0025	SLC22A8	Inhibition	Bumetanide	Approved Drug	7.8	.	Bumetanide inhibits the transportation of Estrone sulfate by SLC22A8 (IC50 = 7.8 microM)	Estrone sulfate	Oocytes-OAT3
DTD0003	ABCB1	Inhibition	o,p'-dichlorodiphenyltrichloroethane (DDT)	Environmental toxicant	7.8	.	O,p'-DDT inhibits the transportation of Verapamil by ABCB1 (IC50 = 7.8 microM)	Verapamil	Spodoptera frugiperda (Sf9) cells-MDR1
DTD0008	SLCO1B1	Inhibition	Digoxin	Approved Drug	7.9	7	Digoxin inhibits the transportation of Cholyl-glycylamido-fluorescein by SLCO1B1 (IC50 = 7.9 microM; Ki = 7 microM)	Cholyl-glycylamido-fluorescein	Chinese hamster ovary (CHO) cells-OATP1B1
DTD0006	SLC22A2	Inhibition	Phosmet	Natural Product	7.9	.	Phosmet inhibits the transportation of Rhodamine 123 by SLC22A2 (IC50 = 7.9 microM)	Rhodamine 123	Human embryonic kidney 293 cells (HEK293)-OCT2
DTD0008	SLCO1B1	Inhibition	Epigallocatechin gallate	Natural Product	8	.	(-)-epigallocatechin-3-gallate inhibits the activity of SLCO1B1 in a substrate-dependent manner (IC50 = 8 microM)	.	Chinese hamster ovary (CHO) cells-OATP1B1
DTD0024	SLC22A6	Inhibition	Ibuprofen	Approved Drug	8	.	Ibuprofen inhibits the transportation of Adefovir by SLC22A6 (IC50 = 8 microM)	Adefovir	Chinese hamster ovary (CHO) cells-OAT1
DTD0031	SLCO2B1	Inhibition	Gemfibrozil	Approved Drug	8	.	Gemfibrozil inhibits the transportation of Rosuvastatin by SLCO2B1 (IC50 = 8 microM)	Rosuvastatin	Human cervical cancer cell line (Hela)-OATP2B1
DTD0010	SLC22A1	Inhibition	Saquinavir	Approved Drug	8.26	.	Saquinavir inhibits the transportation of Tetraethylammonium by SLC22A1 (IC50 = 8.26 microM)	Tetraethylammonium	Human cervical cancer cell line (Hela)-OCT1
DTD0014	ABCB11	Inhibition	Cyclosporine	Approved Drug	8.4	.	Cyclosporine inhibits the transportation of Sodium taurocholate by ABCB11 (IC50 = 8.4 microM)	Sodium taurocholate	Spodoptera frugiperda (Sf9) cells-BSEP
DTD0003	ABCB1	Inhibition	Verapamil	Approved Drug	8.44	.	Verapamil inhibits the transportation of Fexofenadine by ABCB1 (IC50 = 8.44 microM)	Fexofenadine	Human enterocyte-like 2 cell (Caco-2)-MDR1
DTD0503	SLCO4C1	Inhibition	Ritonavir	Approved Drug	8.5	.	Ritonavir inhibits the activity of SLCO4C1 (IC50 = 8.5 microM)	.	.
DTD0008	SLCO1B1	Inhibition	Silybin B	Natural Product	8.5	.	Silybin B inhibits the transportation of Estradiol-17-glucuronide by SLCO1B1 (IC50 = 8.5 microM)	Estradiol-17-glucuronide	Human embryonic kidney 293 cells (HEK293)-OATP1B1
DTD0456	SLC6A4	Inhibition	4-Fluoromethamphetamine	Approved Drug	8.7	.	4-Fluoromethamphetamine inhibits the transportation of Dopamine by SLC6A4 (IC50 = 8.7 microM)	Dopamine	Human embryonic kidney 293 cells (HEK293)-SERT
DTD0006	SLC22A2	Inhibition	Quinine	Approved Drug	8.7	.	Quinine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 8.7 microM)	N-methylpyridinium	Oocytes-OCT2
DTD0026	SLC22A11	Inhibition	Ethacrynic Acid	Approved Drug	8.76	.	Ethacrynic acid inhibits the transportation of Estrone sulfate by SLC22A11 (IC50 = 8.76 microM)	Estrone sulfate	The Proximal Tubule (S2) Cells-OAT4
DTD0024	SLC22A6	Inhibition	Aminohippuric acid	Investigative Drug	8.8	.	Aminohippuric acid inhibits the transportation of 6-Carboxyfluorescein by SLC22A6 (IC50 = 8.8 microM)	6-Carboxyfluorescein	Chinese hamster ovary (CHO) cells-OAT1
DTD0004	ABCG2	Inhibition	Isoflavones	Natural Product	8.8	.	Isoflavones inhibits the transportation of Mitoxantrone by ABCG2 in a non-competitive manner (IC50 = 8.8 microM)	Mitoxantrone	Human breast adenocarcinoma cell line (MCF-7)-BCRP
DTD0010	SLC22A1	Inhibition	Corticosterone	Investigative Drug	8.89	.	Corticosterone inhibits the transportation of YM155 by SLC22A1 (IC50 = 8.89 microM)	YM155	Human embryonic kidney 293 cells (HEK293)-OCT1
DTD0385	SLC4A4	Inhibition	N-cyanosulphonamide S0859	Investigative Drug	9	.	The synthetic compound N-cyanosulphonamide S0859 inhibits the activity of SLC4A4 (IC50 = 9 microM)	.	Xenopus laevis oocytes-NBCe1
DTD0008	SLCO1B1	Inhibition	Clotrimazole	Approved Drug	9	.	Clotrimazole inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (IC50 = 9 microM)	Estradiol-17beta-glucuronide	Chinese hamster ovary (CHO) cells-OATP1B1
DTD0008	SLCO1B1	Inhibition	Silychristin	Natural Product	9	.	Silychristin inhibits the transportation of Estradiol-17-glucuronide by SLCO1B1 (IC50 = 9 microM)	Estradiol-17-glucuronide	Human embryonic kidney 293 cells (HEK293)-OATP1B1
DTD0025	SLC22A8	Inhibition	Gallic Acid	Natural Product	9	.	Gallic acid inhibits the transportation of Estrone sulfate by SLC22A8 (IC50 = 9 microM)	Estrone sulfate	Human embryonic kidney 293 cells (HEK293)-OAT3
DTD0010	SLC22A1	Inhibition	Fenamiphos	Natural Product	9.2	.	Fenamiphos inhibits the transportation of Dopamine by SLC22A1 (IC50 = 9.2 microM)	Dopamine	Human embryonic kidney 293 cells (HEK293)-OCT1
DTD0029	SLCO1A2	Inhibition	Apigenin	Investigative Drug	9.3	22	Apigenin inhibits the transportation of Atorvastatin by SLCO1A2 (IC50 = 9.3 microM; Ki = 22 microM)	Atorvastatin	Human embryonic kidney 293 cells (HEK293)-OATP1A2
DTD0003	ABCB1	Inhibition	Quinine	Approved Drug	9.4	.	Quinine inhibits the transportation of Digoxin by ABCB1 (IC50 = 9.4 microM)	Digoxin	Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DTD0031	SLCO2B1	Inhibition	Quercetin	Approved Drug	9.47	.	Quercetin inhibits the transportation of Estrone sulfate by SLCO2B1 (IC50 = 9.47 microM)	Estrone sulfate	Xenopus laevis oocytes-OATP2B1
DTD0014	ABCB11	Inhibition	Troglitazone	Approved Drug	9.5	.	Troglitazone inhibits the transportation of Sodium taurocholate by ABCB11 (IC50 = 9.5 microM)	Sodium taurocholate	Spodoptera frugiperda (Sf9) cells-BSEP
DTD0003	ABCB1	Inhibition	Quinine	Approved Drug	9.52	.	Quinine inhibits the transportation of Digoxin by ABCB1 (IC50 = 9.52 microM)	Digoxin	LLC-PK1 vesicles-MDR1
DTD0456	SLC6A4	Inhibition	Methylenedioxypyrovalerone (MDPV)	Investigative Drug	9.6	.	Methylenedioxypyrovalerone (MDPV) inhibits the transportation of Dopamine by SLC6A4 (IC50 = 9.6 microM)	Dopamine	Human embryonic kidney 293 cells (HEK293)-SERT
DTD0008	SLCO1B1	Inhibition	Silybin A	Natural Product	9.7	.	Silybin A inhibits the transportation of Estradiol-17-glucuronide by SLCO1B1 (IC50 = 9.7 microM)	Estradiol-17-glucuronide	Human embryonic kidney 293 cells (HEK293)-OATP1B1
DTD0029	SLCO1A2	Inhibition	Epicatechin gallate	Natural Product	10	.	(-)-epicatechin-3-gallate inhibits the activity of SLCO1A2 in a substrate-dependent manner (IC50 = 10 microM)	.	Human embryonic kidney 293 cells (HEK293)-OATP1A2
DTD0015	ABCC4	Inhibition	MK-571	Discontinued Drug	10	.	MK-571 inhibits the transportation of 9-(2-Phosphonomethoxyethyl)adenine by ABCC4 (IC50 = 10 microM)	9-(2-Phosphonomethoxyethyl)adenine	Human embryonic kidney 293 cells (HEK293)-MRP4
DTD0015	ABCC4	Inhibition	Trequinsin	Discontinued Drug	10	.	Trequinsin inhibits the transportation of 9-(2-Phosphonomethoxyethyl)adenine by ABCC4 (IC50 = 10 microM)	9-(2-Phosphonomethoxyethyl)adenine	Human embryonic kidney 293 cells (HEK293)-MRP4
DTD0030	SLCO1B3	Inhibition	Sincalide	Investigative Drug	10	.	Sincalide inhibits the transportation of Amantinin by SLCO1B3 (IC50 = 10 microM)	Amantinin	Madin Darby canine kidney strain II (MDCKII) cells-OATP1B3
DTD0008	SLCO1B1	Inhibition	Montelukast	Approved Drug	10	.	Montelukast inhibits the transportation of Bromsulphthalein by SLCO1B1 (IC50 = 10 microM)	Bromsulphthalein	Madin Darby canine kidney strain II (MDCKII) cells-OATP1B1
DTD0002	ABCC2	Inhibition	Cyclosporine	Approved Drug	10	.	Cyclosporine inhibits the transportation of Calcein AM by ABCC2 (IC50 = 10 microM)	Calcein AM	Madin Darby canine kidney strain II (MDCKII) cells-MRP2
DTD0003	ABCB1	Inhibition	Erythromycin	Approved Drug	10	.	Erythromycin inhibits the transportation of Digoxin by ABCB1 (IC50 = 10 microM)	Digoxin	Human enterocyte-like 2 cell (Caco-2)-MDR1
DTD0008	SLCO1B1	Inhibition	Silibinin dihemisuccinate	Natural Product	10	.	Silibinin dihemisuccinate inhibits the transportation of H-dehydroepiandrosterone sulfate by SLCO1B1 (IC50 = 10 microM)	H-dehydroepiandrosterone sulfate	Madin Darby canine kidney strain II (MDCKII) cells-OATP1B1
DTD0004	ABCG2	Inhibition	Pantoprazole	Approved Drug	10	.	Pantoprazole inhibits the transportation of Methotrexate by ABCG2 (IC50 = 10 microM)	Methotrexate	Spodoptera frugiperda (Sf9) cells-BCRP
DTD0006	SLC22A2	Inhibition	Fenfluramine	Drug Withdrawn	10	.	Fenfluramine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 10 microM)	N-methylpyridinium	Human embryonic kidney 293 cells (HEK293)-OCT2
DTD0026	SLC22A11	Inhibition	Indomethacin	Approved Drug	10.1	.	Indomethacin inhibits the transportation of Estrone sulfate by SLC22A11 (IC50 = 10.1 microM)	Estrone sulfate	The Proximal Tubule (S2) Cells-OAT4
DTD0010	SLC22A1	Inhibition	Phosmet	Natural Product	10.4	.	Phosmet inhibits the transportation of 4',6'-diamidino-2-phenylindole by SLC22A1 (IC50 = 10.4 microM)	4',6'-diamidino-2-phenylindole	Human embryonic kidney 293 cells (HEK293)-OCT1
DTD0003	ABCB1	Inhibition	Fluphenazine	Approved Drug	10.4	.	Fluphenazine inhibits the transportation of Rhodamine 123 by ABCB1 (IC50 = 10.4 microM)	Rhodamine 123	NIH-3T3-G185-MDR1
DTD0004	ABCG2	Inhibition	o,p'-dichlorodiphenyltrichloroethane (DDT)	Environmental toxicant	10.4	.	O,p'-DDT inhibits the transportation of Sulfasalazine by ABCG2 (IC50 = 10.4 microM)	Sulfasalazine	Spodoptera frugiperda (Sf9) cells-BCRP
DTD0014	ABCB11	Inhibition	Rifampicin	Approved Drug	10.5	.	Rifampicin inhibits the transportation of Sodium taurocholate by ABCB11 (IC50 = 10.5 microM)	Sodium taurocholate	Spodoptera frugiperda (Sf9) cells-BSEP
DTD0006	SLC22A2	Inhibition	Pentamidine	Approved Drug	10.6	.	Pentamidine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 10.6 microM)	N-methylpyridinium	Chinese hamster ovary (CHO) cells-OCT2
DTD0003	ABCB1	Inhibition	Verapamil	Approved Drug	10.7	.	Verapamil inhibits the transportation of Digoxin by ABCB1 (IC50 = 10.7 microM)	Digoxin	Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DTD0003	ABCB1	Inhibition	p,p'-tetrachlorodiphenylethane (DDD)	Environmental toxicant	10.7	.	p,p'-DDD inhibits the transportation of Verapamil by ABCB1 (IC50 = 10.7 microM)	Verapamil	Spodoptera frugiperda (Sf9) cells-MDR1
DTD0003	ABCB1	Inhibition	Trifluoperazine	Approved Drug	10.9	.	Trifluoperazine inhibits the transportation of Rhodamine 123 by ABCB1 (IC50 = 10.9 microM)	Rhodamine 123	NIH-3T3-G185-MDR1
DTD0025	SLC22A8	Inhibition	Indapamide	Approved Drug	11	.	Indapamide inhibits the transportation of Sitagliptin by SLC22A8 (IC50 = 11 microM)	Sitagliptin	Chinese hamster ovary (CHO) cells-OAT3
DTD0015	ABCC4	Inhibition	Telmisartan	Approved Drug	11	.	Telmisartan inhibits the transportation of Uric acid by ABCC4 (IC50 = 11 microM)	Uric acid	Spodoptera frugiperda (Sf9) cells-MRP4
DTD0006	SLC22A2	Inhibition	Quinine	Approved Drug	11	.	Quinine inhibits the transportation of YM155 by SLC22A2 (IC50 = 11 microM)	YM155	Human embryonic kidney 293 cells (HEK293)-OCT2
DTD0031	SLCO2B1	Inhibition	Ginkgo leaf extract	Natural Product	11.2	.	Ginkgo leaf extract inhibits the transportation of Estrone sulfate by SLCO2B1 (IC50 = 11.2 microM)	Estrone sulfate	Human embryonic kidney 293 cells (HEK293)-OATP2B1
DTD0006	SLC22A2	Inhibition	Tetramethrin	Natural Product	11.2	.	Tetramethrin inhibits the transportation of Verapamil by SLC22A2 (IC50 = 11.2 microM)	Verapamil	Human embryonic kidney 293 cells (HEK293)-OCT2
DTD0008	SLCO1B1	Inhibition	Biochanin A	Natural Product	11.3	10.2	Biochanin A inhibits the transportation of H-dehydroepiandrosterone sulfate by SLCO1B1 (IC50 = 11.3 microM; Ki = 10.2 microM)	H-dehydroepiandrosterone sulfate	Human cervical cancer cell line (Hela)-OATP1B1
DTD0014	ABCB11	Inhibition	Glyburide	Approved Drug	11.3	.	Glibenclamide inhibits the transportation of Sodium taurocholate by ABCB11 (IC50 = 11.3 microM)	Sodium taurocholate	Spodoptera frugiperda (Sf9) cells-BSEP
DTD0003	ABCB1	Inhibition	Loratadine	Approved Drug	11.4	.	Loratadine inhibits the transportation of Daunorubicin by ABCB1 (IC50 = 11.4 microM)	Daunorubicin	.
DTD0015	ABCC4	Inhibition	Ketoprofen	Approved Drug	11.9	.	Ketoprofen inhibits the transportation of Methotrexate by ABCC4 (IC50 = 11.9 microM)	Methotrexate	Human embryonic kidney 293 cells (HEK293)-MRP4
DTD0024	SLC22A6	Inhibition	Losartan	Approved Drug	12	.	Losartan inhibits the transportation of Uric acid by SLC22A6 (IC50 = 12 microM)	Uric acid	Human embryonic kidney 293 cells (HEK293)-OAT1
DTD0004	ABCG2	Inhibition	Rimsulfuron	Natural Product	12	.	Rimsulfuron inhibits the transportation of WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) by ABCG2 (IC50 = 12 microM)	WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate)	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
DTD0008	SLCO1B1	Inhibition	Indinavir	Approved Drug	12.2	10.8	Indinavir inhibits the transportation of Cholyl-glycylamido-fluorescein by SLCO1B1 (IC50 = 12.2 microM; Ki = 10.8 microM)	Cholyl-glycylamido-fluorescein	Chinese hamster ovary (CHO) cells-OATP1B1
DTD0030	SLCO1B3	Inhibition	Indinavir	Approved Drug	12.3	8.5	Indinavir inhibits the transportation of Cholyl-glycylamido-fluorescein by SLCO1B3 (IC50 = 12.3 microM; Ki = 8.5 microM)	Cholyl-glycylamido-fluorescein	Chinese hamster ovary (CHO) cells-OATP1B3
DTD0024	SLC22A6	Inhibition	Aflatoxin B1	Mycotoxins	12.3	.	Aflatoxin B1 inhibits the transportation of Organic anion by SLC22A6 (IC50 = 12.3 microM)	Organic anion	The Proximal Tubule (S2) Cells-OAT1
DTD0006	SLC22A2	Inhibition	Cigarette smoke condensate	Natural Product	12.5	.	Cigarette smoke condensate inhibits the activity of SLC22A2 (IC50 = 12.5 microM)	.	Human embryonic kidney 293 cells (HEK293)-OCT2
DTD0010	SLC22A1	Inhibition	Cigarette smoke condensate	Natural Product	12.5	.	Cigarette smoke condensate inhibits the transportation of Verapamil by SLC22A1 (IC50 = 12.5 microM)	Verapamil	Human hepatoma HepaRG cells-OCT1
DTD0009	SLC22A3	Inhibition	Prazosin	Approved Drug	12.6	.	Prazosin inhibits the transportation of N-methylpyridinium by SLC22A3 (IC50 = 12.6 microM)	N-methylpyridinium	Human embryonic kidney 293 cells (HEK293)-OCT3
DTD0030	SLCO1B3	Inhibition	Estradiol	Approved Drug	12.9	.	Estradiol inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B3 (IC50 = 12.9 microM)	Estradiol-17beta-glucuronide	Chinese hamster ovary (CHO) cells-OATP1B3
DTD0010	SLC22A1	Inhibition	Quinine	Approved Drug	13	.	Quinine inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 13 microM)	N-methylpyridinium	Human embryonic kidney 293 cells (HEK293)-OCT1
DTD0006	SLC22A2	Inhibition	Doxepin	Approved Drug	13	.	Doxepin inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 13 microM)	N-methylpyridinium	Human embryonic kidney 293 cells (HEK293)-OCT2
DTD0004	ABCG2	Inhibition	Diflufenican	Natural Product	13	.	Diflufenican inhibits the transportation of WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) by ABCG2 (IC50 = 13 microM)	WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate)	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
DTD0025	SLC22A8	Inhibition	Aflatoxin B1	Mycotoxins	13.1	.	Aflatoxin B1 inhibits the transportation of Organic anion by SLC22A8 (IC50 = 13.1 microM)	Organic anion	The Proximal Tubule (S2) Cells-OAT3
DTD0006	SLC22A2	Inhibition	Quinine	Approved Drug	13.3	.	Quinine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 13.3 microM)	N-methylpyridinium	Chinese hamster ovary (CHO) cells-OCT2
DTD0006	SLC22A2	Inhibition	Verapamil	Approved Drug	13.4	.	Verapamil inhibits the transportation of YM155 by SLC22A2 (IC50 = 13.4 microM)	YM155	Human embryonic kidney 293 cells (HEK293)-OCT2
DTD0029	SLCO1A2	Inhibition	Quercetin	Approved Drug	13.5	32.4	Quercetin inhibits the transportation of Atorvastatin by SLCO1A2 (IC50 = 13.5 microM; Ki = 32.4 microM)	Atorvastatin	Human embryonic kidney 293 cells (HEK293)-OATP1A2
DTD0004	ABCG2	Inhibition	Nelfinavir	Approved Drug	13.5	.	Nelfinavir inhibits the transportation of Pheophorbide A by ABCG2 (IC50 = 13.5 microM)	Pheophorbide A	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
DTD0025	SLC22A8	Inhibition	Pravastatin	Approved Drug	13.7	.	Pravastatin inhibits the transportation of Estrone sulfate by SLC22A8 (IC50 = 13.7 microM)	Estrone sulfate	The Proximal Tubule (S2) Cells-OAT3
DTD0006	SLC22A2	Inhibition	Decynium 22	Investigative Drug	13.8	.	Decynium 22 inhibits the transportation of Tetraethylammonium by SLC22A2 (IC50 = 13.8 microM)	Tetraethylammonium	Oocytes-OCT2
DTD0031	SLCO2B1	Inhibition	Apigenin	Investigative Drug	13.9	8.7	Apigenin inhibits the transportation of Atorvastatin by SLCO2B1 (IC50 = 13.9 microM; Ki = 8.7 microM)	Atorvastatin	Human embryonic kidney 293 cells (HEK293)-OATP2B1
DTD0007	SLC47A1	Inhibition	Ritonavir	Approved Drug	13.9	.	Ritonavir inhibits the transportation of Tetraethylammonium by SLC47A1 (IC50 = 13.9 microM)	Tetraethylammonium	Human cervical cancer cell line (Hela)-MATE1
DTD0010	SLC22A1	Inhibition	Ritonavir	Approved Drug	14	.	Ritonavir inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 14 microM)	N-methylpyridinium	Human embryonic kidney 293 cells (HEK293)-OCT1
DTD0006	SLC22A2	Inhibition	Amitriptyline	Approved Drug	14	.	Amitriptyline inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 14 microM)	N-methylpyridinium	Human embryonic kidney 293 cells (HEK293)-OCT2
DTD0006	SLC22A2	Inhibition	Chlorpromazine	Approved Drug	14	.	Chlorpromazine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 14 microM)	N-methylpyridinium	Human embryonic kidney 293 cells (HEK293)-OCT2
DTD0031	SLCO2B1	Inhibition	Quercetin	Approved Drug	14.1	20.8	Quercetin inhibits the transportation of Atorvastatin by SLCO2B1 (IC50 = 14.1 microM; Ki = 20.8 microM)	Atorvastatin	Human embryonic kidney 293 cells (HEK293)-OATP2B1
DTD0005	SLC22A7	Inhibition	Diclofenac	Approved Drug	14.3	.	Diclofenac inhibits the transportation of Prostaglandin F2alpha by SLC22A7 (IC50 = 14.3 microM)	Prostaglandin F2alpha	The Proximal Tubule (S2) Cells-OAT2
DTD0008	SLCO1B1	Inhibition	Amprenavir	Approved Drug	14.4	12.8	Amprenavir inhibits the transportation of Cholyl-glycylamido-fluorescein by SLCO1B1 (IC50 = 14.4 microM; Ki = 12.8 microM)	Cholyl-glycylamido-fluorescein	Chinese hamster ovary (CHO) cells-OATP1B1
DTD0014	ABCB11	Inhibition	Glyburide	Approved Drug	14.7	.	Glibenclamide inhibits the transportation of Sodium taurocholate by ABCB11 (IC50 = 14.7 microM)	Sodium taurocholate	Spodoptera frugiperda (Sf9) cells-BSEP
DTD0009	SLC22A3	Inhibition	Pentamidine	Approved Drug	14.8	.	Pentamidine inhibits the transportation of N-methylpyridinium by SLC22A3 (IC50 = 14.8 microM)	N-methylpyridinium	Chinese hamster ovary (CHO) cells-OCT3
DTD0003	ABCB1	Inhibition	Quinine	Approved Drug	14.9	.	Quinine inhibits the transportation of Digoxin by ABCB1 (IC50 = 14.9 microM)	Digoxin	Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DTD0016	ABCC5	Inhibition	Glyburide	Approved Drug	15	.	Glibenclamide inhibits the transportation of 5-Fluorodeoxyuridine monophosphate by ABCC5 (IC50 = 15 microM)	5-Fluorodeoxyuridine monophosphate	Human embryonic kidney 293 cells (HEK293)-MRP5
DTD0030	SLCO1B3	Inhibition	Montelukast	Approved Drug	15	.	Montelukast inhibits the transportation of Amantinin by SLCO1B3 (IC50 = 15 microM)	Amantinin	Madin Darby canine kidney strain II (MDCKII) cells-OATP1B3
DTD0456	SLC6A4	Inhibition	3',4'-Methylenedioxy-alpha-pyrrolidinobutyrophenone (MDPBP)	Investigative Drug	15	.	3',4'-Methylenedioxy-alpha-pyrrolidinobutyrophenone (MDPBP) inhibits the transportation of Dopamine by SLC6A4 (IC50 = 15 microM)	Dopamine	Human embryonic kidney 293 cells (HEK293)-SERT
DTD0001	ABCC1	Inhibition	Curcumin	Drug in Phase 3 Trial	15	.	Curcumin inhibits the transportation of Ethacrynic acid glutathione by ABCC1 (IC50 = 15 microM)	Ethacrynic acid glutathione	Spodoptera frugiperda (Sf9) cells-MRP1
DTD0006	SLC22A2	Inhibition	Diphenhydramine	Approved Drug	15	.	Diphenhydramine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 15 microM)	N-methylpyridinium	Human embryonic kidney 293 cells (HEK293)-OCT2
DTD0019	SLC10A1	Inhibition	Furosemide	Approved Drug	15	.	Furosemide inhibits the transportation of Sodium taurocholate by SLC10A1 (IC50 = 15 microM)	Sodium taurocholate	Human cervical cancer cell line (Hela)-NTCP
DTD0003	ABCB1	Inhibition	Roxithromycin	Drug Withdrawn	15.4	.	Roxithromycin inhibits the transportation of Digoxin by ABCB1 (IC50 = 15.4 microM)	Digoxin	Human enterocyte-like 2 cell (Caco-2)-MDR1
DTD0003	ABCB1	Inhibition	St Johns wort extract	Natural Product	15.4	.	St Johns wort extract inhibits the transportation of Digoxin by ABCB1 (IC50 = 15.4 microM)	Digoxin	Human enterocyte-like 2 cell (Caco-2)-MDR1
DTD0007	SLC47A1	Inhibition	Ritonavir	Approved Drug	15.4	.	Ritonavir inhibits the transportation of Metformin by SLC47A1 (IC50 = 15.4 microM)	Metformin	Human cervical cancer cell line (Hela)-MATE1
DTD0003	ABCB1	Inhibition	Piperine	Natural Product	15.5	.	Piperine inhibits the transportation of Digoxin by ABCB1 (IC50 = 15.5 microM)	Digoxin	Human enterocyte-like 2 cell (Caco-2)-MDR1
DTD0030	SLCO1B3	Inhibition	Troglitazone	Approved Drug	15.7	.	Troglitazone inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B3 (IC50 = 15.7 microM)	Estradiol-17beta-glucuronide	Chinese hamster ovary (CHO) cells-OATP1B3
DTD0014	ABCB11	Inhibition	Glyburide	Approved Drug	15.8	.	Glibenclamide inhibits the transportation of Taurochenodeoxycholate by ABCB11 (IC50 = 15.8 microM)	Taurochenodeoxycholate	Spodoptera frugiperda (Sf9) cells-BSEP
DTD0016	ABCC5	Inhibition	MK-571	Discontinued Drug	15.9	.	MK-571 inhibits the transportation of Carboxydichlorofluorescein by ABCC5 (IC50 = 15.9 microM)	Carboxydichlorofluorescein	Human embryonic kidney 293 cells (HEK293)-MRP5
DTD0006	SLC22A2	Inhibition	YM155	Drug in Phase 2 Trial	15.9	.	YM155 inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 15.9 microM)	N-methylpyridinium	Human embryonic kidney 293 cells (HEK293)-OCT2
DTD0003	ABCB1	Inhibition	Azelastine	Approved Drug	16	.	Azelastine inhibits the transportation of Daunorubicin by ABCB1 (IC50 = 16 microM)	Daunorubicin	LLC-PK1 vesicles-MDR1
DTD0002	ABCC2	Inhibition	Gemifloxacin	Approved Drug	16	.	Gemifloxacin inhibits the transportation of Erythromycin by ABCC2 (IC50 = 16 microM)	Erythromycin	Madin Darby canine kidney strain II (MDCKII) cells-MRP2
DTD0014	ABCB11	Inhibition	Troglitazone	Approved Drug	16	.	Troglitazone inhibits the transportation of Glycocholate by ABCB11 (IC50 = 16 microM)	Glycocholate	Spodoptera frugiperda (Sf9) cells-BSEP
DTD0010	SLC22A1	Inhibition	Butylscopolamine	Approved Drug	16	.	Butylscopolamine inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 16 microM)	N-methylpyridinium	Human embryonic kidney 293 cells (HEK293)-OCT1
DTD0006	SLC22A2	Inhibition	Clonidine	Approved Drug	16	.	Clonidine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 16 microM)	N-methylpyridinium	Human embryonic kidney 293 cells (HEK293)-OCT2
DTD0006	SLC22A2	Inhibition	Desipramine	Approved Drug	16	.	Desipramine inhibits the transportation of Tetraethylammonium by SLC22A2 (IC50 = 16 microM)	Tetraethylammonium	Oocytes-OCT2
DTD0024	SLC22A6	Inhibition	Valsartan	Approved Drug	16	.	Valsartan inhibits the transportation of Uric acid by SLC22A6 (IC50 = 16 microM)	Uric acid	Human embryonic kidney 293 cells (HEK293)-OAT1
DTD0015	ABCC4	Inhibition	Candesartan	Approved Drug	16	.	Candesartan inhibits the transportation of Uric acid by ABCC4 (IC50 = 16 microM)	Uric acid	Spodoptera frugiperda (Sf9) cells-MRP4
DTD0024	SLC22A6	Inhibition	Betamipron	Approved Drug	16.2	.	Betamipron inhibits the transportation of Aminohippuric acid by SLC22A6 (IC50 = 16.2 microM)	Aminohippuric acid	Chinese hamster ovary (CHO) cells-OAT1
DTD0010	SLC22A1	Inhibition	Pentamidine	Approved Drug	16.4	.	Pentamidine inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 16.4 microM)	N-methylpyridinium	Chinese hamster ovary (CHO) cells-OCT1
DTD0004	ABCG2	Inhibition	Soybean extract (1mg/ml)	Natural Product	16.5	.	Soybean extract (1mg/ml) inhibits the activity of ABCG2 (IC50 = 16.5 microM)	.	Mammalian cells expressing human wild-type BCRP
DTD0008	SLCO1B1	Inhibition	Allethrin	Natural Product	16.5	.	Allethrin inhibits the transportation of Fluorescein by SLCO1B1 (IC50 = 16.5 microM)	Fluorescein	Chinese hamster ovary (CHO) cells-OATP1B1
DTD0005	SLC22A7	Inhibition	Cigarette smoke condensate	Natural Product	16.9	.	Cigarette smoke condensate inhibits the activity of SLC22A7 (IC50 = 16.9 microM)	.	Human hepatoma HepaRG cells-OAT2
DTD0024	SLC22A6	Inhibition	Citreoverdine	Natural Product	16.9	.	Citreoverdine inhibits the transportation of Organic anion by SLC22A6 (IC50 = 16.9 microM)	Organic anion	The Proximal Tubule (S2) Cells-OAT1
DTD0024	SLC22A6	Inhibition	Citrioveridine	Mycotoxins	16.9	.	Citrioveridine inhibits the transportation of Organic anion by SLC22A6 (IC50 = 16.9 microM)	Organic anion	The Proximal Tubule (S2) Cells-OAT1
DTD0016	ABCC5	Inhibition	MK-571	Discontinued Drug	17	.	MK-571 inhibits the transportation of 5-Fluorodeoxyuridine monophosphate by ABCC5 (IC50 = 17 microM)	5-Fluorodeoxyuridine monophosphate	Human embryonic kidney 293 cells (HEK293)-MRP5
DTD0024	SLC22A6	Inhibition	Probenecid	Approved Drug	17	.	Probenecid inhibits the transportation of Aminohippuric acid by SLC22A6 (IC50 = 17 microM)	Aminohippuric acid	Oocytes-OAT1
DTD0024	SLC22A6	Inhibition	Probenecid	Approved Drug	17	.	Probenecid inhibits the transportation of Methotrexate by SLC22A6 (IC50 = 17 microM)	Methotrexate	Oocytes-OAT1
DTD0024	SLC22A6	Inhibition	Candesartan	Approved Drug	17	.	Candesartan inhibits the transportation of Uric acid by SLC22A6 (IC50 = 17 microM)	Uric acid	Human embryonic kidney 293 cells (HEK293)-OAT1
DTD0004	ABCG2	Inhibition	Tolclofos-methyl	Natural Product	17	.	Tolclofos-methyl inhibits the transportation of WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) by ABCG2 (IC50 = 17 microM)	WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate)	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
DTD0003	ABCB1	Inhibition	Verapamil	Approved Drug	17.3	.	Verapamil inhibits the transportation of Colchicine by ABCB1 (IC50 = 17.3 microM)	Colchicine	Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DTD0014	ABCB11	Inhibition	Progesterone	Approved Drug	17.3	.	Progesterone inhibits the transportation of Dihydrofluorescein by ABCB11 (IC50 = 17.3 microM)	Dihydrofluorescein	.
DTD0007	SLC47A1	Inhibition	Ranitidine	Approved Drug	17.5	.	Ranitidine inhibits the transportation of Tetraethylammonium by SLC47A1 (IC50 = 17.5 microM)	Tetraethylammonium	Human cervical cancer cell line (Hela)-MATE1
DTD0003	ABCB1	Inhibition	Omeprazole	Approved Drug	17.7	.	Omeprazole inhibits the transportation of Digoxin by ABCB1 (IC50 = 17.7 microM)	Digoxin	Human enterocyte-like 2 cell (Caco-2)-MDR1
DTD0006	SLC22A2	Inhibition	Citreoverdine	Natural Product	17.7	.	Citreoverdine inhibits the transportation of Organic cation by SLC22A2 (IC50 = 17.7 microM)	Organic cation	The Proximal Tubule (S2) Cells-OCT2
DTD0006	SLC22A2	Inhibition	Citrioveridine	Mycotoxins	17.7	.	Citrioveridine inhibits the transportation of Organic cation by SLC22A2 (IC50 = 17.7 microM)	Organic cation	The Proximal Tubule (S2) Cells-OCT2
DTD0003	ABCB1	Inhibition	Vinblastine	Approved Drug	17.8	.	Vinblastine inhibits the transportation of Digoxin by ABCB1 (IC50 = 17.8 microM)	Digoxin	Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DTD0003	ABCB1	Inhibition	Pantoprazole	Approved Drug	17.9	.	Pantoprazole inhibits the transportation of Digoxin by ABCB1 (IC50 = 17.9 microM)	Digoxin	Human enterocyte-like 2 cell (Caco-2)-MDR1
DTD0008	SLCO1B1	Inhibition	Boceprevir	Approved Drug	18	.	Boceprevir inhibits the activity of SLCO1B1 (IC50 = 18 microM)	.	.
DTD0024	SLC22A6	Inhibition	Furosemide	Approved Drug	18	.	Furosemide inhibits the transportation of Aminohippuric acid by SLC22A6 (IC50 = 18 microM)	Aminohippuric acid	The Proximal Tubule (S2) Cells-OAT1
DTD0456	SLC6A4	Inhibition	Methamphetamine	Approved Drug	18	.	Methamphetamine inhibits the transportation of Dopamine by SLC6A4 (IC50 = 18 microM)	Dopamine	Human embryonic kidney 293 cells (HEK293)-SERT
DTD0003	ABCB1	Inhibition	Vinblastine	Approved Drug	18	.	Vinblastine inhibits the transportation of Rhodamine 123 by ABCB1 (IC50 = 18 microM)	Rhodamine 123	NIH-3T3-G185-MDR1
DTD0026	SLC22A11	Inhibition	Losartan	Approved Drug	18	.	Losartan inhibits the transportation of Uric acid by SLC22A11 (IC50 = 18 microM)	Uric acid	Human embryonic kidney 293 cells (HEK293)-OAT4
DTD0009	SLC22A3	Inhibition	Quinine	Approved Drug	18.3	.	Quinine inhibits the transportation of N-methylpyridinium by SLC22A3 (IC50 = 18.3 microM)	N-methylpyridinium	Oocytes-OCT3
DTD0004	ABCG2	Inhibition	Delavirdine	Approved Drug	18.7	.	Delavirdine inhibits the transportation of Pheophorbide A by ABCG2 (IC50 = 18.7 microM)	Pheophorbide A	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
DTD0014	ABCB11	Inhibition	Glyburide	Approved Drug	18.8	.	Glibenclamide inhibits the transportation of Glycocholate by ABCB11 (IC50 = 18.8 microM)	Glycocholate	Spodoptera frugiperda (Sf9) cells-BSEP
DTD0007	SLC47A1	Inhibition	Ranitidine	Approved Drug	18.9	.	Ranitidine inhibits the transportation of Metformin by SLC47A1 (IC50 = 18.9 microM)	Metformin	Human cervical cancer cell line (Hela)-MATE1
DTD0014	ABCB11	Inhibition	Cyclosporine	Approved Drug	18.9	.	Cyclosporine inhibits the transportation of Sodium taurocholate by ABCB11 (IC50 = 18.9 microM)	Sodium taurocholate	Spodoptera frugiperda (Sf9) cells-BSEP
DTD0456	SLC6A4	Inhibition	4-Fluoroamphetamine	Approved Drug	19	.	4-Fluoroamphetamine inhibits the transportation of Dopamine by SLC6A4 (IC50 = 19 microM)	Dopamine	Human embryonic kidney 293 cells (HEK293)-SERT
DTD0025	SLC22A8	Inhibition	Ursolic acid	Natural Product	19	.	Ursolic acid inhibits the transportation of Estrone sulfate by SLC22A8 (IC50 = 19 microM)	Estrone sulfate	Human embryonic kidney 293 cells (HEK293)-OAT3
DTD0030	SLCO1B3	Inhibition	Amprenavir	Approved Drug	19.1	13.1	Amprenavir inhibits the transportation of Cholyl-glycylamido-fluorescein by SLCO1B3 (IC50 = 19.1 microM; Ki = 13.1 microM)	Cholyl-glycylamido-fluorescein	Chinese hamster ovary (CHO) cells-OATP1B3
DTD0024	SLC22A6	Inhibition	Trichlormethiazide	Approved Drug	19.2	.	Trichloromethiazide inhibits the transportation of Aminohippuric acid by SLC22A6 (IC50 = 19.2 microM)	Aminohippuric acid	The Proximal Tubule (S2) Cells-OAT1
DTD0002	ABCC2	Inhibition	Canagliflozin	Approved Drug	19.3	.	Canagliflozin inhibits the activity of ABCC2 (IC50 = 19.3 microM)	.	.
DTD0025	SLC22A8	Inhibition	Phenacetin	Drug Withdrawn	19.4	.	Phenacetin inhibits the transportation of Estrone sulfate by SLC22A8 (IC50 = 19.4 microM)	Estrone sulfate	The Proximal Tubule (S2) Cells-OAT3
DTD0016	ABCC5	Inhibition	Zaprinast	Discontinued Drug	20	.	Zaprinast inhibits the transportation of 5-Fluorodeoxyuridine monophosphate by ABCC5 (IC50 = 20 microM)	5-Fluorodeoxyuridine monophosphate	Human embryonic kidney 293 cells (HEK293)-MRP5
DTD0015	ABCC4	Inhibition	Dilazep	Investigative Drug	20	.	Dilazep inhibits the transportation of 9-(2-Phosphonomethoxyethyl)adenine by ABCC4 (IC50 = 20 microM)	9-(2-Phosphonomethoxyethyl)adenine	Human embryonic kidney 293 cells (HEK293)-MRP4
DTD0015	ABCC4	Inhibition	Sildenafil	Approved Drug	20	.	Sildenafil inhibits the transportation of 9-(2-Phosphonomethoxyethyl)adenine by ABCC4 (IC50 = 20 microM)	9-(2-Phosphonomethoxyethyl)adenine	Human embryonic kidney 293 cells (HEK293)-MRP4
DTD0031	SLCO2B1	Inhibition	Cyclosporine	Approved Drug	20	.	Cyclosporine inhibits the transportation of Bromsulphthalein by SLCO2B1 (IC50 = 20 microM)	Bromsulphthalein	Madin Darby canine kidney strain II (MDCKII) cells-OATP2B1
DTD0009	SLC22A3	Inhibition	Antiparasitics	Discontinued Drug	20.4	.	Antiparasitics inhibits the transportation of N-methylpyridinium by SLC22A3 (IC50 = 20.4 microM)	N-methylpyridinium	Chinese hamster ovary (CHO) cells-OCT3
DTD0024	SLC22A6	Inhibition	Piroxicam	Approved Drug	20.5	.	Piroxicam inhibits the transportation of Adefovir by SLC22A6 (IC50 = 20.5 microM)	Adefovir	Chinese hamster ovary (CHO) cells-OAT1
DTD0004	ABCG2	Inhibition	Efavirenz	Approved Drug	20.6	.	Efavirenz inhibits the transportation of Pheophorbide A by ABCG2 (IC50 = 20.6 microM)	Pheophorbide A	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
DTD0031	SLCO2B1	Inhibition	Kaempferol	Investigative Drug	20.7	15.1	Kaempferol inhibits the transportation of Atorvastatin by SLCO2B1 (IC50 = 20.7 microM; Ki = 15.1 microM)	Atorvastatin	Human embryonic kidney 293 cells (HEK293)-OATP2B1
DTD0002	ABCC2	Inhibition	Vinblastine	Approved Drug	21	.	Vinblastine inhibits the transportation of Calcein AM by ABCC2 (IC50 = 21 microM)	Calcein AM	Madin-Darby Canine Kidney (MDCK) cells-MRP2
DTD0006	SLC22A2	Inhibition	Diphenhydramine	Approved Drug	21	.	Diphenhydramine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 21 microM)	N-methylpyridinium	Human embryonic kidney 293 cells (HEK293)-OCT2
DTD0005	SLC22A7	Inhibition	Mefenamic Acid	Approved Drug	21.7	.	Mefenamic acid inhibits the transportation of Prostaglandin F2alpha by SLC22A7 (IC50 = 21.7 microM)	Prostaglandin F2alpha	The Proximal Tubule (S2) Cells-OAT2
DTD0003	ABCB1	Inhibition	Azithromycin	Approved Drug	21.8	.	Azithromycin inhibits the transportation of Digoxin by ABCB1 (IC50 = 21.8 microM)	Digoxin	Human enterocyte-like 2 cell (Caco-2)-MDR1
DTD0010	SLC22A1	Inhibition	Nelfinavir	Approved Drug	21.8	.	Nelfinavir inhibits the transportation of Tetraethylammonium by SLC22A1 (IC50 = 21.8 microM)	Tetraethylammonium	Human cervical cancer cell line (Hela)-OCT1
DTD0010	SLC22A1	Inhibition	Decynium 22	Investigative Drug	21.9	.	Decynium 22 inhibits the transportation of Tetraethylammonium by SLC22A1 (IC50 = 21.9 microM)	Tetraethylammonium	Oocytes-OCT1
DTD0003	ABCB1	Inhibition	Amlodipine	Approved Drug	22	.	Amlodipine inhibits the transportation of Daunorubicin by ABCB1 (IC50 = 22 microM)	Daunorubicin	LLC-PK1 vesicles-MDR1
DTD0004	ABCG2	Inhibition	Dimethoate	Natural Product	22	.	Dimethoate inhibits the transportation of WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) by ABCG2 (IC50 = 22 microM)	WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate)	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
DTD0031	SLCO2B1	Inhibition	Epigallocatechin gallate	Natural Product	22.1	.	Green tea extract inhibits the transportation of Estrone sulfate by SLCO2B1 (IC50 = 22.1 microM)	Estrone sulfate	Human embryonic kidney 293 cells (HEK293)-OATP2B1
DTD0003	ABCB1	Inhibition	Quinine	Approved Drug	22.4	.	Quinine inhibits the transportation of Digoxin by ABCB1 (IC50 = 22.4 microM)	Digoxin	Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DTD0003	ABCB1	Inhibition	Amiodarone	Approved Drug	22.5	.	Amiodarone inhibits the transportation of Daunorubicin by ABCB1 (IC50 = 22.5 microM)	Daunorubicin	LLC-PK1 vesicles-MDR1
DTD0003	ABCB1	Inhibition	Erythromycin	Approved Drug	22.7	.	Erythromycin inhibits the transportation of Digoxin by ABCB1 (IC50 = 22.7 microM)	Digoxin	Human enterocyte-like 2 cell (Caco-2)-MDR1
DTD0009	SLC22A3	Inhibition	Quinine	Approved Drug	22.7	.	Quinine inhibits the transportation of N-methylpyridinium by SLC22A3 (IC50 = 22.7 microM)	N-methylpyridinium	Chinese hamster ovary (CHO) cells-OCT3
DTD0003	ABCB1	Inhibition	Quinine	Approved Drug	22.9	.	Quinine inhibits the transportation of Vinblastine by ABCB1 (IC50 = 22.9 microM)	Vinblastine	Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DTD0456	SLC6A4	Inhibition	Pyrovalerone	Investigative Drug	23	.	Pyrovalerone inhibits the transportation of Dopamine by SLC6A4 (IC50 = 23 microM)	Dopamine	Human embryonic kidney 293 cells (HEK293)-SERT
DTD0006	SLC22A2	Inhibition	Clonidine	Approved Drug	23	.	Clonidine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 23 microM)	N-methylpyridinium	Human embryonic kidney 293 cells (HEK293)-OCT2
DTD0006	SLC22A2	Inhibition	Quinine	Approved Drug	23	.	Quinine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 23 microM)	N-methylpyridinium	Human embryonic kidney 293 cells (HEK293)-OCT2
DTD0019	SLC10A1	Inhibition	Gemfibrozil	Approved Drug	23	.	Gemfibrozil inhibits the transportation of Rosuvastatin by SLC10A1 (IC50 = 23 microM)	Rosuvastatin	Human cervical cancer cell line (Hela)-NTCP
DTD0031	SLCO2B1	Inhibition	Phlorizin	Natural Product	23.2	.	Phloridzin inhibits the transportation of Estrone sulfate by SLCO2B1 (IC50 = 23.2 microM)	Estrone sulfate	Xenopus laevis oocytes-OATP2B1
DTD0003	ABCB1	Inhibition	Ginkgo biloba extract	Natural Product	23.6	.	Ginkgo biloba extract inhibits the transportation of Digoxin by ABCB1 (IC50 = 23.6 microM)	Digoxin	Human enterocyte-like 2 cell (Caco-2)-MDR1
DTD0010	SLC22A1	Inhibition	YM155	Drug in Phase 2 Trial	23.8	.	YM155 inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 23.8 microM)	N-methylpyridinium	Human embryonic kidney 293 cells (HEK293)-OCT1
DTD0503	SLCO4C1	Inhibition	Crizotinib	Approved Drug	24	.	Crizotinib inhibits the activity of SLCO4C1 (IC50 = 24 microM)	.	.
DTD0004	ABCG2	Inhibition	Endosulfan	Natural Product	24.8	.	Endosulfan inhibits the transportation of Hoechst 33342 by ABCG2 (IC50 = 24.8 microM)	Hoechst 33342	Human embryonic kidney 293 cells (HEK293)-BCRP
DTD0006	SLC22A2	Inhibition	Zearalenone	Mycotoxins	24.8	.	Zearalenone inhibits the transportation of Organic cation by SLC22A2 (IC50 = 24.8 microM)	Organic cation	The Proximal Tubule (S2) Cells-OCT2
DTD0031	SLCO2B1	Inhibition	Paclitaxel	Approved Drug	25	.	Paclitaxel inhibits the transportation of Bromsulphthalein by SLCO2B1 (IC50 = 25 microM)	Bromsulphthalein	Madin Darby canine kidney strain II (MDCKII) cells-OATP2B1
DTD0006	SLC22A2	Inhibition	Propafenone	Approved Drug	25	.	Propafenone inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 25 microM)	N-methylpyridinium	Human embryonic kidney 293 cells (HEK293)-OCT2
DTD0003	ABCB1	Inhibition	Acetochlor	Natural Product	25	.	Acetochlor inhibits the transportation of Paclitaxel by ABCB1 (IC50 = 25 microM)	Paclitaxel	Myelogenous leukemia cell line (K562)-MDR1
DTD0003	ABCB1	Inhibition	Alachlor	Natural Product	25	.	Alachlor inhibits the transportation of Paclitaxel by ABCB1 (IC50 = 25 microM)	Paclitaxel	Myelogenous leukemia cell line (K562)-MDR1
DTD0008	SLCO1B1	Inhibition	Gemfibrozil	Approved Drug	25	.	Gemfibrozil inhibits the transportation of Rosuvastatin by SLCO1B1 (IC50 = 25 microM)	Rosuvastatin	Human cervical cancer cell line (Hela)-OATP1B1
DTD0003	ABCB1	Inhibition	Lovastatin	Approved Drug	26	.	Lovastatin inhibits the transportation of Daunorubicin by ABCB1 (IC50 = 26 microM)	Daunorubicin	.
DTD0026	SLC22A11	Inhibition	Valsartan	Approved Drug	26	.	Valsartan inhibits the transportation of Uric acid by SLC22A11 (IC50 = 26 microM)	Uric acid	Human embryonic kidney 293 cells (HEK293)-OAT4
DTD0004	ABCG2	Inhibition	Dimethomorph	Natural Product	26	.	Dimethomorph inhibits the transportation of WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) by ABCG2 (IC50 = 26 microM)	WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate)	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
DTD0024	SLC22A6	Inhibition	Fluvastatin	Approved Drug	26.3	.	Fluvastatin inhibits the transportation of Aminohippuric acid by SLC22A6 (IC50 = 26.3 microM)	Aminohippuric acid	The Proximal Tubule (S2) Cells-OAT1
DTD0003	ABCB1	Inhibition	Felodipine	Approved Drug	26.3	.	Felodipine inhibits the transportation of Daunorubicin by ABCB1 (IC50 = 26.3 microM)	Daunorubicin	NIH-3T3-G185-MDR1
DTD0003	ABCB1	Inhibition	Quercetin	Approved Drug	26.4	.	Quercetin inhibits the transportation of Ritonavir by ABCB1 (IC50 = 26.4 microM)	Ritonavir	Madin darby canine kidney strain cell line (MDCK)-MDR1
DTD0006	SLC22A2	Inhibition	Progesterone	Approved Drug	26.7	.	Progesterone inhibits the transportation of 1-Methyl-4-phenylpyridinium by SLC22A2 (IC50 = 26.7 microM)	1-Methyl-4-phenylpyridinium	Human embryonic kidney 293 cells (HEK293)-OCT2
DTD0004	ABCG2	Inhibition	Saquinavir	Approved Drug	27.4	.	Saquinavir inhibits the transportation of Pheophorbide A by ABCG2 (IC50 = 27.4 microM)	Pheophorbide A	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
DTD0010	SLC22A1	Inhibition	Fenamiphos	Natural Product	27.5	.	Fenamiphos inhibits the transportation of 4',6'-diamidino-2-phenylindole by SLC22A1 (IC50 = 27.5 microM)	4',6'-diamidino-2-phenylindole	Human embryonic kidney 293 cells (HEK293)-OCT1
DTD0014	ABCB11	Inhibition	Troglitazone	Approved Drug	27.6	.	Troglitazone inhibits the transportation of Taurochenodeoxycholate by ABCB11 (IC50 = 27.6 microM)	Taurochenodeoxycholate	Spodoptera frugiperda (Sf9) cells-BSEP
DTD0025	SLC22A8	Inhibition	Cyclothiazide	Approved Drug	27.9	.	Cyclothiazide inhibits the transportation of Estrone sulfate by SLC22A8 (IC50 = 27.9 microM)	Estrone sulfate	The Proximal Tubule (S2) Cells-OAT3
DTD0010	SLC22A1	Inhibition	Ranitidine	Approved Drug	28	.	Ranitidine inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 28 microM)	N-methylpyridinium	Human embryonic kidney 293 cells (HEK293)-OCT1
DTD0010	SLC22A1	Inhibition	Famotidine	Approved Drug	28	.	Famotidine inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 28 microM)	N-methylpyridinium	Oocytes-OCT1
DTD0003	ABCB1	Inhibition	Ritonavir	Approved Drug	28.2	.	Ritonavir inhibits the transportation of Digoxin by ABCB1 (IC50 = 28.2 microM)	Digoxin	Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DTD0024	SLC22A6	Inhibition	Alpha-zearalenol	Mycotoxins	28.4	.	Alpha-zearalenol inhibits the transportation of Organic anion by SLC22A6 (IC50 = 28.4 microM)	Organic anion	The Proximal Tubule (S2) Cells-OAT1
DTD0003	ABCB1	Inhibition	Vinblastine	Approved Drug	29	.	Vinblastine inhibits the transportation of Calcein AM by ABCB1 (IC50 = 29 microM)	Calcein AM	Madin-Darby Canine Kidney (MDCK) cells-MDR1
DTD0006	SLC22A2	Inhibition	Sibutramine	Approved Drug	29	.	Sibutramine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 29 microM)	N-methylpyridinium	Human embryonic kidney 293 cells (HEK293)-OCT2
DTD0024	SLC22A6	Inhibition	Ethacrynic Acid	Approved Drug	29.6	.	Ethacrynic acid inhibits the transportation of Aminohippuric acid by SLC22A6 (IC50 = 29.6 microM)	Aminohippuric acid	The Proximal Tubule (S2) Cells-OAT1
DTD0003	ABCB1	Inhibition	Paroxetine	Approved Drug	29.8	.	Paroxetine inhibits the transportation of Calcein by ABCB1 (IC50 = 29.8 microM)	Calcein	.
DTD0014	ABCB11	Inhibition	Peonidin	Natural Product	30	.	Peonidin inhibits the activity of ABCB11 (IC50 = 30 microM)	.	Human breast adenocarcinoma cell line (MCF-7)-BSEP
DTD0016	ABCC5	Inhibition	Dipyridamole	Approved Drug	30	.	Dipyridamole inhibits the transportation of 9-(2-Phosphonomethoxyethyl)adenine by ABCC5 (IC50 = 30 microM)	9-(2-Phosphonomethoxyethyl)adenine	Human embryonic kidney 293 cells (HEK293)-MRP4
DTD0016	ABCC5	Inhibition	Trequinsin	Discontinued Drug	30	.	Trequinsin inhibits the transportation of 9-(2-Phosphonomethoxyethyl)adenine by ABCC5 (IC50 = 30 microM)	9-(2-Phosphonomethoxyethyl)adenine	Human embryonic kidney 293 cells (HEK293)-MRP4
DTD0003	ABCB1	Inhibition	Azelastine	Approved Drug	30	.	Azelastine inhibits the transportation of Digoxin by ABCB1 (IC50 = 30 microM)	Digoxin	LLC-PK1 vesicles-MDR1
DTD0003	ABCB1	Inhibition	Vinblastine	Approved Drug	30.1	.	Vinblastine inhibits the transportation of Colchicine by ABCB1 (IC50 = 30.1 microM)	Colchicine	Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DTD0010	SLC22A1	Inhibition	N-methylpyridinium	Drug in Preclinical Test	30.4	.	N-methylpyridinium inhibits the transportation of YM155 by SLC22A1 (IC50 = 30.4 microM)	YM155	Human embryonic kidney 293 cells (HEK293)-OCT1
DTD0026	SLC22A11	Inhibition	Pratosartan	Drug in Phase 3 Trial	31	.	Pratosartan inhibits the transportation of Uric acid by SLC22A11 (IC50 = 31 microM)	Uric acid	Human embryonic kidney 293 cells (HEK293)-OAT4
DTD0004	ABCG2	Inhibition	Chlorpyrifos-methyl	Natural Product	31	.	Chlorpyrifos-methyl inhibits the transportation of WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) by ABCG2 (IC50 = 31 microM)	WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate)	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
DTD0003	ABCB1	Inhibition	Sertraline	Approved Drug	31.8	.	Sertraline inhibits the transportation of Calcein by ABCB1 (IC50 = 31.8 microM)	Calcein	.
DTD0016	ABCC5	Inhibition	Zaprinast	Discontinued Drug	32.3	.	Zaprinast inhibits the transportation of Carboxydichlorofluorescein by ABCC5 (IC50 = 32.3 microM)	Carboxydichlorofluorescein	Human embryonic kidney 293 cells (HEK293)-MRP5
DTD0025	SLC22A8	Inhibition	Simvastatin	Approved Drug	32.3	.	Simvastatin inhibits the transportation of Estrone sulfate by SLC22A8 (IC50 = 32.3 microM)	Estrone sulfate	The Proximal Tubule (S2) Cells-OAT3
DTD0003	ABCB1	Inhibition	Felodipine	Approved Drug	32.3	.	Felodipine inhibits the transportation of LDS-751 by ABCB1 (IC50 = 32.3 microM)	LDS-751	NIH-3T3-G185-MDR1
DTD0003	ABCB1	Inhibition	Lovastatin	Approved Drug	32.7	.	Lovastatin inhibits the transportation of LDS-751 by ABCB1 (IC50 = 32.7 microM)	LDS-751	NIH-3T3-G185-MDR1
DTD0010	SLC22A1	Inhibition	Ranitidine	Approved Drug	33	.	Ranitidine inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 33 microM)	N-methylpyridinium	Oocytes-OCT1
DTD0003	ABCB1	Inhibition	Verapamil	Approved Drug	33.5	.	Verapamil inhibits the transportation of Vinblastine by ABCB1 (IC50 = 33.5 microM)	Vinblastine	Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DTD0016	ABCC5	Inhibition	Probenecid	Approved Drug	34	.	Probenecid inhibits the transportation of Carboxydichlorofluorescein by ABCC5 (IC50 = 34 microM)	Carboxydichlorofluorescein	Human embryonic kidney 293 cells (HEK293)-MRP5
DTD0003	ABCB1	Inhibition	6,7-dihydroxybergamottin	Natural Product	34	.	6,7-dihydroxybergamottin inhibits the transportation of Talinolol by ABCB1 (IC50 = 34 microM)	Talinolol	Human enterocyte-like 2 cell (Caco-2)-MDR1
DTD0006	SLC22A2	Inhibition	Alpha-zearalenol	Mycotoxins	34.3	.	Alpha-zearalenol inhibits the transportation of Organic cation by SLC22A2 (IC50 = 34.3 microM)	Organic cation	The Proximal Tubule (S2) Cells-OCT2
DTD0026	SLC22A11	Inhibition	Diclofenac	Approved Drug	34.5	.	Diclofenac inhibits the transportation of Estrone sulfate by SLC22A11 (IC50 = 34.5 microM)	Estrone sulfate	The Proximal Tubule (S2) Cells-OAT4
DTD0024	SLC22A6	Inhibition	Novobiocin	Approved Drug	34.8	14.9	Novobiocin inhibits the transportation of Aminohippuric acid by SLC22A6 (IC50 = 34.8 microM; Ki = 14.9 microM)	Aminohippuric acid	Monkey kidney tissue Fibroblast-like cell lines (COS)7-OAT1
DTD0015	ABCC4	Inhibition	Celecoxib	Approved Drug	35	.	Celecoxib inhibits the transportation of Methotrexate by ABCC4 (IC50 = 35 microM)	Methotrexate	Human embryonic kidney 293 cells (HEK293)-MRP4
DTD0027	SLC22A12	Inhibition	Fenofibric acid	Approved Drug	35.68	.	Fenofibric acid inhibits the transportation of Uric acid by SLC22A12 (IC50 = 35.68 microM)	Uric acid	Human embryonic kidney 293 cells (HEK293)-URAT1
DTD0031	SLCO2B1	Inhibition	Epicatechin gallate	Natural Product	36	.	(-)-epicatechin-3-gallate inhibits the activity of SLCO2B1 in a substrate-dependent manner (IC50 = 36 microM)	.	Chinese hamster ovary (CHO) cells-OATP2B1
DTD0024	SLC22A6	Inhibition	Sulindac	Approved Drug	36.2	.	Sulindac inhibits the transportation of Aminohippuric acid by SLC22A6 (IC50 = 36.2 microM)	Aminohippuric acid	The Proximal Tubule (S2) Cells-OAT1
DTD0030	SLCO1B3	Inhibition	Silychristin	Natural Product	36.4	.	Silychristin inhibits the transportation of Estradiol-17-glucuronide by SLCO1B3 (IC50 = 36.4 microM)	Estradiol-17-glucuronide	Human embryonic kidney 293 cells (HEK293)-OATP1B3
DTD0009	SLC22A3	Inhibition	Quinine	Approved Drug	37	.	Quinine inhibits the transportation of N-methylpyridinium by SLC22A3 (IC50 = 37 microM)	N-methylpyridinium	Chinese hamster ovary (CHO) cells-OCT3
DTD0029	SLCO1A2	Inhibition	Kaempferol	Investigative Drug	37.3	25.2	Kaempferol inhibits the transportation of Atorvastatin by SLCO1A2 (IC50 = 37.3 microM; Ki = 25.2 microM)	Atorvastatin	Human embryonic kidney 293 cells (HEK293)-OATP1A2
DTD0006	SLC22A2	Inhibition	Atropine	Approved Drug	39	.	Atropine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 39 microM)	N-methylpyridinium	Human embryonic kidney 293 cells (HEK293)-OCT2
DTD0005	SLC22A7	Inhibition	Cyclothiazide	Approved Drug	39.2	.	Cyclothiazide inhibits the transportation of Prostaglandin F2alpha by SLC22A7 (IC50 = 39.2 microM)	Prostaglandin F2alpha	The Proximal Tubule (S2) Cells-OAT2
DTD0031	SLCO2B1	Inhibition	Cigarette smoke condensate	Natural Product	39.5	.	Cigarette smoke condensate inhibits the transportation of Bromosulfophtalein by by repressing mRNA expression of SLCO2B1 (IC50 = 39.5 microM)	Bromosulfophtalein	Human hepatoma HepaRG cells-OATP2B1
DTD0010	SLC22A1	Inhibition	Amantadine	Approved Drug	39.6	.	Amantadine inhibits the transportation of YM155 by SLC22A1 (IC50 = 39.6 microM)	YM155	Human embryonic kidney 293 cells (HEK293)-OCT1
DTD0003	ABCB1	Inhibition	Dipyridamole	Approved Drug	40	.	Dipyridamole inhibits the transportation of Digoxin by ABCB1 (IC50 = 40 microM)	Digoxin	LLC-PK1 vesicles-MDR1
DTD0012	ABCC3	Inhibition	Sodium taurocholate	Drug in Phase 1/2 Trial	40	.	Sodium taurocholate inhibits the transportation of Estradiol-17beta-glucuronide by ABCC3 (IC50 = 40 microM)	Estradiol-17beta-glucuronide	Human embryonic kidney 293 cells (HEK293)-MRP3
DTD0503	SLCO4C1	Inhibition	Fluvastatin	Approved Drug	41	.	Fluvastatin inhibits the activity of SLCO4C1 (IC50 = 41 microM)	.	.
DTD0024	SLC22A6	Inhibition	Simvastatin	Approved Drug	41.5	.	Simvastatin inhibits the transportation of Aminohippuric acid by SLC22A6 (IC50 = 41.5 microM)	Aminohippuric acid	Oocytes-OAT1
DTD0004	ABCG2	Inhibition	Pyrethroids	Natural Product	42.5	.	Pyrethroids inhibits the transportation of Fmitremorgin C by ABCG2 (IC50 = 42.5 microM)	Fmitremorgin C	Human embryonic kidney 293 cells (HEK293)-BCRP
DTD0006	SLC22A2	Inhibition	Allethrin	Natural Product	42.6	.	Allethrin inhibits the transportation of Verapamil by SLC22A2 (IC50 = 42.6 microM)	Verapamil	Human embryonic kidney 293 cells (HEK293)-OCT2
DTD0014	ABCB11	Inhibition	Cyanidin-3,5-diglucoside	Natural Product	43	.	Cyanidin-3,5-diglucoside inhibits the activity of ABCB11 (IC50 = 43 microM)	.	Human breast adenocarcinoma cell line (MCF-7)-BSEP
DTD0003	ABCB1	Inhibition	Desloratadine	Approved Drug	43	.	Desloratadine inhibits the transportation of Daunorubicin by ABCB1 (IC50 = 43 microM)	Daunorubicin	NIH-3T3-G185-MDR1
DTD0003	ABCB1	Inhibition	Nisoldipine	Approved Drug	44.1	.	Nisoldipine inhibits the transportation of Digoxin by ABCB1 (IC50 = 44.1 microM)	Digoxin	LLC-PK1 vesicles-MDR1
DTD0026	SLC22A11	Inhibition	Furosemide	Approved Drug	44.5	.	Furosemide inhibits the transportation of Estrone sulfate by SLC22A11 (IC50 = 44.5 microM)	Estrone sulfate	The Proximal Tubule (S2) Cells-OAT4
DTD0024	SLC22A6	Inhibition	Patulin	Natural Product	44.8	.	Patulin inhibits the transportation of Organic anion by SLC22A6 (IC50 = 44.8 microM)	Organic anion	The Proximal Tubule (S2) Cells-OAT1
DTD0024	SLC22A6	Inhibition	Patulin	Mycotoxins	44.8	.	Patulin inhibits the transportation of Organic anion by SLC22A6 (IC50 = 44.8 microM)	Organic anion	The Proximal Tubule (S2) Cells-OAT1
DTD0456	SLC6A4	Inhibition	Amphetamine	Approved Drug	45	.	Amphetamine inhibits the transportation of Dopamine by SLC6A4 (IC50 = 45 microM)	Dopamine	Human embryonic kidney 293 cells (HEK293)-SERT
DTD0003	ABCB1	Inhibition	Amiodarone	Approved Drug	45.6	.	Amiodarone inhibits the transportation of Digoxin by ABCB1 (IC50 = 45.6 microM)	Digoxin	LLC-PK1 vesicles-MDR1
DTD0006	SLC22A2	Inhibition	Amantadine	Approved Drug	45.9	.	Amantadine inhibits the transportation of YM155 by SLC22A2 (IC50 = 45.9 microM)	YM155	Human embryonic kidney 293 cells (HEK293)-OCT2
DTD0456	SLC6A4	Inhibition	Methcathinone	Investigative Drug	46	.	Methcathinone inhibits the transportation of Dopamine by SLC6A4 (IC50 = 46 microM)	Dopamine	Human embryonic kidney 293 cells (HEK293)-SERT
DTD0455	SLC6A3	Inhibition	Ephedrine	Approved Drug	46	.	Ephedrine inhibits the transportation of Serotonin by SLC6A3 (IC50 = 46 microM)	Serotonin	Human embryonic kidney 293 cells (HEK293)-DAT1
DTD0007	SLC47A1	Inhibition	Tetramethrin	Natural Product	47.5	.	Tetramethrin inhibits the transportation of Verapamil by SLC47A1 (IC50 = 47.5 microM)	Verapamil	Human embryonic kidney 293 cells (HEK293)-MATE1
DTD0002	ABCC2	Inhibition	Pyrethroids	Natural Product	48.2	.	Pyrethroids inhibits the transportation of Probenecid by ABCC2 (IC50 = 48.2 microM)	Probenecid	Human hepatoma HuH-7 cells-MRP2
DTD0014	ABCB11	Inhibition	Malvidin	Natural Product	49	.	Malvidin inhibits the activity of ABCB11 (IC50 = 49 microM)	.	Human breast adenocarcinoma cell line (MCF-7)-BSEP
DTD0031	SLCO2B1	Inhibition	Naringenin	Drug in Phase 1 Trial	49.2	.	Naringenin inhibits the transportation of Estrone sulfate by SLCO2B1 (IC50 = 49.2 microM)	Estrone sulfate	Xenopus laevis oocytes-OATP2B1
DTD0024	SLC22A6	Inhibition	Etodolac	Approved Drug	50	.	Etodolac inhibits the transportation of Adefovir by SLC22A6 (IC50 = 50 microM)	Adefovir	Chinese hamster ovary (CHO) cells-OAT1
DTD0008	SLCO1B1	Inhibition	Paclitaxel	Approved Drug	50	.	Paclitaxel inhibits the transportation of Bromsulphthalein by SLCO1B1 (IC50 = 50 microM)	Bromsulphthalein	Madin Darby canine kidney strain II (MDCKII) cells-OATP1B1
DTD0003	ABCB1	Inhibition	Etoposide	Approved Drug	50	.	Etoposide inhibits the transportation of Calcein AM by ABCB1 (IC50 = 50 microM)	Calcein AM	LLC-PK1 vesicles-MDR1
DTD0003	ABCB1	Inhibition	Hydrocortisone	Approved Drug	50	.	Hydrocortisone inhibits the transportation of Calcein AM by ABCB1 (IC50 = 50 microM)	Calcein AM	LLC-PK1 vesicles-MDR1
DTD0003	ABCB1	Inhibition	Morphine	Approved Drug	50	.	Morphine inhibits the transportation of Calcein AM by ABCB1 (IC50 = 50 microM)	Calcein AM	LLC-PK1 vesicles-MDR1
DTD0002	ABCC2	Inhibition	MK-571	Discontinued Drug	50	.	MK-571 inhibits the transportation of Irinotecan by ABCC2 (IC50 = 50 microM)	Irinotecan	Human enterocyte-like 2 cell (Caco-2)-MRP2
DTD0027	SLC22A12	Inhibition	Probenecid	Approved Drug	50	.	Probenecid inhibits the transportation of Uric acid by SLC22A12 (IC50 = 50 microM)	Uric acid	Human embryonic kidney 293 cells (HEK293)-URAT1
DTD0007	SLC47A1	Inhibition	Allethrin	Natural Product	50.2	.	Allethrin inhibits the transportation of Verapamil by SLC47A1 (IC50 = 50.2 microM)	Verapamil	Human embryonic kidney 293 cells (HEK293)-MATE1
DTD0503	SLCO4C1	Inhibition	Nicardipine	Approved Drug	51	.	Nicardipine inhibits the activity of SLCO4C1 (IC50 = 51 microM)	.	.
DTD0010	SLC22A1	Inhibition	Procainamide	Approved Drug	51.3	.	Procainamide inhibits the transportation of YM155 by SLC22A1 (IC50 = 51.3 microM)	YM155	Human embryonic kidney 293 cells (HEK293)-OCT1
DTD0003	ABCB1	Inhibition	Quinine	Approved Drug	51.7	.	Quinine inhibits the transportation of Colchicine by ABCB1 (IC50 = 51.7 microM)	Colchicine	Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DTD0503	SLCO4C1	Inhibition	Spironolactone	Approved Drug	53	.	Spironolactone inhibits the activity of SLCO4C1 (IC50 = 53 microM)	.	.
DTD0003	ABCB1	Inhibition	Paclitaxel	Approved Drug	54	.	Paclitaxel inhibits the transportation of Rhodamine 123 by ABCB1 (IC50 = 54 microM)	Rhodamine 123	NIH-3T3-G185-MDR1
DTD0024	SLC22A6	Inhibition	Piperacillin	Approved Drug	54.32	37	Piperacillin inhibits the transporation of tazobactam by SLC22A6 (IC50 = 54.32 microM; Ki = 37 microM)	Tazobactam	Human embryonic kidney 293 cells (HEK293)
DTD0029	SLCO1A2	Inhibition	Epigallocatechin gallate	Natural Product	55	.	(-)-epigallocatechin-3-gallate inhibits the activity of SLCO1A2 in a substrate-dependent manner (IC50 = 55 microM)	.	Human embryonic kidney 293 cells (HEK293)-OATP1A2
DTD0006	SLC22A2	Inhibition	Mexiletine	Approved Drug	55	.	Mexiletine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 55 microM)	N-methylpyridinium	Human embryonic kidney 293 cells (HEK293)-OCT2
DTD0024	SLC22A6	Inhibition	Ibuprofen	Approved Drug	55.6	.	Ibuprofen inhibits the transportation of Aminohippuric acid by SLC22A6 (IC50 = 55.6 microM)	Aminohippuric acid	The Proximal Tubule (S2) Cells-OAT1
DTD0003	ABCB1	Inhibition	Diazinon	Natural Product	58.4	.	Diazinon inhibits the transportation of Verapamil by ABCB1 (IC50 = 58.4 microM)	Verapamil	NIH 3T3 cells-MDR1
DTD0008	SLCO1B1	Inhibition	Epicatechin gallate	Natural Product	59	.	(-)-epicatechin-3-gallate inhibits the activity of SLCO1B1 in a substrate-dependent manner (IC50 = 59 microM)	.	Chinese hamster ovary (CHO) cells-OATP1B1
DTD0004	ABCG2	Inhibition	Daunorubicin	Approved Drug	59	.	Daunorubicin inhibits the transportation of Estrone sulfate by ABCG2 (IC50 = 59 microM)	Estrone sulfate	Mouse lymphoma (P388) cells-BCRP
DTD0006	SLC22A2	Inhibition	Aconitine	Biotoxin	59.2	.	Aconitine inhibits the transportation of Tetraethylammonium by SLC22A2 (IC50 = 59.2 microM)	Tetraethylammonium	The Proximal Tubule (S2) Cells-OCT2
DTD0024	SLC22A6	Inhibition	Cidofovir	Approved Drug	60	.	Cidofovir inhibits the transportation of 6-Carboxyfluorescein by SLC22A6 (IC50 = 60 microM)	6-Carboxyfluorescein	Chinese hamster ovary (CHO) cells-OAT1
DTD0006	SLC22A2	Inhibition	Flurazepam	Approved Drug	60	.	Flurazepam inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 60 microM)	N-methylpyridinium	Human embryonic kidney 293 cells (HEK293)-OCT2
DTD0026	SLC22A11	Inhibition	Candesartan	Approved Drug	60	.	Candesartan inhibits the transportation of Uric acid by SLC22A11 (IC50 = 60 microM)	Uric acid	Human embryonic kidney 293 cells (HEK293)-OAT4
DTD0028	SLC47A2	Inhibition	Cigarette smoke condensate	Natural Product	61.4	.	Cigarette smoke condensate inhibits the activity of SLC47A2 (IC50 = 61.4 microM)	.	Human embryonic kidney 293 cells (HEK293)-MATE2
DTD0026	SLC22A11	Inhibition	Mefenamic Acid	Approved Drug	61.7	.	Mefenamic acid inhibits the transportation of Estrone sulfate by SLC22A11 (IC50 = 61.7 microM)	Estrone sulfate	The Proximal Tubule (S2) Cells-OAT4
DTD0010	SLC22A1	Inhibition	Indinavir	Approved Drug	61.7	.	Indinavir inhibits the transportation of Tetraethylammonium by SLC22A1 (IC50 = 61.7 microM)	Tetraethylammonium	Human cervical cancer cell line (Hela)-OCT1
DTD0010	SLC22A1	Inhibition	Tubocurarine	Approved Drug	62.4	.	Tubocurarine inhibits the transportation of YM155 by SLC22A1 (IC50 = 62.4 microM)	YM155	Human embryonic kidney 293 cells (HEK293)-OCT1
DTD0024	SLC22A6	Inhibition	Piroxicam	Approved Drug	62.8	.	Piroxicam inhibits the transportation of Aminohippuric acid by SLC22A6 (IC50 = 62.8 microM)	Aminohippuric acid	The Proximal Tubule (S2) Cells-OAT1
DTD0006	SLC22A2	Inhibition	Carvedilol	Approved Drug	63	.	Carvedilol inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 63 microM)	N-methylpyridinium	Human embryonic kidney 293 cells (HEK293)-OCT2
DTD0005	SLC22A7	Inhibition	Indomethacin	Approved Drug	64.1	.	Indomethacin inhibits the transportation of Prostaglandin F2alpha by SLC22A7 (IC50 = 64.1 microM)	Prostaglandin F2alpha	The Proximal Tubule (S2) Cells-OAT2
DTD0010	SLC22A1	Inhibition	Aflatoxin B1	Mycotoxins	64.4	.	Aflatoxin B1 inhibits the transportation of Organic cation by SLC22A1 (IC50 = 64.4 microM)	Organic cation	The Proximal Tubule (S2) Cells-OCT1
DTD0025	SLC22A8	Inhibition	Chlorothiazide	Approved Drug	65.3	.	Chlorothiazide inhibits the transportation of Estrone sulfate by SLC22A8 (IC50 = 65.3 microM)	Estrone sulfate	The Proximal Tubule (S2) Cells-OAT3
DTD0002	ABCC2	Inhibition	Tetramethrin	Natural Product	65.5	.	Tetramethrin inhibits the transportation of Probenecid by ABCC2 (IC50 = 65.5 microM)	Probenecid	Human hepatoma HuH-7 cells-MRP2
DTD0003	ABCB1	Inhibition	Pyrethroids	Natural Product	65.5	.	Pyrethroids inhibits the transportation of Verapamil by ABCB1 (IC50 = 65.5 microM)	Verapamil	Human embryonic kidney 293 cells (HEK293)-MDR1
DTD0031	SLCO2B1	Inhibition	Cerivastatin	Approved Drug	66.2	.	Cerivastatin inhibits the transportation of Estrone sulfate by SLCO2B1 (IC50 = 66.2 microM)	Estrone sulfate	Madin Darby canine kidney strain II (MDCKII) cells-OATP2B1
DTD0003	ABCB1	Inhibition	Lovastatin	Approved Drug	67	.	Lovastatin inhibits the transportation of Rhodamine 123 by ABCB1 (IC50 = 67 microM)	Rhodamine 123	.
DTD0024	SLC22A6	Inhibition	Hydrochlorothiazide	Approved Drug	67.3	.	Hydrochlorothiazide inhibits the transportation of Aminohippuric acid by SLC22A6 (IC50 = 67.3 microM)	Aminohippuric acid	The Proximal Tubule (S2) Cells-OAT1
DTD0031	SLCO2B1	Inhibition	Hesperetin	Approved Drug	67.6	.	Hesperetin inhibits the transportation of Estrone sulfate by SLCO2B1 (IC50 = 67.6 microM)	Estrone sulfate	Xenopus laevis oocytes-OATP2B1
DTD0003	ABCB1	Inhibition	Nitrendipine	Approved Drug	68.2	.	Nitrendipine inhibits the transportation of Digoxin by ABCB1 (IC50 = 68.2 microM)	Digoxin	LLC-PK1 vesicles-MDR1
DTD0003	ABCB1	Inhibition	Troleandomycin	Approved Drug	68.3	.	Troleandomycin inhibits the transportation of Daunorubicin by ABCB1 (IC50 = 68.3 microM)	Daunorubicin	NIH-3T3-G185-MDR1
DTD0004	ABCG2	Inhibition	Atazanavir	Approved Drug	69.1	.	Atazanavir inhibits the transportation of Pheophorbide A by ABCG2 (IC50 = 69.1 microM)	Pheophorbide A	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
DTD0025	SLC22A8	Inhibition	Allethrin	Natural Product	69.4	.	Allethrin inhibits the transportation of Fluorescein by SLC22A8 (IC50 = 69.4 microM)	Fluorescein	Human embryonic kidney 293 cells (HEK293)-OAT3
DTD0016	ABCC5	Inhibition	Probenecid	Approved Drug	70	.	Probenecid inhibits the transportation of 5-Fluorodeoxyuridine monophosphate by ABCC5 (IC50 = 70 microM)	5-Fluorodeoxyuridine monophosphate	Human embryonic kidney 293 cells (HEK293)-MRP5
DTD0026	SLC22A11	Inhibition	Ketoprofen	Approved Drug	70.3	.	Ketoprofen inhibits the transportation of Estrone sulfate by SLC22A11 (IC50 = 70.3 microM)	Estrone sulfate	The Proximal Tubule (S2) Cells-OAT4
DTD0005	SLC22A7	Inhibition	Piroxicam	Approved Drug	70.3	.	Piroxicam inhibits the transportation of Prostaglandin F2alpha by SLC22A7 (IC50 = 70.3 microM)	Prostaglandin F2alpha	The Proximal Tubule (S2) Cells-OAT2
DTD0025	SLC22A8	Inhibition	Trichlormethiazide	Approved Drug	71.2	.	Trichloromethiazide inhibits the transportation of Estrone sulfate by SLC22A8 (IC50 = 71.2 microM)	Estrone sulfate	The Proximal Tubule (S2) Cells-OAT3
DTD0004	ABCG2	Inhibition	Tetramethrin	Natural Product	72.5	.	Tetramethrin inhibits the transportation of Fmitremorgin C by ABCG2 (IC50 = 72.5 microM)	Fmitremorgin C	Human embryonic kidney 293 cells (HEK293)-BCRP
DTD0024	SLC22A6	Inhibition	Simvastatin	Approved Drug	73.6	.	Simvastatin inhibits the transportation of Aminohippuric acid by SLC22A6 (IC50 = 73.6 microM)	Aminohippuric acid	The Proximal Tubule (S2) Cells-OAT1
DTD0025	SLC22A8	Inhibition	Gliotoxin	Mycotoxins	73.9	.	Gliotoxin inhibits the transportation of Organic anion by SLC22A8 (IC50 = 73.9 microM)	Organic anion	The Proximal Tubule (S2) Cells-OAT3
DTD0003	ABCB1	Inhibition	Piperine	Natural Product	74.1	.	Piperine inhibits the transportation of Cyclosporine A by ABCB1 (IC50 = 74.1 microM)	Cyclosporine A	Human enterocyte-like 2 cell (Caco-2)-MDR1
DTD0024	SLC22A6	Inhibition	Acetazolamide	Approved Drug	75	.	Acetazolamide inhibits the transportation of Aminohippuric acid by SLC22A6 (IC50 = 75 microM)	Aminohippuric acid	The Proximal Tubule (S2) Cells-OAT1
DTD0456	SLC6A4	Inhibition	3',4'-Methylenedioxy-alpha-pyrrolidinopropiophenone (MDPPP)	Investigative Drug	75	.	3',4'-Methylenedioxy-alpha-pyrrolidinopropiophenone (MDPPP) inhibits the transportation of Dopamine by SLC6A4 (IC50 = 75 microM)	Dopamine	Human embryonic kidney 293 cells (HEK293)-SERT
DTD0014	ABCB11	Inhibition	Pelargonidin	Natural Product	76	.	Pelargonidin inhibits the activity of ABCB11 (IC50 = 76 microM)	.	Human breast adenocarcinoma cell line (MCF-7)-BSEP
DTD0006	SLC22A2	Inhibition	Ranitidine	Approved Drug	76	.	Ranitidine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 76 microM)	N-methylpyridinium	Oocytes-OCT2
DTD0005	SLC22A7	Inhibition	Bumetanide	Approved Drug	77.5	.	Bumetanide inhibits the transportation of Prostaglandin F2alpha by SLC22A7 (IC50 = 77.5 microM)	Prostaglandin F2alpha	The Proximal Tubule (S2) Cells-OAT2
DTD0025	SLC22A8	Inhibition	Tetramethrin	Natural Product	77.6	.	Tetramethrin inhibits the transportation of Fluorescein by SLC22A8 (IC50 = 77.6 microM)	Fluorescein	Human embryonic kidney 293 cells (HEK293)-OAT3
DTD0003	ABCB1	Inhibition	Troleandomycin	Approved Drug	78.2	.	Troleandomycin inhibits the transportation of LDS-751 by ABCB1 (IC50 = 78.2 microM)	LDS-751	NIH-3T3-G185-MDR1
DTD0025	SLC22A8	Inhibition	Glutarate	Investigative Drug	78.5	.	Glutarate inhibits the transportation of Estrone sulfate by SLC22A8 (IC50 = 78.5 microM)	Estrone sulfate	Human embryonic kidney 293 cells (HEK293)-OAT3
DTD0025	SLC22A8	Inhibition	Cimetidine	Approved Drug	79	.	Cimetidine inhibits the transportation of Sitagliptin by SLC22A8 (IC50 = 79 microM)	Sitagliptin	Chinese hamster ovary (CHO) cells-OAT3
DTD0024	SLC22A6	Inhibition	Rifampicin	Approved Drug	79.1	.	Rifampicin inhibits the transportation of Aminohippuric acid by SLC22A6 (IC50 = 79.1 microM)	Aminohippuric acid	Oocytes-OAT1
DTD0001	ABCC1	Inhibition	Genistein	Drug in Phase 2 Trial	80	.	Genistein inhibits the transportation of 2',7'-Bis-(3-carboxy-propyl)-5-(and-6)-carboxyfluorescein (BCPCF) by ABCC1 (IC50 = 80 microM)	2',7'-Bis-(3-carboxy-propyl)-5-(and-6)-carboxyfluorescein (BCPCF)	Human erythrocytes-MRP1
DTD0016	ABCC5	Inhibition	Sildenafil	Approved Drug	80	.	Sildenafil inhibits the transportation of 9-(2-Phosphonomethoxyethyl)adenine by ABCC5 (IC50 = 80 microM)	9-(2-Phosphonomethoxyethyl)adenine	Human embryonic kidney 293 cells (HEK293)-MRP4
DTD0006	SLC22A2	Inhibition	Prazosin	Approved Drug	80.4	.	Prazosin inhibits the transportation of YM155 by SLC22A2 (IC50 = 80.4 microM)	YM155	Human embryonic kidney 293 cells (HEK293)-OCT2
DTD0010	SLC22A1	Inhibition	Disopyramide	Approved Drug	81.7	.	Disopyramide inhibits the transportation of 4-(4-Dimethylamino)styryl-N-methylpyridinium (ASP+) by SLC22A1 (IC50 = 81.7 microM)	4-(4-Dimethylamino)styryl-N-methylpyridinium (ASP+)	Human embryonic kidney 293 cells (HEK293)-OCT1
DTD0024	SLC22A6	Inhibition	Cyclothiazide	Approved Drug	84.3	.	Cyclothiazide inhibits the transportation of Aminohippuric acid by SLC22A6 (IC50 = 84.3 microM)	Aminohippuric acid	The Proximal Tubule (S2) Cells-OAT1
DTD0031	SLCO2B1	Inhibition	Simvastatin	Approved Drug	84.7	.	Simvastatin inhibits the transportation of Estrone sulfate by SLCO2B1 (IC50 = 84.7 microM)	Estrone sulfate	Madin Darby canine kidney strain II (MDCKII) cells-OATP2B1
DTD0026	SLC22A11	Inhibition	Piroxicam	Approved Drug	84.9	.	Piroxicam inhibits the transportation of Estrone sulfate by SLC22A11 (IC50 = 84.9 microM)	Estrone sulfate	The Proximal Tubule (S2) Cells-OAT4
DTD0006	SLC22A2	Inhibition	Verapamil	Approved Drug	85	.	Verapamil inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 85 microM)	N-methylpyridinium	Human embryonic kidney 293 cells (HEK293)-OCT2
DTD0026	SLC22A11	Inhibition	Naproxen	Approved Drug	85.4	.	Naproxen inhibits the transportation of Estrone sulfate by SLC22A11 (IC50 = 85.4 microM)	Estrone sulfate	The Proximal Tubule (S2) Cells-OAT4
DTD0003	ABCB1	Inhibition	Troleandomycin	Approved Drug	86.3	.	Troleandomycin inhibits the transportation of Rhodamine 123 by ABCB1 (IC50 = 86.3 microM)	Rhodamine 123	NIH-3T3-G185-MDR1
DTD0026	SLC22A11	Inhibition	Cyclopiazonic acid	Mycotoxins	86.6	.	Cyclopiazonic acid inhibits the transportation of Organic anion by SLC22A11 (IC50 = 86.6 microM)	Organic anion	The Proximal Tubule (S2) Cells-OAT4
DTD0014	ABCB11	Inhibition	Delphinidin	Natural Product	87	.	Delphinidin inhibits the activity of ABCB11 (IC50 = 87 microM)	.	Human breast adenocarcinoma cell line (MCF-7)-BSEP
DTD0006	SLC22A2	Inhibition	Quinine	Approved Drug	87	.	Quinine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 87 microM)	N-methylpyridinium	Human embryonic kidney 293 cells (HEK293)-OCT2
DTD0006	SLC22A2	Inhibition	Tamoxifen	Approved Drug	87	.	Tamoxifen inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 87 microM)	N-methylpyridinium	Human embryonic kidney 293 cells (HEK293)-OCT2
DTD0003	ABCB1	Inhibition	Progesterone	Approved Drug	88.1	.	Progesterone inhibits the transportation of LDS-751 by ABCB1 (IC50 = 88.1 microM)	LDS-751	NIH-3T3-G185-MDR1
DTD0010	SLC22A1	Inhibition	Simvastatin	Approved Drug	89	.	Simvastatin inhibits the transportation of Metformin by SLC22A1 (IC50 = 89 microM)	Metformin	Human embryonic kidney 293 cells (HEK293)-OCT1
DTD0025	SLC22A8	Inhibition	Piperacillin	Approved Drug	89.04	172	Piperacillin inhibits the transporation of tazobactam by SLC22A8 (IC50 = 89.04 microM; Ki = 172 microM)	Tazobactam	Human embryonic kidney 293 cells (HEK293)
DTD0003	ABCB1	Inhibition	Vinblastine	Approved Drug	89.7	.	Vinblastine inhibits the transportation of Vinblastine by ABCB1 (IC50 = 89.7 microM)	Vinblastine	Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DTD0028	SLC47A2	Inhibition	Ritonavir	Approved Drug	90	.	Ritonavir inhibits the activity of SLC47A2 (IC50 = 90 microM)	.	.
DTD0180	SLC25A20	Inhibition	Mercury ion	Environmental toxicant	90	.	Mercury ion inhibits the activity of SLC25A20 (IC50 = 90 microM)	.	Human cervical cancer cell line (Hela)-CACT
DTD0031	SLCO2B1	Inhibition	Rifampicin	Approved Drug	90	.	Rifampicin inhibits the transportation of Bromsulphthalein by SLCO2B1 (IC50 = 90 microM)	Bromsulphthalein	Madin Darby canine kidney strain II (MDCKII) cells-OATP2B1
DTD0004	ABCG2	Inhibition	Chlordecone	Natural Product	90.4	.	Chlordecone inhibits the transportation of Hoechst 33342 by ABCG2 (IC50 = 90.4 microM)	Hoechst 33342	Human embryonic kidney 293 cells (HEK293)-BCRP
DTD0006	SLC22A2	Inhibition	Procainamide	Approved Drug	91.9	.	Procainamide inhibits the transportation of YM155 by SLC22A2 (IC50 = 91.9 microM)	YM155	Human embryonic kidney 293 cells (HEK293)-OCT2
DTD0026	SLC22A11	Inhibition	Novobiocin	Approved Drug	92.68	90.5	Novobiocin inhibits the transportation of Estrone sulfate by SLC22A11 (IC50 = 92.68 microM; Ki = 90.5 microM)	Estrone sulfate	Monkey kidney tissue Fibroblast-like cell lines (COS)7-OAT4
DTD0025	SLC22A8	Inhibition	Alpha-ketoglutaric acid	Investigative Drug	92.8	.	Alpha-ketoglutaric acid inhibits the transportation of Estrone sulfate by SLC22A8 (IC50 = 92.8 microM)	Estrone sulfate	Human embryonic kidney 293 cells (HEK293)-OAT3
DTD0003	ABCB1	Inhibition	Progesterone	Approved Drug	96.2	.	Progesterone inhibits the transportation of Daunorubicin by ABCB1 (IC50 = 96.2 microM)	Daunorubicin	NIH-3T3-G185-MDR1
DTD0030	SLCO1B3	Inhibition	Estrone sulfate	Investigative Drug	97.1	.	Estrone sulfate inhibits the transportation of Sincalide by SLCO1B3 (IC50 = 97.1 microM)	Sincalide	Human embryonic kidney 293 cells (HEK293)-OATP1B3
DTD0025	SLC22A8	Inhibition	Methazolamide	Approved Drug	97.5	.	Methazolamide inhibits the transportation of Estrone sulfate by SLC22A8 (IC50 = 97.5 microM)	Estrone sulfate	The Proximal Tubule (S2) Cells-OAT3
DTD0503	SLCO4C1	Inhibition	Quinidine	Drug Withdrawn	100	.	Quinidine inhibits the activity of SLCO4C1 (IC50 = 100 microM)	.	.
DTD0015	ABCC4	Inhibition	Probenecid	Approved Drug	100	.	Probenecid inhibits the transportation of Cholyltaurine by ABCC4 (IC50 = 100 microM)	Cholyltaurine	Chinese hamster lung fibroblasts V79 cells (V79)-MRP4
DTD0027	SLC22A12	Inhibition	Sulfinpyrazone	Approved Drug	100	.	Sulfinpyrazone inhibits the transportation of Uric acid by SLC22A12 (IC50 = 100 microM)	Uric acid	Human embryonic kidney 293 cells (HEK293)-URAT1
DTD0003	ABCB1	Inhibition	Tetramethrin	Natural Product	100	.	Tetramethrin inhibits the transportation of Verapamil by ABCB1 (IC50 = 100 microM)	Verapamil	Human embryonic kidney 293 cells (HEK293)-MDR1
DTD0031	SLCO2B1	Inhibition	Epigallocatechin gallate	Natural Product	101	.	(-)-epigallocatechin-3-gallate inhibits the activity of SLCO2B1 in a substrate-dependent manner (IC50 = 101 microM)	.	Chinese hamster ovary (CHO) cells-OATP2B1
DTD0007	SLC47A1	Inhibition	Carvedilol	Approved Drug	103	.	Carvedilol inhibits the activity of SLC47A1 (IC50 = 103 microM)	.	Human embryonic kidney 293 cells (HEK293)-MATE1
DTD0026	SLC22A11	Inhibition	Ibuprofen	Approved Drug	103	.	Ibuprofen inhibits the transportation of Estrone sulfate by SLC22A11 (IC50 = 103 microM)	Estrone sulfate	The Proximal Tubule (S2) Cells-OAT4
DTD0026	SLC22A11	Inhibition	Zearalenone	Mycotoxins	103	.	Zearalenone inhibits the transportation of Organic anion by SLC22A11 (IC50 = 103 microM)	Organic anion	The Proximal Tubule (S2) Cells-OAT4
DTD0016	ABCC5	Inhibition	Sulfinpyrazone	Approved Drug	103.2	.	Sulfinpyrazone inhibits the transportation of Carboxydichlorofluorescein by ABCC5 (IC50 = 103.2 microM)	Carboxydichlorofluorescein	Human embryonic kidney 293 cells (HEK293)-MRP5
DTD0024	SLC22A6	Inhibition	Aminohippuric acid	Investigative Drug	106	92	Aminohippuric acid inhibits the transportation of Bestatin by SLC22A6 (IC50 = 106 microM; Ki = 92 microM)	Bestatin	Human embryonic kidney 293 cells (HEK293)-OAT1
DTD0009	SLC22A3	Inhibition	YM155	Drug in Phase 2 Trial	108	.	YM155 inhibits the transportation of N-methylpyridinium by SLC22A3 (IC50 = 108 microM)	N-methylpyridinium	Human embryonic kidney 293 cells (HEK293)-OCT3
DTD0004	ABCG2	Inhibition	Enilconazole	Natural Product	109	.	Imazalil inhibits the transportation of WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) by ABCG2 (IC50 = 109 microM)	WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate)	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
DTD0503	SLCO4C1	Inhibition	Verapamil	Approved Drug	110	.	Verapamil inhibits the activity of SLCO4C1 (IC50 = 110 microM)	.	.
DTD0009	SLC22A3	Inhibition	Clonidine	Approved Drug	110	.	Clonidine inhibits the transportation of N-methylpyridinium by SLC22A3 (IC50 = 110 microM)	N-methylpyridinium	Chinese hamster ovary (CHO) cells-OCT3
DTD0006	SLC22A2	Inhibition	Cimetidine	Approved Drug	110	.	Cimetidine inhibits the transportation of YM155 by SLC22A2 (IC50 = 110 microM)	YM155	Human embryonic kidney 293 cells (HEK293)-OCT2
DTD0003	ABCB1	Inhibition	Alfentanil	Approved Drug	112	.	Alfentanil inhibits the transportation of Digoxin by ABCB1 (IC50 = 112 microM)	Digoxin	Human enterocyte-like 2 cell (Caco-2)-MDR1
DTD0003	ABCB1	Inhibition	Nifedipine	Approved Drug	113	.	Nifedipine inhibits the transportation of Daunorubicin by ABCB1 (IC50 = 113 microM)	Daunorubicin	NIH-3T3-G185-MDR1
DTD0006	SLC22A2	Inhibition	Famotidine	Approved Drug	114	.	Famotidine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 114 microM)	N-methylpyridinium	Oocytes-OCT2
DTD0003	ABCB1	Inhibition	Lovastatin	Approved Drug	114.4	.	Lovastatin inhibits the transportation of Rhodamine 123 by ABCB1 (IC50 = 114.4 microM)	Rhodamine 123	NIH-3T3-G185-MDR1
DTD0024	SLC22A6	Inhibition	Gliotoxin	Mycotoxins	117	.	Gliotoxin inhibits the transportation of Organic anion by SLC22A6 (IC50 = 117 microM)	Organic anion	The Proximal Tubule (S2) Cells-OAT1
DTD0006	SLC22A2	Inhibition	Gliotoxin	Mycotoxins	117	.	Gliotoxin inhibits the transportation of Organic cation by SLC22A2 (IC50 = 117 microM)	Organic cation	The Proximal Tubule (S2) Cells-OCT2
DTD0003	ABCB1	Inhibition	Erythromycin	Approved Drug	119	.	Erythromycin inhibits the transportation of Ximelagatran by ABCB1 (IC50 = 119 microM)	Ximelagatran	Human enterocyte-like 2 cell (Caco-2)-MDR1
DTD0003	ABCB1	Inhibition	Allicin	Natural Product	119.1	.	Allicin inhibits the transportation of Ritonavir by ABCB1 (IC50 = 119.1 microM)	Ritonavir	Madin darby canine kidney strain cell line (MDCK)-MDR1
DTD0008	SLCO1B1	Inhibition	Rifampicin	Approved Drug	120	.	Rifampicin inhibits the transportation of Bromsulphthalein by SLCO1B1 (IC50 = 120 microM)	Bromsulphthalein	Madin Darby canine kidney strain II (MDCKII) cells-OATP1B1
DTD0006	SLC22A2	Inhibition	Cimetidine	Approved Drug	120	.	Cimetidine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 120 microM)	N-methylpyridinium	Human embryonic kidney 293 cells (HEK293)-OCT2
DTD0006	SLC22A2	Inhibition	Aflatoxin B1	Mycotoxins	121	.	Aflatoxin B1 inhibits the transportation of Organic cation by SLC22A2 (IC50 = 121 microM)	Organic cation	The Proximal Tubule (S2) Cells-OCT2
DTD0005	SLC22A7	Inhibition	Ethacrynic Acid	Approved Drug	121	.	Ethacrynic acid inhibits the transportation of Prostaglandin F2alpha by SLC22A7 (IC50 = 121 microM)	Prostaglandin F2alpha	The Proximal Tubule (S2) Cells-OAT2
DTD0005	SLC22A7	Inhibition	Cyclopiazonic acid	Mycotoxins	126	.	Cyclopiazonic acid inhibits the transportation of Organic anion by SLC22A7 (IC50 = 126 microM)	Organic anion	The Proximal Tubule (S2) Cells-OAT2
DTD0024	SLC22A6	Inhibition	Aminohippuric acid	Investigative Drug	127	.	Aminohippuric acid inhibits the transportation of Uric acid by SLC22A6 (IC50 = 127 microM)	Uric acid	The Proximal Tubule (S2) Cells-OAT1
DTD0026	SLC22A11	Inhibition	Alpha-zearalenol	Mycotoxins	130	.	Alpha-zearalenol inhibits the transportation of Organic anion by SLC22A11 (IC50 = 130 microM)	Organic anion	The Proximal Tubule (S2) Cells-OAT4
DTD0456	SLC6A4	Inhibition	4-Fluoroephedrine	Natural Product	134	.	4-Fluoroephedrine inhibits the transportation of Dopamine by SLC6A4 (IC50 = 134 microM)	Dopamine	Human embryonic kidney 293 cells (HEK293)-SERT
DTD0025	SLC22A8	Inhibition	Adipate	Investigative Drug	136	.	Adipate inhibits the transportation of Estrone sulfate by SLC22A8 (IC50 = 136 microM)	Estrone sulfate	Human embryonic kidney 293 cells (HEK293)-OAT3
DTD0003	ABCB1	Inhibition	Chlordecone	Natural Product	138.8	.	Chlordecone inhibits the transportation of Rhodamine 123 by ABCB1 (IC50 = 138.8 microM)	Rhodamine 123	Human breast adenocarcinoma cell line (MCF-7)-MDR1
DTD0019	SLC10A1	Inhibition	Cigarette smoke condensate	Natural Product	140	.	Cigarette smoke condensate inhibits the transportation of Taurocholate by by repressing mRNA expression of SLC10A1 (IC50 = 140 microM)	Taurocholate	Human hepatoma HepaRG cells-NTCP
DTD0014	ABCB11	Inhibition	Glyburide	Approved Drug	146.5	.	Glibenclamide inhibits the transportation of Dihydrofluorescein by ABCB11 (IC50 = 146.5 microM)	Dihydrofluorescein	.
DTD0003	ABCB1	Inhibition	Kaempferol	Investigative Drug	146.7	.	Kaempferol inhibits the transportation of Ritonavir by ABCB1 (IC50 = 146.7 microM)	Ritonavir	Madin darby canine kidney strain cell line (MDCK)-MDR1
DTD0024	SLC22A6	Inhibition	Zearalenone	Mycotoxins	147	.	Zearalenone inhibits the transportation of Organic anion by SLC22A6 (IC50 = 147 microM)	Organic anion	The Proximal Tubule (S2) Cells-OAT1
DTD0004	ABCG2	Inhibition	Glyphosate	Natural Product	148	.	Glyphosate inhibits the transportation of WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) by ABCG2 (IC50 = 148 microM)	WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate)	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
DTD0005	SLC22A7	Inhibition	Zearalenone	Mycotoxins	149	.	Zearalenone inhibits the transportation of Organic anion by SLC22A7 (IC50 = 149 microM)	Organic anion	The Proximal Tubule (S2) Cells-OAT2
DTD0010	SLC22A1	Inhibition	Cimetidine	Approved Drug	149	.	Cimetidine inhibits the transportation of YM155 by SLC22A1 (IC50 = 149 microM)	YM155	Human embryonic kidney 293 cells (HEK293)-OCT1
DTD0015	ABCC4	Inhibition	Benzbromarone	Approved Drug	150	.	Benzbromarone inhibits the transportation of 9-(2-Phosphonomethoxyethyl)adenine by ABCC4 (IC50 = 150 microM)	9-(2-Phosphonomethoxyethyl)adenine	Human embryonic kidney 293 cells (HEK293)-MRP4
DTD0016	ABCC5	Inhibition	Benzbromarone	Approved Drug	150	.	Benzbromarone inhibits the transportation of 9-(2-Phosphonomethoxyethyl)adenine by ABCC5 (IC50 = 150 microM)	9-(2-Phosphonomethoxyethyl)adenine	Human embryonic kidney 293 cells (HEK293)-MRP4
DTD0025	SLC22A8	Inhibition	Sitagliptin	Approved Drug	160	.	Sitagliptin inhibits the transportation of Cimetidine by SLC22A8 (IC50 = 160 microM)	Cimetidine	Chinese hamster ovary (CHO) cells-OAT3
DTD0455	SLC6A3	Inhibition	4-Fluoroephedrine	Natural Product	163	.	4-Fluoroephedrine inhibits the transportation of Serotonin by SLC6A3 (IC50 = 163 microM)	Serotonin	Human embryonic kidney 293 cells (HEK293)-DAT1
DTD0010	SLC22A1	Inhibition	Tetraethylammonium	Investigative Drug	167	.	Tetraethylammonium inhibits the transportation of Tetraethylammonium by SLC22A1 (IC50 = 167 microM)	Tetraethylammonium	Oocytes-OCT1
DTD0027	SLC22A12	Inhibition	Uric acid	Investigative Drug	170	.	Uric acid inhibits the transportation of Oxypurinol by SLC22A12 (IC50 = 170 microM)	Oxypurinol	Oocytes-URAT1
DTD0005	SLC22A7	Inhibition	Alpha-zearalenol	Mycotoxins	180	.	Alpha-zearalenol inhibits the transportation of Organic anion by SLC22A7 (IC50 = 180 microM)	Organic anion	The Proximal Tubule (S2) Cells-OAT2
DTD0025	SLC22A8	Inhibition	Fumonisin B1	Natural Product	181	.	Fumonisin B1 inhibits the transportation of Organic anion by SLC22A8 (IC50 = 181 microM)	Organic anion	The Proximal Tubule (S2) Cells-OAT3
DTD0025	SLC22A8	Inhibition	Fumonisin B1	Mycotoxins	181	.	Fumonisin B1 inhibits the transportation of Organic anion by SLC22A8 (IC50 = 181 microM)	Organic anion	The Proximal Tubule (S2) Cells-OAT3
DTD0004	ABCG2	Inhibition	Amprenavir	Approved Drug	181	.	Amprenavir inhibits the transportation of Pheophorbide A by ABCG2 (IC50 = 181 microM)	Pheophorbide A	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
DTD0006	SLC22A2	Inhibition	Antiparasitics	Discontinued Drug	182	.	Antiparasitics inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 182 microM)	N-methylpyridinium	Chinese hamster ovary (CHO) cells-OCT2
DTD0010	SLC22A1	Inhibition	Pioglitazone	Approved Drug	185	.	Pioglitazone inhibits the transportation of Metformin by SLC22A1 (IC50 = 185 microM)	Metformin	Human embryonic kidney 293 cells (HEK293)-OCT1
DTD0006	SLC22A2	Inhibition	Tetraethylammonium	Investigative Drug	189.2	.	Tetraethylammonium inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 189.2 microM)	N-methylpyridinium	Chinese hamster ovary (CHO) cells-OCT2
DTD0006	SLC22A2	Inhibition	Flecainide	Approved Drug	191	.	Flecainide inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 191 microM)	N-methylpyridinium	Human embryonic kidney 293 cells (HEK293)-OCT2
DTD0003	ABCB1	Inhibition	Progesterone	Approved Drug	192.2	.	Progesterone inhibits the transportation of Rhodamine 123 by ABCB1 (IC50 = 192.2 microM)	Rhodamine 123	NIH-3T3-G185-MDR1
DTD0014	ABCB11	Inhibition	Petunidin	Natural Product	193	.	Petunidin inhibits the activity of ABCB11 (IC50 = 193 microM)	.	Human breast adenocarcinoma cell line (MCF-7)-BSEP
DTD0002	ABCC2	Inhibition	Cigarette smoke condensate	Natural Product	197.4	.	Cigarette smoke condensate inhibits the transportation of Rhodamine 123 by ABCC2 (IC50 = 197.4 microM)	Rhodamine 123	Human hepatoma HepaRG cells-MRP2
DTD0010	SLC22A1	Inhibition	Glyburide	Approved Drug	199	.	Glibenclamide inhibits the transportation of Metformin by SLC22A1 (IC50 = 199 microM)	Metformin	Human embryonic kidney 293 cells (HEK293)-OCT1
DTD0503	SLCO4C1	Inhibition	Clarithromycin	Approved Drug	200	.	Clarithromycin inhibits the activity of SLCO4C1 (IC50 = 200 microM)	.	.
DTD0016	ABCC5	Inhibition	MK-571	Discontinued Drug	200	.	MK-571 inhibits the transportation of 9-(2-Phosphonomethoxyethyl)adenine by ABCC5 (IC50 = 200 microM)	9-(2-Phosphonomethoxyethyl)adenine	Human embryonic kidney 293 cells (HEK293)-MRP4
DTD0016	ABCC5	Inhibition	Probenecid	Approved Drug	200	.	Probenecid inhibits the transportation of 9-(2-Phosphonomethoxyethyl)adenine by ABCC5 (IC50 = 200 microM)	9-(2-Phosphonomethoxyethyl)adenine	Human embryonic kidney 293 cells (HEK293)-MRP4
DTD0024	SLC22A6	Inhibition	Phenacetin	Drug Withdrawn	200	.	Phenacetin inhibits the transportation of Adefovir by SLC22A6 (IC50 = 200 microM)	Adefovir	Chinese hamster ovary (CHO) cells-OAT1
DTD0392	SLC51B	Inhibition	Indomethacin	Approved Drug	200	.	Indomethacin inhibits the transportation of Estrone sulfate by SLC51B (IC50 = 200 microM)	Estrone sulfate	Oocytes-OSTalpha-OSTbeta
DTD0392	SLC51B	Inhibition	Taurolithocholate	Investigative Drug	200	.	Taurolithocholate inhibits the transportation of Estrone sulfate by SLC51B (IC50 = 200 microM)	Estrone sulfate	Oocytes-OSTalpha-OSTbeta
DTD0028	SLC47A2	Inhibition	Carvedilol	Approved Drug	202	.	Carvedilol inhibits the activity of SLC47A2 (IC50 = 202 microM)	.	Human embryonic kidney 293 cells (HEK293)-MATE2
DTD0004	ABCG2	Inhibition	Dithianon	Natural Product	202	.	Dithianon inhibits the transportation of WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) by ABCG2 (IC50 = 202 microM)	WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate)	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
DTD0006	SLC22A2	Inhibition	Mefloquine	Approved Drug	204	.	Mefloquine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 204 microM)	N-methylpyridinium	Human embryonic kidney 293 cells (HEK293)-OCT2
DTD0014	ABCB11	Inhibition	Epigalocatechin gallate	Investigative Drug	214	.	Epigalocatechin gallate inhibits the transportation of Bodipy by ABCB11 (IC50 = 214 microM)	Bodipy	.
DTD0010	SLC22A1	Inhibition	Tetraethylammonium	Investigative Drug	216	.	Tetraethylammonium inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 216 microM)	N-methylpyridinium	Oocytes-OCT1
DTD0016	ABCC5	Inhibition	Trequinsin	Discontinued Drug	218	.	Trequinsin inhibits the transportation of Carboxydichlorofluorescein by ABCC5 (IC50 = 218 microM)	Carboxydichlorofluorescein	Human embryonic kidney 293 cells (HEK293)-MRP5
DTD0006	SLC22A2	Inhibition	Tetraethylammonium	Investigative Drug	222	.	Tetraethylammonium inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 222 microM)	N-methylpyridinium	Oocytes-OCT2
DTD0003	ABCB1	Inhibition	Cigarette smoke condensate	Natural Product	224.3	.	Cigarette smoke condensate inhibits the transportation of Rhodamine 123 by ABCB1 (IC50 = 224.3 microM)	Rhodamine 123	Human hepatoma HepaRG cells-MDR1
DTD0014	ABCB11	Inhibition	Progesterone	Approved Drug	224.6	.	Progesterone inhibits the transportation of Bodipy by ABCB11 (IC50 = 224.6 microM)	Bodipy	.
DTD0006	SLC22A2	Inhibition	Propranolol	Approved Drug	229	.	Propranolol inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 229 microM)	N-methylpyridinium	Human embryonic kidney 293 cells (HEK293)-OCT2
DTD0456	SLC6A4	Inhibition	Ephedrine	Approved Drug	230	.	Ephedrine inhibits the transportation of Dopamine by SLC6A4 (IC50 = 230 microM)	Dopamine	Human embryonic kidney 293 cells (HEK293)-SERT
DTD0023	SLC22A5	Inhibition	Cephaloridine	Drug Withdrawn	230	.	Cephaloridine inhibits the transportation of L-carnitine by SLC22A5 (IC50 = 230 microM)	L-carnitine	Human cervical cancer cell line (Hela)-OCTN2
DTD0003	ABCB1	Inhibition	Naringin	Investigative Drug	236	.	Naringin inhibits the transportation of Talinolol by ABCB1 (IC50 = 236 microM)	Talinolol	Human enterocyte-like 2 cell (Caco-2)-MDR1
DTD0003	ABCB1	Inhibition	SGX301	Natural Product	247	.	Hypericin inhibits the transportation of Ritonavir by ABCB1 (IC50 = 247 microM)	Ritonavir	Madin darby canine kidney strain cell line (MDCK)-MDR1
DTD0015	ABCC4	Inhibition	Zaprinast	Discontinued Drug	250	.	Zaprinast inhibits the transportation of 9-(2-Phosphonomethoxyethyl)adenine by ABCC4 (IC50 = 250 microM)	9-(2-Phosphonomethoxyethyl)adenine	Human embryonic kidney 293 cells (HEK293)-MRP4
DTD0016	ABCC5	Inhibition	Zaprinast	Discontinued Drug	250	.	Zaprinast inhibits the transportation of 9-(2-Phosphonomethoxyethyl)adenine by ABCC5 (IC50 = 250 microM)	9-(2-Phosphonomethoxyethyl)adenine	Human embryonic kidney 293 cells (HEK293)-MRP4
DTD0014	ABCB11	Inhibition	Glyburide	Approved Drug	260.1	.	Glibenclamide inhibits the transportation of Bodipy by ABCB11 (IC50 = 260.1 microM)	Bodipy	.
DTD0019	SLC10A1	Inhibition	Ketoconazole	Approved Drug	264	.	Ketoconazole inhibits the transportation of Sodium taurocholate by SLC10A1 (IC50 = 264 microM)	Sodium taurocholate	Human cervical cancer cell line (Hela)-NTCP
DTD0024	SLC22A6	Inhibition	Phenacetin	Drug Withdrawn	275	.	Phenacetin inhibits the transportation of Aminohippuric acid by SLC22A6 (IC50 = 275 microM)	Aminohippuric acid	The Proximal Tubule (S2) Cells-OAT1
DTD0024	SLC22A6	Inhibition	Salicylic Acid	Approved Drug	280	.	Salicylic acid inhibits the transportation of 6-Carboxyfluorescein by SLC22A6 (IC50 = 280 microM)	6-Carboxyfluorescein	Chinese hamster ovary (CHO) cells-OAT1
DTD0004	ABCG2	Inhibition	Chlorpyrifos	Natural Product	285	.	Chlorpyrifos inhibits the transportation of WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) by ABCG2 (IC50 = 285 microM)	WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate)	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
DTD0009	SLC22A3	Inhibition	Ranitidine	Approved Drug	290	.	Ranitidine inhibits the transportation of N-methylpyridinium by SLC22A3 (IC50 = 290 microM)	N-methylpyridinium	Oocytes-OCT3
DTD0016	ABCC5	Inhibition	Sulfinpyrazone	Approved Drug	300	.	Sulfinpyrazone inhibits the transportation of 9-(2-Phosphonomethoxyethyl)adenine by ABCC5 (IC50 = 300 microM)	9-(2-Phosphonomethoxyethyl)adenine	Human embryonic kidney 293 cells (HEK293)-MRP4
DTD0024	SLC22A6	Inhibition	Ketoconazole	Approved Drug	319	.	Ketoconazole inhibits the transportation of Aminohippuric acid by SLC22A6 (IC50 = 319 microM)	Aminohippuric acid	Oocytes-OAT1
DTD0006	SLC22A2	Inhibition	Disopyramide	Approved Drug	324	.	Disopyramide inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 324 microM)	N-methylpyridinium	Human embryonic kidney 293 cells (HEK293)-OCT2
DTD0024	SLC22A6	Inhibition	Salicylic Acid	Approved Drug	325	.	Salicylic acid inhibits the transportation of Aminohippuric acid by SLC22A6 (IC50 = 325 microM)	Aminohippuric acid	The Proximal Tubule (S2) Cells-OAT1
DTD0029	SLCO1A2	Inhibition	Naringin	Investigative Drug	343	.	Naringin inhibits the activity of SLCO1A2 (IC50 = 343 microM)	.	Oocytes-OATP1A2
DTD0026	SLC22A11	Inhibition	Bumetanide	Approved Drug	348	.	Bumetanide inhibits the transportation of Estrone sulfate by SLC22A11 (IC50 = 348 microM)	Estrone sulfate	The Proximal Tubule (S2) Cells-OAT4
DTD0021	SLC15A1	Inhibition	Cyclacillin	Approved Drug	350	.	Cyclacillin inhibits the transportation of Glycylsarcosine by SLC15A1 (IC50 = 350 microM)	Glycylsarcosine	Human cervical cancer cell line (Hela)-PEPT1
DTD0009	SLC22A3	Inhibition	Ranitidine	Approved Drug	372	.	Ranitidine inhibits the transportation of N-methylpyridinium by SLC22A3 (IC50 = 372 microM)	N-methylpyridinium	Chinese hamster ovary (CHO) cells-OCT3
DTD0006	SLC22A2	Inhibition	Cimetidine	Approved Drug	373	.	Cimetidine inhibits the transportation of Tetraethylammonium by SLC22A2 (IC50 = 373 microM)	Tetraethylammonium	Oocytes-OCT2
DTD0004	ABCG2	Inhibition	Abacavir	Approved Drug	385	.	Abacavir inhibits the transportation of Pheophorbide A by ABCG2 (IC50 = 385 microM)	Pheophorbide A	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
DTD0004	ABCG2	Inhibition	Thiacloprid	Natural Product	396	.	Thiacloprid inhibits the transportation of WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) by ABCG2 (IC50 = 396 microM)	WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate)	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
DTD0006	SLC22A2	Inhibition	Metformin	Approved Drug	398	.	Metformin inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 398 microM)	N-methylpyridinium	Human embryonic kidney 293 cells (HEK293)-OCT2
DTD0021	SLC15A1	Inhibition	Valacyclovir	Approved Drug	400	.	Valacyclovir inhibits the transportation of Glycylsarcosine by SLC15A1 (IC50 = 400 microM)	Glycylsarcosine	Chinese hamster ovary (CHO) cells-PEPT1
DTD0005	SLC22A7	Inhibition	Ketoprofen	Approved Drug	400	.	Ketoprofen inhibits the transportation of Prostaglandin F2alpha by SLC22A7 (IC50 = 400 microM)	Prostaglandin F2alpha	The Proximal Tubule (S2) Cells-OAT2
DTD0005	SLC22A7	Inhibition	Ketoprofen	Approved Drug	400	.	Ketoprofen inhibits the transportation of Salicylate by SLC22A7 (IC50 = 400 microM)	Salicylate	.
DTD0024	SLC22A6	Inhibition	Pravastatin	Approved Drug	408	.	Pravastatin inhibits the transportation of Aminohippuric acid by SLC22A6 (IC50 = 408 microM)	Aminohippuric acid	The Proximal Tubule (S2) Cells-OAT1
DTD0503	SLCO4C1	Inhibition	Levofloxacin	Approved Drug	420	.	Levofloxacin inhibits the activity of SLCO4C1 (IC50 = 420 microM)	.	.
DTD0015	ABCC4	Inhibition	Sulfinpyrazone	Approved Drug	420	.	Sulfinpyrazone inhibits the transportation of 9-(2-Phosphonomethoxyethyl)adenine by ABCC4 (IC50 = 420 microM)	9-(2-Phosphonomethoxyethyl)adenine	Human embryonic kidney 293 cells (HEK293)-MRP4
DTD0026	SLC22A11	Inhibition	Acetazolamide	Approved Drug	425	.	Acetazolamide inhibits the transportation of Estrone sulfate by SLC22A11 (IC50 = 425 microM)	Estrone sulfate	The Proximal Tubule (S2) Cells-OAT4
DTD0024	SLC22A6	Inhibition	Methazolamide	Approved Drug	438	.	Methazolamide inhibits the transportation of Aminohippuric acid by SLC22A6 (IC50 = 438 microM)	Aminohippuric acid	The Proximal Tubule (S2) Cells-OAT1
DTD0005	SLC22A7	Inhibition	Sulindac	Approved Drug	440	.	Sulindac inhibits the transportation of Prostaglandin F2alpha by SLC22A7 (IC50 = 440 microM)	Prostaglandin F2alpha	The Proximal Tubule (S2) Cells-OAT2
DTD0004	ABCG2	Inhibition	Methiocarb	Natural Product	440	.	Methiocarb inhibits the transportation of WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) by ABCG2 (IC50 = 440 microM)	WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate)	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
DTD0016	ABCC5	Inhibition	Pemetrexed	Approved Drug	442	.	Pemetrexed inhibits the transportation of Carboxydichlorofluorescein by ABCC5 (IC50 = 442 microM)	Carboxydichlorofluorescein	Human embryonic kidney 293 cells (HEK293)-MRP5
DTD0010	SLC22A1	Inhibition	Etilefrine	Drug Withdrawn	447	.	Etilefrine inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 447 microM)	N-methylpyridinium	Human embryonic kidney 293 cells (HEK293)-OCT1
DTD0004	ABCG2	Inhibition	Epoxiconazole	Natural Product	455	.	Epoxiconazole inhibits the transportation of WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) by ABCG2 (IC50 = 455 microM)	WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate)	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
DTD0009	SLC22A3	Inhibition	Atropine	Approved Drug	466	.	Atropine inhibits the transportation of N-methylpyridinium by SLC22A3 (IC50 = 466 microM)	N-methylpyridinium	Chinese hamster ovary (CHO) cells-OCT3
DTD0010	SLC22A1	Inhibition	Tetraethylammonium	Investigative Drug	469.7	.	Tetraethylammonium inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 469.7 microM)	N-methylpyridinium	Chinese hamster ovary (CHO) cells-OCT1
DTD0003	ABCB1	Inhibition	Nifedipine	Approved Drug	472	.	Nifedipine inhibits the transportation of Digoxin by ABCB1 (IC50 = 472 microM)	Digoxin	LLC-PK1 vesicles-MDR1
DTD0005	SLC22A7	Inhibition	Naproxen	Approved Drug	486	.	Naproxen inhibits the transportation of Prostaglandin F2alpha by SLC22A7 (IC50 = 486 microM)	Prostaglandin F2alpha	The Proximal Tubule (S2) Cells-OAT2
DTD0006	SLC22A2	Inhibition	Metformin	Approved Drug	521	.	Metformin inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 521 microM)	N-methylpyridinium	Oocytes-OCT2
DTD0004	ABCG2	Inhibition	Carbendazim	Environmental toxicant	525	.	Carbendazim inhibits the transportation of WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) by ABCG2 (IC50 = 525 microM)	WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate)	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
DTD0004	ABCG2	Inhibition	Ioxynil	Natural Product	540	.	Ioxynil inhibits the transportation of WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) by ABCG2 (IC50 = 540 microM)	WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate)	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
DTD0027	SLC22A12	Inhibition	Losartan	Approved Drug	570.5	.	Losartan inhibits the transportation of Uric acid by SLC22A12 (IC50 = 570.5 microM)	Uric acid	Human embryonic kidney 293 cells (HEK293)-URAT1
DTD0016	ABCC5	Inhibition	Sildenafil	Approved Drug	580	.	Sildenafil inhibits the transportation of 5-Fluorodeoxyuridine monophosphate by ABCC5 (IC50 = 580 microM)	5-Fluorodeoxyuridine monophosphate	Human embryonic kidney 293 cells (HEK293)-MRP5
DTD0016	ABCC5	Inhibition	Trequinsin	Discontinued Drug	580	.	Trequinsin inhibits the transportation of 5-Fluorodeoxyuridine monophosphate by ABCC5 (IC50 = 580 microM)	5-Fluorodeoxyuridine monophosphate	Human embryonic kidney 293 cells (HEK293)-MRP5
DTD0010	SLC22A1	Inhibition	Gliotoxin	Mycotoxins	584	.	Gliotoxin inhibits the transportation of Organic cation by SLC22A1 (IC50 = 584 microM)	Organic cation	The Proximal Tubule (S2) Cells-OCT1
DTD0021	SLC15A1	Inhibition	Cyclacillin	Approved Drug	600	.	Cyclacillin inhibits the transportation of Glycylsarcosine by SLC15A1 (IC50 = 600 microM)	Glycylsarcosine	Human enterocyte-like 2 cell (Caco-2)-PEPT1
DTD0005	SLC22A7	Inhibition	Furosemide	Approved Drug	603	.	Furosemide inhibits the transportation of Prostaglandin F2alpha by SLC22A7 (IC50 = 603 microM)	Prostaglandin F2alpha	The Proximal Tubule (S2) Cells-OAT2
DTD0022	SLC15A2	Inhibition	Cyclacillin	Approved Drug	610	.	Cyclacillin inhibits the transportation of Glycylsarcosine by SLC15A2 (IC50 = 610 microM)	Glycylsarcosine	Human cervical cancer cell line (Hela)-PEPT2
DTD0026	SLC22A11	Inhibition	Sulindac	Approved Drug	617	.	Sulindac inhibits the transportation of Estrone sulfate by SLC22A11 (IC50 = 617 microM)	Estrone sulfate	The Proximal Tubule (S2) Cells-OAT4
DTD0005	SLC22A7	Inhibition	Ibuprofen	Approved Drug	692	.	Ibuprofen inhibits the transportation of Prostaglandin F2alpha by SLC22A7 (IC50 = 692 microM)	Prostaglandin F2alpha	The Proximal Tubule (S2) Cells-OAT2
DTD0009	SLC22A3	Inhibition	Diphenhydramine	Approved Drug	695	.	Diphenhydramine inhibits the transportation of N-methylpyridinium by SLC22A3 (IC50 = 695 microM)	N-methylpyridinium	Chinese hamster ovary (CHO) cells-OCT3
DTD0006	SLC22A2	Inhibition	Butylscopolamine	Approved Drug	764	.	Butylscopolamine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 764 microM)	N-methylpyridinium	Human embryonic kidney 293 cells (HEK293)-OCT2
DTD0024	SLC22A6	Inhibition	Fumonisin B1	Natural Product	768	.	Fumonisin B1 inhibits the transportation of Organic anion by SLC22A6 (IC50 = 768 microM)	Organic anion	The Proximal Tubule (S2) Cells-OAT1
DTD0024	SLC22A6	Inhibition	Fumonisin B1	Mycotoxins	768	.	Fumonisin B1 inhibits the transportation of Organic anion by SLC22A6 (IC50 = 768 microM)	Organic anion	The Proximal Tubule (S2) Cells-OAT1
DTD0024	SLC22A6	Inhibition	Aspirin	Approved Drug	769	.	Aspirin inhibits the transportation of Aminohippuric acid by SLC22A6 (IC50 = 769 microM)	Aminohippuric acid	The Proximal Tubule (S2) Cells-OAT1
DTD0016	ABCC5	Inhibition	Methotrexate	Approved Drug	780	.	Methotrexate inhibits the transportation of 5-Fluorodeoxyuridine monophosphate by ABCC5 (IC50 = 780 microM)	5-Fluorodeoxyuridine monophosphate	Human embryonic kidney 293 cells (HEK293)-MRP5
DTD0006	SLC22A2	Inhibition	Pyridine	Drug in Phase 4 Trial	790	.	Pyridine inhibits the transportation of Tetraethylammonium by SLC22A2 (IC50 = 790 microM)	Tetraethylammonium	Chinese hamster ovary (CHO) cells-OCT2
DTD0025	SLC22A8	Inhibition	Acetazolamide	Approved Drug	816	.	Acetazolamide inhibits the transportation of Estrone sulfate by SLC22A8 (IC50 = 816 microM)	Estrone sulfate	The Proximal Tubule (S2) Cells-OAT3
DTD0026	SLC22A11	Inhibition	Citrioveridine	Mycotoxins	823	.	Citrioveridine inhibits the transportation of Organic anion by SLC22A11 (IC50 = 823 microM)	Organic anion	The Proximal Tubule (S2) Cells-OAT4
DTD0025	SLC22A8	Inhibition	Hydrochlorothiazide	Approved Drug	942	.	Hydrochlorothiazide inhibits the transportation of Estrone sulfate by SLC22A8 (IC50 = 942 microM)	Estrone sulfate	The Proximal Tubule (S2) Cells-OAT3
DTD0021	SLC15A1	Inhibition	Bestatin	Approved Drug	1000	.	Bestatin inhibits the transporation of melatonin by SLC15A1 (IC50 = 1000 microM)	Melatonin	Human enterocyte-like 2 cell (Caco-2)
DTD0022	SLC15A2	Inhibition	Bestatin	Approved Drug	1000	.	Bestatin inhibits the transporation of melatonin by SLC15A2 (IC50 = 1000 microM)	Melatonin	Human enterocyte-like 2 cell (Caco-2)
DTD0005	SLC22A7	Inhibition	Hydrochlorothiazide	Approved Drug	1023	.	Hydrochlorothiazide inhibits the transportation of Prostaglandin F2alpha by SLC22A7 (IC50 = 1023 microM)	Prostaglandin F2alpha	The Proximal Tubule (S2) Cells-OAT2
DTD0006	SLC22A2	Inhibition	Chloroquine	Approved Drug	1096	.	Chloroquine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 1096 microM)	N-methylpyridinium	Human embryonic kidney 293 cells (HEK293)-OCT2
DTD0024	SLC22A6	Inhibition	Cyclic cidofovir	Discontinued Drug	1100	.	Cyclic cidofovir inhibits the transportation of 6-Carboxyfluorescein by SLC22A6 (IC50 = 1100 microM)	6-Carboxyfluorescein	Chinese hamster ovary (CHO) cells-OAT1
DTD0005	SLC22A7	Inhibition	Trichlormethiazide	Approved Drug	1120	.	Trichloromethiazide inhibits the transportation of Prostaglandin F2alpha by SLC22A7 (IC50 = 1120 microM)	Prostaglandin F2alpha	The Proximal Tubule (S2) Cells-OAT2
DTD0010	SLC22A1	Inhibition	Metformin	Approved Drug	1231	.	Metformin inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 1231 microM)	N-methylpyridinium	Oocytes-OCT1
DTD0180	SLC25A20	Inhibition	Methyl mercury ion	Environmental toxicant	1237	.	Methyl mercury ion inhibits the activity of SLC25A20 (IC50 = 1237 microM)	.	Human cervical cancer cell line (Hela)-CACT
DTD0009	SLC22A3	Inhibition	Tetraethylammonium	Investigative Drug	1237	.	Tetraethylammonium inhibits the transportation of N-methylpyridinium by SLC22A3 (IC50 = 1237 microM)	N-methylpyridinium	Oocytes-OCT3
DTD0024	SLC22A6	Inhibition	Cephaloridine	Drug Withdrawn	1250	.	Cephaloridine inhibits the transportation of 6-Carboxyfluorescein by SLC22A6 (IC50 = 1250 microM)	6-Carboxyfluorescein	Chinese hamster ovary (CHO) cells-OAT1
DTD0004	ABCG2	Inhibition	Chlormequate chloride	Natural Product	1260	.	Chlormequate chloride inhibits the transportation of WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) by ABCG2 (IC50 = 1260 microM)	WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate)	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
DTD0006	SLC22A2	Inhibition	Trimethoprim	Approved Drug	1318	.	Trimethoprim inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 1318 microM)	N-methylpyridinium	Human embryonic kidney 293 cells (HEK293)-OCT2
DTD0005	SLC22A7	Inhibition	Cefoperazone	Approved Drug	1330	.	Cefoperazone inhibits the transportation of Prostaglandin F2alpha by SLC22A7 (IC50 = 1330 microM)	Prostaglandin F2alpha	The Proximal Tubule (S2) Cells-OAT2
DTD0005	SLC22A7	Inhibition	Cephalothin	Approved Drug	1410	.	Cephalothin inhibits the transportation of Prostaglandin F2alpha by SLC22A7 (IC50 = 1410 microM)	Prostaglandin F2alpha	The Proximal Tubule (S2) Cells-OAT2
DTD0009	SLC22A3	Inhibition	Tetraethylammonium	Investigative Drug	1476.6	.	Tetraethylammonium inhibits the transportation of N-methylpyridinium by SLC22A3 (IC50 = 1476.6 microM)	N-methylpyridinium	Chinese hamster ovary (CHO) cells-OCT3
DTD0005	SLC22A7	Inhibition	Aflatoxin B1	Mycotoxins	1502	.	Aflatoxin B1 inhibits the transportation of Organic anion by SLC22A7 (IC50 = 1502 microM)	Organic anion	The Proximal Tubule (S2) Cells-OAT2
DTD0026	SLC22A11	Inhibition	Trichlormethiazide	Approved Drug	1505	.	Trichloromethiazide inhibits the transportation of Estrone sulfate by SLC22A11 (IC50 = 1505 microM)	Estrone sulfate	The Proximal Tubule (S2) Cells-OAT4
DTD0005	SLC22A7	Inhibition	Cefamandole	Approved Drug	1570	.	Cefamandole inhibits the transportation of Prostaglandin F2alpha by SLC22A7 (IC50 = 1570 microM)	Prostaglandin F2alpha	The Proximal Tubule (S2) Cells-OAT2
DTD0024	SLC22A6	Inhibition	Cephradine	Approved Drug	1600	.	Cephradine inhibits the transportation of 6-Carboxyfluorescein by SLC22A6 (IC50 = 1600 microM)	6-Carboxyfluorescein	Chinese hamster ovary (CHO) cells-OAT1
DTD0006	SLC22A2	Inhibition	Ranitidine	Approved Drug	1617	.	Ranitidine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 1617 microM)	N-methylpyridinium	Human embryonic kidney 293 cells (HEK293)-OCT2
DTD0023	SLC22A5	Inhibition	Cefepime	Approved Drug	1700	.	Cefepime inhibits the transportation of L-carnitine by SLC22A5 (IC50 = 1700 microM)	L-carnitine	Human cervical cancer cell line (Hela)-OCTN2
DTD0024	SLC22A6	Inhibition	Fumarate	Investigative Drug	1733	.	Fumarate inhibits the transportation of Aminohippuric acid by SLC22A6 (IC50 = 1733 microM)	Aminohippuric acid	Human embryonic kidney 293 cells (HEK293)-OAT1
DTD0004	ABCG2	Inhibition	Azoxystrobin	Natural Product	1860	.	Azoxystrobin inhibits the transportation of WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) by ABCG2 (IC50 = 1860 microM)	WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate)	Madin Darby canine kidney strain II (MDCKII) cells-BCRP
DTD0005	SLC22A7	Inhibition	Phenacetin	Drug Withdrawn	1878	.	Phenacetin inhibits the transportation of Prostaglandin F2alpha by SLC22A7 (IC50 = 1878 microM)	Prostaglandin F2alpha	The Proximal Tubule (S2) Cells-OAT2
DTD0016	ABCC5	Inhibition	Pemetrexed	Approved Drug	2110	.	Pemetrexed inhibits the transportation of 5-Fluorodeoxyuridine monophosphate by ABCC5 (IC50 = 2110 microM)	5-Fluorodeoxyuridine monophosphate	Human embryonic kidney 293 cells (HEK293)-MRP5
DTD0005	SLC22A7	Inhibition	Chlorothiazide	Approved Drug	2205	.	Chlorothiazide inhibits the transportation of Prostaglandin F2alpha by SLC22A7 (IC50 = 2205 microM)	Prostaglandin F2alpha	The Proximal Tubule (S2) Cells-OAT2
DTD0015	ABCC4	Inhibition	Probenecid	Approved Drug	2300	.	Probenecid inhibits the transportation of 9-(2-Phosphonomethoxyethyl)adenine by ABCC4 (IC50 = 2300 microM)	9-(2-Phosphonomethoxyethyl)adenine	Human embryonic kidney 293 cells (HEK293)-MRP4
DTD0009	SLC22A3	Inhibition	Metformin	Approved Drug	2332	.	Metformin inhibits the transportation of N-methylpyridinium by SLC22A3 (IC50 = 2332 microM)	N-methylpyridinium	Oocytes-OCT3
DTD0003	ABCB1	Inhibition	Naringenin	Drug in Phase 1 Trial	2409	.	Naringenin inhibits the transportation of Talinolol by ABCB1 (IC50 = 2409 microM)	Talinolol	Human enterocyte-like 2 cell (Caco-2)-MDR1
DTD0026	SLC22A11	Inhibition	Chlorothiazide	Approved Drug	2632	.	Chlorothiazide inhibits the transportation of Estrone sulfate by SLC22A11 (IC50 = 2632 microM)	Estrone sulfate	The Proximal Tubule (S2) Cells-OAT4
DTD0006	SLC22A2	Inhibition	Etilefrine	Drug Withdrawn	4009	.	Etilefrine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 4009 microM)	N-methylpyridinium	Human embryonic kidney 293 cells (HEK293)-OCT2
DTD0009	SLC22A3	Inhibition	Etilefrine	Drug Withdrawn	4448	.	Etilefrine inhibits the transportation of N-methylpyridinium by SLC22A3 (IC50 = 4448 microM)	N-methylpyridinium	Chinese hamster ovary (CHO) cells-OCT3
DTD0005	SLC22A7	Inhibition	Cephaloridine	Drug Withdrawn	4480	.	Cephaloridine inhibits the transportation of Prostaglandin F2alpha by SLC22A7 (IC50 = 4480 microM)	Prostaglandin F2alpha	The Proximal Tubule (S2) Cells-OAT2
DTD0005	SLC22A7	Inhibition	Cefotaxime	Approved Drug	4680	.	Cefotaxime inhibits the transportation of Prostaglandin F2alpha by SLC22A7 (IC50 = 4680 microM)	Prostaglandin F2alpha	The Proximal Tubule (S2) Cells-OAT2
DTD0023	SLC22A5	Inhibition	Cefoselis	Approved Drug	6400	.	Cefoselis inhibits the transportation of L-carnitine by SLC22A5 (IC50 = 6400 microM)	L-carnitine	Human cervical cancer cell line (Hela)-OCTN2
DTD0021	SLC15A1	Inhibition	Ampicillin	Approved Drug	10000	.	Ampicillin inhibits the transportation of Glycylsarcosine by SLC15A1 (IC50 = 10000 microM)	Glycylsarcosine	Chinese hamster ovary (CHO) cells-PEPT1
DTD0021	SLC15A1	Inhibition	Cefixime	Approved Drug	10000	.	Cefixime inhibits the transportation of Glycylsarcosine by SLC15A1 (IC50 = 10000 microM)	Glycylsarcosine	Human enterocyte-like 2 cell (Caco-2)-PEPT1
DTD0021	SLC15A1	Inhibition	Levodopa	Approved Drug	141200	.	Levodopa inhibits the transportation of Glycylsarcosine by SLC15A1 (IC50 = 141200 microM)	Glycylsarcosine	Chinese hamster ovary (CHO) cells-PEPT1
DTD0021	SLC15A1	Inhibition	Methyldopa	Approved Drug	151600	.	Methyldopa inhibits the transportation of Glycylsarcosine by SLC15A1 (IC50 = 151600 microM)	Glycylsarcosine	Chinese hamster ovary (CHO) cells-PEPT1
DTD0001	ABCC1	Inducer	27-hydroxycholesterol	Investigative Drug	.	.	27-hydroxycholesterol increases the expression of ABCC1	.	.
DTD0001	ABCC1	Inducer	2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine	Acute Toxic Substance	.	.	2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine increases the expression of ABCC1	.	.
DTD0001	ABCC1	Inducer	2-tert-butylhydroquinone	Environmental toxicant	.	.	2-tert-butylhydroquinone increases the expression of ABCC1	.	.
DTD0001	ABCC1	Inhibition	3,3',4,5'-tetrahydroxystilbene	Investigative Drug	.	.	3,3',4,5'-tetrahydroxystilbene inhibits the activity of ABCC1	.	.
DTD0001	ABCC1	Inhibition	3-methylquercetin	Health and Environmental Toxicant	.	.	3-methylquercetin inhibits the activity of ABCC1	.	.
DTD0001	ABCC1	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen induces the activity of ABCC1	.	.
DTD0001	ABCC1	Modulator	Adenosine Triphosphate	Drug in Phase 1 Trial	.	.	Adenosine Triphosphate affects the activity of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Apigenin	Natural Product	.	.	Apigenin inhibits the activity of ABCC1	.	.
DTD0001	ABCC1	Inducer	Apple polyphenol extract	Plant Extract	.	.	Apple polyphenol extract increases the expression of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Arsenic Trioxide	Approved Drug	.	.	Arsenic Trioxide inhibits the expression of ABCC1	.	.
DTD0001	ABCC1	Inducer	Aspirin	Approved Drug	.	.	Aspirin increases the expression of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Avermectin B1a	Acute Toxic Substance	.	.	Avermectin B1a inhibits the activity of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Baicalein	Natural Product	.	.	Baicalein inhibits the activity of ABCC1	.	.
DTD0001	ABCC1	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Biochanin A	Natural Product	.	.	Biochanin A inhibits the activity of ABCC1	.	.
DTD0001	ABCC1	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Bortezomib	Approved Drug	.	.	Bortezomib inhibits the expression of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Budesonide	Approved Drug	.	.	Budesonide inhibits the activity of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde inhibits the expression of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Cannabidiol	Approved Drug	.	.	Cannabidiol inhibits the activity of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Celecoxib	Approved Drug	.	.	Celecoxib inhibits the activity of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Chloroquine	Approved Drug	.	.	Chloroquine inhibits the expression of ABCC1	.	.
DTD0001	ABCC1	Inducer	Clothianidin	Pesticide/Insecticide	.	.	Clothianidin increases the expression of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Clotrimazole	Approved Drug	.	.	Clotrimazole inhibits the activity of ABCC1	.	.
DTD0001	ABCC1	Inducer	Copper Sulfate	Approved Drug	.	.	Copper Sulfate increases the expression of ABCC1	.	.
DTD0001	ABCC1	Inducer	Dabrafenib	Approved Drug	.	.	Dabrafenib increases the expression of ABCC1	.	.
DTD0001	ABCC1	Inducer	Daunorubicin	Approved Drug	.	.	Daunorubicin induces the activity of ABCC1	.	.
DTD0001	ABCC1	Inducer	Decitabine	Approved Drug	.	.	Decitabine increases the expression of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Demethoxycurcumin	Environmental toxicant	.	.	Demethoxycurcumin inhibits the activity of ABCC1	.	.
DTD0001	ABCC1	Inducer	Dicrotophos	Pesticide/Insecticide	.	.	Dicrotophos increases the expression of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Dihydrotestosterone	Drug in Phase 1 Trial	.	.	Dihydrotestosterone inhibits the expression of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Diosmetin	Natural Product	.	.	Diosmetin inhibits the activity of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Dipyridamole	Approved Drug	.	.	Dipyridamole inhibits the activity of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Disulfiram	Approved Drug	.	.	Disulfiram inhibits the activity of ABCC1	.	.
DTD0001	ABCC1	Inducer	Docetaxel	Approved Drug	.	.	Docetaxel increases the expression of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Dronabinol	Approved Drug	.	.	Dronabinol inhibits the activity of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Epigallocatechin gallate	Drug in Phase 3 Trial	.	.	Epigallocatechin gallate inhibits the expression of ABCC1	.	.
DTD0001	ABCC1	Inducer	Epirubicin	Approved Drug	.	.	Epirubicin induces the activity of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Epsilon-viniferin	Drug in Phase 1 Trial	.	.	Epsilon-viniferin inhibits the activity of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Eriodictyol	Drug in Phase 1 Trial	.	.	Eriodictyol inhibits the activity of ABCC1	.	.
DTD0001	ABCC1	Inducer	Estradiol	Approved Drug	.	.	Estradiol induces the activity of ABCC1	.	.
DTD0001	ABCC1	Inducer	Ethanol	Approved Drug	.	.	Ethanol induces the activity of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Flavone	Natural Product	.	.	Flavone inhibits the activity of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Flavonoids	Natural Product	.	.	Flavonoids inhibits the expression of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Formononetin	Drug Marketed but not Approved by US FDA	.	.	Formononetin inhibits the expression of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Galangin	Natural Product	.	.	Galangin inhibits the activity of ABCC1	.	.
DTD0001	ABCC1	Modulator	Gallocatechol	Natural Product	.	.	Gallocatechol affects the activity of ABCC1	.	.
DTD0001	ABCC1	Inducer	Glutathiol	Drug in Phase 1 Trial	.	.	Glutathiol increases the activity of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Glyburide	Approved Drug	.	.	Glibenclamide inhibits the activity of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Haloperidol	Approved Drug	.	.	Haloperidol inhibits the expression of ABCC1	.	.
DTD0001	ABCC1	Modulator	Heparin	Approved Drug	.	.	Heparin affects the activity of ABCC1	.	.
DTD0001	ABCC1	Inducer	HSDB-3466	Drug in Phase 1 Trial	.	.	HSDB-3466 increases the expression of ABCC1	.	.
DTD0001	ABCC1	Inhibition	HSDB-595	Patented Pharmaceutical Agent	.	.	HSDB-595 inhibits the expression of ABCC1	.	.
DTD0001	ABCC1	Inhibition	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 inhibits the expression of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Indomethacin	Approved Drug	.	.	Indomethacin inhibits the activity of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Irinotecan	Approved Drug	.	.	Irinotecan inhibits the expression of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Ivermectin	Approved Drug	.	.	Ivermectin inhibits the activity of ABCC1	.	.
DTD0001	ABCC1	Inducer	Leflunomide	Approved Drug	.	.	Leflunomide increases the expression of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Lovastatin	Approved Drug	.	.	Lovastatin inhibits the activity of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Luteolin	Drug in Phase 1 Trial	.	.	Luteolin inhibits the activity of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Mebendazole	Approved Drug	.	.	Mebendazole inhibits the expression of ABCC1	.	.
DTD0001	ABCC1	Inducer	Menadione	Approved Drug	.	.	Menadione induces the activity of ABCC1	.	.
DTD0001	ABCC1	Inducer	Mercuric Chloride	Acute Toxic Substance	.	.	Mercuric Chloride increases the expression of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Methotrexate	Approved Drug	.	.	Methotrexate inhibits the expression of ABCC1	.	.
DTD0001	ABCC1	Inducer	Methoxsalen	Approved Drug	.	.	Methoxsalen increases the expression of ABCC1	.	.
DTD0001	ABCC1	Inhibition	MK-571	Discontinued Drug	.	.	MK-571 inhibits the activity of ABCC1	.	.
DTD0001	ABCC1	Modulator	Monomethylarsonic acid	Herbicide	.	.	Monomethylarsonic acid affects the expression of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Morin	Acute Toxic Substance	.	.	Morin inhibits the activity of ABCC1	.	.
DTD0001	ABCC1	Inducer	Naringenin	Drug in Phase 1 Trial	.	.	Naringenin increases the activity of ABCC1	.	.
DTD0001	ABCC1	Modulator	N-ethylmaleimide	Investigative Drug	.	.	N-ethylmaleimide affects the activity of ABCC1	.	.
DTD0001	ABCC1	Inducer	Nimesulide	Drug Withdrawn	.	.	Nimesulide increases the expression of ABCC1	.	.
DTD0001	ABCC1	Inducer	Nimustine	Drug in Phase 2 Trial	.	.	Nimustine increases the expression of ABCC1	.	.
DTD0001	ABCC1	Inducer	NS-398	Drug in Phase 1 Trial	.	.	NS-398 increases the expression of ABCC1	.	.
DTD0001	ABCC1	Inducer	Ouabain	Approved Drug	.	.	Ouabain induces the activity of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Paraquat	Acute Toxic Substance	.	.	Paraquat inhibits the expression of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Perfluorooctane sulfonic acid	Health and Environmental Toxicant	.	.	Perfluorooctane sulfonic acid inhibits the expression of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Phenethyl caffeate	Drug in Phase 1 Trial	.	.	Phenethyl caffeate inhibits the activity of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Plant Extracts	Plant Extract	.	.	Plant Extracts inhibits the expression of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Polyphenols	Natural Product	.	.	Polyphenols inhibits the expression of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Probenecid	Approved Drug	.	.	Probenecid inhibits the activity of ABCC1	.	.
DTD0001	ABCC1	Inducer	Puromycin	Mycotoxins	.	.	Puromycin increases the expression of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Quinine	Approved Drug	.	.	Quinine inhibits the activity of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Resveratrol	Drug in Phase 3 Trial	.	.	Resveratrol inhibits the expression of ABCC1	.	.
DTD0001	ABCC1	Inducer	Rifampin	Approved Drug	.	.	Rifampin increases the expression of ABCC1	.	.
DTD0001	ABCC1	Inducer	Ritonavir	Approved Drug	.	.	Ritonavir induces the activity of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Robinetin	Natural Product	.	.	Robinetin inhibits the activity of ABCC1	.	.
DTD0001	ABCC1	Inducer	Rofecoxib	Approved Drug	.	.	Rofecoxib induces the activity of ABCC1	.	.
DTD0001	ABCC1	Inducer	Saquinavir	Approved Drug	.	.	Saquinavir induces the activity of ABCC1	.	.
DTD0001	ABCC1	Inducer	SGX301	Drug in Phase 3 Trial	.	.	SGX301 increases the expression of ABCC1	.	.
DTD0001	ABCC1	Inducer	Silver nanoparticle	Nanoparticle	.	.	Silver nanoparticle increases the expression of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Silymarin	Drug in Phase 4 Trial	.	.	Silymarin inhibits the activity of ABCC1	.	.
DTD0001	ABCC1	Inducer	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite increases the expression of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Sulfinpyrazone	Approved Drug	.	.	Sulfinpyrazone inhibits the activity of ABCC1	.	.
DTD0001	ABCC1	Inducer	Sulindac	Approved Drug	.	.	Sulindac increases the expression of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Taxifolin	Natural Product	.	.	Taxifolin inhibits the activity of ABCC1	.	.
DTD0001	ABCC1	Inducer	Temozolomide	Approved Drug	.	.	Temozolomide induces the activity of ABCC1	.	.
DTD0001	ABCC1	Inducer	Testosterone	Approved Drug	.	.	Testosterone increases the expression of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Tetrabromobisphenol A	Environmental toxicant	.	.	Tetrabromobisphenol A inhibits the activity of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Tetradecanoylphorbol Acetate	Drug in Phase 1 Trial	.	.	Tetradecanoylphorbol Acetate inhibits the expression of ABCC1	.	.
DTD0001	ABCC1	Inducer	Titanium dioxide	Approved Drug	.	.	Titanium dioxide increases the expression of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Trastuzumab	Approved Drug	.	.	Trastuzumab inhibits the activity of ABCC1	.	.
DTD0001	ABCC1	Inducer	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan increases the expression of ABCC1	.	.
DTD0001	ABCC1	Modulator	Valproic Acid	Approved Drug	.	.	Valproic Acid affects the expression of ABCC1	.	.
DTD0001	ABCC1	Inducer	Venlafaxine Hydrochloride	Approved Drug	.	.	Venlafaxine Hydrochloride increases the expression of ABCC1	.	.
DTD0001	ABCC1	Inhibition	Verapamil	Approved Drug	.	.	Verapamil inhibits the activity of ABCC1	.	.
DTD0001	ABCC1	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of ABCC1	.	.
DTD0002	ABCC2	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of ABCC2	.	.
DTD0002	ABCC2	Inducer	2,4,5-trichlorophenoxyacetic Acid	Herbicide	.	.	2,4,5-trichlorophenoxyacetic Acid increases the expression of ABCC2	.	.
DTD0002	ABCC2	Inducer	2-acetylaminofluorene	Carcinogen	.	.	2-acetylaminofluorene increases the expression of ABCC2	.	.
DTD0002	ABCC2	Inducer	2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine	Acute Toxic Substance	.	.	2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine increases the expression of ABCC2	.	.
DTD0002	ABCC2	Inducer	2-methyl-4-isothiazolin-3-one	Acute Toxic Substance	.	.	2-methyl-4-isothiazolin-3-one increases the expression of ABCC2	.	.
DTD0002	ABCC2	Inducer	2-tert-butylhydroquinone	Environmental toxicant	.	.	2-tert-butylhydroquinone increases the expression of ABCC2	.	.
DTD0002	ABCC2	Inducer	6-bromoindirubin-3'-oxime	Natural Product	.	.	6-bromoindirubin-3'-oxime increases the expression of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of ABCC2	.	.
DTD0002	ABCC2	Modulator	Adenosine Triphosphate	Drug in Phase 1 Trial	.	.	Adenosine Triphosphate affects the activity of ABCC2	.	.
DTD0002	ABCC2	Inducer	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 increases the expression of ABCC2	.	.
DTD0002	ABCC2	Inducer	Apple polyphenol extract	Plant Extract	.	.	Apple polyphenol extract increases the expression of ABCC2	.	.
DTD0002	ABCC2	Inducer	Arsenic	Approved Drug	.	.	Arsenic increases the expression of ABCC2	.	.
DTD0002	ABCC2	Inducer	Arsenic Trioxide	Approved Drug	.	.	Arsenic trioxide induces the activity of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Atazanavir	Approved Drug	.	.	Atazanavir inhibits the activity of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Atorvastatin	Approved Drug	.	.	Atorvastatin inhibits the activity of ABCC2	.	.
DTD0002	ABCC2	Inducer	Azathioprine	Approved Drug	.	.	Azathioprine increases the expression of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Baohuoside I	Investigative Drug	.	.	Baohuoside I inhibits the expression of ABCC2	.	.
DTD0002	ABCC2	Inducer	Benzbromarone	Approved Drug	.	.	Benzbromarone induces the activity of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of ABCC2	.	.
DTD0002	ABCC2	Inducer	Benzylpenicillin	Drug in Phase 3 Trial	.	.	Benzylpenicillin induces the activity of ABCC2	.	.
DTD0002	ABCC2	Inducer	Beta-naphthoflavone	Investigative Drug	.	.	Beta-naphthoflavone increases the expression of ABCC2	.	.
DTD0002	ABCC2	Inducer	Bezafibrate	Drug Marketed but not Approved by US FDA	.	.	Bezafibrate increases the expression of ABCC2	.	.
DTD0002	ABCC2	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of ABCC2	.	.
DTD0002	ABCC2	Inhibition	BMS 536924	Patented Pharmaceutical Agent	.	.	BMS 536924 inhibits the expression of ABCC2	.	.
DTD0002	ABCC2	Inducer	Bortezomib	Approved Drug	.	.	Bortezomib increases the expression of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Bromfenac	Approved Drug	.	.	Bromfenac inhibits the activity of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde inhibits the expression of ABCC2	.	.
DTD0002	ABCC2	Inducer	Calcitriol	Approved Drug	.	.	Calcitriol increases the expression of ABCC2	.	.
DTD0002	ABCC2	Inducer	Carbamazepine	Approved Drug	.	.	Carbamazepine increases the expression of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Celecoxib	Approved Drug	.	.	Celecoxib inhibits the activity of ABCC2	.	.
DTD0002	ABCC2	Inducer	Chenodeoxycholic acid	Approved Drug	.	.	Chenodeoxycholic acid induces the activity of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Chlordan	Health and Environmental Toxicant	.	.	Chlordan inhibits the activity of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Chlordecone	Pesticide/Insecticide	.	.	Chlordecone inhibits the activity of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Chloroquine	Approved Drug	.	.	Chloroquine inhibits the expression of ABCC2	.	.
DTD0002	ABCC2	Inducer	Cholic Acid	Approved Drug	.	.	Cholic Acid increases the expression of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Chrysin	Natural Product	.	.	Chrysin inhibits the activity of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Cimetidine	Approved Drug	.	.	Cimetidine inhibits the activity of ABCC2	.	.
DTD0002	ABCC2	Inducer	Citalopram	Approved Drug	.	.	Citalopram increases the expression of ABCC2	.	.
DTD0002	ABCC2	Inducer	Colforsin	Drug in Phase 2 Trial	.	.	Colforsin increases the expression of ABCC2	.	.
DTD0002	ABCC2	Inducer	Copper Sulfate	Approved Drug	.	.	Copper Sulfate increases the expression of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the activity of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Darunavir	Approved Drug	.	.	Darunavir inhibits the activity of ABCC2	.	.
DTD0002	ABCC2	Inducer	Decitabine	Approved Drug	.	.	Decitabine increases the expression of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Demethoxycurcumin	Environmental toxicant	.	.	Demethoxycurcumin inhibits the activity of ABCC2	.	.
DTD0002	ABCC2	Inducer	Dexamethasone	Approved Drug	.	.	Dexamethasone induces the activity of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Diclofenac	Approved Drug	.	.	Diclofenac inhibits the activity of ABCC2	.	.
DTD0002	ABCC2	Inducer	Dicrotophos	Pesticide/Insecticide	.	.	Dicrotophos increases the expression of ABCC2	.	.
DTD0002	ABCC2	Inducer	Dieldrin	Pesticide/Insecticide	.	.	Dieldrin increases the expression of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Endosulfan	Pesticide/Insecticide	.	.	Endosulfan inhibits the activity of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Enoxolone	Investigative Drug	.	.	Enoxolone inhibits the activity of ABCC2	.	.
DTD0002	ABCC2	Inducer	Epirubicin	Approved Drug	.	.	Epirubicin increases the expression of ABCC2	.	.
DTD0002	ABCC2	Inducer	Eprosartan	Approved Drug	.	.	Eprosartan induces the activity of ABCC2	.	.
DTD0002	ABCC2	Inducer	Estradiol	Approved Drug	.	.	Estradiol induces the activity of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Estrone	Approved Drug	.	.	Estrone inhibits the activity of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Ethinyl Estradiol	Approved Drug	.	.	Ethinyl Estradiol inhibits the expression of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Etodolac	Approved Drug	.	.	Etodolac inhibits the activity of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Formononetin	Drug Marketed but not Approved by US FDA	.	.	Formononetin inhibits the expression of ABCC2	.	.
DTD0002	ABCC2	Inducer	Fulvestrant	Approved Drug	.	.	Fulvestrant increases the expression of ABCC2	.	.
DTD0002	ABCC2	Inducer	Gentamicin	Approved Drug	.	.	Gentamicin induces the activity of ABCC2	.	.
DTD0002	ABCC2	Inducer	Ginkgo biloba extract	Plant Extract	.	.	Ginkgo biloba extract increases the expression of ABCC2	.	.
DTD0002	ABCC2	Inducer	Ginkgolide A	Drug Marketed but not Approved by US FDA	.	.	Ginkgolide A increases the expression of ABCC2	.	.
DTD0002	ABCC2	Inducer	Ginkgolide B	Natural Product	.	.	Ginkgolide B increases the expression of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Glyburide	Approved Drug	.	.	Glibenclamide inhibits the activity of ABCC2	.	.
DTD0002	ABCC2	Inducer	Gold	Chemical Compound	.	.	Gold increases the expression of ABCC2	.	.
DTD0002	ABCC2	Inducer	GSK-J4	Patented Pharmaceutical Agent	.	.	GSK-J4 increases the expression of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Heptachlor	Pesticide/Insecticide	.	.	Heptachlor inhibits the activity of ABCC2	.	.
DTD0002	ABCC2	Inhibition	HSDB-3466	Drug in Phase 1 Trial	.	.	HSDB-3466 inhibits the expression of ABCC2	.	.
DTD0002	ABCC2	Inducer	Hydrocortisone	Approved Drug	.	.	Hydrocortisone induces the activity of ABCC2	.	.
DTD0002	ABCC2	Modulator	Hydrogen Peroxide	Approved Drug	.	.	Hydrogen Peroxide affects the expression of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Indinavir	Approved Drug	.	.	Indinavir inhibits the activity of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Indomethacin	Approved Drug	.	.	Indomethacin inhibits the activity of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Itraconazole	Approved Drug	.	.	Itraconazole inhibits the activity of ABCC2	.	.
DTD0002	ABCC2	Inducer	K-7174	Patented Pharmaceutical Agent	.	.	K-7174 increases the expression of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Ketoconazole	Approved Drug	.	.	Ketoconazole inhibits the activity of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Lansoprazole	Approved Drug	.	.	Lansoprazole inhibits the activity of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Levonorgestrel	Approved Drug	.	.	Levonorgestrel inhibits the activity of ABCC2	.	.
DTD0002	ABCC2	Inducer	Lithocholic Acid	Investigative Drug	.	.	Lithocholic Acid increases the expression of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Lopinavir	Approved Drug	.	.	Lopinavir inhibits the activity of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Lovastatin	Approved Drug	.	.	Lovastatin inhibits the activity of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Macitentan	Approved Drug	.	.	Macitentan inhibits the expression of ABCC2	.	.
DTD0002	ABCC2	Inducer	Metformin	Approved Drug	.	.	Metformin increases the expression of ABCC2	.	.
DTD0002	ABCC2	Inducer	Methotrexate	Approved Drug	.	.	Methotrexate increases the expression of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Methoxsalen	Approved Drug	.	.	Methoxsalen inhibits the expression of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Micafungin	Approved Drug	.	.	Micafungin inhibits the activity of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Midecamycin	Approved Drug	.	.	Midecamycin inhibits the activity of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Mitoxantrone	Approved Drug	.	.	Mitoxantrone inhibits the activity of ABCC2	.	.
DTD0002	ABCC2	Inducer	Monomethylarsonic acid	Herbicide	.	.	Monomethylarsonic acid increases the expression of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Montelukast	Approved Drug	.	.	Montelukast inhibits the activity of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Mycophenolic Acid	Approved Drug	.	.	Mycophenolic acid inhibits the activity of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Myricetin	Drug in Preclinical Test	.	.	Myricetin inhibits the activity of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Norgestimate	Drug Marketed but not Approved by US FDA	.	.	Norgestimate inhibits the activity of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Ochratoxin A	Acute Toxic Substance	.	.	Ochratoxin A inhibits the expression of ABCC2	.	.
DTD0002	ABCC2	Inducer	Oltipraz	Drug in Phase 3 Trial	.	.	Oltipraz increases the expression of ABCC2	.	.
DTD0002	ABCC2	Modulator	Paclitaxel	Approved Drug	.	.	Paclitaxel affects the expression of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Particulate Matter	Natural Product	.	.	Particulate Matter inhibits the activity of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Perfluorooctane sulfonic acid	Health and Environmental Toxicant	.	.	Perfluorooctane sulfonic acid inhibits the expression of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Plant Extracts	Plant Extract	.	.	Plant Extracts inhibits the activity of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Pravastatin	Approved Drug	.	.	Pravastatin inhibits the activity of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Proadifen	Drug in Preclinical Test	.	.	Proadifen inhibits the expression of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Probenecid	Approved Drug	.	.	Probenecid inhibits the activity of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Progesterone	Approved Drug	.	.	Progesterone inhibits the activity of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Resveratrol	Drug in Phase 3 Trial	.	.	Resveratrol inhibits the expression of ABCC2	.	.
DTD0002	ABCC2	Inducer	Rifampin	Approved Drug	.	.	Rifampin increases the expression of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Ritonavir	Approved Drug	.	.	Ritonavir inhibits the activity of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Robinetin	Natural Product	.	.	Robinetin inhibits the activity of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Rosiglitazone	Approved Drug	.	.	Rosiglitazone inhibits the activity of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Rotenone	Drug Marketed but not Approved by US FDA	.	.	Rotenone inhibits the expression of ABCC2	.	.
DTD0002	ABCC2	Inducer	Rubitecan	Drug in Phase 1 Trial	.	.	Rubitecan increases the expression of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Saquinavir	Approved Drug	.	.	Saquinavir inhibits the activity of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Senecionine	Natural Product	.	.	Senecionine inhibits the expression of ABCC2	.	.
DTD0002	ABCC2	Inducer	Sodium arsenate	Environmental toxicant	.	.	Sodium arsenate increases the expression of ABCC2	.	.
DTD0002	ABCC2	Inducer	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite increases the expression of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Sulfinpyrazone	Approved Drug	.	.	Sulfinpyrazone inhibits the activity of ABCC2	.	.
DTD0002	ABCC2	Inducer	Sulforafan	Drug in Phase 3 Trial	.	.	Sulforafan increases the expression of ABCC2	.	.
DTD0002	ABCC2	Inhibition	TAK-875	Drug in Phase 1 Trial	.	.	TAK-875 inhibits the activity of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Ticlopidine	Approved Drug	.	.	Ticlopidine inhibits the activity of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Tipranavir	Approved Drug	.	.	Tipranavir inhibits the activity of ABCC2	.	.
DTD0002	ABCC2	Inducer	Titanium dioxide	Approved Drug	.	.	Titanium dioxide increases the expression of ABCC2	.	.
DTD0002	ABCC2	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Tolvaptan	Approved Drug	.	.	Tolvaptan inhibits the activity of ABCC2	.	.
DTD0002	ABCC2	Inducer	Topotecan	Approved Drug	.	.	Topotecan increases the expression of ABCC2	.	.
DTD0002	ABCC2	Inducer	Triamcinolone	Approved Drug	.	.	Triamcinolone induces the activity of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A inhibits the expression of ABCC2	.	.
DTD0002	ABCC2	Inducer	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan increases the expression of ABCC2	.	.
DTD0002	ABCC2	Inducer	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate increases the expression of ABCC2	.	.
DTD0002	ABCC2	Inducer	Troleandomycin	Approved Drug	.	.	Troleandomycin induces the activity of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of ABCC2	.	.
DTD0002	ABCC2	Inducer	Ursodeoxycholic Acid	Approved Drug	.	.	Ursodeoxycholic Acid increases the expression of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Vancomycin	Approved Drug	.	.	Vancomycin inhibits the activity of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Verapamil	Approved Drug	.	.	Verapamil inhibits the activity of ABCC2	.	.
DTD0002	ABCC2	Inhibition	Vinblastine	Approved Drug	.	.	Vinblastine inhibits the activity of ABCC2	.	.
DTD0003	ABCB1	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	27-hydroxycholesterol	Investigative Drug	.	.	27-hydroxycholesterol increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	2-acetylaminofluorene	Carcinogen	.	.	2-acetylaminofluorene inhibits the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	2-methylindole	Health and Environmental Toxicant	.	.	2-methylindole increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	3,3',4,5'-tetrahydroxystilbene	Investigative Drug	.	.	3,3',4,5'-tetrahydroxystilbene increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	3-methylquercetin	Health and Environmental Toxicant	.	.	3-methylquercetin inhibits the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	6-bromoindirubin-3'-oxime	Natural Product	.	.	6-bromoindirubin-3'-oxime increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	7-methylindole	Chemical Compound	.	.	7-methylindole increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Abemaciclib	Approved Drug	.	.	Abemaciclib inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen induces the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Acetylcysteine	Approved Drug	.	.	Acetylcysteine induces the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Acrylamide	Acute Toxic Substance	.	.	Acrylamide increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Afimoxifene	Drug in Phase 3 Trial	.	.	Afimoxifene increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Aldosterone	Approved Drug	.	.	Aldosterone induces the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Amprenavir	Approved Drug	.	.	Amprenavir induces the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Arsenic Trioxide	Approved Drug	.	.	Arsenic trioxide inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Artemisinin	Approved Drug	.	.	Artemisinin induces the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Asunaprevir	Drug in Phase 3 Trial	.	.	Asunaprevir inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Atorvastatin	Approved Drug	.	.	Atorvastatin inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Modulator	Atorvastatin	Approved Drug	.	.	Atorvastatin modulates the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Avermectin B1a	Acute Toxic Substance	.	.	Avermectin B1a inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Basil oil	Plant Extract	.	.	Basil oil increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Bergamottin	Natural Product	.	.	Bergamottin increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Betamethasone	Approved Drug	.	.	Betamethasone induces the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Biricodar	Approved Drug	.	.	Biricodar inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Modulator	Biricodar	Approved Drug	.	.	Biricodar modulates the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Bisphenol B	Drug in Phase 2 Trial	.	.	Bisphenol B increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	BMS 536924	Patented Pharmaceutical Agent	.	.	BMS 536924 inhibits the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Bortezomib	Approved Drug	.	.	Bortezomib inhibits the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Bosentan	Approved Drug	.	.	Bosentan inhibits the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Brilinta	Approved Drug	.	.	Brilinta inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Bromocriptine	Approved Drug	.	.	Bromocriptine inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Budesonide	Approved Drug	.	.	Budesonide induces the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Butyrate	Drug in Phase 1 Trial	.	.	Butyrate increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Butyric Acid	Drug in Phase 2/3 Trial	.	.	Butyric Acid increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Camptothecin	Drug in Phase 2 Trial	.	.	Camptothecin inhibits the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Canagliflozin	Approved Drug	.	.	Canagliflozin inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Captopril	Approved Drug	.	.	Captopril inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Caraway oil	Plant Extract	.	.	Caraway oil increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Carbamazepine	Approved Drug	.	.	Carbamazepine induces the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Carbon Tetrachloride	Peptide	.	.	Carbon Tetrachloride increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Carmustine	Approved Drug	.	.	Carmustine increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	CCRIS-9277	Drug in Phase 1 Trial	.	.	CCRIS-9277 inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Celecoxib	Approved Drug	.	.	Celecoxib inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Cepharanthine	Approved Drug	.	.	Cepharanthine inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Chenodeoxycholic acid	Approved Drug	.	.	Chenodeoxycholic acid induces the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Chlorambucil	Approved Drug	.	.	Chlorambucil increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Chlordan	Health and Environmental Toxicant	.	.	Chlordan increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Chloropyrifos oxon	Investigative Drug	.	.	Chloropyrifos oxon increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Chloroquine	Approved Drug	.	.	Chloroquine inhibits the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Chlorpromazine	Approved Drug	.	.	Chlorpromazine inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Chlorpyrifos	Acute Toxic Substance	.	.	Chlorpyrifos increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Chrysin	Natural Product	.	.	Chrysin inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Ciclesonide	Approved Drug	.	.	Ciclesonide increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Cinnamon oil, bark	Plant Extract	.	.	Cinnamon oil, bark increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Cisplatin	Approved Drug	.	.	Cisplatin induces the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Clopidogrel	Approved Drug	.	.	Clopidogrel inhibits the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Clove Oil	Natural Product	.	.	Clove Oil increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Clozapine	Approved Drug	.	.	Clozapine inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Cobicistat	Approved Drug	.	.	Cobicistat inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Colforsin	Drug in Phase 2 Trial	.	.	Colforsin increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Conivaptan	Approved Drug	.	.	Conivaptan inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Coriander oil	Plant Extract	.	.	Coriander oil increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Cycloheximide	Acute Toxic Substance	.	.	Cycloheximide increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Cyclophosphamide	Approved Drug	.	.	Cyclophosphamide increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine induces the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Cytarabine	Approved Drug	.	.	Cytarabine induces the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Daclatasvir	Approved Drug	.	.	Daclatasvir inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Dacomitinib	Approved Drug	.	.	Dacomitinib inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Dactinomycin	Approved Drug	.	.	Dactinomycin induces the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Daunorubicin	Approved Drug	.	.	Daunorubicin induces the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Demecolcine	Drug Marketed but not Approved by US FDA	.	.	Demecolcine increases the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Deoxycholic acid	Approved Drug	.	.	Deoxycholic acid increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Dichlorodiphenyl Dichloroethylene	Environmental toxicant	.	.	Dichlorodiphenyl Dichloroethylene inhibits the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Diclofenac	Approved Drug	.	.	Diclofenac induces the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Dicrotophos	Pesticide/Insecticide	.	.	Dicrotophos inhibits the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Dieldrin	Pesticide/Insecticide	.	.	Dieldrin increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Diethylhexyl Phthalate	Health and Environmental Toxicant	.	.	Diethylhexyl Phthalate increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Diethylstilbestrol	Approved Drug	.	.	Diethylstilbestrol inhibits the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Diltiazem	Approved Drug	.	.	Diltiazem inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Dimethyl Sulfoxide	Approved Drug	.	.	Dimethyl sulfoxide induces the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Dinoprostone	Approved Drug	.	.	Dinoprostone induces the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Dioscin	Drug in Preclinical Test	.	.	Dioscin inhibits the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Dipyridamole	Approved Drug	.	.	Dipyridamole inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Disulfiram	Approved Drug	.	.	Disulfiram inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Docetaxel	Approved Drug	.	.	Docetaxel induces the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Donepezil	Approved Drug	.	.	Donepezil inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Doxorubicin	Approved Drug	.	.	Doxorubicin induces the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Doxycycline	Approved Drug	.	.	Doxycycline inhibits the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Eetuximab	Approved Drug	.	.	Eetuximab induces the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Eliglustat	Approved Drug	.	.	Eliglustat inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Elobixibat	Drug in Phase 3 Trial	.	.	Elobixibat inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Epigallocatechin gallate	Drug in Phase 3 Trial	.	.	Epigallocatechin gallate inhibits the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Epinephrine	Drug in Preclinical Test	.	.	Epinephrine induces the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Epirubicin	Approved Drug	.	.	Epirubicin induces the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Erythromycin	Approved Drug	.	.	Erythromycin induces the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Estriol	Drug Marketed but not Approved by US FDA	.	.	Estriol increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Estrone	Approved Drug	.	.	Estrone inhibits the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Ethanol	Drug in Phase 2 Trial	.	.	Ethanol increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Ethinyl Estradiol	Approved Drug	.	.	Ethinyl Estradiol increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Etoposide	Approved Drug	.	.	Etoposide induces the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Etravirine	Approved Drug	.	.	Etravirine inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Everolimus	Approved Drug	.	.	Everolimus inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Fenbufen	Approved Drug	.	.	Fenbufen induces the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Fenvalerate	Pesticide/Insecticide	.	.	Fenvalerate inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Fidaxomicin	Approved Drug	.	.	Fidaxomicin inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Flavone	Natural Product	.	.	Flavone inhibits the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Flibanserin	Approved Drug	.	.	Flibanserin inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Floxacillin	Approved Drug	.	.	Flucloxacillin induces the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Fluorouracil	Approved Drug	.	.	Fluorouracil induces the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Fluoxetine	Approved Drug	.	.	Fluoxetine inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Flupenthixol	Drug Withdrawn	.	.	Flupenthixol inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Flutamide	Approved Drug	.	.	Flutamide increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Formaldehyde	Acute Toxic Substance	.	.	Formaldehyde increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Formononetin	Drug Marketed but not Approved by US FDA	.	.	Formononetin increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Fosamprenavir	Approved Drug	.	.	Fosamprenavir induces the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Fosphenytoin	Approved Drug	.	.	Fosphenytoin induces the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Fulvestrant	Approved Drug	.	.	Fulvestrant increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Gabapentin	Approved Drug	.	.	Gabapentin inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Gallic Acid	Natural Product	.	.	Gallic Acid inhibits the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Gemcitabine	Approved Drug	.	.	Gemcitabine inhibits the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Geneticin	Patented Pharmaceutical Agent	.	.	Geneticin inhibits the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Ginkgolide A	Drug Marketed but not Approved by US FDA	.	.	Ginkgolide A increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Ginkgolide B	Natural Product	.	.	Ginkgolide B increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Glecaprevir	Approved Drug	.	.	Glecaprevir inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Glucose	Investigative Drug	.	.	Glucose inhibits the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Gold	Chemical Compound	.	.	Gold increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	GSK-J4	Patented Pharmaceutical Agent	.	.	GSK-J4 increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	GW-7647	Patented Pharmaceutical Agent	.	.	GW-7647 increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Heptachlor	Pesticide/Insecticide	.	.	Heptachlor increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	HSDB-3466	Drug in Phase 1 Trial	.	.	HSDB-3466 inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	HSDB-595	Patented Pharmaceutical Agent	.	.	HSDB-595 increases the expression of ABCB1	.	.
DTD0003	ABCB1	Modulator	Hydrogen Peroxide	Approved Drug	.	.	Hydrogen Peroxide affects the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Hydroxyurea	Approved Drug	.	.	Hydroxyurea induces the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Ifosfamide	Approved Drug	.	.	Ifosfamide increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Imatinib Mesylate	Approved Drug	.	.	Imatinib Mesylate increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Indole	Acute Toxic Substance	.	.	Indole increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Indomethacin	Approved Drug	.	.	Indomethacin inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Insulin	Approved Drug	.	.	Insulin inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Isavuconazole	Drug in Phase 3 Trial	.	.	Isavuconazole inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Isosafrole	Health and Environmental Toxicant	.	.	Isosafrole increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Isradipine	Approved Drug	.	.	Isradipine inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Ivacaftor	Approved Drug	.	.	Ivacaftor inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Ivermectin	Approved Drug	.	.	Ivermectin inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Juniper berry oil	Plant Extract	.	.	Juniper berry oil increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	K-7174	Patented Pharmaceutical Agent	.	.	K-7174 increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Lamotrigine	Approved Drug	.	.	Lamotrigine inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Lapatinib	Approved Drug	.	.	Lapatinib inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Ledipasvir	Approved Drug	.	.	Ledipasvir inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Lemongrass oil	Natural Product	.	.	Lemongrass oil increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Levetiracetam	Approved Drug	.	.	Levetiracetam inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Levonorgestrel	Approved Drug	.	.	Levonorgestrel increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Lindane	Approved Drug	.	.	Lindane increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Lithium Chloride	Health and Environmental Toxicant	.	.	Lithium Chloride increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Lithocholic Acid	Investigative Drug	.	.	Lithocholic Acid increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Lomitapide	Approved Drug	.	.	Lomitapide inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Luteolin	Drug in Phase 1 Trial	.	.	Luteolin inhibits the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	LY-294002	Drug in Phase 1 Trial	.	.	LY-294002 inhibits the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Macitentan	Approved Drug	.	.	Macitentan inhibits the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Manganese	Investigative Drug	.	.	Manganese increases the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Mangifera indica extract	Plant Extract	.	.	Mangifera indica extract inhibits the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Mangiferin	Natural Product	.	.	Mangiferin increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Metformin	Approved Drug	.	.	Metformin inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Methotrexate	Approved Drug	.	.	Methotrexate increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Methoxsalen	Approved Drug	.	.	Methoxsalen inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Methoxyamphetamine beta	Investigative Drug	.	.	Methoxyamphetamine beta inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Methylenedioxyamphetamine	Investigative Drug	.	.	Methylenedioxyamphetamine increases the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Methylprednisolone	Approved Drug	.	.	Methylprednisolone increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	metolachlor	Herbicide	.	.	metolachlor increases the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Micafungin	Approved Drug	.	.	Micafungin inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Midazolam	Approved Drug	.	.	Midazolam induces the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Midostaurin	Approved Drug	.	.	Midostaurin inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Mirabegron	Approved Drug	.	.	Mirabegron inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Mitomycin	Approved Drug	.	.	Mitomycin increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Mitotane	Approved Drug	.	.	Mitotane inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Mitoxantrone	Approved Drug	.	.	Mitoxantrone induces the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Morin	Acute Toxic Substance	.	.	Morin increases the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Naphthalene	Chemical Compound	.	.	Naphthalene inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Naproxen	Approved Drug	.	.	Naproxen inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Nelfinavir	Approved Drug	.	.	Nelfinavir induces the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	N-ethylmaleimide	Investigative Drug	.	.	N-ethylmaleimide inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Nilotinib	Approved Drug	.	.	Nilotinib inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Nimesulide	Drug Withdrawn	.	.	Nimesulide inhibits the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Notoginsenoside R1	Natural Product	.	.	Notoginsenoside R1 increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	NS-398	Drug in Phase 1 Trial	.	.	NS-398 inhibits the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Okadaic Acid	Acute Toxic Substance	.	.	Okadaic Acid increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Olanzapine	Approved Drug	.	.	Olanzapine inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Oltipraz	Drug in Phase 3 Trial	.	.	Oltipraz increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Ouabain	Approved Drug	.	.	Ouabain induces the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Oxycodone	Approved Drug	.	.	Oxycodone induces the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Oxytetracycline	Approved Drug	.	.	Oxytetracycline induces the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	PB28	Investigative Drug	.	.	PB28 inhibits the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Pentoxifylline	Approved Drug	.	.	Pentoxifylline inhibits the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Peppermint oil	Natural Product	.	.	Peppermint oil increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Perfluorooctane sulfonic acid	Health and Environmental Toxicant	.	.	Perfluorooctane sulfonic acid inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Phenobarbital	Approved Drug	.	.	Phenobarbital induces the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Phenytoin	Approved Drug	.	.	Phenytoin induces the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Phloxine	Investigative Drug	.	.	Phloxine inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Pibrentasvir	Approved Drug	.	.	Pibrentasvir inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Pioglitazone	Approved Drug	.	.	Pioglitazone increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Plant Extracts	Plant Extract	.	.	Plant Extracts inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Posaconazole	Approved Drug	.	.	Posaconazole inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Probenecid	Approved Drug	.	.	Probenecid inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Propafenone	Approved Drug	.	.	Propafenone inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Quetiapine	Approved Drug	.	.	Quetiapine inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Quinidine	Drug Withdrawn	.	.	Quinidine inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Raloxifene Hydrochloride	Approved Drug	.	.	Raloxifene Hydrochloride inhibits the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Ranolazine	Approved Drug	.	.	Ranolazine inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Rescinnamine	Approved Drug	.	.	Rescinnamine induces the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Reserpine	Approved Drug	.	.	Reserpine inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Resveratrol	Drug in Phase 3 Trial	.	.	Resveratrol inhibits the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Rifampin	Approved Drug	.	.	Rifampin increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Rifaximin	Approved Drug	.	.	Rifaximin inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Risperidone	Approved Drug	.	.	Risperidone inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Ritonavir	Approved Drug	.	.	Ritonavir induces the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Ro-21-5104	Patented Pharmaceutical Agent	.	.	Ro-21-5104 increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Rolapitant	Approved Drug	.	.	Rolapitant inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Romidepsin	Approved Drug	.	.	Romidepsin increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Rosiglitazone	Approved Drug	.	.	Rosiglitazone increases the expression of ABCB1	.	.
DTD0003	ABCB1	Modulator	Rotenone	Drug Marketed but not Approved by US FDA	.	.	Rotenone affects the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Saquinavir	Approved Drug	.	.	Saquinavir induces the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Sarin	Acute Toxic Substance	.	.	Sarin inhibits the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Sinensetin	Acute Toxic Substance	.	.	Sinensetin inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Sirolimus	Approved Drug	.	.	Sirolimus induces the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Spironolactone	Approved Drug	.	.	Spironolactone increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	SR-12813	Drug in Phase 1 Trial	.	.	SR-12813 increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Sulforafan	Drug in Phase 3 Trial	.	.	Sulforafan inhibits the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Suvorexant	Approved Drug	.	.	Suvorexant inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Tacrolimus	Approved Drug	.	.	Tacrolimus induces the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Tamarixetin	Natural Product	.	.	Tamarixetin increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Tamoxifen	Approved Drug	.	.	Tamoxifen induces the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Tariquidar	Discontinued Drug	.	.	Tariquidar inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Telaprevir	Approved Drug	.	.	Telaprevir inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Telmisartan	Approved Drug	.	.	Telmisartan inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Terfenadine	Drug Withdrawn	.	.	Terfenadine inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Tetrabromobisphenol A	Environmental toxicant	.	.	Tetrabromobisphenol A inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Tetrandrine	Drug in Phase 1 Trial	.	.	Tetrandrine inhibits the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Thalidomide	Approved Drug	.	.	Thalidomide inhibits the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Thapsigargin	Natural Product	.	.	Thapsigargin inhibits the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Ticagrelor	Approved Drug	.	.	Ticagrelor inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Titanium dioxide	Approved Drug	.	.	Titanium dioxide increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Tocotrienol beta	Drug Marketed but not Approved by US FDA	.	.	Tocotrienol beta increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Tocotrienol delta	Drug Marketed but not Approved by US FDA	.	.	Tocotrienol delta increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Tolbutamide	Approved Drug	.	.	Tolbutamide inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Tolvaptan	Approved Drug	.	.	Tolvaptan inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Topotecan	Approved Drug	.	.	Topotecan increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Trabectedin	Drug in Phase 3 Trial	.	.	Trabectedin inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Trazodone	Approved Drug	.	.	Trazodone induces the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin induces the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Triadimefon	Fungicide	.	.	Triadimefon increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Trifluoperazine	Approved Drug	.	.	Trifluoperazine inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Urethane	Approved Drug	.	.	Urethane increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Ursodeoxycholic Acid	Approved Drug	.	.	Ursodeoxycholic Acid increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Ursolic acid	Drug in Phase 2 Trial	.	.	Ursolic acid inhibits the expression of ABCB1	.	.
DTD0003	ABCB1	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid induces the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Vancomycin	Approved Drug	.	.	Vancomycin inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Velpatasvir	Approved Drug	.	.	Velpatasvir inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Vemurafenib	Approved Drug	.	.	Vemurafenib inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Venlafaxine Hydrochloride	Approved Drug	.	.	Venlafaxine Hydrochloride increases the expression of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Verapamil	Approved Drug	.	.	Verapamil inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Vincamine	Approved Drug	.	.	Vincamine inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Vincristine	Approved Drug	.	.	Vincristine induces the activity of ABCB1	.	.
DTD0003	ABCB1	Inhibition	Vismodegib	Approved Drug	.	.	Vismodegib inhibits the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Yohimbine	Approved Drug	.	.	Yohimbine induces the activity of ABCB1	.	.
DTD0003	ABCB1	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of ABCB1	.	.
DTD0004	ABCG2	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of ABCG2	.	.
DTD0004	ABCG2	Inducer	2-acetylaminofluorene	Carcinogen	.	.	2-acetylaminofluorene increases the activity of ABCG2	.	.
DTD0004	ABCG2	Inhibition	2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine	Acute Toxic Substance	.	.	2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine inhibits the expression of ABCG2	.	.
DTD0004	ABCG2	Inducer	2-tert-butylhydroquinone	Environmental toxicant	.	.	2-tert-butylhydroquinone increases the expression of ABCG2	.	.
DTD0004	ABCG2	Inducer	6-bromoindirubin-3'-oxime	Natural Product	.	.	6-bromoindirubin-3'-oxime increases the expression of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Abemaciclib	Approved Drug	.	.	Abemaciclib inhibits the activity of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of ABCG2	.	.
DTD0004	ABCG2	Inducer	AM-251	Patented Pharmaceutical Agent	.	.	AM-251 increases the expression of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Anandamide	Drug in Preclinical Test	.	.	Anandamide inhibits the expression of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Androstenedione	Health and Environmental Toxicant	.	.	Androstenedione inhibits the activity of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Arsenic Trioxide	Approved Drug	.	.	Arsenic Trioxide inhibits the expression of ABCG2	.	.
DTD0004	ABCG2	Inducer	Azaspiracid	Health and Environmental Toxicant	.	.	Azaspiracid increases the expression of ABCG2	.	.
DTD0004	ABCG2	Inducer	Beta-naphthoflavone	Investigative Drug	.	.	Beta-naphthoflavone increases the expression of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A inhibits the expression of ABCG2	.	.
DTD0004	ABCG2	Inducer	Butyric Acid	Drug in Phase 2/3 Trial	.	.	Butyric Acid increases the expression of ABCG2	.	.
DTD0004	ABCG2	Inducer	Cadmium	Acute Toxic Substance	.	.	Cadmium increases the expression of ABCG2	.	.
DTD0004	ABCG2	Inducer	Carbamazepine	Approved Drug	.	.	Carbamazepine increases the expression of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Catechin	Drug Marketed but not Approved by US FDA	.	.	Catechin inhibits the expression of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Celecoxib	Approved Drug	.	.	Celecoxib inhibits the expression of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Chlordan	Health and Environmental Toxicant	.	.	Chlordan inhibits the activity of ABCG2	.	.
DTD0004	ABCG2	Inducer	Chloropyrifos oxon	Investigative Drug	.	.	Chloropyrifos oxon increases the expression of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Chloroquine	Approved Drug	.	.	Chloroquine inhibits the expression of ABCG2	.	.
DTD0004	ABCG2	Inducer	Cholesterol	Natural Product	.	.	Cholesterol increases the activity of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Chrysin	Natural Product	.	.	Chrysin inhibits the expression of ABCG2	.	.
DTD0004	ABCG2	Inducer	Ciprofloxacin	Approved Drug	.	.	Ciprofloxacin increases the expression of ABCG2	.	.
DTD0004	ABCG2	Inducer	Cisplatin	Approved Drug	.	.	Cisplatin increases the expression of ABCG2	.	.
DTD0004	ABCG2	Inducer	Clofibrate	Approved Drug	.	.	Clofibrate induces the activity of ABCG2	.	.
DTD0004	ABCG2	Inducer	Colforsin	Drug in Phase 2 Trial	.	.	Colforsin increases the expression of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Corticosterone	Drug in Phase 3 Trial	.	.	Corticosterone inhibits the activity of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Crizotinib	Approved Drug	.	.	Crizotinib inhibits the activity of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the activity of ABCG2	.	.
DTD0004	ABCG2	Inducer	Dabrafenib	Approved Drug	.	.	Dabrafenib increases the expression of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Dacomitinib	Approved Drug	.	.	Dacomitinib inhibits the activity of ABCG2	.	.
DTD0004	ABCG2	Inducer	Desisobutyryl-ciclesonide	Investigative Drug	.	.	Desisobutyryl-ciclesonide increases the activity of ABCG2	.	.
DTD0004	ABCG2	Inducer	Dexamethasone	Approved Drug	.	.	Dexamethasone induces the activity of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Dichlorodiphenyl Dichloroethylene	Environmental toxicant	.	.	Dichlorodiphenyl Dichloroethylene inhibits the activity of ABCG2	.	.
DTD0004	ABCG2	Inducer	Dieldrin	Pesticide/Insecticide	.	.	Dieldrin increases the expression of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Digoxin	Approved Drug	.	.	Digoxin inhibits the activity of ABCG2	.	.
DTD0004	ABCG2	Inducer	Dimethyl nitrosamine	Carcinogen	.	.	Dimethyl nitrosamine increases the expression of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Dipyridamole	Approved Drug	.	.	Dipyridamole inhibits the activity of ABCG2	.	.
DTD0004	ABCG2	Inducer	Doxorubicin	Approved Drug	.	.	Doxorubicin increases the expression of ABCG2	.	.
DTD0004	ABCG2	Inducer	Doxycycline	Approved Drug	.	.	Doxycycline induces the activity of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Eetuximab	Approved Drug	.	.	Eetuximab inhibits the activity of ABCG2	.	.
DTD0004	ABCG2	Inducer	Estradiol	Approved Drug	.	.	Estradiol induces the activity of ABCG2	.	.
DTD0004	ABCG2	Inducer	Estriol	Drug Marketed but not Approved by US FDA	.	.	Estriol increases the expression of ABCG2	.	.
DTD0004	ABCG2	Inducer	Estrone	Approved Drug	.	.	Estrone increases the expression of ABCG2	.	.
DTD0004	ABCG2	Inducer	Ethanol	Drug in Phase 2 Trial	.	.	Ethanol increases the expression of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Etravirine	Approved Drug	.	.	Etravirine inhibits the activity of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Febuxostat	Approved Drug	.	.	Febuxostat inhibits the activity of ABCG2	.	.
DTD0004	ABCG2	Inducer	Flavone	Natural Product	.	.	Flavone increases the expression of ABCG2	.	.
DTD0004	ABCG2	Inducer	Folic Acid	Approved Drug	.	.	Folic acid induces the activity of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Gefitinib	Approved Drug	.	.	Gefitinib inhibits the activity of ABCG2	.	.
DTD0004	ABCG2	Inducer	Ginkgo biloba extract	Plant Extract	.	.	Ginkgo biloba extract increases the expression of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Glafenine	Drug in Phase 4 Trial	.	.	Glafenine inhibits the activity of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Glecaprevir	Approved Drug	.	.	Glecaprevir inhibits the activity of ABCG2	.	.
DTD0004	ABCG2	Inhibition	GW-4064	Patented Pharmaceutical Agent	.	.	GW-4064 inhibits the expression of ABCG2	.	.
DTD0004	ABCG2	Modulator	GW9662	Investigative Drug	.	.	GW9662 affects the expression of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Heptachlor	Pesticide/Insecticide	.	.	Heptachlor inhibits the activity of ABCG2	.	.
DTD0004	ABCG2	Inhibition	HSDB-3466	Drug in Phase 1 Trial	.	.	HSDB-3466 inhibits the activity of ABCG2	.	.
DTD0004	ABCG2	Modulator	Hydrogen Peroxide	Approved Drug	.	.	Hydrogen Peroxide affects the expression of ABCG2	.	.
DTD0004	ABCG2	Inducer	Imatinib	Approved Drug	.	.	Imatinib induces the activity of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Imatinib	Approved Drug	.	.	Imatinib inhibits the activity of ABCG2	.	.
DTD0004	ABCG2	Inducer	Imatinib Mesylate	Approved Drug	.	.	Imatinib Mesylate increases the expression of ABCG2	.	.
DTD0004	ABCG2	Inducer	Indolo(3,2-b)carbazole	Natural Product	.	.	Indolo(3,2-b)carbazole increases the expression of ABCG2	.	.
DTD0004	ABCG2	Inducer	Insulin	Approved Drug	.	.	Insulin induces the activity of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Itraconazole	Approved Drug	.	.	Itraconazole inhibits the activity of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Ketoconazole	Approved Drug	.	.	Ketoconazole inhibits the activity of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Leflunomide	Approved Drug	.	.	Leflunomide inhibits the activity of ABCG2	.	.
DTD0004	ABCG2	Inducer	Lindane	Approved Drug	.	.	Lindane increases the expression of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Lopinavir	Approved Drug	.	.	Lopinavir inhibits the activity of ABCG2	.	.
DTD0004	ABCG2	Modulator	Menadione	Approved Drug	.	.	Menadione affects the expression of ABCG2	.	.
DTD0004	ABCG2	Inducer	Mercuric Chloride	Acute Toxic Substance	.	.	Mercuric Chloride increases the expression of ABCG2	.	.
DTD0004	ABCG2	Inducer	Mercury	Acute Toxic Substance	.	.	Mercury increases the expression of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Methotrexate	Approved Drug	.	.	Methotrexate inhibits the activity of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Methoxsalen	Approved Drug	.	.	Methoxsalen inhibits the activity of ABCG2	.	.
DTD0004	ABCG2	Inducer	Methylcholanthrene	Carcinogen	.	.	Methylcholanthrene increases the expression of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Micafungin	Approved Drug	.	.	Micafungin inhibits the activity of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Mitoxantrone	Approved Drug	.	.	Mitoxantrone inhibits the activity of ABCG2	.	.
DTD0004	ABCG2	Modulator	Mitragynine	Natural Product	.	.	Mitragynine affects the activity of ABCG2	.	.
DTD0004	ABCG2	Inducer	Mometasone Furoate	Approved Drug	.	.	Mometasone Furoate increases the activity of ABCG2	.	.
DTD0004	ABCG2	Inducer	NCX-4040	Environmental toxicant	.	.	NCX-4040 increases the expression of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Nelfinavir	Approved Drug	.	.	Nelfinavir inhibits the activity of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Nicardipine	Approved Drug	.	.	Nicardipine inhibits the activity of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Nimesulide	Drug Withdrawn	.	.	Nimesulide inhibits the expression of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Nimodipine	Approved Drug	.	.	Nimodipine inhibits the activity of ABCG2	.	.
DTD0004	ABCG2	Inhibition	N-nonylphenol	Investigative Drug	.	.	N-nonylphenol inhibits the expression of ABCG2	.	.
DTD0004	ABCG2	Inducer	Okadaic Acid	Acute Toxic Substance	.	.	Okadaic Acid increases the expression of ABCG2	.	.
DTD0004	ABCG2	Inducer	Oleic Acid	Drug in Preclinical Test	.	.	Oleic Acid increases the expression of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Omeprazole	Approved Drug	.	.	Omeprazole inhibits the activity of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Osimertinib	Approved Drug	.	.	Osimertinib inhibits the activity of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Oxfendazole	Drug in Phase 1 Trial	.	.	Oxfendazole inhibits the activity of ABCG2	.	.
DTD0004	ABCG2	Inducer	Oxycodone	Approved Drug	.	.	Oxycodone induces the activity of ABCG2	.	.
DTD0004	ABCG2	Inducer	Oxytetracycline	Approved Drug	.	.	Oxytetracycline induces the activity of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Paclitaxel	Approved Drug	.	.	Paclitaxel inhibits the expression of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Pantoprazole	Approved Drug	.	.	Pantoprazole inhibits the activity of ABCG2	.	.
DTD0004	ABCG2	Inducer	Particulate Matter	Natural Product	.	.	Particulate Matter increases the expression of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Perfluorooctane sulfonic acid	Health and Environmental Toxicant	.	.	Perfluorooctane sulfonic acid inhibits the activity of ABCG2	.	.
DTD0004	ABCG2	Inducer	Phenobarbital	Approved Drug	.	.	Phenobarbital increases the expression of ABCG2	.	.
DTD0004	ABCG2	Inducer	Phenylmercuric Acetate	Investigative Drug	.	.	Phenylmercuric Acetate increases the expression of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Plicamycin	Approved Drug	.	.	Plicamycin inhibits the activity of ABCG2	.	.
DTD0004	ABCG2	Inducer	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin increases the expression of ABCG2	.	.
DTD0004	ABCG2	Inducer	Pravastatin	Approved Drug	.	.	Pravastatin increases the activity of ABCG2	.	.
DTD0004	ABCG2	Inducer	Progesterone	Approved Drug	.	.	Progesterone induces the activity of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Progesterone	Approved Drug	.	.	Progesterone inhibits the activity of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Propafenone	Approved Drug	.	.	Propafenone inhibits the activity of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Q-100154	Drug in Phase 1 Trial	.	.	Q-100154 inhibits the expression of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Reserpine	Approved Drug	.	.	Reserpine inhibits the activity of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Resveratrol	Drug in Phase 3 Trial	.	.	Resveratrol inhibits the expression of ABCG2	.	.
DTD0004	ABCG2	Inducer	Rifampin	Approved Drug	.	.	Rifampin increases the expression of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Ritonavir	Approved Drug	.	.	Ritonavir inhibits the activity of ABCG2	.	.
DTD0004	ABCG2	Inducer	Rosiglitazone	Approved Drug	.	.	Rosiglitazone induces the activity of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Rutin	Investigative Drug	.	.	Rutin inhibits the activity of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Selexipag	Approved Drug	.	.	Selexipag inhibits the activity of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Sirolimus	Approved Drug	.	.	Sirolimus inhibits the activity of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Sulfasalazine	Approved Drug	.	.	Sulfasalazine inhibits the activity of ABCG2	.	.
DTD0004	ABCG2	Inducer	Sulindac sulfide	Drug in Phase 2 Trial	.	.	Sulindac sulfide increases the expression of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Tacrolimus	Approved Drug	.	.	Tacrolimus inhibits the activity of ABCG2	.	.
DTD0004	ABCG2	Inhibition	TAK-875	Drug in Phase 1 Trial	.	.	TAK-875 inhibits the activity of ABCG2	.	.
DTD0004	ABCG2	Inducer	Tamoxifen	Approved Drug	.	.	Tamoxifen increases the expression of ABCG2	.	.
DTD0004	ABCG2	Inducer	Telaprevir	Approved Drug	.	.	Telaprevir induces the activity of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Testosterone	Approved Drug	.	.	Testosterone inhibits the activity of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Tetrabromobisphenol A	Environmental toxicant	.	.	Tetrabromobisphenol A inhibits the activity of ABCG2	.	.
DTD0004	ABCG2	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Tolcapone	Approved Drug	.	.	Tolcapone inhibits the activity of ABCG2	.	.
DTD0004	ABCG2	Inducer	Topotecan	Approved Drug	.	.	Topotecan induces the activity of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Toremifene	Approved Drug	.	.	Toremifene inhibits the activity of ABCG2	.	.
DTD0004	ABCG2	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of ABCG2	.	.
DTD0004	ABCG2	Inducer	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A increases the expression of ABCG2	.	.
DTD0004	ABCG2	Inducer	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan increases the expression of ABCG2	.	.
DTD0004	ABCG2	Inducer	Troglitazone	Approved Drug	.	.	Troglitazone increases the expression of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of ABCG2	.	.
DTD0004	ABCG2	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of ABCG2	.	.
DTD0004	ABCG2	Inducer	Venlafaxine	Approved Drug	.	.	Venlafaxine induces the activity of ABCG2	.	.
DTD0004	ABCG2	Inhibition	Vitallium	Natural Product	.	.	Vitallium inhibits the expression of ABCG2	.	.
DTD0004	ABCG2	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of ABCG2	.	.
DTD0004	ABCG2	Inducer	Zoledronic Acid	Approved Drug	.	.	Zoledronic Acid increases the expression of ABCG2	.	.
DTD0005	SLC22A7	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC22A7	.	.
DTD0005	SLC22A7	Inhibition	Aspirin	Approved Drug	.	.	Aspirin inhibits the activity of SLC22A7	.	.
DTD0005	SLC22A7	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC22A7	.	.
DTD0005	SLC22A7	Modulator	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A affects the expression of SLC22A7	.	.
DTD0005	SLC22A7	Modulator	Bosentan	Approved Drug	.	.	Bosentan affects the expression of SLC22A7	.	.
DTD0005	SLC22A7	Inhibition	Chenodeoxycholic acid	Approved Drug	.	.	Chenodeoxycholic acid inhibits the expression of SLC22A7	.	.
DTD0005	SLC22A7	Inducer	Coal Ash	Natural Product	.	.	Coal Ash increases the expression of SLC22A7	.	.
DTD0005	SLC22A7	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC22A7	.	.
DTD0005	SLC22A7	Inhibition	Endosulfan	Pesticide/Insecticide	.	.	Endosulfan inhibits the expression of SLC22A7	.	.
DTD0005	SLC22A7	Inhibition	Erythromycin	Approved Drug	.	.	Erythromycin inhibits the activity of SLC22A7	.	.
DTD0005	SLC22A7	Inducer	Estradiol	Approved Drug	.	.	Estradiol induces the activity of SLC22A7	.	.
DTD0005	SLC22A7	Inhibition	Heliotrine	Natural Product	.	.	Heliotrine inhibits the expression of SLC22A7	.	.
DTD0005	SLC22A7	Inducer	Methotrexate	Approved Drug	.	.	Methotrexate increases the expression of SLC22A7	.	.
DTD0005	SLC22A7	Inhibition	Methyleugenol	Natural Product	.	.	Methyleugenol inhibits the expression of SLC22A7	.	.
DTD0005	SLC22A7	Inhibition	Oltipraz	Drug in Phase 3 Trial	.	.	Oltipraz inhibits the expression of SLC22A7	.	.
DTD0005	SLC22A7	Inhibition	Particulate Matter	Natural Product	.	.	Particulate Matter inhibits the expression of SLC22A7	.	.
DTD0005	SLC22A7	Inhibition	Phenobarbital	Approved Drug	.	.	Phenobarbital inhibits the expression of SLC22A7	.	.
DTD0005	SLC22A7	Inhibition	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin inhibits the expression of SLC22A7	.	.
DTD0005	SLC22A7	Inhibition	Probenecid	Approved Drug	.	.	Probenecid inhibits the activity of SLC22A7	.	.
DTD0005	SLC22A7	Inhibition	Rifampin	Approved Drug	.	.	Rifampin inhibits the expression of SLC22A7	.	.
DTD0005	SLC22A7	Inhibition	Rosiglitazone	Approved Drug	.	.	Rosiglitazone inhibits the expression of SLC22A7	.	.
DTD0005	SLC22A7	Inhibition	Salicylic Acid	Approved Drug	.	.	Salicylic acid inhibits the activity of SLC22A7	.	.
DTD0005	SLC22A7	Inhibition	Senecionine	Natural Product	.	.	Senecionine inhibits the expression of SLC22A7	.	.
DTD0005	SLC22A7	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC22A7	.	.
DTD0005	SLC22A7	Inducer	Tamoxifen	Approved Drug	.	.	Tamoxifen increases the expression of SLC22A7	.	.
DTD0005	SLC22A7	Inhibition	Tebuconazole	Fungicide	.	.	Tebuconazole inhibits the expression of SLC22A7	.	.
DTD0005	SLC22A7	Inhibition	Theophylline	Approved Drug	.	.	Theophylline inhibits the activity of SLC22A7	.	.
DTD0005	SLC22A7	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC22A7	.	.
DTD0005	SLC22A7	Inhibition	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate inhibits the expression of SLC22A7	.	.
DTD0005	SLC22A7	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of SLC22A7	.	.
DTD0005	SLC22A7	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC22A7	.	.
DTD0006	SLC22A2	Inhibition	2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine	Acute Toxic Substance	.	.	2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine inhibits the activity of SLC22A2	.	.
DTD0006	SLC22A2	Inhibition	2-amino-3-methylimidazo(4,5-f)quinoline	Carcinogen	.	.	2-amino-3-methylimidazo(4,5-f)quinoline inhibits the activity of SLC22A2	.	.
DTD0006	SLC22A2	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC22A2	.	.
DTD0006	SLC22A2	Inhibition	Beta-carboline	Drug in Preclinical Test	.	.	Beta-carboline inhibits the activity of SLC22A2	.	.
DTD0006	SLC22A2	Inhibition	Budesonide	Approved Drug	.	.	Budesonide inhibits the activity of SLC22A2	.	.
DTD0006	SLC22A2	Inhibition	Chlorpyrifos	Natural Product	.	.	Chlorpyrifos inhibits the activity of SLC22A2	.	.
DTD0006	SLC22A2	Inhibition	Cimetidine	Approved Drug	.	.	Cimetidine inhibits the activity of SLC22A2	.	.
DTD0006	SLC22A2	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the activity of SLC22A2	.	.
DTD0006	SLC22A2	Inhibition	Clothianidin	Pesticide/Insecticide	.	.	Clothianidin inhibits the activity of SLC22A2	.	.
DTD0006	SLC22A2	Inhibition	Dexamethasone	Approved Drug	.	.	Dexamethasone induces the activity of SLC22A2	.	.
DTD0006	SLC22A2	Inhibition	Diazepam	Approved Drug	.	.	Diazepam inhibits the activity of SLC22A2	.	.
DTD0006	SLC22A2	Inhibition	Dolutegravir	Approved Drug	.	.	Dolutegravir inhibits the activity of SLC22A2	.	.
DTD0006	SLC22A2	Inhibition	Fenitrothion	Environmental toxicant	.	.	Fenitrothion inhibits the activity of SLC22A2	.	.
DTD0006	SLC22A2	Inhibition	Flurazepam	Approved Drug	.	.	Flurazepam inhibits the activity of SLC22A2	.	.
DTD0006	SLC22A2	Inducer	GSK-J4	Patented Pharmaceutical Agent	.	.	GSK-J4 increases the expression of SLC22A2	.	.
DTD0006	SLC22A2	Inhibition	Haloperidol	Approved Drug	.	.	Haloperidol inhibits the activity of SLC22A2	.	.
DTD0006	SLC22A2	Inhibition	Imidacloprid	Pesticide/Insecticide	.	.	Imidacloprid inhibits the activity of SLC22A2	.	.
DTD0006	SLC22A2	Inhibition	Indomethacin	Approved Drug	.	.	Indomethacin inhibits the activity of SLC22A2	.	.
DTD0006	SLC22A2	Inhibition	Itraconazole	Approved Drug	.	.	Itraconazole inhibits the activity of SLC22A2	.	.
DTD0006	SLC22A2	Inhibition	Ketoconazole	Approved Drug	.	.	Ketoconazole inhibits the activity of SLC22A2	.	.
DTD0006	SLC22A2	Inhibition	Lidocaine	Approved Drug	.	.	Lidocaine inhibits the activity of SLC22A2	.	.
DTD0006	SLC22A2	Inhibition	Malathion	Approved Drug	.	.	Malathion inhibits the activity of SLC22A2	.	.
DTD0006	SLC22A2	Inhibition	MeIQx	Drug in Phase 2 Trial	.	.	MeIQx inhibits the activity of SLC22A2	.	.
DTD0006	SLC22A2	Inhibition	Mercuric Chloride	Acute Toxic Substance	.	.	Mercuric Chloride inhibits the activity of SLC22A2	.	.
DTD0006	SLC22A2	Inhibition	Mexiletine	Approved Drug	.	.	Mexiletine inhibits the activity of SLC22A2	.	.
DTD0006	SLC22A2	Inhibition	Mianserin	Approved Drug	.	.	Mianserin inhibits the activity of SLC22A2	.	.
DTD0006	SLC22A2	Inhibition	Naproxen	Approved Drug	.	.	Naproxen inhibits the activity of SLC22A2	.	.
DTD0006	SLC22A2	Inhibition	Piroxicam	Approved Drug	.	.	Piroxicam inhibits the activity of SLC22A2	.	.
DTD0006	SLC22A2	Inhibition	Plazomicin	Approved Drug	.	.	Plazomicin inhibits the activity of SLC22A2	.	.
DTD0006	SLC22A2	Inhibition	Propranolol	Approved Drug	.	.	Propranolol inhibits the activity of SLC22A2	.	.
DTD0006	SLC22A2	Inhibition	Sulindac	Approved Drug	.	.	Sulindac inhibits the activity of SLC22A2	.	.
DTD0006	SLC22A2	Inhibition	Telaprevir	Approved Drug	.	.	Telaprevir inhibits the activity of SLC22A2	.	.
DTD0006	SLC22A2	Inhibition	Thiamethoxam	Pesticide/Insecticide	.	.	Thiamethoxam inhibits the activity of SLC22A2	.	.
DTD0006	SLC22A2	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the activity of SLC22A2	.	.
DTD0006	SLC22A2	Inhibition	Triazolam	Approved Drug	.	.	Triazolam inhibits the activity of SLC22A2	.	.
DTD0006	SLC22A2	Modulator	Valproic Acid	Approved Drug	.	.	Valproic Acid affects the expression of SLC22A2	.	.
DTD0006	SLC22A2	Inhibition	Vancomycin	Approved Drug	.	.	Vancomycin inhibits the activity of SLC22A2	.	.
DTD0007	SLC47A1	Inhibition	1-methyl-4-phenylpyridinium	Health and Environmental Toxicant	.	.	1-methyl-4-phenylpyridinium inhibits the activity of SLC47A1	.	.
DTD0007	SLC47A1	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC47A1	.	.
DTD0007	SLC47A1	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC47A1	.	.
DTD0007	SLC47A1	Inhibition	Amiloride	Approved Drug	.	.	Amiloride inhibits the activity of SLC47A1	.	.
DTD0007	SLC47A1	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC47A1	.	.
DTD0007	SLC47A1	Inhibition	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A inhibits the activity of SLC47A1	.	.
DTD0007	SLC47A1	Inhibition	Chloroquine	Approved Drug	.	.	Chloroquine inhibits the activity of SLC47A1	.	.
DTD0007	SLC47A1	Inducer	Cisplatin	Approved Drug	.	.	Cisplatin increases the expression of SLC47A1	.	.
DTD0007	SLC47A1	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC47A1	.	.
DTD0007	SLC47A1	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC47A1	.	.
DTD0007	SLC47A1	Inhibition	Cytarabine	Approved Drug	.	.	Cytarabine inhibits the expression of SLC47A1	.	.
DTD0007	SLC47A1	Inhibition	Diethylhexyl Phthalate	Health and Environmental Toxicant	.	.	Diethylhexyl Phthalate inhibits the expression of SLC47A1	.	.
DTD0007	SLC47A1	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC47A1	.	.
DTD0007	SLC47A1	Inducer	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 increases the expression of SLC47A1	.	.
DTD0007	SLC47A1	Inhibition	Itraconazole	Approved Drug	.	.	Itraconazole inhibits the activity of SLC47A1	.	.
DTD0007	SLC47A1	Inhibition	Ketoconazole	Approved Drug	.	.	Ketoconazole inhibits the activity of SLC47A1	.	.
DTD0007	SLC47A1	Inhibition	Mebendazole	Approved Drug	.	.	Mebendazole inhibits the expression of SLC47A1	.	.
DTD0007	SLC47A1	Inhibition	Medroxyprogesterone Acetate	Approved Drug	.	.	Medroxyprogesterone Acetate inhibits the expression of SLC47A1	.	.
DTD0007	SLC47A1	Modulator	Metformin	Approved Drug	.	.	Metformin modulates the activity of SLC47A1	.	.
DTD0007	SLC47A1	Inducer	Methotrexate	Approved Drug	.	.	Methotrexate increases the expression of SLC47A1	.	.
DTD0007	SLC47A1	Inhibition	Methyleugenol	Natural Product	.	.	Methyleugenol inhibits the expression of SLC47A1	.	.
DTD0007	SLC47A1	Inducer	MS-275	Drug in Phase 2 Trial	.	.	MS-275 increases the expression of SLC47A1	.	.
DTD0007	SLC47A1	Inducer	Paraquat	Acute Toxic Substance	.	.	Paraquat increases the expression of SLC47A1	.	.
DTD0007	SLC47A1	Inhibition	Plazomicin	Approved Drug	.	.	Plazomicin inhibits the activity of SLC47A1	.	.
DTD0007	SLC47A1	Inhibition	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin inhibits the expression of SLC47A1	.	.
DTD0007	SLC47A1	Inhibition	Pyrimethamine	Approved Drug	.	.	Pyrimethamine inhibits the activity of SLC47A1	.	.
DTD0007	SLC47A1	Inhibition	Quinidine	Approved Drug	.	.	Quinidine inhibits the activity of SLC47A1	.	.
DTD0007	SLC47A1	Inducer	Rifampin	Approved Drug	.	.	Rifampin increases the expression of SLC47A1	.	.
DTD0007	SLC47A1	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC47A1	.	.
DTD0007	SLC47A1	Inducer	Sulforafan	Drug in Phase 3 Trial	.	.	Sulforafan increases the expression of SLC47A1	.	.
DTD0007	SLC47A1	Inhibition	Sunitinib	Approved Drug	.	.	Sunitinib inhibits the expression of SLC47A1	.	.
DTD0007	SLC47A1	Inhibition	Tetrabromobisphenol A	Environmental toxicant	.	.	Tetrabromobisphenol A inhibits the activity of SLC47A1	.	.
DTD0007	SLC47A1	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC47A1	.	.
DTD0007	SLC47A1	Inhibition	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan inhibits the expression of SLC47A1	.	.
DTD0007	SLC47A1	Inhibition	Trimethoprim	Approved Drug	.	.	Trimethoprim inhibits the activity of SLC47A1	.	.
DTD0007	SLC47A1	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of SLC47A1	.	.
DTD0007	SLC47A1	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC47A1	.	.
DTD0007	SLC47A1	Inducer	Vitamin E	Drug in Phase 3 Trial	.	.	Vitamin E increases the expression of SLC47A1	.	.
DTD0007	SLC47A1	Inhibition	Zoledronic Acid	Approved Drug	.	.	Zoledronic Acid inhibits the expression of SLC47A1	.	.
DTD0008	SLCO1B1	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLCO1B1	.	.
DTD0008	SLCO1B1	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLCO1B1	.	.
DTD0008	SLCO1B1	Inhibition	Amiodarone	Approved Drug	.	.	Amiodarone inhibits the activity of SLCO1B1	.	.
DTD0008	SLCO1B1	Inhibition	Asunaprevir	Drug in Phase 3 Trial	.	.	Asunaprevir inhibits the activity of SLCO1B1	.	.
DTD0008	SLCO1B1	Inducer	Atorvastatin	Approved Drug	.	.	Atorvastatin induces the activity of SLCO1B1	.	.
DTD0008	SLCO1B1	Inducer	Belinostat	Approved Drug	.	.	Belinostat increases the expression of SLCO1B1	.	.
DTD0008	SLCO1B1	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLCO1B1	.	.
DTD0008	SLCO1B1	Inhibition	Bezafibrate	Approved Drug	.	.	Bezafibrate inhibits the activity of SLCO1B1	.	.
DTD0008	SLCO1B1	Inducer	Bilirubin	Natural Product	.	.	Bilirubin increases the expression of SLCO1B1	.	.
DTD0008	SLCO1B1	Inhibition	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A inhibits the activity of SLCO1B1	.	.
DTD0008	SLCO1B1	Inhibition	Bisphenol F	Environmental toxicant	.	.	Bisphenol F inhibits the activity of SLCO1B1	.	.
DTD0008	SLCO1B1	Inhibition	Bosentan	Approved Drug	.	.	Bosentan inhibits the expression of SLCO1B1	.	.
DTD0008	SLCO1B1	Inducer	Bucladesine	Discontinued Drug	.	.	Bucladesine induces the activity of SLCO1B1	.	.
DTD0008	SLCO1B1	Inhibition	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde inhibits the expression of SLCO1B1	.	.
DTD0008	SLCO1B1	Inhibition	Chenodeoxycholic acid	Approved Drug	.	.	Chenodeoxycholic acid inhibits the activity of SLCO1B1	.	.
DTD0008	SLCO1B1	Inducer	Clorgyline	Investigative Drug	.	.	Clorgyline increases the expression of SLCO1B1	.	.
DTD0008	SLCO1B1	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the activity of SLCO1B1	.	.
DTD0008	SLCO1B1	Inhibition	Diethylhexyl Phthalate	Health and Environmental Toxicant	.	.	Diethylhexyl Phthalate inhibits the expression of SLCO1B1	.	.
DTD0008	SLCO1B1	Inhibition	Elagolix sodium	Approved Drug	.	.	Elagolix sodium inhibits the activity of SLCO1B1	.	.
DTD0008	SLCO1B1	Inhibition	Fusidic Acid	Drug in Phase 3 Trial	.	.	Fusidic Acid inhibits the activity of SLCO1B1	.	.
DTD0008	SLCO1B1	Inhibition	Glecaprevir	Approved Drug	.	.	Glecaprevir inhibits the activity of SLCO1B1	.	.
DTD0008	SLCO1B1	Inducer	Ibuprofen	Approved Drug	.	.	Ibuprofen induces the activity of SLCO1B1	.	.
DTD0008	SLCO1B1	Inhibition	Isoliquiritigenin	Drug in Preclinical Test	.	.	Isoliquiritigenin inhibits the activity of SLCO1B1	.	.
DTD0008	SLCO1B1	Inhibition	Itraconazole	Approved Drug	.	.	Itraconazole inhibits the activity of SLCO1B1	.	.
DTD0008	SLCO1B1	Inhibition	Jinfukang	Traditional Medicine	.	.	Jinfukang inhibits the expression of SLCO1B1	.	.
DTD0008	SLCO1B1	Inhibition	Kaempferol	Acute Toxic Substance	.	.	Kaempferol inhibits the activity of SLCO1B1	.	.
DTD0008	SLCO1B1	Inhibition	Ketoconazole	Approved Drug	.	.	Ketoconazole inhibits the activity of SLCO1B1	.	.
DTD0008	SLCO1B1	Inhibition	Letermovir	Approved Drug	.	.	Letermovir inhibits the activity of SLCO1B1	.	.
DTD0008	SLCO1B1	Inhibition	Licochalcone A	Drug in Phase 1 Trial	.	.	Licochalcone A inhibits the activity of SLCO1B1	.	.
DTD0008	SLCO1B1	Inhibition	Lopinavir	Approved Drug	.	.	Lopinavir inhibits the activity of SLCO1B1	.	.
DTD0008	SLCO1B1	Inhibition	Luteolin	Drug in Phase 1 Trial	.	.	Luteolin inhibits the activity of SLCO1B1	.	.
DTD0008	SLCO1B1	Inhibition	Obeticholic acid	Approved Drug	.	.	Obeticholic acid inhibits the expression of SLCO1B1	.	.
DTD0008	SLCO1B1	Inhibition	Okadaic Acid	Acute Toxic Substance	.	.	Okadaic Acid inhibits the expression of SLCO1B1	.	.
DTD0008	SLCO1B1	Inhibition	Particulate Matter	Natural Product	.	.	Particulate Matter inhibits the activity of SLCO1B1	.	.
DTD0008	SLCO1B1	Inhibition	Pentanal	Chemical Compound	.	.	Pentanal inhibits the expression of SLCO1B1	.	.
DTD0008	SLCO1B1	Inducer	Perfluorodecanoic acid	Acute Toxic Substance	.	.	Perfluorodecanoic acid increases the expression of SLCO1B1	.	.
DTD0008	SLCO1B1	Inhibition	Perfluorododecanoic acid	Drug in Preclinical Test	.	.	Perfluorododecanoic acid inhibits the expression of SLCO1B1	.	.
DTD0008	SLCO1B1	Inhibition	Perfluorooctane sulfonic acid	Health and Environmental Toxicant	.	.	Perfluorooctane sulfonic acid inhibits the expression of SLCO1B1	.	.
DTD0008	SLCO1B1	Inducer	Phenobarbital	Approved Drug	.	.	Phenobarbital induces the activity of SLCO1B1	.	.
DTD0008	SLCO1B1	Inhibition	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin inhibits the expression of SLCO1B1	.	.
DTD0008	SLCO1B1	Inhibition	Quinine	Approved Drug	.	.	Quinine inhibits the activity of SLCO1B1	.	.
DTD0008	SLCO1B1	Inhibition	Rifampin	Approved Drug	.	.	Rifampin inhibits the activity of SLCO1B1	.	.
DTD0008	SLCO1B1	Inhibition	Rifamycin SV	Approved Drug	.	.	Rifamycin SV inhibits the activity of SLCO1B1	.	.
DTD0008	SLCO1B1	Inhibition	Rifapentine	Approved Drug	.	.	Rifapentine inhibits the activity of SLCO1B1	.	.
DTD0008	SLCO1B1	Inhibition	Rifaximin	Approved Drug	.	.	Rifaximin inhibits the activity of SLCO1B1	.	.
DTD0008	SLCO1B1	Inhibition	Selexipag	Approved Drug	.	.	Selexipag inhibits the activity of SLCO1B1	.	.
DTD0008	SLCO1B1	Inhibition	Silymarin	Drug in Phase 4 Trial	.	.	Silymarin inhibits the activity of SLCO1B1	.	.
DTD0008	SLCO1B1	Inhibition	Sinensetin	Acute Toxic Substance	.	.	Sinensetin inhibits the activity of SLCO1B1	.	.
DTD0008	SLCO1B1	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLCO1B1	.	.
DTD0008	SLCO1B1	Inhibition	TAK-875	Drug in Phase 1 Trial	.	.	TAK-875 inhibits the activity of SLCO1B1	.	.
DTD0008	SLCO1B1	Inhibition	Tetrabromobisphenol A	Environmental toxicant	.	.	Tetrabromobisphenol A inhibits the activity of SLCO1B1	.	.
DTD0008	SLCO1B1	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLCO1B1	.	.
DTD0009	SLC22A3	Inhibition	2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine	Acute Toxic Substance	.	.	2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine inhibits the activity of SLC22A3	.	.
DTD0009	SLC22A3	Inhibition	2-amino-3-methylimidazo(4,5-f)quinoline	Carcinogen	.	.	2-amino-3-methylimidazo(4,5-f)quinoline inhibits the activity of SLC22A3	.	.
DTD0009	SLC22A3	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC22A3	.	.
DTD0009	SLC22A3	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC22A3	.	.
DTD0009	SLC22A3	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC22A3	.	.
DTD0009	SLC22A3	Inhibition	Beta-carboline	Drug in Preclinical Test	.	.	Beta-carboline inhibits the activity of SLC22A3	.	.
DTD0009	SLC22A3	Inhibition	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde inhibits the expression of SLC22A3	.	.
DTD0009	SLC22A3	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the expression of SLC22A3	.	.
DTD0009	SLC22A3	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC22A3	.	.
DTD0009	SLC22A3	Inhibition	Corticosterone	Drug in Phase 3 Trial	.	.	Corticosterone inhibits the activity of SLC22A3	.	.
DTD0009	SLC22A3	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC22A3	.	.
DTD0009	SLC22A3	Modulator	Decitabine	Approved Drug	.	.	Decitabine affects the expression of SLC22A3	.	.
DTD0009	SLC22A3	Inhibition	Desipramine	Approved Drug	.	.	Desipramine inhibits the activity of SLC22A3	.	.
DTD0009	SLC22A3	Modulator	Doxorubicin	Approved Drug	.	.	Doxorubicin affects the expression of SLC22A3	.	.
DTD0009	SLC22A3	Inducer	Formaldehyde	Acute Toxic Substance	.	.	Formaldehyde increases the expression of SLC22A3	.	.
DTD0009	SLC22A3	Modulator	Hydrogen Peroxide	Approved Drug	.	.	Hydrogen Peroxide affects the expression of SLC22A3	.	.
DTD0009	SLC22A3	Inhibition	Mdv-3100	Approved Drug	.	.	Mdv-3100 inhibits the expression of SLC22A3	.	.
DTD0009	SLC22A3	Inhibition	MeIQx	Drug in Phase 2 Trial	.	.	MeIQx inhibits the activity of SLC22A3	.	.
DTD0009	SLC22A3	Modulator	Menadione	Approved Drug	.	.	Menadione affects the expression of SLC22A3	.	.
DTD0009	SLC22A3	Inhibition	Mifepristone	Approved Drug	.	.	Mifepristone inhibits the expression of SLC22A3	.	.
DTD0009	SLC22A3	Inhibition	Oxyquinoline	Acute Toxic Substance	.	.	Oxyquinoline inhibits the expression of SLC22A3	.	.
DTD0009	SLC22A3	Inhibition	Particulate Matter	Natural Product	.	.	Particulate Matter inhibits the expression of SLC22A3	.	.
DTD0009	SLC22A3	Inhibition	Pentanal	Chemical Compound	.	.	Pentanal inhibits the expression of SLC22A3	.	.
DTD0009	SLC22A3	Modulator	Phenobarbital	Approved Drug	.	.	Phenobarbital affects the expression of SLC22A3	.	.
DTD0009	SLC22A3	Inhibition	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin inhibits the expression of SLC22A3	.	.
DTD0009	SLC22A3	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of SLC22A3	.	.
DTD0009	SLC22A3	Inhibition	Quinine	Approved Drug	.	.	Quinine inhibits the activity of SLC22A3	.	.
DTD0009	SLC22A3	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC22A3	.	.
DTD0009	SLC22A3	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC22A3	.	.
DTD0009	SLC22A3	Inhibition	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan inhibits the expression of SLC22A3	.	.
DTD0009	SLC22A3	Inhibition	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate inhibits the expression of SLC22A3	.	.
DTD0009	SLC22A3	Modulator	Valproic Acid	Approved Drug	.	.	Valproic Acid affects the expression of SLC22A3	.	.
DTD0010	SLC22A1	Inhibition	Amiloride	Approved Drug	.	.	Amiloride inhibits the activity of SLC22A1	.	.
DTD0010	SLC22A1	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC22A1	.	.
DTD0010	SLC22A1	Inhibition	Beta-carboline	Drug in Preclinical Test	.	.	Beta-carboline inhibits the activity of SLC22A1	.	.
DTD0010	SLC22A1	Inhibition	Beta-naphthoflavone	Investigative Drug	.	.	Beta-naphthoflavone inhibits the expression of SLC22A1	.	.
DTD0010	SLC22A1	Inhibition	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A inhibits the activity of SLC22A1	.	.
DTD0010	SLC22A1	Inhibition	Carvedilol	Approved Drug	.	.	Carvedilol inhibits the activity of SLC22A1	.	.
DTD0010	SLC22A1	Inhibition	Chenodeoxycholic acid	Approved Drug	.	.	Chenodeoxycholic acid inhibits the expression of SLC22A1	.	.
DTD0010	SLC22A1	Inhibition	Chlordan	Health and Environmental Toxicant	.	.	Chlordan inhibits the activity of SLC22A1	.	.
DTD0010	SLC22A1	Inhibition	Cimetidine	Approved Drug	.	.	Cimetidine inhibits the activity of SLC22A1	.	.
DTD0010	SLC22A1	Inhibition	Crizotinib	Approved Drug	.	.	Crizotinib inhibits the activity of SLC22A1	.	.
DTD0010	SLC22A1	Inducer	Dexamethasone	Approved Drug	.	.	Dexamethasone induces the activity of SLC22A1	.	.
DTD0010	SLC22A1	Inhibition	Endosulfan	Pesticide/Insecticide	.	.	Endosulfan inhibits the expression of SLC22A1	.	.
DTD0010	SLC22A1	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the activity of SLC22A1	.	.
DTD0010	SLC22A1	Inhibition	Heptachlor	Pesticide/Insecticide	.	.	Heptachlor inhibits the activity of SLC22A1	.	.
DTD0010	SLC22A1	Inhibition	Hyperforin	Natural Product	.	.	Hyperforin inhibits the expression of SLC22A1	.	.
DTD0010	SLC22A1	Inducer	Imidacloprid	Pesticide/Insecticide	.	.	Imidacloprid increases the activity of SLC22A1	.	.
DTD0010	SLC22A1	Inhibition	Indomethacin	Approved Drug	.	.	Indomethacin inhibits the activity of SLC22A1	.	.
DTD0010	SLC22A1	Inducer	Insulin	Approved Drug	.	.	Insulin induces the activity of SLC22A1	.	.
DTD0010	SLC22A1	Inhibition	Itraconazole	Approved Drug	.	.	Itraconazole inhibits the activity of SLC22A1	.	.
DTD0010	SLC22A1	Inhibition	Mefenamic Acid	Approved Drug	.	.	Mefenamic Acid inhibits the activity of SLC22A1	.	.
DTD0010	SLC22A1	Inhibition	Methyleugenol	Natural Product	.	.	Methyleugenol inhibits the expression of SLC22A1	.	.
DTD0010	SLC22A1	Inhibition	Nicotine polacrilex	Approved Drug	.	.	Nicotine inhibits the activity of SLC22A1	.	.
DTD0010	SLC22A1	Inhibition	Particulate Matter	Natural Product	.	.	Particulate Matter inhibits the expression of SLC22A1	.	.
DTD0010	SLC22A1	Inhibition	Perfluorooctane sulfonic acid	Health and Environmental Toxicant	.	.	Perfluorooctane sulfonic acid inhibits the expression of SLC22A1	.	.
DTD0010	SLC22A1	Inhibition	Phenformin	Drug Withdrawn	.	.	Phenformin inhibits the activity of SLC22A1	.	.
DTD0010	SLC22A1	Inhibition	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin inhibits the expression of SLC22A1	.	.
DTD0010	SLC22A1	Inhibition	Prazosin	Approved Drug	.	.	Prazosin inhibits the activity of SLC22A1	.	.
DTD0010	SLC22A1	Inhibition	Pyrazinamide	Approved Drug	.	.	Pyrazinamide inhibits the activity of SLC22A1	.	.
DTD0010	SLC22A1	Inducer	Rifampin	Approved Drug	.	.	Rifampicin induces the activity of SLC22A1	.	.
DTD0010	SLC22A1	Inhibition	Rosiglitazone	Approved Drug	.	.	Rosiglitazone inhibits the expression of SLC22A1	.	.
DTD0010	SLC22A1	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC22A1	.	.
DTD0010	SLC22A1	Inhibition	Sparfloxacin	Approved Drug	.	.	Sparfloxacin inhibits the activity of SLC22A1	.	.
DTD0010	SLC22A1	Inhibition	Tetrabromobisphenol A	Environmental toxicant	.	.	Tetrabromobisphenol A inhibits the activity of SLC22A1	.	.
DTD0010	SLC22A1	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC22A1	.	.
DTD0010	SLC22A1	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of SLC22A1	.	.
DTD0010	SLC22A1	Inhibition	Tubocurarine	Approved Drug	.	.	Tubocurarine inhibits the activity of SLC22A1	.	.
DTD0010	SLC22A1	Inducer	Urethane	Approved Drug	.	.	Urethane increases the expression of SLC22A1	.	.
DTD0012	ABCC3	Inducer	2-acetylaminofluorene	Carcinogen	.	.	2-acetylaminofluorene increases the expression of ABCC3	.	.
DTD0012	ABCC3	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen induces the activity of ABCC3	.	.
DTD0012	ABCC3	Inducer	Afimoxifene	Drug in Phase 3 Trial	.	.	Afimoxifene increases the expression of ABCC3	.	.
DTD0012	ABCC3	Inhibition	Ampicillin	Approved Drug	.	.	Ampicillin inhibits the expression of ABCC3	.	.
DTD0012	ABCC3	Inducer	Anisomycin	Acute Toxic Substance	.	.	Anisomycin increases the expression of ABCC3	.	.
DTD0012	ABCC3	Inhibition	Arsenic Trioxide	Approved Drug	.	.	Arsenic Trioxide inhibits the expression of ABCC3	.	.
DTD0012	ABCC3	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of ABCC3	.	.
DTD0012	ABCC3	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of ABCC3	.	.
DTD0012	ABCC3	Inhibition	Bosentan	Approved Drug	.	.	Bosentan inhibits the expression of ABCC3	.	.
DTD0012	ABCC3	Inhibition	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde inhibits the expression of ABCC3	.	.
DTD0012	ABCC3	Inducer	Calcipotriene	Approved Drug	.	.	Calcipotriene increases the expression of ABCC3	.	.
DTD0012	ABCC3	Inducer	Calcitriol	Approved Drug	.	.	Calcitriol increases the expression of ABCC3	.	.
DTD0012	ABCC3	Inducer	Cannabidiol	Approved Drug	.	.	Cannabidiol increases the expression of ABCC3	.	.
DTD0012	ABCC3	Inducer	Chenodeoxycholic acid	Approved Drug	.	.	Chenodeoxycholic acid induces the activity of ABCC3	.	.
DTD0012	ABCC3	Inducer	Chlorpromazine	Approved Drug	.	.	Chlorpromazine increases the expression of ABCC3	.	.
DTD0012	ABCC3	Inducer	Cholic Acid	Approved Drug	.	.	Cholic Acid increases the expression of ABCC3	.	.
DTD0012	ABCC3	Inducer	Cinnamic aldehyde	Natural Product	.	.	Cinnamic aldehyde increases the expression of ABCC3	.	.
DTD0012	ABCC3	Inducer	Cisplatin	Approved Drug	.	.	Cisplatin increases the expression of ABCC3	.	.
DTD0012	ABCC3	Inducer	Clodronic Acid	Drug Marketed but not Approved by US FDA	.	.	Clodronic Acid increases the expression of ABCC3	.	.
DTD0012	ABCC3	Inducer	Clotrimazole	Approved Drug	.	.	Clotrimazole increases the expression of ABCC3	.	.
DTD0012	ABCC3	Inducer	Copper Sulfate	Approved Drug	.	.	Copper Sulfate increases the expression of ABCC3	.	.
DTD0012	ABCC3	Inducer	Cycloheximide	Acute Toxic Substance	.	.	Cycloheximide increases the expression of ABCC3	.	.
DTD0012	ABCC3	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of ABCC3	.	.
DTD0012	ABCC3	Inducer	Dasatinib	Approved Drug	.	.	Dasatinib increases the expression of ABCC3	.	.
DTD0012	ABCC3	Inducer	Decitabine	Approved Drug	.	.	Decitabine increases the expression of ABCC3	.	.
DTD0012	ABCC3	Inhibition	Deoxynivalenol	Mycotoxins	.	.	Deoxynivalenol inhibits the expression of ABCC3	.	.
DTD0012	ABCC3	Inhibition	Diethylstilbestrol	Approved Drug	.	.	Diethylstilbestrol inhibits the expression of ABCC3	.	.
DTD0012	ABCC3	Inducer	Dihydrotestosterone	Drug in Phase 1 Trial	.	.	Dihydrotestosterone increases the expression of ABCC3	.	.
DTD0012	ABCC3	Inducer	Dimethyl nitrosamine	Carcinogen	.	.	Dimethyl nitrosamine increases the expression of ABCC3	.	.
DTD0012	ABCC3	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the expression of ABCC3	.	.
DTD0012	ABCC3	Inducer	Ethanol	Drug in Phase 2 Trial	.	.	Ethanol increases the expression of ABCC3	.	.
DTD0012	ABCC3	Inhibition	Etoposide	Approved Drug	.	.	Etoposide inhibits the activity of ABCC3	.	.
DTD0012	ABCC3	Inducer	Formaldehyde	Acute Toxic Substance	.	.	Formaldehyde increases the expression of ABCC3	.	.
DTD0012	ABCC3	Inducer	Fulvestrant	Approved Drug	.	.	Fulvestrant increases the expression of ABCC3	.	.
DTD0012	ABCC3	Inhibition	Genistein	Drug in Phase 2 Trial	.	.	Genistein inhibits the expression of ABCC3	.	.
DTD0012	ABCC3	Inducer	HSDB-595	Patented Pharmaceutical Agent	.	.	HSDB-595 increases the expression of ABCC3	.	.
DTD0012	ABCC3	Modulator	Hydrogen Peroxide	Approved Drug	.	.	Hydrogen Peroxide affects the expression of ABCC3	.	.
DTD0012	ABCC3	Inducer	Hydroquinone	Approved Drug	.	.	Hydroquinone increases the expression of ABCC3	.	.
DTD0012	ABCC3	Inducer	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 increases the expression of ABCC3	.	.
DTD0012	ABCC3	Inducer	Indomethacin	Approved Drug	.	.	Indomethacin increases the expression of ABCC3	.	.
DTD0012	ABCC3	Inhibition	Isoproterenol	Approved Drug	.	.	Isoproterenol inhibits the expression of ABCC3	.	.
DTD0012	ABCC3	Inducer	K-7174	Patented Pharmaceutical Agent	.	.	K-7174 increases the expression of ABCC3	.	.
DTD0012	ABCC3	Inducer	Lead	Health and Environmental Toxicant	.	.	Lead increases the expression of ABCC3	.	.
DTD0012	ABCC3	Inhibition	Macitentan	Approved Drug	.	.	Macitentan inhibits the expression of ABCC3	.	.
DTD0012	ABCC3	Inducer	Meclizine	Approved Drug	.	.	Meclizine increases the expression of ABCC3	.	.
DTD0012	ABCC3	Modulator	Menadione	Approved Drug	.	.	Menadione affects the expression of ABCC3	.	.
DTD0012	ABCC3	Inhibition	Methotrexate	Approved Drug	.	.	Methotrexate inhibits the activity of ABCC3	.	.
DTD0012	ABCC3	Inducer	Methoxsalen	Approved Drug	.	.	Methoxsalen increases the expression of ABCC3	.	.
DTD0012	ABCC3	Inhibition	Micafungin	Approved Drug	.	.	Micafungin inhibits the activity of ABCC3	.	.
DTD0012	ABCC3	Inhibition	Nefazodone	Approved Drug	.	.	Nefazodone inhibits the expression of ABCC3	.	.
DTD0012	ABCC3	Inhibition	Okadaic Acid	Acute Toxic Substance	.	.	Okadaic Acid inhibits the expression of ABCC3	.	.
DTD0012	ABCC3	Inducer	Oltipraz	Drug in Phase 3 Trial	.	.	Oltipraz increases the expression of ABCC3	.	.
DTD0012	ABCC3	Inducer	Oxypertine	Drug in Preclinical Test	.	.	Oxypertine induces the activity of ABCC3	.	.
DTD0012	ABCC3	Inducer	Paclitaxel	Approved Drug	.	.	Paclitaxel increases the expression of ABCC3	.	.
DTD0012	ABCC3	Inducer	Particulate Matter	Natural Product	.	.	Particulate Matter increases the expression of ABCC3	.	.
DTD0012	ABCC3	Inhibition	Perfluorooctane sulfonic acid	Health and Environmental Toxicant	.	.	Perfluorooctane sulfonic acid inhibits the expression of ABCC3	.	.
DTD0012	ABCC3	Inducer	Phenobarbital	Approved Drug	.	.	Phenobarbital induces the activity of ABCC3	.	.
DTD0012	ABCC3	Inducer	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin increases the expression of ABCC3	.	.
DTD0012	ABCC3	Inducer	Prasterone	Approved Drug	.	.	Prasterone induces the activity of ABCC3	.	.
DTD0012	ABCC3	Inducer	Progesterone	Approved Drug	.	.	Progesterone increases the expression of ABCC3	.	.
DTD0012	ABCC3	Inducer	Resveratrol	Drug in Phase 3 Trial	.	.	Resveratrol increases the expression of ABCC3	.	.
DTD0012	ABCC3	Inhibition	Senecionine	Natural Product	.	.	Senecionine inhibits the expression of ABCC3	.	.
DTD0012	ABCC3	Inducer	Silver nanoparticle	Nanoparticle	.	.	Silver nanoparticle increases the expression of ABCC3	.	.
DTD0012	ABCC3	Inducer	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite increases the expression of ABCC3	.	.
DTD0012	ABCC3	Inhibition	Sodium bichromate	Carcinogen	.	.	Sodium bichromate inhibits the expression of ABCC3	.	.
DTD0012	ABCC3	Inducer	Sulforafan	Drug in Phase 3 Trial	.	.	Sulforafan increases the expression of ABCC3	.	.
DTD0012	ABCC3	Inducer	Sulindac	Approved Drug	.	.	Sulindac increases the expression of ABCC3	.	.
DTD0012	ABCC3	Inhibition	TAK-875	Drug in Phase 1 Trial	.	.	TAK-875 inhibits the activity of ABCC3	.	.
DTD0012	ABCC3	Inducer	Taurocholic Acid	Drug in Phase 2 Trial	.	.	Taurocholic Acid increases the activity of ABCC3	.	.
DTD0012	ABCC3	Inducer	Temozolomide	Approved Drug	.	.	Temozolomide increases the expression of ABCC3	.	.
DTD0012	ABCC3	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of ABCC3	.	.
DTD0012	ABCC3	Inhibition	Tolvaptan	Approved Drug	.	.	Tolvaptan inhibits the activity of ABCC3	.	.
DTD0012	ABCC3	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of ABCC3	.	.
DTD0012	ABCC3	Inhibition	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A inhibits the expression of ABCC3	.	.
DTD0012	ABCC3	Inducer	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan increases the expression of ABCC3	.	.
DTD0012	ABCC3	Inducer	Troglitazone	Approved Drug	.	.	Troglitazone increases the expression of ABCC3	.	.
DTD0012	ABCC3	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of ABCC3	.	.
DTD0012	ABCC3	Inducer	Ursodeoxycholic Acid	Approved Drug	.	.	Ursodeoxycholic Acid increases the expression of ABCC3	.	.
DTD0012	ABCC3	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of ABCC3	.	.
DTD0012	ABCC3	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of ABCC3	.	.
DTD0013	ABCB4	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of ABCB4	.	.
DTD0013	ABCB4	Modulator	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 affects the expression of ABCB4	.	.
DTD0013	ABCB4	Inhibition	ANA-756	Drug in Phase 1 Trial	.	.	ANA-756 inhibits the activity of ABCB4	.	.
DTD0013	ABCB4	Inducer	Arsenic Trioxide	Approved Drug	.	.	Arsenic Trioxide increases the expression of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Benzatropine	Approved Drug	.	.	Benzatropine inhibits the activity of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Benzbromarone	Drug Marketed but not Approved by US FDA	.	.	Benzbromarone inhibits the activity of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of ABCB4	.	.
DTD0013	ABCB4	Inducer	Bezafibrate	Approved Drug	.	.	Bezafibrate induces the activity of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Bicalutamide	Approved Drug	.	.	Bicalutamide inhibits the activity of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Biperiden	Approved Drug	.	.	Biperiden inhibits the activity of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Bosentan	Approved Drug	.	.	Bosentan inhibits the expression of ABCB4	.	.
DTD0013	ABCB4	Inducer	Chenodeoxycholic acid	Approved Drug	.	.	Chenodeoxycholic acid increases the expression of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Chlorpheniramine	Approved Drug	.	.	Chlorpheniramine inhibits the activity of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Clemastine	Approved Drug	.	.	Clemastine inhibits the activity of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Colforsin	Drug in Phase 2 Trial	.	.	Colforsin inhibits the expression of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Diclofenac	Approved Drug	.	.	Diclofenac inhibits the expression of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Dihydroergotamine	Approved Drug	.	.	Dihydroergotamine inhibits the activity of ABCB4	.	.
DTD0013	ABCB4	Inducer	Doxorubicin	Approved Drug	.	.	Doxorubicin induces the activity of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Esmolol	Approved Drug	.	.	Esmolol inhibits the activity of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the expression of ABCB4	.	.
DTD0013	ABCB4	Inducer	Fenofibrate	Approved Drug	.	.	Fenofibrate increases the expression of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Flutamide	Approved Drug	.	.	Flutamide inhibits the activity of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Fluvoxamine	Approved Drug	.	.	Fluvoxamine inhibits the activity of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Gold	Chemical Compound	.	.	Gold inhibits the expression of ABCB4	.	.
DTD0013	ABCB4	Inducer	GW-4064	Patented Pharmaceutical Agent	.	.	GW-4064 increases the expression of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Hydroxyzine	Approved Drug	.	.	Hydroxyzine inhibits the activity of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Isoproterenol	Approved Drug	.	.	Isoproterenol inhibits the expression of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Ketoconazole	Approved Drug	.	.	Ketoconazole inhibits the activity of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Labetalol	Approved Drug	.	.	Labetalol inhibits the activity of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Lapatinib	Approved Drug	.	.	Lapatinib inhibits the activity of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Leflunomide	Approved Drug	.	.	Leflunomide inhibits the activity of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Liothyronine	Approved Drug	.	.	Liothyronine inhibits the activity of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Loratadine	Approved Drug	.	.	Loratadine inhibits the activity of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Methotrexate	Approved Drug	.	.	Methotrexate inhibits the activity of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Methoxsalen	Approved Drug	.	.	Methoxsalen inhibits the expression of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Methyleugenol	Natural Product	.	.	Methyleugenol inhibits the expression of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Methysergide	Approved Drug	.	.	Methysergide inhibits the activity of ABCB4	.	.
DTD0013	ABCB4	Inducer	MS-275	Drug in Phase 2 Trial	.	.	MS-275 increases the expression of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Nefazodone	Approved Drug	.	.	Nefazodone inhibits the activity of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Nitrofurantoin	Approved Drug	.	.	Nitrofurantoin inhibits the activity of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Nomifensine	Drug Withdrawn	.	.	Nomifensine inhibits the activity of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Nortriptyline	Approved Drug	.	.	Nortriptyline inhibits the activity of ABCB4	.	.
DTD0013	ABCB4	Inducer	Obeticholic acid	Approved Drug	.	.	Obeticholic acid increases the expression of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Omeprazole	Approved Drug	.	.	Omeprazole inhibits the expression of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Pazopanib	Approved Drug	.	.	Pazopanib inhibits the activity of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Penbutolol	Approved Drug	.	.	Penbutolol inhibits the activity of ABCB4	.	.
DTD0013	ABCB4	Inducer	Perfluorooctane sulfonic acid	Health and Environmental Toxicant	.	.	Perfluorooctane sulfonic acid increases the expression of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Phenazopyridine	Drug in Phase 1 Trial	.	.	Phenazopyridine inhibits the activity of ABCB4	.	.
DTD0013	ABCB4	Inducer	Phenobarbital	Approved Drug	.	.	Phenobarbital induces the activity of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Phenoxybenzamine	Approved Drug	.	.	Phenoxybenzamine inhibits the activity of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Phentolamine	Approved Drug	.	.	Phentolamine inhibits the activity of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Primaquine	Approved Drug	.	.	Primaquine inhibits the activity of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Protriptyline	Approved Drug	.	.	Protriptyline inhibits the activity of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of ABCB4	.	.
DTD0013	ABCB4	Inducer	Rifampin	Approved Drug	.	.	Rifampin increases the expression of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Ritonavir	Approved Drug	.	.	Ritonavir inhibits the expression of ABCB4	.	.
DTD0013	ABCB4	Inducer	Simvastatin	Approved Drug	.	.	Simvastatin induces the activity of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Tacrine	Approved Drug	.	.	Tacrine inhibits the activity of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Tamoxifen	Approved Drug	.	.	Tamoxifen inhibits the activity of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Tamsulosin	Approved Drug	.	.	Tamsulosin inhibits the activity of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Tenofovir	Approved Drug	.	.	Tenofovir inhibits the activity of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Tetradecanoylphorbol Acetate	Drug in Phase 1 Trial	.	.	Tetradecanoylphorbol Acetate inhibits the expression of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Tipranavir	Approved Drug	.	.	Tipranavir inhibits the activity of ABCB4	.	.
DTD0013	ABCB4	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of ABCB4	.	.
DTD0013	ABCB4	Inducer	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan increases the expression of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Troglitazone	Approved Drug	.	.	Troglitazone inhibits the activity of ABCB4	.	.
DTD0013	ABCB4	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of ABCB4	.	.
DTD0013	ABCB4	Inducer	Vorinostat	Approved Drug	.	.	Vorinostat increases the expression of ABCB4	.	.
DTD0013	ABCB4	Inhibition	WSM-3978G	Drug in Phase 1 Trial	.	.	WSM-3978G inhibits the activity of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Zafirlukast	Approved Drug	.	.	Zafirlukast inhibits the activity of ABCB4	.	.
DTD0013	ABCB4	Inhibition	Zimeldine	Drug Withdrawn	.	.	Zimeldine inhibits the activity of ABCB4	.	.
DTD0014	ABCB11	Inducer	2-methyl-4-isothiazolin-3-one	Acute Toxic Substance	.	.	2-methyl-4-isothiazolin-3-one increases the expression of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of ABCB11	.	.
DTD0014	ABCB11	Inhibition	AM-2282	Drug in Preclinical Test	.	.	AM-2282 inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Amiodarone	Approved Drug	.	.	Amiodarone inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Amprenavir	Approved Drug	.	.	Amprenavir inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	ANA-756	Drug in Phase 1 Trial	.	.	ANA-756 inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Astemizole	Drug in Phase 1 Trial	.	.	Astemizole inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Atenolol	Approved Drug	.	.	Atenolol inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Atropine	Approved Drug	.	.	Atropine inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Baohuoside I	Investigative Drug	.	.	Baohuoside I inhibits the expression of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Benzbromarone	Drug Marketed but not Approved by US FDA	.	.	Benzbromarone inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Bezafibrate	Drug Marketed but not Approved by US FDA	.	.	Bezafibrate inhibits the expression of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Bicalutamide	Approved Drug	.	.	Bicalutamide inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Bosentan	Approved Drug	.	.	Bosentan inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Bromfenac	Approved Drug	.	.	Bromfenac inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Budesonide	Approved Drug	.	.	Budesonide inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Cefaclor	Approved Drug	.	.	Cefaclor inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Celecoxib	Approved Drug	.	.	Celecoxib inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Chelerythrine	Investigative Drug	.	.	Chelerythrine inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inducer	Chenodeoxycholic acid	Approved Drug	.	.	Chenodeoxycholic acid induces the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Cholic Acid	Approved Drug	.	.	Cholic Acid inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Ciglitazone	Investigative Drug	.	.	Ciglitazone inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Cinnarizine	Drug in Phase 1 Trial	.	.	Cinnarizine inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Cisapride	Approved Drug	.	.	Cisapride inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Clarithromycin	Approved Drug	.	.	Clarithromycin inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Clofibrate	Approved Drug	.	.	Clofibrate inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Clotrimazole	Approved Drug	.	.	Clotrimazole inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Cloxacillin	Approved Drug	.	.	Cloxacillin inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Clozapine	Approved Drug	.	.	Clozapine inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inducer	Colchicine	Approved Drug	.	.	Colchicine induces the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Conjugated estrogens	Approved Drug	.	.	Conjugated estrogens inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Danazol	Approved Drug	.	.	Danazol inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Dasatinib	Approved Drug	.	.	Dasatinib inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inducer	Deoxycholic acid	Approved Drug	.	.	Deoxycholic acid increases the expression of ABCB11	.	.
DTD0014	ABCB11	Inducer	Dexamethasone	Approved Drug	.	.	Dexamethasone increases the expression of ABCB11	.	.
DTD0014	ABCB11	Inducer	Dichlorodiphenyl Dichloroethylene	Environmental toxicant	.	.	Dichlorodiphenyl Dichloroethylene increases the expression of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Diclofenac	Approved Drug	.	.	Diclofenac inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Dicloxacillin	Approved Drug	.	.	Dicloxacillin inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Diethylhexyl Phthalate	Health and Environmental Toxicant	.	.	Diethylhexyl Phthalate inhibits the expression of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Diethylstilbestrol	Approved Drug	.	.	Diethylstilbestrol inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Diethyltoluamide	Drug in Phase 3 Trial	.	.	Diethyltoluamide inhibits the expression of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Dihydroergotamine	Approved Drug	.	.	Dihydroergotamine inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Dipyridamole	Approved Drug	.	.	Dipyridamole inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Disulfiram	Approved Drug	.	.	Disulfiram inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Drospirenone	Approved Drug	.	.	Drospirenone inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Efavirenz	Approved Drug	.	.	Efavirenz inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inducer	Epicatechin gallate	Natural Product	.	.	Epicatechin gallate increases the expression of ABCB11	.	.
DTD0014	ABCB11	Inducer	Epigallocatechin gallate	Drug in Phase 3 Trial	.	.	Epigallocatechin gallate increases the expression of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Erythromycin	Approved Drug	.	.	Erythromycin inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Ethanol	Drug in Phase 2 Trial	.	.	Ethanol inhibits the expression of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Ethinyl Estradiol	Approved Drug	.	.	Ethinyl Estradiol inhibits the expression of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Etoricoxib	Drug Marketed but not Approved by US FDA	.	.	Etoricoxib inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Everolimus	Approved Drug	.	.	Everolimus inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Ezetimibe	Approved Drug	.	.	Ezetimibe inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Felodipine	Approved Drug	.	.	Felodipine inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Fenofibrate	Approved Drug	.	.	Fenofibrate inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Finasteride	Approved Drug	.	.	Finasteride inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Floxacillin	Drug Marketed but not Approved by US FDA	.	.	Floxacillin inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Fluvastatin	Approved Drug	.	.	Fluvastatin inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Fluvoxamine	Approved Drug	.	.	Fluvoxamine inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Fusidic Acid	Drug in Phase 3 Trial	.	.	Fusidic Acid inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inducer	Gallocatechol	Natural Product	.	.	Gallocatechol increases the expression of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Gefitinib	Approved Drug	.	.	Gefitinib inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Glimepiride	Approved Drug	.	.	Glimepiride inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Glipizide	Approved Drug	.	.	Glipizide inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Gliquidone	Drug Marketed but not Approved by US FDA	.	.	Gliquidone inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Glyburide	Approved Drug	.	.	Glibenclamide inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Glycyrrhizic Acid	Drug in Phase 3 Trial	.	.	Glycyrrhizic Acid inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inducer	Guggulsterone	Natural Product	.	.	Guggulsterone increases the expression of ABCB11	.	.
DTD0014	ABCB11	Inducer	GW-4064	Patented Pharmaceutical Agent	.	.	GW-4064 increases the expression of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Heliotrine	Natural Product	.	.	Heliotrine inhibits the expression of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Iloperidone	Approved Drug	.	.	Iloperidone inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Imatinib Mesylate	Approved Drug	.	.	Imatinib Mesylate inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Indinavir	Approved Drug	.	.	Indinavir inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Indocyanine green	Approved Drug	.	.	Indocyanine green inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Indomethacin	Approved Drug	.	.	Indomethacin inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Irbesartan	Approved Drug	.	.	Irbesartan inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Isradipine	Approved Drug	.	.	Isradipine inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Itraconazole	Approved Drug	.	.	Itraconazole inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Ketoconazole	Approved Drug	.	.	Ketoconazole inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Lapatinib	Approved Drug	.	.	Lapatinib inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Liothyronine	Approved Drug	.	.	Liothyronine inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inducer	Lithocholic Acid	Investigative Drug	.	.	Lithocholic Acid increases the expression of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Lopinavir	Approved Drug	.	.	Lopinavir inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Loratadine	Approved Drug	.	.	Loratadine inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Losartan	Approved Drug	.	.	Losartan inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Lovastatin	Approved Drug	.	.	Lovastatin inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Medroxyprogesterone Acetate	Approved Drug	.	.	Medroxyprogesterone Acetate inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Megestrol Acetate	Approved Drug	.	.	Megestrol Acetate inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Menadione	Approved Drug	.	.	Menadione inhibits the expression of ABCB11	.	.
DTD0014	ABCB11	Inducer	Methimazole	Approved Drug	.	.	Methimazole increases the expression of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Methyleugenol	Natural Product	.	.	Methyleugenol inhibits the expression of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Mibefradil	Approved Drug	.	.	Mibefradil inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Micafungin	Approved Drug	.	.	Micafungin inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Midazolam	Approved Drug	.	.	Midazolam inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Midecamycin	Approved Drug	.	.	Midecamycin inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Mifepristone	Approved Drug	.	.	Mifepristone inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Morin	Acute Toxic Substance	.	.	Morin inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Naproxen	Approved Drug	.	.	Naproxen inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Nefazodone	Approved Drug	.	.	Nefazodone inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Nelfinavir	Approved Drug	.	.	Nelfinavir inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Neratinib	Approved Drug	.	.	Neratinib inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Nicardipine	Approved Drug	.	.	Nicardipine inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Nifedipine	Approved Drug	.	.	Nifedipine inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Nitrendipine	Drug Marketed but not Approved by US FDA	.	.	Nitrendipine inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Nitrofurantoin	Approved Drug	.	.	Nitrofurantoin inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inducer	Obeticholic acid	Approved Drug	.	.	Obeticholic acid increases the expression of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Ofloxacin	Approved Drug	.	.	Ofloxacin inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Olanzapine	Approved Drug	.	.	Olanzapine inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Olmesartan medoxomil	Approved Drug	.	.	Olmesartan medoxomil inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Oltipraz	Drug in Phase 3 Trial	.	.	Oltipraz inhibits the expression of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Omeprazole	Approved Drug	.	.	Omeprazole inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Paclitaxel	Approved Drug	.	.	Paclitaxel inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Particulate Matter	Natural Product	.	.	Particulate Matter inhibits the expression of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Pazopanib	Approved Drug	.	.	Pazopanib inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Perfluorooctane sulfonic acid	Health and Environmental Toxicant	.	.	Perfluorooctane sulfonic acid inhibits the expression of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Phenobarbital	Approved Drug	.	.	Phenobarbital inhibits the expression of ABCB11	.	.
DTD0014	ABCB11	Inhibition	pimecrolimus	Approved Drug	.	.	pimecrolimus inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Pioglitazone	Approved Drug	.	.	Pioglitazone inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Pirinixic acid	Health and Environmental Toxicant	.	.	Pirinixic acid inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Pitavastatin	Approved Drug	.	.	Pitavastatin inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin inhibits the expression of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Posaconazole	Approved Drug	.	.	Posaconazole inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Pranlukast	Drug Marketed but not Approved by US FDA	.	.	Pranlukast inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Prasterone sulfate	Drug in Phase 1 Trial	.	.	Prasterone sulfate inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Pravastatin	Approved Drug	.	.	Pravastatin inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Primaquine	Approved Drug	.	.	Primaquine inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Primidone	Approved Drug	.	.	Primidone inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Ranolazine	Approved Drug	.	.	Ranolazine inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Repaglinide	Approved Drug	.	.	Repaglinide inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Rifampin	Approved Drug	.	.	Rifampin inhibits the expression of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Rifamycin SV	Approved Drug	.	.	Rifamycin SV inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Rifapentine	Approved Drug	.	.	Rifapentine inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Ritonavir	Approved Drug	.	.	Ritonavir inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Rosiglitazone	Approved Drug	.	.	Rosiglitazone inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Saquinavir	Approved Drug	.	.	Saquinavir inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Senecionine	Natural Product	.	.	Senecionine inhibits the expression of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Simvastatin	Approved Drug	.	.	Simvastatin inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Sitaxsentan	Drug Withdrawn	.	.	Sitaxsentan inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Sorafenib	Approved Drug	.	.	Sorafenib inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Spironolactone	Approved Drug	.	.	Spironolactone inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Sulfinpyrazone	Approved Drug	.	.	Sulfinpyrazone inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Tacrolimus	Approved Drug	.	.	Tacrolimus inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	TAK-875	Drug in Phase 1 Trial	.	.	TAK-875 inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Tamoxifen	Approved Drug	.	.	Tamoxifen inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Taurolithocholate	Investigative Drug	.	.	Taurolithocholate inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Telmisartan	Approved Drug	.	.	Telmisartan inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Temsirolimus	Approved Drug	.	.	Temsirolimus inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Terfenadine	Drug Withdrawn	.	.	Terfenadine inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Ticlopidine	Approved Drug	.	.	Ticlopidine inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Tinidazole	Approved Drug	.	.	Tinidazole inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Tipranavir	Approved Drug	.	.	Tipranavir inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Tolcapone	Approved Drug	.	.	Tolcapone inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Tolvaptan	Approved Drug	.	.	Tolvaptan inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of ABCB11	.	.
DTD0014	ABCB11	Inducer	Troglitazone	Approved Drug	.	.	Troglitazone induces the activity of ABCB11	.	.
DTD0014	ABCB11	Inducer	Ursodeoxycholic Acid	Approved Drug	.	.	Ursodeoxycholic Acid increases the expression of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Vinblastine	Approved Drug	.	.	Vinblastine inhibits the activity of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Vitamin E	Drug in Phase 3 Trial	.	.	Vitamin E inhibits the expression of ABCB11	.	.
DTD0014	ABCB11	Inhibition	Zafirlukast	Approved Drug	.	.	Zafirlukast inhibits the activity of ABCB11	.	.
DTD0015	ABCC4	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of ABCC4	.	.
DTD0015	ABCC4	Inducer	6-bromoindirubin-3'-oxime	Natural Product	.	.	6-bromoindirubin-3'-oxime increases the expression of ABCC4	.	.
DTD0015	ABCC4	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen induces the activity of ABCC4	.	.
DTD0015	ABCC4	Modulator	Adenosine Triphosphate	Drug in Phase 1 Trial	.	.	Adenosine Triphosphate affects the activity of ABCC4	.	.
DTD0015	ABCC4	Inhibition	Aflatoxin M1	Mycotoxins	.	.	Aflatoxin M1 inhibits the expression of ABCC4	.	.
DTD0015	ABCC4	Inducer	Arsenic	Approved Drug	.	.	Arsenic increases the expression of ABCC4	.	.
DTD0015	ABCC4	Inhibition	Arsenic Trioxide	Approved Drug	.	.	Arsenic Trioxide inhibits the expression of ABCC4	.	.
DTD0015	ABCC4	Inducer	Aspirin	Approved Drug	.	.	Aspirin increases the expression of ABCC4	.	.
DTD0015	ABCC4	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of ABCC4	.	.
DTD0015	ABCC4	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of ABCC4	.	.
DTD0015	ABCC4	Inhibition	Bortezomib	Approved Drug	.	.	Bortezomib inhibits the expression of ABCC4	.	.
DTD0015	ABCC4	Modulator	Carbamazepine	Approved Drug	.	.	Carbamazepine affects the expression of ABCC4	.	.
DTD0015	ABCC4	Inhibition	Cefmetazole	Approved Drug	.	.	Cefmetazole inhibits the activity of ABCC4	.	.
DTD0015	ABCC4	Inhibition	Celecoxib	Approved Drug	.	.	Celecoxib inhibits the activity of ABCC4	.	.
DTD0015	ABCC4	Inhibition	Chenodeoxycholic acid	Approved Drug	.	.	Chenodeoxycholic acid inhibits the expression of ABCC4	.	.
DTD0015	ABCC4	Inhibition	Chlorothiazide	Approved Drug	.	.	Chlorothiazide inhibits the activity of ABCC4	.	.
DTD0015	ABCC4	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the expression of ABCC4	.	.
DTD0015	ABCC4	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of ABCC4	.	.
DTD0015	ABCC4	Inducer	Deguelin	Natural Product	.	.	Deguelin increases the expression of ABCC4	.	.
DTD0015	ABCC4	Inhibition	Diclofenac	Approved Drug	.	.	Diclofenac inhibits the activity of ABCC4	.	.
DTD0015	ABCC4	Inducer	Dihydrotestosterone	Drug in Phase 4 Trial	.	.	Dihydrotestosterone induces the activity of ABCC4	.	.
DTD0015	ABCC4	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of ABCC4	.	.
DTD0015	ABCC4	Inducer	Eetuximab	Approved Drug	.	.	Eetuximab induces the activity of ABCC4	.	.
DTD0015	ABCC4	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of ABCC4	.	.
DTD0015	ABCC4	Inhibition	Ethyl Methanesulfonate	Carcinogen	.	.	Ethyl Methanesulfonate inhibits the expression of ABCC4	.	.
DTD0015	ABCC4	Inhibition	Etodolac	Approved Drug	.	.	Etodolac inhibits the activity of ABCC4	.	.
DTD0015	ABCC4	Inducer	Flutamide	Approved Drug	.	.	Flutamide induces the activity of ABCC4	.	.
DTD0015	ABCC4	Inhibition	Furosemide	Approved Drug	.	.	Furosemide inhibits the activity of ABCC4	.	.
DTD0015	ABCC4	Inhibition	GSK-J4	Patented Pharmaceutical Agent	.	.	GSK-J4 inhibits the expression of ABCC4	.	.
DTD0015	ABCC4	Inhibition	HSDB-595	Patented Pharmaceutical Agent	.	.	HSDB-595 inhibits the expression of ABCC4	.	.
DTD0015	ABCC4	Inhibition	Indomethacin	Approved Drug	.	.	Indomethacin inhibits the activity of ABCC4	.	.
DTD0015	ABCC4	Inhibition	Ivermectin	Approved Drug	.	.	Ivermectin inhibits the expression of ABCC4	.	.
DTD0015	ABCC4	Inhibition	Ketoprofen	Approved Drug	.	.	Ketoprofen inhibits the activity of ABCC4	.	.
DTD0015	ABCC4	Inhibition	Mdv-3100	Approved Drug	.	.	Mdv-3100 inhibits the expression of ABCC4	.	.
DTD0015	ABCC4	Inhibition	Methotrexate	Approved Drug	.	.	Methotrexate inhibits the expression of ABCC4	.	.
DTD0015	ABCC4	Inducer	Methylcholanthrene	Carcinogen	.	.	Methylcholanthrene increases the expression of ABCC4	.	.
DTD0015	ABCC4	Inducer	Metribolone	Investigative Drug	.	.	Metribolone increases the expression of ABCC4	.	.
DTD0015	ABCC4	Inducer	MS-275	Drug in Phase 2 Trial	.	.	MS-275 increases the expression of ABCC4	.	.
DTD0015	ABCC4	Inducer	Nefazodone	Approved Drug	.	.	Nefazodone increases the expression of ABCC4	.	.
DTD0015	ABCC4	Inducer	Oltipraz	Drug in Phase 3 Trial	.	.	Oltipraz increases the expression of ABCC4	.	.
DTD0015	ABCC4	Inhibition	Perfluorooctane sulfonic acid	Health and Environmental Toxicant	.	.	Perfluorooctane sulfonic acid inhibits the activity of ABCC4	.	.
DTD0015	ABCC4	Inhibition	Phenylmercuric Acetate	Investigative Drug	.	.	Phenylmercuric Acetate inhibits the expression of ABCC4	.	.
DTD0015	ABCC4	Inducer	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin increases the expression of ABCC4	.	.
DTD0015	ABCC4	Inhibition	Quercitrin	Natural Product	.	.	Quercitrin inhibits the expression of ABCC4	.	.
DTD0015	ABCC4	Inducer	Rotenone	Drug Marketed but not Approved by US FDA	.	.	Rotenone increases the expression of ABCC4	.	.
DTD0015	ABCC4	Inducer	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite increases the expression of ABCC4	.	.
DTD0015	ABCC4	Inhibition	Sulindac	Approved Drug	.	.	Sulindac inhibits the activity of ABCC4	.	.
DTD0015	ABCC4	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of ABCC4	.	.
DTD0015	ABCC4	Inhibition	TAK-875	Drug in Phase 1 Trial	.	.	TAK-875 inhibits the activity of ABCC4	.	.
DTD0015	ABCC4	Inhibition	Telmisartan	Approved Drug	.	.	Telmisartan inhibits the activity of ABCC4	.	.
DTD0015	ABCC4	Inhibition	Temozolomide	Approved Drug	.	.	Temozolomide inhibits the expression of ABCC4	.	.
DTD0015	ABCC4	Inhibition	Tetrabromobisphenol A	Environmental toxicant	.	.	Tetrabromobisphenol A inhibits the activity of ABCC4	.	.
DTD0015	ABCC4	Inhibition	Tetradecanoylphorbol Acetate	Drug in Phase 1 Trial	.	.	Tetradecanoylphorbol Acetate inhibits the expression of ABCC4	.	.
DTD0015	ABCC4	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of ABCC4	.	.
DTD0015	ABCC4	Inhibition	Tolvaptan	Approved Drug	.	.	Tolvaptan inhibits the activity of ABCC4	.	.
DTD0015	ABCC4	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of ABCC4	.	.
DTD0015	ABCC4	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of ABCC4	.	.
DTD0015	ABCC4	Inhibition	Vitamin D	Approved Drug	.	.	Vitamin D inhibits the expression of ABCC4	.	.
DTD0015	ABCC4	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of ABCC4	.	.
DTD0016	ABCC5	Inducer	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 increases the expression of ABCC5	.	.
DTD0016	ABCC5	Inhibition	2-butenal	Acute Toxic Substance	.	.	2-butenal inhibits the expression of ABCC5	.	.
DTD0016	ABCC5	Inhibition	4-(2-Aminoethyl) benzenesulfonyl fluoride	Investigative Drug	.	.	4-(2-Aminoethyl) benzenesulfonyl fluoride inhibits the activity of ABCC5	.	.
DTD0016	ABCC5	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of ABCC5	.	.
DTD0016	ABCC5	Inducer	Afimoxifene	Drug in Phase 3 Trial	.	.	Afimoxifene increases the expression of ABCC5	.	.
DTD0016	ABCC5	Inducer	Arsenic Trioxide	Approved Drug	.	.	Arsenic Trioxide increases the expression of ABCC5	.	.
DTD0016	ABCC5	Inducer	Aspirin	Approved Drug	.	.	Aspirin increases the expression of ABCC5	.	.
DTD0016	ABCC5	Inhibition	Azoxystrobin	Fungicide	.	.	Azoxystrobin inhibits the expression of ABCC5	.	.
DTD0016	ABCC5	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of ABCC5	.	.
DTD0016	ABCC5	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of ABCC5	.	.
DTD0016	ABCC5	Inducer	Celecoxib	Approved Drug	.	.	Celecoxib increases the expression of ABCC5	.	.
DTD0016	ABCC5	Inhibition	Chrysin	Natural Product	.	.	Chrysin inhibits the expression of ABCC5	.	.
DTD0016	ABCC5	Inhibition	Cycloheximide	Acute Toxic Substance	.	.	Cycloheximide inhibits the expression of ABCC5	.	.
DTD0016	ABCC5	Inducer	Decitabine	Approved Drug	.	.	Decitabine increases the expression of ABCC5	.	.
DTD0016	ABCC5	Inhibition	Deguelin	Natural Product	.	.	Deguelin inhibits the expression of ABCC5	.	.
DTD0016	ABCC5	Inducer	Dicrotophos	Pesticide/Insecticide	.	.	Dicrotophos increases the expression of ABCC5	.	.
DTD0016	ABCC5	Modulator	Dihydrotestosterone	Drug in Phase 1 Trial	.	.	Dihydrotestosterone affects the expression of ABCC5	.	.
DTD0016	ABCC5	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the expression of ABCC5	.	.
DTD0016	ABCC5	Inducer	Ethyl Methanesulfonate	Carcinogen	.	.	Ethyl Methanesulfonate increases the expression of ABCC5	.	.
DTD0016	ABCC5	Inducer	Fluorouracil	Approved Drug	.	.	Fluorouracil induces the activity of ABCC5	.	.
DTD0016	ABCC5	Inducer	Formaldehyde	Acute Toxic Substance	.	.	Formaldehyde increases the expression of ABCC5	.	.
DTD0016	ABCC5	Inhibition	Fulvestrant	Approved Drug	.	.	Fulvestrant inhibits the expression of ABCC5	.	.
DTD0016	ABCC5	Inducer	Gemcitabine	Approved Drug	.	.	Gemcitabine induces the activity of ABCC5	.	.
DTD0016	ABCC5	Inhibition	Genistein	Drug in Phase 2 Trial	.	.	Genistein inhibits the expression of ABCC5	.	.
DTD0016	ABCC5	Modulator	Hydrogen Peroxide	Approved Drug	.	.	Hydrogen Peroxide affects the expression of ABCC5	.	.
DTD0016	ABCC5	Inducer	Jinfukang	Traditional Medicine	.	.	Jinfukang increases the expression of ABCC5	.	.
DTD0016	ABCC5	Inhibition	LY-294002	Drug in Phase 1 Trial	.	.	LY-294002 inhibits the expression of ABCC5	.	.
DTD0016	ABCC5	Inhibition	Micafungin	Approved Drug	.	.	Micafungin inhibits the activity of ABCC5	.	.
DTD0016	ABCC5	Inducer	Paclitaxel	Approved Drug	.	.	Paclitaxel increases the expression of ABCC5	.	.
DTD0016	ABCC5	Inducer	Particulate Matter	Natural Product	.	.	Particulate Matter increases the expression of ABCC5	.	.
DTD0016	ABCC5	Inhibition	Perfluorooctane sulfonic acid	Health and Environmental Toxicant	.	.	Perfluorooctane sulfonic acid inhibits the expression of ABCC5	.	.
DTD0016	ABCC5	Inducer	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin increases the expression of ABCC5	.	.
DTD0016	ABCC5	Inhibition	Probenecid	Approved Drug	.	.	Probenecid inhibits the activity of ABCC5	.	.
DTD0016	ABCC5	Inducer	Rifampin	Approved Drug	.	.	Rifampin increases the expression of ABCC5	.	.
DTD0016	ABCC5	Inhibition	Rotenone	Drug Marketed but not Approved by US FDA	.	.	Rotenone inhibits the expression of ABCC5	.	.
DTD0016	ABCC5	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of ABCC5	.	.
DTD0016	ABCC5	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of ABCC5	.	.
DTD0016	ABCC5	Inducer	Urethane	Approved Drug	.	.	Urethane increases the expression of ABCC5	.	.
DTD0016	ABCC5	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of ABCC5	.	.
DTD0016	ABCC5	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of ABCC5	.	.
DTD0016	ABCC5	Inhibition	Zoledronic Acid	Approved Drug	.	.	Zoledronic Acid inhibits the expression of ABCC5	.	.
DTD0017	ABCC6	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of ABCC6	.	.
DTD0017	ABCC6	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of ABCC6	.	.
DTD0017	ABCC6	Inducer	Alitretinoin	Approved Drug	.	.	Alitretinoin increases the expression of ABCC6	.	.
DTD0017	ABCC6	Inhibition	Belinostat	Approved Drug	.	.	Belinostat inhibits the expression of ABCC6	.	.
DTD0017	ABCC6	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of ABCC6	.	.
DTD0017	ABCC6	Modulator	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A affects the expression of ABCC6	.	.
DTD0017	ABCC6	Inhibition	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde inhibits the expression of ABCC6	.	.
DTD0017	ABCC6	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of ABCC6	.	.
DTD0017	ABCC6	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of ABCC6	.	.
DTD0017	ABCC6	Inhibition	Diethylhexyl Phthalate	Health and Environmental Toxicant	.	.	Diethylhexyl Phthalate inhibits the expression of ABCC6	.	.
DTD0017	ABCC6	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of ABCC6	.	.
DTD0017	ABCC6	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the expression of ABCC6	.	.
DTD0017	ABCC6	Inducer	Fluorouracil	Approved Drug	.	.	Fluorouracil increases the expression of ABCC6	.	.
DTD0017	ABCC6	Inhibition	Heliotrine	Natural Product	.	.	Heliotrine inhibits the expression of ABCC6	.	.
DTD0017	ABCC6	Inhibition	HSDB-595	Patented Pharmaceutical Agent	.	.	HSDB-595 inhibits the expression of ABCC6	.	.
DTD0017	ABCC6	Inhibition	Methamphetamine	Approved Drug	.	.	Methamphetamine inhibits the expression of ABCC6	.	.
DTD0017	ABCC6	Inhibition	Methyleugenol	Natural Product	.	.	Methyleugenol inhibits the expression of ABCC6	.	.
DTD0017	ABCC6	Inhibition	Micafungin	Approved Drug	.	.	Micafungin inhibits the activity of ABCC6	.	.
DTD0017	ABCC6	Inhibition	Phenobarbital	Approved Drug	.	.	Phenobarbital inhibits the expression of ABCC6	.	.
DTD0017	ABCC6	Inhibition	Progesterone	Approved Drug	.	.	Progesterone inhibits the expression of ABCC6	.	.
DTD0017	ABCC6	Inducer	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin increases the expression of ABCC6	.	.
DTD0017	ABCC6	Inducer	Rifampin	Approved Drug	.	.	Rifampin increases the expression of ABCC6	.	.
DTD0017	ABCC6	Inhibition	Rosiglitazone	Approved Drug	.	.	Rosiglitazone inhibits the expression of ABCC6	.	.
DTD0017	ABCC6	Inhibition	Senecionine	Natural Product	.	.	Senecionine inhibits the expression of ABCC6	.	.
DTD0017	ABCC6	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of ABCC6	.	.
DTD0017	ABCC6	Inhibition	Sunitinib	Approved Drug	.	.	Sunitinib inhibits the expression of ABCC6	.	.
DTD0017	ABCC6	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of ABCC6	.	.
DTD0017	ABCC6	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of ABCC6	.	.
DTD0017	ABCC6	Inhibition	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A inhibits the expression of ABCC6	.	.
DTD0017	ABCC6	Inhibition	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan inhibits the expression of ABCC6	.	.
DTD0017	ABCC6	Inhibition	Troglitazone	Approved Drug	.	.	Troglitazone inhibits the expression of ABCC6	.	.
DTD0017	ABCC6	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of ABCC6	.	.
DTD0017	ABCC6	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of ABCC6	.	.
DTD0017	ABCC6	Inhibition	Verapamil	Approved Drug	.	.	Verapamil inhibits the activity of ABCC6	.	.
DTD0017	ABCC6	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of ABCC6	.	.
DTD0019	SLC10A1	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC10A1	.	.
DTD0019	SLC10A1	Inducer	Adenosine	Approved Drug	.	.	Adenosine induces the activity of SLC10A1	.	.
DTD0019	SLC10A1	Inhibition	Afimoxifene	Drug in Phase 3 Trial	.	.	Afimoxifene inhibits the expression of SLC10A1	.	.
DTD0019	SLC10A1	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC10A1	.	.
DTD0019	SLC10A1	Inducer	Baohuoside I	Investigative Drug	.	.	Baohuoside I increases the expression of SLC10A1	.	.
DTD0019	SLC10A1	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC10A1	.	.
DTD0019	SLC10A1	Inhibition	Beta-naphthoflavone	Investigative Drug	.	.	Beta-naphthoflavone inhibits the expression of SLC10A1	.	.
DTD0019	SLC10A1	Inhibition	Bosentan	Approved Drug	.	.	Bosentan inhibits the activity of SLC10A1	.	.
DTD0019	SLC10A1	Inducer	Carbamazepine	Approved Drug	.	.	Carbamazepine increases the expression of SLC10A1	.	.
DTD0019	SLC10A1	Inducer	Carmustine	Approved Drug	.	.	Carmustine increases the expression of SLC10A1	.	.
DTD0019	SLC10A1	Inhibition	Chlordan	Health and Environmental Toxicant	.	.	Chlordan inhibits the expression of SLC10A1	.	.
DTD0019	SLC10A1	Inhibition	Cholic Acid	Approved Drug	.	.	Cholic Acid inhibits the expression of SLC10A1	.	.
DTD0019	SLC10A1	Inhibition	Coal Ash	Natural Product	.	.	Coal Ash inhibits the expression of SLC10A1	.	.
DTD0019	SLC10A1	Inhibition	Cocaine	Approved Drug	.	.	Cocaine inhibits the expression of SLC10A1	.	.
DTD0019	SLC10A1	Inhibition	Cylindrospermopsin	Cyanotoxin	.	.	Cylindrospermopsin inhibits the expression of SLC10A1	.	.
DTD0019	SLC10A1	Inducer	Dexamethasone	Approved Drug	.	.	Dexamethasone induces the activity of SLC10A1	.	.
DTD0019	SLC10A1	Inhibition	Dieldrin	Pesticide/Insecticide	.	.	Dieldrin inhibits the expression of SLC10A1	.	.
DTD0019	SLC10A1	Inhibition	Endosulfan	Pesticide/Insecticide	.	.	Endosulfan inhibits the expression of SLC10A1	.	.
DTD0019	SLC10A1	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the expression of SLC10A1	.	.
DTD0019	SLC10A1	Inhibition	Ethinyl Estradiol	Approved Drug	.	.	Ethinyl Estradiol inhibits the expression of SLC10A1	.	.
DTD0019	SLC10A1	Inhibition	Fenofibrate	Approved Drug	.	.	Fenofibrate inhibits the expression of SLC10A1	.	.
DTD0019	SLC10A1	Inhibition	Heliotrine	Natural Product	.	.	Heliotrine inhibits the expression of SLC10A1	.	.
DTD0019	SLC10A1	Inhibition	Heptachlor	Pesticide/Insecticide	.	.	Heptachlor inhibits the expression of SLC10A1	.	.
DTD0019	SLC10A1	Inhibition	Irbesartan	Approved Drug	.	.	Irbesartan inhibits the activity of SLC10A1	.	.
DTD0019	SLC10A1	Inhibition	Lindane	Approved Drug	.	.	Lindane inhibits the expression of SLC10A1	.	.
DTD0019	SLC10A1	Inhibition	LUM001	Drug in Phase 2 Trial	.	.	LUM001 inhibits the activity of SLC10A1	.	.
DTD0019	SLC10A1	Inhibition	Macitentan	Approved Drug	.	.	Macitentan inhibits the expression of SLC10A1	.	.
DTD0019	SLC10A1	Inhibition	Methyleugenol	Natural Product	.	.	Methyleugenol inhibits the expression of SLC10A1	.	.
DTD0019	SLC10A1	Inhibition	Nefazodone	Approved Drug	.	.	Nefazodone inhibits the expression of SLC10A1	.	.
DTD0019	SLC10A1	Inhibition	Obeticholic acid	Approved Drug	.	.	Obeticholic acid inhibits the expression of SLC10A1	.	.
DTD0019	SLC10A1	Inhibition	Oltipraz	Drug in Phase 3 Trial	.	.	Oltipraz inhibits the expression of SLC10A1	.	.
DTD0019	SLC10A1	Inhibition	Particulate Matter	Natural Product	.	.	Particulate Matter inhibits the expression of SLC10A1	.	.
DTD0019	SLC10A1	Inducer	Perfluorooctane sulfonic acid	Health and Environmental Toxicant	.	.	Perfluorooctane sulfonic acid increases the expression of SLC10A1	.	.
DTD0019	SLC10A1	Inhibition	Phenobarbital	Approved Drug	.	.	Phenobarbital inhibits the expression of SLC10A1	.	.
DTD0019	SLC10A1	Inhibition	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin inhibits the expression of SLC10A1	.	.
DTD0019	SLC10A1	Inhibition	Rifampicin	Approved Drug	.	.	Rifampicin inhibits the activity of SLC10A1	.	.
DTD0019	SLC10A1	Inhibition	Rifampin	Approved Drug	.	.	Rifampin inhibits the expression of SLC10A1	.	.
DTD0019	SLC10A1	Inhibition	Ritonavir	Approved Drug	.	.	Ritonavir inhibits the activity of SLC10A1	.	.
DTD0019	SLC10A1	Inhibition	Ro-41-5253	Patented Pharmaceutical Agent	.	.	Ro-41-5253 inhibits the expression of SLC10A1	.	.
DTD0019	SLC10A1	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC10A1	.	.
DTD0019	SLC10A1	Inhibition	Sulforafan	Drug in Phase 3 Trial	.	.	Sulforafan inhibits the expression of SLC10A1	.	.
DTD0019	SLC10A1	Inhibition	TAK-875	Drug in Phase 1 Trial	.	.	TAK-875 inhibits the activity of SLC10A1	.	.
DTD0019	SLC10A1	Inducer	Tamoxifen	Approved Drug	.	.	Tamoxifen increases the expression of SLC10A1	.	.
DTD0019	SLC10A1	Inhibition	Tetrabromobisphenol A	Environmental toxicant	.	.	Tetrabromobisphenol A inhibits the activity of SLC10A1	.	.
DTD0019	SLC10A1	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC10A1	.	.
DTD0019	SLC10A1	Inhibition	Tolvaptan	Approved Drug	.	.	Tolvaptan inhibits the activity of SLC10A1	.	.
DTD0019	SLC10A1	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC10A1	.	.
DTD0019	SLC10A1	Inhibition	Troglitazone	Approved Drug	.	.	Troglitazone inhibits the expression of SLC10A1	.	.
DTD0019	SLC10A1	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC10A1	.	.
DTD0020	SLC10A2	Modulator	264W94	Drug in Phase 2 Trial	.	.	264W94 modulates the activity of SLC10A2	.	.
DTD0020	SLC10A2	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of SLC10A2	.	.
DTD0020	SLC10A2	Inducer	Budesonide	Approved Drug	.	.	Budesonide induces the activity of SLC10A2	.	.
DTD0020	SLC10A2	Inducer	Calcitriol	Approved Drug	.	.	Calcitriol increases the expression of SLC10A2	.	.
DTD0020	SLC10A2	Inducer	Ciprofibrate	Approved Drug	.	.	Ciprofibrate induces the activity of SLC10A2	.	.
DTD0020	SLC10A2	Inducer	Colestyramine	Drug in Phase 2 Trial	.	.	Colestyramine induces the activity of SLC10A2	.	.
DTD0020	SLC10A2	Inhibition	Deoxynivalenol	Mycotoxins	.	.	Deoxynivalenol inhibits the expression of SLC10A2	.	.
DTD0020	SLC10A2	Inducer	Dexamethasone	Approved Drug	.	.	Dexamethasone induces the activity of SLC10A2	.	.
DTD0020	SLC10A2	Inhibition	Elobixibat	Drug in Phase 3 Trial	.	.	Elobixibat inhibits the activity of SLC10A2	.	.
DTD0020	SLC10A2	Modulator	GSK1614235 + GSK2330672	Drug in Phase 1 Trial	.	.	GSK1614235 + GSK2330672 modulates the activity of SLC10A2	.	.
DTD0020	SLC10A2	Modulator	GSK2330672	Drug in Phase 2 Trial	.	.	GSK2330672 modulates the activity of SLC10A2	.	.
DTD0020	SLC10A2	Inhibition	Irbesartan	Approved Drug	.	.	Irbesartan inhibits the activity of SLC10A2	.	.
DTD0020	SLC10A2	Inhibition	LUM001	Drug in Phase 2 Trial	.	.	LUM001 inhibits the activity of SLC10A2	.	.
DTD0020	SLC10A2	Inhibition	Resveratrol	Drug in Phase 3 Trial	.	.	Resveratrol inhibits the expression of SLC10A2	.	.
DTD0020	SLC10A2	Inhibition	S-8921	Drug in Phase 2 Trial	.	.	S-8921 inhibits the activity of SLC10A2	.	.
DTD0020	SLC10A2	Inducer	Secretin	Approved Drug	.	.	Secretin induces the activity of SLC10A2	.	.
DTD0020	SLC10A2	Modulator	Taurocholic Acid	Drug in Phase 1/2 Trial	.	.	Taurocholic acid modulates the activity of SLC10A2	.	.
DTD0021	SLC15A1	Modulator	[11C]GlySar	Investigative Drug	.	.	[11C]GlySar modulates the activity of SLC15A1	.	.
DTD0021	SLC15A1	Modulator	[14C]GlySar	Investigative Drug	.	.	[14C]GlySar modulates the activity of SLC15A1	.	.
DTD0021	SLC15A1	Modulator	[3H]GlySar	Investigative Drug	.	.	[3H]GlySar modulates the activity of SLC15A1	.	.
DTD0021	SLC15A1	Inhibition	4-AMBA	Investigative Drug	.	.	4-AMBA inhibits the activity of SLC15A1	.	.
DTD0021	SLC15A1	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC15A1	.	.
DTD0021	SLC15A1	Modulator	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 affects the expression of SLC15A1	.	.
DTD0021	SLC15A1	Inhibition	AICA ribonucleotide	Drug in Phase 1 Trial	.	.	AICA ribonucleotide inhibits the activity of SLC15A1	.	.
DTD0021	SLC15A1	Inhibition	Arsenic Trioxide	Approved Drug	.	.	Arsenic Trioxide inhibits the expression of SLC15A1	.	.
DTD0021	SLC15A1	Inhibition	Aspartame	Drug in Phase 1 Trial	.	.	Aspartame inhibits the activity of SLC15A1	.	.
DTD0021	SLC15A1	Inhibition	Azathioprine	Approved Drug	.	.	Azathioprine inhibits the expression of SLC15A1	.	.
DTD0021	SLC15A1	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC15A1	.	.
DTD0021	SLC15A1	Inducer	Cisplatin	Approved Drug	.	.	Cisplatin induces the activity of SLC15A1	.	.
DTD0021	SLC15A1	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC15A1	.	.
DTD0021	SLC15A1	Inhibition	Enalapril	Approved Drug	.	.	Enalapril inhibits the activity of SLC15A1	.	.
DTD0021	SLC15A1	Inhibition	Fluorouracil	Approved Drug	.	.	Fluorouracil inhibits the expression of SLC15A1	.	.
DTD0021	SLC15A1	Inhibition	Fluvastatin	Approved Drug	.	.	Fluvastatin inhibits the activity of SLC15A1	.	.
DTD0021	SLC15A1	Inducer	Insulin	Approved Drug	.	.	Insulin induces the activity of SLC15A1	.	.
DTD0021	SLC15A1	Inhibition	Isotretinoin	Approved Drug	.	.	Isotretinoin inhibits the expression of SLC15A1	.	.
DTD0021	SLC15A1	Inhibition	Liothyronine	Approved Drug	.	.	Liothyronine inhibits the expression of SLC15A1	.	.
DTD0021	SLC15A1	Inhibition	MeIQx	Drug in Phase 2 Trial	.	.	MeIQx inhibits the expression of SLC15A1	.	.
DTD0021	SLC15A1	Inducer	Metformin	Approved Drug	.	.	Metformin increases the expression of SLC15A1	.	.
DTD0021	SLC15A1	Inhibition	Methyleugenol	Natural Product	.	.	Methyleugenol inhibits the expression of SLC15A1	.	.
DTD0021	SLC15A1	Inhibition	Milchsaure	Investigative Drug	.	.	Milchsaure inhibits the expression of SLC15A1	.	.
DTD0021	SLC15A1	Inducer	Pirinixic acid	Health and Environmental Toxicant	.	.	Pirinixic acid increases the expression of SLC15A1	.	.
DTD0021	SLC15A1	Inhibition	Quinapril	Approved Drug	.	.	Quinapril inhibits the activity of SLC15A1	.	.
DTD0021	SLC15A1	Inhibition	Repaglinide	Approved Drug	.	.	Repaglinide inhibits the activity of SLC15A1	.	.
DTD0021	SLC15A1	Inducer	Resveratrol	Drug in Phase 3 Trial	.	.	Resveratrol increases the expression of SLC15A1	.	.
DTD0021	SLC15A1	Inhibition	Rifampin	Approved Drug	.	.	Rifampin inhibits the expression of SLC15A1	.	.
DTD0021	SLC15A1	Modulator	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution affects the expression of SLC15A1	.	.
DTD0021	SLC15A1	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of SLC15A1	.	.
DTD0021	SLC15A1	Modulator	Valproic Acid	Approved Drug	.	.	Valproic Acid affects the expression of SLC15A1	.	.
DTD0021	SLC15A1	Inhibition	Zinc	Environmental toxicant	.	.	Zinc inhibits the activity of SLC15A1	.	.
DTD0021	SLC15A1	Inducer	Zoledronic Acid	Approved Drug	.	.	Zoledronic Acid increases the expression of SLC15A1	.	.
DTD0022	SLC15A2	Inducer	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 increases the expression of SLC15A2	.	.
DTD0022	SLC15A2	Inhibition	Amoxicillin	Approved Drug	.	.	Amoxicillin inhibits the activity of SLC15A2	.	.
DTD0022	SLC15A2	Inhibition	Ampicillin	Approved Drug	.	.	Ampicillin inhibits the activity of SLC15A2	.	.
DTD0022	SLC15A2	Inhibition	Benzylpenicillin	Drug in Phase 3 Trial	.	.	Benzylpenicillin inhibits the activity of SLC15A2	.	.
DTD0022	SLC15A2	Inducer	Calcitriol	Approved Drug	.	.	Calcitriol increases the expression of SLC15A2	.	.
DTD0022	SLC15A2	Inhibition	Cefaclor	Approved Drug	.	.	Cefaclor inhibits the activity of SLC15A2	.	.
DTD0022	SLC15A2	Inhibition	Cefadroxil	Approved Drug	.	.	Cefadroxil inhibits the activity of SLC15A2	.	.
DTD0022	SLC15A2	Inhibition	Cefamandole	Approved Drug	.	.	Cefamandole inhibits the activity of SLC15A2	.	.
DTD0022	SLC15A2	Inhibition	Cefepime	Approved Drug	.	.	Cefepime inhibits the activity of SLC15A2	.	.
DTD0022	SLC15A2	Inhibition	Cefixime	Approved Drug	.	.	Cefixime inhibits the activity of SLC15A2	.	.
DTD0022	SLC15A2	Inhibition	Cefmetazole	Approved Drug	.	.	Cefmetazole inhibits the activity of SLC15A2	.	.
DTD0022	SLC15A2	Inhibition	Cefotaxime	Approved Drug	.	.	Cefotaxime inhibits the activity of SLC15A2	.	.
DTD0022	SLC15A2	Inhibition	Cefpodoxime	Approved Drug	.	.	Cefpodoxime inhibits the activity of SLC15A2	.	.
DTD0022	SLC15A2	Inhibition	Cefuroxime	Approved Drug	.	.	Cefuroxime inhibits the activity of SLC15A2	.	.
DTD0022	SLC15A2	Inhibition	Cephalexin	Approved Drug	.	.	Cephalexin inhibits the activity of SLC15A2	.	.
DTD0022	SLC15A2	Inhibition	Cephaloridine	Drug Withdrawn	.	.	Cephaloridine inhibits the activity of SLC15A2	.	.
DTD0022	SLC15A2	Inhibition	Cephalothin	Approved Drug	.	.	Cephalothin inhibits the activity of SLC15A2	.	.
DTD0022	SLC15A2	Inhibition	Cephapirin	Approved Drug	.	.	Cephapirin inhibits the activity of SLC15A2	.	.
DTD0022	SLC15A2	Inhibition	Cloxacillin	Approved Drug	.	.	Cloxacillin inhibits the activity of SLC15A2	.	.
DTD0022	SLC15A2	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC15A2	.	.
DTD0022	SLC15A2	Inhibition	Cyclacillin	Approved Drug	.	.	Cyclacillin inhibits the activity of SLC15A2	.	.
DTD0022	SLC15A2	Inhibition	Dicloxacillin	Approved Drug	.	.	Dicloxacillin inhibits the activity of SLC15A2	.	.
DTD0022	SLC15A2	Inducer	Dihydrotestosterone	Drug in Phase 1 Trial	.	.	Dihydrotestosterone increases the expression of SLC15A2	.	.
DTD0022	SLC15A2	Inhibition	Genistein	Drug in Phase 2 Trial	.	.	Genistein inhibits the expression of SLC15A2	.	.
DTD0022	SLC15A2	Inhibition	Glyburide	Approved Drug	.	.	Glibenclamide inhibits the activity of SLC15A2	.	.
DTD0022	SLC15A2	Inhibition	Laevulinic acid	Investigative Drug	.	.	Laevulinic acid inhibits the activity of SLC15A2	.	.
DTD0022	SLC15A2	Inhibition	MDL-28170	Discontinued Drug	.	.	MDL-28170 inhibits the activity of SLC15A2	.	.
DTD0022	SLC15A2	Inhibition	Oxacillin	Approved Drug	.	.	Oxacillin inhibits the activity of SLC15A2	.	.
DTD0022	SLC15A2	Inhibition	Progesterone	Approved Drug	.	.	Progesterone inhibits the expression of SLC15A2	.	.
DTD0022	SLC15A2	Inhibition	Quinapril	Approved Drug	.	.	Quinapril inhibits the activity of SLC15A2	.	.
DTD0022	SLC15A2	Inducer	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite increases the expression of SLC15A2	.	.
DTD0022	SLC15A2	Inhibition	Sunitinib	Approved Drug	.	.	Sunitinib inhibits the expression of SLC15A2	.	.
DTD0022	SLC15A2	Inducer	Testosterone	Approved Drug	.	.	Testosterone increases the expression of SLC15A2	.	.
DTD0022	SLC15A2	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC15A2	.	.
DTD0022	SLC15A2	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of SLC15A2	.	.
DTD0022	SLC15A2	Inhibition	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan inhibits the expression of SLC15A2	.	.
DTD0022	SLC15A2	Inhibition	Valganciclovir	Approved Drug	.	.	Valganciclovir inhibits the activity of SLC15A2	.	.
DTD0022	SLC15A2	Inhibition	Zoledronic Acid	Approved Drug	.	.	Zoledronic Acid inhibits the expression of SLC15A2	.	.
DTD0023	SLC22A5	Modulator	Arsenic	Approved Drug	.	.	Arsenic affects the expression of SLC22A5	.	.
DTD0023	SLC22A5	Inhibition	Carbamazepine	Approved Drug	.	.	Carbamazepine inhibits the expression of SLC22A5	.	.
DTD0023	SLC22A5	Inhibition	Cefepime	Approved Drug	.	.	Cefepime inhibits the activity of SLC22A5	.	.
DTD0023	SLC22A5	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the expression of SLC22A5	.	.
DTD0023	SLC22A5	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of SLC22A5	.	.
DTD0023	SLC22A5	Inducer	Decitabine	Approved Drug	.	.	Decitabine increases the expression of SLC22A5	.	.
DTD0023	SLC22A5	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC22A5	.	.
DTD0023	SLC22A5	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC22A5	.	.
DTD0023	SLC22A5	Inducer	Ethyl Methanesulfonate	Carcinogen	.	.	Ethyl Methanesulfonate increases the expression of SLC22A5	.	.
DTD0023	SLC22A5	Inducer	Genistein	Drug in Phase 2 Trial	.	.	Genistein increases the expression of SLC22A5	.	.
DTD0023	SLC22A5	Modulator	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin affects the expression of SLC22A5	.	.
DTD0023	SLC22A5	Inhibition	Progesterone	Approved Drug	.	.	Progesterone inhibits the activity of SLC22A5	.	.
DTD0023	SLC22A5	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of SLC22A5	.	.
DTD0023	SLC22A5	Modulator	Raloxifene Hydrochloride	Approved Drug	.	.	Raloxifene Hydrochloride affects the expression of SLC22A5	.	.
DTD0023	SLC22A5	Inducer	Rosiglitazone	Approved Drug	.	.	Rosiglitazone increases the expression of SLC22A5	.	.
DTD0023	SLC22A5	Inhibition	Sunitinib	Approved Drug	.	.	Sunitinib inhibits the expression of SLC22A5	.	.
DTD0023	SLC22A5	Modulator	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution affects the expression of SLC22A5	.	.
DTD0023	SLC22A5	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of SLC22A5	.	.
DTD0023	SLC22A5	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of SLC22A5	.	.
DTD0023	SLC22A5	Inhibition	Verapamil	Approved Drug	.	.	Verapamil inhibits the activity of SLC22A5	.	.
DTD0023	SLC22A5	Inhibition	Vorinostat	Approved Drug	.	.	Vorinostat inhibits the expression of SLC22A5	.	.
DTD0023	SLC22A5	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of SLC22A5	.	.
DTD0024	SLC22A6	Inhibition	2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine	Acute Toxic Substance	.	.	2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine inhibits the activity of SLC22A6	.	.
DTD0024	SLC22A6	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC22A6	.	.
DTD0024	SLC22A6	Inhibition	Amoxicillin	Approved Drug	.	.	Amoxicillin inhibits the activity of SLC22A6	.	.
DTD0024	SLC22A6	Inhibition	Baicalein	Natural Product	.	.	Baicalein inhibits the activity of SLC22A6	.	.
DTD0024	SLC22A6	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the activity of SLC22A6	.	.
DTD0024	SLC22A6	Inhibition	Cefaclor	Approved Drug	.	.	Cefaclor inhibits the activity of SLC22A6	.	.
DTD0024	SLC22A6	Inhibition	Chlorothiazide	Approved Drug	.	.	Chlorothiazide inhibits the activity of SLC22A6	.	.
DTD0024	SLC22A6	Inhibition	Chrysophanic acid	Natural Product	.	.	Chrysophanic acid inhibits the activity of SLC22A6	.	.
DTD0024	SLC22A6	Inhibition	Cimetidine	Approved Drug	.	.	Cimetidine inhibits the activity of SLC22A6	.	.
DTD0024	SLC22A6	Inhibition	Clothianidin	Pesticide/Insecticide	.	.	Clothianidin inhibits the activity of SLC22A6	.	.
DTD0024	SLC22A6	Inhibition	Cyclothiazide	Approved Drug	.	.	Cyclothiazide inhibits the activity of SLC22A6	.	.
DTD0024	SLC22A6	Inhibition	Eetuximab	Approved Drug	.	.	Eetuximab inhibits the activity of SLC22A6	.	.
DTD0024	SLC22A6	Inhibition	Emodin	Drug in Preclinical Test	.	.	Emodin inhibits the activity of SLC22A6	.	.
DTD0024	SLC22A6	Inducer	FT-0755769	Drug in Phase 1 Trial	.	.	FT-0755769 increases the activity of SLC22A6	.	.
DTD0024	SLC22A6	Inhibition	Furosemide	Approved Drug	.	.	Furosemide inhibits the activity of SLC22A6	.	.
DTD0024	SLC22A6	Inhibition	Hydrochlorothiazide	Approved Drug	.	150	Hydrochlorothiazide inhibits the activity of SLC22A6 (Ki = 150 microM)	.	.
DTD0024	SLC22A6	Inhibition	Indomethacin	Approved Drug	.	.	Indomethacin inhibits the activity of SLC22A6	.	.
DTD0024	SLC22A6	Inhibition	Linoleic Acid	Drug Marketed but not Approved by US FDA	.	.	Linoleic Acid inhibits the activity of SLC22A6	.	.
DTD0024	SLC22A6	Inhibition	Lumiracoxib	Approved Drug	.	.	Lumiracoxib inhibits the activity of SLC22A6	.	.
DTD0024	SLC22A6	Inhibition	Piroxicam	Approved Drug	.	.	Piroxicam inhibits the activity of SLC22A6	.	.
DTD0024	SLC22A6	Inhibition	Probenecid	Approved Drug	.	.	Probenecid inhibits the activity of SLC22A6	.	.
DTD0024	SLC22A6	Inhibition	Selexipag	Approved Drug	.	.	Selexipag inhibits the activity of SLC22A6	.	.
DTD0024	SLC22A6	Inhibition	Simvastatin	Approved Drug	.	.	Simvastatin inhibits the activity of SLC22A6	.	.
DTD0024	SLC22A6	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the activity of SLC22A6	.	.
DTD0024	SLC22A6	Inhibition	Vancomycin	Approved Drug	.	.	Vancomycin inhibits the activity of SLC22A6	.	.
DTD0024	SLC22A6	Inhibition	Wogonin	Natural Product	.	.	Wogonin inhibits the activity of SLC22A6	.	.
DTD0025	SLC22A8	Inhibition	2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine	Acute Toxic Substance	.	.	2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine inhibits the activity of SLC22A8	.	.
DTD0025	SLC22A8	Inhibition	Angiotensinamide	Investigative Drug	.	.	Angiotensinamide inhibits the activity of SLC22A8	.	.
DTD0025	SLC22A8	Inducer	Atrazine	Herbicide	.	.	Atrazine increases the expression of SLC22A8	.	.
DTD0025	SLC22A8	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the activity of SLC22A8	.	.
DTD0025	SLC22A8	Inhibition	Benzylpenicillin	Drug in Phase 3 Trial	.	.	Benzylpenicillin inhibits the activity of SLC22A8	.	.
DTD0025	SLC22A8	Inhibition	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A inhibits the activity of SLC22A8	.	.
DTD0025	SLC22A8	Inhibition	Bisphenol F	Environmental toxicant	.	.	Bisphenol F inhibits the activity of SLC22A8	.	.
DTD0025	SLC22A8	Inhibition	Celecoxib	Approved Drug	.	.	Celecoxib inhibits the activity of SLC22A8	.	.
DTD0025	SLC22A8	Inhibition	Chrysophanic acid	Natural Product	.	.	Chrysophanic acid inhibits the activity of SLC22A8	.	.
DTD0025	SLC22A8	Inhibition	Ciprofloxacin	Approved Drug	.	.	Ciprofloxacin inhibits the activity of SLC22A8	.	.
DTD0025	SLC22A8	Inhibition	Clothianidin	Pesticide/Insecticide	.	.	Clothianidin inhibits the activity of SLC22A8	.	.
DTD0025	SLC22A8	Inducer	Dihydrotestosterone	Drug in Phase 4 Trial	.	.	Dihydrotestosterone induces the activity of SLC22A8	.	.
DTD0025	SLC22A8	Inhibition	Emodin	Drug in Preclinical Test	.	.	Emodin inhibits the activity of SLC22A8	.	.
DTD0025	SLC22A8	Inhibition	Etoricoxib	Approved Drug	.	.	Etoricoxib inhibits the activity of SLC22A8	.	.
DTD0025	SLC22A8	Inhibition	Fluorescein	Approved Drug	.	.	Fluorescein inhibits the activity of SLC22A8	.	.
DTD0025	SLC22A8	Inhibition	Fluvastatin	Approved Drug	.	.	Fluvastatin inhibits the activity of SLC22A8	.	.
DTD0025	SLC22A8	Inhibition	Folic Acid	Approved Drug	.	.	Folic Acid inhibits the expression of SLC22A8	.	.
DTD0025	SLC22A8	Inhibition	Furosemide	Approved Drug	.	.	Furosemide inhibits the activity of SLC22A8	.	.
DTD0025	SLC22A8	Inhibition	Gatifloxacin	Approved Drug	.	.	Gatifloxacin inhibits the activity of SLC22A8	.	.
DTD0025	SLC22A8	Inhibition	Gemfibrozil	Approved Drug	.	.	Gemfibrozil inhibits the activity of SLC22A8	.	.
DTD0025	SLC22A8	Inhibition	Ibuprofen	Approved Drug	.	.	Ibuprofen inhibits the activity of SLC22A8	.	.
DTD0025	SLC22A8	Inhibition	Imidacloprid	Pesticide/Insecticide	.	.	Imidacloprid inhibits the activity of SLC22A8	.	.
DTD0025	SLC22A8	Inhibition	Itraconazole	Approved Drug	.	.	Itraconazole inhibits the activity of SLC22A8	.	.
DTD0025	SLC22A8	Inhibition	Ketoconazole	Approved Drug	.	.	Ketoconazole inhibits the activity of SLC22A8	.	.
DTD0025	SLC22A8	Inhibition	Lansoprazole	Approved Drug	.	.	Lansoprazole inhibits the activity of SLC22A8	.	.
DTD0025	SLC22A8	Inducer	Lead chloride	Health and Environmental Toxicant	.	.	Lead chloride increases the activity of SLC22A8	.	.
DTD0025	SLC22A8	Inhibition	Linoleic Acid	Drug Marketed but not Approved by US FDA	.	.	Linoleic Acid inhibits the activity of SLC22A8	.	.
DTD0025	SLC22A8	Inhibition	Luteolin	Drug in Phase 1 Trial	.	.	Luteolin inhibits the activity of SLC22A8	.	.
DTD0025	SLC22A8	Inhibition	Metronidazole	Approved Drug	.	.	Metronidazole inhibits the activity of SLC22A8	.	.
DTD0025	SLC22A8	Inhibition	Nitrofurantoin	Approved Drug	.	.	Nitrofurantoin inhibits the activity of SLC22A8	.	.
DTD0025	SLC22A8	Inhibition	Omeprazole	Approved Drug	.	.	Esomeprazole inhibits the activity of SLC22A8	.	.
DTD0025	SLC22A8	Blocker	Probenecid	Approved Drug	.	.	Probenecid blocks the activity of SLC22A8	.	.
DTD0025	SLC22A8	Inhibition	Probenecid	Approved Drug	.	.	Probenecid inhibits the activity of SLC22A8	.	.
DTD0025	SLC22A8	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the activity of SLC22A8	.	.
DTD0025	SLC22A8	Inhibition	Retigabine	Drug Withdrawn	.	.	Ezogabine inhibits the activity of SLC22A8	.	.
DTD0025	SLC22A8	Inhibition	Rofecoxib	Approved Drug	.	.	Rofecoxib inhibits the activity of SLC22A8	.	.
DTD0025	SLC22A8	Inhibition	Selexipag	Approved Drug	.	.	Selexipag inhibits the activity of SLC22A8	.	.
DTD0025	SLC22A8	Inhibition	Simvastatin	Approved Drug	.	.	Simvastatin inhibits the activity of SLC22A8	.	.
DTD0025	SLC22A8	Inducer	Sodium arsenate	Environmental toxicant	.	.	Sodium arsenate increases the activity of SLC22A8	.	.
DTD0025	SLC22A8	Inhibition	Sulfadiazine	Approved Drug	.	.	Sulfadiazine inhibits the activity of SLC22A8	.	.
DTD0025	SLC22A8	Inhibition	Sulfasalazine	Approved Drug	.	.	Sulfasalazine inhibits the activity of SLC22A8	.	.
DTD0025	SLC22A8	Inhibition	Testosterone	Approved Drug	.	.	Testosterone inhibits the expression of SLC22A8	.	.
DTD0025	SLC22A8	Inhibition	Tetrabromobisphenol A	Environmental toxicant	.	.	Tetrabromobisphenol A inhibits the activity of SLC22A8	.	.
DTD0025	SLC22A8	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the activity of SLC22A8	.	.
DTD0025	SLC22A8	Inducer	Toluene	Health and Environmental Toxicant	.	.	Toluene increases the expression of SLC22A8	.	.
DTD0025	SLC22A8	Inhibition	Torasemide	Approved Drug	.	.	Torsemide inhibits the activity of SLC22A8	.	.
DTD0025	SLC22A8	Inhibition	Valdecoxib	Approved Drug	.	.	Valdecoxib inhibits the activity of SLC22A8	.	.
DTD0025	SLC22A8	Inhibition	Vancomycin	Approved Drug	.	.	Vancomycin inhibits the activity of SLC22A8	.	.
DTD0025	SLC22A8	Inhibition	Wogonin	Natural Product	.	.	Wogonin inhibits the activity of SLC22A8	.	.
DTD0026	SLC22A11	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the activity of SLC22A11	.	.
DTD0026	SLC22A11	Inhibition	Aspirin	Approved Drug	.	.	Aspirin inhibits the activity of SLC22A11	.	.
DTD0026	SLC22A11	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of SLC22A11	.	.
DTD0026	SLC22A11	Inhibition	Beta-naphthoflavone	Investigative Drug	.	.	Beta-naphthoflavone inhibits the expression of SLC22A11	.	.
DTD0026	SLC22A11	Inhibition	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A inhibits the expression of SLC22A11	.	.
DTD0026	SLC22A11	Inhibition	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde inhibits the expression of SLC22A11	.	.
DTD0026	SLC22A11	Inhibition	Cabazitaxel	Approved Drug	.	.	Cabazitaxel inhibits the activity of SLC22A11	.	.
DTD0026	SLC22A11	Inhibition	Calcitriol	Approved Drug	.	.	Calcitriol inhibits the expression of SLC22A11	.	.
DTD0026	SLC22A11	Inhibition	Candesartan	Approved Drug	.	.	Candesartan inhibits the activity of SLC22A11	.	.
DTD0026	SLC22A11	Inducer	Decitabine	Approved Drug	.	.	Decitabine increases the expression of SLC22A11	.	.
DTD0026	SLC22A11	Inducer	Lead	Health and Environmental Toxicant	.	.	Lead increases the expression of SLC22A11	.	.
DTD0026	SLC22A11	Inhibition	Lesinurad	Approved Drug	.	.	Lesinurad inhibits the activity of SLC22A11	.	.
DTD0026	SLC22A11	Inhibition	Phenacetin	Drug Withdrawn	.	.	Phenacetin inhibits the activity of SLC22A11	.	.
DTD0026	SLC22A11	Inhibition	Pranlukast	Approved Drug	.	.	Pranlukast inhibits the activity of SLC22A11	.	.
DTD0026	SLC22A11	Inhibition	Salicylic Acid	Drug in Phase 2/3 Trial	.	.	Salicylic Acid inhibits the activity of SLC22A11	.	.
DTD0026	SLC22A11	Inducer	Tetrabromobisphenol A	Environmental toxicant	.	.	Tetrabromobisphenol A increases the expression of SLC22A11	.	.
DTD0026	SLC22A11	Inducer	Troglitazone	Approved Drug	.	.	Troglitazone increases the expression of SLC22A11	.	.
DTD0027	SLC22A12	Inhibition	Irbesartan	Approved Drug	.	.	Irbesartan inhibits the activity of SLC22A12	.	.
DTD0027	SLC22A12	Inhibition	Lesinurad	Approved Drug	.	.	Lesinurad inhibits the activity of SLC22A12	.	.
DTD0027	SLC22A12	Modulator	Lesinurad	Approved Drug	.	.	Lesinurad modulates the activity of SLC22A12	.	.
DTD0027	SLC22A12	Modulator	Pyrazinamide	Approved Drug	.	.	Pyrazinamide affects the activity of SLC22A12	.	.
DTD0027	SLC22A12	Inducer	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite increases the expression of SLC22A12	.	.
DTD0028	SLC47A2	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC47A2	.	.
DTD0028	SLC47A2	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of SLC47A2	.	.
DTD0028	SLC47A2	Inhibition	Cannabidiol	Approved Drug	.	.	Cannabidiol inhibits the expression of SLC47A2	.	.
DTD0028	SLC47A2	Inhibition	Clothianidin	Pesticide/Insecticide	.	.	Clothianidin inhibits the activity of SLC47A2	.	.
DTD0028	SLC47A2	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC47A2	.	.
DTD0028	SLC47A2	Inhibition	Diethylhexyl Phthalate	Health and Environmental Toxicant	.	.	Diethylhexyl Phthalate inhibits the expression of SLC47A2	.	.
DTD0028	SLC47A2	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC47A2	.	.
DTD0028	SLC47A2	Inducer	Genistein	Drug in Phase 2 Trial	.	.	Genistein increases the expression of SLC47A2	.	.
DTD0028	SLC47A2	Inhibition	Itraconazole	Approved Drug	.	.	Itraconazole inhibits the activity of SLC47A2	.	.
DTD0028	SLC47A2	Inhibition	Ketoconazole	Approved Drug	.	.	Ketoconazole inhibits the activity of SLC47A2	.	.
DTD0028	SLC47A2	Modulator	Lead	Health and Environmental Toxicant	.	.	Lead affects the expression of SLC47A2	.	.
DTD0028	SLC47A2	Inhibition	Plazomicin	Approved Drug	.	.	Plazomicin inhibits the activity of SLC47A2	.	.
DTD0028	SLC47A2	Inducer	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin increases the expression of SLC47A2	.	.
DTD0028	SLC47A2	Inhibition	Pyrimethamine	Approved Drug	.	.	Pyrimethamine inhibits the activity of SLC47A2	.	.
DTD0028	SLC47A2	Modulator	Tetraethylammonium	Investigative Drug	.	.	Tetraethylammonium modulates the activity of SLC47A2	.	.
DTD0028	SLC47A2	Inhibition	Titanium dioxide	Approved Drug	.	.	Titanium dioxide inhibits the expression of SLC47A2	.	.
DTD0028	SLC47A2	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the activity of SLC47A2	.	.
DTD0029	SLCO1A2	Inhibition	Acrylamide	Acute Toxic Substance	.	.	Acrylamide inhibits the expression of SLCO1A2	.	.
DTD0029	SLCO1A2	Inhibition	Bromsulphthalein	Investigative Drug	.	.	Bromsulphthalein inhibits the activity of SLCO1A2	.	.
DTD0029	SLCO1A2	Inducer	Calcitriol	Approved Drug	.	.	Calcitriol increases the expression of SLCO1A2	.	.
DTD0029	SLCO1A2	Inducer	Carbamazepine	Approved Drug	.	.	Carbamazepine increases the expression of SLCO1A2	.	.
DTD0029	SLCO1A2	Inhibition	Carmustine	Approved Drug	.	.	Carmustine inhibits the expression of SLCO1A2	.	.
DTD0029	SLCO1A2	Inhibition	Clarithromycin	Approved Drug	.	.	Clarithromycin inhibits the activity of SLCO1A2	.	.
DTD0029	SLCO1A2	Inducer	Curcumin	Drug in Phase 3 Trial	.	.	Curcumin increases the expression of SLCO1A2	.	.
DTD0029	SLCO1A2	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the activity of SLCO1A2	.	.
DTD0029	SLCO1A2	Inhibition	Diethylhexyl Phthalate	Health and Environmental Toxicant	.	.	Diethylhexyl Phthalate inhibits the expression of SLCO1A2	.	.
DTD0029	SLCO1A2	Inhibition	Ethinyl Estradiol	Approved Drug	.	.	Ethinyl Estradiol inhibits the expression of SLCO1A2	.	.
DTD0029	SLCO1A2	Inhibition	Mifepristone	Approved Drug	.	.	Mifepristone inhibits the activity of SLCO1A2	.	.
DTD0029	SLCO1A2	Inhibition	Okadaic Acid	Acute Toxic Substance	.	.	Okadaic Acid inhibits the expression of SLCO1A2	.	.
DTD0029	SLCO1A2	Inducer	Omeprazole	Approved Drug	.	.	Omeprazole increases the expression of SLCO1A2	.	.
DTD0029	SLCO1A2	Inhibition	Phenylmercuric Acetate	Investigative Drug	.	.	Phenylmercuric Acetate inhibits the expression of SLCO1A2	.	.
DTD0029	SLCO1A2	Inhibition	Pravastatin	Approved Drug	.	.	Pravastatin inhibits the activity of SLCO1A2	.	.
DTD0029	SLCO1A2	Inducer	Pregnenolone Carbonitrile	Investigative Drug	.	.	Pregnenolone Carbonitrile increases the expression of SLCO1A2	.	.
DTD0029	SLCO1A2	Inhibition	Rifampicin	Approved Drug	.	.	Rifampicin induces the activity of SLCO1A2	.	.
DTD0029	SLCO1A2	Inhibition	Rifamycin SV	Approved Drug	.	.	Rifamycin SV inhibits the activity of SLCO1A2	.	.
DTD0029	SLCO1A2	Inhibition	Rifaximin	Approved Drug	.	.	Rifaximin inhibits the activity of SLCO1A2	.	.
DTD0029	SLCO1A2	Inhibition	Ritonavir	Approved Drug	.	.	Ritonavir inhibits the activity of SLCO1A2	.	.
DTD0029	SLCO1A2	Modulator	Testosterone enanthate	Approved Drug	.	.	Testosterone enanthate affects the expression of SLCO1A2	.	.
DTD0029	SLCO1A2	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLCO1A2	.	.
DTD0029	SLCO1A2	Inducer	Vitamin D	Approved Drug	.	.	Vitamin D increases the expression of SLCO1A2	.	.
DTD0029	SLCO1A2	Inducer	Vorinostat	Approved Drug	.	.	Vorinostat increases the expression of SLCO1A2	.	.
DTD0030	SLCO1B3	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of SLCO1B3	.	.
DTD0030	SLCO1B3	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLCO1B3	.	.
DTD0030	SLCO1B3	Inhibition	Asunaprevir	Drug in Phase 3 Trial	.	.	Asunaprevir inhibits the activity of SLCO1B3	.	.
DTD0030	SLCO1B3	Inducer	Calcitriol	Approved Drug	.	.	Calcitriol increases the expression of SLCO1B3	.	.
DTD0030	SLCO1B3	Inducer	Chenodeoxycholic acid	Approved Drug	.	.	Chenodeoxycholic acid increases the expression of SLCO1B3	.	.
DTD0030	SLCO1B3	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the expression of SLCO1B3	.	.
DTD0030	SLCO1B3	Inhibition	Dactinomycin	Approved Drug	.	.	Dactinomycin inhibits the activity of SLCO1B3	.	.
DTD0030	SLCO1B3	Inducer	Deoxycholic acid	Approved Drug	.	.	Deoxycholic acid increases the expression of SLCO1B3	.	.
DTD0030	SLCO1B3	Inhibition	Diclofenac	Approved Drug	.	.	Diclofenac inhibits the activity of SLCO1B3	.	.
DTD0030	SLCO1B3	Inhibition	Docetaxel	Approved Drug	.	.	Docetaxel inhibits the activity of SLCO1B3	.	.
DTD0030	SLCO1B3	Modulator	Estradiol-17beta-glucuronide	Investigative Drug	.	.	Estradiol-17beta-glucuronide modulates the activity of SLCO1B3	.	.
DTD0030	SLCO1B3	Inhibition	Fusidic Acid	Drug in Phase 3 Trial	.	.	Fusidic Acid inhibits the activity of SLCO1B3	.	.
DTD0030	SLCO1B3	Inhibition	Glecaprevir	Approved Drug	.	.	Glecaprevir inhibits the activity of SLCO1B3	.	.
DTD0030	SLCO1B3	Inhibition	Icariin	Drug in Phase 3 Trial	.	.	Icariin inhibits the activity of SLCO1B3	.	.
DTD0030	SLCO1B3	Inhibition	Itraconazole	Approved Drug	.	.	Itraconazole inhibits the activity of SLCO1B3	.	.
DTD0030	SLCO1B3	Inhibition	Jinfukang	Traditional Medicine	.	.	Jinfukang inhibits the expression of SLCO1B3	.	.
DTD0030	SLCO1B3	Inhibition	Letermovir	Approved Drug	.	.	Letermovir inhibits the activity of SLCO1B3	.	.
DTD0030	SLCO1B3	Inhibition	Mitoxantrone	Approved Drug	.	.	Mitoxantrone inhibits the activity of SLCO1B3	.	.
DTD0030	SLCO1B3	Inducer	Obeticholic acid	Approved Drug	.	.	Obeticholic acid increases the expression of SLCO1B3	.	.
DTD0030	SLCO1B3	Inhibition	Oltipraz	Drug in Phase 3 Trial	.	.	Oltipraz inhibits the expression of SLCO1B3	.	.
DTD0030	SLCO1B3	Inhibition	Paclitaxel	Approved Drug	.	.	Paclitaxel inhibits the activity of SLCO1B3	.	.
DTD0030	SLCO1B3	Inhibition	Particulate Matter	Natural Product	.	.	Particulate Matter inhibits the expression of SLCO1B3	.	.
DTD0030	SLCO1B3	Inhibition	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin inhibits the expression of SLCO1B3	.	.
DTD0030	SLCO1B3	Inhibition	Rifampicin	Approved Drug	.	.	Rifampicin inhibits the activity of SLCO1B3	.	.
DTD0030	SLCO1B3	Inhibition	Rifampin	Approved Drug	.	.	Rifampin inhibits the expression of SLCO1B3	.	.
DTD0030	SLCO1B3	Inhibition	Rifaximin	Approved Drug	.	.	Rifaximin inhibits the activity of SLCO1B3	.	.
DTD0030	SLCO1B3	Inhibition	Selexipag	Approved Drug	.	.	Selexipag inhibits the activity of SLCO1B3	.	.
DTD0030	SLCO1B3	Inhibition	Senecionine	Natural Product	.	.	Senecionine inhibits the expression of SLCO1B3	.	.
DTD0030	SLCO1B3	Inhibition	TAK-875	Drug in Phase 1 Trial	.	.	TAK-875 inhibits the activity of SLCO1B3	.	.
DTD0030	SLCO1B3	Inhibition	Telithromycin	Approved Drug	.	.	Telithromycin inhibits the activity of SLCO1B3	.	.
DTD0030	SLCO1B3	Inducer	Temozolomide	Approved Drug	.	.	Temozolomide increases the expression of SLCO1B3	.	.
DTD0030	SLCO1B3	Inhibition	Tetrabromobisphenol A	Environmental toxicant	.	.	Tetrabromobisphenol A inhibits the activity of SLCO1B3	.	.
DTD0030	SLCO1B3	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLCO1B3	.	.
DTD0031	SLCO2B1	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLCO2B1	.	.
DTD0031	SLCO2B1	Inducer	Adefovir dipivoxil	Approved Drug	.	.	Adefovir dipivoxil increases the expression of SLCO2B1	.	.
DTD0031	SLCO2B1	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLCO2B1	.	.
DTD0031	SLCO2B1	Inducer	Arsenic Trioxide	Approved Drug	.	.	Arsenic Trioxide increases the expression of SLCO2B1	.	.
DTD0031	SLCO2B1	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLCO2B1	.	.
DTD0031	SLCO2B1	Modulator	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A affects the expression of SLCO2B1	.	.
DTD0031	SLCO2B1	Modulator	Bromsulphthalein	Investigative Drug	.	.	Bromsulphthalein modulates the activity of SLCO2B1	.	.
DTD0031	SLCO2B1	Inhibition	Calcitriol	Approved Drug	.	.	Calcitriol inhibits the expression of SLCO2B1	.	.
DTD0031	SLCO2B1	Inducer	Cidofovir	Approved Drug	.	.	Cidofovir increases the expression of SLCO2B1	.	.
DTD0031	SLCO2B1	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLCO2B1	.	.
DTD0031	SLCO2B1	Inhibition	Ergoloid mesylates	Approved Drug	.	.	Ergoloid mesylates inhibits the activity of SLCO2B1	.	.
DTD0031	SLCO2B1	Modulator	Estrone sulfate	Investigative Drug	.	.	Estrone sulfate modulates the activity of SLCO2B1	.	.
DTD0031	SLCO2B1	Inducer	Ethanol	Drug in Phase 2 Trial	.	.	Ethanol increases the expression of SLCO2B1	.	.
DTD0031	SLCO2B1	Inhibition	Heliotrine	Natural Product	.	.	Heliotrine inhibits the expression of SLCO2B1	.	.
DTD0031	SLCO2B1	Modulator	Hydrogen Peroxide	Approved Drug	.	.	Hydrogen Peroxide affects the expression of SLCO2B1	.	.
DTD0031	SLCO2B1	Inhibition	Icariin	Drug in Phase 3 Trial	.	.	Icariin inhibits the activity of SLCO2B1	.	.
DTD0031	SLCO2B1	Inducer	Meclizine	Approved Drug	.	.	Meclizine increases the expression of SLCO2B1	.	.
DTD0031	SLCO2B1	Inhibition	Methyleugenol	Natural Product	.	.	Methyleugenol inhibits the expression of SLCO2B1	.	.
DTD0031	SLCO2B1	Inhibition	Okadaic Acid	Acute Toxic Substance	.	.	Okadaic Acid inhibits the expression of SLCO2B1	.	.
DTD0031	SLCO2B1	Inhibition	Particulate Matter	Natural Product	.	.	Particulate Matter inhibits the expression of SLCO2B1	.	.
DTD0031	SLCO2B1	Inhibition	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin inhibits the expression of SLCO2B1	.	.
DTD0031	SLCO2B1	Inducer	Rifampin	Approved Drug	.	.	Rifampin increases the expression of SLCO2B1	.	.
DTD0031	SLCO2B1	Inhibition	Rosiglitazone	Approved Drug	.	.	Rosiglitazone inhibits the expression of SLCO2B1	.	.
DTD0031	SLCO2B1	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLCO2B1	.	.
DTD0031	SLCO2B1	Inhibition	Sodium bichromate	Carcinogen	.	.	Sodium bichromate inhibits the expression of SLCO2B1	.	.
DTD0031	SLCO2B1	Inhibition	Testosterone	Approved Drug	.	.	Testosterone inhibits the activity of SLCO2B1	.	.
DTD0031	SLCO2B1	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLCO2B1	.	.
DTD0031	SLCO2B1	Inducer	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan increases the expression of SLCO2B1	.	.
DTD0031	SLCO2B1	Inhibition	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate inhibits the expression of SLCO2B1	.	.
DTD0031	SLCO2B1	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of SLCO2B1	.	.
DTD0031	SLCO2B1	Inducer	Zoledronic Acid	Approved Drug	.	.	Zoledronic Acid increases the expression of SLCO2B1	.	.
DTD0034	SLC18A2	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of SLC18A2	.	.
DTD0034	SLC18A2	Modulator	Alkavervir	Approved Drug	.	.	Alkavervir modulates the activity of SLC18A2	.	.
DTD0034	SLC18A2	Blocker	Alseroxylon	Approved Drug	.	.	Alseroxylon blocks the activity of SLC18A2	.	.
DTD0034	SLC18A2	Inducer	Antimycin A	Acute Toxic Substance	.	.	Antimycin A increases the expression of SLC18A2	.	.
DTD0034	SLC18A2	Inhibition	Arbutin	Drug Marketed but not Approved by US FDA	.	.	Arbutin inhibits the expression of SLC18A2	.	.
DTD0034	SLC18A2	Enhancer	AV-133	Drug in Phase 3 Trial	.	.	AV 133 enhances the activity of SLC18A2	.	.
DTD0034	SLC18A2	Modulator	Carbamazepine	Approved Drug	.	.	Carbamazepine affects the expression of SLC18A2	.	.
DTD0034	SLC18A2	Inhibition	Cocaine	Approved Drug	.	.	Cocaine inhibits the expression of SLC18A2	.	.
DTD0034	SLC18A2	Inhibition	Deutetrabenazine	Approved Drug	.	.	Deutetrabenazine inhibits the activity of SLC18A2	.	.
DTD0034	SLC18A2	Modulator	Deutetrabenazine	Approved Drug	.	.	Deutetrabenazine modulates the activity of SLC18A2	.	.
DTD0034	SLC18A2	Inducer	Dexamethasone	Approved Drug	.	.	Dexamethasone increases the expression of SLC18A2	.	.
DTD0034	SLC18A2	Inhibition	Dopamine	Approved Drug	.	.	Dopamine inhibits the activity of SLC18A2	.	.
DTD0034	SLC18A2	Inducer	GSK-J4	Patented Pharmaceutical Agent	.	.	GSK-J4 increases the expression of SLC18A2	.	.
DTD0034	SLC18A2	Inhibition	Jinfukang	Traditional Medicine	.	.	Jinfukang inhibits the expression of SLC18A2	.	.
DTD0034	SLC18A2	Inhibition	Leflunomide	Approved Drug	.	.	Leflunomide inhibits the expression of SLC18A2	.	.
DTD0034	SLC18A2	Inhibition	Lobeline	Drug in Phase 2 Trial	.	.	Lobeline inhibits the activity of SLC18A2	.	.
DTD0034	SLC18A2	Inhibition	Methamphetamine	Approved Drug	.	.	Methamphetamine inhibits the expression of SLC18A2	.	.
DTD0034	SLC18A2	Inhibition	Methylphenidate	Approved Drug	.	.	Methylphenidate inhibits the activity of SLC18A2	.	.
DTD0034	SLC18A2	Inducer	MS-275	Drug in Phase 2 Trial	.	.	MS-275 increases the expression of SLC18A2	.	.
DTD0034	SLC18A2	Inhibition	NBI-98854	Drug in Phase 3 Trial	.	.	NBI-98854 inhibits the activity of SLC18A2	.	.
DTD0034	SLC18A2	Inhibition	Norepinephrine	Approved Drug	.	.	Norepinephrine inhibits the activity of SLC18A2	.	.
DTD0034	SLC18A2	Inhibition	Paraquat	Acute Toxic Substance	.	.	Paraquat inhibits the activity of SLC18A2	.	.
DTD0034	SLC18A2	Inhibition	Phenylmercuric Acetate	Investigative Drug	.	.	Phenylmercuric Acetate inhibits the expression of SLC18A2	.	.
DTD0034	SLC18A2	Blocker	Reserpine	Approved Drug	.	.	Reserpine blocks the activity of SLC18A2	.	.
DTD0034	SLC18A2	Inhibition	Rotenone	Drug Marketed but not Approved by US FDA	.	.	Rotenone inhibits the activity of SLC18A2	.	.
DTD0034	SLC18A2	Inhibition	SOM3355	Drug in Phase 1 Trial	.	.	SOM3355 inhibits the activity of SLC18A2	.	.
DTD0034	SLC18A2	Blocker	Tetrabenazine	Approved Drug	.	.	Tetrabenazine blocks the activity of SLC18A2	.	.
DTD0034	SLC18A2	Inhibition	Tetrabenazine	Approved Drug	.	.	Tetrabenazine inhibits the activity of SLC18A2	.	.
DTD0034	SLC18A2	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC18A2	.	.
DTD0034	SLC18A2	Inducer	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A increases the expression of SLC18A2	.	.
DTD0034	SLC18A2	Inhibition	Valbenazine	Approved Drug	.	.	Valbenazine inhibits the activity of SLC18A2	.	.
DTD0034	SLC18A2	Modulator	Valbenazine tosylate	Approved Drug	.	.	Valbenazine tosylate modulates the activity of SLC18A2	.	.
DTD0034	SLC18A2	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC18A2	.	.
DTD0035	SLC30A8	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC30A8	.	.
DTD0035	SLC30A8	Inhibition	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A inhibits the expression of SLC30A8	.	.
DTD0035	SLC30A8	Inducer	MS-275	Drug in Phase 2 Trial	.	.	MS-275 increases the expression of SLC30A8	.	.
DTD0035	SLC30A8	Inhibition	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan inhibits the expression of SLC30A8	.	.
DTD0035	SLC30A8	Modulator	Valproic Acid	Approved Drug	.	.	Valproic Acid affects the expression of SLC30A8	.	.
DTD0036	ABCA1	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of ABCA1	.	.
DTD0036	ABCA1	Inducer	27-hydroxycholesterol	Investigative Drug	.	.	27-hydroxycholesterol increases the expression of ABCA1	.	.
DTD0036	ABCA1	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of ABCA1	.	.
DTD0036	ABCA1	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of ABCA1	.	.
DTD0036	ABCA1	Inhibition	Amiodarone	Approved Drug	.	.	Amiodarone inhibits the expression of ABCA1	.	.
DTD0036	ABCA1	Inhibition	Archazolid B	Investigative Drug	.	.	Archazolid B inhibits the expression of ABCA1	.	.
DTD0036	ABCA1	Inhibition	Arsenic Trioxide	Approved Drug	.	.	Arsenic Trioxide inhibits the expression of ABCA1	.	.
DTD0036	ABCA1	Inhibition	Aspirin	Approved Drug	.	.	Aspirin inhibits the expression of ABCA1	.	.
DTD0036	ABCA1	Inhibition	Atorvastatin	Approved Drug	.	.	Atorvastatin inhibits the expression of ABCA1	.	.
DTD0036	ABCA1	Inhibition	Azoxystrobin	Fungicide	.	.	Azoxystrobin inhibits the expression of ABCA1	.	.
DTD0036	ABCA1	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of ABCA1	.	.
DTD0036	ABCA1	Inducer	Bezafibrate	Drug Marketed but not Approved by US FDA	.	.	Bezafibrate increases the expression of ABCA1	.	.
DTD0036	ABCA1	Inhibition	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A inhibits the expression of ABCA1	.	.
DTD0036	ABCA1	Inducer	Butylated Hydroxytoluene	Drug in Phase 1 Trial	.	.	Butylated Hydroxytoluene increases the expression of ABCA1	.	.
DTD0036	ABCA1	Inducer	Calcitriol	Approved Drug	.	.	Calcitriol increases the expression of ABCA1	.	.
DTD0036	ABCA1	Modulator	Carbamazepine	Approved Drug	.	.	Carbamazepine affects the expression of ABCA1	.	.
DTD0036	ABCA1	Inducer	Clofibrate	Approved Drug	.	.	Clofibrate induces the activity of ABCA1	.	.
DTD0036	ABCA1	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of ABCA1	.	.
DTD0036	ABCA1	Inducer	CS-6969	Investigative Drug	.	.	CS-6969 increases the expression of ABCA1	.	.
DTD0036	ABCA1	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of ABCA1	.	.
DTD0036	ABCA1	Inducer	Dasatinib	Approved Drug	.	.	Dasatinib increases the expression of ABCA1	.	.
DTD0036	ABCA1	Inhibition	Dibutyl Phthalate	Health and Environmental Toxicant	.	.	Dibutyl Phthalate inhibits the expression of ABCA1	.	.
DTD0036	ABCA1	Inducer	Efonidipine	Drug Marketed but not Approved by US FDA	.	.	Efonidipine increases the expression of ABCA1	.	.
DTD0036	ABCA1	Inhibition	Enniatins	Acute Toxic Substance	.	.	Enniatins inhibits the expression of ABCA1	.	.
DTD0036	ABCA1	Inducer	Epigallocatechin gallate	Drug in Phase 3 Trial	.	.	Epigallocatechin gallate increases the expression of ABCA1	.	.
DTD0036	ABCA1	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the expression of ABCA1	.	.
DTD0036	ABCA1	Inhibition	Ethanol	Drug in Phase 2 Trial	.	.	Ethanol inhibits the expression of ABCA1	.	.
DTD0036	ABCA1	Inhibition	Ethyl paraoxon	Pesticide/Insecticide	.	.	Ethyl paraoxon inhibits the expression of ABCA1	.	.
DTD0036	ABCA1	Inhibition	Ezetimibe	Approved Drug	.	.	Ezetimibe inhibits the expression of ABCA1	.	.
DTD0036	ABCA1	Inducer	Fenofibrate	Approved Drug	.	.	Fenofibrate increases the expression of ABCA1	.	.
DTD0036	ABCA1	Inducer	Fenofibric acid	Approved Drug	.	.	Fenofibric acid induces the activity of ABCA1	.	.
DTD0036	ABCA1	Inducer	Fingolimod Hydrochloride	Drug in Phase 1 Trial	.	.	Fingolimod Hydrochloride increases the expression of ABCA1	.	.
DTD0036	ABCA1	Inducer	Folic Acid	Approved Drug	.	.	Folic Acid increases the expression of ABCA1	.	.
DTD0036	ABCA1	Inducer	Gemfibrozil	Approved Drug	.	.	Gemfibrozil increases the expression of ABCA1	.	.
DTD0036	ABCA1	Inducer	Genistein	Drug in Phase 2 Trial	.	.	Genistein increases the expression of ABCA1	.	.
DTD0036	ABCA1	Inducer	GW-3965	Patented Pharmaceutical Agent	.	.	GW-3965 increases the expression of ABCA1	.	.
DTD0036	ABCA1	Inhibition	GW-4064	Patented Pharmaceutical Agent	.	.	GW-4064 inhibits the expression of ABCA1	.	.
DTD0036	ABCA1	Inhibition	GW9662	Investigative Drug	.	.	GW9662 inhibits the expression of ABCA1	.	.
DTD0036	ABCA1	Inducer	Haloperidol	Approved Drug	.	.	Haloperidol induces the activity of ABCA1	.	.
DTD0036	ABCA1	Inhibition	Icosapentum	Investigative Drug	.	.	Icosapentum inhibits the expression of ABCA1	.	.
DTD0036	ABCA1	Inducer	Lansoprazole	Approved Drug	.	.	Lansoprazole increases the expression of ABCA1	.	.
DTD0036	ABCA1	Inducer	Lindane	Approved Drug	.	.	Lindane increases the expression of ABCA1	.	.
DTD0036	ABCA1	Inhibition	Lithocholic Acid	Investigative Drug	.	.	Lithocholic Acid inhibits the expression of ABCA1	.	.
DTD0036	ABCA1	Inducer	Lovastatin	Approved Drug	.	.	Lovastatin increases the expression of ABCA1	.	.
DTD0036	ABCA1	Modulator	Mercury	Acute Toxic Substance	.	.	Mercury affects the expression of ABCA1	.	.
DTD0036	ABCA1	Inducer	Methotrexate	Approved Drug	.	.	Methotrexate increases the expression of ABCA1	.	.
DTD0036	ABCA1	Inhibition	Methyleugenol	Natural Product	.	.	Methyleugenol inhibits the expression of ABCA1	.	.
DTD0036	ABCA1	Inducer	MPC1304	Investigative Drug	.	.	MPC1304 increases the expression of ABCA1	.	.
DTD0036	ABCA1	Inducer	MRK-003	Drug in Preclinical Test	.	.	MRK-003 increases the expression of ABCA1	.	.
DTD0036	ABCA1	Inducer	Nickel chloride	Acute Toxic Substance	.	.	Nickel chloride increases the expression of ABCA1	.	.
DTD0036	ABCA1	Inhibition	Nicotine polacrilex	Approved Drug	.	.	Nicotine polacrilex inhibits the expression of ABCA1	.	.
DTD0036	ABCA1	Inducer	Nicotinic acid	Drug in Phase 1 Trial	.	.	Nicotinic acid increases the expression of ABCA1	.	.
DTD0036	ABCA1	Inhibition	NS-398	Drug in Phase 1 Trial	.	.	NS-398 inhibits the expression of ABCA1	.	.
DTD0036	ABCA1	Inducer	NSC-305787	Investigative Drug	.	.	NSC-305787 increases the expression of ABCA1	.	.
DTD0036	ABCA1	Inhibition	Obeticholic acid	Approved Drug	.	.	Obeticholic acid inhibits the expression of ABCA1	.	.
DTD0036	ABCA1	Inducer	Omeprazole	Approved Drug	.	.	Omeprazole increases the expression of ABCA1	.	.
DTD0036	ABCA1	Inducer	palbociclib	Approved Drug	.	.	palbociclib increases the expression of ABCA1	.	.
DTD0036	ABCA1	Inducer	Pantoprazole	Approved Drug	.	.	Pantoprazole increases the expression of ABCA1	.	.
DTD0036	ABCA1	Inducer	Particulate Matter	Natural Product	.	.	Particulate Matter increases the expression of ABCA1	.	.
DTD0036	ABCA1	Inducer	Perfluorodecanoic acid	Acute Toxic Substance	.	.	Perfluorodecanoic acid increases the expression of ABCA1	.	.
DTD0036	ABCA1	Inducer	Perfluorododecanoic acid	Drug in Preclinical Test	.	.	Perfluorododecanoic acid increases the expression of ABCA1	.	.
DTD0036	ABCA1	Inducer	Perfluorohexanoic acid	Environmental toxicant	.	.	Perfluorohexanoic acid increases the expression of ABCA1	.	.
DTD0036	ABCA1	Inhibition	Perfluorooctane sulfonic acid	Health and Environmental Toxicant	.	.	Perfluorooctane sulfonic acid inhibits the expression of ABCA1	.	.
DTD0036	ABCA1	Inducer	Phenylmercuric Acetate	Investigative Drug	.	.	Phenylmercuric Acetate increases the expression of ABCA1	.	.
DTD0036	ABCA1	Inducer	Pioglitazone	Approved Drug	.	.	Pioglitazone increases the expression of ABCA1	.	.
DTD0036	ABCA1	Inducer	Pitavastatin	Approved Drug	.	.	Pitavastatin increases the expression of ABCA1	.	.
DTD0036	ABCA1	Modulator	Polyhexamethyleneguanidine	Fungicide	.	.	Polyhexamethyleneguanidine affects the expression of ABCA1	.	.
DTD0036	ABCA1	Inhibition	Pravastatin	Approved Drug	.	.	Pravastatin inhibits the expression of ABCA1	.	.
DTD0036	ABCA1	Inhibition	Probucol	Approved Drug	.	.	Probucol inhibits the activity of ABCA1	.	.
DTD0036	ABCA1	Inducer	Propofol	Approved Drug	.	.	Propofol induces the activity of ABCA1	.	.
DTD0036	ABCA1	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of ABCA1	.	.
DTD0036	ABCA1	Inhibition	Resveratrol	Drug in Phase 3 Trial	.	.	Resveratrol inhibits the expression of ABCA1	.	.
DTD0036	ABCA1	Inhibition	Rifampin	Approved Drug	.	.	Rifampin inhibits the expression of ABCA1	.	.
DTD0036	ABCA1	Inhibition	Rofecoxib	Approved Drug	.	.	Rofecoxib inhibits the activity of ABCA1	.	.
DTD0036	ABCA1	Inducer	Rosiglitazone	Approved Drug	.	.	Rosiglitazone increases the expression of ABCA1	.	.
DTD0036	ABCA1	Inhibition	Rosuvastatin Calcium	Approved Drug	.	.	Rosuvastatin Calcium inhibits the expression of ABCA1	.	.
DTD0036	ABCA1	Inhibition	Rotenone	Drug Marketed but not Approved by US FDA	.	.	Rotenone inhibits the expression of ABCA1	.	.
DTD0036	ABCA1	Inhibition	Simvastatin	Approved Drug	.	.	Simvastatin inhibits the expression of ABCA1	.	.
DTD0036	ABCA1	Inducer	Sirolimus	Approved Drug	.	.	Sirolimus increases the expression of ABCA1	.	.
DTD0036	ABCA1	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of ABCA1	.	.
DTD0036	ABCA1	Inhibition	Sunitinib	Approved Drug	.	.	Sunitinib inhibits the expression of ABCA1	.	.
DTD0036	ABCA1	Inducer	Tamoxifen	Approved Drug	.	.	Tamoxifen increases the expression of ABCA1	.	.
DTD0036	ABCA1	Inhibition	Temozolomide	Approved Drug	.	.	Temozolomide inhibits the expression of ABCA1	.	.
DTD0036	ABCA1	Inducer	Testosterone	Approved Drug	.	.	Testosterone increases the expression of ABCA1	.	.
DTD0036	ABCA1	Inducer	Tetramethylpyrazine	Drug in Preclinical Test	.	.	Tetramethylpyrazine increases the expression of ABCA1	.	.
DTD0036	ABCA1	Inducer	TO-901317	Patented Pharmaceutical Agent	.	.	TO-901317 increases the expression of ABCA1	.	.
DTD0036	ABCA1	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of ABCA1	.	.
DTD0036	ABCA1	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of ABCA1	.	.
DTD0036	ABCA1	Inducer	Tributyltin	Investigative Drug	.	.	Tributyltin increases the expression of ABCA1	.	.
DTD0036	ABCA1	Inhibition	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A inhibits the expression of ABCA1	.	.
DTD0036	ABCA1	Inducer	Troglitazone	Approved Drug	.	.	Troglitazone increases the expression of ABCA1	.	.
DTD0036	ABCA1	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of ABCA1	.	.
DTD0036	ABCA1	Inhibition	Vorinostat	Approved Drug	.	.	Vorinostat inhibits the expression of ABCA1	.	.
DTD0036	ABCA1	Inducer	Zinc	Environmental toxicant	.	.	Zinc increases the expression of ABCA1	.	.
DTD0037	ABCA10	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of ABCA10	.	.
DTD0037	ABCA10	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of ABCA10	.	.
DTD0037	ABCA10	Inhibition	Arbutin	Drug Marketed but not Approved by US FDA	.	.	Arbutin inhibits the expression of ABCA10	.	.
DTD0037	ABCA10	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of ABCA10	.	.
DTD0037	ABCA10	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of ABCA10	.	.
DTD0037	ABCA10	Modulator	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite affects the expression of ABCA10	.	.
DTD0037	ABCA10	Inhibition	Testosterone	Approved Drug	.	.	Testosterone inhibits the expression of ABCA10	.	.
DTD0037	ABCA10	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of ABCA10	.	.
DTD0038	ABCA12	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of ABCA12	.	.
DTD0038	ABCA12	Inducer	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 increases the expression of ABCA12	.	.
DTD0038	ABCA12	Inducer	Atrazine	Herbicide	.	.	Atrazine increases the expression of ABCA12	.	.
DTD0038	ABCA12	Inhibition	Avobenzone	Approved Drug	.	.	Avobenzone inhibits the expression of ABCA12	.	.
DTD0038	ABCA12	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of ABCA12	.	.
DTD0038	ABCA12	Inhibition	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A inhibits the expression of ABCA12	.	.
DTD0038	ABCA12	Inhibition	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde inhibits the expression of ABCA12	.	.
DTD0038	ABCA12	Inhibition	Calcitriol	Approved Drug	.	.	Calcitriol inhibits the expression of ABCA12	.	.
DTD0038	ABCA12	Inducer	Cisplatin	Approved Drug	.	.	Cisplatin increases the expression of ABCA12	.	.
DTD0038	ABCA12	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of ABCA12	.	.
DTD0038	ABCA12	Inducer	Demecolcine	Drug Marketed but not Approved by US FDA	.	.	Demecolcine increases the expression of ABCA12	.	.
DTD0038	ABCA12	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the expression of ABCA12	.	.
DTD0038	ABCA12	Inducer	Ethyl Methanesulfonate	Carcinogen	.	.	Ethyl Methanesulfonate increases the expression of ABCA12	.	.
DTD0038	ABCA12	Inducer	Formaldehyde	Acute Toxic Substance	.	.	Formaldehyde increases the expression of ABCA12	.	.
DTD0038	ABCA12	Inhibition	Jinfukang	Traditional Medicine	.	.	Jinfukang inhibits the expression of ABCA12	.	.
DTD0038	ABCA12	Inducer	Lucanthone	Drug in Phase 2 Trial	.	.	Lucanthone increases the expression of ABCA12	.	.
DTD0038	ABCA12	Inhibition	Milchsaure	Investigative Drug	.	.	Milchsaure inhibits the expression of ABCA12	.	.
DTD0038	ABCA12	Inhibition	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin inhibits the expression of ABCA12	.	.
DTD0038	ABCA12	Inducer	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin increases the expression of ABCA12	.	.
DTD0038	ABCA12	Inducer	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite increases the expression of ABCA12	.	.
DTD0038	ABCA12	Inhibition	Testosterone	Approved Drug	.	.	Testosterone inhibits the expression of ABCA12	.	.
DTD0038	ABCA12	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of ABCA12	.	.
DTD0038	ABCA12	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of ABCA12	.	.
DTD0038	ABCA12	Inducer	Vincristine	Approved Drug	.	.	Vincristine increases the expression of ABCA12	.	.
DTD0038	ABCA12	Inducer	Zoledronic Acid	Approved Drug	.	.	Zoledronic Acid increases the expression of ABCA12	.	.
DTD0040	ABCA2	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of ABCA2	.	.
DTD0040	ABCA2	Inhibition	Acrylamide	Acute Toxic Substance	.	.	Acrylamide inhibits the expression of ABCA2	.	.
DTD0040	ABCA2	Inducer	Amiodarone	Approved Drug	.	.	Amiodarone increases the expression of ABCA2	.	.
DTD0040	ABCA2	Inhibition	Bortezomib	Approved Drug	.	.	Bortezomib inhibits the expression of ABCA2	.	.
DTD0040	ABCA2	Inducer	Cisplatin	Approved Drug	.	.	Cisplatin increases the expression of ABCA2	.	.
DTD0040	ABCA2	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of ABCA2	.	.
DTD0040	ABCA2	Inducer	Doxorubicin	Approved Drug	.	.	Doxorubicin increases the expression of ABCA2	.	.
DTD0040	ABCA2	Inhibition	Gallic Acid	Natural Product	.	.	Gallic Acid inhibits the expression of ABCA2	.	.
DTD0040	ABCA2	Inducer	Jinfukang	Traditional Medicine	.	.	Jinfukang increases the expression of ABCA2	.	.
DTD0040	ABCA2	Modulator	Lead	Health and Environmental Toxicant	.	.	Lead affects the expression of ABCA2	.	.
DTD0040	ABCA2	Inducer	Methotrexate	Approved Drug	.	.	Methotrexate increases the expression of ABCA2	.	.
DTD0040	ABCA2	Modulator	Palmitic Acid	Drug in Phase 1 Trial	.	.	Palmitic Acid affects the expression of ABCA2	.	.
DTD0040	ABCA2	Inducer	Rifampin	Approved Drug	.	.	Rifampin increases the expression of ABCA2	.	.
DTD0040	ABCA2	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of ABCA2	.	.
DTD0040	ABCA2	Inhibition	Toluene	Health and Environmental Toxicant	.	.	Toluene inhibits the expression of ABCA2	.	.
DTD0040	ABCA2	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of ABCA2	.	.
DTD0040	ABCA2	Inhibition	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan inhibits the expression of ABCA2	.	.
DTD0040	ABCA2	Inducer	Vinblastine	Approved Drug	.	.	Vinblastine increases the expression of ABCA2	.	.
DTD0041	ABCA3	Inducer	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 increases the expression of ABCA3	.	.
DTD0041	ABCA3	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of ABCA3	.	.
DTD0041	ABCA3	Inducer	Arsenic Trioxide	Approved Drug	.	.	Arsenic Trioxide increases the expression of ABCA3	.	.
DTD0041	ABCA3	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of ABCA3	.	.
DTD0041	ABCA3	Inducer	Calcitriol	Approved Drug	.	.	Calcitriol increases the expression of ABCA3	.	.
DTD0041	ABCA3	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of ABCA3	.	.
DTD0041	ABCA3	Inducer	Doxorubicin	Approved Drug	.	.	Doxorubicin induces the activity of ABCA3	.	.
DTD0041	ABCA3	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of ABCA3	.	.
DTD0041	ABCA3	Inhibition	GSK-J4	Patented Pharmaceutical Agent	.	.	GSK-J4 inhibits the expression of ABCA3	.	.
DTD0041	ABCA3	Modulator	Hydrogen Peroxide	Approved Drug	.	.	Hydrogen Peroxide affects the expression of ABCA3	.	.
DTD0041	ABCA3	Inducer	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 increases the expression of ABCA3	.	.
DTD0041	ABCA3	Inhibition	Imatinib	Approved Drug	.	.	Imatinib inhibits the activity of ABCA3	.	.
DTD0041	ABCA3	Inhibition	Indomethacin	Approved Drug	.	.	Indomethacin inhibits the expression of ABCA3	.	.
DTD0041	ABCA3	Modulator	Lead	Health and Environmental Toxicant	.	.	Lead affects the expression of ABCA3	.	.
DTD0041	ABCA3	Inducer	Methotrexate	Approved Drug	.	.	Methotrexate induces the activity of ABCA3	.	.
DTD0041	ABCA3	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of ABCA3	.	.
DTD0041	ABCA3	Inducer	Temozolomide	Approved Drug	.	.	Temozolomide increases the expression of ABCA3	.	.
DTD0041	ABCA3	Inhibition	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan inhibits the expression of ABCA3	.	.
DTD0041	ABCA3	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of ABCA3	.	.
DTD0041	ABCA3	Inducer	Vinblastine	Approved Drug	.	.	Vinblastine increases the expression of ABCA3	.	.
DTD0041	ABCA3	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of ABCA3	.	.
DTD0042	ABCA4	Inducer	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 increases the expression of ABCA4	.	.
DTD0042	ABCA4	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of ABCA4	.	.
DTD0042	ABCA4	Inducer	Copper Sulfate	Approved Drug	.	.	Copper Sulfate increases the expression of ABCA4	.	.
DTD0042	ABCA4	Inducer	MS-275	Drug in Phase 2 Trial	.	.	MS-275 increases the expression of ABCA4	.	.
DTD0042	ABCA4	Inducer	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite increases the expression of ABCA4	.	.
DTD0042	ABCA4	Modulator	StarGen	Drug in Phase 1/2 Trial	.	.	StarGen modulates the activity of ABCA4	.	.
DTD0042	ABCA4	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of ABCA4	.	.
DTD0042	ABCA4	Inducer	Zoledronic Acid	Approved Drug	.	.	Zoledronic Acid increases the expression of ABCA4	.	.
DTD0043	ABCA5	Inducer	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 increases the expression of ABCA5	.	.
DTD0043	ABCA5	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of ABCA5	.	.
DTD0043	ABCA5	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of ABCA5	.	.
DTD0043	ABCA5	Inhibition	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A inhibits the expression of ABCA5	.	.
DTD0043	ABCA5	Inducer	Clorgyline	Investigative Drug	.	.	Clorgyline increases the expression of ABCA5	.	.
DTD0043	ABCA5	Inducer	Copper Sulfate	Approved Drug	.	.	Copper Sulfate increases the expression of ABCA5	.	.
DTD0043	ABCA5	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of ABCA5	.	.
DTD0043	ABCA5	Inducer	Dihydrotestosterone	Drug in Phase 1 Trial	.	.	Dihydrotestosterone increases the expression of ABCA5	.	.
DTD0043	ABCA5	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of ABCA5	.	.
DTD0043	ABCA5	Inhibition	Gallic Acid	Natural Product	.	.	Gallic Acid inhibits the expression of ABCA5	.	.
DTD0043	ABCA5	Inhibition	Jinfukang	Traditional Medicine	.	.	Jinfukang inhibits the expression of ABCA5	.	.
DTD0043	ABCA5	Inhibition	Manganese	Investigative Drug	.	.	Manganese inhibits the expression of ABCA5	.	.
DTD0043	ABCA5	Inhibition	Manganese chloride	Approved Drug	.	.	Manganese chloride inhibits the expression of ABCA5	.	.
DTD0043	ABCA5	Inhibition	MS-275	Drug in Phase 2 Trial	.	.	MS-275 inhibits the expression of ABCA5	.	.
DTD0043	ABCA5	Inducer	Paclitaxel	Approved Drug	.	.	Paclitaxel increases the expression of ABCA5	.	.
DTD0043	ABCA5	Inhibition	Panobinostat	Approved Drug	.	.	Panobinostat inhibits the expression of ABCA5	.	.
DTD0043	ABCA5	Inducer	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin increases the expression of ABCA5	.	.
DTD0043	ABCA5	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of ABCA5	.	.
DTD0043	ABCA5	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of ABCA5	.	.
DTD0043	ABCA5	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of ABCA5	.	.
DTD0043	ABCA5	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of ABCA5	.	.
DTD0043	ABCA5	Inhibition	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A inhibits the expression of ABCA5	.	.
DTD0043	ABCA5	Inducer	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate increases the expression of ABCA5	.	.
DTD0043	ABCA5	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of ABCA5	.	.
DTD0044	ABCA6	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of ABCA6	.	.
DTD0044	ABCA6	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of ABCA6	.	.
DTD0044	ABCA6	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of ABCA6	.	.
DTD0044	ABCA6	Inducer	Bisphenol F	Environmental toxicant	.	.	Bisphenol F increases the expression of ABCA6	.	.
DTD0044	ABCA6	Inhibition	Cadmium	Acute Toxic Substance	.	.	Cadmium inhibits the expression of ABCA6	.	.
DTD0044	ABCA6	Inducer	Carbamazepine	Approved Drug	.	.	Carbamazepine increases the expression of ABCA6	.	.
DTD0044	ABCA6	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of ABCA6	.	.
DTD0044	ABCA6	Inducer	Dexamethasone	Approved Drug	.	.	Dexamethasone increases the expression of ABCA6	.	.
DTD0044	ABCA6	Inhibition	Dinitrochlorobenzene	Drug in Phase 1 Trial	.	.	Dinitrochlorobenzene inhibits the expression of ABCA6	.	.
DTD0044	ABCA6	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of ABCA6	.	.
DTD0044	ABCA6	Inhibition	Eugenol	Patented Pharmaceutical Agent	.	.	Eugenol inhibits the expression of ABCA6	.	.
DTD0044	ABCA6	Inhibition	Methyleugenol	Natural Product	.	.	Methyleugenol inhibits the expression of ABCA6	.	.
DTD0044	ABCA6	Inhibition	Perfluorooctane sulfonic acid	Health and Environmental Toxicant	.	.	Perfluorooctane sulfonic acid inhibits the expression of ABCA6	.	.
DTD0044	ABCA6	Modulator	Phenobarbital	Approved Drug	.	.	Phenobarbital affects the expression of ABCA6	.	.
DTD0044	ABCA6	Inducer	Progesterone	Approved Drug	.	.	Progesterone increases the expression of ABCA6	.	.
DTD0044	ABCA6	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of ABCA6	.	.
DTD0044	ABCA6	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of ABCA6	.	.
DTD0045	ABCA7	Inducer	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 increases the expression of ABCA7	.	.
DTD0045	ABCA7	Inhibition	Acrylamide	Acute Toxic Substance	.	.	Acrylamide inhibits the expression of ABCA7	.	.
DTD0045	ABCA7	Modulator	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A affects the expression of ABCA7	.	.
DTD0045	ABCA7	Inducer	Cisplatin	Approved Drug	.	.	Cisplatin increases the expression of ABCA7	.	.
DTD0045	ABCA7	Inducer	Copper Sulfate	Approved Drug	.	.	Copper Sulfate increases the expression of ABCA7	.	.
DTD0045	ABCA7	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of ABCA7	.	.
DTD0045	ABCA7	Inducer	Ethyl Methanesulfonate	Carcinogen	.	.	Ethyl Methanesulfonate increases the expression of ABCA7	.	.
DTD0045	ABCA7	Inducer	Paclitaxel	Approved Drug	.	.	Paclitaxel increases the expression of ABCA7	.	.
DTD0045	ABCA7	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of ABCA7	.	.
DTD0045	ABCA7	Inducer	Selenium nanoparticles	Natural Product	.	.	Selenium nanoparticles increases the expression of ABCA7	.	.
DTD0045	ABCA7	Inducer	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite increases the expression of ABCA7	.	.
DTD0045	ABCA7	Inhibition	Sulforafan	Drug in Phase 3 Trial	.	.	Sulforafan inhibits the expression of ABCA7	.	.
DTD0045	ABCA7	Inducer	Testosterone	Approved Drug	.	.	Testosterone increases the expression of ABCA7	.	.
DTD0045	ABCA7	Modulator	Testosterone enanthate	Approved Drug	.	.	Testosterone enanthate affects the expression of ABCA7	.	.
DTD0045	ABCA7	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of ABCA7	.	.
DTD0045	ABCA7	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of ABCA7	.	.
DTD0045	ABCA7	Modulator	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A affects the expression of ABCA7	.	.
DTD0045	ABCA7	Inhibition	Zidovudine	Approved Drug	.	.	Zidovudine inhibits the expression of ABCA7	.	.
DTD0046	ABCA8	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of ABCA8	.	.
DTD0046	ABCA8	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of ABCA8	.	.
DTD0046	ABCA8	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of ABCA8	.	.
DTD0046	ABCA8	Inhibition	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde inhibits the expression of ABCA8	.	.
DTD0046	ABCA8	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of ABCA8	.	.
DTD0046	ABCA8	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of ABCA8	.	.
DTD0046	ABCA8	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the expression of ABCA8	.	.
DTD0046	ABCA8	Inducer	Formaldehyde	Acute Toxic Substance	.	.	Formaldehyde increases the expression of ABCA8	.	.
DTD0046	ABCA8	Inducer	Indomethacin	Approved Drug	.	.	Indomethacin increases the expression of ABCA8	.	.
DTD0046	ABCA8	Inhibition	Particulate Matter	Natural Product	.	.	Particulate Matter inhibits the expression of ABCA8	.	.
DTD0046	ABCA8	Inhibition	Perfluorooctane sulfonic acid	Health and Environmental Toxicant	.	.	Perfluorooctane sulfonic acid inhibits the expression of ABCA8	.	.
DTD0046	ABCA8	Inhibition	Rifampin	Approved Drug	.	.	Rifampin inhibits the expression of ABCA8	.	.
DTD0046	ABCA8	Inhibition	Rosiglitazone	Approved Drug	.	.	Rosiglitazone inhibits the expression of ABCA8	.	.
DTD0046	ABCA8	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of ABCA8	.	.
DTD0046	ABCA8	Inhibition	Sunitinib	Approved Drug	.	.	Sunitinib inhibits the expression of ABCA8	.	.
DTD0046	ABCA8	Inhibition	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan inhibits the expression of ABCA8	.	.
DTD0046	ABCA8	Modulator	Valproic Acid	Approved Drug	.	.	Valproic Acid affects the expression of ABCA8	.	.
DTD0046	ABCA8	Inhibition	Vorinostat	Approved Drug	.	.	Vorinostat inhibits the expression of ABCA8	.	.
DTD0047	ABCA9	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of ABCA9	.	.
DTD0047	ABCA9	Inducer	Arsenic Trioxide	Approved Drug	.	.	Arsenic Trioxide increases the expression of ABCA9	.	.
DTD0047	ABCA9	Inhibition	Cadmium	Acute Toxic Substance	.	.	Cadmium inhibits the expression of ABCA9	.	.
DTD0047	ABCA9	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of ABCA9	.	.
DTD0047	ABCA9	Inducer	Manganese	Investigative Drug	.	.	Manganese increases the expression of ABCA9	.	.
DTD0047	ABCA9	Inducer	Manganese chloride	Approved Drug	.	.	Manganese chloride increases the expression of ABCA9	.	.
DTD0047	ABCA9	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of ABCA9	.	.
DTD0051	ABCB5	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of ABCB5	.	.
DTD0051	ABCB5	Inducer	Calcitriol	Approved Drug	.	.	Calcitriol increases the expression of ABCB5	.	.
DTD0051	ABCB5	Inhibition	Folic Acid	Approved Drug	.	.	Folic Acid inhibits the expression of ABCB5	.	.
DTD0051	ABCB5	Inducer	Methotrexate	Approved Drug	.	.	Methotrexate increases the expression of ABCB5	.	.
DTD0051	ABCB5	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of ABCB5	.	.
DTD0052	ABCB6	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of ABCB6	.	.
DTD0052	ABCB6	Inhibition	Acrylamide	Acute Toxic Substance	.	.	Acrylamide inhibits the expression of ABCB6	.	.
DTD0052	ABCB6	Inducer	Antimycin A	Acute Toxic Substance	.	.	Antimycin A increases the expression of ABCB6	.	.
DTD0052	ABCB6	Inhibition	Atrazine	Herbicide	.	.	Atrazine inhibits the expression of ABCB6	.	.
DTD0052	ABCB6	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of ABCB6	.	.
DTD0052	ABCB6	Inducer	Beta-naphthoflavone	Investigative Drug	.	.	Beta-naphthoflavone increases the expression of ABCB6	.	.
DTD0052	ABCB6	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of ABCB6	.	.
DTD0052	ABCB6	Inhibition	Cannabidiol	Approved Drug	.	.	Cannabidiol inhibits the expression of ABCB6	.	.
DTD0052	ABCB6	Inducer	Cidofovir	Approved Drug	.	.	Cidofovir increases the expression of ABCB6	.	.
DTD0052	ABCB6	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the expression of ABCB6	.	.
DTD0052	ABCB6	Inhibition	Clothianidin	Pesticide/Insecticide	.	.	Clothianidin inhibits the expression of ABCB6	.	.
DTD0052	ABCB6	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of ABCB6	.	.
DTD0052	ABCB6	Inducer	Ethyl Methanesulfonate	Carcinogen	.	.	Ethyl Methanesulfonate increases the expression of ABCB6	.	.
DTD0052	ABCB6	Inhibition	Fluorouracil	Approved Drug	.	.	Fluorouracil inhibits the expression of ABCB6	.	.
DTD0052	ABCB6	Inducer	Glycidamide	Health and Environmental Toxicant	.	.	Glycidamide increases the expression of ABCB6	.	.
DTD0052	ABCB6	Inhibition	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 inhibits the expression of ABCB6	.	.
DTD0052	ABCB6	Inducer	Ifosfamide	Approved Drug	.	.	Ifosfamide increases the expression of ABCB6	.	.
DTD0052	ABCB6	Inhibition	Ivermectin	Approved Drug	.	.	Ivermectin inhibits the expression of ABCB6	.	.
DTD0052	ABCB6	Inducer	Jinfukang	Traditional Medicine	.	.	Jinfukang increases the expression of ABCB6	.	.
DTD0052	ABCB6	Inhibition	Leflunomide	Approved Drug	.	.	Leflunomide inhibits the expression of ABCB6	.	.
DTD0052	ABCB6	Inducer	Methylcholanthrene	Carcinogen	.	.	Methylcholanthrene increases the expression of ABCB6	.	.
DTD0052	ABCB6	Inhibition	Ochratoxin A	Acute Toxic Substance	.	.	Ochratoxin A inhibits the expression of ABCB6	.	.
DTD0052	ABCB6	Inhibition	Paclitaxel	Approved Drug	.	.	Paclitaxel inhibits the expression of ABCB6	.	.
DTD0052	ABCB6	Inducer	Paraquat	Acute Toxic Substance	.	.	Paraquat increases the expression of ABCB6	.	.
DTD0052	ABCB6	Modulator	Phenobarbital	Approved Drug	.	.	Phenobarbital affects the expression of ABCB6	.	.
DTD0052	ABCB6	Inducer	Phenylmercuric Acetate	Investigative Drug	.	.	Phenylmercuric Acetate increases the expression of ABCB6	.	.
DTD0052	ABCB6	Inducer	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin increases the expression of ABCB6	.	.
DTD0052	ABCB6	Inducer	Rifampin	Approved Drug	.	.	Rifampin increases the expression of ABCB6	.	.
DTD0052	ABCB6	Inducer	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite increases the expression of ABCB6	.	.
DTD0052	ABCB6	Inducer	Sulforafan	Drug in Phase 3 Trial	.	.	Sulforafan increases the expression of ABCB6	.	.
DTD0052	ABCB6	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of ABCB6	.	.
DTD0052	ABCB6	Inducer	Temozolomide	Approved Drug	.	.	Temozolomide increases the expression of ABCB6	.	.
DTD0052	ABCB6	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of ABCB6	.	.
DTD0052	ABCB6	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of ABCB6	.	.
DTD0052	ABCB6	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of ABCB6	.	.
DTD0052	ABCB6	Inhibition	Verteporfin	Approved Drug	.	.	Verteporfin inhibits the activity of ABCB6	.	.
DTD0052	ABCB6	Inducer	Vitallium	Natural Product	.	.	Vitallium increases the expression of ABCB6	.	.
DTD0052	ABCB6	Inhibition	Zoledronic Acid	Approved Drug	.	.	Zoledronic Acid inhibits the expression of ABCB6	.	.
DTD0053	ABCB7	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of ABCB7	.	.
DTD0053	ABCB7	Inducer	Carbamazepine	Approved Drug	.	.	Carbamazepine increases the expression of ABCB7	.	.
DTD0053	ABCB7	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of ABCB7	.	.
DTD0053	ABCB7	Inhibition	Dicrotophos	Pesticide/Insecticide	.	.	Dicrotophos inhibits the expression of ABCB7	.	.
DTD0053	ABCB7	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of ABCB7	.	.
DTD0053	ABCB7	Inhibition	Gallium nitrate	Approved Drug	.	.	Gallium nitrate inhibits the expression of ABCB7	.	.
DTD0053	ABCB7	Inhibition	Ivermectin	Approved Drug	.	.	Ivermectin inhibits the expression of ABCB7	.	.
DTD0053	ABCB7	Modulator	Menadione	Approved Drug	.	.	Menadione affects the expression of ABCB7	.	.
DTD0053	ABCB7	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of ABCB7	.	.
DTD0054	ABCB8	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of ABCB8	.	.
DTD0054	ABCB8	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the expression of ABCB8	.	.
DTD0054	ABCB8	Inhibition	GSK-J4	Patented Pharmaceutical Agent	.	.	GSK-J4 inhibits the expression of ABCB8	.	.
DTD0054	ABCB8	Inhibition	Sunitinib	Approved Drug	.	.	Sunitinib inhibits the expression of ABCB8	.	.
DTD0054	ABCB8	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of ABCB8	.	.
DTD0055	ABCB9	Inducer	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 increases the expression of ABCB9	.	.
DTD0055	ABCB9	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of ABCB9	.	.
DTD0055	ABCB9	Inducer	Cidofovir	Approved Drug	.	.	Cidofovir increases the expression of ABCB9	.	.
DTD0055	ABCB9	Inducer	Cisplatin	Approved Drug	.	.	Cisplatin increases the expression of ABCB9	.	.
DTD0055	ABCB9	Inducer	Clodronic Acid	Drug Marketed but not Approved by US FDA	.	.	Clodronic Acid increases the expression of ABCB9	.	.
DTD0055	ABCB9	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of ABCB9	.	.
DTD0055	ABCB9	Inducer	Ifosfamide	Approved Drug	.	.	Ifosfamide increases the expression of ABCB9	.	.
DTD0055	ABCB9	Inhibition	Progesterone	Approved Drug	.	.	Progesterone inhibits the expression of ABCB9	.	.
DTD0055	ABCB9	Modulator	Raloxifene Hydrochloride	Approved Drug	.	.	Raloxifene Hydrochloride affects the expression of ABCB9	.	.
DTD0055	ABCB9	Inducer	Resveratrol	Drug in Phase 3 Trial	.	.	Resveratrol increases the expression of ABCB9	.	.
DTD0055	ABCB9	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of ABCB9	.	.
DTD0055	ABCB9	Inhibition	Toluene	Health and Environmental Toxicant	.	.	Toluene inhibits the expression of ABCB9	.	.
DTD0055	ABCB9	Inhibition	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate inhibits the expression of ABCB9	.	.
DTD0055	ABCB9	Inducer	Urethane	Approved Drug	.	.	Urethane increases the expression of ABCB9	.	.
DTD0055	ABCB9	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of ABCB9	.	.
DTD0055	ABCB9	Inducer	Zinc	Environmental toxicant	.	.	Zinc increases the expression of ABCB9	.	.
DTD0056	ABCC10	Inducer	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 increases the expression of ABCC10	.	.
DTD0056	ABCC10	Inducer	2-acetylaminofluorene	Carcinogen	.	.	2-acetylaminofluorene increases the expression of ABCC10	.	.
DTD0056	ABCC10	Inhibition	Acrylamide	Acute Toxic Substance	.	.	Acrylamide inhibits the expression of ABCC10	.	.
DTD0056	ABCC10	Modulator	Carbamazepine	Approved Drug	.	.	Carbamazepine affects the expression of ABCC10	.	.
DTD0056	ABCC10	Inducer	Doxorubicin	Approved Drug	.	.	Doxorubicin induces the activity of ABCC10	.	.
DTD0056	ABCC10	Inducer	Jinfukang	Traditional Medicine	.	.	Jinfukang increases the expression of ABCC10	.	.
DTD0056	ABCC10	Inducer	Paclitaxel	Approved Drug	.	.	Paclitaxel induces the activity of ABCC10	.	.
DTD0056	ABCC10	Inducer	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin increases the expression of ABCC10	.	.
DTD0056	ABCC10	Inducer	Rifampin	Approved Drug	.	.	Rifampin increases the expression of ABCC10	.	.
DTD0056	ABCC10	Inhibition	Sulfinpyrazone	Approved Drug	.	.	Sulfinpyrazone inhibits the activity of ABCC10	.	.
DTD0056	ABCC10	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of ABCC10	.	.
DTD0056	ABCC10	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of ABCC10	.	.
DTD0056	ABCC10	Inducer	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A increases the expression of ABCC10	.	.
DTD0056	ABCC10	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of ABCC10	.	.
DTD0056	ABCC10	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of ABCC10	.	.
DTD0056	ABCC10	Inducer	Zinc Sulfate	Drug Marketed but not Approved by US FDA	.	.	Zinc Sulfate increases the expression of ABCC10	.	.
DTD0057	ABCC11	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of ABCC11	.	.
DTD0057	ABCC11	Inducer	Amiodarone	Approved Drug	.	.	Amiodarone increases the expression of ABCC11	.	.
DTD0057	ABCC11	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of ABCC11	.	.
DTD0057	ABCC11	Inhibition	Cadmium	Acute Toxic Substance	.	.	Cadmium inhibits the expression of ABCC11	.	.
DTD0057	ABCC11	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the expression of ABCC11	.	.
DTD0057	ABCC11	Inducer	Fluorouracil	Approved Drug	.	.	Fluorouracil induces the activity of ABCC11	.	.
DTD0057	ABCC11	Inducer	Genistein	Drug in Phase 2 Trial	.	.	Genistein increases the expression of ABCC11	.	.
DTD0057	ABCC11	Inducer	Methotrexate	Approved Drug	.	.	Methotrexate induces the activity of ABCC11	.	.
DTD0057	ABCC11	Inhibition	Methyleugenol	Natural Product	.	.	Methyleugenol inhibits the expression of ABCC11	.	.
DTD0057	ABCC11	Inducer	Rifampin	Approved Drug	.	.	Rifampin increases the expression of ABCC11	.	.
DTD0057	ABCC11	Inducer	Tamoxifen	Approved Drug	.	.	Tamoxifen increases the expression of ABCC11	.	.
DTD0057	ABCC11	Inhibition	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate inhibits the expression of ABCC11	.	.
DTD0057	ABCC11	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of ABCC11	.	.
DTD0057	ABCC11	Modulator	Valproic Acid	Approved Drug	.	.	Valproic Acid affects the expression of ABCC11	.	.
DTD0057	ABCC11	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of ABCC11	.	.
DTD0060	ABCC7	Inducer	1,10-phenanthroline	Chemical Compound	.	.	1,10-phenanthroline increases the activity of ABCC7	.	.
DTD0060	ABCC7	Inducer	1-methyl-3-isobutylxanthine	Investigative Drug	.	.	1-methyl-3-isobutylxanthine increases the activity of ABCC7	.	.
DTD0060	ABCC7	Inducer	4-phenylbutyric acid	Drug in Phase 2/3 Trial	.	.	4-phenylbutyric acid increases the activity of ABCC7	.	.
DTD0060	ABCC7	Inducer	Adenosine	Approved Drug	.	.	Adenosine increases the activity of ABCC7	.	.
DTD0060	ABCC7	Inducer	Apigenin	Natural Product	.	.	Apigenin increases the activity of ABCC7	.	.
DTD0060	ABCC7	Inducer	Baicalein	Natural Product	.	.	Baicalein increases the activity of ABCC7	.	.
DTD0060	ABCC7	Inhibition	Belinostat	Approved Drug	.	.	Belinostat inhibits the expression of ABCC7	.	.
DTD0060	ABCC7	Inhibition	Bicarbonate	Drug in Phase 1 Trial	.	.	Bicarbonate inhibits the activity of ABCC7	.	.
DTD0060	ABCC7	Inhibition	Bumetanide	Approved Drug	.	.	Bumetanide inhibits the activity of ABCC7	.	.
DTD0060	ABCC7	Inducer	Butyrate	Drug in Phase 1 Trial	.	.	Butyrate increases the expression of ABCC7	.	.
DTD0060	ABCC7	Inhibition	Cadmium	Acute Toxic Substance	.	.	Cadmium inhibits the expression of ABCC7	.	.
DTD0060	ABCC7	Inhibition	Chelerythrine	Investigative Drug	.	.	Chelerythrine inhibits the activity of ABCC7	.	.
DTD0060	ABCC7	Inducer	Cilostazol	Approved Drug	.	.	Cilostazol increases the activity of ABCC7	.	.
DTD0060	ABCC7	Inducer	Colforsin	Drug in Phase 2 Trial	.	.	Colforsin increases the activity of ABCC7	.	.
DTD0060	ABCC7	Inducer	Curcumin	Drug in Phase 3 Trial	.	.	Curcumin increases the activity of ABCC7	.	.
DTD0060	ABCC7	Inducer	Cyclic AMP	Drug in Phase 1 Trial	.	.	Cyclic AMP increases the activity of ABCC7	.	.
DTD0060	ABCC7	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of ABCC7	.	.
DTD0060	ABCC7	Inhibition	Fenamic acid	Investigative Drug	.	.	Fenamic acid inhibits the activity of ABCC7	.	.
DTD0060	ABCC7	Inhibition	Ferric citrate	Approved Drug	.	.	Ferric citrate inhibits the expression of ABCC7	.	.
DTD0060	ABCC7	Inhibition	Flufenamic Acid	Drug Marketed but not Approved by US FDA	.	.	Flufenamic Acid inhibits the activity of ABCC7	.	.
DTD0060	ABCC7	Inducer	Geneticin	Patented Pharmaceutical Agent	.	.	Geneticin increases the expression of ABCC7	.	.
DTD0060	ABCC7	Inducer	Genistein	Drug in Phase 2 Trial	.	.	Genistein increases the activity of ABCC7	.	.
DTD0060	ABCC7	Inducer	Gentamicin	Approved Drug	.	.	Gentamicin increases the activity of ABCC7	.	.
DTD0060	ABCC7	Inhibition	Glutathiol	Drug in Phase 1 Trial	.	.	Glutathiol inhibits the activity of ABCC7	.	.
DTD0060	ABCC7	Inhibition	Glutathione	Drug in Phase 2 Trial	.	.	Glutathione inhibits the activity of ABCC7	.	.
DTD0060	ABCC7	Inhibition	Glyburide	Approved Drug	.	.	Glyburide inhibits the activity of ABCC7	.	.
DTD0060	ABCC7	Inducer	HE4 peptide	Peptide	.	.	HE4 peptide increases the activity of ABCC7	.	.
DTD0060	ABCC7	Inducer	Heptyl carbinol	Investigative Drug	.	.	Heptyl carbinol increases the activity of ABCC7	.	.
DTD0060	ABCC7	Modulator	Hydrogen Peroxide	Approved Drug	.	.	Hydrogen Peroxide affects the expression of ABCC7	.	.
DTD0060	ABCC7	Inducer	Isoproterenol	Approved Drug	.	.	Isoproterenol increases the activity of ABCC7	.	.
DTD0060	ABCC7	Inducer	Ivacaftor	Approved Drug	.	.	Ivacaftor increases the activity of ABCC7	.	.
DTD0060	ABCC7	Inducer	Lithium Chloride	Health and Environmental Toxicant	.	.	Lithium Chloride increases the expression of ABCC7	.	.
DTD0060	ABCC7	Inhibition	Niflumic Acid	Investigative Drug	.	.	Niflumic Acid inhibits the activity of ABCC7	.	.
DTD0060	ABCC7	Inducer	Nimodipine	Approved Drug	.	.	Nimodipine increases the activity of ABCC7	.	.
DTD0060	ABCC7	Inhibition	Nitrate	Drug in Phase 1 Trial	.	.	Nitrate inhibits the activity of ABCC7	.	.
DTD0060	ABCC7	Inhibition	Nitrosoglutathione	Investigative Drug	.	.	Nitrosoglutathione inhibits the expression of ABCC7	.	.
DTD0060	ABCC7	Inhibition	Okadaic Acid	Acute Toxic Substance	.	.	Okadaic Acid inhibits the activity of ABCC7	.	.
DTD0060	ABCC7	Inducer	Papaverine	Drug in Phase 1 Trial	.	.	Papaverine increases the activity of ABCC7	.	.
DTD0060	ABCC7	Inducer	Phenylmercuric Acetate	Investigative Drug	.	.	Phenylmercuric Acetate increases the expression of ABCC7	.	.
DTD0060	ABCC7	Inducer	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin increases the expression of ABCC7	.	.
DTD0060	ABCC7	Inhibition	Progesterone	Approved Drug	.	.	Progesterone inhibits the expression of ABCC7	.	.
DTD0060	ABCC7	Inducer	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin increases the activity of ABCC7	.	.
DTD0060	ABCC7	Inducer	Resveratrol	Drug in Phase 3 Trial	.	.	Resveratrol increases the activity of ABCC7	.	.
DTD0060	ABCC7	Inducer	Roflumilast	Approved Drug	.	.	Roflumilast induces the activity of ABCC7	.	.
DTD0060	ABCC7	Inducer	Salmeterol Xinafoate	Approved Drug	.	.	Salmeterol Xinafoate increases the expression of ABCC7	.	.
DTD0060	ABCC7	Inducer	Serotonin	Investigative Drug	.	.	Serotonin increases the activity of ABCC7	.	.
DTD0060	ABCC7	Inducer	Sildenafil Citrate	Approved Drug	.	.	Sildenafil Citrate increases the activity of ABCC7	.	.
DTD0060	ABCC7	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of ABCC7	.	.
DTD0060	ABCC7	Inducer	Tetramethylpyrazine	Drug in Preclinical Test	.	.	Tetramethylpyrazine increases the activity of ABCC7	.	.
DTD0060	ABCC7	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of ABCC7	.	.
DTD0060	ABCC7	Inducer	Trequinsin	Drug Withdrawn	.	.	Trequinsin increases the activity of ABCC7	.	.
DTD0060	ABCC7	Inducer	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A increases the expression of ABCC7	.	.
DTD0060	ABCC7	Inhibition	Tungsten	Chemical Compound	.	.	Tungsten inhibits the expression of ABCC7	.	.
DTD0060	ABCC7	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of ABCC7	.	.
DTD0060	ABCC7	Inducer	Vitamin C	Approved Drug	.	.	Vitamin C increases the activity of ABCC7	.	.
DTD0060	ABCC7	Inducer	Zinc	Environmental toxicant	.	.	Zinc increases the expression of ABCC7	.	.
DTD0060	ABCC7	Inducer	Zinc chloride	Drug Marketed but not Approved by US FDA	.	.	Zinc chloride increases the expression of ABCC7	.	.
DTD0061	ABCC8	Inhibition	1-methyl-4-phenylpyridinium	Health and Environmental Toxicant	.	.	1-methyl-4-phenylpyridinium inhibits the expression of ABCC8	.	.
DTD0061	ABCC8	Modulator	Acetohexamide	Approved Drug	.	.	Acetohexamide modulates the activity of ABCC8	.	.
DTD0061	ABCC8	Inhibition	Atrazine	Herbicide	.	.	Atrazine inhibits the expression of ABCC8	.	.
DTD0061	ABCC8	Inhibition	Diethylhexyl Phthalate	Health and Environmental Toxicant	.	.	Diethylhexyl Phthalate inhibits the expression of ABCC8	.	.
DTD0061	ABCC8	Blocker	Gliclazide	Approved Drug	.	.	Gliclazide blocks the activity of ABCC8	.	.
DTD0061	ABCC8	Blocker	Glimepiride	Approved Drug	.	.	Glimepiride blocks the activity of ABCC8	.	.
DTD0061	ABCC8	Inhibition	Glyburide	Approved Drug	.	.	Glibenclamide inhibits the activity of ABCC8	.	.
DTD0061	ABCC8	Modulator	Glyburide	Approved Drug	.	.	Glibenclamide modulates the activity of ABCC8	.	.
DTD0061	ABCC8	Inhibition	HBR-985	Investigative Drug	.	.	HBR-985 inhibits the activity of ABCC8	.	.
DTD0061	ABCC8	Inhibition	Mifepristone	Approved Drug	.	.	Mifepristone inhibits the expression of ABCC8	.	.
DTD0061	ABCC8	Modulator	NN-414	Drug in Phase 1 Trial	.	.	NN-414 modulates the activity of ABCC8	.	.
DTD0061	ABCC8	Blocker	Repaglinide	Approved Drug	.	.	Repaglinide blocks the activity of ABCC8	.	.
DTD0061	ABCC8	Inducer	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite increases the expression of ABCC8	.	.
DTD0061	ABCC8	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of ABCC8	.	.
DTD0061	ABCC8	Blocker	Tolbutamide	Approved Drug	.	.	Tolbutamide blocks the activity of ABCC8	.	.
DTD0061	ABCC8	Modulator	Uranium	Acute Toxic Substance	.	.	Uranium affects the expression of ABCC8	.	.
DTD0062	ABCC9	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of ABCC9	.	.
DTD0062	ABCC9	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of ABCC9	.	.
DTD0062	ABCC9	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of ABCC9	.	.
DTD0062	ABCC9	Inhibition	Aflatoxin M1	Mycotoxins	.	.	Aflatoxin M1 inhibits the expression of ABCC9	.	.
DTD0062	ABCC9	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of ABCC9	.	.
DTD0062	ABCC9	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the expression of ABCC9	.	.
DTD0062	ABCC9	Inducer	Copper Sulfate	Approved Drug	.	.	Copper Sulfate increases the expression of ABCC9	.	.
DTD0062	ABCC9	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of ABCC9	.	.
DTD0062	ABCC9	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of ABCC9	.	.
DTD0062	ABCC9	Blocker	Glimepiride	Approved Drug	.	.	Glimepiride blocks the activity of ABCC9	.	.
DTD0062	ABCC9	Inhibition	Ivermectin	Approved Drug	.	.	Ivermectin inhibits the expression of ABCC9	.	.
DTD0062	ABCC9	Inhibition	Jinfukang	Traditional Medicine	.	.	Jinfukang inhibits the expression of ABCC9	.	.
DTD0062	ABCC9	Inhibition	MeIQx	Drug in Phase 2 Trial	.	.	MeIQx inhibits the expression of ABCC9	.	.
DTD0062	ABCC9	Inhibition	Methyleugenol	Natural Product	.	.	Methyleugenol inhibits the expression of ABCC9	.	.
DTD0062	ABCC9	Activator	Nicorandil	Approved Drug	.	.	Nicorandil activates the activity of ABCC9	.	.
DTD0062	ABCC9	Inhibition	Permethrin	Approved Drug	.	.	Permethrin inhibits the expression of ABCC9	.	.
DTD0062	ABCC9	Modulator	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin affects the expression of ABCC9	.	.
DTD0062	ABCC9	Inducer	Progesterone	Approved Drug	.	.	Progesterone increases the expression of ABCC9	.	.
DTD0062	ABCC9	Blocker	Repaglinide	Approved Drug	.	.	Repaglinide blocks the activity of ABCC9	.	.
DTD0062	ABCC9	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of ABCC9	.	.
DTD0062	ABCC9	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of ABCC9	.	.
DTD0062	ABCC9	Blocker	Tolbutamide	Approved Drug	.	.	Tolbutamide blocks the activity of ABCC9	.	.
DTD0062	ABCC9	Inhibition	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan inhibits the expression of ABCC9	.	.
DTD0062	ABCC9	Inhibition	Zinc Sulfate	Drug Marketed but not Approved by US FDA	.	.	Zinc Sulfate inhibits the expression of ABCC9	.	.
DTD0063	ABCD1	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of ABCD1	.	.
DTD0063	ABCD1	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of ABCD1	.	.
DTD0063	ABCD1	Inhibition	Acrylamide	Acute Toxic Substance	.	.	Acrylamide inhibits the expression of ABCD1	.	.
DTD0063	ABCD1	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of ABCD1	.	.
DTD0063	ABCD1	Inducer	Bisphenol B	Drug in Phase 2 Trial	.	.	Bisphenol B increases the expression of ABCD1	.	.
DTD0063	ABCD1	Inducer	Bisphenol F	Environmental toxicant	.	.	Bisphenol F increases the expression of ABCD1	.	.
DTD0063	ABCD1	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the expression of ABCD1	.	.
DTD0063	ABCD1	Inducer	Dicrotophos	Pesticide/Insecticide	.	.	Dicrotophos increases the expression of ABCD1	.	.
DTD0063	ABCD1	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of ABCD1	.	.
DTD0063	ABCD1	Inhibition	GSK-J4	Patented Pharmaceutical Agent	.	.	GSK-J4 inhibits the expression of ABCD1	.	.
DTD0063	ABCD1	Inhibition	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 inhibits the expression of ABCD1	.	.
DTD0063	ABCD1	Inhibition	Methotrexate	Approved Drug	.	.	Methotrexate inhibits the expression of ABCD1	.	.
DTD0063	ABCD1	Inhibition	Sunitinib	Approved Drug	.	.	Sunitinib inhibits the expression of ABCD1	.	.
DTD0063	ABCD1	Inducer	Titanium dioxide	Approved Drug	.	.	Titanium dioxide increases the expression of ABCD1	.	.
DTD0063	ABCD1	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of ABCD1	.	.
DTD0063	ABCD1	Inducer	Urethane	Approved Drug	.	.	Urethane increases the expression of ABCD1	.	.
DTD0063	ABCD1	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of ABCD1	.	.
DTD0064	ABCD2	Modulator	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 affects the expression of ABCD2	.	.
DTD0064	ABCD2	Inhibition	Clothianidin	Pesticide/Insecticide	.	.	Clothianidin inhibits the expression of ABCD2	.	.
DTD0064	ABCD2	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of ABCD2	.	.
DTD0064	ABCD2	Inducer	Dexamethasone	Approved Drug	.	.	Dexamethasone increases the expression of ABCD2	.	.
DTD0064	ABCD2	Inhibition	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin inhibits the expression of ABCD2	.	.
DTD0064	ABCD2	Inhibition	Silver nanoparticle	Nanoparticle	.	.	Silver nanoparticle inhibits the expression of ABCD2	.	.
DTD0064	ABCD2	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of ABCD2	.	.
DTD0064	ABCD2	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of ABCD2	.	.
DTD0065	ABCD3	Inducer	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 increases the expression of ABCD3	.	.
DTD0065	ABCD3	Inhibition	Aflatoxin M1	Mycotoxins	.	.	Aflatoxin M1 inhibits the expression of ABCD3	.	.
DTD0065	ABCD3	Inhibition	Arachidonic acid	Investigative Drug	.	.	Arachidonic acid inhibits the expression of ABCD3	.	.
DTD0065	ABCD3	Inhibition	Atrazine	Herbicide	.	.	Atrazine inhibits the expression of ABCD3	.	.
DTD0065	ABCD3	Inducer	Bisphenol B	Drug in Phase 2 Trial	.	.	Bisphenol B increases the expression of ABCD3	.	.
DTD0065	ABCD3	Inducer	Calcitriol	Approved Drug	.	.	Calcitriol increases the expression of ABCD3	.	.
DTD0065	ABCD3	Inhibition	Clothianidin	Pesticide/Insecticide	.	.	Clothianidin inhibits the expression of ABCD3	.	.
DTD0065	ABCD3	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of ABCD3	.	.
DTD0065	ABCD3	Inhibition	Coumestrol	Investigative Drug	.	.	Coumestrol inhibits the expression of ABCD3	.	.
DTD0065	ABCD3	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of ABCD3	.	.
DTD0065	ABCD3	Inhibition	Dicrotophos	Pesticide/Insecticide	.	.	Dicrotophos inhibits the expression of ABCD3	.	.
DTD0065	ABCD3	Modulator	Estradiol	Approved Drug	.	.	Estradiol affects the expression of ABCD3	.	.
DTD0065	ABCD3	Inducer	Formaldehyde	Acute Toxic Substance	.	.	Formaldehyde increases the expression of ABCD3	.	.
DTD0065	ABCD3	Inhibition	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 inhibits the expression of ABCD3	.	.
DTD0065	ABCD3	Inhibition	Ivermectin	Approved Drug	.	.	Ivermectin inhibits the expression of ABCD3	.	.
DTD0065	ABCD3	Inhibition	Leflunomide	Approved Drug	.	.	Leflunomide inhibits the expression of ABCD3	.	.
DTD0065	ABCD3	Inducer	MeIQx	Drug in Phase 2 Trial	.	.	MeIQx increases the expression of ABCD3	.	.
DTD0065	ABCD3	Inducer	Methotrexate	Approved Drug	.	.	Methotrexate increases the expression of ABCD3	.	.
DTD0065	ABCD3	Inhibition	Milchsaure	Investigative Drug	.	.	Milchsaure inhibits the expression of ABCD3	.	.
DTD0065	ABCD3	Inducer	Particulate Matter	Natural Product	.	.	Particulate Matter increases the expression of ABCD3	.	.
DTD0065	ABCD3	Inducer	Phenylmercuric Acetate	Investigative Drug	.	.	Phenylmercuric Acetate increases the expression of ABCD3	.	.
DTD0065	ABCD3	Inhibition	Piroxicam	Approved Drug	.	.	Piroxicam inhibits the expression of ABCD3	.	.
DTD0065	ABCD3	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of ABCD3	.	.
DTD0065	ABCD3	Inhibition	Sarin	Acute Toxic Substance	.	.	Sarin inhibits the expression of ABCD3	.	.
DTD0065	ABCD3	Inhibition	Sirolimus	Approved Drug	.	.	Sirolimus inhibits the expression of ABCD3	.	.
DTD0065	ABCD3	Inducer	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite increases the expression of ABCD3	.	.
DTD0065	ABCD3	Inducer	Temozolomide	Approved Drug	.	.	Temozolomide increases the expression of ABCD3	.	.
DTD0065	ABCD3	Inhibition	Testosterone	Approved Drug	.	.	Testosterone inhibits the expression of ABCD3	.	.
DTD0065	ABCD3	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of ABCD3	.	.
DTD0065	ABCD3	Inducer	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A increases the expression of ABCD3	.	.
DTD0065	ABCD3	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of ABCD3	.	.
DTD0065	ABCD3	Inducer	Vorinostat	Approved Drug	.	.	Vorinostat increases the expression of ABCD3	.	.
DTD0066	ABCD4	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of ABCD4	.	.
DTD0066	ABCD4	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the expression of ABCD4	.	.
DTD0066	ABCD4	Inducer	K-7174	Patented Pharmaceutical Agent	.	.	K-7174 increases the expression of ABCD4	.	.
DTD0066	ABCD4	Inhibition	Leflunomide	Approved Drug	.	.	Leflunomide inhibits the expression of ABCD4	.	.
DTD0066	ABCD4	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of ABCD4	.	.
DTD0066	ABCD4	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of ABCD4	.	.
DTD0066	ABCD4	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of ABCD4	.	.
DTD0071	ABCG1	Inducer	27-hydroxycholesterol	Investigative Drug	.	.	27-hydroxycholesterol increases the expression of ABCG1	.	.
DTD0071	ABCG1	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of ABCG1	.	.
DTD0071	ABCG1	Inhibition	Acetylcysteine	Approved Drug	.	.	Acetylcysteine inhibits the expression of ABCG1	.	.
DTD0071	ABCG1	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of ABCG1	.	.
DTD0071	ABCG1	Inducer	Alitretinoin	Approved Drug	.	.	Alitretinoin increases the expression of ABCG1	.	.
DTD0071	ABCG1	Inhibition	Arachidonic acid	Investigative Drug	.	.	Arachidonic acid inhibits the expression of ABCG1	.	.
DTD0071	ABCG1	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of ABCG1	.	.
DTD0071	ABCG1	Inhibition	Cidofovir	Approved Drug	.	.	Cidofovir inhibits the expression of ABCG1	.	.
DTD0071	ABCG1	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the expression of ABCG1	.	.
DTD0071	ABCG1	Inhibition	Clodronic Acid	Drug Marketed but not Approved by US FDA	.	.	Clodronic Acid inhibits the expression of ABCG1	.	.
DTD0071	ABCG1	Inhibition	Clothianidin	Pesticide/Insecticide	.	.	Clothianidin inhibits the expression of ABCG1	.	.
DTD0071	ABCG1	Inducer	Clozapine	Approved Drug	.	.	Clozapine increases the expression of ABCG1	.	.
DTD0071	ABCG1	Inducer	CS-6969	Investigative Drug	.	.	CS-6969 increases the expression of ABCG1	.	.
DTD0071	ABCG1	Inducer	Curcumin	Drug in Phase 3 Trial	.	.	Curcumin increases the expression of ABCG1	.	.
DTD0071	ABCG1	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of ABCG1	.	.
DTD0071	ABCG1	Inhibition	Cypermethrin	Pesticide/Insecticide	.	.	Cypermethrin inhibits the expression of ABCG1	.	.
DTD0071	ABCG1	Modulator	Decitabine	Approved Drug	.	.	Decitabine affects the expression of ABCG1	.	.
DTD0071	ABCG1	Inducer	Diazinon	Environmental toxicant	.	.	Diazinon increases the expression of ABCG1	.	.
DTD0071	ABCG1	Inhibition	Dibutyl Phthalate	Health and Environmental Toxicant	.	.	Dibutyl Phthalate inhibits the expression of ABCG1	.	.
DTD0071	ABCG1	Inhibition	Dronabinol	Approved Drug	.	.	Dronabinol inhibits the expression of ABCG1	.	.
DTD0071	ABCG1	Inhibition	Epigallocatechin gallate	Drug in Phase 3 Trial	.	.	Epigallocatechin gallate inhibits the expression of ABCG1	.	.
DTD0071	ABCG1	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the expression of ABCG1	.	.
DTD0071	ABCG1	Inhibition	Ethanol	Drug in Phase 2 Trial	.	.	Ethanol inhibits the expression of ABCG1	.	.
DTD0071	ABCG1	Inducer	GSK-J4	Patented Pharmaceutical Agent	.	.	GSK-J4 increases the expression of ABCG1	.	.
DTD0071	ABCG1	Inducer	GW-3965	Patented Pharmaceutical Agent	.	.	GW-3965 increases the expression of ABCG1	.	.
DTD0071	ABCG1	Inducer	Ibuprofen	Approved Drug	.	.	Ibuprofen increases the expression of ABCG1	.	.
DTD0071	ABCG1	Inhibition	Icosapentum	Investigative Drug	.	.	Icosapentum inhibits the expression of ABCG1	.	.
DTD0071	ABCG1	Inhibition	Ifosfamide	Approved Drug	.	.	Ifosfamide inhibits the expression of ABCG1	.	.
DTD0071	ABCG1	Inducer	Lindane	Approved Drug	.	.	Lindane increases the expression of ABCG1	.	.
DTD0071	ABCG1	Inhibition	Linoleic Acid	Drug Marketed but not Approved by US FDA	.	.	Linoleic Acid inhibits the expression of ABCG1	.	.
DTD0071	ABCG1	Inducer	Mercury	Acute Toxic Substance	.	.	Mercury increases the expression of ABCG1	.	.
DTD0071	ABCG1	Inducer	MS-275	Drug in Phase 2 Trial	.	.	MS-275 increases the expression of ABCG1	.	.
DTD0071	ABCG1	Inducer	Nickel chloride	Acute Toxic Substance	.	.	Nickel chloride increases the expression of ABCG1	.	.
DTD0071	ABCG1	Inhibition	Nicotine polacrilex	Approved Drug	.	.	Nicotine polacrilex inhibits the expression of ABCG1	.	.
DTD0071	ABCG1	Inhibition	Obeticholic acid	Approved Drug	.	.	Obeticholic acid inhibits the expression of ABCG1	.	.
DTD0071	ABCG1	Inhibition	Ochratoxin A	Acute Toxic Substance	.	.	Ochratoxin A inhibits the expression of ABCG1	.	.
DTD0071	ABCG1	Inhibition	Oleic Acid	Drug in Preclinical Test	.	.	Oleic Acid inhibits the expression of ABCG1	.	.
DTD0071	ABCG1	Inducer	Palmitic Acid	Drug in Phase 1 Trial	.	.	Palmitic Acid increases the expression of ABCG1	.	.
DTD0071	ABCG1	Inducer	Perfluorooctane sulfonic acid	Health and Environmental Toxicant	.	.	Perfluorooctane sulfonic acid increases the expression of ABCG1	.	.
DTD0071	ABCG1	Inhibition	Potassium perchlorate	Approved Drug	.	.	Potassium perchlorate inhibits the expression of ABCG1	.	.
DTD0071	ABCG1	Inhibition	Progesterone	Approved Drug	.	.	Progesterone inhibits the expression of ABCG1	.	.
DTD0071	ABCG1	Modulator	Raloxifene Hydrochloride	Approved Drug	.	.	Raloxifene Hydrochloride affects the expression of ABCG1	.	.
DTD0071	ABCG1	Inducer	Rifampin	Approved Drug	.	.	Rifampin increases the expression of ABCG1	.	.
DTD0071	ABCG1	Inducer	Rosiglitazone	Approved Drug	.	.	Rosiglitazone increases the expression of ABCG1	.	.
DTD0071	ABCG1	Inhibition	Rosuvastatin Calcium	Approved Drug	.	.	Rosuvastatin Calcium inhibits the expression of ABCG1	.	.
DTD0071	ABCG1	Inhibition	Simvastatin	Approved Drug	.	.	Simvastatin inhibits the expression of ABCG1	.	.
DTD0071	ABCG1	Inducer	Stearic acid	Dietary Constituent	.	.	Stearic acid increases the expression of ABCG1	.	.
DTD0071	ABCG1	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of ABCG1	.	.
DTD0071	ABCG1	Inducer	Tamoxifen	Approved Drug	.	.	Tamoxifen increases the expression of ABCG1	.	.
DTD0071	ABCG1	Inhibition	Tebuconazole	Fungicide	.	.	Tebuconazole inhibits the expression of ABCG1	.	.
DTD0071	ABCG1	Inducer	Telmisartan	Approved Drug	.	.	Telmisartan increases the expression of ABCG1	.	.
DTD0071	ABCG1	Inducer	TO-901317	Patented Pharmaceutical Agent	.	.	TO-901317 increases the expression of ABCG1	.	.
DTD0071	ABCG1	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of ABCG1	.	.
DTD0071	ABCG1	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of ABCG1	.	.
DTD0071	ABCG1	Inducer	Triadimefon	Fungicide	.	.	Triadimefon increases the expression of ABCG1	.	.
DTD0071	ABCG1	Inducer	Tributyltin	Investigative Drug	.	.	Tributyltin increases the expression of ABCG1	.	.
DTD0071	ABCG1	Inhibition	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A inhibits the expression of ABCG1	.	.
DTD0071	ABCG1	Inducer	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan increases the expression of ABCG1	.	.
DTD0071	ABCG1	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of ABCG1	.	.
DTD0071	ABCG1	Inducer	Zinc	Environmental toxicant	.	.	Zinc increases the expression of ABCG1	.	.
DTD0076	SLC10A4	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of SLC10A4	.	.
DTD0076	SLC10A4	Inducer	Folic Acid	Approved Drug	.	.	Folic Acid increases the expression of SLC10A4	.	.
DTD0076	SLC10A4	Inducer	MS-275	Drug in Phase 2 Trial	.	.	MS-275 increases the expression of SLC10A4	.	.
DTD0076	SLC10A4	Inhibition	NSC-689534	Patented Pharmaceutical Agent	.	.	NSC-689534 inhibits the expression of SLC10A4	.	.
DTD0076	SLC10A4	Inducer	Particulate Matter	Natural Product	.	.	Particulate Matter increases the expression of SLC10A4	.	.
DTD0076	SLC10A4	Inhibition	Rotenone	Drug Marketed but not Approved by US FDA	.	.	Rotenone inhibits the expression of SLC10A4	.	.
DTD0076	SLC10A4	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC10A4	.	.
DTD0076	SLC10A4	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of SLC10A4	.	.
DTD0076	SLC10A4	Inducer	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A increases the expression of SLC10A4	.	.
DTD0076	SLC10A4	Inhibition	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan inhibits the expression of SLC10A4	.	.
DTD0076	SLC10A4	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC10A4	.	.
DTD0077	SLC10A5	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of SLC10A5	.	.
DTD0077	SLC10A5	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC10A5	.	.
DTD0077	SLC10A5	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the expression of SLC10A5	.	.
DTD0077	SLC10A5	Inhibition	Jinfukang	Traditional Medicine	.	.	Jinfukang inhibits the expression of SLC10A5	.	.
DTD0077	SLC10A5	Inhibition	Methyleugenol	Natural Product	.	.	Methyleugenol inhibits the expression of SLC10A5	.	.
DTD0077	SLC10A5	Inducer	Particulate Matter	Natural Product	.	.	Particulate Matter increases the expression of SLC10A5	.	.
DTD0077	SLC10A5	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC10A5	.	.
DTD0077	SLC10A5	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of SLC10A5	.	.
DTD0077	SLC10A5	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC10A5	.	.
DTD0078	SLC10A6	Inducer	Arsenic	Approved Drug	.	.	Arsenic increases the expression of SLC10A6	.	.
DTD0078	SLC10A6	Inducer	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite increases the expression of SLC10A6	.	.
DTD0078	SLC10A6	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC10A6	.	.
DTD0079	SLC10A7	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC10A7	.	.
DTD0079	SLC10A7	Inducer	Bortezomib	Approved Drug	.	.	Bortezomib increases the expression of SLC10A7	.	.
DTD0079	SLC10A7	Inducer	Calcitriol	Approved Drug	.	.	Calcitriol increases the expression of SLC10A7	.	.
DTD0079	SLC10A7	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of SLC10A7	.	.
DTD0079	SLC10A7	Inducer	Dihydrotestosterone	Drug in Phase 1 Trial	.	.	Dihydrotestosterone increases the expression of SLC10A7	.	.
DTD0079	SLC10A7	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC10A7	.	.
DTD0079	SLC10A7	Inhibition	Jinfukang	Traditional Medicine	.	.	Jinfukang inhibits the expression of SLC10A7	.	.
DTD0079	SLC10A7	Inhibition	Methyleugenol	Natural Product	.	.	Methyleugenol inhibits the expression of SLC10A7	.	.
DTD0079	SLC10A7	Inhibition	Milchsaure	Investigative Drug	.	.	Milchsaure inhibits the expression of SLC10A7	.	.
DTD0079	SLC10A7	Modulator	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin affects the expression of SLC10A7	.	.
DTD0079	SLC10A7	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of SLC10A7	.	.
DTD0079	SLC10A7	Inducer	Testosterone	Approved Drug	.	.	Testosterone increases the expression of SLC10A7	.	.
DTD0079	SLC10A7	Inducer	Thimerosal	Acute Toxic Substance	.	.	Thimerosal increases the expression of SLC10A7	.	.
DTD0079	SLC10A7	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC10A7	.	.
DTD0079	SLC10A7	Inducer	Tobacco tar	Natural Product	.	.	Tobacco tar increases the expression of SLC10A7	.	.
DTD0079	SLC10A7	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of SLC10A7	.	.
DTD0079	SLC10A7	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC10A7	.	.
DTD0080	SLC11A1	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of SLC11A1	.	.
DTD0080	SLC11A1	Inducer	Arsenic Trioxide	Approved Drug	.	.	Arsenic Trioxide increases the expression of SLC11A1	.	.
DTD0080	SLC11A1	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC11A1	.	.
DTD0080	SLC11A1	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the expression of SLC11A1	.	.
DTD0080	SLC11A1	Inducer	Mercury	Acute Toxic Substance	.	.	Mercury increases the expression of SLC11A1	.	.
DTD0080	SLC11A1	Inhibition	Methotrexate	Approved Drug	.	.	Methotrexate inhibits the expression of SLC11A1	.	.
DTD0080	SLC11A1	Inhibition	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan inhibits the expression of SLC11A1	.	.
DTD0081	SLC11A2	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC11A2	.	.
DTD0081	SLC11A2	Inhibition	Antimycin A	Acute Toxic Substance	.	.	Antimycin A inhibits the expression of SLC11A2	.	.
DTD0081	SLC11A2	Modulator	Arsenic	Approved Drug	.	.	Arsenic affects the expression of SLC11A2	.	.
DTD0081	SLC11A2	Inhibition	Azoxystrobin	Fungicide	.	.	Azoxystrobin inhibits the expression of SLC11A2	.	.
DTD0081	SLC11A2	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC11A2	.	.
DTD0081	SLC11A2	Inhibition	Cadmium	Acute Toxic Substance	.	.	Cadmium inhibits the expression of SLC11A2	.	.
DTD0081	SLC11A2	Inhibition	Copper	Approved Drug	.	.	Copper inhibits the expression of SLC11A2	.	.
DTD0081	SLC11A2	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC11A2	.	.
DTD0081	SLC11A2	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC11A2	.	.
DTD0081	SLC11A2	Inhibition	Deguelin	Natural Product	.	.	Deguelin inhibits the expression of SLC11A2	.	.
DTD0081	SLC11A2	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC11A2	.	.
DTD0081	SLC11A2	Inducer	Ethanol	Drug in Phase 2 Trial	.	.	Ethanol increases the expression of SLC11A2	.	.
DTD0081	SLC11A2	Inhibition	Excavatolide B	Natural Product	.	.	Excavatolide B inhibits the expression of SLC11A2	.	.
DTD0081	SLC11A2	Inducer	Hydrogen Peroxide	Approved Drug	.	.	Hydrogen Peroxide increases the expression of SLC11A2	.	.
DTD0081	SLC11A2	Inhibition	Isotretinoin	Approved Drug	.	.	Isotretinoin inhibits the expression of SLC11A2	.	.
DTD0081	SLC11A2	Inhibition	K-7174	Patented Pharmaceutical Agent	.	.	K-7174 inhibits the expression of SLC11A2	.	.
DTD0081	SLC11A2	Inducer	Manganese	Investigative Drug	.	.	Manganese increases the expression of SLC11A2	.	.
DTD0081	SLC11A2	Inducer	Manganese chloride	Approved Drug	.	.	Manganese chloride increases the expression of SLC11A2	.	.
DTD0081	SLC11A2	Inhibition	Mercury	Acute Toxic Substance	.	.	Mercury inhibits the expression of SLC11A2	.	.
DTD0081	SLC11A2	Inhibition	Nano-sized iron particle	Health and Environmental Toxicant	.	.	Nano-sized iron particle inhibits the expression of SLC11A2	.	.
DTD0081	SLC11A2	Inhibition	Ochratoxin A	Acute Toxic Substance	.	.	Ochratoxin A inhibits the expression of SLC11A2	.	.
DTD0081	SLC11A2	Inhibition	PP242	Investigative Drug	.	.	PP242 inhibits the expression of SLC11A2	.	.
DTD0081	SLC11A2	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of SLC11A2	.	.
DTD0081	SLC11A2	Inhibition	Rotenone	Drug Marketed but not Approved by US FDA	.	.	Rotenone inhibits the expression of SLC11A2	.	.
DTD0081	SLC11A2	Modulator	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution affects the expression of SLC11A2	.	.
DTD0081	SLC11A2	Inhibition	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A inhibits the expression of SLC11A2	.	.
DTD0081	SLC11A2	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of SLC11A2	.	.
DTD0081	SLC11A2	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC11A2	.	.
DTD0081	SLC11A2	Inhibition	Vitamin C	Approved Drug	.	.	Vitamin C inhibits the expression of SLC11A2	.	.
DTD0081	SLC11A2	Inhibition	Vitamin E	Drug in Phase 3 Trial	.	.	Vitamin E inhibits the expression of SLC11A2	.	.
DTD0081	SLC11A2	Inducer	Zinc Sulfate	Drug Marketed but not Approved by US FDA	.	.	Zinc Sulfate increases the expression of SLC11A2	.	.
DTD0081	SLC11A2	Inducer	Zoledronic Acid	Approved Drug	.	.	Zoledronic Acid increases the expression of SLC11A2	.	.
DTD0082	SLC12A1	Blocker	Bendroflumethiazide	Approved Drug	.	.	Bendroflumethiazide blocks the activity of SLC12A1	.	.
DTD0082	SLC12A1	Blocker	Bumetanide	Approved Drug	.	.	Bumetanide blocks the activity of SLC12A1	.	.
DTD0082	SLC12A1	Inhibition	Bumetanide	Approved Drug	.	.	Bumetanide inhibits the activity of SLC12A1	.	.
DTD0082	SLC12A1	Inhibition	Chloroquine	Approved Drug	.	.	Chloroquine inhibits the expression of SLC12A1	.	.
DTD0082	SLC12A1	Blocker	Chlorthalidone	Approved Drug	.	.	Chlorthalidone blocks the activity of SLC12A1	.	.
DTD0082	SLC12A1	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the expression of SLC12A1	.	.
DTD0082	SLC12A1	Modulator	Ethacrynate sodium	Approved Drug	.	.	Ethacrynate sodium modulates the activity of SLC12A1	.	.
DTD0082	SLC12A1	Blocker	Ethacrynic Acid	Approved Drug	.	.	Ethacrynic acid blocks the activity of SLC12A1	.	.
DTD0082	SLC12A1	Blocker	Furosemide	Approved Drug	.	.	Furosemide blocks the activity of SLC12A1	.	.
DTD0082	SLC12A1	Inducer	Furosemide	Approved Drug	.	.	Furosemide induces the activity of SLC12A1	.	.
DTD0082	SLC12A1	Inducer	Hydrochlorothiazide	Approved Drug	.	.	Hydrochlorothiazide induces the activity of SLC12A1	.	.
DTD0082	SLC12A1	Blocker	Hydroflumethiazide	Approved Drug	.	.	Hydroflumethiazide blocks the activity of SLC12A1	.	.
DTD0082	SLC12A1	Blocker	Methyclothiazide	Approved Drug	.	.	Methyclothiazide blocks the activity of SLC12A1	.	.
DTD0082	SLC12A1	Inhibition	Nitric oxide	Drug in Preclinical Test	.	.	Nitric oxide inhibits the activity of SLC12A1	.	.
DTD0082	SLC12A1	Modulator	Potassium chloride	Approved Drug	.	.	Potassium chloride modulates the activity of SLC12A1	.	.
DTD0082	SLC12A1	Blocker	Torasemide	Approved Drug	.	.	Torsemide blocks the activity of SLC12A1	.	.
DTD0082	SLC12A1	Blocker	Trichlormethiazide	Approved Drug	.	.	Trichloromethiazide blocks the activity of SLC12A1	.	.
DTD0082	SLC12A1	Inhibition	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate inhibits the activity of SLC12A1	.	.
DTD0082	SLC12A1	Inducer	Vasopressin	Approved Drug	.	.	Vasopressin induces the activity of SLC12A1	.	.
DTD0082	SLC12A1	Inhibition	Zinc Oxide	Environmental toxicant	.	.	Zinc Oxide inhibits the expression of SLC12A1	.	.
DTD0082	SLC12A1	Inhibition	Zoledronic Acid	Approved Drug	.	.	Zoledronic Acid inhibits the expression of SLC12A1	.	.
DTD0083	SLC12A2	Inducer	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 increases the expression of SLC12A2	.	.
DTD0083	SLC12A2	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of SLC12A2	.	.
DTD0083	SLC12A2	Inducer	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 increases the expression of SLC12A2	.	.
DTD0083	SLC12A2	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC12A2	.	.
DTD0083	SLC12A2	Inhibition	Bumetanide	Approved Drug	.	.	Bumetanide inhibits the activity of SLC12A2	.	.
DTD0083	SLC12A2	Inhibition	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde inhibits the expression of SLC12A2	.	.
DTD0083	SLC12A2	Modulator	Carbamazepine	Approved Drug	.	.	Carbamazepine affects the expression of SLC12A2	.	.
DTD0083	SLC12A2	Inducer	Copper Sulfate	Approved Drug	.	.	Copper Sulfate increases the expression of SLC12A2	.	.
DTD0083	SLC12A2	Inhibition	Coumestrol	Investigative Drug	.	.	Coumestrol inhibits the expression of SLC12A2	.	.
DTD0083	SLC12A2	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC12A2	.	.
DTD0083	SLC12A2	Inhibition	Daidzein	Drug Marketed but not Approved by US FDA	.	.	Daidzein inhibits the expression of SLC12A2	.	.
DTD0083	SLC12A2	Inhibition	Diethylstilbestrol	Approved Drug	.	.	Diethylstilbestrol inhibits the expression of SLC12A2	.	.
DTD0083	SLC12A2	Modulator	Doxorubicin	Approved Drug	.	.	Doxorubicin affects the expression of SLC12A2	.	.
DTD0083	SLC12A2	Inducer	Estradiol	Approved Drug	.	.	Estradiol induces the activity of SLC12A2	.	.
DTD0083	SLC12A2	Inhibition	Estriol	Drug Marketed but not Approved by US FDA	.	.	Estriol inhibits the expression of SLC12A2	.	.
DTD0083	SLC12A2	Inhibition	Estrone	Approved Drug	.	.	Estrone inhibits the expression of SLC12A2	.	.
DTD0083	SLC12A2	Inhibition	Ethacrynic Acid	Approved Drug	.	.	Ethacrynic Acid inhibits the activity of SLC12A2	.	.
DTD0083	SLC12A2	Inhibition	Ethyl Methanesulfonate	Carcinogen	.	.	Ethyl Methanesulfonate inhibits the expression of SLC12A2	.	.
DTD0083	SLC12A2	Inducer	Fasudil	Drug in Phase 1 Trial	.	.	Fasudil increases the expression of SLC12A2	.	.
DTD0083	SLC12A2	Inhibition	Furosemide	Approved Drug	.	.	Furosemide inhibits the activity of SLC12A2	.	.
DTD0083	SLC12A2	Inducer	Gallic Acid	Natural Product	.	.	Gallic Acid increases the expression of SLC12A2	.	.
DTD0083	SLC12A2	Inhibition	Genistein	Drug in Phase 2 Trial	.	.	Genistein inhibits the expression of SLC12A2	.	.
DTD0083	SLC12A2	Inhibition	Glyburide	Approved Drug	.	.	Glibenclamide inhibits the activity of SLC12A2	.	.
DTD0083	SLC12A2	Inhibition	Glycitein	Investigative Drug	.	.	Glycitein inhibits the expression of SLC12A2	.	.
DTD0083	SLC12A2	Modulator	Hydrogen Peroxide	Approved Drug	.	.	Hydrogen Peroxide affects the expression of SLC12A2	.	.
DTD0083	SLC12A2	Inhibition	Ivermectin	Approved Drug	.	.	Ivermectin inhibits the expression of SLC12A2	.	.
DTD0083	SLC12A2	Inhibition	Jinfukang	Traditional Medicine	.	.	Jinfukang inhibits the expression of SLC12A2	.	.
DTD0083	SLC12A2	Inhibition	Kanamycin	Approved Drug	.	.	Kanamycin inhibits the activity of SLC12A2	.	.
DTD0083	SLC12A2	Inducer	Methoxamine	Approved Drug	.	.	Methoxamine induces the activity of SLC12A2	.	.
DTD0083	SLC12A2	Inducer	Nickel chloride	Acute Toxic Substance	.	.	Nickel chloride increases the expression of SLC12A2	.	.
DTD0083	SLC12A2	Inhibition	Nitric oxide	Drug in Preclinical Test	.	.	Nitric oxide inhibits the activity of SLC12A2	.	.
DTD0083	SLC12A2	Inhibition	Nitroprusside	Approved Drug	.	.	Nitroprusside inhibits the activity of SLC12A2	.	.
DTD0083	SLC12A2	Inducer	Oxytocin	Approved Drug	.	.	Oxytocin induces the activity of SLC12A2	.	.
DTD0083	SLC12A2	Inhibition	Particulate Matter	Natural Product	.	.	Particulate Matter inhibits the expression of SLC12A2	.	.
DTD0083	SLC12A2	Inducer	Phenylephrine	Approved Drug	.	.	Phenylephrine induces the activity of SLC12A2	.	.
DTD0083	SLC12A2	Inducer	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin increases the expression of SLC12A2	.	.
DTD0083	SLC12A2	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of SLC12A2	.	.
DTD0083	SLC12A2	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of SLC12A2	.	.
DTD0083	SLC12A2	Inducer	Thimerosal	Acute Toxic Substance	.	.	Thimerosal increases the expression of SLC12A2	.	.
DTD0083	SLC12A2	Inhibition	Ticrynafen	Drug Withdrawn	.	.	Ticrynafen inhibits the activity of SLC12A2	.	.
DTD0083	SLC12A2	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC12A2	.	.
DTD0083	SLC12A2	Inhibition	Torasemide	Approved Drug	.	.	Torasemide inhibits the activity of SLC12A2	.	.
DTD0083	SLC12A2	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC12A2	.	.
DTD0083	SLC12A2	Inhibition	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate inhibits the expression of SLC12A2	.	.
DTD0083	SLC12A2	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC12A2	.	.
DTD0083	SLC12A2	Inhibition	Verteporfin	Approved Drug	.	.	Verteporfin inhibits the activity of SLC12A2	.	.
DTD0083	SLC12A2	Inhibition	Vitamin E	Drug in Phase 3 Trial	.	.	Vitamin E inhibits the expression of SLC12A2	.	.
DTD0084	SLC12A3	Blocker	Bendroflumethiazide	Approved Drug	.	.	Bendroflumethiazide blocks the activity of SLC12A3	.	.
DTD0084	SLC12A3	Inducer	Coal Ash	Natural Product	.	.	Coal Ash increases the expression of SLC12A3	.	.
DTD0084	SLC12A3	Blocker	Metolazone	Approved Drug	.	.	Metolazone blocks the activity of SLC12A3	.	.
DTD0084	SLC12A3	Blocker	Polythiazide	Approved Drug	.	.	Polythiazide blocks the activity of SLC12A3	.	.
DTD0084	SLC12A3	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC12A3	.	.
DTD0084	SLC12A3	Inhibition	Sulforafan	Drug in Phase 3 Trial	.	.	Sulforafan inhibits the expression of SLC12A3	.	.
DTD0084	SLC12A3	Inhibition	Trichlormethiazide	Approved Drug	.	.	Trichlormethiazide inhibits the activity of SLC12A3	.	.
DTD0084	SLC12A3	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of SLC12A3	.	.
DTD0084	SLC12A3	Inhibition	Zidovudine	Approved Drug	.	.	Zidovudine inhibits the expression of SLC12A3	.	.
DTD0085	SLC12A4	Inducer	1-methyl-4-phenylpyridinium	Health and Environmental Toxicant	.	.	1-methyl-4-phenylpyridinium increases the expression of SLC12A4	.	.
DTD0085	SLC12A4	Inhibition	Acrylamide	Acute Toxic Substance	.	.	Acrylamide inhibits the expression of SLC12A4	.	.
DTD0085	SLC12A4	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of SLC12A4	.	.
DTD0085	SLC12A4	Inducer	Bisphenol B	Drug in Phase 2 Trial	.	.	Bisphenol B increases the expression of SLC12A4	.	.
DTD0085	SLC12A4	Inducer	Bisphenol F	Environmental toxicant	.	.	Bisphenol F increases the expression of SLC12A4	.	.
DTD0085	SLC12A4	Inducer	Coal Ash	Natural Product	.	.	Coal Ash increases the expression of SLC12A4	.	.
DTD0085	SLC12A4	Inducer	Coumestrol	Investigative Drug	.	.	Coumestrol increases the expression of SLC12A4	.	.
DTD0085	SLC12A4	Inducer	Dactinomycin	Approved Drug	.	.	Dactinomycin induces the activity of SLC12A4	.	.
DTD0085	SLC12A4	Inducer	Decitabine	Approved Drug	.	.	Decitabine increases the expression of SLC12A4	.	.
DTD0085	SLC12A4	Inducer	Doxorubicin	Approved Drug	.	.	Doxorubicin increases the expression of SLC12A4	.	.
DTD0085	SLC12A4	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC12A4	.	.
DTD0085	SLC12A4	Inhibition	Genistein	Drug in Phase 2 Trial	.	.	Genistein inhibits the expression of SLC12A4	.	.
DTD0085	SLC12A4	Inducer	K-7174	Patented Pharmaceutical Agent	.	.	K-7174 increases the expression of SLC12A4	.	.
DTD0085	SLC12A4	Modulator	Lead	Health and Environmental Toxicant	.	.	Lead affects the expression of SLC12A4	.	.
DTD0085	SLC12A4	Inducer	Leflunomide	Approved Drug	.	.	Leflunomide increases the expression of SLC12A4	.	.
DTD0085	SLC12A4	Inducer	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin increases the expression of SLC12A4	.	.
DTD0085	SLC12A4	Inducer	Resveratrol	Drug in Phase 3 Trial	.	.	Resveratrol increases the expression of SLC12A4	.	.
DTD0085	SLC12A4	Inducer	Rotenone	Drug Marketed but not Approved by US FDA	.	.	Rotenone increases the expression of SLC12A4	.	.
DTD0085	SLC12A4	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of SLC12A4	.	.
DTD0085	SLC12A4	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of SLC12A4	.	.
DTD0085	SLC12A4	Inducer	Zinc	Environmental toxicant	.	.	Zinc increases the expression of SLC12A4	.	.
DTD0086	SLC12A5	Inducer	AM-2282	Drug in Preclinical Test	.	.	AM-2282 increases the activity of SLC12A5	.	.
DTD0086	SLC12A5	Inhibition	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A inhibits the expression of SLC12A5	.	.
DTD0086	SLC12A5	Inhibition	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde inhibits the expression of SLC12A5	.	.
DTD0086	SLC12A5	Inhibition	Furosemide	Approved Drug	.	.	Furosemide inhibits the activity of SLC12A5	.	.
DTD0086	SLC12A5	Inhibition	Ivermectin	Approved Drug	.	.	Ivermectin inhibits the expression of SLC12A5	.	.
DTD0086	SLC12A5	Modulator	Lead	Health and Environmental Toxicant	.	.	Lead affects the expression of SLC12A5	.	.
DTD0086	SLC12A5	Inducer	N-ethylmaleimide	Investigative Drug	.	.	N-ethylmaleimide increases the activity of SLC12A5	.	.
DTD0086	SLC12A5	Inhibition	Reserpine	Approved Drug	.	.	Reserpine inhibits the activity of SLC12A5	.	.
DTD0087	SLC12A6	Inducer	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 increases the expression of SLC12A6	.	.
DTD0087	SLC12A6	Inducer	Avobenzone	Approved Drug	.	.	Avobenzone increases the expression of SLC12A6	.	.
DTD0087	SLC12A6	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC12A6	.	.
DTD0087	SLC12A6	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC12A6	.	.
DTD0087	SLC12A6	Inhibition	Cytarabine	Approved Drug	.	.	Cytarabine inhibits the expression of SLC12A6	.	.
DTD0087	SLC12A6	Inducer	Dimethyl nitrosamine	Carcinogen	.	.	Dimethyl nitrosamine increases the expression of SLC12A6	.	.
DTD0087	SLC12A6	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC12A6	.	.
DTD0087	SLC12A6	Inducer	Dronabinol	Approved Drug	.	.	Dronabinol increases the expression of SLC12A6	.	.
DTD0087	SLC12A6	Inducer	NSC-689534	Patented Pharmaceutical Agent	.	.	NSC-689534 increases the expression of SLC12A6	.	.
DTD0087	SLC12A6	Inducer	Phenol	Drug in Phase 2/3 Trial	.	.	Phenol increases the expression of SLC12A6	.	.
DTD0087	SLC12A6	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC12A6	.	.
DTD0087	SLC12A6	Inhibition	Testosterone	Approved Drug	.	.	Testosterone inhibits the expression of SLC12A6	.	.
DTD0087	SLC12A6	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC12A6	.	.
DTD0087	SLC12A6	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of SLC12A6	.	.
DTD0087	SLC12A6	Inducer	Urethane	Approved Drug	.	.	Urethane increases the expression of SLC12A6	.	.
DTD0088	SLC12A7	Inducer	1-methyl-4-phenylpyridinium	Health and Environmental Toxicant	.	.	1-methyl-4-phenylpyridinium increases the expression of SLC12A7	.	.
DTD0088	SLC12A7	Inducer	Coal Ash	Natural Product	.	.	Coal Ash increases the expression of SLC12A7	.	.
DTD0088	SLC12A7	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of SLC12A7	.	.
DTD0088	SLC12A7	Inducer	Jinfukang	Traditional Medicine	.	.	Jinfukang increases the expression of SLC12A7	.	.
DTD0088	SLC12A7	Inducer	K-7174	Patented Pharmaceutical Agent	.	.	K-7174 increases the expression of SLC12A7	.	.
DTD0088	SLC12A7	Inducer	Leflunomide	Approved Drug	.	.	Leflunomide increases the expression of SLC12A7	.	.
DTD0088	SLC12A7	Modulator	Menadione	Approved Drug	.	.	Menadione affects the expression of SLC12A7	.	.
DTD0088	SLC12A7	Inhibition	Methotrexate	Approved Drug	.	.	Methotrexate inhibits the expression of SLC12A7	.	.
DTD0088	SLC12A7	Inducer	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin increases the expression of SLC12A7	.	.
DTD0088	SLC12A7	Inducer	Rotenone	Drug Marketed but not Approved by US FDA	.	.	Rotenone increases the expression of SLC12A7	.	.
DTD0088	SLC12A7	Inducer	Sulforafan	Drug in Phase 3 Trial	.	.	Sulforafan increases the expression of SLC12A7	.	.
DTD0088	SLC12A7	Inhibition	Sunitinib	Approved Drug	.	.	Sunitinib inhibits the expression of SLC12A7	.	.
DTD0088	SLC12A7	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC12A7	.	.
DTD0088	SLC12A7	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC12A7	.	.
DTD0089	SLC12A8	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of SLC12A8	.	.
DTD0089	SLC12A8	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC12A8	.	.
DTD0089	SLC12A8	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC12A8	.	.
DTD0089	SLC12A8	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC12A8	.	.
DTD0089	SLC12A8	Modulator	Cidofovir	Approved Drug	.	.	Cidofovir affects the expression of SLC12A8	.	.
DTD0089	SLC12A8	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the expression of SLC12A8	.	.
DTD0089	SLC12A8	Inhibition	Clodronic Acid	Drug Marketed but not Approved by US FDA	.	.	Clodronic Acid inhibits the expression of SLC12A8	.	.
DTD0089	SLC12A8	Inhibition	Coumestrol	Investigative Drug	.	.	Coumestrol inhibits the expression of SLC12A8	.	.
DTD0089	SLC12A8	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of SLC12A8	.	.
DTD0089	SLC12A8	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC12A8	.	.
DTD0089	SLC12A8	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the expression of SLC12A8	.	.
DTD0089	SLC12A8	Inhibition	Gallic Acid	Natural Product	.	.	Gallic Acid inhibits the expression of SLC12A8	.	.
DTD0089	SLC12A8	Inhibition	GSK-J4	Patented Pharmaceutical Agent	.	.	GSK-J4 inhibits the expression of SLC12A8	.	.
DTD0089	SLC12A8	Inhibition	Hydrogen Peroxide	Approved Drug	.	.	Hydrogen Peroxide inhibits the expression of SLC12A8	.	.
DTD0089	SLC12A8	Inducer	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 increases the expression of SLC12A8	.	.
DTD0089	SLC12A8	Inhibition	Ifosfamide	Approved Drug	.	.	Ifosfamide inhibits the expression of SLC12A8	.	.
DTD0089	SLC12A8	Inducer	Jinfukang	Traditional Medicine	.	.	Jinfukang increases the expression of SLC12A8	.	.
DTD0089	SLC12A8	Inducer	MS-275	Drug in Phase 2 Trial	.	.	MS-275 increases the expression of SLC12A8	.	.
DTD0089	SLC12A8	Inducer	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite increases the expression of SLC12A8	.	.
DTD0089	SLC12A8	Inducer	Sulforafan	Drug in Phase 3 Trial	.	.	Sulforafan increases the expression of SLC12A8	.	.
DTD0089	SLC12A8	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of SLC12A8	.	.
DTD0089	SLC12A8	Inhibition	Temozolomide	Approved Drug	.	.	Temozolomide inhibits the expression of SLC12A8	.	.
DTD0089	SLC12A8	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC12A8	.	.
DTD0089	SLC12A8	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC12A8	.	.
DTD0091	SLC13A1	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of SLC13A1	.	.
DTD0091	SLC13A1	Inducer	Sulforafan	Drug in Phase 3 Trial	.	.	Sulforafan increases the expression of SLC13A1	.	.
DTD0091	SLC13A1	Inducer	Zinc	Environmental toxicant	.	.	Zinc increases the expression of SLC13A1	.	.
DTD0092	SLC13A2	Inhibition	Arbutin	Drug Marketed but not Approved by US FDA	.	.	Arbutin inhibits the expression of SLC13A2	.	.
DTD0092	SLC13A2	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC13A2	.	.
DTD0092	SLC13A2	Modulator	Estradiol	Approved Drug	.	.	Estradiol affects the expression of SLC13A2	.	.
DTD0092	SLC13A2	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC13A2	.	.
DTD0093	SLC13A3	Inducer	Arsenic	Approved Drug	.	.	Arsenic increases the expression of SLC13A3	.	.
DTD0093	SLC13A3	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC13A3	.	.
DTD0093	SLC13A3	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC13A3	.	.
DTD0093	SLC13A3	Modulator	Carbamazepine	Approved Drug	.	.	Carbamazepine affects the expression of SLC13A3	.	.
DTD0093	SLC13A3	Modulator	Cisplatin	Approved Drug	.	.	Cisplatin affects the expression of SLC13A3	.	.
DTD0093	SLC13A3	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC13A3	.	.
DTD0093	SLC13A3	Inhibition	Cupric chloride	Approved Drug	.	.	Cupric chloride inhibits the expression of SLC13A3	.	.
DTD0093	SLC13A3	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC13A3	.	.
DTD0093	SLC13A3	Modulator	Decitabine	Approved Drug	.	.	Decitabine affects the expression of SLC13A3	.	.
DTD0093	SLC13A3	Inhibition	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin inhibits the expression of SLC13A3	.	.
DTD0093	SLC13A3	Modulator	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin affects the expression of SLC13A3	.	.
DTD0093	SLC13A3	Inducer	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite increases the expression of SLC13A3	.	.
DTD0093	SLC13A3	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC13A3	.	.
DTD0093	SLC13A3	Inhibition	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate inhibits the expression of SLC13A3	.	.
DTD0093	SLC13A3	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC13A3	.	.
DTD0093	SLC13A3	Inducer	Vanadyl sulfate	Drug in Phase 3 Trial	.	.	Vanadyl sulfate increases the expression of SLC13A3	.	.
DTD0093	SLC13A3	Inhibition	Zidovudine	Approved Drug	.	.	Zidovudine inhibits the expression of SLC13A3	.	.
DTD0094	SLC13A4	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of SLC13A4	.	.
DTD0094	SLC13A4	Inducer	Amiodarone	Approved Drug	.	.	Amiodarone increases the expression of SLC13A4	.	.
DTD0094	SLC13A4	Inducer	Diethylhexyl Phthalate	Health and Environmental Toxicant	.	.	Diethylhexyl Phthalate increases the expression of SLC13A4	.	.
DTD0094	SLC13A4	Inducer	Exemestane	Approved Drug	.	.	Exemestane increases the expression of SLC13A4	.	.
DTD0094	SLC13A4	Inhibition	Milchsaure	Investigative Drug	.	.	Milchsaure inhibits the expression of SLC13A4	.	.
DTD0094	SLC13A4	Inducer	MS-275	Drug in Phase 2 Trial	.	.	MS-275 increases the expression of SLC13A4	.	.
DTD0094	SLC13A4	Inducer	Phenylmercuric Acetate	Investigative Drug	.	.	Phenylmercuric Acetate increases the expression of SLC13A4	.	.
DTD0094	SLC13A4	Inhibition	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate inhibits the expression of SLC13A4	.	.
DTD0094	SLC13A4	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC13A4	.	.
DTD0095	SLC13A5	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC13A5	.	.
DTD0095	SLC13A5	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC13A5	.	.
DTD0095	SLC13A5	Modulator	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A affects the expression of SLC13A5	.	.
DTD0095	SLC13A5	Inducer	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde increases the expression of SLC13A5	.	.
DTD0095	SLC13A5	Modulator	Cisplatin	Approved Drug	.	.	Cisplatin affects the expression of SLC13A5	.	.
DTD0095	SLC13A5	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC13A5	.	.
DTD0095	SLC13A5	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC13A5	.	.
DTD0095	SLC13A5	Modulator	Decitabine	Approved Drug	.	.	Decitabine affects the expression of SLC13A5	.	.
DTD0095	SLC13A5	Inhibition	K-7174	Patented Pharmaceutical Agent	.	.	K-7174 inhibits the expression of SLC13A5	.	.
DTD0095	SLC13A5	Inhibition	Milchsaure	Investigative Drug	.	.	Milchsaure inhibits the expression of SLC13A5	.	.
DTD0095	SLC13A5	Inhibition	Obeticholic acid	Approved Drug	.	.	Obeticholic acid inhibits the expression of SLC13A5	.	.
DTD0095	SLC13A5	Inducer	Particulate Matter	Natural Product	.	.	Particulate Matter increases the expression of SLC13A5	.	.
DTD0095	SLC13A5	Inducer	Pentanal	Chemical Compound	.	.	Pentanal increases the expression of SLC13A5	.	.
DTD0095	SLC13A5	Modulator	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin affects the expression of SLC13A5	.	.
DTD0095	SLC13A5	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of SLC13A5	.	.
DTD0095	SLC13A5	Inducer	Rifampin	Approved Drug	.	.	Rifampin increases the expression of SLC13A5	.	.
DTD0095	SLC13A5	Inhibition	Testosterone	Approved Drug	.	.	Testosterone inhibits the expression of SLC13A5	.	.
DTD0095	SLC13A5	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC13A5	.	.
DTD0095	SLC13A5	Inhibition	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan inhibits the expression of SLC13A5	.	.
DTD0095	SLC13A5	Inhibition	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate inhibits the expression of SLC13A5	.	.
DTD0095	SLC13A5	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC13A5	.	.
DTD0095	SLC13A5	Inhibition	Zidovudine	Approved Drug	.	.	Zidovudine inhibits the expression of SLC13A5	.	.
DTD0096	SLC14A1	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of SLC14A1	.	.
DTD0096	SLC14A1	Inducer	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 increases the expression of SLC14A1	.	.
DTD0096	SLC14A1	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC14A1	.	.
DTD0096	SLC14A1	Inhibition	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A inhibits the expression of SLC14A1	.	.
DTD0096	SLC14A1	Inducer	Cinnamic aldehyde	Natural Product	.	.	Cinnamic aldehyde increases the expression of SLC14A1	.	.
DTD0096	SLC14A1	Inhibition	Clothianidin	Pesticide/Insecticide	.	.	Clothianidin inhibits the expression of SLC14A1	.	.
DTD0096	SLC14A1	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC14A1	.	.
DTD0096	SLC14A1	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the expression of SLC14A1	.	.
DTD0096	SLC14A1	Inducer	GSK-J4	Patented Pharmaceutical Agent	.	.	GSK-J4 increases the expression of SLC14A1	.	.
DTD0096	SLC14A1	Inhibition	Malathion	Approved Drug	.	.	Malathion inhibits the expression of SLC14A1	.	.
DTD0096	SLC14A1	Inhibition	Mancozeb	Fungicide	.	.	Mancozeb inhibits the expression of SLC14A1	.	.
DTD0096	SLC14A1	Inhibition	Melphalan	Approved Drug	.	.	Melphalan inhibits the expression of SLC14A1	.	.
DTD0096	SLC14A1	Inducer	Pentanal	Chemical Compound	.	.	Pentanal increases the expression of SLC14A1	.	.
DTD0096	SLC14A1	Inhibition	Permethrin	Approved Drug	.	.	Permethrin inhibits the expression of SLC14A1	.	.
DTD0096	SLC14A1	Inhibition	Phenobarbital	Approved Drug	.	.	Phenobarbital inhibits the expression of SLC14A1	.	.
DTD0096	SLC14A1	Inducer	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin increases the expression of SLC14A1	.	.
DTD0096	SLC14A1	Inhibition	Progesterone	Approved Drug	.	.	Progesterone inhibits the expression of SLC14A1	.	.
DTD0096	SLC14A1	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC14A1	.	.
DTD0096	SLC14A1	Inhibition	Testosterone	Approved Drug	.	.	Testosterone inhibits the expression of SLC14A1	.	.
DTD0096	SLC14A1	Inhibition	Zoledronic Acid	Approved Drug	.	.	Zoledronic Acid inhibits the expression of SLC14A1	.	.
DTD0097	SLC14A2	Inducer	Amiodarone	Approved Drug	.	.	Amiodarone increases the expression of SLC14A2	.	.
DTD0097	SLC14A2	Inducer	Arsenic Trioxide	Approved Drug	.	.	Arsenic Trioxide increases the expression of SLC14A2	.	.
DTD0097	SLC14A2	Inducer	Atrazine	Herbicide	.	.	Atrazine increases the expression of SLC14A2	.	.
DTD0097	SLC14A2	Inhibition	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A inhibits the expression of SLC14A2	.	.
DTD0097	SLC14A2	Inhibition	Coal Ash	Natural Product	.	.	Coal Ash inhibits the expression of SLC14A2	.	.
DTD0097	SLC14A2	Inducer	Zinc	Environmental toxicant	.	.	Zinc increases the expression of SLC14A2	.	.
DTD0098	SLC15A3	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of SLC15A3	.	.
DTD0098	SLC15A3	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC15A3	.	.
DTD0098	SLC15A3	Inhibition	Arbutin	Drug Marketed but not Approved by US FDA	.	.	Arbutin inhibits the expression of SLC15A3	.	.
DTD0098	SLC15A3	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of SLC15A3	.	.
DTD0098	SLC15A3	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC15A3	.	.
DTD0098	SLC15A3	Inhibition	Dronabinol	Approved Drug	.	.	Dronabinol inhibits the expression of SLC15A3	.	.
DTD0098	SLC15A3	Inducer	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 increases the expression of SLC15A3	.	.
DTD0098	SLC15A3	Inducer	Temozolomide	Approved Drug	.	.	Temozolomide increases the expression of SLC15A3	.	.
DTD0098	SLC15A3	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC15A3	.	.
DTD0098	SLC15A3	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of SLC15A3	.	.
DTD0098	SLC15A3	Modulator	Valproic Acid	Approved Drug	.	.	Valproic Acid affects the expression of SLC15A3	.	.
DTD0099	SLC15A4	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of SLC15A4	.	.
DTD0099	SLC15A4	Inhibition	Cacodylic Acid	Acute Toxic Substance	.	.	Cacodylic Acid inhibits the expression of SLC15A4	.	.
DTD0099	SLC15A4	Inducer	Cadmium	Acute Toxic Substance	.	.	Cadmium increases the expression of SLC15A4	.	.
DTD0099	SLC15A4	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC15A4	.	.
DTD0099	SLC15A4	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of SLC15A4	.	.
DTD0099	SLC15A4	Inhibition	Demecolcine	Drug Marketed but not Approved by US FDA	.	.	Demecolcine inhibits the expression of SLC15A4	.	.
DTD0099	SLC15A4	Modulator	Menadione	Approved Drug	.	.	Menadione affects the expression of SLC15A4	.	.
DTD0099	SLC15A4	Modulator	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite affects the expression of SLC15A4	.	.
DTD0099	SLC15A4	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC15A4	.	.
DTD0099	SLC15A4	Inhibition	Vincristine	Approved Drug	.	.	Vincristine inhibits the expression of SLC15A4	.	.
DTD0100	SLC16A1	Inhibition	4-oxoretinoic acid	Natural Product	.	.	4-oxoretinoic acid inhibits the expression of SLC16A1	.	.
DTD0100	SLC16A1	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of SLC16A1	.	.
DTD0100	SLC16A1	Inhibition	Alitretinoin	Approved Drug	.	.	Alitretinoin inhibits the expression of SLC16A1	.	.
DTD0100	SLC16A1	Modulator	AM-80	Drug in Phase 2/3 Trial	.	.	AM-80 affects the expression of SLC16A1	.	.
DTD0100	SLC16A1	Inhibition	Aspirin	Approved Drug	.	.	Aspirin inhibits the expression of SLC16A1	.	.
DTD0100	SLC16A1	Inhibition	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A inhibits the expression of SLC16A1	.	.
DTD0100	SLC16A1	Inducer	Bisphenol B	Drug in Phase 2 Trial	.	.	Bisphenol B increases the expression of SLC16A1	.	.
DTD0100	SLC16A1	Inducer	Cadmium	Acute Toxic Substance	.	.	Cadmium increases the expression of SLC16A1	.	.
DTD0100	SLC16A1	Inducer	Caffeine	Approved Drug	.	.	Caffeine increases the expression of SLC16A1	.	.
DTD0100	SLC16A1	Inducer	CCRIS-9277	Drug in Phase 1 Trial	.	.	CCRIS-9277 increases the expression of SLC16A1	.	.
DTD0100	SLC16A1	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC16A1	.	.
DTD0100	SLC16A1	Inducer	Decitabine	Approved Drug	.	.	Decitabine increases the expression of SLC16A1	.	.
DTD0100	SLC16A1	Inducer	Doxorubicin	Approved Drug	.	.	Doxorubicin increases the expression of SLC16A1	.	.
DTD0100	SLC16A1	Inducer	Dronabinol	Approved Drug	.	.	Dronabinol increases the expression of SLC16A1	.	.
DTD0100	SLC16A1	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC16A1	.	.
DTD0100	SLC16A1	Inhibition	Ethyl Methanesulfonate	Carcinogen	.	.	Ethyl Methanesulfonate inhibits the expression of SLC16A1	.	.
DTD0100	SLC16A1	Inhibition	Fluorouracil	Approved Drug	.	.	Fluorouracil inhibits the expression of SLC16A1	.	.
DTD0100	SLC16A1	Inhibition	Folic Acid	Approved Drug	.	.	Folic Acid inhibits the expression of SLC16A1	.	.
DTD0100	SLC16A1	Inhibition	Formaldehyde	Acute Toxic Substance	.	.	Formaldehyde inhibits the expression of SLC16A1	.	.
DTD0100	SLC16A1	Inducer	Geldanamycin	Drug in Phase 1 Trial	.	.	Geldanamycin increases the expression of SLC16A1	.	.
DTD0100	SLC16A1	Inducer	Genistein	Drug in Phase 2 Trial	.	.	Genistein increases the expression of SLC16A1	.	.
DTD0100	SLC16A1	Modulator	Hydrogen Peroxide	Approved Drug	.	.	Hydrogen Peroxide affects the expression of SLC16A1	.	.
DTD0100	SLC16A1	Inhibition	Indomethacin	Approved Drug	.	.	Indomethacin inhibits the expression of SLC16A1	.	.
DTD0100	SLC16A1	Inhibition	Irbesartan	Approved Drug	.	.	Irbesartan inhibits the activity of SLC16A1	.	.
DTD0100	SLC16A1	Inhibition	Isotretinoin	Approved Drug	.	.	Isotretinoin inhibits the expression of SLC16A1	.	.
DTD0100	SLC16A1	Inhibition	Ivermectin	Approved Drug	.	.	Ivermectin inhibits the expression of SLC16A1	.	.
DTD0100	SLC16A1	Inducer	Ketogenic diet	Dietary Constituent	.	.	Ketogenic diet induces the activity of SLC16A1	.	.
DTD0100	SLC16A1	Inhibition	Mersalyl	Investigative Drug	.	.	Mersalyl inhibits the activity of SLC16A1	.	.
DTD0100	SLC16A1	Inducer	Motexafin gadolinium	Drug in Phase 2 Trial	.	.	Motexafin gadolinium increases the expression of SLC16A1	.	.
DTD0100	SLC16A1	Inducer	MS-275	Drug in Phase 2 Trial	.	.	MS-275 increases the expression of SLC16A1	.	.
DTD0100	SLC16A1	Inhibition	Nateglinide	Approved Drug	.	.	Nateglinide inhibits the activity of SLC16A1	.	.
DTD0100	SLC16A1	Inducer	Nicotine polacrilex	Approved Drug	.	.	Nicotine induces the activity of SLC16A1	.	.
DTD0100	SLC16A1	Inhibition	Niflumic Acid	Approved Drug	.	.	Niflumic acid inhibits the activity of SLC16A1	.	.
DTD0100	SLC16A1	Inducer	Nitric oxide	Drug in Preclinical Test	.	.	Nitric oxide induces the activity of SLC16A1	.	.
DTD0100	SLC16A1	Inducer	Panobinostat	Approved Drug	.	.	Panobinostat increases the expression of SLC16A1	.	.
DTD0100	SLC16A1	Inducer	Piroxicam	Approved Drug	.	.	Piroxicam increases the expression of SLC16A1	.	.
DTD0100	SLC16A1	Inducer	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin increases the expression of SLC16A1	.	.
DTD0100	SLC16A1	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC16A1	.	.
DTD0100	SLC16A1	Inhibition	Sunitinib	Approved Drug	.	.	Sunitinib inhibits the expression of SLC16A1	.	.
DTD0100	SLC16A1	Inducer	Testosterone	Approved Drug	.	.	Testosterone induces the activity of SLC16A1	.	.
DTD0100	SLC16A1	Inhibition	Thimerosal	Acute Toxic Substance	.	.	Thimerosal inhibits the expression of SLC16A1	.	.
DTD0100	SLC16A1	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC16A1	.	.
DTD0100	SLC16A1	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC16A1	.	.
DTD0100	SLC16A1	Inducer	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A increases the expression of SLC16A1	.	.
DTD0100	SLC16A1	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC16A1	.	.
DTD0100	SLC16A1	Inhibition	Zidovudine	Approved Drug	.	.	Zidovudine inhibits the expression of SLC16A1	.	.
DTD0100	SLC16A1	Inducer	Zinc Acetate	Approved Drug	.	.	Zinc Acetate increases the expression of SLC16A1	.	.
DTD0100	SLC16A1	Inducer	Zoledronic Acid	Approved Drug	.	.	Zoledronic Acid increases the expression of SLC16A1	.	.
DTD0101	SLC16A10	Inducer	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 increases the expression of SLC16A10	.	.
DTD0101	SLC16A10	Inducer	2-methyl-4-isothiazolin-3-one	Acute Toxic Substance	.	.	2-methyl-4-isothiazolin-3-one increases the expression of SLC16A10	.	.
DTD0101	SLC16A10	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC16A10	.	.
DTD0101	SLC16A10	Inhibition	Azathioprine	Approved Drug	.	.	Azathioprine inhibits the expression of SLC16A10	.	.
DTD0101	SLC16A10	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC16A10	.	.
DTD0101	SLC16A10	Inhibition	Beta-naphthoflavone	Investigative Drug	.	.	Beta-naphthoflavone inhibits the expression of SLC16A10	.	.
DTD0101	SLC16A10	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC16A10	.	.
DTD0101	SLC16A10	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC16A10	.	.
DTD0101	SLC16A10	Inhibition	Dicrotophos	Pesticide/Insecticide	.	.	Dicrotophos inhibits the expression of SLC16A10	.	.
DTD0101	SLC16A10	Inducer	Dinitrochlorobenzene	Drug in Phase 1 Trial	.	.	Dinitrochlorobenzene increases the expression of SLC16A10	.	.
DTD0101	SLC16A10	Inducer	Doxorubicin	Approved Drug	.	.	Doxorubicin increases the expression of SLC16A10	.	.
DTD0101	SLC16A10	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the expression of SLC16A10	.	.
DTD0101	SLC16A10	Inducer	Eugenol	Patented Pharmaceutical Agent	.	.	Eugenol increases the expression of SLC16A10	.	.
DTD0101	SLC16A10	Inducer	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 increases the expression of SLC16A10	.	.
DTD0101	SLC16A10	Inducer	MS-275	Drug in Phase 2 Trial	.	.	MS-275 increases the expression of SLC16A10	.	.
DTD0101	SLC16A10	Inhibition	Particulate Matter	Natural Product	.	.	Particulate Matter inhibits the expression of SLC16A10	.	.
DTD0101	SLC16A10	Inducer	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin increases the expression of SLC16A10	.	.
DTD0101	SLC16A10	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of SLC16A10	.	.
DTD0101	SLC16A10	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC16A10	.	.
DTD0101	SLC16A10	Inhibition	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A inhibits the expression of SLC16A10	.	.
DTD0101	SLC16A10	Inhibition	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan inhibits the expression of SLC16A10	.	.
DTD0101	SLC16A10	Inducer	Urethane	Approved Drug	.	.	Urethane increases the expression of SLC16A10	.	.
DTD0101	SLC16A10	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC16A10	.	.
DTD0101	SLC16A10	Inducer	Vorinostat	Approved Drug	.	.	Vorinostat increases the expression of SLC16A10	.	.
DTD0101	SLC16A10	Inducer	Zoledronic Acid	Approved Drug	.	.	Zoledronic Acid increases the expression of SLC16A10	.	.
DTD0102	SLC16A11	Inhibition	GSK-J4	Patented Pharmaceutical Agent	.	.	GSK-J4 inhibits the expression of SLC16A11	.	.
DTD0102	SLC16A11	Inhibition	Potassium perchlorate	Approved Drug	.	.	Potassium perchlorate inhibits the expression of SLC16A11	.	.
DTD0102	SLC16A11	Inhibition	Tebuconazole	Fungicide	.	.	Tebuconazole inhibits the expression of SLC16A11	.	.
DTD0102	SLC16A11	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC16A11	.	.
DTD0102	SLC16A11	Inducer	Urethane	Approved Drug	.	.	Urethane increases the expression of SLC16A11	.	.
DTD0102	SLC16A11	Modulator	Valproic Acid	Approved Drug	.	.	Valproic Acid affects the expression of SLC16A11	.	.
DTD0103	SLC16A12	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of SLC16A12	.	.
DTD0103	SLC16A12	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC16A12	.	.
DTD0103	SLC16A12	Inhibition	Bilirubin	Natural Product	.	.	Bilirubin inhibits the expression of SLC16A12	.	.
DTD0103	SLC16A12	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC16A12	.	.
DTD0103	SLC16A12	Inhibition	Cadmium	Acute Toxic Substance	.	.	Cadmium inhibits the expression of SLC16A12	.	.
DTD0103	SLC16A12	Inducer	Chloropicrin	Acute Toxic Substance	.	.	Chloropicrin increases the expression of SLC16A12	.	.
DTD0103	SLC16A12	Inducer	Cisplatin	Approved Drug	.	.	Cisplatin increases the expression of SLC16A12	.	.
DTD0103	SLC16A12	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC16A12	.	.
DTD0103	SLC16A12	Modulator	Hydrogen Peroxide	Approved Drug	.	.	Hydrogen Peroxide affects the expression of SLC16A12	.	.
DTD0103	SLC16A12	Inducer	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 increases the expression of SLC16A12	.	.
DTD0103	SLC16A12	Inhibition	Methyleugenol	Natural Product	.	.	Methyleugenol inhibits the expression of SLC16A12	.	.
DTD0103	SLC16A12	Inhibition	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin inhibits the expression of SLC16A12	.	.
DTD0103	SLC16A12	Inhibition	Rifampin	Approved Drug	.	.	Rifampin inhibits the expression of SLC16A12	.	.
DTD0103	SLC16A12	Inducer	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite increases the expression of SLC16A12	.	.
DTD0103	SLC16A12	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC16A12	.	.
DTD0103	SLC16A12	Inhibition	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan inhibits the expression of SLC16A12	.	.
DTD0104	SLC16A13	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC16A13	.	.
DTD0104	SLC16A13	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC16A13	.	.
DTD0104	SLC16A13	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC16A13	.	.
DTD0104	SLC16A13	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC16A13	.	.
DTD0104	SLC16A13	Inducer	Fenofibrate	Approved Drug	.	.	Fenofibrate increases the expression of SLC16A13	.	.
DTD0104	SLC16A13	Inducer	Jinfukang	Traditional Medicine	.	.	Jinfukang increases the expression of SLC16A13	.	.
DTD0104	SLC16A13	Inhibition	Quercitrin	Natural Product	.	.	Quercitrin inhibits the expression of SLC16A13	.	.
DTD0104	SLC16A13	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of SLC16A13	.	.
DTD0104	SLC16A13	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC16A13	.	.
DTD0104	SLC16A13	Inhibition	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate inhibits the expression of SLC16A13	.	.
DTD0105	SLC16A14	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of SLC16A14	.	.
DTD0105	SLC16A14	Inducer	1-methyl-4-phenylpyridinium	Health and Environmental Toxicant	.	.	1-methyl-4-phenylpyridinium increases the expression of SLC16A14	.	.
DTD0105	SLC16A14	Inhibition	Belinostat	Approved Drug	.	.	Belinostat inhibits the expression of SLC16A14	.	.
DTD0105	SLC16A14	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC16A14	.	.
DTD0105	SLC16A14	Inhibition	Calcitriol	Approved Drug	.	.	Calcitriol inhibits the expression of SLC16A14	.	.
DTD0105	SLC16A14	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC16A14	.	.
DTD0105	SLC16A14	Inhibition	Demecolcine	Drug Marketed but not Approved by US FDA	.	.	Demecolcine inhibits the expression of SLC16A14	.	.
DTD0105	SLC16A14	Inhibition	Diethylhexyl Phthalate	Health and Environmental Toxicant	.	.	Diethylhexyl Phthalate inhibits the expression of SLC16A14	.	.
DTD0105	SLC16A14	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC16A14	.	.
DTD0105	SLC16A14	Inducer	Ethanol	Drug in Phase 2 Trial	.	.	Ethanol increases the expression of SLC16A14	.	.
DTD0105	SLC16A14	Inhibition	Ethyl Methanesulfonate	Carcinogen	.	.	Ethyl Methanesulfonate inhibits the expression of SLC16A14	.	.
DTD0105	SLC16A14	Inhibition	Formaldehyde	Acute Toxic Substance	.	.	Formaldehyde inhibits the expression of SLC16A14	.	.
DTD0105	SLC16A14	Inducer	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 increases the expression of SLC16A14	.	.
DTD0105	SLC16A14	Inducer	Leflunomide	Approved Drug	.	.	Leflunomide increases the expression of SLC16A14	.	.
DTD0105	SLC16A14	Inhibition	MS-275	Drug in Phase 2 Trial	.	.	MS-275 inhibits the expression of SLC16A14	.	.
DTD0105	SLC16A14	Inhibition	Panobinostat	Approved Drug	.	.	Panobinostat inhibits the expression of SLC16A14	.	.
DTD0105	SLC16A14	Inducer	Particulate Matter	Natural Product	.	.	Particulate Matter increases the expression of SLC16A14	.	.
DTD0105	SLC16A14	Inhibition	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin inhibits the expression of SLC16A14	.	.
DTD0105	SLC16A14	Inducer	Rotenone	Drug Marketed but not Approved by US FDA	.	.	Rotenone increases the expression of SLC16A14	.	.
DTD0105	SLC16A14	Inducer	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite increases the expression of SLC16A14	.	.
DTD0105	SLC16A14	Inducer	Sulforafan	Drug in Phase 3 Trial	.	.	Sulforafan increases the expression of SLC16A14	.	.
DTD0105	SLC16A14	Inhibition	Sunitinib	Approved Drug	.	.	Sunitinib inhibits the expression of SLC16A14	.	.
DTD0105	SLC16A14	Inhibition	Temozolomide	Approved Drug	.	.	Temozolomide inhibits the expression of SLC16A14	.	.
DTD0105	SLC16A14	Inhibition	Testosterone	Approved Drug	.	.	Testosterone inhibits the expression of SLC16A14	.	.
DTD0105	SLC16A14	Inducer	Thimerosal	Acute Toxic Substance	.	.	Thimerosal increases the expression of SLC16A14	.	.
DTD0105	SLC16A14	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC16A14	.	.
DTD0105	SLC16A14	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC16A14	.	.
DTD0105	SLC16A14	Inhibition	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A inhibits the expression of SLC16A14	.	.
DTD0105	SLC16A14	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC16A14	.	.
DTD0105	SLC16A14	Inhibition	Vincristine	Approved Drug	.	.	Vincristine inhibits the expression of SLC16A14	.	.
DTD0105	SLC16A14	Inhibition	Zoledronic Acid	Approved Drug	.	.	Zoledronic Acid inhibits the expression of SLC16A14	.	.
DTD0106	SLC16A2	Inhibition	Acrylamide	Acute Toxic Substance	.	.	Acrylamide inhibits the expression of SLC16A2	.	.
DTD0106	SLC16A2	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC16A2	.	.
DTD0106	SLC16A2	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC16A2	.	.
DTD0106	SLC16A2	Inducer	Carbamazepine	Approved Drug	.	.	Carbamazepine increases the expression of SLC16A2	.	.
DTD0106	SLC16A2	Inducer	Carmustine	Approved Drug	.	.	Carmustine increases the expression of SLC16A2	.	.
DTD0106	SLC16A2	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC16A2	.	.
DTD0106	SLC16A2	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC16A2	.	.
DTD0106	SLC16A2	Inducer	Dronabinol	Approved Drug	.	.	Dronabinol increases the expression of SLC16A2	.	.
DTD0106	SLC16A2	Inhibition	Fipronil	Acute Toxic Substance	.	.	Fipronil inhibits the expression of SLC16A2	.	.
DTD0106	SLC16A2	Inhibition	Methyleugenol	Natural Product	.	.	Methyleugenol inhibits the expression of SLC16A2	.	.
DTD0106	SLC16A2	Modulator	Phenobarbital	Approved Drug	.	.	Phenobarbital affects the expression of SLC16A2	.	.
DTD0106	SLC16A2	Inhibition	Phenylmercuric Acetate	Investigative Drug	.	.	Phenylmercuric Acetate inhibits the expression of SLC16A2	.	.
DTD0106	SLC16A2	Inducer	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite increases the expression of SLC16A2	.	.
DTD0106	SLC16A2	Inhibition	Sunitinib	Approved Drug	.	.	Sunitinib inhibits the expression of SLC16A2	.	.
DTD0106	SLC16A2	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC16A2	.	.
DTD0106	SLC16A2	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC16A2	.	.
DTD0106	SLC16A2	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC16A2	.	.
DTD0106	SLC16A2	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of SLC16A2	.	.
DTD0107	SLC16A3	Inducer	1-methyl-4-phenylpyridinium	Health and Environmental Toxicant	.	.	1-methyl-4-phenylpyridinium increases the expression of SLC16A3	.	.
DTD0107	SLC16A3	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC16A3	.	.
DTD0107	SLC16A3	Inhibition	Acrylamide	Acute Toxic Substance	.	.	Acrylamide inhibits the expression of SLC16A3	.	.
DTD0107	SLC16A3	Inducer	AM-80	Drug in Phase 2/3 Trial	.	.	AM-80 increases the expression of SLC16A3	.	.
DTD0107	SLC16A3	Inducer	Atrazine	Herbicide	.	.	Atrazine increases the expression of SLC16A3	.	.
DTD0107	SLC16A3	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC16A3	.	.
DTD0107	SLC16A3	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC16A3	.	.
DTD0107	SLC16A3	Inhibition	Chloropicrin	Acute Toxic Substance	.	.	Chloropicrin inhibits the expression of SLC16A3	.	.
DTD0107	SLC16A3	Modulator	Cisplatin	Approved Drug	.	.	Cisplatin affects the expression of SLC16A3	.	.
DTD0107	SLC16A3	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC16A3	.	.
DTD0107	SLC16A3	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of SLC16A3	.	.
DTD0107	SLC16A3	Inhibition	Cytarabine	Approved Drug	.	.	Cytarabine inhibits the expression of SLC16A3	.	.
DTD0107	SLC16A3	Inducer	Decitabine	Approved Drug	.	.	Decitabine increases the expression of SLC16A3	.	.
DTD0107	SLC16A3	Inducer	Diethylhexyl Phthalate	Health and Environmental Toxicant	.	.	Diethylhexyl Phthalate increases the expression of SLC16A3	.	.
DTD0107	SLC16A3	Inducer	Dinophysistoxin 1	Biotoxin	.	.	Dinophysistoxin 1 increases the expression of SLC16A3	.	.
DTD0107	SLC16A3	Modulator	Doxorubicin	Approved Drug	.	.	Doxorubicin affects the expression of SLC16A3	.	.
DTD0107	SLC16A3	Inhibition	Dronabinol	Approved Drug	.	.	Dronabinol inhibits the expression of SLC16A3	.	.
DTD0107	SLC16A3	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the expression of SLC16A3	.	.
DTD0107	SLC16A3	Inducer	Genistein	Drug in Phase 2 Trial	.	.	Genistein increases the expression of SLC16A3	.	.
DTD0107	SLC16A3	Modulator	Hydrogen Peroxide	Approved Drug	.	.	Hydrogen Peroxide affects the expression of SLC16A3	.	.
DTD0107	SLC16A3	Inhibition	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 inhibits the expression of SLC16A3	.	.
DTD0107	SLC16A3	Inhibition	Irbesartan	Approved Drug	.	.	Irbesartan inhibits the activity of SLC16A3	.	.
DTD0107	SLC16A3	Inhibition	Ivermectin	Approved Drug	.	.	Ivermectin inhibits the expression of SLC16A3	.	.
DTD0107	SLC16A3	Inducer	Jinfukang	Traditional Medicine	.	.	Jinfukang increases the expression of SLC16A3	.	.
DTD0107	SLC16A3	Inducer	Liothyronine	Approved Drug	.	.	Liothyronine increases the expression of SLC16A3	.	.
DTD0107	SLC16A3	Inducer	Manganese	Investigative Drug	.	.	Manganese increases the expression of SLC16A3	.	.
DTD0107	SLC16A3	Inducer	Manganese chloride	Approved Drug	.	.	Manganese chloride increases the expression of SLC16A3	.	.
DTD0107	SLC16A3	Modulator	Menadione	Approved Drug	.	.	Menadione affects the expression of SLC16A3	.	.
DTD0107	SLC16A3	Inducer	MS-275	Drug in Phase 2 Trial	.	.	MS-275 increases the expression of SLC16A3	.	.
DTD0107	SLC16A3	Inducer	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin increases the expression of SLC16A3	.	.
DTD0107	SLC16A3	Inducer	Temozolomide	Approved Drug	.	.	Temozolomide increases the expression of SLC16A3	.	.
DTD0107	SLC16A3	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC16A3	.	.
DTD0107	SLC16A3	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of SLC16A3	.	.
DTD0107	SLC16A3	Inducer	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A increases the expression of SLC16A3	.	.
DTD0107	SLC16A3	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC16A3	.	.
DTD0107	SLC16A3	Inhibition	Zidovudine	Approved Drug	.	.	Zidovudine inhibits the expression of SLC16A3	.	.
DTD0109	SLC16A5	Inducer	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 increases the expression of SLC16A5	.	.
DTD0109	SLC16A5	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of SLC16A5	.	.
DTD0109	SLC16A5	Inducer	Calcitriol	Approved Drug	.	.	Calcitriol increases the expression of SLC16A5	.	.
DTD0109	SLC16A5	Inhibition	Cimetidine	Approved Drug	.	.	Cimetidine inhibits the activity of SLC16A5	.	.
DTD0109	SLC16A5	Inducer	Coal Ash	Natural Product	.	.	Coal Ash increases the expression of SLC16A5	.	.
DTD0109	SLC16A5	Inducer	Copper Sulfate	Approved Drug	.	.	Copper Sulfate increases the expression of SLC16A5	.	.
DTD0109	SLC16A5	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of SLC16A5	.	.
DTD0109	SLC16A5	Modulator	Estradiol	Approved Drug	.	.	Estradiol affects the expression of SLC16A5	.	.
DTD0109	SLC16A5	Inhibition	GSK-J4	Patented Pharmaceutical Agent	.	.	GSK-J4 inhibits the expression of SLC16A5	.	.
DTD0109	SLC16A5	Inducer	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 increases the expression of SLC16A5	.	.
DTD0109	SLC16A5	Inducer	Jinfukang	Traditional Medicine	.	.	Jinfukang increases the expression of SLC16A5	.	.
DTD0109	SLC16A5	Inhibition	Phenylmercuric Acetate	Investigative Drug	.	.	Phenylmercuric Acetate inhibits the expression of SLC16A5	.	.
DTD0109	SLC16A5	Inhibition	Rotenone	Drug Marketed but not Approved by US FDA	.	.	Rotenone inhibits the expression of SLC16A5	.	.
DTD0109	SLC16A5	Inhibition	Sunitinib	Approved Drug	.	.	Sunitinib inhibits the expression of SLC16A5	.	.
DTD0109	SLC16A5	Inducer	Testosterone	Approved Drug	.	.	Testosterone increases the expression of SLC16A5	.	.
DTD0109	SLC16A5	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC16A5	.	.
DTD0109	SLC16A5	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of SLC16A5	.	.
DTD0109	SLC16A5	Inducer	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate increases the expression of SLC16A5	.	.
DTD0109	SLC16A5	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC16A5	.	.
DTD0110	SLC16A6	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of SLC16A6	.	.
DTD0110	SLC16A6	Inducer	1-methyl-4-phenylpyridinium	Health and Environmental Toxicant	.	.	1-methyl-4-phenylpyridinium increases the expression of SLC16A6	.	.
DTD0110	SLC16A6	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of SLC16A6	.	.
DTD0110	SLC16A6	Inducer	Acrylamide	Acute Toxic Substance	.	.	Acrylamide increases the expression of SLC16A6	.	.
DTD0110	SLC16A6	Inducer	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 increases the expression of SLC16A6	.	.
DTD0110	SLC16A6	Inducer	Azathioprine	Approved Drug	.	.	Azathioprine increases the expression of SLC16A6	.	.
DTD0110	SLC16A6	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of SLC16A6	.	.
DTD0110	SLC16A6	Inducer	Beta-naphthoflavone	Investigative Drug	.	.	Beta-naphthoflavone increases the expression of SLC16A6	.	.
DTD0110	SLC16A6	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC16A6	.	.
DTD0110	SLC16A6	Inducer	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde increases the expression of SLC16A6	.	.
DTD0110	SLC16A6	Inducer	Copper Sulfate	Approved Drug	.	.	Copper Sulfate increases the expression of SLC16A6	.	.
DTD0110	SLC16A6	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of SLC16A6	.	.
DTD0110	SLC16A6	Inhibition	Dasatinib	Approved Drug	.	.	Dasatinib inhibits the expression of SLC16A6	.	.
DTD0110	SLC16A6	Inducer	Dihydrotestosterone	Drug in Phase 1 Trial	.	.	Dihydrotestosterone increases the expression of SLC16A6	.	.
DTD0110	SLC16A6	Inducer	Diuron	Herbicide	.	.	Diuron increases the expression of SLC16A6	.	.
DTD0110	SLC16A6	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC16A6	.	.
DTD0110	SLC16A6	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the expression of SLC16A6	.	.
DTD0110	SLC16A6	Inhibition	Ethyl Methanesulfonate	Carcinogen	.	.	Ethyl Methanesulfonate inhibits the expression of SLC16A6	.	.
DTD0110	SLC16A6	Inhibition	Fluorouracil	Approved Drug	.	.	Fluorouracil inhibits the expression of SLC16A6	.	.
DTD0110	SLC16A6	Inhibition	Formaldehyde	Acute Toxic Substance	.	.	Formaldehyde inhibits the expression of SLC16A6	.	.
DTD0110	SLC16A6	Inhibition	Hydroquinone	Approved Drug	.	.	Hydroquinone inhibits the expression of SLC16A6	.	.
DTD0110	SLC16A6	Inducer	Ibuprofen	Approved Drug	.	.	Ibuprofen increases the expression of SLC16A6	.	.
DTD0110	SLC16A6	Inducer	Jinfukang	Traditional Medicine	.	.	Jinfukang increases the expression of SLC16A6	.	.
DTD0110	SLC16A6	Inducer	Leflunomide	Approved Drug	.	.	Leflunomide increases the expression of SLC16A6	.	.
DTD0110	SLC16A6	Inducer	Liothyronine	Approved Drug	.	.	Liothyronine increases the expression of SLC16A6	.	.
DTD0110	SLC16A6	Inducer	Motexafin gadolinium	Drug in Phase 2 Trial	.	.	Motexafin gadolinium increases the expression of SLC16A6	.	.
DTD0110	SLC16A6	Inhibition	Oxyquinoline	Acute Toxic Substance	.	.	Oxyquinoline inhibits the expression of SLC16A6	.	.
DTD0110	SLC16A6	Inducer	Particulate Matter	Natural Product	.	.	Particulate Matter increases the expression of SLC16A6	.	.
DTD0110	SLC16A6	Inducer	Pentanal	Chemical Compound	.	.	Pentanal increases the expression of SLC16A6	.	.
DTD0110	SLC16A6	Inducer	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin increases the expression of SLC16A6	.	.
DTD0110	SLC16A6	Inhibition	Progesterone	Approved Drug	.	.	Progesterone inhibits the expression of SLC16A6	.	.
DTD0110	SLC16A6	Inducer	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin increases the expression of SLC16A6	.	.
DTD0110	SLC16A6	Inducer	Rotenone	Drug Marketed but not Approved by US FDA	.	.	Rotenone increases the expression of SLC16A6	.	.
DTD0110	SLC16A6	Inducer	Sulindac	Approved Drug	.	.	Sulindac increases the expression of SLC16A6	.	.
DTD0110	SLC16A6	Inducer	Thimerosal	Acute Toxic Substance	.	.	Thimerosal increases the expression of SLC16A6	.	.
DTD0110	SLC16A6	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC16A6	.	.
DTD0110	SLC16A6	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of SLC16A6	.	.
DTD0110	SLC16A6	Inducer	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A increases the expression of SLC16A6	.	.
DTD0110	SLC16A6	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of SLC16A6	.	.
DTD0110	SLC16A6	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC16A6	.	.
DTD0110	SLC16A6	Inhibition	Zidovudine	Approved Drug	.	.	Zidovudine inhibits the expression of SLC16A6	.	.
DTD0110	SLC16A6	Inducer	Zinc Acetate	Approved Drug	.	.	Zinc Acetate increases the expression of SLC16A6	.	.
DTD0111	SLC16A7	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC16A7	.	.
DTD0111	SLC16A7	Modulator	AM-80	Drug in Phase 2/3 Trial	.	.	AM-80 affects the expression of SLC16A7	.	.
DTD0111	SLC16A7	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC16A7	.	.
DTD0111	SLC16A7	Inducer	Bisphenol B	Drug in Phase 2 Trial	.	.	Bisphenol B increases the expression of SLC16A7	.	.
DTD0111	SLC16A7	Inducer	Bisphenol F	Environmental toxicant	.	.	Bisphenol F increases the expression of SLC16A7	.	.
DTD0111	SLC16A7	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the expression of SLC16A7	.	.
DTD0111	SLC16A7	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC16A7	.	.
DTD0111	SLC16A7	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC16A7	.	.
DTD0111	SLC16A7	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC16A7	.	.
DTD0111	SLC16A7	Inhibition	Formaldehyde	Acute Toxic Substance	.	.	Formaldehyde inhibits the expression of SLC16A7	.	.
DTD0111	SLC16A7	Inducer	Geldanamycin	Drug in Phase 1 Trial	.	.	Geldanamycin increases the expression of SLC16A7	.	.
DTD0111	SLC16A7	Inhibition	Isotretinoin	Approved Drug	.	.	Isotretinoin inhibits the expression of SLC16A7	.	.
DTD0111	SLC16A7	Inhibition	Jinfukang	Traditional Medicine	.	.	Jinfukang inhibits the expression of SLC16A7	.	.
DTD0111	SLC16A7	Inducer	Ketogenic diet	Dietary Constituent	.	.	Ketogenic diet induces the activity of SLC16A7	.	.
DTD0111	SLC16A7	Inducer	Phenylmercuric Acetate	Investigative Drug	.	.	Phenylmercuric Acetate increases the expression of SLC16A7	.	.
DTD0111	SLC16A7	Inducer	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin increases the expression of SLC16A7	.	.
DTD0111	SLC16A7	Inhibition	Progesterone	Approved Drug	.	.	Progesterone inhibits the expression of SLC16A7	.	.
DTD0111	SLC16A7	Inhibition	Testosterone	Approved Drug	.	.	Testosterone inhibits the activity of SLC16A7	.	.
DTD0111	SLC16A7	Modulator	Testosterone enanthate	Approved Drug	.	.	Testosterone enanthate affects the expression of SLC16A7	.	.
DTD0111	SLC16A7	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC16A7	.	.
DTD0111	SLC16A7	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC16A7	.	.
DTD0111	SLC16A7	Inducer	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A increases the expression of SLC16A7	.	.
DTD0111	SLC16A7	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC16A7	.	.
DTD0112	SLC16A8	Inducer	Atrazine	Herbicide	.	.	Atrazine increases the expression of SLC16A8	.	.
DTD0112	SLC16A8	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the expression of SLC16A8	.	.
DTD0112	SLC16A8	Inhibition	GSK-J4	Patented Pharmaceutical Agent	.	.	GSK-J4 inhibits the expression of SLC16A8	.	.
DTD0113	SLC16A9	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of SLC16A9	.	.
DTD0113	SLC16A9	Inducer	1-methyl-4-phenylpyridinium	Health and Environmental Toxicant	.	.	1-methyl-4-phenylpyridinium increases the expression of SLC16A9	.	.
DTD0113	SLC16A9	Inducer	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 increases the expression of SLC16A9	.	.
DTD0113	SLC16A9	Inhibition	Avobenzone	Approved Drug	.	.	Avobenzone inhibits the expression of SLC16A9	.	.
DTD0113	SLC16A9	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC16A9	.	.
DTD0113	SLC16A9	Modulator	Carbamazepine	Approved Drug	.	.	Carbamazepine affects the expression of SLC16A9	.	.
DTD0113	SLC16A9	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the expression of SLC16A9	.	.
DTD0113	SLC16A9	Inducer	Cytarabine	Approved Drug	.	.	Cytarabine increases the expression of SLC16A9	.	.
DTD0113	SLC16A9	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC16A9	.	.
DTD0113	SLC16A9	Inducer	Ethanol	Drug in Phase 2 Trial	.	.	Ethanol increases the expression of SLC16A9	.	.
DTD0113	SLC16A9	Inhibition	Ethyl Methanesulfonate	Carcinogen	.	.	Ethyl Methanesulfonate inhibits the expression of SLC16A9	.	.
DTD0113	SLC16A9	Inhibition	Formaldehyde	Acute Toxic Substance	.	.	Formaldehyde inhibits the expression of SLC16A9	.	.
DTD0113	SLC16A9	Inducer	Leflunomide	Approved Drug	.	.	Leflunomide increases the expression of SLC16A9	.	.
DTD0113	SLC16A9	Inhibition	Phenylmercuric Acetate	Investigative Drug	.	.	Phenylmercuric Acetate inhibits the expression of SLC16A9	.	.
DTD0113	SLC16A9	Inducer	Rotenone	Drug Marketed but not Approved by US FDA	.	.	Rotenone increases the expression of SLC16A9	.	.
DTD0113	SLC16A9	Inhibition	Sunitinib	Approved Drug	.	.	Sunitinib inhibits the expression of SLC16A9	.	.
DTD0113	SLC16A9	Inducer	Temozolomide	Approved Drug	.	.	Temozolomide increases the expression of SLC16A9	.	.
DTD0113	SLC16A9	Inhibition	Testosterone undecanoate	Approved Drug	.	.	Testosterone undecanoate inhibits the expression of SLC16A9	.	.
DTD0113	SLC16A9	Inducer	Thimerosal	Acute Toxic Substance	.	.	Thimerosal increases the expression of SLC16A9	.	.
DTD0113	SLC16A9	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC16A9	.	.
DTD0113	SLC16A9	Inhibition	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A inhibits the expression of SLC16A9	.	.
DTD0113	SLC16A9	Modulator	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate affects the expression of SLC16A9	.	.
DTD0113	SLC16A9	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC16A9	.	.
DTD0114	SLC17A1	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC17A1	.	.
DTD0114	SLC17A1	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC17A1	.	.
DTD0114	SLC17A1	Inducer	Cadmium	Acute Toxic Substance	.	.	Cadmium increases the expression of SLC17A1	.	.
DTD0114	SLC17A1	Inhibition	Coal Ash	Natural Product	.	.	Coal Ash inhibits the expression of SLC17A1	.	.
DTD0114	SLC17A1	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC17A1	.	.
DTD0114	SLC17A1	Inhibition	Rifampin	Approved Drug	.	.	Rifampin inhibits the expression of SLC17A1	.	.
DTD0114	SLC17A1	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC17A1	.	.
DTD0115	SLC17A2	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC17A2	.	.
DTD0115	SLC17A2	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC17A2	.	.
DTD0115	SLC17A2	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC17A2	.	.
DTD0115	SLC17A2	Inducer	Copper Sulfate	Approved Drug	.	.	Copper Sulfate increases the expression of SLC17A2	.	.
DTD0115	SLC17A2	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of SLC17A2	.	.
DTD0115	SLC17A2	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the expression of SLC17A2	.	.
DTD0115	SLC17A2	Modulator	Hydrogen Peroxide	Approved Drug	.	.	Hydrogen Peroxide affects the expression of SLC17A2	.	.
DTD0115	SLC17A2	Inhibition	Kojic acid	Health and Environmental Toxicant	.	.	Kojic acid inhibits the expression of SLC17A2	.	.
DTD0115	SLC17A2	Modulator	Menadione	Approved Drug	.	.	Menadione affects the expression of SLC17A2	.	.
DTD0115	SLC17A2	Inhibition	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin inhibits the expression of SLC17A2	.	.
DTD0115	SLC17A2	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of SLC17A2	.	.
DTD0115	SLC17A2	Inhibition	Resorcinol	Environmental toxicant	.	.	Resorcinol inhibits the expression of SLC17A2	.	.
DTD0115	SLC17A2	Modulator	Uranium	Acute Toxic Substance	.	.	Uranium affects the expression of SLC17A2	.	.
DTD0115	SLC17A2	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of SLC17A2	.	.
DTD0115	SLC17A2	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC17A2	.	.
DTD0115	SLC17A2	Inhibition	Zidovudine	Approved Drug	.	.	Zidovudine inhibits the expression of SLC17A2	.	.
DTD0116	SLC17A3	Inducer	Cadmium	Acute Toxic Substance	.	.	Cadmium increases the expression of SLC17A3	.	.
DTD0116	SLC17A3	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC17A3	.	.
DTD0116	SLC17A3	Modulator	Phenobarbital	Approved Drug	.	.	Phenobarbital affects the expression of SLC17A3	.	.
DTD0116	SLC17A3	Inhibition	Titanium dioxide	Approved Drug	.	.	Titanium dioxide inhibits the expression of SLC17A3	.	.
DTD0117	SLC17A4	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC17A4	.	.
DTD0117	SLC17A4	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC17A4	.	.
DTD0117	SLC17A4	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC17A4	.	.
DTD0117	SLC17A4	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the expression of SLC17A4	.	.
DTD0117	SLC17A4	Inhibition	Ethanol	Drug in Phase 2 Trial	.	.	Ethanol inhibits the expression of SLC17A4	.	.
DTD0117	SLC17A4	Inhibition	Perfluorooctane sulfonic acid	Health and Environmental Toxicant	.	.	Perfluorooctane sulfonic acid inhibits the expression of SLC17A4	.	.
DTD0117	SLC17A4	Inhibition	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin inhibits the expression of SLC17A4	.	.
DTD0117	SLC17A4	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC17A4	.	.
DTD0117	SLC17A4	Inhibition	Troglitazone	Approved Drug	.	.	Troglitazone inhibits the expression of SLC17A4	.	.
DTD0117	SLC17A4	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC17A4	.	.
DTD0118	SLC17A5	Inducer	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 increases the expression of SLC17A5	.	.
DTD0118	SLC17A5	Inducer	Atrazine	Herbicide	.	.	Atrazine increases the expression of SLC17A5	.	.
DTD0118	SLC17A5	Inducer	Avobenzone	Approved Drug	.	.	Avobenzone increases the expression of SLC17A5	.	.
DTD0118	SLC17A5	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC17A5	.	.
DTD0118	SLC17A5	Inducer	Bisphenol B	Drug in Phase 2 Trial	.	.	Bisphenol B increases the expression of SLC17A5	.	.
DTD0118	SLC17A5	Inducer	Bisphenol F	Environmental toxicant	.	.	Bisphenol F increases the expression of SLC17A5	.	.
DTD0118	SLC17A5	Inducer	Calcitriol	Approved Drug	.	.	Calcitriol increases the expression of SLC17A5	.	.
DTD0118	SLC17A5	Modulator	Carbamazepine	Approved Drug	.	.	Carbamazepine affects the expression of SLC17A5	.	.
DTD0118	SLC17A5	Inhibition	Coumestrol	Investigative Drug	.	.	Coumestrol inhibits the expression of SLC17A5	.	.
DTD0118	SLC17A5	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC17A5	.	.
DTD0118	SLC17A5	Inducer	Dexamethasone	Approved Drug	.	.	Dexamethasone increases the expression of SLC17A5	.	.
DTD0118	SLC17A5	Modulator	DMU-212	Patented Pharmaceutical Agent	.	.	DMU-212 affects the expression of SLC17A5	.	.
DTD0118	SLC17A5	Inhibition	Dronabinol	Approved Drug	.	.	Dronabinol inhibits the expression of SLC17A5	.	.
DTD0118	SLC17A5	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the expression of SLC17A5	.	.
DTD0118	SLC17A5	Inhibition	Formaldehyde	Acute Toxic Substance	.	.	Formaldehyde inhibits the expression of SLC17A5	.	.
DTD0118	SLC17A5	Inducer	K-7174	Patented Pharmaceutical Agent	.	.	K-7174 increases the expression of SLC17A5	.	.
DTD0118	SLC17A5	Inducer	MS-275	Drug in Phase 2 Trial	.	.	MS-275 increases the expression of SLC17A5	.	.
DTD0118	SLC17A5	Inhibition	PP242	Investigative Drug	.	.	PP242 inhibits the expression of SLC17A5	.	.
DTD0118	SLC17A5	Modulator	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite affects the expression of SLC17A5	.	.
DTD0118	SLC17A5	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of SLC17A5	.	.
DTD0118	SLC17A5	Inducer	Testosterone	Approved Drug	.	.	Testosterone increases the expression of SLC17A5	.	.
DTD0118	SLC17A5	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC17A5	.	.
DTD0118	SLC17A5	Inducer	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A increases the expression of SLC17A5	.	.
DTD0118	SLC17A5	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC17A5	.	.
DTD0119	SLC17A6	Inhibition	Antimycin A	Acute Toxic Substance	.	.	Antimycin A inhibits the expression of SLC17A6	.	.
DTD0119	SLC17A6	Inhibition	Azoxystrobin	Fungicide	.	.	Azoxystrobin inhibits the expression of SLC17A6	.	.
DTD0119	SLC17A6	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC17A6	.	.
DTD0119	SLC17A6	Inducer	Cytarabine	Approved Drug	.	.	Cytarabine increases the expression of SLC17A6	.	.
DTD0119	SLC17A6	Inhibition	Deguelin	Natural Product	.	.	Deguelin inhibits the expression of SLC17A6	.	.
DTD0119	SLC17A6	Inducer	Dexamethasone	Approved Drug	.	.	Dexamethasone increases the expression of SLC17A6	.	.
DTD0119	SLC17A6	Inhibition	MS-275	Drug in Phase 2 Trial	.	.	MS-275 inhibits the expression of SLC17A6	.	.
DTD0119	SLC17A6	Modulator	Valproic Acid	Approved Drug	.	.	Valproic Acid affects the expression of SLC17A6	.	.
DTD0120	SLC17A7	Inducer	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 increases the expression of SLC17A7	.	.
DTD0120	SLC17A7	Inhibition	Clothianidin	Pesticide/Insecticide	.	.	Clothianidin inhibits the expression of SLC17A7	.	.
DTD0120	SLC17A7	Inhibition	Diethylhexyl Phthalate	Health and Environmental Toxicant	.	.	Diethylhexyl Phthalate inhibits the expression of SLC17A7	.	.
DTD0120	SLC17A7	Inducer	Ivermectin	Approved Drug	.	.	Ivermectin increases the expression of SLC17A7	.	.
DTD0120	SLC17A7	Modulator	Lead	Health and Environmental Toxicant	.	.	Lead affects the expression of SLC17A7	.	.
DTD0120	SLC17A7	Inhibition	Raloxifene Hydrochloride	Approved Drug	.	.	Raloxifene Hydrochloride inhibits the expression of SLC17A7	.	.
DTD0120	SLC17A7	Inhibition	Silver nanoparticle	Nanoparticle	.	.	Silver nanoparticle inhibits the expression of SLC17A7	.	.
DTD0120	SLC17A7	Modulator	Tretinoin	Approved Drug	.	.	Tretinoin affects the expression of SLC17A7	.	.
DTD0120	SLC17A7	Inducer	Urethane	Approved Drug	.	.	Urethane increases the expression of SLC17A7	.	.
DTD0120	SLC17A7	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC17A7	.	.
DTD0121	SLC17A8	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC17A8	.	.
DTD0121	SLC17A8	Inducer	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 increases the expression of SLC17A8	.	.
DTD0121	SLC17A8	Modulator	Lead	Health and Environmental Toxicant	.	.	Lead affects the expression of SLC17A8	.	.
DTD0121	SLC17A8	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC17A8	.	.
DTD0121	SLC17A8	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC17A8	.	.
DTD0121	SLC17A8	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC17A8	.	.
DTD0121	SLC17A8	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of SLC17A8	.	.
DTD0122	SLC17A9	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC17A9	.	.
DTD0122	SLC17A9	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC17A9	.	.
DTD0122	SLC17A9	Modulator	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A affects the expression of SLC17A9	.	.
DTD0122	SLC17A9	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the expression of SLC17A9	.	.
DTD0122	SLC17A9	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of SLC17A9	.	.
DTD0122	SLC17A9	Inhibition	Ethyl Methanesulfonate	Carcinogen	.	.	Ethyl Methanesulfonate inhibits the expression of SLC17A9	.	.
DTD0122	SLC17A9	Inhibition	Formaldehyde	Acute Toxic Substance	.	.	Formaldehyde inhibits the expression of SLC17A9	.	.
DTD0122	SLC17A9	Inhibition	Ivermectin	Approved Drug	.	.	Ivermectin inhibits the expression of SLC17A9	.	.
DTD0122	SLC17A9	Inhibition	Perfluorooctane sulfonic acid	Health and Environmental Toxicant	.	.	Perfluorooctane sulfonic acid inhibits the expression of SLC17A9	.	.
DTD0122	SLC17A9	Inhibition	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin inhibits the expression of SLC17A9	.	.
DTD0122	SLC17A9	Inducer	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin increases the expression of SLC17A9	.	.
DTD0122	SLC17A9	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC17A9	.	.
DTD0122	SLC17A9	Inducer	Testosterone	Approved Drug	.	.	Testosterone increases the expression of SLC17A9	.	.
DTD0122	SLC17A9	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of SLC17A9	.	.
DTD0123	SLC18A1	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of SLC18A1	.	.
DTD0123	SLC18A1	Inhibition	Fenfluramine	Drug Withdrawn	.	.	Fenfluramine inhibits the activity of SLC18A1	.	.
DTD0123	SLC18A1	Inducer	Permethrin	Approved Drug	.	.	Permethrin increases the expression of SLC18A1	.	.
DTD0123	SLC18A1	Inhibition	Reserpine	Approved Drug	.	.	Reserpine inhibits the activity of SLC18A1	.	.
DTD0123	SLC18A1	Inhibition	Tetrabenazine	Approved Drug	.	.	Tetrabenazine inhibits the activity of SLC18A1	.	.
DTD0123	SLC18A1	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of SLC18A1	.	.
DTD0124	SLC18A3	Inhibition	Potassium perchlorate	Approved Drug	.	.	Potassium perchlorate inhibits the expression of SLC18A3	.	.
DTD0124	SLC18A3	Inhibition	Testosterone	Approved Drug	.	.	Testosterone inhibits the expression of SLC18A3	.	.
DTD0124	SLC18A3	Inducer	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan increases the expression of SLC18A3	.	.
DTD0124	SLC18A3	Modulator	Valproic Acid	Approved Drug	.	.	Valproic Acid affects the expression of SLC18A3	.	.
DTD0125	SLC18B1	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of SLC18B1	.	.
DTD0125	SLC18B1	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC18B1	.	.
DTD0125	SLC18B1	Inhibition	Acrylamide	Acute Toxic Substance	.	.	Acrylamide inhibits the expression of SLC18B1	.	.
DTD0125	SLC18B1	Inhibition	AM-251	Patented Pharmaceutical Agent	.	.	AM-251 inhibits the expression of SLC18B1	.	.
DTD0125	SLC18B1	Inhibition	Calcitriol	Approved Drug	.	.	Calcitriol inhibits the expression of SLC18B1	.	.
DTD0125	SLC18B1	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC18B1	.	.
DTD0125	SLC18B1	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC18B1	.	.
DTD0125	SLC18B1	Inhibition	GSK-J4	Patented Pharmaceutical Agent	.	.	GSK-J4 inhibits the expression of SLC18B1	.	.
DTD0125	SLC18B1	Modulator	Hydrogen Peroxide	Approved Drug	.	.	Hydrogen Peroxide affects the expression of SLC18B1	.	.
DTD0125	SLC18B1	Inhibition	Ivermectin	Approved Drug	.	.	Ivermectin inhibits the expression of SLC18B1	.	.
DTD0125	SLC18B1	Inducer	MS-275	Drug in Phase 2 Trial	.	.	MS-275 increases the expression of SLC18B1	.	.
DTD0125	SLC18B1	Inducer	Panobinostat	Approved Drug	.	.	Panobinostat increases the expression of SLC18B1	.	.
DTD0125	SLC18B1	Inducer	Paraquat	Acute Toxic Substance	.	.	Paraquat increases the expression of SLC18B1	.	.
DTD0125	SLC18B1	Inhibition	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin inhibits the expression of SLC18B1	.	.
DTD0125	SLC18B1	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of SLC18B1	.	.
DTD0125	SLC18B1	Inhibition	Testosterone	Approved Drug	.	.	Testosterone inhibits the expression of SLC18B1	.	.
DTD0125	SLC18B1	Inhibition	Thimerosal	Acute Toxic Substance	.	.	Thimerosal inhibits the expression of SLC18B1	.	.
DTD0125	SLC18B1	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of SLC18B1	.	.
DTD0125	SLC18B1	Inducer	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A increases the expression of SLC18B1	.	.
DTD0125	SLC18B1	Inhibition	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate inhibits the expression of SLC18B1	.	.
DTD0125	SLC18B1	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of SLC18B1	.	.
DTD0125	SLC18B1	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC18B1	.	.
DTD0125	SLC18B1	Inducer	Vorinostat	Approved Drug	.	.	Vorinostat increases the expression of SLC18B1	.	.
DTD0126	SLC19A1	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of SLC19A1	.	.
DTD0126	SLC19A1	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC19A1	.	.
DTD0126	SLC19A1	Inhibition	Acrylamide	Acute Toxic Substance	.	.	Acrylamide inhibits the expression of SLC19A1	.	.
DTD0126	SLC19A1	Inhibition	Atenolol	Approved Drug	.	.	Atenolol inhibits the expression of SLC19A1	.	.
DTD0126	SLC19A1	Inhibition	Atrazine	Herbicide	.	.	Atrazine inhibits the expression of SLC19A1	.	.
DTD0126	SLC19A1	Inhibition	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A inhibits the expression of SLC19A1	.	.
DTD0126	SLC19A1	Modulator	Carbamazepine	Approved Drug	.	.	Carbamazepine affects the expression of SLC19A1	.	.
DTD0126	SLC19A1	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC19A1	.	.
DTD0126	SLC19A1	Inducer	Decitabine	Approved Drug	.	.	Decitabine increases the expression of SLC19A1	.	.
DTD0126	SLC19A1	Modulator	Diclofenac	Approved Drug	.	.	Diclofenac affects the expression of SLC19A1	.	.
DTD0126	SLC19A1	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC19A1	.	.
DTD0126	SLC19A1	Inhibition	Dronabinol	Approved Drug	.	.	Dronabinol inhibits the expression of SLC19A1	.	.
DTD0126	SLC19A1	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC19A1	.	.
DTD0126	SLC19A1	Inhibition	Ethanol	Drug in Phase 2 Trial	.	.	Ethanol inhibits the expression of SLC19A1	.	.
DTD0126	SLC19A1	Inhibition	Ethyl Methanesulfonate	Carcinogen	.	.	Ethyl Methanesulfonate inhibits the expression of SLC19A1	.	.
DTD0126	SLC19A1	Modulator	Folic Acid	Approved Drug	.	.	Folic acid modulates the activity of SLC19A1	.	.
DTD0126	SLC19A1	Inhibition	Formaldehyde	Acute Toxic Substance	.	.	Formaldehyde inhibits the expression of SLC19A1	.	.
DTD0126	SLC19A1	Inducer	Genistein	Drug in Phase 2 Trial	.	.	Genistein increases the expression of SLC19A1	.	.
DTD0126	SLC19A1	Modulator	Hydrogen Peroxide	Approved Drug	.	.	Hydrogen Peroxide affects the expression of SLC19A1	.	.
DTD0126	SLC19A1	Inhibition	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 inhibits the expression of SLC19A1	.	.
DTD0126	SLC19A1	Inhibition	Irinotecan	Approved Drug	.	.	Irinotecan inhibits the expression of SLC19A1	.	.
DTD0126	SLC19A1	Inducer	Jinfukang	Traditional Medicine	.	.	Jinfukang increases the expression of SLC19A1	.	.
DTD0126	SLC19A1	Inhibition	Leucovorin	Approved Drug	.	.	Leucovorin inhibits the activity of SLC19A1	.	.
DTD0126	SLC19A1	Inhibition	Nicotine polacrilex	Approved Drug	.	.	Nicotine polacrilex inhibits the expression of SLC19A1	.	.
DTD0126	SLC19A1	Inhibition	Pemetrexed	Approved Drug	.	.	Pemetrexed inhibits the activity of SLC19A1	.	.
DTD0126	SLC19A1	Inhibition	Raltitrexed	Approved Drug	.	.	Raltitrexed inhibits the activity of SLC19A1	.	.
DTD0126	SLC19A1	Inhibition	Selenium nanoparticles	Natural Product	.	.	Selenium nanoparticles inhibits the expression of SLC19A1	.	.
DTD0126	SLC19A1	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC19A1	.	.
DTD0126	SLC19A1	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC19A1	.	.
DTD0126	SLC19A1	Inhibition	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A inhibits the expression of SLC19A1	.	.
DTD0126	SLC19A1	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of SLC19A1	.	.
DTD0126	SLC19A1	Inhibition	Vitamin E	Drug in Phase 3 Trial	.	.	Vitamin E inhibits the expression of SLC19A1	.	.
DTD0127	SLC19A2	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of SLC19A2	.	.
DTD0127	SLC19A2	Inducer	Atrazine	Herbicide	.	.	Atrazine increases the expression of SLC19A2	.	.
DTD0127	SLC19A2	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of SLC19A2	.	.
DTD0127	SLC19A2	Modulator	Carbamazepine	Approved Drug	.	.	Carbamazepine affects the expression of SLC19A2	.	.
DTD0127	SLC19A2	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC19A2	.	.
DTD0127	SLC19A2	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of SLC19A2	.	.
DTD0127	SLC19A2	Inducer	Dexamethasone	Approved Drug	.	.	Dexamethasone increases the expression of SLC19A2	.	.
DTD0127	SLC19A2	Inducer	Dihydrotestosterone	Drug in Phase 1 Trial	.	.	Dihydrotestosterone increases the expression of SLC19A2	.	.
DTD0127	SLC19A2	Inducer	Doxorubicin	Approved Drug	.	.	Doxorubicin increases the expression of SLC19A2	.	.
DTD0127	SLC19A2	Inhibition	Dronabinol	Approved Drug	.	.	Dronabinol inhibits the expression of SLC19A2	.	.
DTD0127	SLC19A2	Inducer	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 increases the expression of SLC19A2	.	.
DTD0127	SLC19A2	Inducer	Indomethacin	Approved Drug	.	.	Indomethacin increases the expression of SLC19A2	.	.
DTD0127	SLC19A2	Inhibition	Jinfukang	Traditional Medicine	.	.	Jinfukang inhibits the expression of SLC19A2	.	.
DTD0127	SLC19A2	Inducer	K-7174	Patented Pharmaceutical Agent	.	.	K-7174 increases the expression of SLC19A2	.	.
DTD0127	SLC19A2	Inducer	Leflunomide	Approved Drug	.	.	Leflunomide increases the expression of SLC19A2	.	.
DTD0127	SLC19A2	Inducer	Melphalan	Approved Drug	.	.	Melphalan increases the expression of SLC19A2	.	.
DTD0127	SLC19A2	Inducer	Milchsaure	Investigative Drug	.	.	Milchsaure increases the expression of SLC19A2	.	.
DTD0127	SLC19A2	Inducer	Particulate Matter	Natural Product	.	.	Particulate Matter increases the expression of SLC19A2	.	.
DTD0127	SLC19A2	Inhibition	Perfluorooctane sulfonic acid	Health and Environmental Toxicant	.	.	Perfluorooctane sulfonic acid inhibits the expression of SLC19A2	.	.
DTD0127	SLC19A2	Modulator	Phenobarbital	Approved Drug	.	.	Phenobarbital affects the expression of SLC19A2	.	.
DTD0127	SLC19A2	Inducer	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin increases the expression of SLC19A2	.	.
DTD0127	SLC19A2	Inducer	Progesterone	Approved Drug	.	.	Progesterone increases the expression of SLC19A2	.	.
DTD0127	SLC19A2	Inhibition	Selenium nanoparticles	Natural Product	.	.	Selenium nanoparticles inhibits the expression of SLC19A2	.	.
DTD0127	SLC19A2	Inducer	STA-4783	Drug in Phase 2 Trial	.	.	STA-4783 increases the expression of SLC19A2	.	.
DTD0127	SLC19A2	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of SLC19A2	.	.
DTD0127	SLC19A2	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC19A2	.	.
DTD0127	SLC19A2	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC19A2	.	.
DTD0127	SLC19A2	Modulator	Vitamin B1	Investigative Drug	.	.	[3H]Thiamine modulates the activity of SLC19A2	.	.
DTD0127	SLC19A2	Inhibition	Zidovudine	Approved Drug	.	.	Zidovudine inhibits the expression of SLC19A2	.	.
DTD0128	SLC19A3	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC19A3	.	.
DTD0128	SLC19A3	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC19A3	.	.
DTD0128	SLC19A3	Inhibition	Beta-naphthoflavone	Investigative Drug	.	.	Beta-naphthoflavone inhibits the expression of SLC19A3	.	.
DTD0128	SLC19A3	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC19A3	.	.
DTD0128	SLC19A3	Inhibition	Cadmium	Acute Toxic Substance	.	.	Cadmium inhibits the expression of SLC19A3	.	.
DTD0128	SLC19A3	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the expression of SLC19A3	.	.
DTD0128	SLC19A3	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC19A3	.	.
DTD0128	SLC19A3	Inhibition	Ethanol	Drug in Phase 2 Trial	.	.	Ethanol inhibits the expression of SLC19A3	.	.
DTD0128	SLC19A3	Modulator	Hydrogen Peroxide	Approved Drug	.	.	Hydrogen Peroxide affects the expression of SLC19A3	.	.
DTD0128	SLC19A3	Modulator	Menadione	Approved Drug	.	.	Menadione affects the expression of SLC19A3	.	.
DTD0128	SLC19A3	Inducer	MS-275	Drug in Phase 2 Trial	.	.	MS-275 increases the expression of SLC19A3	.	.
DTD0128	SLC19A3	Inducer	Panobinostat	Approved Drug	.	.	Panobinostat increases the expression of SLC19A3	.	.
DTD0128	SLC19A3	Inhibition	Perfluorooctane sulfonic acid	Health and Environmental Toxicant	.	.	Perfluorooctane sulfonic acid inhibits the expression of SLC19A3	.	.
DTD0128	SLC19A3	Modulator	Phenobarbital	Approved Drug	.	.	Phenobarbital affects the expression of SLC19A3	.	.
DTD0128	SLC19A3	Inducer	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin increases the expression of SLC19A3	.	.
DTD0128	SLC19A3	Inducer	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite increases the expression of SLC19A3	.	.
DTD0128	SLC19A3	Inducer	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A increases the expression of SLC19A3	.	.
DTD0128	SLC19A3	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of SLC19A3	.	.
DTD0128	SLC19A3	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC19A3	.	.
DTD0128	SLC19A3	Modulator	Vitamin B1	Investigative Drug	.	.	[3H]Thiamine modulates the activity of SLC19A3	.	.
DTD0128	SLC19A3	Inducer	Vorinostat	Approved Drug	.	.	Vorinostat increases the expression of SLC19A3	.	.
DTD0128	SLC19A3	Inhibition	Zidovudine	Approved Drug	.	.	Zidovudine inhibits the expression of SLC19A3	.	.
DTD0129	SLC1A1	Inhibition	Afimoxifene	Drug in Phase 3 Trial	.	.	Afimoxifene inhibits the expression of SLC1A1	.	.
DTD0129	SLC1A1	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC1A1	.	.
DTD0129	SLC1A1	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of SLC1A1	.	.
DTD0129	SLC1A1	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC1A1	.	.
DTD0129	SLC1A1	Inducer	Calcitriol	Approved Drug	.	.	Calcitriol increases the expression of SLC1A1	.	.
DTD0129	SLC1A1	Modulator	Carbamazepine	Approved Drug	.	.	Carbamazepine affects the expression of SLC1A1	.	.
DTD0129	SLC1A1	Inhibition	Coal Ash	Natural Product	.	.	Coal Ash inhibits the expression of SLC1A1	.	.
DTD0129	SLC1A1	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC1A1	.	.
DTD0129	SLC1A1	Inducer	Desflurane	Approved Drug	.	.	Desflurane induces the activity of SLC1A1	.	.
DTD0129	SLC1A1	Inducer	Diethylhexyl Phthalate	Health and Environmental Toxicant	.	.	Diethylhexyl Phthalate increases the expression of SLC1A1	.	.
DTD0129	SLC1A1	Inhibition	Dinophysistoxin 1	Biotoxin	.	.	Dinophysistoxin 1 inhibits the expression of SLC1A1	.	.
DTD0129	SLC1A1	Modulator	Doxorubicin	Approved Drug	.	.	Doxorubicin affects the expression of SLC1A1	.	.
DTD0129	SLC1A1	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC1A1	.	.
DTD0129	SLC1A1	Inducer	GSK-J4	Patented Pharmaceutical Agent	.	.	GSK-J4 increases the expression of SLC1A1	.	.
DTD0129	SLC1A1	Inhibition	Ivermectin	Approved Drug	.	.	Ivermectin inhibits the expression of SLC1A1	.	.
DTD0129	SLC1A1	Modulator	Menadione	Approved Drug	.	.	Menadione affects the expression of SLC1A1	.	.
DTD0129	SLC1A1	Inducer	MS-275	Drug in Phase 2 Trial	.	.	MS-275 increases the expression of SLC1A1	.	.
DTD0129	SLC1A1	Inducer	Phenylmercuric Acetate	Investigative Drug	.	.	Phenylmercuric Acetate increases the expression of SLC1A1	.	.
DTD0129	SLC1A1	Inhibition	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin inhibits the expression of SLC1A1	.	.
DTD0129	SLC1A1	Inducer	Progesterone	Approved Drug	.	.	Progesterone increases the expression of SLC1A1	.	.
DTD0129	SLC1A1	Inhibition	Rotenone	Drug Marketed but not Approved by US FDA	.	.	Rotenone inhibits the expression of SLC1A1	.	.
DTD0129	SLC1A1	Inhibition	Selenium nanoparticles	Natural Product	.	.	Selenium nanoparticles inhibits the expression of SLC1A1	.	.
DTD0129	SLC1A1	Inhibition	Sunitinib	Approved Drug	.	.	Sunitinib inhibits the expression of SLC1A1	.	.
DTD0129	SLC1A1	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC1A1	.	.
DTD0129	SLC1A1	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC1A1	.	.
DTD0129	SLC1A1	Inducer	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A increases the expression of SLC1A1	.	.
DTD0129	SLC1A1	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC1A1	.	.
DTD0129	SLC1A1	Inducer	Vorinostat	Approved Drug	.	.	Vorinostat increases the expression of SLC1A1	.	.
DTD0129	SLC1A1	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of SLC1A1	.	.
DTD0130	SLC1A2	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of SLC1A2	.	.
DTD0130	SLC1A2	Inducer	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 increases the expression of SLC1A2	.	.
DTD0130	SLC1A2	Inducer	Ampicillin	Approved Drug	.	.	Ampicillin increases the expression of SLC1A2	.	.
DTD0130	SLC1A2	Inhibition	Antimycin A	Acute Toxic Substance	.	.	Antimycin A inhibits the expression of SLC1A2	.	.
DTD0130	SLC1A2	Inhibition	Arsenic Trioxide	Approved Drug	.	.	Arsenic Trioxide inhibits the expression of SLC1A2	.	.
DTD0130	SLC1A2	Inhibition	Azoxystrobin	Fungicide	.	.	Azoxystrobin inhibits the expression of SLC1A2	.	.
DTD0130	SLC1A2	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC1A2	.	.
DTD0130	SLC1A2	Inhibition	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A inhibits the expression of SLC1A2	.	.
DTD0130	SLC1A2	Inducer	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde increases the expression of SLC1A2	.	.
DTD0130	SLC1A2	Inducer	Cinnamic aldehyde	Natural Product	.	.	Cinnamic aldehyde increases the expression of SLC1A2	.	.
DTD0130	SLC1A2	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC1A2	.	.
DTD0130	SLC1A2	Inducer	Corticosterone	Drug in Phase 3 Trial	.	.	Corticosterone increases the expression of SLC1A2	.	.
DTD0130	SLC1A2	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC1A2	.	.
DTD0130	SLC1A2	Inhibition	Deguelin	Natural Product	.	.	Deguelin inhibits the expression of SLC1A2	.	.
DTD0130	SLC1A2	Inhibition	Diethylhexyl Phthalate	Health and Environmental Toxicant	.	.	Diethylhexyl Phthalate inhibits the expression of SLC1A2	.	.
DTD0130	SLC1A2	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC1A2	.	.
DTD0130	SLC1A2	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the expression of SLC1A2	.	.
DTD0130	SLC1A2	Inducer	Etanercept	Approved Drug	.	.	Etanercept induces the activity of SLC1A2	.	.
DTD0130	SLC1A2	Inducer	Fingolimod	Approved Drug	.	.	Fingolimod induces the activity of SLC1A2	.	.
DTD0130	SLC1A2	Inhibition	Hydrogen Peroxide	Approved Drug	.	.	Hydrogen Peroxide inhibits the expression of SLC1A2	.	.
DTD0130	SLC1A2	Inhibition	Ivermectin	Approved Drug	.	.	Ivermectin inhibits the expression of SLC1A2	.	.
DTD0130	SLC1A2	Inhibition	Manganese chloride	Approved Drug	.	.	Manganese chloride inhibits the expression of SLC1A2	.	.
DTD0130	SLC1A2	Inducer	Pentanal	Chemical Compound	.	.	Pentanal increases the expression of SLC1A2	.	.
DTD0130	SLC1A2	Inducer	Perfluorooctane sulfonic acid	Health and Environmental Toxicant	.	.	Perfluorooctane sulfonic acid increases the expression of SLC1A2	.	.
DTD0130	SLC1A2	Inhibition	Phenylmercuric Acetate	Investigative Drug	.	.	Phenylmercuric Acetate inhibits the expression of SLC1A2	.	.
DTD0130	SLC1A2	Inhibition	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin inhibits the expression of SLC1A2	.	.
DTD0130	SLC1A2	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of SLC1A2	.	.
DTD0130	SLC1A2	Inhibition	Rifampin	Approved Drug	.	.	Rifampin inhibits the expression of SLC1A2	.	.
DTD0130	SLC1A2	Inducer	Thiamphenicol	Approved Drug	.	.	Thiamphenicol increases the expression of SLC1A2	.	.
DTD0130	SLC1A2	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC1A2	.	.
DTD0130	SLC1A2	Inhibition	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A inhibits the expression of SLC1A2	.	.
DTD0130	SLC1A2	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC1A2	.	.
DTD0130	SLC1A2	Inducer	Vitamin A	Drug in Phase 3 Trial	.	.	Vitamin A increases the expression of SLC1A2	.	.
DTD0131	SLC1A3	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC1A3	.	.
DTD0131	SLC1A3	Inducer	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 increases the expression of SLC1A3	.	.
DTD0131	SLC1A3	Inducer	Amiodarone	Approved Drug	.	.	Amiodarone increases the expression of SLC1A3	.	.
DTD0131	SLC1A3	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC1A3	.	.
DTD0131	SLC1A3	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC1A3	.	.
DTD0131	SLC1A3	Inducer	Calcitriol	Approved Drug	.	.	Calcitriol increases the expression of SLC1A3	.	.
DTD0131	SLC1A3	Inducer	Cholesterol	Natural Product	.	.	Cholesterol increases the expression of SLC1A3	.	.
DTD0131	SLC1A3	Inhibition	Coal Ash	Natural Product	.	.	Coal Ash inhibits the expression of SLC1A3	.	.
DTD0131	SLC1A3	Inhibition	Dexamethasone	Approved Drug	.	.	Dexamethasone inhibits the expression of SLC1A3	.	.
DTD0131	SLC1A3	Inhibition	DL-TBOA	Investigative Drug	.	.	DL-TBOA inhibits the activity of SLC1A3	.	.
DTD0131	SLC1A3	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC1A3	.	.
DTD0131	SLC1A3	Inducer	Etanercept	Approved Drug	.	.	Etanercept induces the activity of SLC1A3	.	.
DTD0131	SLC1A3	Inhibition	Genistein	Drug in Phase 2 Trial	.	.	Genistein inhibits the expression of SLC1A3	.	.
DTD0131	SLC1A3	Modulator	Hydrogen Peroxide	Approved Drug	.	.	Hydrogen Peroxide affects the expression of SLC1A3	.	.
DTD0131	SLC1A3	Inhibition	Ivermectin	Approved Drug	.	.	Ivermectin inhibits the expression of SLC1A3	.	.
DTD0131	SLC1A3	Inhibition	Manganese chloride	Approved Drug	.	.	Manganese chloride inhibits the expression of SLC1A3	.	.
DTD0131	SLC1A3	Inducer	Medroxyprogesterone Acetate	Approved Drug	.	.	Medroxyprogesterone Acetate increases the expression of SLC1A3	.	.
DTD0131	SLC1A3	Inducer	Panobinostat	Approved Drug	.	.	Panobinostat increases the expression of SLC1A3	.	.
DTD0131	SLC1A3	Modulator	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin affects the expression of SLC1A3	.	.
DTD0131	SLC1A3	Inducer	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite increases the expression of SLC1A3	.	.
DTD0131	SLC1A3	Inducer	Sulforafan	Drug in Phase 3 Trial	.	.	Sulforafan increases the expression of SLC1A3	.	.
DTD0131	SLC1A3	Inhibition	Sunitinib	Approved Drug	.	.	Sunitinib inhibits the expression of SLC1A3	.	.
DTD0131	SLC1A3	Inducer	Testosterone	Approved Drug	.	.	Testosterone increases the expression of SLC1A3	.	.
DTD0131	SLC1A3	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC1A3	.	.
DTD0131	SLC1A3	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of SLC1A3	.	.
DTD0131	SLC1A3	Inducer	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A increases the expression of SLC1A3	.	.
DTD0131	SLC1A3	Inhibition	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan inhibits the expression of SLC1A3	.	.
DTD0131	SLC1A3	Inhibition	UCPH-101	Investigative Drug	.	.	UCPH-101 inhibits the activity of SLC1A3	.	.
DTD0131	SLC1A3	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC1A3	.	.
DTD0131	SLC1A3	Inducer	Vorinostat	Approved Drug	.	.	Vorinostat increases the expression of SLC1A3	.	.
DTD0131	SLC1A3	Inducer	Zoledronic Acid	Approved Drug	.	.	Zoledronic Acid increases the expression of SLC1A3	.	.
DTD0132	SLC1A4	Inducer	1-methyl-4-phenylpyridinium	Health and Environmental Toxicant	.	.	1-methyl-4-phenylpyridinium increases the expression of SLC1A4	.	.
DTD0132	SLC1A4	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of SLC1A4	.	.
DTD0132	SLC1A4	Inducer	Acrylamide	Acute Toxic Substance	.	.	Acrylamide increases the expression of SLC1A4	.	.
DTD0132	SLC1A4	Inducer	AM-251	Patented Pharmaceutical Agent	.	.	AM-251 increases the expression of SLC1A4	.	.
DTD0132	SLC1A4	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of SLC1A4	.	.
DTD0132	SLC1A4	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC1A4	.	.
DTD0132	SLC1A4	Modulator	Carbamazepine	Approved Drug	.	.	Carbamazepine affects the expression of SLC1A4	.	.
DTD0132	SLC1A4	Inducer	Cidofovir	Approved Drug	.	.	Cidofovir increases the expression of SLC1A4	.	.
DTD0132	SLC1A4	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the expression of SLC1A4	.	.
DTD0132	SLC1A4	Inhibition	Clodronic Acid	Drug Marketed but not Approved by US FDA	.	.	Clodronic Acid inhibits the expression of SLC1A4	.	.
DTD0132	SLC1A4	Inhibition	Coal Ash	Natural Product	.	.	Coal Ash inhibits the expression of SLC1A4	.	.
DTD0132	SLC1A4	Inducer	Copper Sulfate	Approved Drug	.	.	Copper Sulfate increases the expression of SLC1A4	.	.
DTD0132	SLC1A4	Inducer	Coumestrol	Investigative Drug	.	.	Coumestrol increases the expression of SLC1A4	.	.
DTD0132	SLC1A4	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of SLC1A4	.	.
DTD0132	SLC1A4	Inducer	Dasatinib	Approved Drug	.	.	Dasatinib increases the expression of SLC1A4	.	.
DTD0132	SLC1A4	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC1A4	.	.
DTD0132	SLC1A4	Inducer	Ethyl Methanesulfonate	Carcinogen	.	.	Ethyl Methanesulfonate increases the expression of SLC1A4	.	.
DTD0132	SLC1A4	Inducer	Formaldehyde	Acute Toxic Substance	.	.	Formaldehyde increases the expression of SLC1A4	.	.
DTD0132	SLC1A4	Inducer	Genistein	Drug in Phase 2 Trial	.	.	Genistein increases the expression of SLC1A4	.	.
DTD0132	SLC1A4	Inhibition	GSK-J4	Patented Pharmaceutical Agent	.	.	GSK-J4 inhibits the expression of SLC1A4	.	.
DTD0132	SLC1A4	Inducer	Ibuprofen	Approved Drug	.	.	Ibuprofen increases the expression of SLC1A4	.	.
DTD0132	SLC1A4	Inhibition	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 inhibits the expression of SLC1A4	.	.
DTD0132	SLC1A4	Inducer	K-7174	Patented Pharmaceutical Agent	.	.	K-7174 increases the expression of SLC1A4	.	.
DTD0132	SLC1A4	Inhibition	L-phenylglycine	Investigative Drug	.	.	L-phenylglycine inhibits the activity of SLC1A4	.	.
DTD0132	SLC1A4	Inhibition	Lucanthone	Drug in Phase 2 Trial	.	.	Lucanthone inhibits the expression of SLC1A4	.	.
DTD0132	SLC1A4	Inducer	Motexafin gadolinium	Drug in Phase 2 Trial	.	.	Motexafin gadolinium increases the expression of SLC1A4	.	.
DTD0132	SLC1A4	Inhibition	Ochratoxin A	Acute Toxic Substance	.	.	Ochratoxin A inhibits the expression of SLC1A4	.	.
DTD0132	SLC1A4	Inducer	Perfluorooctane sulfonic acid	Health and Environmental Toxicant	.	.	Perfluorooctane sulfonic acid increases the expression of SLC1A4	.	.
DTD0132	SLC1A4	Inducer	Phenylmercuric Acetate	Investigative Drug	.	.	Phenylmercuric Acetate increases the expression of SLC1A4	.	.
DTD0132	SLC1A4	Inducer	Progesterone	Approved Drug	.	.	Progesterone increases the expression of SLC1A4	.	.
DTD0132	SLC1A4	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC1A4	.	.
DTD0132	SLC1A4	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of SLC1A4	.	.
DTD0132	SLC1A4	Inducer	Thapsigargin	Natural Product	.	.	Thapsigargin increases the expression of SLC1A4	.	.
DTD0132	SLC1A4	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC1A4	.	.
DTD0132	SLC1A4	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC1A4	.	.
DTD0132	SLC1A4	Inducer	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate increases the expression of SLC1A4	.	.
DTD0132	SLC1A4	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC1A4	.	.
DTD0132	SLC1A4	Inhibition	Vorinostat	Approved Drug	.	.	Vorinostat inhibits the expression of SLC1A4	.	.
DTD0132	SLC1A4	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of SLC1A4	.	.
DTD0132	SLC1A4	Inducer	Zinc	Environmental toxicant	.	.	Zinc increases the expression of SLC1A4	.	.
DTD0132	SLC1A4	Inducer	Zinc Acetate	Approved Drug	.	.	Zinc Acetate increases the expression of SLC1A4	.	.
DTD0133	SLC1A5	Inducer	[3H]Glutamine	Investigative Drug	.	.	[3H]Glutamine induces the activity of SLC1A5	.	.
DTD0133	SLC1A5	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of SLC1A5	.	.
DTD0133	SLC1A5	Inducer	Acrylamide	Acute Toxic Substance	.	.	Acrylamide increases the expression of SLC1A5	.	.
DTD0133	SLC1A5	Inhibition	Adenine	Approved Drug	.	.	Adenine inhibits the expression of SLC1A5	.	.
DTD0133	SLC1A5	Inducer	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 increases the expression of SLC1A5	.	.
DTD0133	SLC1A5	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC1A5	.	.
DTD0133	SLC1A5	Inhibition	Benzylserine	Investigative Drug	.	.	Benzylserine inhibits the activity of SLC1A5	.	.
DTD0133	SLC1A5	Inducer	Beta-naphthoflavone	Investigative Drug	.	.	Beta-naphthoflavone increases the expression of SLC1A5	.	.
DTD0133	SLC1A5	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC1A5	.	.
DTD0133	SLC1A5	Inducer	Bisphenol F	Environmental toxicant	.	.	Bisphenol F increases the expression of SLC1A5	.	.
DTD0133	SLC1A5	Inhibition	Chloropicrin	Acute Toxic Substance	.	.	Chloropicrin inhibits the expression of SLC1A5	.	.
DTD0133	SLC1A5	Inducer	Cidofovir	Approved Drug	.	.	Cidofovir increases the expression of SLC1A5	.	.
DTD0133	SLC1A5	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the expression of SLC1A5	.	.
DTD0133	SLC1A5	Inhibition	Clodronic Acid	Drug Marketed but not Approved by US FDA	.	.	Clodronic Acid inhibits the expression of SLC1A5	.	.
DTD0133	SLC1A5	Inhibition	Coal Ash	Natural Product	.	.	Coal Ash inhibits the expression of SLC1A5	.	.
DTD0133	SLC1A5	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of SLC1A5	.	.
DTD0133	SLC1A5	Inhibition	Deoxynivalenol	Mycotoxins	.	.	Deoxynivalenol inhibits the expression of SLC1A5	.	.
DTD0133	SLC1A5	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC1A5	.	.
DTD0133	SLC1A5	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC1A5	.	.
DTD0133	SLC1A5	Inducer	Ethinyl Estradiol	Approved Drug	.	.	Ethinyl Estradiol increases the expression of SLC1A5	.	.
DTD0133	SLC1A5	Inhibition	Etoposide	Approved Drug	.	.	Etoposide inhibits the expression of SLC1A5	.	.
DTD0133	SLC1A5	Inducer	Genistein	Drug in Phase 2 Trial	.	.	Genistein increases the expression of SLC1A5	.	.
DTD0133	SLC1A5	Inhibition	GSK-J4	Patented Pharmaceutical Agent	.	.	GSK-J4 inhibits the expression of SLC1A5	.	.
DTD0133	SLC1A5	Inhibition	Hydroxyurea	Approved Drug	.	.	Hydroxyurea inhibits the expression of SLC1A5	.	.
DTD0133	SLC1A5	Inducer	Ifosfamide	Approved Drug	.	.	Ifosfamide increases the expression of SLC1A5	.	.
DTD0133	SLC1A5	Inducer	Insulin	Approved Drug	.	.	Insulin induces the activity of SLC1A5	.	.
DTD0133	SLC1A5	Inhibition	Ivermectin	Approved Drug	.	.	Ivermectin inhibits the expression of SLC1A5	.	.
DTD0133	SLC1A5	Inducer	K-7174	Patented Pharmaceutical Agent	.	.	K-7174 increases the expression of SLC1A5	.	.
DTD0133	SLC1A5	Inhibition	Mitomycin	Approved Drug	.	.	Mitomycin inhibits the expression of SLC1A5	.	.
DTD0133	SLC1A5	Inducer	NSC-668394	Patented Pharmaceutical Agent	.	.	NSC-668394 increases the expression of SLC1A5	.	.
DTD0133	SLC1A5	Inhibition	Ochratoxin A	Acute Toxic Substance	.	.	Ochratoxin A inhibits the expression of SLC1A5	.	.
DTD0133	SLC1A5	Inducer	Perfluorooctane sulfonic acid	Health and Environmental Toxicant	.	.	Perfluorooctane sulfonic acid increases the expression of SLC1A5	.	.
DTD0133	SLC1A5	Inhibition	P-Nitrophenyl glutamyl anilide	Investigative Drug	.	.	P-Nitrophenyl glutamyl anilide inhibits the activity of SLC1A5	.	.
DTD0133	SLC1A5	Inducer	Resveratrol	Drug in Phase 3 Trial	.	.	Resveratrol increases the expression of SLC1A5	.	.
DTD0133	SLC1A5	Inducer	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite increases the expression of SLC1A5	.	.
DTD0133	SLC1A5	Inducer	Sulforafan	Drug in Phase 3 Trial	.	.	Sulforafan increases the expression of SLC1A5	.	.
DTD0133	SLC1A5	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of SLC1A5	.	.
DTD0133	SLC1A5	Inhibition	Titanium dioxide	Approved Drug	.	.	Titanium dioxide inhibits the expression of SLC1A5	.	.
DTD0133	SLC1A5	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC1A5	.	.
DTD0133	SLC1A5	Inhibition	Zinc chloride	Drug Marketed but not Approved by US FDA	.	.	Zinc chloride inhibits the expression of SLC1A5	.	.
DTD0133	SLC1A5	Inhibition	Zoledronic Acid	Approved Drug	.	.	Zoledronic Acid inhibits the expression of SLC1A5	.	.
DTD0134	SLC1A6	Inhibition	Acrylamide	Acute Toxic Substance	.	.	Acrylamide inhibits the expression of SLC1A6	.	.
DTD0134	SLC1A6	Inhibition	AM-80	Drug in Phase 2/3 Trial	.	.	AM-80 inhibits the expression of SLC1A6	.	.
DTD0134	SLC1A6	Inducer	Calcitriol	Approved Drug	.	.	Calcitriol increases the expression of SLC1A6	.	.
DTD0134	SLC1A6	Inducer	Diethylhexyl Phthalate	Health and Environmental Toxicant	.	.	Diethylhexyl Phthalate increases the expression of SLC1A6	.	.
DTD0134	SLC1A6	Inducer	Diuron	Herbicide	.	.	Diuron increases the expression of SLC1A6	.	.
DTD0134	SLC1A6	Inhibition	DL-TBOA	Investigative Drug	.	.	DL-TBOA inhibits the activity of SLC1A6	.	.
DTD0134	SLC1A6	Inducer	Indomethacin	Approved Drug	.	.	Indomethacin increases the expression of SLC1A6	.	.
DTD0134	SLC1A6	Modulator	Lead	Health and Environmental Toxicant	.	.	Lead affects the expression of SLC1A6	.	.
DTD0134	SLC1A6	Inducer	Milchsaure	Investigative Drug	.	.	Milchsaure increases the expression of SLC1A6	.	.
DTD0134	SLC1A6	Inducer	Omega-3 Fatty acids	Drug in Phase 1 Trial	.	.	Omega-3 Fatty acids increases the expression of SLC1A6	.	.
DTD0134	SLC1A6	Inhibition	Omega-6-FA	Drug in Phase 1 Trial	.	.	Omega-6-FA inhibits the expression of SLC1A6	.	.
DTD0134	SLC1A6	Inhibition	Phenylmercuric Acetate	Investigative Drug	.	.	Phenylmercuric Acetate inhibits the expression of SLC1A6	.	.
DTD0134	SLC1A6	Inducer	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite increases the expression of SLC1A6	.	.
DTD0134	SLC1A6	Inhibition	Threo-3-methylglutamate	Investigative Drug	.	.	Threo-3-methylglutamate inhibits the activity of SLC1A6	.	.
DTD0134	SLC1A6	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC1A6	.	.
DTD0134	SLC1A6	Inhibition	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A inhibits the expression of SLC1A6	.	.
DTD0134	SLC1A6	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC1A6	.	.
DTD0135	SLC1A7	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of SLC1A7	.	.
DTD0135	SLC1A7	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC1A7	.	.
DTD0135	SLC1A7	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC1A7	.	.
DTD0135	SLC1A7	Inducer	Cisplatin	Approved Drug	.	.	Cisplatin increases the expression of SLC1A7	.	.
DTD0135	SLC1A7	Inhibition	DL-TBOA	Investigative Drug	.	.	DL-TBOA inhibits the activity of SLC1A7	.	.
DTD0135	SLC1A7	Inhibition	Dronabinol	Approved Drug	.	.	Dronabinol inhibits the expression of SLC1A7	.	.
DTD0135	SLC1A7	Inducer	Fenofibrate	Approved Drug	.	.	Fenofibrate increases the expression of SLC1A7	.	.
DTD0135	SLC1A7	Inhibition	Folic Acid	Approved Drug	.	.	Folic Acid inhibits the expression of SLC1A7	.	.
DTD0135	SLC1A7	Inhibition	GSK-J4	Patented Pharmaceutical Agent	.	.	GSK-J4 inhibits the expression of SLC1A7	.	.
DTD0135	SLC1A7	Inducer	Ibuprofen	Approved Drug	.	.	Ibuprofen increases the expression of SLC1A7	.	.
DTD0136	SLC20A1	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of SLC20A1	.	.
DTD0136	SLC20A1	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of SLC20A1	.	.
DTD0136	SLC20A1	Inducer	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 increases the expression of SLC20A1	.	.
DTD0136	SLC20A1	Inducer	Azathioprine	Approved Drug	.	.	Azathioprine increases the expression of SLC20A1	.	.
DTD0136	SLC20A1	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC20A1	.	.
DTD0136	SLC20A1	Inducer	Beta-naphthoflavone	Investigative Drug	.	.	Beta-naphthoflavone increases the expression of SLC20A1	.	.
DTD0136	SLC20A1	Modulator	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A affects the expression of SLC20A1	.	.
DTD0136	SLC20A1	Inducer	Catechin	Drug Marketed but not Approved by US FDA	.	.	Catechin increases the expression of SLC20A1	.	.
DTD0136	SLC20A1	Modulator	Chloropicrin	Acute Toxic Substance	.	.	Chloropicrin affects the expression of SLC20A1	.	.
DTD0136	SLC20A1	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the expression of SLC20A1	.	.
DTD0136	SLC20A1	Inducer	Copper Sulfate	Approved Drug	.	.	Copper Sulfate increases the expression of SLC20A1	.	.
DTD0136	SLC20A1	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of SLC20A1	.	.
DTD0136	SLC20A1	Inducer	Cylindrospermopsin	Cyanotoxin	.	.	Cylindrospermopsin increases the expression of SLC20A1	.	.
DTD0136	SLC20A1	Inhibition	Dasatinib	Approved Drug	.	.	Dasatinib inhibits the expression of SLC20A1	.	.
DTD0136	SLC20A1	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC20A1	.	.
DTD0136	SLC20A1	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC20A1	.	.
DTD0136	SLC20A1	Inducer	Flavonoids	Natural Product	.	.	Flavonoids increases the expression of SLC20A1	.	.
DTD0136	SLC20A1	Inhibition	Formaldehyde	Acute Toxic Substance	.	.	Formaldehyde inhibits the expression of SLC20A1	.	.
DTD0136	SLC20A1	Modulator	Hydrogen Peroxide	Approved Drug	.	.	Hydrogen Peroxide affects the expression of SLC20A1	.	.
DTD0136	SLC20A1	Modulator	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 affects the expression of SLC20A1	.	.
DTD0136	SLC20A1	Inducer	Indolo(3,2-b)carbazole	Natural Product	.	.	Indolo(3,2-b)carbazole increases the expression of SLC20A1	.	.
DTD0136	SLC20A1	Inducer	Jinfukang	Traditional Medicine	.	.	Jinfukang increases the expression of SLC20A1	.	.
DTD0136	SLC20A1	Inducer	K-7174	Patented Pharmaceutical Agent	.	.	K-7174 increases the expression of SLC20A1	.	.
DTD0136	SLC20A1	Inducer	Leflunomide	Approved Drug	.	.	Leflunomide increases the expression of SLC20A1	.	.
DTD0136	SLC20A1	Inducer	Lithium Chloride	Health and Environmental Toxicant	.	.	Lithium Chloride increases the expression of SLC20A1	.	.
DTD0136	SLC20A1	Modulator	Menadione	Approved Drug	.	.	Menadione affects the expression of SLC20A1	.	.
DTD0136	SLC20A1	Inducer	Methylparaben	Natural Product	.	.	Methylparaben increases the expression of SLC20A1	.	.
DTD0136	SLC20A1	Inducer	Milchsaure	Investigative Drug	.	.	Milchsaure increases the expression of SLC20A1	.	.
DTD0136	SLC20A1	Modulator	Phenobarbital	Approved Drug	.	.	Phenobarbital affects the expression of SLC20A1	.	.
DTD0136	SLC20A1	Inducer	Phosphate	Investigative Drug	.	.	Phosphate increases the expression of SLC20A1	.	.
DTD0136	SLC20A1	Inducer	Plant Extracts	Plant Extract	.	.	Plant Extracts increases the expression of SLC20A1	.	.
DTD0136	SLC20A1	Inducer	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin increases the expression of SLC20A1	.	.
DTD0136	SLC20A1	Inducer	Polyphenols	Natural Product	.	.	Polyphenols increases the expression of SLC20A1	.	.
DTD0136	SLC20A1	Inducer	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin increases the expression of SLC20A1	.	.
DTD0136	SLC20A1	Inhibition	Sarin	Acute Toxic Substance	.	.	Sarin inhibits the expression of SLC20A1	.	.
DTD0136	SLC20A1	Inducer	Sulforafan	Drug in Phase 3 Trial	.	.	Sulforafan increases the expression of SLC20A1	.	.
DTD0136	SLC20A1	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of SLC20A1	.	.
DTD0136	SLC20A1	Inhibition	Temozolomide	Approved Drug	.	.	Temozolomide inhibits the expression of SLC20A1	.	.
DTD0136	SLC20A1	Inducer	Thapsigargin	Natural Product	.	.	Thapsigargin increases the expression of SLC20A1	.	.
DTD0136	SLC20A1	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC20A1	.	.
DTD0136	SLC20A1	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC20A1	.	.
DTD0136	SLC20A1	Inducer	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate increases the expression of SLC20A1	.	.
DTD0136	SLC20A1	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of SLC20A1	.	.
DTD0136	SLC20A1	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC20A1	.	.
DTD0136	SLC20A1	Inhibition	Vincristine	Approved Drug	.	.	Vincristine inhibits the expression of SLC20A1	.	.
DTD0136	SLC20A1	Inhibition	Zidovudine	Approved Drug	.	.	Zidovudine inhibits the expression of SLC20A1	.	.
DTD0137	SLC20A2	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC20A2	.	.
DTD0137	SLC20A2	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC20A2	.	.
DTD0137	SLC20A2	Inducer	Cadmium	Acute Toxic Substance	.	.	Cadmium increases the expression of SLC20A2	.	.
DTD0137	SLC20A2	Inducer	Copper Sulfate	Approved Drug	.	.	Copper Sulfate increases the expression of SLC20A2	.	.
DTD0137	SLC20A2	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC20A2	.	.
DTD0137	SLC20A2	Inducer	Dicrotophos	Pesticide/Insecticide	.	.	Dicrotophos increases the expression of SLC20A2	.	.
DTD0137	SLC20A2	Inducer	Leflunomide	Approved Drug	.	.	Leflunomide increases the expression of SLC20A2	.	.
DTD0137	SLC20A2	Modulator	Menadione	Approved Drug	.	.	Menadione affects the expression of SLC20A2	.	.
DTD0137	SLC20A2	Inducer	Phosphate	Investigative Drug	.	.	Phosphate increases the expression of SLC20A2	.	.
DTD0137	SLC20A2	Inhibition	Phosphonoformate	Approved Drug	.	.	Phosphonoformate inhibits the activity of SLC20A2	.	.
DTD0137	SLC20A2	Inducer	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin increases the expression of SLC20A2	.	.
DTD0137	SLC20A2	Inhibition	Rifampin	Approved Drug	.	.	Rifampin inhibits the expression of SLC20A2	.	.
DTD0137	SLC20A2	Inducer	Silver nanoparticle	Nanoparticle	.	.	Silver nanoparticle increases the expression of SLC20A2	.	.
DTD0137	SLC20A2	Inducer	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite increases the expression of SLC20A2	.	.
DTD0137	SLC20A2	Inhibition	Sunitinib	Approved Drug	.	.	Sunitinib inhibits the expression of SLC20A2	.	.
DTD0137	SLC20A2	Inducer	Testosterone	Approved Drug	.	.	Testosterone increases the expression of SLC20A2	.	.
DTD0137	SLC20A2	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC20A2	.	.
DTD0137	SLC20A2	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC20A2	.	.
DTD0137	SLC20A2	Inhibition	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan inhibits the expression of SLC20A2	.	.
DTD0137	SLC20A2	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of SLC20A2	.	.
DTD0137	SLC20A2	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of SLC20A2	.	.
DTD0139	SLC22A13	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC22A13	.	.
DTD0139	SLC22A13	Inducer	Methotrexate	Approved Drug	.	.	Methotrexate increases the expression of SLC22A13	.	.
DTD0139	SLC22A13	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC22A13	.	.
DTD0142	SLC22A16	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of SLC22A16	.	.
DTD0142	SLC22A16	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC22A16	.	.
DTD0142	SLC22A16	Inhibition	Folic Acid	Approved Drug	.	.	Folic Acid inhibits the expression of SLC22A16	.	.
DTD0142	SLC22A16	Inducer	MS-275	Drug in Phase 2 Trial	.	.	MS-275 increases the expression of SLC22A16	.	.
DTD0142	SLC22A16	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC22A16	.	.
DTD0142	SLC22A16	Inducer	Vanadyl sulfate	Drug in Phase 3 Trial	.	.	Vanadyl sulfate increases the expression of SLC22A16	.	.
DTD0143	SLC22A17	Inducer	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 increases the expression of SLC22A17	.	.
DTD0143	SLC22A17	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC22A17	.	.
DTD0143	SLC22A17	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC22A17	.	.
DTD0143	SLC22A17	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC22A17	.	.
DTD0143	SLC22A17	Inducer	Genistein	Drug in Phase 2 Trial	.	.	Genistein increases the expression of SLC22A17	.	.
DTD0143	SLC22A17	Inducer	Jinfukang	Traditional Medicine	.	.	Jinfukang increases the expression of SLC22A17	.	.
DTD0143	SLC22A17	Modulator	Lead	Health and Environmental Toxicant	.	.	Lead affects the expression of SLC22A17	.	.
DTD0143	SLC22A17	Inducer	MS-275	Drug in Phase 2 Trial	.	.	MS-275 increases the expression of SLC22A17	.	.
DTD0143	SLC22A17	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC22A17	.	.
DTD0143	SLC22A17	Inhibition	Sunitinib	Approved Drug	.	.	Sunitinib inhibits the expression of SLC22A17	.	.
DTD0143	SLC22A17	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC22A17	.	.
DTD0143	SLC22A17	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC22A17	.	.
DTD0143	SLC22A17	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of SLC22A17	.	.
DTD0145	SLC22A20	Inducer	2-methyl-4-isothiazolin-3-one	Acute Toxic Substance	.	.	2-methyl-4-isothiazolin-3-one increases the expression of SLC22A20	.	.
DTD0145	SLC22A20	Inducer	Enniatins	Acute Toxic Substance	.	.	Enniatins increases the expression of SLC22A20	.	.
DTD0145	SLC22A20	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC22A20	.	.
DTD0146	SLC22A23	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC22A23	.	.
DTD0146	SLC22A23	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC22A23	.	.
DTD0146	SLC22A23	Inhibition	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde inhibits the expression of SLC22A23	.	.
DTD0146	SLC22A23	Inducer	Calcitriol	Approved Drug	.	.	Calcitriol increases the expression of SLC22A23	.	.
DTD0146	SLC22A23	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the expression of SLC22A23	.	.
DTD0146	SLC22A23	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC22A23	.	.
DTD0146	SLC22A23	Inhibition	Coumestrol	Investigative Drug	.	.	Coumestrol inhibits the expression of SLC22A23	.	.
DTD0146	SLC22A23	Inhibition	Formaldehyde	Acute Toxic Substance	.	.	Formaldehyde inhibits the expression of SLC22A23	.	.
DTD0146	SLC22A23	Inhibition	GSK-J4	Patented Pharmaceutical Agent	.	.	GSK-J4 inhibits the expression of SLC22A23	.	.
DTD0146	SLC22A23	Modulator	Menadione	Approved Drug	.	.	Menadione affects the expression of SLC22A23	.	.
DTD0146	SLC22A23	Inducer	Phenylmercuric Acetate	Investigative Drug	.	.	Phenylmercuric Acetate increases the expression of SLC22A23	.	.
DTD0146	SLC22A23	Inducer	Sulforafan	Drug in Phase 3 Trial	.	.	Sulforafan increases the expression of SLC22A23	.	.
DTD0146	SLC22A23	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of SLC22A23	.	.
DTD0146	SLC22A23	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of SLC22A23	.	.
DTD0146	SLC22A23	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC22A23	.	.
DTD0146	SLC22A23	Inducer	Vincristine	Approved Drug	.	.	Vincristine increases the expression of SLC22A23	.	.
DTD0146	SLC22A23	Inducer	Zoledronic Acid	Approved Drug	.	.	Zoledronic Acid increases the expression of SLC22A23	.	.
DTD0148	SLC22A25	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC22A25	.	.
DTD0148	SLC22A25	Inhibition	Methyleugenol	Natural Product	.	.	Methyleugenol inhibits the expression of SLC22A25	.	.
DTD0148	SLC22A25	Inhibition	Perfluorooctane sulfonic acid	Health and Environmental Toxicant	.	.	Perfluorooctane sulfonic acid inhibits the expression of SLC22A25	.	.
DTD0151	SLC22A4	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC22A4	.	.
DTD0151	SLC22A4	Inducer	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 increases the expression of SLC22A4	.	.
DTD0151	SLC22A4	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of SLC22A4	.	.
DTD0151	SLC22A4	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC22A4	.	.
DTD0151	SLC22A4	Inhibition	Cadmium	Acute Toxic Substance	.	.	Cadmium inhibits the activity of SLC22A4	.	.
DTD0151	SLC22A4	Inhibition	Cimetidine	Approved Drug	.	.	Cimetidine inhibits the activity of SLC22A4	.	.
DTD0151	SLC22A4	Inducer	Cycloheximide	Acute Toxic Substance	.	.	Cycloheximide increases the expression of SLC22A4	.	.
DTD0151	SLC22A4	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of SLC22A4	.	.
DTD0151	SLC22A4	Inducer	Decitabine	Approved Drug	.	.	Decitabine increases the expression of SLC22A4	.	.
DTD0151	SLC22A4	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC22A4	.	.
DTD0151	SLC22A4	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC22A4	.	.
DTD0151	SLC22A4	Inducer	Formaldehyde	Acute Toxic Substance	.	.	Formaldehyde increases the expression of SLC22A4	.	.
DTD0151	SLC22A4	Inhibition	Leflunomide	Approved Drug	.	.	Leflunomide inhibits the expression of SLC22A4	.	.
DTD0151	SLC22A4	Inducer	Particulate Matter	Natural Product	.	.	Particulate Matter increases the expression of SLC22A4	.	.
DTD0151	SLC22A4	Inducer	Perfluorooctane sulfonic acid	Health and Environmental Toxicant	.	.	Perfluorooctane sulfonic acid increases the expression of SLC22A4	.	.
DTD0151	SLC22A4	Inducer	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin increases the expression of SLC22A4	.	.
DTD0151	SLC22A4	Inhibition	Thimerosal	Acute Toxic Substance	.	.	Thimerosal inhibits the activity of SLC22A4	.	.
DTD0151	SLC22A4	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC22A4	.	.
DTD0151	SLC22A4	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of SLC22A4	.	.
DTD0151	SLC22A4	Inducer	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate increases the expression of SLC22A4	.	.
DTD0151	SLC22A4	Inducer	Troglitazone	Approved Drug	.	.	Troglitazone increases the expression of SLC22A4	.	.
DTD0151	SLC22A4	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC22A4	.	.
DTD0151	SLC22A4	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of SLC22A4	.	.
DTD0151	SLC22A4	Inducer	Zoledronic Acid	Approved Drug	.	.	Zoledronic Acid increases the expression of SLC22A4	.	.
DTD0152	SLC22A9	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the activity of SLC22A9	.	.
DTD0152	SLC22A9	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC22A9	.	.
DTD0152	SLC22A9	Inhibition	Aspirin	Approved Drug	.	.	Aspirin inhibits the activity of SLC22A9	.	.
DTD0152	SLC22A9	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC22A9	.	.
DTD0152	SLC22A9	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC22A9	.	.
DTD0152	SLC22A9	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC22A9	.	.
DTD0152	SLC22A9	Inhibition	Diclofenac	Approved Drug	.	.	Diclofenac inhibits the activity of SLC22A9	.	.
DTD0152	SLC22A9	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the expression of SLC22A9	.	.
DTD0152	SLC22A9	Inhibition	Heliotrine	Natural Product	.	.	Heliotrine inhibits the expression of SLC22A9	.	.
DTD0152	SLC22A9	Inhibition	Ibuprofen	Approved Drug	.	.	Ibuprofen inhibits the activity of SLC22A9	.	.
DTD0152	SLC22A9	Inhibition	Indomethacin	Approved Drug	.	.	Indomethacin inhibits the activity of SLC22A9	.	.
DTD0152	SLC22A9	Inhibition	Ketoprofen	Approved Drug	.	.	Ketoprofen inhibits the activity of SLC22A9	.	.
DTD0152	SLC22A9	Inhibition	Mefenamic Acid	Approved Drug	.	.	Mefenamic Acid inhibits the activity of SLC22A9	.	.
DTD0152	SLC22A9	Inhibition	Methyleugenol	Natural Product	.	.	Methyleugenol inhibits the expression of SLC22A9	.	.
DTD0152	SLC22A9	Inhibition	Naproxen	Approved Drug	.	.	Naproxen inhibits the activity of SLC22A9	.	.
DTD0152	SLC22A9	Inhibition	Phenacetin	Drug Withdrawn	.	.	Phenacetin inhibits the activity of SLC22A9	.	.
DTD0152	SLC22A9	Modulator	Phenobarbital	Approved Drug	.	.	Phenobarbital affects the expression of SLC22A9	.	.
DTD0152	SLC22A9	Inhibition	Piroxicam	Approved Drug	.	.	Piroxicam inhibits the activity of SLC22A9	.	.
DTD0152	SLC22A9	Inhibition	Probenecid	Approved Drug	.	.	Probenecid inhibits the activity of SLC22A9	.	.
DTD0152	SLC22A9	Inhibition	Progesterone	Approved Drug	.	.	Progesterone inhibits the activity of SLC22A9	.	.
DTD0152	SLC22A9	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of SLC22A9	.	.
DTD0152	SLC22A9	Inhibition	Rifampin	Approved Drug	.	.	Rifampin inhibits the expression of SLC22A9	.	.
DTD0152	SLC22A9	Inhibition	Rosiglitazone	Approved Drug	.	.	Rosiglitazone inhibits the expression of SLC22A9	.	.
DTD0152	SLC22A9	Inhibition	Salicylic Acid	Drug in Phase 2/3 Trial	.	.	Salicylic Acid inhibits the activity of SLC22A9	.	.
DTD0152	SLC22A9	Inhibition	Senecionine	Natural Product	.	.	Senecionine inhibits the expression of SLC22A9	.	.
DTD0152	SLC22A9	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC22A9	.	.
DTD0152	SLC22A9	Inhibition	Sulindac	Approved Drug	.	.	Sulindac inhibits the activity of SLC22A9	.	.
DTD0152	SLC22A9	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the activity of SLC22A9	.	.
DTD0152	SLC22A9	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of SLC22A9	.	.
DTD0152	SLC22A9	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC22A9	.	.
DTD0152	SLC22A9	Inhibition	Zidovudine	Approved Drug	.	.	Zidovudine inhibits the expression of SLC22A9	.	.
DTD0155	SLC22B3	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC22B3	.	.
DTD0155	SLC22B3	Inducer	Panobinostat	Approved Drug	.	.	Panobinostat increases the expression of SLC22B3	.	.
DTD0155	SLC22B3	Inducer	Phenylmercuric Acetate	Investigative Drug	.	.	Phenylmercuric Acetate increases the expression of SLC22B3	.	.
DTD0155	SLC22B3	Inducer	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite increases the expression of SLC22B3	.	.
DTD0155	SLC22B3	Inducer	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A increases the expression of SLC22B3	.	.
DTD0155	SLC22B3	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC22B3	.	.
DTD0155	SLC22B3	Inducer	Vorinostat	Approved Drug	.	.	Vorinostat increases the expression of SLC22B3	.	.
DTD0158	SLC23A1	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC23A1	.	.
DTD0158	SLC23A1	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC23A1	.	.
DTD0158	SLC23A1	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC23A1	.	.
DTD0158	SLC23A1	Inducer	Bilirubin	Natural Product	.	.	Bilirubin increases the expression of SLC23A1	.	.
DTD0158	SLC23A1	Inhibition	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A inhibits the expression of SLC23A1	.	.
DTD0158	SLC23A1	Inhibition	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde inhibits the expression of SLC23A1	.	.
DTD0158	SLC23A1	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC23A1	.	.
DTD0158	SLC23A1	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC23A1	.	.
DTD0158	SLC23A1	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the expression of SLC23A1	.	.
DTD0158	SLC23A1	Inhibition	Methyleugenol	Natural Product	.	.	Methyleugenol inhibits the expression of SLC23A1	.	.
DTD0158	SLC23A1	Inhibition	Pentanal	Chemical Compound	.	.	Pentanal inhibits the expression of SLC23A1	.	.
DTD0158	SLC23A1	Inhibition	Phloretin	Investigative Drug	.	.	Phloretin inhibits the activity of SLC23A1	.	.
DTD0158	SLC23A1	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of SLC23A1	.	.
DTD0158	SLC23A1	Inducer	Taurocholic Acid	Drug in Phase 2 Trial	.	.	Taurocholic Acid increases the expression of SLC23A1	.	.
DTD0158	SLC23A1	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC23A1	.	.
DTD0158	SLC23A1	Inhibition	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate inhibits the expression of SLC23A1	.	.
DTD0158	SLC23A1	Inducer	Ursodeoxycholic Acid	Approved Drug	.	.	Ursodeoxycholic Acid increases the expression of SLC23A1	.	.
DTD0158	SLC23A1	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC23A1	.	.
DTD0158	SLC23A1	Modulator	Vitamin C	Approved Drug	.	.	Vitamin C modulates the activity of SLC23A1	.	.
DTD0159	SLC23A2	Inducer	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 increases the expression of SLC23A2	.	.
DTD0159	SLC23A2	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC23A2	.	.
DTD0159	SLC23A2	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of SLC23A2	.	.
DTD0159	SLC23A2	Inducer	Bilirubin	Natural Product	.	.	Bilirubin increases the expression of SLC23A2	.	.
DTD0159	SLC23A2	Inhibition	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A inhibits the expression of SLC23A2	.	.
DTD0159	SLC23A2	Inhibition	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde inhibits the expression of SLC23A2	.	.
DTD0159	SLC23A2	Inducer	Carbamazepine	Approved Drug	.	.	Carbamazepine increases the expression of SLC23A2	.	.
DTD0159	SLC23A2	Activator	Chenodeoxycholic acid	Approved Drug	.	.	Chenodeoxycholic acid activates the activity of SLC23A2	.	.
DTD0159	SLC23A2	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of SLC23A2	.	.
DTD0159	SLC23A2	Inducer	Dicrotophos	Pesticide/Insecticide	.	.	Dicrotophos increases the expression of SLC23A2	.	.
DTD0159	SLC23A2	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC23A2	.	.
DTD0159	SLC23A2	Inducer	Dronabinol	Approved Drug	.	.	Dronabinol increases the expression of SLC23A2	.	.
DTD0159	SLC23A2	Modulator	Lead	Health and Environmental Toxicant	.	.	Lead affects the expression of SLC23A2	.	.
DTD0159	SLC23A2	Inducer	Leflunomide	Approved Drug	.	.	Leflunomide increases the expression of SLC23A2	.	.
DTD0159	SLC23A2	Inhibition	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin inhibits the expression of SLC23A2	.	.
DTD0159	SLC23A2	Inducer	Rifampin	Approved Drug	.	.	Rifampin increases the expression of SLC23A2	.	.
DTD0159	SLC23A2	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of SLC23A2	.	.
DTD0159	SLC23A2	Inducer	Taurocholic Acid	Drug in Phase 2 Trial	.	.	Taurocholic Acid increases the expression of SLC23A2	.	.
DTD0159	SLC23A2	Inducer	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A increases the expression of SLC23A2	.	.
DTD0159	SLC23A2	Inducer	Ursodeoxycholic Acid	Approved Drug	.	.	Ursodeoxycholic Acid increases the expression of SLC23A2	.	.
DTD0159	SLC23A2	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC23A2	.	.
DTD0159	SLC23A2	Modulator	Vitamin C	Approved Drug	.	.	Vitamin C modulates the activity of SLC23A2	.	.
DTD0159	SLC23A2	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of SLC23A2	.	.
DTD0159	SLC23A2	Inducer	Zoledronic Acid	Approved Drug	.	.	Zoledronic Acid increases the expression of SLC23A2	.	.
DTD0160	SLC23A3	Inducer	Arbutin	Drug Marketed but not Approved by US FDA	.	.	Arbutin increases the expression of SLC23A3	.	.
DTD0160	SLC23A3	Modulator	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin affects the expression of SLC23A3	.	.
DTD0160	SLC23A3	Inhibition	Rifampin	Approved Drug	.	.	Rifampin inhibits the expression of SLC23A3	.	.
DTD0160	SLC23A3	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC23A3	.	.
DTD0160	SLC23A3	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC23A3	.	.
DTD0160	SLC23A3	Inducer	Urethane	Approved Drug	.	.	Urethane increases the expression of SLC23A3	.	.
DTD0162	SLC24A1	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC24A1	.	.
DTD0162	SLC24A1	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC24A1	.	.
DTD0162	SLC24A1	Inhibition	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde inhibits the expression of SLC24A1	.	.
DTD0162	SLC24A1	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the expression of SLC24A1	.	.
DTD0162	SLC24A1	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC24A1	.	.
DTD0162	SLC24A1	Inducer	Dicrotophos	Pesticide/Insecticide	.	.	Dicrotophos increases the expression of SLC24A1	.	.
DTD0162	SLC24A1	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC24A1	.	.
DTD0162	SLC24A1	Inducer	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 increases the expression of SLC24A1	.	.
DTD0162	SLC24A1	Inhibition	Pentanal	Chemical Compound	.	.	Pentanal inhibits the expression of SLC24A1	.	.
DTD0162	SLC24A1	Inhibition	Sunitinib	Approved Drug	.	.	Sunitinib inhibits the expression of SLC24A1	.	.
DTD0162	SLC24A1	Inducer	Titanium dioxide	Approved Drug	.	.	Titanium dioxide increases the expression of SLC24A1	.	.
DTD0162	SLC24A1	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC24A1	.	.
DTD0162	SLC24A1	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of SLC24A1	.	.
DTD0163	SLC24A2	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC24A2	.	.
DTD0163	SLC24A2	Inhibition	Calcitriol	Approved Drug	.	.	Calcitriol inhibits the expression of SLC24A2	.	.
DTD0163	SLC24A2	Inhibition	Folic Acid	Approved Drug	.	.	Folic Acid inhibits the expression of SLC24A2	.	.
DTD0163	SLC24A2	Inducer	Pentanal	Chemical Compound	.	.	Pentanal increases the expression of SLC24A2	.	.
DTD0163	SLC24A2	Inducer	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite increases the expression of SLC24A2	.	.
DTD0164	SLC24A3	Inhibition	1-methyl-4-phenylpyridinium	Health and Environmental Toxicant	.	.	1-methyl-4-phenylpyridinium inhibits the expression of SLC24A3	.	.
DTD0164	SLC24A3	Inducer	Arsenic Trioxide	Approved Drug	.	.	Arsenic Trioxide increases the expression of SLC24A3	.	.
DTD0164	SLC24A3	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC24A3	.	.
DTD0164	SLC24A3	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the expression of SLC24A3	.	.
DTD0164	SLC24A3	Modulator	Lead	Health and Environmental Toxicant	.	.	Lead affects the expression of SLC24A3	.	.
DTD0164	SLC24A3	Inhibition	Milchsaure	Investigative Drug	.	.	Milchsaure inhibits the expression of SLC24A3	.	.
DTD0164	SLC24A3	Inducer	MS-275	Drug in Phase 2 Trial	.	.	MS-275 increases the expression of SLC24A3	.	.
DTD0164	SLC24A3	Inducer	Panobinostat	Approved Drug	.	.	Panobinostat increases the expression of SLC24A3	.	.
DTD0164	SLC24A3	Inhibition	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin inhibits the expression of SLC24A3	.	.
DTD0164	SLC24A3	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of SLC24A3	.	.
DTD0164	SLC24A3	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC24A3	.	.
DTD0164	SLC24A3	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of SLC24A3	.	.
DTD0164	SLC24A3	Inducer	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan increases the expression of SLC24A3	.	.
DTD0164	SLC24A3	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC24A3	.	.
DTD0165	SLC24A4	Inhibition	1-methyl-4-phenylpyridinium	Health and Environmental Toxicant	.	.	1-methyl-4-phenylpyridinium inhibits the expression of SLC24A4	.	.
DTD0165	SLC24A4	Inducer	Atrazine	Herbicide	.	.	Atrazine increases the expression of SLC24A4	.	.
DTD0165	SLC24A4	Inhibition	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A inhibits the expression of SLC24A4	.	.
DTD0165	SLC24A4	Inducer	Pentanal	Chemical Compound	.	.	Pentanal increases the expression of SLC24A4	.	.
DTD0165	SLC24A4	Inhibition	Rotenone	Drug Marketed but not Approved by US FDA	.	.	Rotenone inhibits the expression of SLC24A4	.	.
DTD0165	SLC24A4	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of SLC24A4	.	.
DTD0166	SLC24A5	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC24A5	.	.
DTD0166	SLC24A5	Modulator	Polychlorinated Biphenyls	Carcinogen	.	.	Polychlorinated Biphenyls affects the expression of SLC24A5	.	.
DTD0166	SLC24A5	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC24A5	.	.
DTD0167	SLC25A1	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of SLC25A1	.	.
DTD0167	SLC25A1	Inducer	Afimoxifene	Drug in Phase 3 Trial	.	.	Afimoxifene increases the expression of SLC25A1	.	.
DTD0167	SLC25A1	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC25A1	.	.
DTD0167	SLC25A1	Inducer	Atrazine	Herbicide	.	.	Atrazine increases the expression of SLC25A1	.	.
DTD0167	SLC25A1	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC25A1	.	.
DTD0167	SLC25A1	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC25A1	.	.
DTD0167	SLC25A1	Inducer	Bisphenol B	Drug in Phase 2 Trial	.	.	Bisphenol B increases the expression of SLC25A1	.	.
DTD0167	SLC25A1	Inducer	Bisphenol F	Environmental toxicant	.	.	Bisphenol F increases the expression of SLC25A1	.	.
DTD0167	SLC25A1	Inducer	Cannabidiol	Approved Drug	.	.	Cannabidiol increases the expression of SLC25A1	.	.
DTD0167	SLC25A1	Inducer	Cisplatin	Approved Drug	.	.	Cisplatin increases the expression of SLC25A1	.	.
DTD0167	SLC25A1	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC25A1	.	.
DTD0167	SLC25A1	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC25A1	.	.
DTD0167	SLC25A1	Inducer	Decitabine	Approved Drug	.	.	Decitabine increases the expression of SLC25A1	.	.
DTD0167	SLC25A1	Inducer	Dexamethasone	Approved Drug	.	.	Dexamethasone increases the expression of SLC25A1	.	.
DTD0167	SLC25A1	Inducer	Doxorubicin	Approved Drug	.	.	Doxorubicin increases the expression of SLC25A1	.	.
DTD0167	SLC25A1	Inhibition	Formaldehyde	Acute Toxic Substance	.	.	Formaldehyde inhibits the expression of SLC25A1	.	.
DTD0167	SLC25A1	Inhibition	Ivermectin	Approved Drug	.	.	Ivermectin inhibits the expression of SLC25A1	.	.
DTD0167	SLC25A1	Inducer	Jinfukang	Traditional Medicine	.	.	Jinfukang increases the expression of SLC25A1	.	.
DTD0167	SLC25A1	Inhibition	K-7174	Patented Pharmaceutical Agent	.	.	K-7174 inhibits the expression of SLC25A1	.	.
DTD0167	SLC25A1	Inhibition	Obeticholic acid	Approved Drug	.	.	Obeticholic acid inhibits the expression of SLC25A1	.	.
DTD0167	SLC25A1	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of SLC25A1	.	.
DTD0167	SLC25A1	Inducer	Selenium nanoparticles	Natural Product	.	.	Selenium nanoparticles increases the expression of SLC25A1	.	.
DTD0167	SLC25A1	Inhibition	Sulindac sulfide	Drug in Phase 2 Trial	.	.	Sulindac sulfide inhibits the expression of SLC25A1	.	.
DTD0167	SLC25A1	Inhibition	Temozolomide	Approved Drug	.	.	Temozolomide inhibits the expression of SLC25A1	.	.
DTD0167	SLC25A1	Inhibition	Thapsigargin	Natural Product	.	.	Thapsigargin inhibits the expression of SLC25A1	.	.
DTD0167	SLC25A1	Inhibition	Thimerosal	Acute Toxic Substance	.	.	Thimerosal inhibits the expression of SLC25A1	.	.
DTD0167	SLC25A1	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC25A1	.	.
DTD0167	SLC25A1	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of SLC25A1	.	.
DTD0167	SLC25A1	Inducer	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A increases the expression of SLC25A1	.	.
DTD0167	SLC25A1	Inhibition	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate inhibits the expression of SLC25A1	.	.
DTD0167	SLC25A1	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC25A1	.	.
DTD0167	SLC25A1	Inhibition	Vincristine	Approved Drug	.	.	Vincristine inhibits the expression of SLC25A1	.	.
DTD0167	SLC25A1	Inducer	Vitamin E	Drug in Phase 3 Trial	.	.	Vitamin E increases the expression of SLC25A1	.	.
DTD0167	SLC25A1	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of SLC25A1	.	.
DTD0168	SLC25A10	Modulator	Acetaminophen	Approved Drug	.	.	Acetaminophen affects the expression of SLC25A10	.	.
DTD0168	SLC25A10	Inhibition	Acrylamide	Acute Toxic Substance	.	.	Acrylamide inhibits the expression of SLC25A10	.	.
DTD0168	SLC25A10	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC25A10	.	.
DTD0168	SLC25A10	Inhibition	Atrazine	Herbicide	.	.	Atrazine inhibits the expression of SLC25A10	.	.
DTD0168	SLC25A10	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC25A10	.	.
DTD0168	SLC25A10	Modulator	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A affects the expression of SLC25A10	.	.
DTD0168	SLC25A10	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the expression of SLC25A10	.	.
DTD0168	SLC25A10	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC25A10	.	.
DTD0168	SLC25A10	Inhibition	Formaldehyde	Acute Toxic Substance	.	.	Formaldehyde inhibits the expression of SLC25A10	.	.
DTD0168	SLC25A10	Inhibition	GSK-J4	Patented Pharmaceutical Agent	.	.	GSK-J4 inhibits the expression of SLC25A10	.	.
DTD0168	SLC25A10	Inducer	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 increases the expression of SLC25A10	.	.
DTD0168	SLC25A10	Inducer	Jinfukang	Traditional Medicine	.	.	Jinfukang increases the expression of SLC25A10	.	.
DTD0168	SLC25A10	Inhibition	K-7174	Patented Pharmaceutical Agent	.	.	K-7174 inhibits the expression of SLC25A10	.	.
DTD0168	SLC25A10	Inhibition	Obeticholic acid	Approved Drug	.	.	Obeticholic acid inhibits the expression of SLC25A10	.	.
DTD0168	SLC25A10	Inhibition	Plant Extracts	Plant Extract	.	.	Plant Extracts inhibits the expression of SLC25A10	.	.
DTD0168	SLC25A10	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC25A10	.	.
DTD0168	SLC25A10	Inducer	Temozolomide	Approved Drug	.	.	Temozolomide increases the expression of SLC25A10	.	.
DTD0168	SLC25A10	Inducer	Tetrahydropalmatine	Drug in Phase 2 Trial	.	.	Tetrahydropalmatine increases the expression of SLC25A10	.	.
DTD0168	SLC25A10	Inhibition	Thapsigargin	Natural Product	.	.	Thapsigargin inhibits the expression of SLC25A10	.	.
DTD0168	SLC25A10	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC25A10	.	.
DTD0168	SLC25A10	Inhibition	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate inhibits the expression of SLC25A10	.	.
DTD0168	SLC25A10	Inhibition	Troglitazone	Approved Drug	.	.	Troglitazone inhibits the expression of SLC25A10	.	.
DTD0168	SLC25A10	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of SLC25A10	.	.
DTD0168	SLC25A10	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC25A10	.	.
DTD0168	SLC25A10	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of SLC25A10	.	.
DTD0169	SLC25A11	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of SLC25A11	.	.
DTD0169	SLC25A11	Inhibition	Acrylamide	Acute Toxic Substance	.	.	Acrylamide inhibits the expression of SLC25A11	.	.
DTD0169	SLC25A11	Inhibition	Atrazine	Herbicide	.	.	Atrazine inhibits the expression of SLC25A11	.	.
DTD0169	SLC25A11	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC25A11	.	.
DTD0169	SLC25A11	Inducer	Bisphenol B	Drug in Phase 2 Trial	.	.	Bisphenol B increases the expression of SLC25A11	.	.
DTD0169	SLC25A11	Inhibition	Bortezomib	Approved Drug	.	.	Bortezomib inhibits the expression of SLC25A11	.	.
DTD0169	SLC25A11	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC25A11	.	.
DTD0169	SLC25A11	Inducer	Coumestrol	Investigative Drug	.	.	Coumestrol increases the expression of SLC25A11	.	.
DTD0169	SLC25A11	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC25A11	.	.
DTD0169	SLC25A11	Inducer	Doxorubicin	Approved Drug	.	.	Doxorubicin increases the expression of SLC25A11	.	.
DTD0169	SLC25A11	Inhibition	GSK-J4	Patented Pharmaceutical Agent	.	.	GSK-J4 inhibits the expression of SLC25A11	.	.
DTD0169	SLC25A11	Inhibition	Isotretinoin	Approved Drug	.	.	Isotretinoin inhibits the expression of SLC25A11	.	.
DTD0169	SLC25A11	Inhibition	Ivermectin	Approved Drug	.	.	Ivermectin inhibits the expression of SLC25A11	.	.
DTD0169	SLC25A11	Inducer	Jinfukang	Traditional Medicine	.	.	Jinfukang increases the expression of SLC25A11	.	.
DTD0169	SLC25A11	Inhibition	K-7174	Patented Pharmaceutical Agent	.	.	K-7174 inhibits the expression of SLC25A11	.	.
DTD0169	SLC25A11	Inducer	Resveratrol	Drug in Phase 3 Trial	.	.	Resveratrol increases the expression of SLC25A11	.	.
DTD0169	SLC25A11	Inducer	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite increases the expression of SLC25A11	.	.
DTD0169	SLC25A11	Inhibition	Sunitinib	Approved Drug	.	.	Sunitinib inhibits the expression of SLC25A11	.	.
DTD0169	SLC25A11	Inhibition	Thapsigargin	Natural Product	.	.	Thapsigargin inhibits the expression of SLC25A11	.	.
DTD0169	SLC25A11	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of SLC25A11	.	.
DTD0169	SLC25A11	Inhibition	Vincristine	Approved Drug	.	.	Vincristine inhibits the expression of SLC25A11	.	.
DTD0169	SLC25A11	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of SLC25A11	.	.
DTD0170	SLC25A12	Modulator	Acetaminophen	Approved Drug	.	.	Acetaminophen affects the expression of SLC25A12	.	.
DTD0170	SLC25A12	Inhibition	Atrazine	Herbicide	.	.	Atrazine inhibits the expression of SLC25A12	.	.
DTD0170	SLC25A12	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC25A12	.	.
DTD0170	SLC25A12	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC25A12	.	.
DTD0170	SLC25A12	Modulator	Carbamazepine	Approved Drug	.	.	Carbamazepine affects the expression of SLC25A12	.	.
DTD0170	SLC25A12	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC25A12	.	.
DTD0170	SLC25A12	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC25A12	.	.
DTD0170	SLC25A12	Inhibition	Dicrotophos	Pesticide/Insecticide	.	.	Dicrotophos inhibits the expression of SLC25A12	.	.
DTD0170	SLC25A12	Inhibition	Diethylhexyl Phthalate	Health and Environmental Toxicant	.	.	Diethylhexyl Phthalate inhibits the expression of SLC25A12	.	.
DTD0170	SLC25A12	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC25A12	.	.
DTD0170	SLC25A12	Inhibition	Ivermectin	Approved Drug	.	.	Ivermectin inhibits the expression of SLC25A12	.	.
DTD0170	SLC25A12	Inducer	MS-275	Drug in Phase 2 Trial	.	.	MS-275 increases the expression of SLC25A12	.	.
DTD0170	SLC25A12	Inhibition	Obeticholic acid	Approved Drug	.	.	Obeticholic acid inhibits the expression of SLC25A12	.	.
DTD0170	SLC25A12	Inducer	Panobinostat	Approved Drug	.	.	Panobinostat increases the expression of SLC25A12	.	.
DTD0170	SLC25A12	Inducer	Phenylmercuric Acetate	Investigative Drug	.	.	Phenylmercuric Acetate increases the expression of SLC25A12	.	.
DTD0170	SLC25A12	Inhibition	Piroxicam	Approved Drug	.	.	Piroxicam inhibits the expression of SLC25A12	.	.
DTD0170	SLC25A12	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of SLC25A12	.	.
DTD0170	SLC25A12	Inhibition	Selenium nanoparticles	Natural Product	.	.	Selenium nanoparticles inhibits the expression of SLC25A12	.	.
DTD0170	SLC25A12	Inducer	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite increases the expression of SLC25A12	.	.
DTD0170	SLC25A12	Inhibition	Temozolomide	Approved Drug	.	.	Temozolomide inhibits the expression of SLC25A12	.	.
DTD0170	SLC25A12	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC25A12	.	.
DTD0170	SLC25A12	Inducer	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A increases the expression of SLC25A12	.	.
DTD0170	SLC25A12	Inhibition	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan inhibits the expression of SLC25A12	.	.
DTD0170	SLC25A12	Inducer	Urethane	Approved Drug	.	.	Urethane increases the expression of SLC25A12	.	.
DTD0170	SLC25A12	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC25A12	.	.
DTD0170	SLC25A12	Inhibition	Vitamin E	Drug in Phase 3 Trial	.	.	Vitamin E inhibits the expression of SLC25A12	.	.
DTD0171	SLC25A13	Inducer	1-methyl-4-phenylpyridinium	Health and Environmental Toxicant	.	.	1-methyl-4-phenylpyridinium increases the expression of SLC25A13	.	.
DTD0171	SLC25A13	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC25A13	.	.
DTD0171	SLC25A13	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC25A13	.	.
DTD0171	SLC25A13	Inhibition	Atrazine	Herbicide	.	.	Atrazine inhibits the expression of SLC25A13	.	.
DTD0171	SLC25A13	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC25A13	.	.
DTD0171	SLC25A13	Inhibition	Cannabidiol	Approved Drug	.	.	Cannabidiol inhibits the expression of SLC25A13	.	.
DTD0171	SLC25A13	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the expression of SLC25A13	.	.
DTD0171	SLC25A13	Inducer	Clozapine	Approved Drug	.	.	Clozapine increases the expression of SLC25A13	.	.
DTD0171	SLC25A13	Inhibition	Ivermectin	Approved Drug	.	.	Ivermectin inhibits the expression of SLC25A13	.	.
DTD0171	SLC25A13	Inhibition	Perfluorooctane sulfonic acid	Health and Environmental Toxicant	.	.	Perfluorooctane sulfonic acid inhibits the expression of SLC25A13	.	.
DTD0171	SLC25A13	Inducer	Piroxicam	Approved Drug	.	.	Piroxicam increases the expression of SLC25A13	.	.
DTD0171	SLC25A13	Inhibition	Testosterone	Approved Drug	.	.	Testosterone inhibits the expression of SLC25A13	.	.
DTD0171	SLC25A13	Inhibition	Thapsigargin	Natural Product	.	.	Thapsigargin inhibits the expression of SLC25A13	.	.
DTD0171	SLC25A13	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC25A13	.	.
DTD0171	SLC25A13	Inducer	torcetrapib	Drug in Phase 3 Trial	.	.	torcetrapib increases the expression of SLC25A13	.	.
DTD0171	SLC25A13	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of SLC25A13	.	.
DTD0171	SLC25A13	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC25A13	.	.
DTD0172	SLC25A14	Inducer	1-methyl-4-phenylpyridinium	Health and Environmental Toxicant	.	.	1-methyl-4-phenylpyridinium increases the expression of SLC25A14	.	.
DTD0172	SLC25A14	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of SLC25A14	.	.
DTD0172	SLC25A14	Inhibition	Atrazine	Herbicide	.	.	Atrazine inhibits the expression of SLC25A14	.	.
DTD0172	SLC25A14	Inducer	Cisplatin	Approved Drug	.	.	Cisplatin increases the expression of SLC25A14	.	.
DTD0172	SLC25A14	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC25A14	.	.
DTD0172	SLC25A14	Inducer	Dopamine	Approved Drug	.	.	Dopamine increases the expression of SLC25A14	.	.
DTD0172	SLC25A14	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC25A14	.	.
DTD0172	SLC25A14	Inducer	Fenretinide	Drug in Phase 3 Trial	.	.	Fenretinide increases the expression of SLC25A14	.	.
DTD0172	SLC25A14	Inhibition	Leflunomide	Approved Drug	.	.	Leflunomide inhibits the expression of SLC25A14	.	.
DTD0172	SLC25A14	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC25A14	.	.
DTD0172	SLC25A14	Modulator	Valproic Acid	Approved Drug	.	.	Valproic Acid affects the expression of SLC25A14	.	.
DTD0173	SLC25A15	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC25A15	.	.
DTD0173	SLC25A15	Inhibition	Acrylamide	Acute Toxic Substance	.	.	Acrylamide inhibits the expression of SLC25A15	.	.
DTD0173	SLC25A15	Inducer	Cadmium	Acute Toxic Substance	.	.	Cadmium increases the expression of SLC25A15	.	.
DTD0173	SLC25A15	Inducer	Carbamazepine	Approved Drug	.	.	Carbamazepine increases the expression of SLC25A15	.	.
DTD0173	SLC25A15	Inducer	Cisplatin	Approved Drug	.	.	Cisplatin increases the expression of SLC25A15	.	.
DTD0173	SLC25A15	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC25A15	.	.
DTD0173	SLC25A15	Inducer	Coumestrol	Investigative Drug	.	.	Coumestrol increases the expression of SLC25A15	.	.
DTD0173	SLC25A15	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC25A15	.	.
DTD0173	SLC25A15	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC25A15	.	.
DTD0173	SLC25A15	Inhibition	Ethyl Methanesulfonate	Carcinogen	.	.	Ethyl Methanesulfonate inhibits the expression of SLC25A15	.	.
DTD0173	SLC25A15	Inhibition	GSK-J4	Patented Pharmaceutical Agent	.	.	GSK-J4 inhibits the expression of SLC25A15	.	.
DTD0173	SLC25A15	Inhibition	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 inhibits the expression of SLC25A15	.	.
DTD0173	SLC25A15	Inhibition	Isotretinoin	Approved Drug	.	.	Isotretinoin inhibits the expression of SLC25A15	.	.
DTD0173	SLC25A15	Inhibition	Milchsaure	Investigative Drug	.	.	Milchsaure inhibits the expression of SLC25A15	.	.
DTD0173	SLC25A15	Inducer	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite increases the expression of SLC25A15	.	.
DTD0173	SLC25A15	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC25A15	.	.
DTD0173	SLC25A15	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of SLC25A15	.	.
DTD0175	SLC25A16	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC25A16	.	.
DTD0175	SLC25A16	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC25A16	.	.
DTD0175	SLC25A16	Inhibition	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A inhibits the expression of SLC25A16	.	.
DTD0175	SLC25A16	Inducer	Copper Sulfate	Approved Drug	.	.	Copper Sulfate increases the expression of SLC25A16	.	.
DTD0175	SLC25A16	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of SLC25A16	.	.
DTD0175	SLC25A16	Inducer	Formaldehyde	Acute Toxic Substance	.	.	Formaldehyde increases the expression of SLC25A16	.	.
DTD0175	SLC25A16	Inducer	Hydrogen Peroxide	Approved Drug	.	.	Hydrogen Peroxide increases the expression of SLC25A16	.	.
DTD0175	SLC25A16	Inhibition	Isotretinoin	Approved Drug	.	.	Isotretinoin inhibits the expression of SLC25A16	.	.
DTD0175	SLC25A16	Inducer	K-7174	Patented Pharmaceutical Agent	.	.	K-7174 increases the expression of SLC25A16	.	.
DTD0175	SLC25A16	Modulator	Milchsaure	Investigative Drug	.	.	Milchsaure affects the expression of SLC25A16	.	.
DTD0175	SLC25A16	Inducer	Panobinostat	Approved Drug	.	.	Panobinostat increases the expression of SLC25A16	.	.
DTD0175	SLC25A16	Inducer	Phenylmercuric Acetate	Investigative Drug	.	.	Phenylmercuric Acetate increases the expression of SLC25A16	.	.
DTD0175	SLC25A16	Inducer	Progesterone	Approved Drug	.	.	Progesterone increases the expression of SLC25A16	.	.
DTD0175	SLC25A16	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of SLC25A16	.	.
DTD0175	SLC25A16	Inhibition	Selenium nanoparticles	Natural Product	.	.	Selenium nanoparticles inhibits the expression of SLC25A16	.	.
DTD0175	SLC25A16	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of SLC25A16	.	.
DTD0175	SLC25A16	Inhibition	Testosterone	Approved Drug	.	.	Testosterone inhibits the expression of SLC25A16	.	.
DTD0175	SLC25A16	Modulator	Testosterone enanthate	Approved Drug	.	.	Testosterone enanthate affects the expression of SLC25A16	.	.
DTD0175	SLC25A16	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC25A16	.	.
DTD0175	SLC25A16	Inhibition	Vitamin E	Drug in Phase 3 Trial	.	.	Vitamin E inhibits the expression of SLC25A16	.	.
DTD0175	SLC25A16	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of SLC25A16	.	.
DTD0176	SLC25A17	Inducer	Acrylamide	Acute Toxic Substance	.	.	Acrylamide increases the expression of SLC25A17	.	.
DTD0176	SLC25A17	Inhibition	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A inhibits the expression of SLC25A17	.	.
DTD0176	SLC25A17	Inducer	Cisplatin	Approved Drug	.	.	Cisplatin increases the expression of SLC25A17	.	.
DTD0176	SLC25A17	Inhibition	Dicrotophos	Pesticide/Insecticide	.	.	Dicrotophos inhibits the expression of SLC25A17	.	.
DTD0176	SLC25A17	Modulator	Hydrogen Peroxide	Approved Drug	.	.	Hydrogen Peroxide affects the expression of SLC25A17	.	.
DTD0176	SLC25A17	Inhibition	Isotretinoin	Approved Drug	.	.	Isotretinoin inhibits the expression of SLC25A17	.	.
DTD0176	SLC25A17	Inhibition	Selenium nanoparticles	Natural Product	.	.	Selenium nanoparticles inhibits the expression of SLC25A17	.	.
DTD0176	SLC25A17	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of SLC25A17	.	.
DTD0176	SLC25A17	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC25A17	.	.
DTD0177	SLC25A18	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC25A18	.	.
DTD0177	SLC25A18	Inducer	Acrylamide	Acute Toxic Substance	.	.	Acrylamide increases the expression of SLC25A18	.	.
DTD0177	SLC25A18	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC25A18	.	.
DTD0177	SLC25A18	Inducer	Amiodarone	Approved Drug	.	.	Amiodarone increases the expression of SLC25A18	.	.
DTD0177	SLC25A18	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC25A18	.	.
DTD0177	SLC25A18	Inhibition	Jinfukang	Traditional Medicine	.	.	Jinfukang inhibits the expression of SLC25A18	.	.
DTD0177	SLC25A18	Inhibition	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin inhibits the expression of SLC25A18	.	.
DTD0177	SLC25A18	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC25A18	.	.
DTD0178	SLC25A19	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of SLC25A19	.	.
DTD0178	SLC25A19	Inhibition	Atrazine	Herbicide	.	.	Atrazine inhibits the expression of SLC25A19	.	.
DTD0178	SLC25A19	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of SLC25A19	.	.
DTD0178	SLC25A19	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC25A19	.	.
DTD0178	SLC25A19	Inducer	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde increases the expression of SLC25A19	.	.
DTD0178	SLC25A19	Inhibition	Calcitriol	Approved Drug	.	.	Calcitriol inhibits the expression of SLC25A19	.	.
DTD0178	SLC25A19	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC25A19	.	.
DTD0178	SLC25A19	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of SLC25A19	.	.
DTD0178	SLC25A19	Inducer	Dexamethasone	Approved Drug	.	.	Dexamethasone increases the expression of SLC25A19	.	.
DTD0178	SLC25A19	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC25A19	.	.
DTD0178	SLC25A19	Inducer	Genistein	Drug in Phase 2 Trial	.	.	Genistein increases the expression of SLC25A19	.	.
DTD0178	SLC25A19	Inhibition	GSK-J4	Patented Pharmaceutical Agent	.	.	GSK-J4 inhibits the expression of SLC25A19	.	.
DTD0178	SLC25A19	Inhibition	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 inhibits the expression of SLC25A19	.	.
DTD0178	SLC25A19	Inhibition	K-7174	Patented Pharmaceutical Agent	.	.	K-7174 inhibits the expression of SLC25A19	.	.
DTD0178	SLC25A19	Inhibition	Leflunomide	Approved Drug	.	.	Leflunomide inhibits the expression of SLC25A19	.	.
DTD0178	SLC25A19	Inhibition	Silver nanoparticle	Nanoparticle	.	.	Silver nanoparticle inhibits the expression of SLC25A19	.	.
DTD0178	SLC25A19	Inducer	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite increases the expression of SLC25A19	.	.
DTD0178	SLC25A19	Inducer	Temozolomide	Approved Drug	.	.	Temozolomide increases the expression of SLC25A19	.	.
DTD0178	SLC25A19	Inhibition	Testosterone	Approved Drug	.	.	Testosterone inhibits the expression of SLC25A19	.	.
DTD0178	SLC25A19	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC25A19	.	.
DTD0179	SLC25A2	Inhibition	Arbutin	Drug Marketed but not Approved by US FDA	.	.	Arbutin inhibits the expression of SLC25A2	.	.
DTD0179	SLC25A2	Inducer	Epigallocatechin gallate	Drug in Phase 3 Trial	.	.	Epigallocatechin gallate increases the expression of SLC25A2	.	.
DTD0179	SLC25A2	Inhibition	Kojic acid	Health and Environmental Toxicant	.	.	Kojic acid inhibits the expression of SLC25A2	.	.
DTD0180	SLC25A20	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC25A20	.	.
DTD0180	SLC25A20	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC25A20	.	.
DTD0180	SLC25A20	Inducer	Bisphenol B	Drug in Phase 2 Trial	.	.	Bisphenol B increases the expression of SLC25A20	.	.
DTD0180	SLC25A20	Inducer	Bisphenol F	Environmental toxicant	.	.	Bisphenol F increases the expression of SLC25A20	.	.
DTD0180	SLC25A20	Inducer	Calcitriol	Approved Drug	.	.	Calcitriol increases the expression of SLC25A20	.	.
DTD0180	SLC25A20	Inducer	Cidofovir	Approved Drug	.	.	Cidofovir increases the expression of SLC25A20	.	.
DTD0180	SLC25A20	Inducer	Cisplatin	Approved Drug	.	.	Cisplatin increases the expression of SLC25A20	.	.
DTD0180	SLC25A20	Inducer	Clodronic Acid	Drug Marketed but not Approved by US FDA	.	.	Clodronic Acid increases the expression of SLC25A20	.	.
DTD0180	SLC25A20	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC25A20	.	.
DTD0180	SLC25A20	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC25A20	.	.
DTD0180	SLC25A20	Inhibition	Dicrotophos	Pesticide/Insecticide	.	.	Dicrotophos inhibits the expression of SLC25A20	.	.
DTD0180	SLC25A20	Inducer	Dihydrotestosterone	Drug in Phase 1 Trial	.	.	Dihydrotestosterone increases the expression of SLC25A20	.	.
DTD0180	SLC25A20	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the expression of SLC25A20	.	.
DTD0180	SLC25A20	Inducer	Fenofibrate	Approved Drug	.	.	Fenofibrate increases the expression of SLC25A20	.	.
DTD0180	SLC25A20	Inhibition	GSK-J4	Patented Pharmaceutical Agent	.	.	GSK-J4 inhibits the expression of SLC25A20	.	.
DTD0180	SLC25A20	Inducer	GW-7647	Patented Pharmaceutical Agent	.	.	GW-7647 increases the expression of SLC25A20	.	.
DTD0180	SLC25A20	Inducer	Ifosfamide	Approved Drug	.	.	Ifosfamide increases the expression of SLC25A20	.	.
DTD0180	SLC25A20	Inhibition	Mercuric Chloride	Acute Toxic Substance	.	.	Mercuric Chloride inhibits the activity of SLC25A20	.	.
DTD0180	SLC25A20	Inhibition	Perfluorododecanoic acid	Drug in Preclinical Test	.	.	Perfluorododecanoic acid inhibits the expression of SLC25A20	.	.
DTD0180	SLC25A20	Inducer	Phenylmercuric Acetate	Investigative Drug	.	.	Phenylmercuric Acetate increases the expression of SLC25A20	.	.
DTD0180	SLC25A20	Inducer	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin increases the expression of SLC25A20	.	.
DTD0180	SLC25A20	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of SLC25A20	.	.
DTD0180	SLC25A20	Inhibition	Rosiglitazone	Approved Drug	.	.	Rosiglitazone inhibits the expression of SLC25A20	.	.
DTD0180	SLC25A20	Inhibition	Sunitinib	Approved Drug	.	.	Sunitinib inhibits the expression of SLC25A20	.	.
DTD0180	SLC25A20	Inducer	Testosterone	Approved Drug	.	.	Testosterone increases the expression of SLC25A20	.	.
DTD0180	SLC25A20	Inducer	Thapsigargin	Natural Product	.	.	Thapsigargin increases the expression of SLC25A20	.	.
DTD0180	SLC25A20	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC25A20	.	.
DTD0180	SLC25A20	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of SLC25A20	.	.
DTD0180	SLC25A20	Modulator	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A affects the expression of SLC25A20	.	.
DTD0180	SLC25A20	Inhibition	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate inhibits the expression of SLC25A20	.	.
DTD0180	SLC25A20	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of SLC25A20	.	.
DTD0180	SLC25A20	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC25A20	.	.
DTD0180	SLC25A20	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of SLC25A20	.	.
DTD0182	SLC25A21	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC25A21	.	.
DTD0182	SLC25A21	Inhibition	Belinostat	Approved Drug	.	.	Belinostat inhibits the expression of SLC25A21	.	.
DTD0182	SLC25A21	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC25A21	.	.
DTD0182	SLC25A21	Inhibition	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A inhibits the expression of SLC25A21	.	.
DTD0182	SLC25A21	Inhibition	Bisphenol B	Drug in Phase 2 Trial	.	.	Bisphenol B inhibits the expression of SLC25A21	.	.
DTD0182	SLC25A21	Inhibition	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde inhibits the expression of SLC25A21	.	.
DTD0182	SLC25A21	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC25A21	.	.
DTD0182	SLC25A21	Inhibition	Irinotecan	Approved Drug	.	.	Irinotecan inhibits the expression of SLC25A21	.	.
DTD0182	SLC25A21	Inhibition	Jinfukang	Traditional Medicine	.	.	Jinfukang inhibits the expression of SLC25A21	.	.
DTD0182	SLC25A21	Inhibition	Methyleugenol	Natural Product	.	.	Methyleugenol inhibits the expression of SLC25A21	.	.
DTD0182	SLC25A21	Inhibition	MS-275	Drug in Phase 2 Trial	.	.	MS-275 inhibits the expression of SLC25A21	.	.
DTD0182	SLC25A21	Inhibition	Particulate Matter	Natural Product	.	.	Particulate Matter inhibits the expression of SLC25A21	.	.
DTD0182	SLC25A21	Inhibition	Pentanal	Chemical Compound	.	.	Pentanal inhibits the expression of SLC25A21	.	.
DTD0182	SLC25A21	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of SLC25A21	.	.
DTD0182	SLC25A21	Inhibition	Sunitinib	Approved Drug	.	.	Sunitinib inhibits the expression of SLC25A21	.	.
DTD0182	SLC25A21	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of SLC25A21	.	.
DTD0182	SLC25A21	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC25A21	.	.
DTD0182	SLC25A21	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of SLC25A21	.	.
DTD0183	SLC25A22	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of SLC25A22	.	.
DTD0183	SLC25A22	Inducer	Atrazine	Herbicide	.	.	Atrazine increases the expression of SLC25A22	.	.
DTD0183	SLC25A22	Modulator	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A affects the expression of SLC25A22	.	.
DTD0183	SLC25A22	Inducer	Bisphenol B	Drug in Phase 2 Trial	.	.	Bisphenol B increases the expression of SLC25A22	.	.
DTD0183	SLC25A22	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC25A22	.	.
DTD0183	SLC25A22	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC25A22	.	.
DTD0183	SLC25A22	Inducer	Genistein	Drug in Phase 2 Trial	.	.	Genistein increases the expression of SLC25A22	.	.
DTD0183	SLC25A22	Inhibition	GSK-J4	Patented Pharmaceutical Agent	.	.	GSK-J4 inhibits the expression of SLC25A22	.	.
DTD0183	SLC25A22	Modulator	Hydrogen Peroxide	Approved Drug	.	.	Hydrogen Peroxide affects the expression of SLC25A22	.	.
DTD0183	SLC25A22	Inducer	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 increases the expression of SLC25A22	.	.
DTD0183	SLC25A22	Inhibition	Ivermectin	Approved Drug	.	.	Ivermectin inhibits the expression of SLC25A22	.	.
DTD0183	SLC25A22	Inhibition	Mercury	Acute Toxic Substance	.	.	Mercury inhibits the expression of SLC25A22	.	.
DTD0183	SLC25A22	Inducer	Rifampin	Approved Drug	.	.	Rifampin increases the expression of SLC25A22	.	.
DTD0183	SLC25A22	Inducer	Selenium nanoparticles	Natural Product	.	.	Selenium nanoparticles increases the expression of SLC25A22	.	.
DTD0183	SLC25A22	Inducer	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite increases the expression of SLC25A22	.	.
DTD0183	SLC25A22	Inhibition	Sunitinib	Approved Drug	.	.	Sunitinib inhibits the expression of SLC25A22	.	.
DTD0183	SLC25A22	Inhibition	Thapsigargin	Natural Product	.	.	Thapsigargin inhibits the expression of SLC25A22	.	.
DTD0183	SLC25A22	Inducer	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan increases the expression of SLC25A22	.	.
DTD0183	SLC25A22	Modulator	Valproic Acid	Approved Drug	.	.	Valproic Acid affects the expression of SLC25A22	.	.
DTD0184	SLC25A23	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of SLC25A23	.	.
DTD0184	SLC25A23	Inhibition	Acrylamide	Acute Toxic Substance	.	.	Acrylamide inhibits the expression of SLC25A23	.	.
DTD0184	SLC25A23	Inducer	Atrazine	Herbicide	.	.	Atrazine increases the expression of SLC25A23	.	.
DTD0184	SLC25A23	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC25A23	.	.
DTD0184	SLC25A23	Inhibition	Cocaine	Approved Drug	.	.	Cocaine inhibits the expression of SLC25A23	.	.
DTD0184	SLC25A23	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC25A23	.	.
DTD0184	SLC25A23	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC25A23	.	.
DTD0184	SLC25A23	Inducer	Dicrotophos	Pesticide/Insecticide	.	.	Dicrotophos increases the expression of SLC25A23	.	.
DTD0184	SLC25A23	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC25A23	.	.
DTD0184	SLC25A23	Inducer	Dronabinol	Approved Drug	.	.	Dronabinol increases the expression of SLC25A23	.	.
DTD0184	SLC25A23	Modulator	Fluorouracil	Approved Drug	.	.	Fluorouracil affects the expression of SLC25A23	.	.
DTD0184	SLC25A23	Inhibition	Gallic Acid	Natural Product	.	.	Gallic Acid inhibits the expression of SLC25A23	.	.
DTD0184	SLC25A23	Inhibition	GSK-J4	Patented Pharmaceutical Agent	.	.	GSK-J4 inhibits the expression of SLC25A23	.	.
DTD0184	SLC25A23	Inhibition	Heroin	Drug in Phase 1 Trial	.	.	Heroin inhibits the expression of SLC25A23	.	.
DTD0184	SLC25A23	Modulator	Hydrogen Peroxide	Approved Drug	.	.	Hydrogen Peroxide affects the expression of SLC25A23	.	.
DTD0184	SLC25A23	Inducer	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 increases the expression of SLC25A23	.	.
DTD0184	SLC25A23	Modulator	Lead	Health and Environmental Toxicant	.	.	Lead affects the expression of SLC25A23	.	.
DTD0184	SLC25A23	Inhibition	Sunitinib	Approved Drug	.	.	Sunitinib inhibits the expression of SLC25A23	.	.
DTD0184	SLC25A23	Inhibition	Thimerosal	Acute Toxic Substance	.	.	Thimerosal inhibits the expression of SLC25A23	.	.
DTD0184	SLC25A23	Inhibition	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate inhibits the expression of SLC25A23	.	.
DTD0184	SLC25A23	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC25A23	.	.
DTD0185	SLC25A24	Inhibition	Atrazine	Herbicide	.	.	Atrazine inhibits the expression of SLC25A24	.	.
DTD0185	SLC25A24	Inducer	Bisphenol B	Drug in Phase 2 Trial	.	.	Bisphenol B increases the expression of SLC25A24	.	.
DTD0185	SLC25A24	Inducer	Cadmium	Acute Toxic Substance	.	.	Cadmium increases the expression of SLC25A24	.	.
DTD0185	SLC25A24	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the expression of SLC25A24	.	.
DTD0185	SLC25A24	Inducer	Clozapine	Approved Drug	.	.	Clozapine increases the expression of SLC25A24	.	.
DTD0185	SLC25A24	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC25A24	.	.
DTD0185	SLC25A24	Inhibition	Dicrotophos	Pesticide/Insecticide	.	.	Dicrotophos inhibits the expression of SLC25A24	.	.
DTD0185	SLC25A24	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC25A24	.	.
DTD0185	SLC25A24	Modulator	Hydrogen Peroxide	Approved Drug	.	.	Hydrogen Peroxide affects the expression of SLC25A24	.	.
DTD0185	SLC25A24	Inhibition	Ivermectin	Approved Drug	.	.	Ivermectin inhibits the expression of SLC25A24	.	.
DTD0185	SLC25A24	Inducer	NSC-668394	Patented Pharmaceutical Agent	.	.	NSC-668394 increases the expression of SLC25A24	.	.
DTD0185	SLC25A24	Inhibition	Pioglitazone	Approved Drug	.	.	Pioglitazone inhibits the expression of SLC25A24	.	.
DTD0185	SLC25A24	Inducer	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin increases the expression of SLC25A24	.	.
DTD0185	SLC25A24	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of SLC25A24	.	.
DTD0185	SLC25A24	Inducer	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite increases the expression of SLC25A24	.	.
DTD0185	SLC25A24	Inducer	Temozolomide	Approved Drug	.	.	Temozolomide increases the expression of SLC25A24	.	.
DTD0185	SLC25A24	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC25A24	.	.
DTD0185	SLC25A24	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC25A24	.	.
DTD0185	SLC25A24	Inducer	Zoledronic Acid	Approved Drug	.	.	Zoledronic Acid increases the expression of SLC25A24	.	.
DTD0186	SLC25A25	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of SLC25A25	.	.
DTD0186	SLC25A25	Inducer	Acrylamide	Acute Toxic Substance	.	.	Acrylamide increases the expression of SLC25A25	.	.
DTD0186	SLC25A25	Inducer	Amiodarone	Approved Drug	.	.	Amiodarone increases the expression of SLC25A25	.	.
DTD0186	SLC25A25	Inhibition	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A inhibits the expression of SLC25A25	.	.
DTD0186	SLC25A25	Inducer	Cisplatin	Approved Drug	.	.	Cisplatin increases the expression of SLC25A25	.	.
DTD0186	SLC25A25	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of SLC25A25	.	.
DTD0186	SLC25A25	Inducer	Cylindrospermopsin	Cyanotoxin	.	.	Cylindrospermopsin increases the expression of SLC25A25	.	.
DTD0186	SLC25A25	Inducer	Formaldehyde	Acute Toxic Substance	.	.	Formaldehyde increases the expression of SLC25A25	.	.
DTD0186	SLC25A25	Inhibition	Jinfukang	Traditional Medicine	.	.	Jinfukang inhibits the expression of SLC25A25	.	.
DTD0186	SLC25A25	Inducer	Leflunomide	Approved Drug	.	.	Leflunomide increases the expression of SLC25A25	.	.
DTD0186	SLC25A25	Inducer	Milchsaure	Investigative Drug	.	.	Milchsaure increases the expression of SLC25A25	.	.
DTD0186	SLC25A25	Modulator	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin affects the expression of SLC25A25	.	.
DTD0186	SLC25A25	Inhibition	Sunitinib	Approved Drug	.	.	Sunitinib inhibits the expression of SLC25A25	.	.
DTD0186	SLC25A25	Inducer	Teriflunomide	Approved Drug	.	.	Teriflunomide increases the expression of SLC25A25	.	.
DTD0186	SLC25A25	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC25A25	.	.
DTD0186	SLC25A25	Modulator	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A affects the expression of SLC25A25	.	.
DTD0186	SLC25A25	Inducer	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate increases the expression of SLC25A25	.	.
DTD0186	SLC25A25	Inducer	Urethane	Approved Drug	.	.	Urethane increases the expression of SLC25A25	.	.
DTD0186	SLC25A25	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC25A25	.	.
DTD0187	SLC25A26	Inducer	Amiodarone	Approved Drug	.	.	Amiodarone increases the expression of SLC25A26	.	.
DTD0187	SLC25A26	Inhibition	Atrazine	Herbicide	.	.	Atrazine inhibits the expression of SLC25A26	.	.
DTD0187	SLC25A26	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC25A26	.	.
DTD0187	SLC25A26	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of SLC25A26	.	.
DTD0187	SLC25A26	Inducer	Cylindrospermopsin	Cyanotoxin	.	.	Cylindrospermopsin increases the expression of SLC25A26	.	.
DTD0187	SLC25A26	Inhibition	Dicrotophos	Pesticide/Insecticide	.	.	Dicrotophos inhibits the expression of SLC25A26	.	.
DTD0187	SLC25A26	Inducer	Doxorubicin	Approved Drug	.	.	Doxorubicin increases the expression of SLC25A26	.	.
DTD0187	SLC25A26	Inducer	GSK-J4	Patented Pharmaceutical Agent	.	.	GSK-J4 increases the expression of SLC25A26	.	.
DTD0187	SLC25A26	Inducer	Rosiglitazone	Approved Drug	.	.	Rosiglitazone increases the expression of SLC25A26	.	.
DTD0187	SLC25A26	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC25A26	.	.
DTD0188	SLC25A27	Inducer	1-methyl-4-phenylpyridinium	Health and Environmental Toxicant	.	.	1-methyl-4-phenylpyridinium increases the expression of SLC25A27	.	.
DTD0188	SLC25A27	Inhibition	4-hydroxy-2-nonenal	Investigative Drug	.	.	4-hydroxy-2-nonenal inhibits the expression of SLC25A27	.	.
DTD0188	SLC25A27	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of SLC25A27	.	.
DTD0188	SLC25A27	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC25A27	.	.
DTD0188	SLC25A27	Inducer	Calcitriol	Approved Drug	.	.	Calcitriol increases the expression of SLC25A27	.	.
DTD0188	SLC25A27	Inducer	Cycloheximide	Acute Toxic Substance	.	.	Cycloheximide increases the expression of SLC25A27	.	.
DTD0188	SLC25A27	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC25A27	.	.
DTD0188	SLC25A27	Inhibition	Diethylhexyl Phthalate	Health and Environmental Toxicant	.	.	Diethylhexyl Phthalate inhibits the expression of SLC25A27	.	.
DTD0188	SLC25A27	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the expression of SLC25A27	.	.
DTD0188	SLC25A27	Inhibition	Fluorouracil	Approved Drug	.	.	Fluorouracil inhibits the expression of SLC25A27	.	.
DTD0188	SLC25A27	Modulator	Lead	Health and Environmental Toxicant	.	.	Lead affects the expression of SLC25A27	.	.
DTD0188	SLC25A27	Inducer	Milchsaure	Investigative Drug	.	.	Milchsaure increases the expression of SLC25A27	.	.
DTD0188	SLC25A27	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC25A27	.	.
DTD0188	SLC25A27	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of SLC25A27	.	.
DTD0188	SLC25A27	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC25A27	.	.
DTD0188	SLC25A27	Inducer	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A increases the expression of SLC25A27	.	.
DTD0188	SLC25A27	Inducer	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate increases the expression of SLC25A27	.	.
DTD0188	SLC25A27	Inducer	Urethane	Approved Drug	.	.	Urethane increases the expression of SLC25A27	.	.
DTD0188	SLC25A27	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC25A27	.	.
DTD0189	SLC25A28	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC25A28	.	.
DTD0189	SLC25A28	Inhibition	Arsenic Trioxide	Approved Drug	.	.	Arsenic Trioxide inhibits the expression of SLC25A28	.	.
DTD0189	SLC25A28	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of SLC25A28	.	.
DTD0189	SLC25A28	Inhibition	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A inhibits the expression of SLC25A28	.	.
DTD0189	SLC25A28	Inducer	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 increases the expression of SLC25A28	.	.
DTD0189	SLC25A28	Inducer	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite increases the expression of SLC25A28	.	.
DTD0189	SLC25A28	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC25A28	.	.
DTD0189	SLC25A28	Inducer	Urethane	Approved Drug	.	.	Urethane increases the expression of SLC25A28	.	.
DTD0190	SLC25A29	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of SLC25A29	.	.
DTD0190	SLC25A29	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of SLC25A29	.	.
DTD0190	SLC25A29	Inhibition	Acrylamide	Acute Toxic Substance	.	.	Acrylamide inhibits the expression of SLC25A29	.	.
DTD0190	SLC25A29	Inhibition	Coumestrol	Investigative Drug	.	.	Coumestrol inhibits the expression of SLC25A29	.	.
DTD0190	SLC25A29	Inhibition	Dicrotophos	Pesticide/Insecticide	.	.	Dicrotophos inhibits the expression of SLC25A29	.	.
DTD0190	SLC25A29	Inducer	Gemcitabine	Approved Drug	.	.	Gemcitabine increases the expression of SLC25A29	.	.
DTD0190	SLC25A29	Inducer	Jinfukang	Traditional Medicine	.	.	Jinfukang increases the expression of SLC25A29	.	.
DTD0190	SLC25A29	Inhibition	Leflunomide	Approved Drug	.	.	Leflunomide inhibits the expression of SLC25A29	.	.
DTD0190	SLC25A29	Inhibition	Perfluorooctane sulfonic acid	Health and Environmental Toxicant	.	.	Perfluorooctane sulfonic acid inhibits the expression of SLC25A29	.	.
DTD0190	SLC25A29	Inhibition	Progesterone	Approved Drug	.	.	Progesterone inhibits the expression of SLC25A29	.	.
DTD0190	SLC25A29	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC25A29	.	.
DTD0190	SLC25A29	Inhibition	Sulforafan	Drug in Phase 3 Trial	.	.	Sulforafan inhibits the expression of SLC25A29	.	.
DTD0190	SLC25A29	Inhibition	Sunitinib	Approved Drug	.	.	Sunitinib inhibits the expression of SLC25A29	.	.
DTD0190	SLC25A29	Inducer	Temozolomide	Approved Drug	.	.	Temozolomide increases the expression of SLC25A29	.	.
DTD0190	SLC25A29	Inducer	Testosterone	Approved Drug	.	.	Testosterone increases the expression of SLC25A29	.	.
DTD0190	SLC25A29	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC25A29	.	.
DTD0190	SLC25A29	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC25A29	.	.
DTD0190	SLC25A29	Inhibition	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A inhibits the expression of SLC25A29	.	.
DTD0190	SLC25A29	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC25A29	.	.
DTD0191	SLC25A3	Inducer	1-methyl-4-phenylpyridinium	Health and Environmental Toxicant	.	.	1-methyl-4-phenylpyridinium increases the expression of SLC25A3	.	.
DTD0191	SLC25A3	Inducer	Atrazine	Herbicide	.	.	Atrazine increases the expression of SLC25A3	.	.
DTD0191	SLC25A3	Inhibition	Biochanin A	Natural Product	.	.	Biochanin A inhibits the expression of SLC25A3	.	.
DTD0191	SLC25A3	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC25A3	.	.
DTD0191	SLC25A3	Inducer	Bisphenol B	Drug in Phase 2 Trial	.	.	Bisphenol B increases the expression of SLC25A3	.	.
DTD0191	SLC25A3	Inducer	Bisphenol F	Environmental toxicant	.	.	Bisphenol F increases the expression of SLC25A3	.	.
DTD0191	SLC25A3	Inhibition	CD-437	Health and Environmental Toxicant	.	.	CD-437 inhibits the expression of SLC25A3	.	.
DTD0191	SLC25A3	Inhibition	Cupric oxide	Chemical Compound	.	.	Cupric oxide inhibits the expression of SLC25A3	.	.
DTD0191	SLC25A3	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC25A3	.	.
DTD0191	SLC25A3	Inducer	Doxorubicin	Approved Drug	.	.	Doxorubicin increases the expression of SLC25A3	.	.
DTD0191	SLC25A3	Inhibition	Glyphosate	Environmental toxicant	.	.	Glyphosate inhibits the expression of SLC25A3	.	.
DTD0191	SLC25A3	Inhibition	Ivermectin	Approved Drug	.	.	Ivermectin inhibits the expression of SLC25A3	.	.
DTD0191	SLC25A3	Modulator	Menadione	Approved Drug	.	.	Menadione affects the expression of SLC25A3	.	.
DTD0191	SLC25A3	Inducer	Milchsaure	Investigative Drug	.	.	Milchsaure increases the expression of SLC25A3	.	.
DTD0191	SLC25A3	Inducer	Ochratoxin A	Acute Toxic Substance	.	.	Ochratoxin A increases the expression of SLC25A3	.	.
DTD0191	SLC25A3	Inducer	Thapsigargin	Natural Product	.	.	Thapsigargin increases the expression of SLC25A3	.	.
DTD0191	SLC25A3	Modulator	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution affects the expression of SLC25A3	.	.
DTD0193	SLC25A31	Inducer	Atrazine	Herbicide	.	.	Atrazine increases the expression of SLC25A31	.	.
DTD0193	SLC25A31	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of SLC25A31	.	.
DTD0193	SLC25A31	Inhibition	CD-437	Health and Environmental Toxicant	.	.	CD-437 inhibits the activity of SLC25A31	.	.
DTD0194	SLC25A32	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC25A32	.	.
DTD0194	SLC25A32	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of SLC25A32	.	.
DTD0194	SLC25A32	Inducer	Dexamethasone	Approved Drug	.	.	Dexamethasone increases the expression of SLC25A32	.	.
DTD0194	SLC25A32	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC25A32	.	.
DTD0194	SLC25A32	Inhibition	Dronabinol	Approved Drug	.	.	Dronabinol inhibits the expression of SLC25A32	.	.
DTD0194	SLC25A32	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC25A32	.	.
DTD0194	SLC25A32	Inhibition	Ethyl Methanesulfonate	Carcinogen	.	.	Ethyl Methanesulfonate inhibits the expression of SLC25A32	.	.
DTD0194	SLC25A32	Inhibition	Jinfukang	Traditional Medicine	.	.	Jinfukang inhibits the expression of SLC25A32	.	.
DTD0194	SLC25A32	Modulator	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin affects the expression of SLC25A32	.	.
DTD0194	SLC25A32	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of SLC25A32	.	.
DTD0194	SLC25A32	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC25A32	.	.
DTD0194	SLC25A32	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC25A32	.	.
DTD0194	SLC25A32	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC25A32	.	.
DTD0195	SLC25A33	Inducer	2-methyl-4-isothiazolin-3-one	Acute Toxic Substance	.	.	2-methyl-4-isothiazolin-3-one increases the expression of SLC25A33	.	.
DTD0195	SLC25A33	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC25A33	.	.
DTD0195	SLC25A33	Inducer	Acrylamide	Acute Toxic Substance	.	.	Acrylamide increases the expression of SLC25A33	.	.
DTD0195	SLC25A33	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC25A33	.	.
DTD0195	SLC25A33	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC25A33	.	.
DTD0195	SLC25A33	Inducer	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde increases the expression of SLC25A33	.	.
DTD0195	SLC25A33	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC25A33	.	.
DTD0195	SLC25A33	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC25A33	.	.
DTD0195	SLC25A33	Inducer	Dihydrotestosterone	Drug in Phase 1 Trial	.	.	Dihydrotestosterone increases the expression of SLC25A33	.	.
DTD0195	SLC25A33	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC25A33	.	.
DTD0195	SLC25A33	Inducer	GSK-J4	Patented Pharmaceutical Agent	.	.	GSK-J4 increases the expression of SLC25A33	.	.
DTD0195	SLC25A33	Inhibition	K-7174	Patented Pharmaceutical Agent	.	.	K-7174 inhibits the expression of SLC25A33	.	.
DTD0195	SLC25A33	Inducer	Leflunomide	Approved Drug	.	.	Leflunomide increases the expression of SLC25A33	.	.
DTD0195	SLC25A33	Inhibition	Methyleugenol	Natural Product	.	.	Methyleugenol inhibits the expression of SLC25A33	.	.
DTD0195	SLC25A33	Inhibition	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin inhibits the expression of SLC25A33	.	.
DTD0195	SLC25A33	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of SLC25A33	.	.
DTD0195	SLC25A33	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC25A33	.	.
DTD0195	SLC25A33	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC25A33	.	.
DTD0195	SLC25A33	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC25A33	.	.
DTD0198	SLC25A36	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC25A36	.	.
DTD0198	SLC25A36	Modulator	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 affects the expression of SLC25A36	.	.
DTD0198	SLC25A36	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC25A36	.	.
DTD0198	SLC25A36	Inducer	Beta-naphthoflavone	Investigative Drug	.	.	Beta-naphthoflavone increases the expression of SLC25A36	.	.
DTD0198	SLC25A36	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC25A36	.	.
DTD0198	SLC25A36	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of SLC25A36	.	.
DTD0198	SLC25A36	Inhibition	Dicrotophos	Pesticide/Insecticide	.	.	Dicrotophos inhibits the expression of SLC25A36	.	.
DTD0198	SLC25A36	Inducer	Dronabinol	Approved Drug	.	.	Dronabinol increases the expression of SLC25A36	.	.
DTD0198	SLC25A36	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC25A36	.	.
DTD0198	SLC25A36	Inhibition	Formaldehyde	Acute Toxic Substance	.	.	Formaldehyde inhibits the expression of SLC25A36	.	.
DTD0198	SLC25A36	Inducer	GSK-J4	Patented Pharmaceutical Agent	.	.	GSK-J4 increases the expression of SLC25A36	.	.
DTD0198	SLC25A36	Inducer	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 increases the expression of SLC25A36	.	.
DTD0198	SLC25A36	Inhibition	Jinfukang	Traditional Medicine	.	.	Jinfukang inhibits the expression of SLC25A36	.	.
DTD0198	SLC25A36	Inducer	K-7174	Patented Pharmaceutical Agent	.	.	K-7174 increases the expression of SLC25A36	.	.
DTD0198	SLC25A36	Inducer	Leflunomide	Approved Drug	.	.	Leflunomide increases the expression of SLC25A36	.	.
DTD0198	SLC25A36	Modulator	Menadione	Approved Drug	.	.	Menadione affects the expression of SLC25A36	.	.
DTD0198	SLC25A36	Inhibition	Mercuric Chloride	Acute Toxic Substance	.	.	Mercuric Chloride inhibits the expression of SLC25A36	.	.
DTD0198	SLC25A36	Inducer	Milchsaure	Investigative Drug	.	.	Milchsaure increases the expression of SLC25A36	.	.
DTD0198	SLC25A36	Inhibition	Perfluorooctane sulfonic acid	Health and Environmental Toxicant	.	.	Perfluorooctane sulfonic acid inhibits the expression of SLC25A36	.	.
DTD0198	SLC25A36	Inhibition	Selenium nanoparticles	Natural Product	.	.	Selenium nanoparticles inhibits the expression of SLC25A36	.	.
DTD0198	SLC25A36	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC25A36	.	.
DTD0198	SLC25A36	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of SLC25A36	.	.
DTD0198	SLC25A36	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC25A36	.	.
DTD0198	SLC25A36	Inhibition	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A inhibits the expression of SLC25A36	.	.
DTD0198	SLC25A36	Inducer	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate increases the expression of SLC25A36	.	.
DTD0198	SLC25A36	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC25A36	.	.
DTD0198	SLC25A36	Inhibition	Vitamin E	Drug in Phase 3 Trial	.	.	Vitamin E inhibits the expression of SLC25A36	.	.
DTD0198	SLC25A36	Inhibition	Vorinostat	Approved Drug	.	.	Vorinostat inhibits the expression of SLC25A36	.	.
DTD0199	SLC25A37	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC25A37	.	.
DTD0199	SLC25A37	Inducer	Atrazine	Herbicide	.	.	Atrazine increases the expression of SLC25A37	.	.
DTD0199	SLC25A37	Inducer	Avobenzone	Approved Drug	.	.	Avobenzone increases the expression of SLC25A37	.	.
DTD0199	SLC25A37	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC25A37	.	.
DTD0199	SLC25A37	Inhibition	CD-437	Health and Environmental Toxicant	.	.	CD-437 inhibits the expression of SLC25A37	.	.
DTD0199	SLC25A37	Inducer	Cocaine	Approved Drug	.	.	Cocaine increases the expression of SLC25A37	.	.
DTD0199	SLC25A37	Inducer	Copper Sulfate	Approved Drug	.	.	Copper Sulfate increases the expression of SLC25A37	.	.
DTD0199	SLC25A37	Inhibition	Coumestrol	Investigative Drug	.	.	Coumestrol inhibits the expression of SLC25A37	.	.
DTD0199	SLC25A37	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of SLC25A37	.	.
DTD0199	SLC25A37	Inhibition	Demecolcine	Drug Marketed but not Approved by US FDA	.	.	Demecolcine inhibits the expression of SLC25A37	.	.
DTD0199	SLC25A37	Inducer	Dihydrotestosterone	Drug in Phase 1 Trial	.	.	Dihydrotestosterone increases the expression of SLC25A37	.	.
DTD0199	SLC25A37	Inhibition	Ethyl Methanesulfonate	Carcinogen	.	.	Ethyl Methanesulfonate inhibits the expression of SLC25A37	.	.
DTD0199	SLC25A37	Inducer	Heroin	Drug in Phase 1 Trial	.	.	Heroin increases the expression of SLC25A37	.	.
DTD0199	SLC25A37	Modulator	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 affects the expression of SLC25A37	.	.
DTD0199	SLC25A37	Inducer	K-7174	Patented Pharmaceutical Agent	.	.	K-7174 increases the expression of SLC25A37	.	.
DTD0199	SLC25A37	Inhibition	MS-275	Drug in Phase 2 Trial	.	.	MS-275 inhibits the expression of SLC25A37	.	.
DTD0199	SLC25A37	Modulator	Polychlorinated Biphenyls	Carcinogen	.	.	Polychlorinated Biphenyls affects the expression of SLC25A37	.	.
DTD0199	SLC25A37	Inducer	Rotenone	Drug Marketed but not Approved by US FDA	.	.	Rotenone increases the expression of SLC25A37	.	.
DTD0199	SLC25A37	Inducer	Selenium nanoparticles	Natural Product	.	.	Selenium nanoparticles increases the expression of SLC25A37	.	.
DTD0199	SLC25A37	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC25A37	.	.
DTD0199	SLC25A37	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of SLC25A37	.	.
DTD0199	SLC25A37	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of SLC25A37	.	.
DTD0199	SLC25A37	Inducer	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate increases the expression of SLC25A37	.	.
DTD0199	SLC25A37	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC25A37	.	.
DTD0199	SLC25A37	Inhibition	Vincristine	Approved Drug	.	.	Vincristine inhibits the expression of SLC25A37	.	.
DTD0199	SLC25A37	Inducer	Zinc	Environmental toxicant	.	.	Zinc increases the expression of SLC25A37	.	.
DTD0200	SLC25A38	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC25A38	.	.
DTD0200	SLC25A38	Inhibition	Atrazine	Herbicide	.	.	Atrazine inhibits the expression of SLC25A38	.	.
DTD0200	SLC25A38	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC25A38	.	.
DTD0200	SLC25A38	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of SLC25A38	.	.
DTD0200	SLC25A38	Inducer	K-7174	Patented Pharmaceutical Agent	.	.	K-7174 increases the expression of SLC25A38	.	.
DTD0200	SLC25A38	Modulator	Phenobarbital	Approved Drug	.	.	Phenobarbital affects the expression of SLC25A38	.	.
DTD0200	SLC25A38	Inducer	Temozolomide	Approved Drug	.	.	Temozolomide increases the expression of SLC25A38	.	.
DTD0200	SLC25A38	Inhibition	Testosterone	Approved Drug	.	.	Testosterone inhibits the expression of SLC25A38	.	.
DTD0200	SLC25A38	Inducer	Thapsigargin	Natural Product	.	.	Thapsigargin increases the expression of SLC25A38	.	.
DTD0200	SLC25A38	Modulator	Valproic Acid	Approved Drug	.	.	Valproic Acid affects the expression of SLC25A38	.	.
DTD0202	SLC25A4	Inducer	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 increases the expression of SLC25A4	.	.
DTD0202	SLC25A4	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of SLC25A4	.	.
DTD0202	SLC25A4	Inhibition	Antimycin A	Acute Toxic Substance	.	.	Antimycin A inhibits the expression of SLC25A4	.	.
DTD0202	SLC25A4	Inducer	Arsenic Trioxide	Approved Drug	.	.	Arsenic Trioxide increases the expression of SLC25A4	.	.
DTD0202	SLC25A4	Inhibition	Atrazine	Herbicide	.	.	Atrazine inhibits the expression of SLC25A4	.	.
DTD0202	SLC25A4	Inducer	Azoxystrobin	Fungicide	.	.	Azoxystrobin increases the expression of SLC25A4	.	.
DTD0202	SLC25A4	Inhibition	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A inhibits the expression of SLC25A4	.	.
DTD0202	SLC25A4	Inducer	Bisphenol B	Drug in Phase 2 Trial	.	.	Bisphenol B increases the expression of SLC25A4	.	.
DTD0202	SLC25A4	Inducer	Cadmium	Acute Toxic Substance	.	.	Cadmium increases the expression of SLC25A4	.	.
DTD0202	SLC25A4	Inducer	Calcitriol	Approved Drug	.	.	Calcitriol increases the expression of SLC25A4	.	.
DTD0202	SLC25A4	Inhibition	CD-437	Health and Environmental Toxicant	.	.	CD-437 inhibits the activity of SLC25A4	.	.
DTD0202	SLC25A4	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC25A4	.	.
DTD0202	SLC25A4	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC25A4	.	.
DTD0202	SLC25A4	Inhibition	Deguelin	Natural Product	.	.	Deguelin inhibits the expression of SLC25A4	.	.
DTD0202	SLC25A4	Inducer	Doxorubicin	Approved Drug	.	.	Doxorubicin increases the expression of SLC25A4	.	.
DTD0202	SLC25A4	Inhibition	Dronabinol	Approved Drug	.	.	Dronabinol inhibits the expression of SLC25A4	.	.
DTD0202	SLC25A4	Modulator	Folic Acid	Approved Drug	.	.	Folic Acid affects the expression of SLC25A4	.	.
DTD0202	SLC25A4	Inhibition	Formaldehyde	Acute Toxic Substance	.	.	Formaldehyde inhibits the expression of SLC25A4	.	.
DTD0202	SLC25A4	Inhibition	Ivermectin	Approved Drug	.	.	Ivermectin inhibits the expression of SLC25A4	.	.
DTD0202	SLC25A4	Modulator	Lead	Health and Environmental Toxicant	.	.	Lead affects the expression of SLC25A4	.	.
DTD0202	SLC25A4	Inhibition	Menthol	Approved Drug	.	.	Menthol inhibits the expression of SLC25A4	.	.
DTD0202	SLC25A4	Inhibition	Milchsaure	Investigative Drug	.	.	Milchsaure inhibits the expression of SLC25A4	.	.
DTD0202	SLC25A4	Modulator	Okadaic Acid	Acute Toxic Substance	.	.	Okadaic Acid affects the expression of SLC25A4	.	.
DTD0202	SLC25A4	Inhibition	Paclitaxel	Approved Drug	.	.	Paclitaxel inhibits the expression of SLC25A4	.	.
DTD0202	SLC25A4	Inducer	Temozolomide	Approved Drug	.	.	Temozolomide increases the expression of SLC25A4	.	.
DTD0202	SLC25A4	Inducer	Testosterone	Approved Drug	.	.	Testosterone increases the expression of SLC25A4	.	.
DTD0202	SLC25A4	Inhibition	Thapsigargin	Natural Product	.	.	Thapsigargin inhibits the expression of SLC25A4	.	.
DTD0202	SLC25A4	Modulator	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A affects the expression of SLC25A4	.	.
DTD0202	SLC25A4	Inhibition	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan inhibits the expression of SLC25A4	.	.
DTD0202	SLC25A4	Inhibition	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate inhibits the expression of SLC25A4	.	.
DTD0202	SLC25A4	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC25A4	.	.
DTD0202	SLC25A4	Inducer	Vitamin E	Drug in Phase 3 Trial	.	.	Vitamin E increases the expression of SLC25A4	.	.
DTD0205	SLC25A42	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC25A42	.	.
DTD0205	SLC25A42	Inducer	Acrylamide	Acute Toxic Substance	.	.	Acrylamide increases the expression of SLC25A42	.	.
DTD0205	SLC25A42	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC25A42	.	.
DTD0205	SLC25A42	Inducer	Atrazine	Herbicide	.	.	Atrazine increases the expression of SLC25A42	.	.
DTD0205	SLC25A42	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC25A42	.	.
DTD0205	SLC25A42	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC25A42	.	.
DTD0205	SLC25A42	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC25A42	.	.
DTD0205	SLC25A42	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC25A42	.	.
DTD0205	SLC25A42	Inducer	Temozolomide	Approved Drug	.	.	Temozolomide increases the expression of SLC25A42	.	.
DTD0205	SLC25A42	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC25A42	.	.
DTD0205	SLC25A42	Inhibition	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate inhibits the expression of SLC25A42	.	.
DTD0213	SLC25A5	Inducer	1-methyl-4-phenylpyridinium	Health and Environmental Toxicant	.	.	1-methyl-4-phenylpyridinium increases the expression of SLC25A5	.	.
DTD0213	SLC25A5	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of SLC25A5	.	.
DTD0213	SLC25A5	Inducer	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 increases the expression of SLC25A5	.	.
DTD0213	SLC25A5	Inducer	Atrazine	Herbicide	.	.	Atrazine increases the expression of SLC25A5	.	.
DTD0213	SLC25A5	Inducer	Azoxystrobin	Fungicide	.	.	Azoxystrobin increases the expression of SLC25A5	.	.
DTD0213	SLC25A5	Inhibition	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A inhibits the expression of SLC25A5	.	.
DTD0213	SLC25A5	Inhibition	Cadmium	Acute Toxic Substance	.	.	Cadmium inhibits the expression of SLC25A5	.	.
DTD0213	SLC25A5	Inhibition	CD-437	Health and Environmental Toxicant	.	.	CD-437 inhibits the expression of SLC25A5	.	.
DTD0213	SLC25A5	Modulator	Chloropicrin	Acute Toxic Substance	.	.	Chloropicrin affects the expression of SLC25A5	.	.
DTD0213	SLC25A5	Inhibition	Coal Ash	Natural Product	.	.	Coal Ash inhibits the expression of SLC25A5	.	.
DTD0213	SLC25A5	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC25A5	.	.
DTD0213	SLC25A5	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC25A5	.	.
DTD0213	SLC25A5	Inducer	Dopamine	Approved Drug	.	.	Dopamine increases the expression of SLC25A5	.	.
DTD0213	SLC25A5	Inducer	Doxorubicin	Approved Drug	.	.	Doxorubicin increases the expression of SLC25A5	.	.
DTD0213	SLC25A5	Inhibition	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 inhibits the expression of SLC25A5	.	.
DTD0213	SLC25A5	Inhibition	Ivermectin	Approved Drug	.	.	Ivermectin inhibits the expression of SLC25A5	.	.
DTD0213	SLC25A5	Inducer	K-7174	Patented Pharmaceutical Agent	.	.	K-7174 increases the expression of SLC25A5	.	.
DTD0213	SLC25A5	Modulator	Menadione	Approved Drug	.	.	Menadione affects the expression of SLC25A5	.	.
DTD0213	SLC25A5	Inducer	Rotenone	Drug Marketed but not Approved by US FDA	.	.	Rotenone increases the expression of SLC25A5	.	.
DTD0213	SLC25A5	Inducer	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite increases the expression of SLC25A5	.	.
DTD0213	SLC25A5	Modulator	Ursodeoxycholic Acid	Approved Drug	.	.	Ursodeoxycholic Acid affects the expression of SLC25A5	.	.
DTD0222	SLC25A6	Inducer	1-methyl-4-phenylpyridinium	Health and Environmental Toxicant	.	.	1-methyl-4-phenylpyridinium increases the expression of SLC25A6	.	.
DTD0222	SLC25A6	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC25A6	.	.
DTD0222	SLC25A6	Inducer	Azoxystrobin	Fungicide	.	.	Azoxystrobin increases the expression of SLC25A6	.	.
DTD0222	SLC25A6	Inducer	Benzatropine	Approved Drug	.	.	Benzatropine increases the expression of SLC25A6	.	.
DTD0222	SLC25A6	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC25A6	.	.
DTD0222	SLC25A6	Inducer	Bisphenol B	Drug in Phase 2 Trial	.	.	Bisphenol B increases the expression of SLC25A6	.	.
DTD0222	SLC25A6	Inducer	Bisphenol F	Environmental toxicant	.	.	Bisphenol F increases the expression of SLC25A6	.	.
DTD0222	SLC25A6	Inhibition	CD-437	Health and Environmental Toxicant	.	.	CD-437 inhibits the expression of SLC25A6	.	.
DTD0222	SLC25A6	Inhibition	Chloropicrin	Acute Toxic Substance	.	.	Chloropicrin inhibits the expression of SLC25A6	.	.
DTD0222	SLC25A6	Inducer	Clozapine	Approved Drug	.	.	Clozapine increases the expression of SLC25A6	.	.
DTD0222	SLC25A6	Inducer	Deguelin	Natural Product	.	.	Deguelin increases the expression of SLC25A6	.	.
DTD0222	SLC25A6	Inhibition	Deoxynivalenol	Mycotoxins	.	.	Deoxynivalenol inhibits the expression of SLC25A6	.	.
DTD0222	SLC25A6	Inhibition	Dietary Carbohydrates	Natural Product	.	.	Dietary Carbohydrates inhibits the expression of SLC25A6	.	.
DTD0222	SLC25A6	Inducer	Dopamine	Approved Drug	.	.	Dopamine increases the expression of SLC25A6	.	.
DTD0222	SLC25A6	Inhibition	Ivermectin	Approved Drug	.	.	Ivermectin inhibits the expression of SLC25A6	.	.
DTD0222	SLC25A6	Inhibition	Perfluorooctane sulfonic acid	Health and Environmental Toxicant	.	.	Perfluorooctane sulfonic acid inhibits the expression of SLC25A6	.	.
DTD0222	SLC25A6	Inducer	Rotenone	Drug Marketed but not Approved by US FDA	.	.	Rotenone increases the expression of SLC25A6	.	.
DTD0222	SLC25A6	Inducer	Selenium nanoparticles	Natural Product	.	.	Selenium nanoparticles increases the expression of SLC25A6	.	.
DTD0222	SLC25A6	Inducer	Temozolomide	Approved Drug	.	.	Temozolomide increases the expression of SLC25A6	.	.
DTD0222	SLC25A6	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC25A6	.	.
DTD0222	SLC25A6	Modulator	Uranium	Acute Toxic Substance	.	.	Uranium affects the expression of SLC25A6	.	.
DTD0222	SLC25A6	Inducer	Vitamin E	Drug in Phase 3 Trial	.	.	Vitamin E increases the expression of SLC25A6	.	.
DTD0224	SLC25A7	Inducer	Abacavir	Approved Drug	.	.	Abacavir increases the expression of SLC25A7	.	.
DTD0224	SLC25A7	Inducer	Arsenic Trioxide	Approved Drug	.	.	Arsenic Trioxide increases the expression of SLC25A7	.	.
DTD0224	SLC25A7	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC25A7	.	.
DTD0224	SLC25A7	Inhibition	Cyclophosphamide	Approved Drug	.	.	Cyclophosphamide inhibits the expression of SLC25A7	.	.
DTD0224	SLC25A7	Inducer	Dexamethasone	Approved Drug	.	.	Dexamethasone increases the expression of SLC25A7	.	.
DTD0224	SLC25A7	Inducer	Enniatins	Acute Toxic Substance	.	.	Enniatins increases the expression of SLC25A7	.	.
DTD0224	SLC25A7	Inducer	Methotrexate	Approved Drug	.	.	Methotrexate increases the expression of SLC25A7	.	.
DTD0224	SLC25A7	Inhibition	Ochratoxin A	Acute Toxic Substance	.	.	Ochratoxin A inhibits the expression of SLC25A7	.	.
DTD0224	SLC25A7	Inducer	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A increases the expression of SLC25A7	.	.
DTD0224	SLC25A7	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC25A7	.	.
DTD0224	SLC25A7	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of SLC25A7	.	.
DTD0225	SLC25A8	Inhibition	1-methyl-4-phenylpyridinium	Health and Environmental Toxicant	.	.	1-methyl-4-phenylpyridinium inhibits the expression of SLC25A8	.	.
DTD0225	SLC25A8	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of SLC25A8	.	.
DTD0225	SLC25A8	Inhibition	Acrylamide	Acute Toxic Substance	.	.	Acrylamide inhibits the expression of SLC25A8	.	.
DTD0225	SLC25A8	Inducer	Arsenic Trioxide	Approved Drug	.	.	Arsenic Trioxide increases the expression of SLC25A8	.	.
DTD0225	SLC25A8	Inhibition	Atrazine	Herbicide	.	.	Atrazine inhibits the expression of SLC25A8	.	.
DTD0225	SLC25A8	Inhibition	Beauvericin	Mycotoxins	.	.	Beauvericin inhibits the expression of SLC25A8	.	.
DTD0225	SLC25A8	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of SLC25A8	.	.
DTD0225	SLC25A8	Inhibition	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A inhibits the expression of SLC25A8	.	.
DTD0225	SLC25A8	Inducer	Cadmium	Acute Toxic Substance	.	.	Cadmium increases the expression of SLC25A8	.	.
DTD0225	SLC25A8	Modulator	Carbamazepine	Approved Drug	.	.	Carbamazepine affects the expression of SLC25A8	.	.
DTD0225	SLC25A8	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the expression of SLC25A8	.	.
DTD0225	SLC25A8	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC25A8	.	.
DTD0225	SLC25A8	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of SLC25A8	.	.
DTD0225	SLC25A8	Inducer	Dexamethasone	Approved Drug	.	.	Dexamethasone increases the expression of SLC25A8	.	.
DTD0225	SLC25A8	Inducer	Dicrotophos	Pesticide/Insecticide	.	.	Dicrotophos increases the expression of SLC25A8	.	.
DTD0225	SLC25A8	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC25A8	.	.
DTD0225	SLC25A8	Inducer	Dronabinol	Approved Drug	.	.	Dronabinol increases the expression of SLC25A8	.	.
DTD0225	SLC25A8	Inhibition	Etoposide	Approved Drug	.	.	Etoposide inhibits the expression of SLC25A8	.	.
DTD0225	SLC25A8	Inducer	Fenofibrate	Approved Drug	.	.	Fenofibrate increases the expression of SLC25A8	.	.
DTD0225	SLC25A8	Inhibition	Fluorouracil	Approved Drug	.	.	Fluorouracil inhibits the expression of SLC25A8	.	.
DTD0225	SLC25A8	Inducer	Glucose	Investigative Drug	.	.	Glucose increases the expression of SLC25A8	.	.
DTD0225	SLC25A8	Inhibition	GSK-J4	Patented Pharmaceutical Agent	.	.	GSK-J4 inhibits the expression of SLC25A8	.	.
DTD0225	SLC25A8	Inducer	Indomethacin	Approved Drug	.	.	Indomethacin increases the expression of SLC25A8	.	.
DTD0225	SLC25A8	Inducer	Jinfukang	Traditional Medicine	.	.	Jinfukang increases the expression of SLC25A8	.	.
DTD0225	SLC25A8	Modulator	Lead	Health and Environmental Toxicant	.	.	Lead affects the expression of SLC25A8	.	.
DTD0225	SLC25A8	Inducer	Linalool	Natural Product	.	.	Linalool increases the expression of SLC25A8	.	.
DTD0225	SLC25A8	Modulator	Menadione	Approved Drug	.	.	Menadione affects the expression of SLC25A8	.	.
DTD0225	SLC25A8	Inducer	Methotrexate	Approved Drug	.	.	Methotrexate increases the expression of SLC25A8	.	.
DTD0225	SLC25A8	Inhibition	Ochratoxin A	Acute Toxic Substance	.	.	Ochratoxin A inhibits the expression of SLC25A8	.	.
DTD0225	SLC25A8	Inducer	Palmitic Acid	Drug in Phase 1 Trial	.	.	Palmitic Acid increases the activity of SLC25A8	.	.
DTD0225	SLC25A8	Inducer	Plant Extracts	Plant Extract	.	.	Plant Extracts increases the expression of SLC25A8	.	.
DTD0225	SLC25A8	Inducer	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin increases the expression of SLC25A8	.	.
DTD0225	SLC25A8	Inducer	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin increases the expression of SLC25A8	.	.
DTD0225	SLC25A8	Inducer	Rosiglitazone	Approved Drug	.	.	Rosiglitazone increases the expression of SLC25A8	.	.
DTD0225	SLC25A8	Inducer	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite increases the expression of SLC25A8	.	.
DTD0225	SLC25A8	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of SLC25A8	.	.
DTD0225	SLC25A8	Inhibition	Thapsigargin	Natural Product	.	.	Thapsigargin inhibits the expression of SLC25A8	.	.
DTD0225	SLC25A8	Inhibition	Thimerosal	Acute Toxic Substance	.	.	Thimerosal inhibits the expression of SLC25A8	.	.
DTD0225	SLC25A8	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC25A8	.	.
DTD0225	SLC25A8	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC25A8	.	.
DTD0225	SLC25A8	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of SLC25A8	.	.
DTD0225	SLC25A8	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC25A8	.	.
DTD0225	SLC25A8	Inhibition	Vincristine	Approved Drug	.	.	Vincristine inhibits the expression of SLC25A8	.	.
DTD0226	SLC25A9	Inducer	Acrylamide	Acute Toxic Substance	.	.	Acrylamide increases the expression of SLC25A9	.	.
DTD0226	SLC25A9	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the expression of SLC25A9	.	.
DTD0226	SLC25A9	Inhibition	Glucose	Investigative Drug	.	.	Glucose inhibits the expression of SLC25A9	.	.
DTD0226	SLC25A9	Inhibition	Isoproterenol	Approved Drug	.	.	Isoproterenol inhibits the expression of SLC25A9	.	.
DTD0226	SLC25A9	Inducer	Kaempferol	Acute Toxic Substance	.	.	Kaempferol increases the expression of SLC25A9	.	.
DTD0226	SLC25A9	Inducer	Ochratoxin A	Acute Toxic Substance	.	.	Ochratoxin A increases the expression of SLC25A9	.	.
DTD0226	SLC25A9	Inhibition	Particulate Matter	Natural Product	.	.	Particulate Matter inhibits the expression of SLC25A9	.	.
DTD0226	SLC25A9	Modulator	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin affects the expression of SLC25A9	.	.
DTD0226	SLC25A9	Inducer	Testosterone	Approved Drug	.	.	Testosterone increases the expression of SLC25A9	.	.
DTD0226	SLC25A9	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC25A9	.	.
DTD0227	SLC26A1	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC26A1	.	.
DTD0227	SLC26A1	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC26A1	.	.
DTD0227	SLC26A1	Inducer	Endosulfan	Pesticide/Insecticide	.	.	Endosulfan increases the expression of SLC26A1	.	.
DTD0227	SLC26A1	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC26A1	.	.
DTD0227	SLC26A1	Inducer	Jinfukang	Traditional Medicine	.	.	Jinfukang increases the expression of SLC26A1	.	.
DTD0227	SLC26A1	Modulator	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution affects the expression of SLC26A1	.	.
DTD0227	SLC26A1	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of SLC26A1	.	.
DTD0227	SLC26A1	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of SLC26A1	.	.
DTD0230	SLC26A2	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of SLC26A2	.	.
DTD0230	SLC26A2	Inhibition	Afimoxifene	Drug in Phase 3 Trial	.	.	Afimoxifene inhibits the expression of SLC26A2	.	.
DTD0230	SLC26A2	Inducer	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 increases the expression of SLC26A2	.	.
DTD0230	SLC26A2	Inhibition	Aflatoxin M1	Mycotoxins	.	.	Aflatoxin M1 inhibits the expression of SLC26A2	.	.
DTD0230	SLC26A2	Modulator	AM-80	Drug in Phase 2/3 Trial	.	.	AM-80 affects the expression of SLC26A2	.	.
DTD0230	SLC26A2	Inducer	Atrazine	Herbicide	.	.	Atrazine increases the expression of SLC26A2	.	.
DTD0230	SLC26A2	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of SLC26A2	.	.
DTD0230	SLC26A2	Inducer	Cadmium	Acute Toxic Substance	.	.	Cadmium increases the expression of SLC26A2	.	.
DTD0230	SLC26A2	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the expression of SLC26A2	.	.
DTD0230	SLC26A2	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC26A2	.	.
DTD0230	SLC26A2	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC26A2	.	.
DTD0230	SLC26A2	Inducer	Dihydrotestosterone	Drug in Phase 1 Trial	.	.	Dihydrotestosterone increases the expression of SLC26A2	.	.
DTD0230	SLC26A2	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the expression of SLC26A2	.	.
DTD0230	SLC26A2	Inhibition	Fulvestrant	Approved Drug	.	.	Fulvestrant inhibits the expression of SLC26A2	.	.
DTD0230	SLC26A2	Modulator	Menadione	Approved Drug	.	.	Menadione affects the expression of SLC26A2	.	.
DTD0230	SLC26A2	Inhibition	Nickel chloride	Acute Toxic Substance	.	.	Nickel chloride inhibits the expression of SLC26A2	.	.
DTD0230	SLC26A2	Inducer	PCI-5002	Investigative Drug	.	.	PCI-5002 increases the expression of SLC26A2	.	.
DTD0230	SLC26A2	Inhibition	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin inhibits the expression of SLC26A2	.	.
DTD0230	SLC26A2	Inducer	Progesterone	Approved Drug	.	.	Progesterone increases the expression of SLC26A2	.	.
DTD0230	SLC26A2	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of SLC26A2	.	.
DTD0230	SLC26A2	Inhibition	Raloxifene Hydrochloride	Approved Drug	.	.	Raloxifene Hydrochloride inhibits the expression of SLC26A2	.	.
DTD0230	SLC26A2	Inhibition	Rifampin	Approved Drug	.	.	Rifampin inhibits the expression of SLC26A2	.	.
DTD0230	SLC26A2	Inducer	Sulforafan	Drug in Phase 3 Trial	.	.	Sulforafan increases the expression of SLC26A2	.	.
DTD0230	SLC26A2	Inhibition	Tetrabromobisphenol A	Environmental toxicant	.	.	Tetrabromobisphenol A inhibits the expression of SLC26A2	.	.
DTD0230	SLC26A2	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC26A2	.	.
DTD0230	SLC26A2	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC26A2	.	.
DTD0230	SLC26A2	Inducer	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A increases the expression of SLC26A2	.	.
DTD0230	SLC26A2	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of SLC26A2	.	.
DTD0230	SLC26A2	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC26A2	.	.
DTD0230	SLC26A2	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of SLC26A2	.	.
DTD0231	SLC26A3	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC26A3	.	.
DTD0231	SLC26A3	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC26A3	.	.
DTD0231	SLC26A3	Inducer	Calcitriol	Approved Drug	.	.	Calcitriol increases the expression of SLC26A3	.	.
DTD0231	SLC26A3	Inducer	Capecitabine	Approved Drug	.	.	Capecitabine increases the expression of SLC26A3	.	.
DTD0231	SLC26A3	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC26A3	.	.
DTD0231	SLC26A3	Inducer	Dihydrotestosterone	Drug in Phase 1 Trial	.	.	Dihydrotestosterone increases the expression of SLC26A3	.	.
DTD0231	SLC26A3	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the expression of SLC26A3	.	.
DTD0231	SLC26A3	Inducer	Folic Acid	Approved Drug	.	.	Folic Acid increases the expression of SLC26A3	.	.
DTD0231	SLC26A3	Inhibition	Isotretinoin	Approved Drug	.	.	Isotretinoin inhibits the expression of SLC26A3	.	.
DTD0231	SLC26A3	Inhibition	Methotrexate	Approved Drug	.	.	Methotrexate inhibits the expression of SLC26A3	.	.
DTD0231	SLC26A3	Inhibition	Methyleugenol	Natural Product	.	.	Methyleugenol inhibits the expression of SLC26A3	.	.
DTD0231	SLC26A3	Inhibition	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin inhibits the expression of SLC26A3	.	.
DTD0231	SLC26A3	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of SLC26A3	.	.
DTD0231	SLC26A3	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC26A3	.	.
DTD0231	SLC26A3	Inhibition	Tenidap	Drug in Phase 2 Trial	.	.	Tenidap inhibits the activity of SLC26A3	.	.
DTD0231	SLC26A3	Inducer	Testosterone	Approved Drug	.	.	Testosterone increases the expression of SLC26A3	.	.
DTD0231	SLC26A3	Inhibition	Vanadyl sulfate	Drug in Phase 3 Trial	.	.	Vanadyl sulfate inhibits the expression of SLC26A3	.	.
DTD0231	SLC26A3	Inhibition	Zidovudine	Approved Drug	.	.	Zidovudine inhibits the expression of SLC26A3	.	.
DTD0232	SLC26A4	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC26A4	.	.
DTD0232	SLC26A4	Inhibition	Amiodarone	Approved Drug	.	.	Amiodarone inhibits the expression of SLC26A4	.	.
DTD0232	SLC26A4	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC26A4	.	.
DTD0232	SLC26A4	Inhibition	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde inhibits the expression of SLC26A4	.	.
DTD0232	SLC26A4	Inducer	Omega-3 Fatty acids	Drug in Phase 1 Trial	.	.	Omega-3 Fatty acids increases the expression of SLC26A4	.	.
DTD0232	SLC26A4	Inhibition	Omega-6-FA	Drug in Phase 1 Trial	.	.	Omega-6-FA inhibits the expression of SLC26A4	.	.
DTD0232	SLC26A4	Modulator	Phenobarbital	Approved Drug	.	.	Phenobarbital affects the expression of SLC26A4	.	.
DTD0232	SLC26A4	Inhibition	Rifampin	Approved Drug	.	.	Rifampin inhibits the expression of SLC26A4	.	.
DTD0232	SLC26A4	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC26A4	.	.
DTD0233	SLC26A5	Inhibition	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde inhibits the expression of SLC26A5	.	.
DTD0233	SLC26A5	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC26A5	.	.
DTD0234	SLC26A6	Inducer	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 increases the expression of SLC26A6	.	.
DTD0234	SLC26A6	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of SLC26A6	.	.
DTD0234	SLC26A6	Modulator	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 affects the expression of SLC26A6	.	.
DTD0234	SLC26A6	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC26A6	.	.
DTD0234	SLC26A6	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC26A6	.	.
DTD0234	SLC26A6	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC26A6	.	.
DTD0234	SLC26A6	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the expression of SLC26A6	.	.
DTD0234	SLC26A6	Inhibition	Lead	Health and Environmental Toxicant	.	.	Lead inhibits the expression of SLC26A6	.	.
DTD0234	SLC26A6	Inhibition	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin inhibits the expression of SLC26A6	.	.
DTD0234	SLC26A6	Inducer	Temozolomide	Approved Drug	.	.	Temozolomide increases the expression of SLC26A6	.	.
DTD0234	SLC26A6	Modulator	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution affects the expression of SLC26A6	.	.
DTD0234	SLC26A6	Inhibition	Vorinostat	Approved Drug	.	.	Vorinostat inhibits the expression of SLC26A6	.	.
DTD0235	SLC26A7	Inducer	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 increases the expression of SLC26A7	.	.
DTD0235	SLC26A7	Inducer	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 increases the expression of SLC26A7	.	.
DTD0235	SLC26A7	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC26A7	.	.
DTD0235	SLC26A7	Inducer	Cinnamic aldehyde	Natural Product	.	.	Cinnamic aldehyde increases the expression of SLC26A7	.	.
DTD0235	SLC26A7	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the expression of SLC26A7	.	.
DTD0235	SLC26A7	Inhibition	Genistein	Drug in Phase 2 Trial	.	.	Genistein inhibits the expression of SLC26A7	.	.
DTD0235	SLC26A7	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC26A7	.	.
DTD0235	SLC26A7	Modulator	Tretinoin	Approved Drug	.	.	Tretinoin affects the expression of SLC26A7	.	.
DTD0237	SLC26A9	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of SLC26A9	.	.
DTD0237	SLC26A9	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC26A9	.	.
DTD0237	SLC26A9	Inhibition	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde inhibits the expression of SLC26A9	.	.
DTD0237	SLC26A9	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC26A9	.	.
DTD0237	SLC26A9	Inhibition	Milchsaure	Investigative Drug	.	.	Milchsaure inhibits the expression of SLC26A9	.	.
DTD0237	SLC26A9	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC26A9	.	.
DTD0237	SLC26A9	Inhibition	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan inhibits the expression of SLC26A9	.	.
DTD0237	SLC26A9	Inhibition	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate inhibits the expression of SLC26A9	.	.
DTD0237	SLC26A9	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of SLC26A9	.	.
DTD0238	SLC27A1	Inducer	Alitretinoin	Approved Drug	.	.	Alitretinoin increases the expression of SLC27A1	.	.
DTD0238	SLC27A1	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC27A1	.	.
DTD0238	SLC27A1	Inducer	Calcitriol	Approved Drug	.	.	Calcitriol increases the expression of SLC27A1	.	.
DTD0238	SLC27A1	Modulator	Cisplatin	Approved Drug	.	.	Cisplatin affects the expression of SLC27A1	.	.
DTD0238	SLC27A1	Inducer	Copper Sulfate	Approved Drug	.	.	Copper Sulfate increases the expression of SLC27A1	.	.
DTD0238	SLC27A1	Modulator	Decitabine	Approved Drug	.	.	Decitabine affects the expression of SLC27A1	.	.
DTD0238	SLC27A1	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC27A1	.	.
DTD0238	SLC27A1	Inhibition	Ivermectin	Approved Drug	.	.	Ivermectin inhibits the expression of SLC27A1	.	.
DTD0238	SLC27A1	Inducer	Jinfukang	Traditional Medicine	.	.	Jinfukang increases the expression of SLC27A1	.	.
DTD0238	SLC27A1	Inhibition	Lead	Health and Environmental Toxicant	.	.	Lead inhibits the expression of SLC27A1	.	.
DTD0238	SLC27A1	Inhibition	Methotrexate	Approved Drug	.	.	Methotrexate inhibits the expression of SLC27A1	.	.
DTD0238	SLC27A1	Modulator	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin affects the expression of SLC27A1	.	.
DTD0238	SLC27A1	Inhibition	Rosiglitazone	Approved Drug	.	.	Rosiglitazone inhibits the expression of SLC27A1	.	.
DTD0238	SLC27A1	Inducer	Temozolomide	Approved Drug	.	.	Temozolomide increases the expression of SLC27A1	.	.
DTD0238	SLC27A1	Inducer	Testosterone	Approved Drug	.	.	Testosterone increases the expression of SLC27A1	.	.
DTD0238	SLC27A1	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC27A1	.	.
DTD0238	SLC27A1	Modulator	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A affects the expression of SLC27A1	.	.
DTD0238	SLC27A1	Inducer	Urethane	Approved Drug	.	.	Urethane increases the expression of SLC27A1	.	.
DTD0238	SLC27A1	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC27A1	.	.
DTD0238	SLC27A1	Inducer	Zoledronic Acid	Approved Drug	.	.	Zoledronic Acid increases the expression of SLC27A1	.	.
DTD0239	SLC27A2	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC27A2	.	.
DTD0239	SLC27A2	Inhibition	Adefovir dipivoxil	Approved Drug	.	.	Adefovir dipivoxil inhibits the expression of SLC27A2	.	.
DTD0239	SLC27A2	Modulator	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 affects the expression of SLC27A2	.	.
DTD0239	SLC27A2	Inducer	Arsenic Trioxide	Approved Drug	.	.	Arsenic Trioxide increases the expression of SLC27A2	.	.
DTD0239	SLC27A2	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC27A2	.	.
DTD0239	SLC27A2	Inducer	Calcitriol	Approved Drug	.	.	Calcitriol increases the expression of SLC27A2	.	.
DTD0239	SLC27A2	Inhibition	Cidofovir	Approved Drug	.	.	Cidofovir inhibits the expression of SLC27A2	.	.
DTD0239	SLC27A2	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC27A2	.	.
DTD0239	SLC27A2	Inducer	Coumestrol	Investigative Drug	.	.	Coumestrol increases the expression of SLC27A2	.	.
DTD0239	SLC27A2	Inhibition	Cupric oxide	Chemical Compound	.	.	Cupric oxide inhibits the expression of SLC27A2	.	.
DTD0239	SLC27A2	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC27A2	.	.
DTD0239	SLC27A2	Inhibition	Dicrotophos	Pesticide/Insecticide	.	.	Dicrotophos inhibits the expression of SLC27A2	.	.
DTD0239	SLC27A2	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC27A2	.	.
DTD0239	SLC27A2	Inducer	Farnesol	Investigative Drug	.	.	Farnesol increases the expression of SLC27A2	.	.
DTD0239	SLC27A2	Inducer	Fenofibrate	Approved Drug	.	.	Fenofibrate increases the expression of SLC27A2	.	.
DTD0239	SLC27A2	Inducer	GW-4064	Patented Pharmaceutical Agent	.	.	GW-4064 increases the expression of SLC27A2	.	.
DTD0239	SLC27A2	Inducer	GW-7647	Patented Pharmaceutical Agent	.	.	GW-7647 increases the expression of SLC27A2	.	.
DTD0239	SLC27A2	Modulator	Hydrogen Peroxide	Approved Drug	.	.	Hydrogen Peroxide affects the expression of SLC27A2	.	.
DTD0239	SLC27A2	Inducer	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 increases the expression of SLC27A2	.	.
DTD0239	SLC27A2	Inhibition	Isotretinoin	Approved Drug	.	.	Isotretinoin inhibits the expression of SLC27A2	.	.
DTD0239	SLC27A2	Inhibition	Jinfukang	Traditional Medicine	.	.	Jinfukang inhibits the expression of SLC27A2	.	.
DTD0239	SLC27A2	Modulator	Menadione	Approved Drug	.	.	Menadione affects the expression of SLC27A2	.	.
DTD0239	SLC27A2	Inducer	Methotrexate	Approved Drug	.	.	Methotrexate increases the expression of SLC27A2	.	.
DTD0239	SLC27A2	Inducer	Nicotinic acid	Drug in Phase 1 Trial	.	.	Nicotinic acid increases the expression of SLC27A2	.	.
DTD0239	SLC27A2	Inducer	Olanzapine	Approved Drug	.	.	Olanzapine increases the expression of SLC27A2	.	.
DTD0239	SLC27A2	Inducer	Perfluorooctane sulfonic acid	Health and Environmental Toxicant	.	.	Perfluorooctane sulfonic acid increases the expression of SLC27A2	.	.
DTD0239	SLC27A2	Inducer	Phenobarbital	Approved Drug	.	.	Phenobarbital increases the expression of SLC27A2	.	.
DTD0239	SLC27A2	Inhibition	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin inhibits the expression of SLC27A2	.	.
DTD0239	SLC27A2	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of SLC27A2	.	.
DTD0239	SLC27A2	Inducer	Rifampin	Approved Drug	.	.	Rifampin increases the expression of SLC27A2	.	.
DTD0239	SLC27A2	Inhibition	Rosiglitazone	Approved Drug	.	.	Rosiglitazone inhibits the expression of SLC27A2	.	.
DTD0239	SLC27A2	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC27A2	.	.
DTD0239	SLC27A2	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC27A2	.	.
DTD0239	SLC27A2	Inducer	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A increases the expression of SLC27A2	.	.
DTD0239	SLC27A2	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC27A2	.	.
DTD0239	SLC27A2	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of SLC27A2	.	.
DTD0239	SLC27A2	Inhibition	Zoledronic Acid	Approved Drug	.	.	Zoledronic Acid inhibits the expression of SLC27A2	.	.
DTD0240	SLC27A3	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of SLC27A3	.	.
DTD0240	SLC27A3	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC27A3	.	.
DTD0240	SLC27A3	Inhibition	Acrylamide	Acute Toxic Substance	.	.	Acrylamide inhibits the expression of SLC27A3	.	.
DTD0240	SLC27A3	Modulator	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 affects the expression of SLC27A3	.	.
DTD0240	SLC27A3	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of SLC27A3	.	.
DTD0240	SLC27A3	Inducer	Bisphenol B	Drug in Phase 2 Trial	.	.	Bisphenol B increases the expression of SLC27A3	.	.
DTD0240	SLC27A3	Inducer	Bisphenol F	Environmental toxicant	.	.	Bisphenol F increases the expression of SLC27A3	.	.
DTD0240	SLC27A3	Inhibition	Cannabidiol	Approved Drug	.	.	Cannabidiol inhibits the expression of SLC27A3	.	.
DTD0240	SLC27A3	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the expression of SLC27A3	.	.
DTD0240	SLC27A3	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC27A3	.	.
DTD0240	SLC27A3	Inducer	Coumestrol	Investigative Drug	.	.	Coumestrol increases the expression of SLC27A3	.	.
DTD0240	SLC27A3	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC27A3	.	.
DTD0240	SLC27A3	Inducer	Dexamethasone	Approved Drug	.	.	Dexamethasone increases the expression of SLC27A3	.	.
DTD0240	SLC27A3	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC27A3	.	.
DTD0240	SLC27A3	Inhibition	GSK-J4	Patented Pharmaceutical Agent	.	.	GSK-J4 inhibits the expression of SLC27A3	.	.
DTD0240	SLC27A3	Inhibition	Paraquat	Acute Toxic Substance	.	.	Paraquat inhibits the expression of SLC27A3	.	.
DTD0240	SLC27A3	Modulator	Phenobarbital	Approved Drug	.	.	Phenobarbital affects the expression of SLC27A3	.	.
DTD0240	SLC27A3	Inhibition	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin inhibits the expression of SLC27A3	.	.
DTD0240	SLC27A3	Inhibition	Rifampin	Approved Drug	.	.	Rifampin inhibits the expression of SLC27A3	.	.
DTD0240	SLC27A3	Inducer	Temozolomide	Approved Drug	.	.	Temozolomide increases the expression of SLC27A3	.	.
DTD0240	SLC27A3	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC27A3	.	.
DTD0240	SLC27A3	Inhibition	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A inhibits the expression of SLC27A3	.	.
DTD0240	SLC27A3	Inducer	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan increases the expression of SLC27A3	.	.
DTD0240	SLC27A3	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of SLC27A3	.	.
DTD0240	SLC27A3	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC27A3	.	.
DTD0240	SLC27A3	Inhibition	Vorinostat	Approved Drug	.	.	Vorinostat inhibits the expression of SLC27A3	.	.
DTD0241	SLC27A4	Inducer	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 increases the expression of SLC27A4	.	.
DTD0241	SLC27A4	Inducer	1-methyl-4-phenylpyridinium	Health and Environmental Toxicant	.	.	1-methyl-4-phenylpyridinium increases the expression of SLC27A4	.	.
DTD0241	SLC27A4	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC27A4	.	.
DTD0241	SLC27A4	Inhibition	Arbutin	Drug Marketed but not Approved by US FDA	.	.	Arbutin inhibits the expression of SLC27A4	.	.
DTD0241	SLC27A4	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC27A4	.	.
DTD0241	SLC27A4	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the expression of SLC27A4	.	.
DTD0241	SLC27A4	Inducer	Dicrotophos	Pesticide/Insecticide	.	.	Dicrotophos increases the expression of SLC27A4	.	.
DTD0241	SLC27A4	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC27A4	.	.
DTD0241	SLC27A4	Inducer	Fenofibrate	Approved Drug	.	.	Fenofibrate increases the expression of SLC27A4	.	.
DTD0241	SLC27A4	Inhibition	Ivermectin	Approved Drug	.	.	Ivermectin inhibits the expression of SLC27A4	.	.
DTD0241	SLC27A4	Inducer	Jinfukang	Traditional Medicine	.	.	Jinfukang increases the expression of SLC27A4	.	.
DTD0241	SLC27A4	Inducer	Linalool	Natural Product	.	.	Linalool increases the expression of SLC27A4	.	.
DTD0241	SLC27A4	Inhibition	Milchsaure	Investigative Drug	.	.	Milchsaure inhibits the expression of SLC27A4	.	.
DTD0241	SLC27A4	Inducer	Nicotinic acid	Drug in Phase 1 Trial	.	.	Nicotinic acid increases the expression of SLC27A4	.	.
DTD0241	SLC27A4	Inhibition	Perfluorooctane sulfonic acid	Health and Environmental Toxicant	.	.	Perfluorooctane sulfonic acid inhibits the expression of SLC27A4	.	.
DTD0241	SLC27A4	Modulator	Polychlorinated Biphenyls	Carcinogen	.	.	Polychlorinated Biphenyls affects the expression of SLC27A4	.	.
DTD0241	SLC27A4	Inducer	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin increases the expression of SLC27A4	.	.
DTD0241	SLC27A4	Inducer	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite increases the expression of SLC27A4	.	.
DTD0241	SLC27A4	Modulator	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution affects the expression of SLC27A4	.	.
DTD0241	SLC27A4	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC27A4	.	.
DTD0241	SLC27A4	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC27A4	.	.
DTD0242	SLC27A5	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC27A5	.	.
DTD0242	SLC27A5	Modulator	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 affects the expression of SLC27A5	.	.
DTD0242	SLC27A5	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC27A5	.	.
DTD0242	SLC27A5	Inhibition	Berberine	Drug Marketed but not Approved by US FDA	.	.	Berberine inhibits the expression of SLC27A5	.	.
DTD0242	SLC27A5	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC27A5	.	.
DTD0242	SLC27A5	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC27A5	.	.
DTD0242	SLC27A5	Inhibition	Dicrotophos	Pesticide/Insecticide	.	.	Dicrotophos inhibits the expression of SLC27A5	.	.
DTD0242	SLC27A5	Inhibition	Ethyl Methanesulfonate	Carcinogen	.	.	Ethyl Methanesulfonate inhibits the expression of SLC27A5	.	.
DTD0242	SLC27A5	Inhibition	Formaldehyde	Acute Toxic Substance	.	.	Formaldehyde inhibits the expression of SLC27A5	.	.
DTD0242	SLC27A5	Inducer	Jinfukang	Traditional Medicine	.	.	Jinfukang increases the expression of SLC27A5	.	.
DTD0242	SLC27A5	Inhibition	K-7174	Patented Pharmaceutical Agent	.	.	K-7174 inhibits the expression of SLC27A5	.	.
DTD0242	SLC27A5	Inhibition	Methyleugenol	Natural Product	.	.	Methyleugenol inhibits the expression of SLC27A5	.	.
DTD0242	SLC27A5	Inhibition	Mifepristone	Approved Drug	.	.	Mifepristone inhibits the expression of SLC27A5	.	.
DTD0242	SLC27A5	Inhibition	Obeticholic acid	Approved Drug	.	.	Obeticholic acid inhibits the expression of SLC27A5	.	.
DTD0242	SLC27A5	Inducer	Olanzapine	Approved Drug	.	.	Olanzapine increases the expression of SLC27A5	.	.
DTD0242	SLC27A5	Inducer	Rifampin	Approved Drug	.	.	Rifampin increases the expression of SLC27A5	.	.
DTD0242	SLC27A5	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC27A5	.	.
DTD0242	SLC27A5	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC27A5	.	.
DTD0242	SLC27A5	Inhibition	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate inhibits the expression of SLC27A5	.	.
DTD0242	SLC27A5	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC27A5	.	.
DTD0242	SLC27A5	Inhibition	Zinc	Environmental toxicant	.	.	Zinc inhibits the expression of SLC27A5	.	.
DTD0243	SLC27A6	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC27A6	.	.
DTD0243	SLC27A6	Inducer	Atrazine	Herbicide	.	.	Atrazine increases the expression of SLC27A6	.	.
DTD0243	SLC27A6	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC27A6	.	.
DTD0243	SLC27A6	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of SLC27A6	.	.
DTD0243	SLC27A6	Inhibition	Diethylhexyl Phthalate	Health and Environmental Toxicant	.	.	Diethylhexyl Phthalate inhibits the expression of SLC27A6	.	.
DTD0243	SLC27A6	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC27A6	.	.
DTD0243	SLC27A6	Inducer	Methotrexate	Approved Drug	.	.	Methotrexate increases the expression of SLC27A6	.	.
DTD0243	SLC27A6	Inducer	MS-275	Drug in Phase 2 Trial	.	.	MS-275 increases the expression of SLC27A6	.	.
DTD0243	SLC27A6	Inducer	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin increases the expression of SLC27A6	.	.
DTD0243	SLC27A6	Inhibition	Sunitinib	Approved Drug	.	.	Sunitinib inhibits the expression of SLC27A6	.	.
DTD0243	SLC27A6	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC27A6	.	.
DTD0243	SLC27A6	Inducer	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A increases the expression of SLC27A6	.	.
DTD0243	SLC27A6	Inhibition	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan inhibits the expression of SLC27A6	.	.
DTD0243	SLC27A6	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC27A6	.	.
DTD0244	SLC28A1	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC28A1	.	.
DTD0244	SLC28A1	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC28A1	.	.
DTD0244	SLC28A1	Inducer	Atrazine	Herbicide	.	.	Atrazine increases the expression of SLC28A1	.	.
DTD0244	SLC28A1	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC28A1	.	.
DTD0244	SLC28A1	Inducer	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde increases the expression of SLC28A1	.	.
DTD0244	SLC28A1	Inducer	Clothianidin	Pesticide/Insecticide	.	.	Clothianidin increases the expression of SLC28A1	.	.
DTD0244	SLC28A1	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC28A1	.	.
DTD0244	SLC28A1	Inducer	Formaldehyde	Acute Toxic Substance	.	.	Formaldehyde increases the expression of SLC28A1	.	.
DTD0244	SLC28A1	Inhibition	Rosiglitazone	Approved Drug	.	.	Rosiglitazone inhibits the expression of SLC28A1	.	.
DTD0244	SLC28A1	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC28A1	.	.
DTD0244	SLC28A1	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of SLC28A1	.	.
DTD0244	SLC28A1	Inhibition	Uridine	Approved Drug	.	.	Uridine inhibits the activity of SLC28A1	.	.
DTD0244	SLC28A1	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC28A1	.	.
DTD0245	SLC28A2	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of SLC28A2	.	.
DTD0245	SLC28A2	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of SLC28A2	.	.
DTD0245	SLC28A2	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC28A2	.	.
DTD0245	SLC28A2	Modulator	Carbamazepine	Approved Drug	.	.	Carbamazepine affects the expression of SLC28A2	.	.
DTD0245	SLC28A2	Inhibition	Uridine	Approved Drug	.	.	Uridine inhibits the activity of SLC28A2	.	.
DTD0245	SLC28A2	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC28A2	.	.
DTD0246	SLC28A3	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of SLC28A3	.	.
DTD0246	SLC28A3	Inhibition	Arsenic Trioxide	Approved Drug	.	.	Arsenic Trioxide inhibits the expression of SLC28A3	.	.
DTD0246	SLC28A3	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC28A3	.	.
DTD0246	SLC28A3	Inducer	Cholesterol	Natural Product	.	.	Cholesterol increases the expression of SLC28A3	.	.
DTD0246	SLC28A3	Inhibition	Inosine	Drug in Phase 3 Trial	.	.	Inosine inhibits the activity of SLC28A3	.	.
DTD0246	SLC28A3	Inhibition	Milchsaure	Investigative Drug	.	.	Milchsaure inhibits the expression of SLC28A3	.	.
DTD0246	SLC28A3	Inhibition	Sulforafan	Drug in Phase 3 Trial	.	.	Sulforafan inhibits the expression of SLC28A3	.	.
DTD0246	SLC28A3	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC28A3	.	.
DTD0246	SLC28A3	Inhibition	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan inhibits the expression of SLC28A3	.	.
DTD0246	SLC28A3	Inhibition	Uridine	Approved Drug	.	.	Uridine inhibits the activity of SLC28A3	.	.
DTD0246	SLC28A3	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of SLC28A3	.	.
DTD0246	SLC28A3	Inducer	Zoledronic Acid	Approved Drug	.	.	Zoledronic Acid increases the expression of SLC28A3	.	.
DTD0247	SLC29A1	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of SLC29A1	.	.
DTD0247	SLC29A1	Inducer	1-methyl-4-phenylpyridinium	Health and Environmental Toxicant	.	.	1-methyl-4-phenylpyridinium increases the expression of SLC29A1	.	.
DTD0247	SLC29A1	Inhibition	6-Benzylthioinosine	Investigative Drug	.	.	6-Benzylthioinosine inhibits the activity of SLC29A1	.	.
DTD0247	SLC29A1	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of SLC29A1	.	.
DTD0247	SLC29A1	Inducer	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 increases the expression of SLC29A1	.	.
DTD0247	SLC29A1	Inducer	Atrazine	Herbicide	.	.	Atrazine increases the expression of SLC29A1	.	.
DTD0247	SLC29A1	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of SLC29A1	.	.
DTD0247	SLC29A1	Modulator	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A affects the expression of SLC29A1	.	.
DTD0247	SLC29A1	Inhibition	Cadmium	Acute Toxic Substance	.	.	Cadmium inhibits the expression of SLC29A1	.	.
DTD0247	SLC29A1	Inhibition	Calcitriol	Approved Drug	.	.	Calcitriol inhibits the expression of SLC29A1	.	.
DTD0247	SLC29A1	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the expression of SLC29A1	.	.
DTD0247	SLC29A1	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC29A1	.	.
DTD0247	SLC29A1	Inducer	Coumestrol	Investigative Drug	.	.	Coumestrol increases the expression of SLC29A1	.	.
DTD0247	SLC29A1	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC29A1	.	.
DTD0247	SLC29A1	Inhibition	Demecolcine	Drug Marketed but not Approved by US FDA	.	.	Demecolcine inhibits the expression of SLC29A1	.	.
DTD0247	SLC29A1	Modulator	Doxorubicin	Approved Drug	.	.	Doxorubicin affects the expression of SLC29A1	.	.
DTD0247	SLC29A1	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC29A1	.	.
DTD0247	SLC29A1	Inducer	Fluorouracil	Approved Drug	.	.	Fluorouracil increases the expression of SLC29A1	.	.
DTD0247	SLC29A1	Inhibition	GSK-J4	Patented Pharmaceutical Agent	.	.	GSK-J4 inhibits the expression of SLC29A1	.	.
DTD0247	SLC29A1	Inhibition	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 inhibits the expression of SLC29A1	.	.
DTD0247	SLC29A1	Inducer	Jinfukang	Traditional Medicine	.	.	Jinfukang increases the expression of SLC29A1	.	.
DTD0247	SLC29A1	Inducer	Methyleugenol	Natural Product	.	.	Methyleugenol increases the expression of SLC29A1	.	.
DTD0247	SLC29A1	Inducer	MG-132	Investigative Drug	.	.	MG-132 increases the expression of SLC29A1	.	.
DTD0247	SLC29A1	Inhibition	Particulate Matter	Natural Product	.	.	Particulate Matter inhibits the expression of SLC29A1	.	.
DTD0247	SLC29A1	Inhibition	Plant Extracts	Plant Extract	.	.	Plant Extracts inhibits the expression of SLC29A1	.	.
DTD0247	SLC29A1	Inducer	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin increases the expression of SLC29A1	.	.
DTD0247	SLC29A1	Inducer	Rifampin	Approved Drug	.	.	Rifampin increases the expression of SLC29A1	.	.
DTD0247	SLC29A1	Inducer	Rotenone	Drug Marketed but not Approved by US FDA	.	.	Rotenone increases the expression of SLC29A1	.	.
DTD0247	SLC29A1	Inhibition	Seocalcitol	Drug in Phase 3 Trial	.	.	Seocalcitol inhibits the expression of SLC29A1	.	.
DTD0247	SLC29A1	Inducer	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite increases the expression of SLC29A1	.	.
DTD0247	SLC29A1	Inhibition	Sulindac	Approved Drug	.	.	Sulindac inhibits the activity of SLC29A1	.	.
DTD0247	SLC29A1	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of SLC29A1	.	.
DTD0247	SLC29A1	Inducer	Tegafur-uracil	Drug in Phase 1 Trial	.	.	Tegafur-uracil increases the expression of SLC29A1	.	.
DTD0247	SLC29A1	Inhibition	Testosterone	Approved Drug	.	.	Testosterone inhibits the expression of SLC29A1	.	.
DTD0247	SLC29A1	Inhibition	Ticagrelor	Approved Drug	.	.	Ticagrelor inhibits the activity of SLC29A1	.	.
DTD0247	SLC29A1	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC29A1	.	.
DTD0247	SLC29A1	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC29A1	.	.
DTD0247	SLC29A1	Inhibition	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan inhibits the expression of SLC29A1	.	.
DTD0247	SLC29A1	Inhibition	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate inhibits the expression of SLC29A1	.	.
DTD0247	SLC29A1	Inducer	Urethane	Approved Drug	.	.	Urethane increases the expression of SLC29A1	.	.
DTD0247	SLC29A1	Inhibition	Uridine	Approved Drug	.	.	Uridine inhibits the activity of SLC29A1	.	.
DTD0247	SLC29A1	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC29A1	.	.
DTD0247	SLC29A1	Inhibition	Vincristine	Approved Drug	.	.	Vincristine inhibits the expression of SLC29A1	.	.
DTD0247	SLC29A1	Inducer	Vitamin E	Drug in Phase 3 Trial	.	.	Vitamin E increases the expression of SLC29A1	.	.
DTD0247	SLC29A1	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of SLC29A1	.	.
DTD0248	SLC29A2	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC29A2	.	.
DTD0248	SLC29A2	Inhibition	Azacitidine	Approved Drug	.	.	Azacitidine inhibits the expression of SLC29A2	.	.
DTD0248	SLC29A2	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC29A2	.	.
DTD0248	SLC29A2	Inducer	Cadmium	Acute Toxic Substance	.	.	Cadmium increases the expression of SLC29A2	.	.
DTD0248	SLC29A2	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the expression of SLC29A2	.	.
DTD0248	SLC29A2	Inhibition	Decitabine	Approved Drug	.	.	Decitabine inhibits the expression of SLC29A2	.	.
DTD0248	SLC29A2	Inducer	Dicrotophos	Pesticide/Insecticide	.	.	Dicrotophos increases the expression of SLC29A2	.	.
DTD0248	SLC29A2	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC29A2	.	.
DTD0248	SLC29A2	Inhibition	Ethyl Methanesulfonate	Carcinogen	.	.	Ethyl Methanesulfonate inhibits the expression of SLC29A2	.	.
DTD0248	SLC29A2	Inhibition	Fatostatin	Acute Toxic Substance	.	.	Fatostatin inhibits the expression of SLC29A2	.	.
DTD0248	SLC29A2	Inhibition	Formaldehyde	Acute Toxic Substance	.	.	Formaldehyde inhibits the expression of SLC29A2	.	.
DTD0248	SLC29A2	Inducer	Jinfukang	Traditional Medicine	.	.	Jinfukang increases the expression of SLC29A2	.	.
DTD0248	SLC29A2	Inducer	Particulate Matter	Natural Product	.	.	Particulate Matter increases the expression of SLC29A2	.	.
DTD0248	SLC29A2	Inducer	Rotenone	Drug Marketed but not Approved by US FDA	.	.	Rotenone increases the expression of SLC29A2	.	.
DTD0248	SLC29A2	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of SLC29A2	.	.
DTD0248	SLC29A2	Inhibition	Thimerosal	Acute Toxic Substance	.	.	Thimerosal inhibits the expression of SLC29A2	.	.
DTD0248	SLC29A2	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC29A2	.	.
DTD0248	SLC29A2	Inhibition	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan inhibits the expression of SLC29A2	.	.
DTD0248	SLC29A2	Inhibition	Uridine	Approved Drug	.	.	Uridine inhibits the activity of SLC29A2	.	.
DTD0248	SLC29A2	Modulator	Valproic Acid	Approved Drug	.	.	Valproic Acid affects the expression of SLC29A2	.	.
DTD0248	SLC29A2	Inhibition	Vincristine	Approved Drug	.	.	Vincristine inhibits the expression of SLC29A2	.	.
DTD0248	SLC29A2	Inducer	Zinc	Environmental toxicant	.	.	Zinc increases the expression of SLC29A2	.	.
DTD0249	SLC29A3	Modulator	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A affects the expression of SLC29A3	.	.
DTD0249	SLC29A3	Inducer	Cisplatin	Approved Drug	.	.	Cisplatin increases the expression of SLC29A3	.	.
DTD0249	SLC29A3	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC29A3	.	.
DTD0249	SLC29A3	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC29A3	.	.
DTD0249	SLC29A3	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the expression of SLC29A3	.	.
DTD0249	SLC29A3	Inducer	Jinfukang	Traditional Medicine	.	.	Jinfukang increases the expression of SLC29A3	.	.
DTD0249	SLC29A3	Inducer	Perfluorooctane sulfonic acid	Health and Environmental Toxicant	.	.	Perfluorooctane sulfonic acid increases the expression of SLC29A3	.	.
DTD0249	SLC29A3	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of SLC29A3	.	.
DTD0249	SLC29A3	Inducer	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite increases the expression of SLC29A3	.	.
DTD0249	SLC29A3	Inhibition	Sunitinib	Approved Drug	.	.	Sunitinib inhibits the expression of SLC29A3	.	.
DTD0249	SLC29A3	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC29A3	.	.
DTD0249	SLC29A3	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of SLC29A3	.	.
DTD0249	SLC29A3	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC29A3	.	.
DTD0249	SLC29A3	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of SLC29A3	.	.
DTD0250	SLC29A4	Inducer	Atrazine	Herbicide	.	.	Atrazine increases the expression of SLC29A4	.	.
DTD0250	SLC29A4	Modulator	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A affects the expression of SLC29A4	.	.
DTD0250	SLC29A4	Inhibition	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde inhibits the expression of SLC29A4	.	.
DTD0250	SLC29A4	Inducer	Cisplatin	Approved Drug	.	.	Cisplatin increases the expression of SLC29A4	.	.
DTD0250	SLC29A4	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC29A4	.	.
DTD0250	SLC29A4	Inhibition	Decynium 22	Investigative Drug	.	.	Decynium 22 inhibits the activity of SLC29A4	.	.
DTD0250	SLC29A4	Inhibition	Diethylhexyl Phthalate	Health and Environmental Toxicant	.	.	Diethylhexyl Phthalate inhibits the expression of SLC29A4	.	.
DTD0250	SLC29A4	Inhibition	Dipyridamole	Approved Drug	.	.	Dipyridamole inhibits the activity of SLC29A4	.	.
DTD0250	SLC29A4	Inducer	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 increases the expression of SLC29A4	.	.
DTD0250	SLC29A4	Inducer	Jinfukang	Traditional Medicine	.	.	Jinfukang increases the expression of SLC29A4	.	.
DTD0250	SLC29A4	Inhibition	K-7174	Patented Pharmaceutical Agent	.	.	K-7174 inhibits the expression of SLC29A4	.	.
DTD0250	SLC29A4	Inducer	Rifampin	Approved Drug	.	.	Rifampin increases the expression of SLC29A4	.	.
DTD0250	SLC29A4	Inducer	Rosiglitazone	Approved Drug	.	.	Rosiglitazone increases the expression of SLC29A4	.	.
DTD0250	SLC29A4	Modulator	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution affects the expression of SLC29A4	.	.
DTD0250	SLC29A4	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC29A4	.	.
DTD0250	SLC29A4	Inhibition	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate inhibits the expression of SLC29A4	.	.
DTD0250	SLC29A4	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of SLC29A4	.	.
DTD0250	SLC29A4	Modulator	Valproic Acid	Approved Drug	.	.	Valproic Acid affects the expression of SLC29A4	.	.
DTD0250	SLC29A4	Inhibition	Zoledronic Acid	Approved Drug	.	.	Zoledronic Acid inhibits the expression of SLC29A4	.	.
DTD0251	SLC2A1	Inhibition	7-hydroxyflavone	Natural Product	.	.	7-hydroxyflavone inhibits the activity of SLC2A1	.	.
DTD0251	SLC2A1	Inducer	Alpha-naphthoflavone	Natural Product	.	.	Alpha-naphthoflavone increases the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inducer	Aluminum	Chemical Compound	.	.	Aluminum increases the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	Amiodarone	Approved Drug	.	.	Amiodarone inhibits the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inducer	Arsenic Trioxide	Approved Drug	.	.	Arsenic Trioxide increases the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	Atrazine	Herbicide	.	.	Atrazine inhibits the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inducer	Azaspiracid	Health and Environmental Toxicant	.	.	Azaspiracid increases the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	Benzatropine	Approved Drug	.	.	Benzatropine inhibits the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	Beta-naphthoflavone	Investigative Drug	.	.	Beta-naphthoflavone inhibits the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inducer	Cadmium	Acute Toxic Substance	.	.	Cadmium increases the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	Cannabidiol	Approved Drug	.	.	Cannabidiol inhibits the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inducer	Celecoxib	Approved Drug	.	.	Celecoxib increases the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	Chloropicrin	Acute Toxic Substance	.	.	Chloropicrin inhibits the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inducer	Cidofovir	Approved Drug	.	.	Cidofovir increases the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	Ciprofloxacin	Approved Drug	.	.	Ciprofloxacin inhibits the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the expression of SLC2A1	.	.
DTD0251	SLC2A1	Modulator	Copper Sulfate	Approved Drug	.	.	Copper Sulfate affects the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inducer	Cupric chloride	Approved Drug	.	.	Cupric chloride increases the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	Cytarabine	Approved Drug	.	.	Cytarabine inhibits the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	Daidzein	Drug Marketed but not Approved by US FDA	.	.	Daidzein inhibits the activity of SLC2A1	.	.
DTD0251	SLC2A1	Inducer	Deguelin	Natural Product	.	.	Deguelin increases the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inducer	Dicrotophos	Pesticide/Insecticide	.	.	Dicrotophos increases the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	Diethylhexyl Phthalate	Health and Environmental Toxicant	.	.	Diethylhexyl Phthalate inhibits the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	Diethylstilbestrol	Approved Drug	.	.	Diethylstilbestrol inhibits the activity of SLC2A1	.	.
DTD0251	SLC2A1	Inducer	Dihydroergotamine	Approved Drug	.	.	Dihydroergotamine induces the activity of SLC2A1	.	.
DTD0251	SLC2A1	Inducer	Dihydrotestosterone	Drug in Phase 1 Trial	.	.	Dihydrotestosterone increases the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inducer	Dinophysistoxin 1	Biotoxin	.	.	Dinophysistoxin 1 increases the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	Dronabinol	Approved Drug	.	.	Dronabinol inhibits the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inducer	Dust	Natural Product	.	.	Dust increases the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inducer	Ergotamine	Approved Drug	.	.	Ergotamine induces the activity of SLC2A1	.	.
DTD0251	SLC2A1	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	Ethyl Methanesulfonate	Carcinogen	.	.	Ethyl Methanesulfonate inhibits the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	Fluorouracil	Approved Drug	.	.	Fluorouracil inhibits the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inducer	Formaldehyde	Acute Toxic Substance	.	.	Formaldehyde increases the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	Genistein	Drug in Phase 2 Trial	.	.	Genistein inhibits the activity of SLC2A1	.	.
DTD0251	SLC2A1	Inducer	Glucose	Investigative Drug	.	.	Glucose increases the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	Glycine	Approved Drug	.	.	Glycine inhibits the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inducer	Glyphosate	Environmental toxicant	.	.	Glyphosate increases the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	Hydrogen Peroxide	Approved Drug	.	.	Hydrogen Peroxide inhibits the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	Ibuprofen	Approved Drug	.	.	Ibuprofen inhibits the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inducer	Ifosfamide	Approved Drug	.	.	Ifosfamide increases the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	Imatinib Mesylate	Approved Drug	.	.	Imatinib Mesylate inhibits the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	Isoliquiritigenin	Drug in Preclinical Test	.	.	Isoliquiritigenin inhibits the activity of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	Ivermectin	Approved Drug	.	.	Ivermectin inhibits the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inducer	Jinfukang	Traditional Medicine	.	.	Jinfukang increases the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	Kaempferol	Acute Toxic Substance	.	.	Kaempferol inhibits the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inducer	Leflunomide	Approved Drug	.	.	Leflunomide increases the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inducer	Liothyronine	Approved Drug	.	.	Liothyronine increases the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	LY-294002	Drug in Phase 1 Trial	.	.	LY-294002 inhibits the expression of SLC2A1	.	.
DTD0251	SLC2A1	Modulator	Menadione	Approved Drug	.	.	Menadione affects the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inducer	MG-132	Investigative Drug	.	.	MG-132 increases the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	MRK-003	Drug in Preclinical Test	.	.	MRK-003 inhibits the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	Myricetin	Drug in Preclinical Test	.	.	Myricetin inhibits the activity of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	Naringenin	Drug in Phase 1 Trial	.	.	Naringenin inhibits the activity of SLC2A1	.	.
DTD0251	SLC2A1	Inducer	Nickel chloride	Acute Toxic Substance	.	.	Nickel chloride increases the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	Niclosamide	Approved Drug	.	.	Niclosamide inhibits the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inducer	Ochratoxin A	Acute Toxic Substance	.	.	Ochratoxin A increases the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	Ofloxacin	Approved Drug	.	.	Ofloxacin inhibits the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inducer	Okadaic Acid	Acute Toxic Substance	.	.	Okadaic Acid increases the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	Particulate Matter	Natural Product	.	.	Particulate Matter inhibits the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	Pentobarbital	Approved Drug	.	.	Pentobarbital inhibits the activity of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	Perfluorooctane sulfonic acid	Health and Environmental Toxicant	.	.	Perfluorooctane sulfonic acid inhibits the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	Phenobarbital	Approved Drug	.	.	Phenobarbital inhibits the activity of SLC2A1	.	.
DTD0251	SLC2A1	Inducer	Phenylmercuric Acetate	Investigative Drug	.	.	Phenylmercuric Acetate increases the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	Phloretin	Natural Product	.	.	Phloretin inhibits the activity of SLC2A1	.	.
DTD0251	SLC2A1	Inducer	Pioglitazone	Approved Drug	.	.	Pioglitazone induces the activity of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin inhibits the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	PP242	Investigative Drug	.	.	PP242 inhibits the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	Prochloraz	Fungicide	.	.	Prochloraz inhibits the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inducer	Progesterone	Approved Drug	.	.	Progesterone increases the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	Propofol	Approved Drug	.	.	Propofol inhibits the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	Protoporphyrin IX	Investigative Drug	.	.	Protoporphyrin IX inhibits the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	Rosiglitazone	Approved Drug	.	.	Rosiglitazone inhibits the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	Rotenone	Drug Marketed but not Approved by US FDA	.	.	Rotenone inhibits the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inducer	Sevoflurane	Approved Drug	.	.	Sevoflurane increases the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	Sodium bichromate	Carcinogen	.	.	Sodium bichromate inhibits the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	Tamoxifen	Approved Drug	.	.	Tamoxifen inhibits the activity of SLC2A1	.	.
DTD0251	SLC2A1	Inducer	Temozolomide	Approved Drug	.	.	Temozolomide increases the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	Thimerosal	Acute Toxic Substance	.	.	Thimerosal inhibits the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inducer	Tolazamide	Approved Drug	.	.	Tolazamide induces the activity of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inducer	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A increases the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inducer	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan increases the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate inhibits the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	Troglitazone	Approved Drug	.	.	Troglitazone inhibits the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	Vorinostat	Approved Drug	.	.	Vorinostat inhibits the expression of SLC2A1	.	.
DTD0251	SLC2A1	Inhibition	Zidovudine	Approved Drug	.	.	Zidovudine inhibits the expression of SLC2A1	.	.
DTD0252	SLC2A10	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC2A10	.	.
DTD0252	SLC2A10	Inhibition	Azathioprine	Approved Drug	.	.	Azathioprine inhibits the expression of SLC2A10	.	.
DTD0252	SLC2A10	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC2A10	.	.
DTD0252	SLC2A10	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC2A10	.	.
DTD0252	SLC2A10	Inhibition	Caffeine	Approved Drug	.	.	Caffeine inhibits the expression of SLC2A10	.	.
DTD0252	SLC2A10	Inducer	Cannabidiol	Approved Drug	.	.	Cannabidiol increases the expression of SLC2A10	.	.
DTD0252	SLC2A10	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC2A10	.	.
DTD0252	SLC2A10	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC2A10	.	.
DTD0252	SLC2A10	Inhibition	Epigallocatechin gallate	Drug in Phase 3 Trial	.	.	Epigallocatechin gallate inhibits the expression of SLC2A10	.	.
DTD0252	SLC2A10	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the expression of SLC2A10	.	.
DTD0252	SLC2A10	Inhibition	Folic Acid	Approved Drug	.	.	Folic Acid inhibits the expression of SLC2A10	.	.
DTD0252	SLC2A10	Inducer	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin increases the expression of SLC2A10	.	.
DTD0252	SLC2A10	Inhibition	Sunitinib	Approved Drug	.	.	Sunitinib inhibits the expression of SLC2A10	.	.
DTD0252	SLC2A10	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC2A10	.	.
DTD0252	SLC2A10	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC2A10	.	.
DTD0252	SLC2A10	Inducer	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A increases the expression of SLC2A10	.	.
DTD0252	SLC2A10	Inhibition	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate inhibits the expression of SLC2A10	.	.
DTD0252	SLC2A10	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of SLC2A10	.	.
DTD0252	SLC2A10	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC2A10	.	.
DTD0252	SLC2A10	Inhibition	Vorinostat	Approved Drug	.	.	Vorinostat inhibits the expression of SLC2A10	.	.
DTD0252	SLC2A10	Inhibition	Zidovudine	Approved Drug	.	.	Zidovudine inhibits the expression of SLC2A10	.	.
DTD0253	SLC2A11	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of SLC2A11	.	.
DTD0253	SLC2A11	Inhibition	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde inhibits the expression of SLC2A11	.	.
DTD0253	SLC2A11	Modulator	Cidofovir	Approved Drug	.	.	Cidofovir affects the expression of SLC2A11	.	.
DTD0253	SLC2A11	Inducer	Cisplatin	Approved Drug	.	.	Cisplatin increases the expression of SLC2A11	.	.
DTD0253	SLC2A11	Inducer	Clodronic Acid	Drug Marketed but not Approved by US FDA	.	.	Clodronic Acid increases the expression of SLC2A11	.	.
DTD0253	SLC2A11	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC2A11	.	.
DTD0253	SLC2A11	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC2A11	.	.
DTD0253	SLC2A11	Inhibition	GSK-J4	Patented Pharmaceutical Agent	.	.	GSK-J4 inhibits the expression of SLC2A11	.	.
DTD0253	SLC2A11	Inducer	Jinfukang	Traditional Medicine	.	.	Jinfukang increases the expression of SLC2A11	.	.
DTD0253	SLC2A11	Inducer	Leflunomide	Approved Drug	.	.	Leflunomide increases the expression of SLC2A11	.	.
DTD0253	SLC2A11	Inducer	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin increases the expression of SLC2A11	.	.
DTD0253	SLC2A11	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC2A11	.	.
DTD0253	SLC2A11	Inducer	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate increases the expression of SLC2A11	.	.
DTD0253	SLC2A11	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of SLC2A11	.	.
DTD0253	SLC2A11	Inhibition	Zoledronic Acid	Approved Drug	.	.	Zoledronic Acid inhibits the expression of SLC2A11	.	.
DTD0254	SLC2A12	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC2A12	.	.
DTD0254	SLC2A12	Inducer	Avobenzone	Approved Drug	.	.	Avobenzone increases the expression of SLC2A12	.	.
DTD0254	SLC2A12	Inhibition	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A inhibits the expression of SLC2A12	.	.
DTD0254	SLC2A12	Inhibition	Bisphenol F	Environmental toxicant	.	.	Bisphenol F inhibits the expression of SLC2A12	.	.
DTD0254	SLC2A12	Inducer	Cisplatin	Approved Drug	.	.	Cisplatin increases the expression of SLC2A12	.	.
DTD0254	SLC2A12	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC2A12	.	.
DTD0254	SLC2A12	Inducer	Dihydrotestosterone	Drug in Phase 1 Trial	.	.	Dihydrotestosterone increases the expression of SLC2A12	.	.
DTD0254	SLC2A12	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC2A12	.	.
DTD0254	SLC2A12	Modulator	Ethinyl Estradiol	Approved Drug	.	.	Ethinyl Estradiol affects the expression of SLC2A12	.	.
DTD0254	SLC2A12	Inhibition	Folic Acid	Approved Drug	.	.	Folic Acid inhibits the expression of SLC2A12	.	.
DTD0254	SLC2A12	Modulator	Genistein	Drug in Phase 2 Trial	.	.	Genistein affects the expression of SLC2A12	.	.
DTD0254	SLC2A12	Inhibition	Hydroquinone	Approved Drug	.	.	Hydroquinone inhibits the expression of SLC2A12	.	.
DTD0254	SLC2A12	Inhibition	MS-275	Drug in Phase 2 Trial	.	.	MS-275 inhibits the expression of SLC2A12	.	.
DTD0254	SLC2A12	Inducer	Phenylmercuric Acetate	Investigative Drug	.	.	Phenylmercuric Acetate increases the expression of SLC2A12	.	.
DTD0254	SLC2A12	Inducer	Rifampin	Approved Drug	.	.	Rifampin increases the expression of SLC2A12	.	.
DTD0254	SLC2A12	Inducer	Silver nanoparticle	Nanoparticle	.	.	Silver nanoparticle increases the expression of SLC2A12	.	.
DTD0254	SLC2A12	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC2A12	.	.
DTD0254	SLC2A12	Inhibition	Sunitinib	Approved Drug	.	.	Sunitinib inhibits the expression of SLC2A12	.	.
DTD0254	SLC2A12	Inhibition	Thimerosal	Acute Toxic Substance	.	.	Thimerosal inhibits the expression of SLC2A12	.	.
DTD0254	SLC2A12	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC2A12	.	.
DTD0254	SLC2A12	Inhibition	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A inhibits the expression of SLC2A12	.	.
DTD0254	SLC2A12	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC2A12	.	.
DTD0254	SLC2A12	Inhibition	Vorinostat	Approved Drug	.	.	Vorinostat inhibits the expression of SLC2A12	.	.
DTD0255	SLC2A13	Inducer	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 increases the expression of SLC2A13	.	.
DTD0255	SLC2A13	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of SLC2A13	.	.
DTD0255	SLC2A13	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC2A13	.	.
DTD0255	SLC2A13	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC2A13	.	.
DTD0255	SLC2A13	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC2A13	.	.
DTD0255	SLC2A13	Inducer	Cinnamic aldehyde	Natural Product	.	.	Cinnamic aldehyde increases the expression of SLC2A13	.	.
DTD0255	SLC2A13	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the expression of SLC2A13	.	.
DTD0255	SLC2A13	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of SLC2A13	.	.
DTD0255	SLC2A13	Inducer	Ethyl Methanesulfonate	Carcinogen	.	.	Ethyl Methanesulfonate increases the expression of SLC2A13	.	.
DTD0255	SLC2A13	Inducer	Geldanamycin	Drug in Phase 1 Trial	.	.	Geldanamycin increases the expression of SLC2A13	.	.
DTD0255	SLC2A13	Inducer	GSK-J4	Patented Pharmaceutical Agent	.	.	GSK-J4 increases the expression of SLC2A13	.	.
DTD0255	SLC2A13	Modulator	Lead	Health and Environmental Toxicant	.	.	Lead affects the expression of SLC2A13	.	.
DTD0255	SLC2A13	Inducer	Manganese	Investigative Drug	.	.	Manganese increases the expression of SLC2A13	.	.
DTD0255	SLC2A13	Inducer	Manganese chloride	Approved Drug	.	.	Manganese chloride increases the expression of SLC2A13	.	.
DTD0255	SLC2A13	Inhibition	Perfluorooctane sulfonic acid	Health and Environmental Toxicant	.	.	Perfluorooctane sulfonic acid inhibits the expression of SLC2A13	.	.
DTD0255	SLC2A13	Inducer	Phenylmercuric Acetate	Investigative Drug	.	.	Phenylmercuric Acetate increases the expression of SLC2A13	.	.
DTD0255	SLC2A13	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC2A13	.	.
DTD0255	SLC2A13	Inducer	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A increases the expression of SLC2A13	.	.
DTD0255	SLC2A13	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC2A13	.	.
DTD0255	SLC2A13	Inducer	Vorinostat	Approved Drug	.	.	Vorinostat increases the expression of SLC2A13	.	.
DTD0256	SLC2A14	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC2A14	.	.
DTD0256	SLC2A14	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC2A14	.	.
DTD0256	SLC2A14	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC2A14	.	.
DTD0256	SLC2A14	Modulator	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A affects the expression of SLC2A14	.	.
DTD0256	SLC2A14	Inhibition	Cadmium	Acute Toxic Substance	.	.	Cadmium inhibits the expression of SLC2A14	.	.
DTD0256	SLC2A14	Inducer	Calcitriol	Approved Drug	.	.	Calcitriol increases the expression of SLC2A14	.	.
DTD0256	SLC2A14	Inducer	Cannabidiol	Approved Drug	.	.	Cannabidiol increases the expression of SLC2A14	.	.
DTD0256	SLC2A14	Inducer	Cisplatin	Approved Drug	.	.	Cisplatin increases the expression of SLC2A14	.	.
DTD0256	SLC2A14	Inhibition	Clothianidin	Pesticide/Insecticide	.	.	Clothianidin inhibits the expression of SLC2A14	.	.
DTD0256	SLC2A14	Inducer	Dihydrotestosterone	Drug in Phase 1 Trial	.	.	Dihydrotestosterone increases the expression of SLC2A14	.	.
DTD0256	SLC2A14	Modulator	Doxorubicin	Approved Drug	.	.	Doxorubicin affects the expression of SLC2A14	.	.
DTD0256	SLC2A14	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC2A14	.	.
DTD0256	SLC2A14	Inducer	Gemcitabine	Approved Drug	.	.	Gemcitabine increases the expression of SLC2A14	.	.
DTD0256	SLC2A14	Inducer	Leflunomide	Approved Drug	.	.	Leflunomide increases the expression of SLC2A14	.	.
DTD0256	SLC2A14	Inhibition	MeIQx	Drug in Phase 2 Trial	.	.	MeIQx inhibits the expression of SLC2A14	.	.
DTD0256	SLC2A14	Inhibition	Methyleugenol	Natural Product	.	.	Methyleugenol inhibits the expression of SLC2A14	.	.
DTD0256	SLC2A14	Inducer	Nano-sized iron particle	Health and Environmental Toxicant	.	.	Nano-sized iron particle increases the expression of SLC2A14	.	.
DTD0256	SLC2A14	Inducer	Silver nanoparticle	Nanoparticle	.	.	Silver nanoparticle increases the expression of SLC2A14	.	.
DTD0256	SLC2A14	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC2A14	.	.
DTD0256	SLC2A14	Inhibition	Testosterone	Approved Drug	.	.	Testosterone inhibits the expression of SLC2A14	.	.
DTD0256	SLC2A14	Modulator	Testosterone enanthate	Approved Drug	.	.	Testosterone enanthate affects the expression of SLC2A14	.	.
DTD0256	SLC2A14	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of SLC2A14	.	.
DTD0256	SLC2A14	Inhibition	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate inhibits the expression of SLC2A14	.	.
DTD0256	SLC2A14	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of SLC2A14	.	.
DTD0256	SLC2A14	Inducer	Vandetanib	Approved Drug	.	.	Vandetanib increases the expression of SLC2A14	.	.
DTD0256	SLC2A14	Modulator	Vitamin D	Approved Drug	.	.	Vitamin D affects the expression of SLC2A14	.	.
DTD0256	SLC2A14	Inhibition	Zidovudine	Approved Drug	.	.	Zidovudine inhibits the expression of SLC2A14	.	.
DTD0257	SLC2A2	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC2A2	.	.
DTD0257	SLC2A2	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC2A2	.	.
DTD0257	SLC2A2	Inducer	Arsenic Trioxide	Approved Drug	.	.	Arsenic Trioxide increases the expression of SLC2A2	.	.
DTD0257	SLC2A2	Inhibition	Atorvastatin	Approved Drug	.	.	Atorvastatin inhibits the expression of SLC2A2	.	.
DTD0257	SLC2A2	Inhibition	Azathioprine	Approved Drug	.	.	Azathioprine inhibits the expression of SLC2A2	.	.
DTD0257	SLC2A2	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC2A2	.	.
DTD0257	SLC2A2	Modulator	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A affects the expression of SLC2A2	.	.
DTD0257	SLC2A2	Inducer	Caffeic acid	Health and Environmental Toxicant	.	.	Caffeic acid increases the expression of SLC2A2	.	.
DTD0257	SLC2A2	Inhibition	Calcitriol	Approved Drug	.	.	Calcitriol inhibits the expression of SLC2A2	.	.
DTD0257	SLC2A2	Inducer	Coal Ash	Natural Product	.	.	Coal Ash increases the expression of SLC2A2	.	.
DTD0257	SLC2A2	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC2A2	.	.
DTD0257	SLC2A2	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC2A2	.	.
DTD0257	SLC2A2	Inhibition	Dicrotophos	Pesticide/Insecticide	.	.	Dicrotophos inhibits the expression of SLC2A2	.	.
DTD0257	SLC2A2	Inhibition	Endosulfan	Pesticide/Insecticide	.	.	Endosulfan inhibits the expression of SLC2A2	.	.
DTD0257	SLC2A2	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the expression of SLC2A2	.	.
DTD0257	SLC2A2	Inhibition	Folic Acid	Approved Drug	.	.	Folic Acid inhibits the expression of SLC2A2	.	.
DTD0257	SLC2A2	Inhibition	Glucose	Investigative Drug	.	.	Glucose inhibits the expression of SLC2A2	.	.
DTD0257	SLC2A2	Inhibition	Hydrogen Peroxide	Approved Drug	.	.	Hydrogen Peroxide inhibits the expression of SLC2A2	.	.
DTD0257	SLC2A2	Inducer	Hyperoside	Natural Product	.	.	Hyperoside increases the expression of SLC2A2	.	.
DTD0257	SLC2A2	Inhibition	Indirubin	Natural Product	.	.	Indirubin inhibits the expression of SLC2A2	.	.
DTD0257	SLC2A2	Inducer	Methotrexate	Approved Drug	.	.	Methotrexate increases the expression of SLC2A2	.	.
DTD0257	SLC2A2	Inhibition	Methyleugenol	Natural Product	.	.	Methyleugenol inhibits the expression of SLC2A2	.	.
DTD0257	SLC2A2	Inducer	Oleic Acid	Drug in Preclinical Test	.	.	Oleic Acid increases the expression of SLC2A2	.	.
DTD0257	SLC2A2	Inducer	Pentoxifylline	Approved Drug	.	.	Pentoxifylline induces the activity of SLC2A2	.	.
DTD0257	SLC2A2	Inhibition	Perfluorooctane sulfonic acid	Health and Environmental Toxicant	.	.	Perfluorooctane sulfonic acid inhibits the expression of SLC2A2	.	.
DTD0257	SLC2A2	Inhibition	Phloretin	Natural Product	.	.	Phloretin inhibits the expression of SLC2A2	.	.
DTD0257	SLC2A2	Inhibition	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin inhibits the expression of SLC2A2	.	.
DTD0257	SLC2A2	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of SLC2A2	.	.
DTD0257	SLC2A2	Inducer	Resveratrol	Drug in Phase 3 Trial	.	.	Resveratrol increases the expression of SLC2A2	.	.
DTD0257	SLC2A2	Inhibition	Rifampin	Approved Drug	.	.	Rifampin inhibits the expression of SLC2A2	.	.
DTD0257	SLC2A2	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC2A2	.	.
DTD0257	SLC2A2	Inhibition	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate inhibits the expression of SLC2A2	.	.
DTD0257	SLC2A2	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of SLC2A2	.	.
DTD0257	SLC2A2	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC2A2	.	.
DTD0258	SLC2A3	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inhibition	Amiodarone	Approved Drug	.	.	Amiodarone inhibits the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inhibition	Amitriptyline	Approved Drug	.	.	Amitriptyline inhibits the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inducer	Ampicillin	Approved Drug	.	.	Ampicillin increases the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inducer	Archazolid B	Investigative Drug	.	.	Archazolid B increases the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inducer	Arsenic Trioxide	Approved Drug	.	.	Arsenic Trioxide increases the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inducer	Avobenzone	Approved Drug	.	.	Avobenzone increases the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC2A3	.	.
DTD0258	SLC2A3	Modulator	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A affects the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inducer	Bortezomib	Approved Drug	.	.	Bortezomib increases the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inhibition	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde inhibits the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inhibition	Cadmium	Acute Toxic Substance	.	.	Cadmium inhibits the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inducer	Caffeine	Approved Drug	.	.	Caffeine increases the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inducer	Calcitriol	Approved Drug	.	.	Calcitriol increases the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inducer	Cannabidiol	Approved Drug	.	.	Cannabidiol increases the expression of SLC2A3	.	.
DTD0258	SLC2A3	Modulator	Carbamazepine	Approved Drug	.	.	Carbamazepine affects the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inhibition	Chlorcyclizine	Drug in Phase 1 Trial	.	.	Chlorcyclizine inhibits the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inhibition	Chlorpromazine	Approved Drug	.	.	Chlorpromazine inhibits the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inducer	Cisplatin	Approved Drug	.	.	Cisplatin increases the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inhibition	Citalopram	Approved Drug	.	.	Citalopram inhibits the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inhibition	Clomipramine	Approved Drug	.	.	Clomipramine inhibits the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inhibition	Clozapine	Approved Drug	.	.	Clozapine inhibits the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inducer	Demecolcine	Drug Marketed but not Approved by US FDA	.	.	Demecolcine increases the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inducer	Diethylhexyl Phthalate	Health and Environmental Toxicant	.	.	Diethylhexyl Phthalate increases the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inducer	Dihydrotestosterone	Drug in Phase 1 Trial	.	.	Dihydrotestosterone increases the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inhibition	Dinitrochlorobenzene	Drug in Phase 1 Trial	.	.	Dinitrochlorobenzene inhibits the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inducer	Dinitrofluorobenzene	Chemical Compound	.	.	Dinitrofluorobenzene increases the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inhibition	Doxepin	Approved Drug	.	.	Doxepin inhibits the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inducer	Epigallocatechin gallate	Drug in Phase 3 Trial	.	.	Epigallocatechin gallate increases the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inducer	Eugenol	Patented Pharmaceutical Agent	.	.	Eugenol increases the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inhibition	Flecainide	Approved Drug	.	.	Flecainide inhibits the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inhibition	Fluoxetine	Approved Drug	.	.	Fluoxetine inhibits the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inducer	Formaldehyde	Acute Toxic Substance	.	.	Formaldehyde increases the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inducer	Gemcitabine	Approved Drug	.	.	Gemcitabine increases the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inducer	GSK-J4	Patented Pharmaceutical Agent	.	.	GSK-J4 increases the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inhibition	Imipramine	Approved Drug	.	.	Imipramine inhibits the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inhibition	K-7174	Patented Pharmaceutical Agent	.	.	K-7174 inhibits the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inhibition	Ketoconazole	Approved Drug	.	.	Ketoconazole inhibits the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inhibition	Loratadine	Approved Drug	.	.	Loratadine inhibits the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inhibition	Methotrexate	Approved Drug	.	.	Methotrexate inhibits the expression of SLC2A3	.	.
DTD0258	SLC2A3	Modulator	Milchsaure	Investigative Drug	.	.	Milchsaure affects the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inducer	MS-275	Drug in Phase 2 Trial	.	.	MS-275 increases the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inducer	Nickel chloride	Acute Toxic Substance	.	.	Nickel chloride increases the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inhibition	Niclosamide	Approved Drug	.	.	Niclosamide inhibits the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inhibition	Oxaliplatin	Approved Drug	.	.	Oxaliplatin inhibits the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inducer	Panobinostat	Approved Drug	.	.	Panobinostat increases the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inducer	Particulate Matter	Natural Product	.	.	Particulate Matter increases the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inhibition	Pentamidine	Approved Drug	.	.	Pentamidine inhibits the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inhibition	Pentanal	Chemical Compound	.	.	Pentanal inhibits the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inducer	Phenylmercuric Acetate	Investigative Drug	.	.	Phenylmercuric Acetate increases the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inhibition	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin inhibits the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inhibition	PP242	Investigative Drug	.	.	PP242 inhibits the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inhibition	Quinidine	Approved Drug	.	.	Quinidine inhibits the expression of SLC2A3	.	.
DTD0258	SLC2A3	Modulator	Raloxifene Hydrochloride	Approved Drug	.	.	Raloxifene Hydrochloride affects the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inducer	Resorcinol	Environmental toxicant	.	.	Resorcinol increases the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inhibition	Rotenone	Drug Marketed but not Approved by US FDA	.	.	Rotenone inhibits the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inducer	SB-431542	Investigative Drug	.	.	SB-431542 increases the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inhibition	Sertraline	Approved Drug	.	.	Sertraline inhibits the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inducer	Silver nanoparticle	Nanoparticle	.	.	Silver nanoparticle increases the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inducer	Sotalol	Approved Drug	.	.	Sotalol increases the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inducer	Sulforafan	Drug in Phase 3 Trial	.	.	Sulforafan increases the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inhibition	Tamoxifen	Approved Drug	.	.	Tamoxifen inhibits the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inducer	Testosterone	Approved Drug	.	.	Testosterone increases the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inhibition	Thimerosal	Acute Toxic Substance	.	.	Thimerosal inhibits the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inhibition	Thioridazine	Approved Drug	.	.	Thioridazine inhibits the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inducer	torcetrapib	Drug in Phase 3 Trial	.	.	torcetrapib increases the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inhibition	trans-1,4-Bis(2-chlorobenzaminomethyl)cyclohexane Dihydrochloride	Acute Toxic Substance	.	.	trans-1,4-Bis(2-chlorobenzaminomethyl)cyclohexane Dihydrochloride inhibits the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inhibition	Tributyltin	Investigative Drug	.	.	Tributyltin inhibits the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inducer	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A increases the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inhibition	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan inhibits the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inhibition	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate inhibits the expression of SLC2A3	.	.
DTD0258	SLC2A3	Modulator	Uranium	Acute Toxic Substance	.	.	Uranium affects the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inducer	Vandetanib	Approved Drug	.	.	Vandetanib increases the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inducer	Vorinostat	Approved Drug	.	.	Vorinostat increases the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inhibition	WSM-3978G	Drug in Phase 1 Trial	.	.	WSM-3978G inhibits the expression of SLC2A3	.	.
DTD0258	SLC2A3	Inhibition	Zidovudine	Approved Drug	.	.	Zidovudine inhibits the expression of SLC2A3	.	.
DTD0262	SLC2A4	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of SLC2A4	.	.
DTD0262	SLC2A4	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC2A4	.	.
DTD0262	SLC2A4	Modulator	Arsenic	Approved Drug	.	.	Arsenic affects the expression of SLC2A4	.	.
DTD0262	SLC2A4	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC2A4	.	.
DTD0262	SLC2A4	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC2A4	.	.
DTD0262	SLC2A4	Inducer	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde increases the expression of SLC2A4	.	.
DTD0262	SLC2A4	Inducer	Calcitriol	Approved Drug	.	.	Calcitriol increases the expression of SLC2A4	.	.
DTD0262	SLC2A4	Inducer	Coal Ash	Natural Product	.	.	Coal Ash increases the expression of SLC2A4	.	.
DTD0262	SLC2A4	Modulator	Dexamethasone	Approved Drug	.	.	Dexamethasone affects the expression of SLC2A4	.	.
DTD0262	SLC2A4	Inducer	Diazoxide	Approved Drug	.	.	Diazoxide induces the activity of SLC2A4	.	.
DTD0262	SLC2A4	Inhibition	Diethylhexyl Phthalate	Health and Environmental Toxicant	.	.	Diethylhexyl Phthalate inhibits the expression of SLC2A4	.	.
DTD0262	SLC2A4	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC2A4	.	.
DTD0262	SLC2A4	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC2A4	.	.
DTD0262	SLC2A4	Inhibition	Fructose	Natural Product	.	.	Fructose inhibits the expression of SLC2A4	.	.
DTD0262	SLC2A4	Inhibition	Glucosamine	Drug Marketed but not Approved by US FDA	.	.	Glucosamine inhibits the expression of SLC2A4	.	.
DTD0262	SLC2A4	Inhibition	Glucose	Investigative Drug	.	.	Glucose inhibits the expression of SLC2A4	.	.
DTD0262	SLC2A4	Inducer	Haloperidol	Approved Drug	.	.	Haloperidol increases the expression of SLC2A4	.	.
DTD0262	SLC2A4	Inducer	Leflunomide	Approved Drug	.	.	Leflunomide increases the expression of SLC2A4	.	.
DTD0262	SLC2A4	Inducer	Metformin	Approved Drug	.	.	Metformin increases the expression of SLC2A4	.	.
DTD0262	SLC2A4	Inducer	Mirtazapine	Approved Drug	.	.	Mirtazapine increases the expression of SLC2A4	.	.
DTD0262	SLC2A4	Inducer	MRK-003	Drug in Preclinical Test	.	.	MRK-003 increases the expression of SLC2A4	.	.
DTD0262	SLC2A4	Inducer	Olanzapine	Approved Drug	.	.	Olanzapine increases the expression of SLC2A4	.	.
DTD0262	SLC2A4	Inhibition	Palmitic Acid	Drug in Phase 1 Trial	.	.	Palmitic Acid inhibits the expression of SLC2A4	.	.
DTD0262	SLC2A4	Inducer	P-coumaric acid	Investigative Drug	.	.	P-coumaric acid increases the expression of SLC2A4	.	.
DTD0262	SLC2A4	Inhibition	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin inhibits the expression of SLC2A4	.	.
DTD0262	SLC2A4	Inhibition	Prochloraz	Fungicide	.	.	Prochloraz inhibits the expression of SLC2A4	.	.
DTD0262	SLC2A4	Inducer	Raloxifene Hydrochloride	Approved Drug	.	.	Raloxifene Hydrochloride increases the expression of SLC2A4	.	.
DTD0262	SLC2A4	Inducer	Rosiglitazone	Approved Drug	.	.	Rosiglitazone increases the expression of SLC2A4	.	.
DTD0262	SLC2A4	Inhibition	Salmeterol Xinafoate	Approved Drug	.	.	Salmeterol xinafoate inhibits the activity of SLC2A4	.	.
DTD0262	SLC2A4	Inducer	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite increases the expression of SLC2A4	.	.
DTD0262	SLC2A4	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of SLC2A4	.	.
DTD0262	SLC2A4	Inhibition	Tamoxifen	Approved Drug	.	.	Tamoxifen inhibits the expression of SLC2A4	.	.
DTD0262	SLC2A4	Inhibition	Testosterone	Approved Drug	.	.	Testosterone inhibits the expression of SLC2A4	.	.
DTD0262	SLC2A4	Inhibition	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan inhibits the expression of SLC2A4	.	.
DTD0262	SLC2A4	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of SLC2A4	.	.
DTD0262	SLC2A4	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC2A4	.	.
DTD0262	SLC2A4	Modulator	Zidovudine	Approved Drug	.	.	Zidovudine affects the expression of SLC2A4	.	.
DTD0263	SLC2A5	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of SLC2A5	.	.
DTD0263	SLC2A5	Inducer	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 increases the expression of SLC2A5	.	.
DTD0263	SLC2A5	Inducer	AM-80	Drug in Phase 2/3 Trial	.	.	AM-80 increases the expression of SLC2A5	.	.
DTD0263	SLC2A5	Inducer	Arsenic Trioxide	Approved Drug	.	.	Arsenic Trioxide increases the expression of SLC2A5	.	.
DTD0263	SLC2A5	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC2A5	.	.
DTD0263	SLC2A5	Inhibition	Beta-naphthoflavone	Investigative Drug	.	.	Beta-naphthoflavone inhibits the expression of SLC2A5	.	.
DTD0263	SLC2A5	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC2A5	.	.
DTD0263	SLC2A5	Inducer	Bisphenol F	Environmental toxicant	.	.	Bisphenol F increases the expression of SLC2A5	.	.
DTD0263	SLC2A5	Inhibition	Calcitriol	Approved Drug	.	.	Calcitriol inhibits the expression of SLC2A5	.	.
DTD0263	SLC2A5	Inducer	Cisplatin	Approved Drug	.	.	Cisplatin increases the expression of SLC2A5	.	.
DTD0263	SLC2A5	Inducer	Colforsin	Drug in Phase 2 Trial	.	.	Colforsin increases the expression of SLC2A5	.	.
DTD0263	SLC2A5	Modulator	Cyclic AMP	Drug in Phase 1 Trial	.	.	Cyclic AMP affects the expression of SLC2A5	.	.
DTD0263	SLC2A5	Inducer	Demecolcine	Drug Marketed but not Approved by US FDA	.	.	Demecolcine increases the expression of SLC2A5	.	.
DTD0263	SLC2A5	Inducer	Ethyl Methanesulfonate	Carcinogen	.	.	Ethyl Methanesulfonate increases the expression of SLC2A5	.	.
DTD0263	SLC2A5	Inhibition	Formaldehyde	Acute Toxic Substance	.	.	Formaldehyde inhibits the expression of SLC2A5	.	.
DTD0263	SLC2A5	Inducer	Fructose	Natural Product	.	.	Fructose increases the expression of SLC2A5	.	.
DTD0263	SLC2A5	Inducer	Glucose	Investigative Drug	.	.	Glucose increases the expression of SLC2A5	.	.
DTD0263	SLC2A5	Inhibition	Hydroquinone	Approved Drug	.	.	Hydroquinone inhibits the expression of SLC2A5	.	.
DTD0263	SLC2A5	Inducer	Methamphetamine	Approved Drug	.	.	Methamphetamine increases the expression of SLC2A5	.	.
DTD0263	SLC2A5	Inducer	Mirtazapine	Approved Drug	.	.	Mirtazapine increases the expression of SLC2A5	.	.
DTD0263	SLC2A5	Inhibition	Nano-sized iron particle	Health and Environmental Toxicant	.	.	Nano-sized iron particle inhibits the expression of SLC2A5	.	.
DTD0263	SLC2A5	Inhibition	Pioglitazone	Approved Drug	.	.	Pioglitazone inhibits the expression of SLC2A5	.	.
DTD0263	SLC2A5	Inhibition	Sulforafan	Drug in Phase 3 Trial	.	.	Sulforafan inhibits the expression of SLC2A5	.	.
DTD0263	SLC2A5	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of SLC2A5	.	.
DTD0263	SLC2A5	Inducer	Zinc	Environmental toxicant	.	.	Zinc increases the expression of SLC2A5	.	.
DTD0264	SLC2A6	Inhibition	Acrylamide	Acute Toxic Substance	.	.	Acrylamide inhibits the expression of SLC2A6	.	.
DTD0264	SLC2A6	Inhibition	Antimycin A	Acute Toxic Substance	.	.	Antimycin A inhibits the expression of SLC2A6	.	.
DTD0264	SLC2A6	Inhibition	Atrazine	Herbicide	.	.	Atrazine inhibits the expression of SLC2A6	.	.
DTD0264	SLC2A6	Inducer	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde increases the expression of SLC2A6	.	.
DTD0264	SLC2A6	Inducer	Cisplatin	Approved Drug	.	.	Cisplatin increases the expression of SLC2A6	.	.
DTD0264	SLC2A6	Inducer	Cyclophosphamide	Approved Drug	.	.	Cyclophosphamide increases the expression of SLC2A6	.	.
DTD0264	SLC2A6	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC2A6	.	.
DTD0264	SLC2A6	Inhibition	Deguelin	Natural Product	.	.	Deguelin inhibits the expression of SLC2A6	.	.
DTD0264	SLC2A6	Inducer	Dexamethasone	Approved Drug	.	.	Dexamethasone increases the expression of SLC2A6	.	.
DTD0264	SLC2A6	Modulator	Dimethyl Sulfoxide	Approved Drug	.	.	Dimethyl Sulfoxide affects the expression of SLC2A6	.	.
DTD0264	SLC2A6	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC2A6	.	.
DTD0264	SLC2A6	Inducer	Epigallocatechin gallate	Drug in Phase 3 Trial	.	.	Epigallocatechin gallate increases the expression of SLC2A6	.	.
DTD0264	SLC2A6	Inducer	Etoposide	Approved Drug	.	.	Etoposide increases the expression of SLC2A6	.	.
DTD0264	SLC2A6	Inhibition	GSK-J4	Patented Pharmaceutical Agent	.	.	GSK-J4 inhibits the expression of SLC2A6	.	.
DTD0264	SLC2A6	Inducer	Jinfukang	Traditional Medicine	.	.	Jinfukang increases the expression of SLC2A6	.	.
DTD0264	SLC2A6	Inducer	K-7174	Patented Pharmaceutical Agent	.	.	K-7174 increases the expression of SLC2A6	.	.
DTD0264	SLC2A6	Inducer	Pentanal	Chemical Compound	.	.	Pentanal increases the expression of SLC2A6	.	.
DTD0264	SLC2A6	Inhibition	Rotenone	Drug Marketed but not Approved by US FDA	.	.	Rotenone inhibits the expression of SLC2A6	.	.
DTD0264	SLC2A6	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of SLC2A6	.	.
DTD0264	SLC2A6	Inducer	Temozolomide	Approved Drug	.	.	Temozolomide increases the expression of SLC2A6	.	.
DTD0264	SLC2A6	Inhibition	Thapsigargin	Natural Product	.	.	Thapsigargin inhibits the expression of SLC2A6	.	.
DTD0264	SLC2A6	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC2A6	.	.
DTD0264	SLC2A6	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of SLC2A6	.	.
DTD0264	SLC2A6	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC2A6	.	.
DTD0264	SLC2A6	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of SLC2A6	.	.
DTD0266	SLC2A8	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of SLC2A8	.	.
DTD0266	SLC2A8	Inducer	Avobenzone	Approved Drug	.	.	Avobenzone increases the expression of SLC2A8	.	.
DTD0266	SLC2A8	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of SLC2A8	.	.
DTD0266	SLC2A8	Inducer	Beta-naphthoflavone	Investigative Drug	.	.	Beta-naphthoflavone increases the expression of SLC2A8	.	.
DTD0266	SLC2A8	Inducer	Cisplatin	Approved Drug	.	.	Cisplatin increases the expression of SLC2A8	.	.
DTD0266	SLC2A8	Inducer	Copper Sulfate	Approved Drug	.	.	Copper Sulfate increases the expression of SLC2A8	.	.
DTD0266	SLC2A8	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of SLC2A8	.	.
DTD0266	SLC2A8	Inhibition	Gallic Acid	Natural Product	.	.	Gallic Acid inhibits the expression of SLC2A8	.	.
DTD0266	SLC2A8	Modulator	Hydrogen Peroxide	Approved Drug	.	.	Hydrogen Peroxide affects the expression of SLC2A8	.	.
DTD0266	SLC2A8	Inducer	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 increases the expression of SLC2A8	.	.
DTD0266	SLC2A8	Inducer	Ivermectin	Approved Drug	.	.	Ivermectin increases the expression of SLC2A8	.	.
DTD0266	SLC2A8	Inducer	Leflunomide	Approved Drug	.	.	Leflunomide increases the expression of SLC2A8	.	.
DTD0266	SLC2A8	Inducer	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin increases the expression of SLC2A8	.	.
DTD0266	SLC2A8	Inducer	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin increases the expression of SLC2A8	.	.
DTD0266	SLC2A8	Inhibition	Sunitinib	Approved Drug	.	.	Sunitinib inhibits the expression of SLC2A8	.	.
DTD0266	SLC2A8	Inducer	Temozolomide	Approved Drug	.	.	Temozolomide increases the expression of SLC2A8	.	.
DTD0266	SLC2A8	Inhibition	Testosterone	Approved Drug	.	.	Testosterone inhibits the expression of SLC2A8	.	.
DTD0266	SLC2A8	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC2A8	.	.
DTD0266	SLC2A8	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of SLC2A8	.	.
DTD0267	SLC2A9	Modulator	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 affects the expression of SLC2A9	.	.
DTD0267	SLC2A9	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC2A9	.	.
DTD0267	SLC2A9	Inducer	Calcitriol	Approved Drug	.	.	Calcitriol increases the expression of SLC2A9	.	.
DTD0267	SLC2A9	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC2A9	.	.
DTD0267	SLC2A9	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC2A9	.	.
DTD0267	SLC2A9	Inhibition	K-7174	Patented Pharmaceutical Agent	.	.	K-7174 inhibits the expression of SLC2A9	.	.
DTD0267	SLC2A9	Inhibition	Methyleugenol	Natural Product	.	.	Methyleugenol inhibits the expression of SLC2A9	.	.
DTD0267	SLC2A9	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of SLC2A9	.	.
DTD0267	SLC2A9	Inhibition	Testosterone	Approved Drug	.	.	Testosterone inhibits the expression of SLC2A9	.	.
DTD0267	SLC2A9	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC2A9	.	.
DTD0267	SLC2A9	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of SLC2A9	.	.
DTD0269	SLC30A1	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inducer	Acrylamide	Acute Toxic Substance	.	.	Acrylamide increases the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inducer	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 increases the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inducer	AM-251	Patented Pharmaceutical Agent	.	.	AM-251 increases the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inducer	Amiodarone	Approved Drug	.	.	Amiodarone increases the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inducer	Antimycin A	Acute Toxic Substance	.	.	Antimycin A increases the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inducer	Arsenic Trioxide	Approved Drug	.	.	Arsenic Trioxide increases the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inducer	Cadmium	Acute Toxic Substance	.	.	Cadmium increases the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inducer	Calcitriol	Approved Drug	.	.	Calcitriol increases the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inducer	Cannabidiol	Approved Drug	.	.	Cannabidiol increases the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inducer	Cisplatin	Approved Drug	.	.	Cisplatin increases the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inducer	Colforsin	Drug in Phase 2 Trial	.	.	Colforsin increases the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inducer	Copper Sulfate	Approved Drug	.	.	Copper Sulfate increases the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inhibition	Coumestrol	Investigative Drug	.	.	Coumestrol inhibits the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inducer	Cupric chloride	Approved Drug	.	.	Cupric chloride increases the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inducer	Cupric oxide	Chemical Compound	.	.	Cupric oxide increases the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inducer	Curcumin	Drug in Phase 3 Trial	.	.	Curcumin increases the expression of SLC30A1	.	.
DTD0269	SLC30A1	Modulator	Decitabine	Approved Drug	.	.	Decitabine affects the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inducer	Deguelin	Natural Product	.	.	Deguelin increases the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inducer	Demecolcine	Drug Marketed but not Approved by US FDA	.	.	Demecolcine increases the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inhibition	Dicrotophos	Pesticide/Insecticide	.	.	Dicrotophos inhibits the expression of SLC30A1	.	.
DTD0269	SLC30A1	Modulator	Doxorubicin	Approved Drug	.	.	Doxorubicin affects the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inhibition	Dronabinol	Approved Drug	.	.	Dronabinol inhibits the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inhibition	Epigallocatechin gallate	Drug in Phase 3 Trial	.	.	Epigallocatechin gallate inhibits the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC30A1	.	.
DTD0269	SLC30A1	Modulator	Ethinyl Estradiol	Approved Drug	.	.	Ethinyl Estradiol affects the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inducer	Ethyl Methanesulfonate	Carcinogen	.	.	Ethyl Methanesulfonate increases the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inducer	Formaldehyde	Acute Toxic Substance	.	.	Formaldehyde increases the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inducer	Gallium nitrate	Approved Drug	.	.	Gallium nitrate induces the activity of SLC30A1	.	.
DTD0269	SLC30A1	Inducer	Gardiquimod	Drug in Preclinical Test	.	.	Gardiquimod increases the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inducer	Genistein	Drug in Phase 2 Trial	.	.	Genistein increases the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inducer	Genistin	Drug in Phase 2 Trial	.	.	Genistin increases the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inhibition	Grape Seed Proanthocyanidins	Plant Extract	.	.	Grape Seed Proanthocyanidins inhibits the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inducer	GSK-J4	Patented Pharmaceutical Agent	.	.	GSK-J4 increases the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inhibition	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 inhibits the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inhibition	Irinotecan	Approved Drug	.	.	Irinotecan inhibits the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inhibition	Isotretinoin	Approved Drug	.	.	Isotretinoin inhibits the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inhibition	Ivermectin	Approved Drug	.	.	Ivermectin inhibits the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inhibition	Jinfukang	Traditional Medicine	.	.	Jinfukang inhibits the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inducer	Leflunomide	Approved Drug	.	.	Leflunomide increases the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inducer	Motexafin gadolinium	Drug in Phase 2 Trial	.	.	Motexafin gadolinium increases the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inducer	Nitroprusside	Approved Drug	.	.	Nitroprusside increases the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inhibition	Oxyquinoline	Acute Toxic Substance	.	.	Oxyquinoline inhibits the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inducer	PCI-5002	Investigative Drug	.	.	PCI-5002 increases the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inhibition	Perfluorooctane sulfonic acid	Health and Environmental Toxicant	.	.	Perfluorooctane sulfonic acid inhibits the expression of SLC30A1	.	.
DTD0269	SLC30A1	Modulator	Phenobarbital	Approved Drug	.	.	Phenobarbital affects the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inducer	Phenylmercuric Acetate	Investigative Drug	.	.	Phenylmercuric Acetate increases the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inducer	Rotenone	Drug Marketed but not Approved by US FDA	.	.	Rotenone increases the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inducer	Silver nanoparticle	Nanoparticle	.	.	Silver nanoparticle increases the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inducer	Silver Nitrate	Drug Marketed but not Approved by US FDA	.	.	Silver Nitrate increases the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inducer	STA-4783	Drug in Phase 2 Trial	.	.	STA-4783 increases the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inducer	Sulindac	Approved Drug	.	.	Sulindac increases the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inducer	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A increases the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inducer	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate increases the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inducer	Vorinostat	Approved Drug	.	.	Vorinostat increases the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inducer	Zinc Acetate	Approved Drug	.	.	Zinc Acetate increases the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inducer	Zinc chloride	Drug Marketed but not Approved by US FDA	.	.	Zinc chloride increases the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inducer	Zinc Oxide	Environmental toxicant	.	.	Zinc Oxide increases the expression of SLC30A1	.	.
DTD0269	SLC30A1	Inducer	Zinc Sulfate	Drug Marketed but not Approved by US FDA	.	.	Zinc Sulfate increases the expression of SLC30A1	.	.
DTD0270	SLC30A10	Inducer	1-methyl-4-phenylpyridinium	Health and Environmental Toxicant	.	.	1-methyl-4-phenylpyridinium increases the expression of SLC30A10	.	.
DTD0270	SLC30A10	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC30A10	.	.
DTD0270	SLC30A10	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC30A10	.	.
DTD0270	SLC30A10	Inhibition	Azathioprine	Approved Drug	.	.	Azathioprine inhibits the expression of SLC30A10	.	.
DTD0270	SLC30A10	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC30A10	.	.
DTD0270	SLC30A10	Inhibition	Beta-naphthoflavone	Investigative Drug	.	.	Beta-naphthoflavone inhibits the expression of SLC30A10	.	.
DTD0270	SLC30A10	Modulator	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A affects the expression of SLC30A10	.	.
DTD0270	SLC30A10	Inducer	Calcitriol	Approved Drug	.	.	Calcitriol increases the expression of SLC30A10	.	.
DTD0270	SLC30A10	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC30A10	.	.
DTD0270	SLC30A10	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC30A10	.	.
DTD0270	SLC30A10	Inducer	Edetic Acid	Drug Marketed but not Approved by US FDA	.	.	Edetic Acid increases the expression of SLC30A10	.	.
DTD0270	SLC30A10	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the expression of SLC30A10	.	.
DTD0270	SLC30A10	Inhibition	Grape Seed Proanthocyanidins	Plant Extract	.	.	Grape Seed Proanthocyanidins inhibits the expression of SLC30A10	.	.
DTD0270	SLC30A10	Inhibition	Isotretinoin	Approved Drug	.	.	Isotretinoin inhibits the expression of SLC30A10	.	.
DTD0270	SLC30A10	Inhibition	Oxyquinoline	Acute Toxic Substance	.	.	Oxyquinoline inhibits the expression of SLC30A10	.	.
DTD0270	SLC30A10	Inducer	Phenylmercuric Acetate	Investigative Drug	.	.	Phenylmercuric Acetate increases the expression of SLC30A10	.	.
DTD0270	SLC30A10	Inhibition	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin inhibits the expression of SLC30A10	.	.
DTD0270	SLC30A10	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of SLC30A10	.	.
DTD0270	SLC30A10	Inhibition	Rifampin	Approved Drug	.	.	Rifampin inhibits the expression of SLC30A10	.	.
DTD0270	SLC30A10	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC30A10	.	.
DTD0270	SLC30A10	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC30A10	.	.
DTD0270	SLC30A10	Inducer	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A increases the expression of SLC30A10	.	.
DTD0270	SLC30A10	Inducer	Vorinostat	Approved Drug	.	.	Vorinostat increases the expression of SLC30A10	.	.
DTD0271	SLC30A2	Inhibition	1-methyl-4-phenylpyridinium	Health and Environmental Toxicant	.	.	1-methyl-4-phenylpyridinium inhibits the expression of SLC30A2	.	.
DTD0271	SLC30A2	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of SLC30A2	.	.
DTD0271	SLC30A2	Inhibition	Beta-naphthoflavone	Investigative Drug	.	.	Beta-naphthoflavone inhibits the expression of SLC30A2	.	.
DTD0271	SLC30A2	Inducer	Cadmium	Acute Toxic Substance	.	.	Cadmium increases the expression of SLC30A2	.	.
DTD0271	SLC30A2	Inducer	Colforsin	Drug in Phase 2 Trial	.	.	Colforsin increases the expression of SLC30A2	.	.
DTD0271	SLC30A2	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC30A2	.	.
DTD0271	SLC30A2	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC30A2	.	.
DTD0271	SLC30A2	Inducer	Leflunomide	Approved Drug	.	.	Leflunomide increases the expression of SLC30A2	.	.
DTD0271	SLC30A2	Inducer	MS-275	Drug in Phase 2 Trial	.	.	MS-275 increases the expression of SLC30A2	.	.
DTD0271	SLC30A2	Inhibition	Paraquat	Acute Toxic Substance	.	.	Paraquat inhibits the expression of SLC30A2	.	.
DTD0271	SLC30A2	Inducer	Silver nanoparticle	Nanoparticle	.	.	Silver nanoparticle increases the expression of SLC30A2	.	.
DTD0271	SLC30A2	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of SLC30A2	.	.
DTD0271	SLC30A2	Inhibition	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan inhibits the expression of SLC30A2	.	.
DTD0271	SLC30A2	Inducer	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate increases the expression of SLC30A2	.	.
DTD0271	SLC30A2	Inducer	Zinc	Environmental toxicant	.	.	Zinc increases the expression of SLC30A2	.	.
DTD0272	SLC30A3	Inducer	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 increases the expression of SLC30A3	.	.
DTD0272	SLC30A3	Inducer	Atrazine	Herbicide	.	.	Atrazine increases the expression of SLC30A3	.	.
DTD0272	SLC30A3	Inducer	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde increases the expression of SLC30A3	.	.
DTD0272	SLC30A3	Inhibition	Carmustine	Approved Drug	.	.	Carmustine inhibits the expression of SLC30A3	.	.
DTD0272	SLC30A3	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the expression of SLC30A3	.	.
DTD0272	SLC30A3	Inhibition	Diethylhexyl Phthalate	Health and Environmental Toxicant	.	.	Diethylhexyl Phthalate inhibits the expression of SLC30A3	.	.
DTD0272	SLC30A3	Inhibition	Folic Acid	Approved Drug	.	.	Folic Acid inhibits the expression of SLC30A3	.	.
DTD0272	SLC30A3	Inducer	Grape Seed Proanthocyanidins	Plant Extract	.	.	Grape Seed Proanthocyanidins increases the expression of SLC30A3	.	.
DTD0272	SLC30A3	Modulator	Lead	Health and Environmental Toxicant	.	.	Lead affects the expression of SLC30A3	.	.
DTD0272	SLC30A3	Inducer	Metribolone	Investigative Drug	.	.	Metribolone increases the expression of SLC30A3	.	.
DTD0272	SLC30A3	Inducer	Pentanal	Chemical Compound	.	.	Pentanal increases the expression of SLC30A3	.	.
DTD0272	SLC30A3	Inhibition	Sunitinib	Approved Drug	.	.	Sunitinib inhibits the expression of SLC30A3	.	.
DTD0272	SLC30A3	Inducer	Temozolomide	Approved Drug	.	.	Temozolomide increases the expression of SLC30A3	.	.
DTD0272	SLC30A3	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC30A3	.	.
DTD0272	SLC30A3	Inducer	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate increases the expression of SLC30A3	.	.
DTD0272	SLC30A3	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC30A3	.	.
DTD0272	SLC30A3	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of SLC30A3	.	.
DTD0272	SLC30A3	Inhibition	Zinc	Environmental toxicant	.	.	Zinc inhibits the expression of SLC30A3	.	.
DTD0273	SLC30A4	Inducer	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 increases the expression of SLC30A4	.	.
DTD0273	SLC30A4	Inhibition	Coal Ash	Natural Product	.	.	Coal Ash inhibits the expression of SLC30A4	.	.
DTD0273	SLC30A4	Inducer	Colforsin	Drug in Phase 2 Trial	.	.	Colforsin increases the expression of SLC30A4	.	.
DTD0273	SLC30A4	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC30A4	.	.
DTD0273	SLC30A4	Inhibition	Folic Acid	Approved Drug	.	.	Folic Acid inhibits the expression of SLC30A4	.	.
DTD0273	SLC30A4	Modulator	Lead	Health and Environmental Toxicant	.	.	Lead affects the expression of SLC30A4	.	.
DTD0273	SLC30A4	Inducer	Panobinostat	Approved Drug	.	.	Panobinostat increases the expression of SLC30A4	.	.
DTD0273	SLC30A4	Inducer	Phenylmercuric Acetate	Investigative Drug	.	.	Phenylmercuric Acetate increases the expression of SLC30A4	.	.
DTD0273	SLC30A4	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC30A4	.	.
DTD0273	SLC30A4	Inducer	torcetrapib	Drug in Phase 3 Trial	.	.	torcetrapib increases the expression of SLC30A4	.	.
DTD0273	SLC30A4	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC30A4	.	.
DTD0273	SLC30A4	Inhibition	Zinc	Environmental toxicant	.	.	Zinc inhibits the expression of SLC30A4	.	.
DTD0274	SLC30A5	Inhibition	Calcitriol	Approved Drug	.	.	Calcitriol inhibits the expression of SLC30A5	.	.
DTD0274	SLC30A5	Inhibition	CD-437	Health and Environmental Toxicant	.	.	CD-437 inhibits the expression of SLC30A5	.	.
DTD0274	SLC30A5	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC30A5	.	.
DTD0274	SLC30A5	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of SLC30A5	.	.
DTD0274	SLC30A5	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC30A5	.	.
DTD0274	SLC30A5	Inducer	Grape Seed Proanthocyanidins	Plant Extract	.	.	Grape Seed Proanthocyanidins increases the expression of SLC30A5	.	.
DTD0274	SLC30A5	Modulator	Hydrogen Peroxide	Approved Drug	.	.	Hydrogen Peroxide affects the expression of SLC30A5	.	.
DTD0274	SLC30A5	Inhibition	Milchsaure	Investigative Drug	.	.	Milchsaure inhibits the expression of SLC30A5	.	.
DTD0274	SLC30A5	Inhibition	Pentanal	Chemical Compound	.	.	Pentanal inhibits the expression of SLC30A5	.	.
DTD0274	SLC30A5	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC30A5	.	.
DTD0274	SLC30A5	Inhibition	Vitamin E	Drug in Phase 3 Trial	.	.	Vitamin E inhibits the expression of SLC30A5	.	.
DTD0274	SLC30A5	Inhibition	Zinc	Environmental toxicant	.	.	Zinc inhibits the expression of SLC30A5	.	.
DTD0274	SLC30A5	Inhibition	Zinc chloride	Drug Marketed but not Approved by US FDA	.	.	Zinc chloride inhibits the expression of SLC30A5	.	.
DTD0275	SLC30A6	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC30A6	.	.
DTD0275	SLC30A6	Inhibition	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A inhibits the expression of SLC30A6	.	.
DTD0275	SLC30A6	Inhibition	Calcitriol	Approved Drug	.	.	Calcitriol inhibits the expression of SLC30A6	.	.
DTD0275	SLC30A6	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC30A6	.	.
DTD0275	SLC30A6	Inhibition	Dicrotophos	Pesticide/Insecticide	.	.	Dicrotophos inhibits the expression of SLC30A6	.	.
DTD0275	SLC30A6	Inducer	Grape Seed Proanthocyanidins	Plant Extract	.	.	Grape Seed Proanthocyanidins increases the expression of SLC30A6	.	.
DTD0275	SLC30A6	Inhibition	Jinfukang	Traditional Medicine	.	.	Jinfukang inhibits the expression of SLC30A6	.	.
DTD0275	SLC30A6	Modulator	Lead	Health and Environmental Toxicant	.	.	Lead affects the expression of SLC30A6	.	.
DTD0275	SLC30A6	Inhibition	Milchsaure	Investigative Drug	.	.	Milchsaure inhibits the expression of SLC30A6	.	.
DTD0275	SLC30A6	Inhibition	Testosterone	Approved Drug	.	.	Testosterone inhibits the expression of SLC30A6	.	.
DTD0275	SLC30A6	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC30A6	.	.
DTD0276	SLC30A7	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC30A7	.	.
DTD0276	SLC30A7	Inducer	Chloropicrin	Acute Toxic Substance	.	.	Chloropicrin increases the expression of SLC30A7	.	.
DTD0276	SLC30A7	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the expression of SLC30A7	.	.
DTD0276	SLC30A7	Inhibition	Colforsin	Drug in Phase 2 Trial	.	.	Colforsin inhibits the expression of SLC30A7	.	.
DTD0276	SLC30A7	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of SLC30A7	.	.
DTD0276	SLC30A7	Inducer	Dihydrotestosterone	Drug in Phase 1 Trial	.	.	Dihydrotestosterone increases the expression of SLC30A7	.	.
DTD0276	SLC30A7	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC30A7	.	.
DTD0276	SLC30A7	Inducer	Grape Seed Proanthocyanidins	Plant Extract	.	.	Grape Seed Proanthocyanidins increases the expression of SLC30A7	.	.
DTD0276	SLC30A7	Inhibition	Ivermectin	Approved Drug	.	.	Ivermectin inhibits the expression of SLC30A7	.	.
DTD0276	SLC30A7	Inhibition	Jinfukang	Traditional Medicine	.	.	Jinfukang inhibits the expression of SLC30A7	.	.
DTD0276	SLC30A7	Inducer	Metribolone	Investigative Drug	.	.	Metribolone increases the expression of SLC30A7	.	.
DTD0276	SLC30A7	Inhibition	Ochratoxin A	Acute Toxic Substance	.	.	Ochratoxin A inhibits the expression of SLC30A7	.	.
DTD0276	SLC30A7	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC30A7	.	.
DTD0276	SLC30A7	Inhibition	Vorinostat	Approved Drug	.	.	Vorinostat inhibits the expression of SLC30A7	.	.
DTD0276	SLC30A7	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of SLC30A7	.	.
DTD0276	SLC30A7	Inhibition	Zinc	Environmental toxicant	.	.	Zinc inhibits the expression of SLC30A7	.	.
DTD0276	SLC30A7	Inhibition	Zinc chloride	Drug Marketed but not Approved by US FDA	.	.	Zinc chloride inhibits the expression of SLC30A7	.	.
DTD0277	SLC30A9	Inducer	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 increases the expression of SLC30A9	.	.
DTD0277	SLC30A9	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC30A9	.	.
DTD0277	SLC30A9	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC30A9	.	.
DTD0277	SLC30A9	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC30A9	.	.
DTD0277	SLC30A9	Inhibition	Dicrotophos	Pesticide/Insecticide	.	.	Dicrotophos inhibits the expression of SLC30A9	.	.
DTD0277	SLC30A9	Inhibition	Grape Seed Proanthocyanidins	Plant Extract	.	.	Grape Seed Proanthocyanidins inhibits the expression of SLC30A9	.	.
DTD0277	SLC30A9	Inhibition	GSK-J4	Patented Pharmaceutical Agent	.	.	GSK-J4 inhibits the expression of SLC30A9	.	.
DTD0277	SLC30A9	Inhibition	Jinfukang	Traditional Medicine	.	.	Jinfukang inhibits the expression of SLC30A9	.	.
DTD0277	SLC30A9	Inhibition	Methylparaben	Natural Product	.	.	Methylparaben inhibits the expression of SLC30A9	.	.
DTD0277	SLC30A9	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC30A9	.	.
DTD0277	SLC30A9	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of SLC30A9	.	.
DTD0278	SLC31A1	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC31A1	.	.
DTD0278	SLC31A1	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC31A1	.	.
DTD0278	SLC31A1	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC31A1	.	.
DTD0278	SLC31A1	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC31A1	.	.
DTD0278	SLC31A1	Inhibition	Celecoxib	Approved Drug	.	.	Celecoxib inhibits the expression of SLC31A1	.	.
DTD0278	SLC31A1	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the activity of SLC31A1	.	.
DTD0278	SLC31A1	Inhibition	Coal Ash	Natural Product	.	.	Coal Ash inhibits the expression of SLC31A1	.	.
DTD0278	SLC31A1	Inhibition	Copper	Approved Drug	.	.	Copper inhibits the expression of SLC31A1	.	.
DTD0278	SLC31A1	Inhibition	Copper Sulfate	Approved Drug	.	.	Cupric sulfate inhibits the activity of SLC31A1	.	.
DTD0278	SLC31A1	Inducer	Coumestrol	Investigative Drug	.	.	Coumestrol increases the expression of SLC31A1	.	.
DTD0278	SLC31A1	Inhibition	Cupric chloride	Approved Drug	.	.	Cupric chloride inhibits the expression of SLC31A1	.	.
DTD0278	SLC31A1	Inducer	Cupric oxide	Chemical Compound	.	.	Cupric oxide increases the expression of SLC31A1	.	.
DTD0278	SLC31A1	Inducer	Decitabine	Approved Drug	.	.	Decitabine increases the expression of SLC31A1	.	.
DTD0278	SLC31A1	Inducer	Epigallocatechin gallate	Drug in Phase 3 Trial	.	.	Epigallocatechin gallate increases the expression of SLC31A1	.	.
DTD0278	SLC31A1	Inducer	Estradiol	Approved Drug	.	.	Estradiol induces the activity of SLC31A1	.	.
DTD0278	SLC31A1	Inhibition	Ethyl Methanesulfonate	Carcinogen	.	.	Ethyl Methanesulfonate inhibits the expression of SLC31A1	.	.
DTD0278	SLC31A1	Inhibition	Formaldehyde	Acute Toxic Substance	.	.	Formaldehyde inhibits the expression of SLC31A1	.	.
DTD0278	SLC31A1	Inducer	Genistein	Drug in Phase 2 Trial	.	.	Genistein increases the expression of SLC31A1	.	.
DTD0278	SLC31A1	Inducer	GSK-J4	Patented Pharmaceutical Agent	.	.	GSK-J4 increases the expression of SLC31A1	.	.
DTD0278	SLC31A1	Inhibition	Isotretinoin	Approved Drug	.	.	Isotretinoin inhibits the expression of SLC31A1	.	.
DTD0278	SLC31A1	Inhibition	Ivermectin	Approved Drug	.	.	Ivermectin inhibits the expression of SLC31A1	.	.
DTD0278	SLC31A1	Inducer	Metribolone	Investigative Drug	.	.	Metribolone increases the expression of SLC31A1	.	.
DTD0278	SLC31A1	Inhibition	Milchsaure	Investigative Drug	.	.	Milchsaure inhibits the expression of SLC31A1	.	.
DTD0278	SLC31A1	Inducer	Paclitaxel	Approved Drug	.	.	Paclitaxel increases the expression of SLC31A1	.	.
DTD0278	SLC31A1	Inducer	Paraquat	Acute Toxic Substance	.	.	Paraquat increases the expression of SLC31A1	.	.
DTD0278	SLC31A1	Inducer	Penicillamine	Approved Drug	.	.	Penicillamine increases the expression of SLC31A1	.	.
DTD0278	SLC31A1	Inducer	Phenylmercuric Acetate	Investigative Drug	.	.	Phenylmercuric Acetate increases the expression of SLC31A1	.	.
DTD0278	SLC31A1	Inducer	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin increases the expression of SLC31A1	.	.
DTD0278	SLC31A1	Inducer	Resveratrol	Drug in Phase 3 Trial	.	.	Resveratrol increases the expression of SLC31A1	.	.
DTD0278	SLC31A1	Inhibition	SC-58236	Drug in Preclinical Test	.	.	SC-58236 inhibits the expression of SLC31A1	.	.
DTD0278	SLC31A1	Inducer	Silver Nitrate	Drug Marketed but not Approved by US FDA	.	.	Silver Nitrate increases the expression of SLC31A1	.	.
DTD0278	SLC31A1	Inducer	Tetrathiomolybdate	Drug in Phase 3 Trial	.	.	Tetrathiomolybdate increases the expression of SLC31A1	.	.
DTD0278	SLC31A1	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC31A1	.	.
DTD0278	SLC31A1	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of SLC31A1	.	.
DTD0278	SLC31A1	Modulator	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A affects the expression of SLC31A1	.	.
DTD0278	SLC31A1	Inducer	Zinc Acetate	Approved Drug	.	.	Zinc Acetate increases the expression of SLC31A1	.	.
DTD0280	SLC31A2	Inducer	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 increases the expression of SLC31A2	.	.
DTD0280	SLC31A2	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC31A2	.	.
DTD0280	SLC31A2	Inducer	Calcitriol	Approved Drug	.	.	Calcitriol increases the expression of SLC31A2	.	.
DTD0280	SLC31A2	Modulator	Carbamazepine	Approved Drug	.	.	Carbamazepine affects the expression of SLC31A2	.	.
DTD0280	SLC31A2	Inducer	Cisplatin	Approved Drug	.	.	Cisplatin increases the expression of SLC31A2	.	.
DTD0280	SLC31A2	Inhibition	Copper	Approved Drug	.	.	Copper inhibits the expression of SLC31A2	.	.
DTD0280	SLC31A2	Inducer	Copper Sulfate	Approved Drug	.	.	Copper Sulfate increases the expression of SLC31A2	.	.
DTD0280	SLC31A2	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC31A2	.	.
DTD0280	SLC31A2	Inhibition	Dexamethasone	Approved Drug	.	.	Dexamethasone inhibits the expression of SLC31A2	.	.
DTD0280	SLC31A2	Inhibition	Dicrotophos	Pesticide/Insecticide	.	.	Dicrotophos inhibits the expression of SLC31A2	.	.
DTD0280	SLC31A2	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the expression of SLC31A2	.	.
DTD0280	SLC31A2	Inducer	Ethyl Methanesulfonate	Carcinogen	.	.	Ethyl Methanesulfonate increases the expression of SLC31A2	.	.
DTD0280	SLC31A2	Inducer	Formaldehyde	Acute Toxic Substance	.	.	Formaldehyde increases the expression of SLC31A2	.	.
DTD0280	SLC31A2	Inducer	Methotrexate	Approved Drug	.	.	Methotrexate increases the expression of SLC31A2	.	.
DTD0280	SLC31A2	Inducer	Paraquat	Acute Toxic Substance	.	.	Paraquat increases the expression of SLC31A2	.	.
DTD0280	SLC31A2	Inhibition	Particulate Matter	Natural Product	.	.	Particulate Matter inhibits the expression of SLC31A2	.	.
DTD0280	SLC31A2	Inhibition	Sunitinib	Approved Drug	.	.	Sunitinib inhibits the expression of SLC31A2	.	.
DTD0280	SLC31A2	Inhibition	Temozolomide	Approved Drug	.	.	Temozolomide inhibits the expression of SLC31A2	.	.
DTD0280	SLC31A2	Inducer	Testosterone	Approved Drug	.	.	Testosterone increases the expression of SLC31A2	.	.
DTD0280	SLC31A2	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of SLC31A2	.	.
DTD0280	SLC31A2	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC31A2	.	.
DTD0280	SLC31A2	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of SLC31A2	.	.
DTD0280	SLC31A2	Inhibition	Zinc chloride	Drug Marketed but not Approved by US FDA	.	.	Zinc chloride inhibits the expression of SLC31A2	.	.
DTD0281	SLC32A1	Inducer	1-methyl-4-phenylpyridinium	Health and Environmental Toxicant	.	.	1-methyl-4-phenylpyridinium increases the expression of SLC32A1	.	.
DTD0281	SLC32A1	Inducer	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde increases the expression of SLC32A1	.	.
DTD0281	SLC32A1	Inhibition	DQlIdElW	Investigative Drug	.	828 +/- 252	DQlIdElW inhibits the activity of SLC32A1 (Ki = 828 +/- 252 microM)	.	.
DTD0281	SLC32A1	Modulator	Lead	Health and Environmental Toxicant	.	.	Lead affects the expression of SLC32A1	.	.
DTD0281	SLC32A1	Inducer	Pentanal	Chemical Compound	.	.	Pentanal increases the expression of SLC32A1	.	.
DTD0281	SLC32A1	Inhibition	Quinoline-2,4-dicarboxylic acids	Investigative Drug	.	.	Quinoline-2,4-dicarboxylic acids inhibits the activity of SLC32A1	.	.
DTD0281	SLC32A1	Inducer	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite increases the expression of SLC32A1	.	.
DTD0281	SLC32A1	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC32A1	.	.
DTD0281	SLC32A1	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC32A1	.	.
DTD0281	SLC32A1	Inducer	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A increases the expression of SLC32A1	.	.
DTD0281	SLC32A1	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC32A1	.	.
DTD0282	SLC33A1	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC33A1	.	.
DTD0282	SLC33A1	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC33A1	.	.
DTD0282	SLC33A1	Inducer	Avobenzone	Approved Drug	.	.	Avobenzone increases the expression of SLC33A1	.	.
DTD0282	SLC33A1	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC33A1	.	.
DTD0282	SLC33A1	Modulator	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A affects the expression of SLC33A1	.	.
DTD0282	SLC33A1	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC33A1	.	.
DTD0282	SLC33A1	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of SLC33A1	.	.
DTD0282	SLC33A1	Inducer	Dihydrotestosterone	Drug in Phase 1 Trial	.	.	Dihydrotestosterone increases the expression of SLC33A1	.	.
DTD0282	SLC33A1	Inhibition	Ivermectin	Approved Drug	.	.	Ivermectin inhibits the expression of SLC33A1	.	.
DTD0282	SLC33A1	Inducer	K-7174	Patented Pharmaceutical Agent	.	.	K-7174 increases the expression of SLC33A1	.	.
DTD0282	SLC33A1	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of SLC33A1	.	.
DTD0282	SLC33A1	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC33A1	.	.
DTD0282	SLC33A1	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC33A1	.	.
DTD0282	SLC33A1	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC33A1	.	.
DTD0284	SLC34A1	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC34A1	.	.
DTD0284	SLC34A1	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC34A1	.	.
DTD0284	SLC34A1	Inhibition	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A inhibits the expression of SLC34A1	.	.
DTD0284	SLC34A1	Inhibition	PF-06869206	Investigative Drug	.	.	PF-06869206 inhibits the activity of SLC34A1	.	.
DTD0284	SLC34A1	Inhibition	Testosterone	Approved Drug	.	.	Testosterone inhibits the expression of SLC34A1	.	.
DTD0284	SLC34A1	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC34A1	.	.
DTD0285	SLC34A2	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC34A2	.	.
DTD0285	SLC34A2	Inducer	Calcitriol	Approved Drug	.	.	Calcitriol increases the expression of SLC34A2	.	.
DTD0285	SLC34A2	Inducer	Formaldehyde	Acute Toxic Substance	.	.	Formaldehyde increases the expression of SLC34A2	.	.
DTD0285	SLC34A2	Inhibition	Methotrexate	Approved Drug	.	.	Methotrexate inhibits the expression of SLC34A2	.	.
DTD0285	SLC34A2	Inhibition	Phosphonoformate	Approved Drug	.	.	Phosphonoformate inhibits the activity of SLC34A2	.	.
DTD0285	SLC34A2	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC34A2	.	.
DTD0285	SLC34A2	Modulator	Tretinoin	Approved Drug	.	.	Tretinoin affects the expression of SLC34A2	.	.
DTD0285	SLC34A2	Inducer	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan increases the expression of SLC34A2	.	.
DTD0285	SLC34A2	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC34A2	.	.
DTD0285	SLC34A2	Inducer	Zoledronic Acid	Approved Drug	.	.	Zoledronic Acid increases the expression of SLC34A2	.	.
DTD0286	SLC34A3	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC34A3	.	.
DTD0286	SLC34A3	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of SLC34A3	.	.
DTD0287	SLC35A1	Inhibition	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A inhibits the expression of SLC35A1	.	.
DTD0287	SLC35A1	Modulator	Cisplatin	Approved Drug	.	.	Cisplatin affects the expression of SLC35A1	.	.
DTD0287	SLC35A1	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC35A1	.	.
DTD0287	SLC35A1	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC35A1	.	.
DTD0287	SLC35A1	Modulator	Decitabine	Approved Drug	.	.	Decitabine affects the expression of SLC35A1	.	.
DTD0287	SLC35A1	Inhibition	Dicrotophos	Pesticide/Insecticide	.	.	Dicrotophos inhibits the expression of SLC35A1	.	.
DTD0287	SLC35A1	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the expression of SLC35A1	.	.
DTD0287	SLC35A1	Inhibition	Jinfukang	Traditional Medicine	.	.	Jinfukang inhibits the expression of SLC35A1	.	.
DTD0287	SLC35A1	Inhibition	Milchsaure	Investigative Drug	.	.	Milchsaure inhibits the expression of SLC35A1	.	.
DTD0287	SLC35A1	Inducer	Nicotine polacrilex	Approved Drug	.	.	Nicotine polacrilex increases the expression of SLC35A1	.	.
DTD0287	SLC35A1	Inducer	Particulate Matter	Natural Product	.	.	Particulate Matter increases the expression of SLC35A1	.	.
DTD0287	SLC35A1	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of SLC35A1	.	.
DTD0287	SLC35A1	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of SLC35A1	.	.
DTD0287	SLC35A1	Modulator	Valproic Acid	Approved Drug	.	.	Valproic Acid affects the expression of SLC35A1	.	.
DTD0288	SLC35A2	Inducer	Amiodarone	Approved Drug	.	.	Amiodarone increases the expression of SLC35A2	.	.
DTD0288	SLC35A2	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC35A2	.	.
DTD0288	SLC35A2	Inhibition	Isotretinoin	Approved Drug	.	.	Isotretinoin inhibits the expression of SLC35A2	.	.
DTD0288	SLC35A2	Inhibition	Lead	Health and Environmental Toxicant	.	.	Lead inhibits the expression of SLC35A2	.	.
DTD0288	SLC35A2	Inhibition	Methotrexate	Approved Drug	.	.	Methotrexate inhibits the expression of SLC35A2	.	.
DTD0288	SLC35A2	Inducer	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin increases the expression of SLC35A2	.	.
DTD0288	SLC35A2	Inducer	Thapsigargin	Natural Product	.	.	Thapsigargin increases the expression of SLC35A2	.	.
DTD0288	SLC35A2	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC35A2	.	.
DTD0288	SLC35A2	Modulator	Valproic Acid	Approved Drug	.	.	Valproic Acid affects the expression of SLC35A2	.	.
DTD0289	SLC35A3	Inhibition	2-butenal	Acute Toxic Substance	.	.	2-butenal inhibits the expression of SLC35A3	.	.
DTD0289	SLC35A3	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC35A3	.	.
DTD0289	SLC35A3	Inhibition	Aflatoxin M1	Mycotoxins	.	.	Aflatoxin M1 inhibits the expression of SLC35A3	.	.
DTD0289	SLC35A3	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC35A3	.	.
DTD0289	SLC35A3	Inhibition	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde inhibits the expression of SLC35A3	.	.
DTD0289	SLC35A3	Inducer	Cocaine	Approved Drug	.	.	Cocaine increases the expression of SLC35A3	.	.
DTD0289	SLC35A3	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC35A3	.	.
DTD0289	SLC35A3	Inhibition	Coumestrol	Investigative Drug	.	.	Coumestrol inhibits the expression of SLC35A3	.	.
DTD0289	SLC35A3	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of SLC35A3	.	.
DTD0289	SLC35A3	Inducer	Gallic Acid	Natural Product	.	.	Gallic Acid increases the expression of SLC35A3	.	.
DTD0289	SLC35A3	Inducer	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 increases the expression of SLC35A3	.	.
DTD0289	SLC35A3	Inhibition	Perfluorooctane sulfonic acid	Health and Environmental Toxicant	.	.	Perfluorooctane sulfonic acid inhibits the expression of SLC35A3	.	.
DTD0289	SLC35A3	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC35A3	.	.
DTD0289	SLC35A3	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC35A3	.	.
DTD0289	SLC35A3	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC35A3	.	.
DTD0290	SLC35A4	Inhibition	14-deoxy-11,12-didehydroandrographolide	Natural Product	.	.	14-deoxy-11,12-didehydroandrographolide inhibits the expression of SLC35A4	.	.
DTD0290	SLC35A4	Inhibition	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde inhibits the expression of SLC35A4	.	.
DTD0290	SLC35A4	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the expression of SLC35A4	.	.
DTD0290	SLC35A4	Inducer	Dicrotophos	Pesticide/Insecticide	.	.	Dicrotophos increases the expression of SLC35A4	.	.
DTD0290	SLC35A4	Inducer	Dronabinol	Approved Drug	.	.	Dronabinol increases the expression of SLC35A4	.	.
DTD0290	SLC35A4	Inhibition	GSK-J4	Patented Pharmaceutical Agent	.	.	GSK-J4 inhibits the expression of SLC35A4	.	.
DTD0290	SLC35A4	Inhibition	Ivermectin	Approved Drug	.	.	Ivermectin inhibits the expression of SLC35A4	.	.
DTD0290	SLC35A4	Modulator	Lead	Health and Environmental Toxicant	.	.	Lead affects the expression of SLC35A4	.	.
DTD0290	SLC35A4	Inducer	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite increases the expression of SLC35A4	.	.
DTD0290	SLC35A4	Inhibition	Sunitinib	Approved Drug	.	.	Sunitinib inhibits the expression of SLC35A4	.	.
DTD0290	SLC35A4	Inhibition	Testosterone	Approved Drug	.	.	Testosterone inhibits the expression of SLC35A4	.	.
DTD0290	SLC35A4	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC35A4	.	.
DTD0290	SLC35A4	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC35A4	.	.
DTD0290	SLC35A4	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC35A4	.	.
DTD0290	SLC35A4	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of SLC35A4	.	.
DTD0291	SLC35A5	Inhibition	Antimycin A	Acute Toxic Substance	.	.	Antimycin A inhibits the expression of SLC35A5	.	.
DTD0291	SLC35A5	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC35A5	.	.
DTD0291	SLC35A5	Inhibition	Deguelin	Natural Product	.	.	Deguelin inhibits the expression of SLC35A5	.	.
DTD0291	SLC35A5	Inhibition	Dicrotophos	Pesticide/Insecticide	.	.	Dicrotophos inhibits the expression of SLC35A5	.	.
DTD0291	SLC35A5	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC35A5	.	.
DTD0291	SLC35A5	Inducer	K-7174	Patented Pharmaceutical Agent	.	.	K-7174 increases the expression of SLC35A5	.	.
DTD0291	SLC35A5	Inhibition	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin inhibits the expression of SLC35A5	.	.
DTD0291	SLC35A5	Modulator	Polyhexamethyleneguanidine	Fungicide	.	.	Polyhexamethyleneguanidine affects the expression of SLC35A5	.	.
DTD0291	SLC35A5	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC35A5	.	.
DTD0291	SLC35A5	Inducer	Urethane	Approved Drug	.	.	Urethane increases the expression of SLC35A5	.	.
DTD0291	SLC35A5	Inducer	Zinc	Environmental toxicant	.	.	Zinc increases the expression of SLC35A5	.	.
DTD0292	SLC35B1	Inhibition	Atrazine	Herbicide	.	.	Atrazine inhibits the expression of SLC35B1	.	.
DTD0292	SLC35B1	Modulator	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A affects the expression of SLC35B1	.	.
DTD0292	SLC35B1	Modulator	Carbamazepine	Approved Drug	.	.	Carbamazepine affects the expression of SLC35B1	.	.
DTD0292	SLC35B1	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC35B1	.	.
DTD0292	SLC35B1	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of SLC35B1	.	.
DTD0292	SLC35B1	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC35B1	.	.
DTD0292	SLC35B1	Inhibition	Isotretinoin	Approved Drug	.	.	Isotretinoin inhibits the expression of SLC35B1	.	.
DTD0292	SLC35B1	Inducer	Rotenone	Drug Marketed but not Approved by US FDA	.	.	Rotenone increases the expression of SLC35B1	.	.
DTD0292	SLC35B1	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC35B1	.	.
DTD0292	SLC35B1	Inducer	Thapsigargin	Natural Product	.	.	Thapsigargin increases the expression of SLC35B1	.	.
DTD0292	SLC35B1	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC35B1	.	.
DTD0292	SLC35B1	Inducer	Zinc	Environmental toxicant	.	.	Zinc increases the expression of SLC35B1	.	.
DTD0293	SLC35B2	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC35B2	.	.
DTD0293	SLC35B2	Modulator	Chloropicrin	Acute Toxic Substance	.	.	Chloropicrin affects the expression of SLC35B2	.	.
DTD0293	SLC35B2	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC35B2	.	.
DTD0293	SLC35B2	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC35B2	.	.
DTD0293	SLC35B2	Inhibition	Dronabinol	Approved Drug	.	.	Dronabinol inhibits the expression of SLC35B2	.	.
DTD0293	SLC35B2	Inhibition	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 inhibits the expression of SLC35B2	.	.
DTD0293	SLC35B2	Inhibition	Ivermectin	Approved Drug	.	.	Ivermectin inhibits the expression of SLC35B2	.	.
DTD0293	SLC35B2	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC35B2	.	.
DTD0293	SLC35B2	Modulator	Valproic Acid	Approved Drug	.	.	Valproic Acid affects the expression of SLC35B2	.	.
DTD0294	SLC35B3	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of SLC35B3	.	.
DTD0294	SLC35B3	Inducer	Acrylamide	Acute Toxic Substance	.	.	Acrylamide increases the expression of SLC35B3	.	.
DTD0294	SLC35B3	Inhibition	Aflatoxin M1	Mycotoxins	.	.	Aflatoxin M1 inhibits the expression of SLC35B3	.	.
DTD0294	SLC35B3	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC35B3	.	.
DTD0294	SLC35B3	Inhibition	Dicrotophos	Pesticide/Insecticide	.	.	Dicrotophos inhibits the expression of SLC35B3	.	.
DTD0294	SLC35B3	Inhibition	GSK-J4	Patented Pharmaceutical Agent	.	.	GSK-J4 inhibits the expression of SLC35B3	.	.
DTD0294	SLC35B3	Inducer	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 increases the expression of SLC35B3	.	.
DTD0294	SLC35B3	Inducer	N-butyrylglucosamine	Investigative Drug	.	.	N-butyrylglucosamine increases the expression of SLC35B3	.	.
DTD0294	SLC35B3	Inhibition	Oxyquinoline	Acute Toxic Substance	.	.	Oxyquinoline inhibits the expression of SLC35B3	.	.
DTD0294	SLC35B3	Inducer	Phenylmercuric Acetate	Investigative Drug	.	.	Phenylmercuric Acetate increases the expression of SLC35B3	.	.
DTD0294	SLC35B3	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of SLC35B3	.	.
DTD0294	SLC35B3	Inducer	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A increases the expression of SLC35B3	.	.
DTD0294	SLC35B3	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC35B3	.	.
DTD0294	SLC35B3	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of SLC35B3	.	.
DTD0294	SLC35B3	Inducer	Zoledronic Acid	Approved Drug	.	.	Zoledronic Acid increases the expression of SLC35B3	.	.
DTD0295	SLC35B4	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC35B4	.	.
DTD0295	SLC35B4	Inhibition	Acrylamide	Acute Toxic Substance	.	.	Acrylamide inhibits the expression of SLC35B4	.	.
DTD0295	SLC35B4	Inhibition	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde inhibits the expression of SLC35B4	.	.
DTD0295	SLC35B4	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the expression of SLC35B4	.	.
DTD0295	SLC35B4	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC35B4	.	.
DTD0295	SLC35B4	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC35B4	.	.
DTD0295	SLC35B4	Inhibition	Methylparaben	Natural Product	.	.	Methylparaben inhibits the expression of SLC35B4	.	.
DTD0295	SLC35B4	Inhibition	Temozolomide	Approved Drug	.	.	Temozolomide inhibits the expression of SLC35B4	.	.
DTD0295	SLC35B4	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC35B4	.	.
DTD0295	SLC35B4	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of SLC35B4	.	.
DTD0295	SLC35B4	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC35B4	.	.
DTD0295	SLC35B4	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of SLC35B4	.	.
DTD0296	SLC35C1	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC35C1	.	.
DTD0296	SLC35C1	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC35C1	.	.
DTD0296	SLC35C1	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC35C1	.	.
DTD0296	SLC35C1	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC35C1	.	.
DTD0296	SLC35C1	Inhibition	GSK-J4	Patented Pharmaceutical Agent	.	.	GSK-J4 inhibits the expression of SLC35C1	.	.
DTD0296	SLC35C1	Inhibition	Milchsaure	Investigative Drug	.	.	Milchsaure inhibits the expression of SLC35C1	.	.
DTD0296	SLC35C1	Inducer	Particulate Matter	Natural Product	.	.	Particulate Matter increases the expression of SLC35C1	.	.
DTD0296	SLC35C1	Inhibition	Sunitinib	Approved Drug	.	.	Sunitinib inhibits the expression of SLC35C1	.	.
DTD0296	SLC35C1	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC35C1	.	.
DTD0296	SLC35C1	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC35C1	.	.
DTD0298	SLC35D1	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC35D1	.	.
DTD0298	SLC35D1	Inhibition	Acrylamide	Acute Toxic Substance	.	.	Acrylamide inhibits the expression of SLC35D1	.	.
DTD0298	SLC35D1	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC35D1	.	.
DTD0298	SLC35D1	Inducer	Cacodylic Acid	Acute Toxic Substance	.	.	Cacodylic Acid increases the expression of SLC35D1	.	.
DTD0298	SLC35D1	Modulator	Carbamazepine	Approved Drug	.	.	Carbamazepine affects the expression of SLC35D1	.	.
DTD0298	SLC35D1	Inducer	Cisplatin	Approved Drug	.	.	Cisplatin increases the expression of SLC35D1	.	.
DTD0298	SLC35D1	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC35D1	.	.
DTD0298	SLC35D1	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC35D1	.	.
DTD0298	SLC35D1	Inducer	Ethyl Methanesulfonate	Carcinogen	.	.	Ethyl Methanesulfonate increases the expression of SLC35D1	.	.
DTD0298	SLC35D1	Inducer	Formaldehyde	Acute Toxic Substance	.	.	Formaldehyde increases the expression of SLC35D1	.	.
DTD0298	SLC35D1	Inhibition	Jinfukang	Traditional Medicine	.	.	Jinfukang inhibits the expression of SLC35D1	.	.
DTD0298	SLC35D1	Inhibition	MS-275	Drug in Phase 2 Trial	.	.	MS-275 inhibits the expression of SLC35D1	.	.
DTD0298	SLC35D1	Inhibition	Oxyquinoline	Acute Toxic Substance	.	.	Oxyquinoline inhibits the expression of SLC35D1	.	.
DTD0298	SLC35D1	Inducer	Phenylmercuric Acetate	Investigative Drug	.	.	Phenylmercuric Acetate increases the expression of SLC35D1	.	.
DTD0298	SLC35D1	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of SLC35D1	.	.
DTD0298	SLC35D1	Inhibition	Selenium nanoparticles	Natural Product	.	.	Selenium nanoparticles inhibits the expression of SLC35D1	.	.
DTD0298	SLC35D1	Modulator	Testosterone enanthate	Approved Drug	.	.	Testosterone enanthate affects the expression of SLC35D1	.	.
DTD0298	SLC35D1	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC35D1	.	.
DTD0298	SLC35D1	Inducer	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A increases the expression of SLC35D1	.	.
DTD0298	SLC35D1	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC35D1	.	.
DTD0298	SLC35D1	Inhibition	Vitamin E	Drug in Phase 3 Trial	.	.	Vitamin E inhibits the expression of SLC35D1	.	.
DTD0298	SLC35D1	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of SLC35D1	.	.
DTD0299	SLC35D2	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of SLC35D2	.	.
DTD0299	SLC35D2	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC35D2	.	.
DTD0299	SLC35D2	Modulator	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 affects the expression of SLC35D2	.	.
DTD0299	SLC35D2	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC35D2	.	.
DTD0299	SLC35D2	Modulator	Carbamazepine	Approved Drug	.	.	Carbamazepine affects the expression of SLC35D2	.	.
DTD0299	SLC35D2	Inhibition	Cinnamic aldehyde	Natural Product	.	.	Cinnamic aldehyde inhibits the expression of SLC35D2	.	.
DTD0299	SLC35D2	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC35D2	.	.
DTD0299	SLC35D2	Inhibition	Coumestrol	Investigative Drug	.	.	Coumestrol inhibits the expression of SLC35D2	.	.
DTD0299	SLC35D2	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC35D2	.	.
DTD0299	SLC35D2	Modulator	Doxorubicin	Approved Drug	.	.	Doxorubicin affects the expression of SLC35D2	.	.
DTD0299	SLC35D2	Inducer	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 increases the expression of SLC35D2	.	.
DTD0299	SLC35D2	Inducer	Lead	Health and Environmental Toxicant	.	.	Lead increases the expression of SLC35D2	.	.
DTD0299	SLC35D2	Inhibition	Sunitinib	Approved Drug	.	.	Sunitinib inhibits the expression of SLC35D2	.	.
DTD0299	SLC35D2	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC35D2	.	.
DTD0299	SLC35D2	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC35D2	.	.
DTD0299	SLC35D2	Inhibition	Vanillin	Patented Pharmaceutical Agent	.	.	Vanillin inhibits the expression of SLC35D2	.	.
DTD0299	SLC35D2	Inhibition	Vorinostat	Approved Drug	.	.	Vorinostat inhibits the expression of SLC35D2	.	.
DTD0300	SLC35D3	Inducer	Belinostat	Approved Drug	.	.	Belinostat increases the expression of SLC35D3	.	.
DTD0300	SLC35D3	Inducer	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde increases the expression of SLC35D3	.	.
DTD0300	SLC35D3	Inducer	MS-275	Drug in Phase 2 Trial	.	.	MS-275 increases the expression of SLC35D3	.	.
DTD0300	SLC35D3	Inducer	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A increases the expression of SLC35D3	.	.
DTD0300	SLC35D3	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC35D3	.	.
DTD0305	SLC35E4	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of SLC35E4	.	.
DTD0305	SLC35E4	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of SLC35E4	.	.
DTD0305	SLC35E4	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of SLC35E4	.	.
DTD0305	SLC35E4	Inducer	Cisplatin	Approved Drug	.	.	Cisplatin increases the expression of SLC35E4	.	.
DTD0305	SLC35E4	Inducer	Copper Sulfate	Approved Drug	.	.	Copper Sulfate increases the expression of SLC35E4	.	.
DTD0305	SLC35E4	Modulator	Dimethyl Sulfoxide	Approved Drug	.	.	Dimethyl Sulfoxide affects the expression of SLC35E4	.	.
DTD0305	SLC35E4	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC35E4	.	.
DTD0305	SLC35E4	Inducer	Ethyl Methanesulfonate	Carcinogen	.	.	Ethyl Methanesulfonate increases the expression of SLC35E4	.	.
DTD0305	SLC35E4	Modulator	Lead	Health and Environmental Toxicant	.	.	Lead affects the expression of SLC35E4	.	.
DTD0305	SLC35E4	Inhibition	Milchsaure	Investigative Drug	.	.	Milchsaure inhibits the expression of SLC35E4	.	.
DTD0305	SLC35E4	Inducer	MS-275	Drug in Phase 2 Trial	.	.	MS-275 increases the expression of SLC35E4	.	.
DTD0305	SLC35E4	Inhibition	Particulate Matter	Natural Product	.	.	Particulate Matter inhibits the expression of SLC35E4	.	.
DTD0305	SLC35E4	Inducer	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan increases the expression of SLC35E4	.	.
DTD0305	SLC35E4	Inducer	Urethane	Approved Drug	.	.	Urethane increases the expression of SLC35E4	.	.
DTD0305	SLC35E4	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC35E4	.	.
DTD0308	SLC35F3	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC35F3	.	.
DTD0308	SLC35F3	Inhibition	Belinostat	Approved Drug	.	.	Belinostat inhibits the expression of SLC35F3	.	.
DTD0308	SLC35F3	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the expression of SLC35F3	.	.
DTD0308	SLC35F3	Inhibition	Ethyl Methanesulfonate	Carcinogen	.	.	Ethyl Methanesulfonate inhibits the expression of SLC35F3	.	.
DTD0308	SLC35F3	Inhibition	Formaldehyde	Acute Toxic Substance	.	.	Formaldehyde inhibits the expression of SLC35F3	.	.
DTD0308	SLC35F3	Inhibition	Phenylmercuric Acetate	Investigative Drug	.	.	Phenylmercuric Acetate inhibits the expression of SLC35F3	.	.
DTD0308	SLC35F3	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC35F3	.	.
DTD0308	SLC35F3	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC35F3	.	.
DTD0308	SLC35F3	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC35F3	.	.
DTD0308	SLC35F3	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC35F3	.	.
DTD0311	SLC35F6	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC35F6	.	.
DTD0311	SLC35F6	Inhibition	Atrazine	Herbicide	.	.	Atrazine inhibits the expression of SLC35F6	.	.
DTD0311	SLC35F6	Inhibition	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A inhibits the expression of SLC35F6	.	.
DTD0311	SLC35F6	Inducer	Bisphenol B	Drug in Phase 2 Trial	.	.	Bisphenol B increases the expression of SLC35F6	.	.
DTD0311	SLC35F6	Inducer	Bisphenol F	Environmental toxicant	.	.	Bisphenol F increases the expression of SLC35F6	.	.
DTD0311	SLC35F6	Modulator	Carbamazepine	Approved Drug	.	.	Carbamazepine affects the expression of SLC35F6	.	.
DTD0311	SLC35F6	Inducer	Copper Sulfate	Approved Drug	.	.	Copper Sulfate increases the expression of SLC35F6	.	.
DTD0311	SLC35F6	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of SLC35F6	.	.
DTD0311	SLC35F6	Inducer	Dicrotophos	Pesticide/Insecticide	.	.	Dicrotophos increases the expression of SLC35F6	.	.
DTD0311	SLC35F6	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC35F6	.	.
DTD0311	SLC35F6	Inhibition	Milchsaure	Investigative Drug	.	.	Milchsaure inhibits the expression of SLC35F6	.	.
DTD0311	SLC35F6	Inducer	Phenylmercuric Acetate	Investigative Drug	.	.	Phenylmercuric Acetate increases the expression of SLC35F6	.	.
DTD0311	SLC35F6	Inducer	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin increases the expression of SLC35F6	.	.
DTD0311	SLC35F6	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of SLC35F6	.	.
DTD0311	SLC35F6	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC35F6	.	.
DTD0311	SLC35F6	Inducer	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate increases the expression of SLC35F6	.	.
DTD0311	SLC35F6	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC35F6	.	.
DTD0318	SLC36A1	Inhibition	5-Hydroxy-L-tryptophan	Investigative Drug	.	.	5-Hydroxy-L-tryptophan inhibits the activity of SLC36A1	.	.
DTD0318	SLC36A1	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of SLC36A1	.	.
DTD0318	SLC36A1	Inducer	AM-80	Drug in Phase 2/3 Trial	.	.	AM-80 increases the expression of SLC36A1	.	.
DTD0318	SLC36A1	Inhibition	Atrazine	Herbicide	.	.	Atrazine inhibits the expression of SLC36A1	.	.
DTD0318	SLC36A1	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of SLC36A1	.	.
DTD0318	SLC36A1	Inhibition	Caffeine	Approved Drug	.	.	Caffeine inhibits the activity of SLC36A1	.	.
DTD0318	SLC36A1	Inducer	Dicrotophos	Pesticide/Insecticide	.	.	Dicrotophos increases the expression of SLC36A1	.	.
DTD0318	SLC36A1	Inhibition	Milchsaure	Investigative Drug	.	.	Milchsaure inhibits the expression of SLC36A1	.	.
DTD0318	SLC36A1	Inhibition	Sodium bichromate	Carcinogen	.	.	Sodium bichromate inhibits the expression of SLC36A1	.	.
DTD0318	SLC36A1	Inhibition	Thapsigargin	Natural Product	.	.	Thapsigargin inhibits the expression of SLC36A1	.	.
DTD0318	SLC36A1	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC36A1	.	.
DTD0318	SLC36A1	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of SLC36A1	.	.
DTD0318	SLC36A1	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC36A1	.	.
DTD0319	SLC36A2	Inhibition	5-Hydroxy-L-tryptophan	Investigative Drug	.	.	5-Hydroxy-L-tryptophan inhibits the activity of SLC36A2	.	.
DTD0319	SLC36A2	Inducer	Cisplatin	Approved Drug	.	.	Cisplatin increases the expression of SLC36A2	.	.
DTD0319	SLC36A2	Inhibition	NOX-200	Discontinued Drug	.	.	NOX-200 inhibits the activity of SLC36A2	.	.
DTD0320	SLC36A3	Inhibition	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A inhibits the expression of SLC36A3	.	.
DTD0321	SLC36A4	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of SLC36A4	.	.
DTD0321	SLC36A4	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of SLC36A4	.	.
DTD0321	SLC36A4	Inhibition	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde inhibits the expression of SLC36A4	.	.
DTD0321	SLC36A4	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC36A4	.	.
DTD0321	SLC36A4	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of SLC36A4	.	.
DTD0321	SLC36A4	Inducer	Dihydrotestosterone	Drug in Phase 1 Trial	.	.	Dihydrotestosterone increases the expression of SLC36A4	.	.
DTD0321	SLC36A4	Inhibition	Jinfukang	Traditional Medicine	.	.	Jinfukang inhibits the expression of SLC36A4	.	.
DTD0321	SLC36A4	Inhibition	Milchsaure	Investigative Drug	.	.	Milchsaure inhibits the expression of SLC36A4	.	.
DTD0321	SLC36A4	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of SLC36A4	.	.
DTD0321	SLC36A4	Inhibition	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate inhibits the expression of SLC36A4	.	.
DTD0321	SLC36A4	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC36A4	.	.
DTD0322	SLC37A1	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of SLC37A1	.	.
DTD0322	SLC37A1	Inducer	Cisplatin	Approved Drug	.	.	Cisplatin increases the expression of SLC37A1	.	.
DTD0322	SLC37A1	Inhibition	Nitrobenzanthrone	Investigative Drug	.	.	Nitrobenzanthrone inhibits the expression of SLC37A1	.	.
DTD0322	SLC37A1	Inhibition	Perfluorooctane sulfonic acid	Health and Environmental Toxicant	.	.	Perfluorooctane sulfonic acid inhibits the expression of SLC37A1	.	.
DTD0322	SLC37A1	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of SLC37A1	.	.
DTD0322	SLC37A1	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC37A1	.	.
DTD0322	SLC37A1	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of SLC37A1	.	.
DTD0322	SLC37A1	Inducer	Zoledronic Acid	Approved Drug	.	.	Zoledronic Acid increases the expression of SLC37A1	.	.
DTD0323	SLC37A2	Inducer	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 increases the expression of SLC37A2	.	.
DTD0323	SLC37A2	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of SLC37A2	.	.
DTD0323	SLC37A2	Inducer	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde increases the expression of SLC37A2	.	.
DTD0323	SLC37A2	Modulator	Copper Sulfate	Approved Drug	.	.	Copper Sulfate affects the expression of SLC37A2	.	.
DTD0323	SLC37A2	Modulator	Hydrogen Peroxide	Approved Drug	.	.	Hydrogen Peroxide affects the expression of SLC37A2	.	.
DTD0323	SLC37A2	Inducer	Methyleugenol	Natural Product	.	.	Methyleugenol increases the expression of SLC37A2	.	.
DTD0323	SLC37A2	Inhibition	Milchsaure	Investigative Drug	.	.	Milchsaure inhibits the expression of SLC37A2	.	.
DTD0323	SLC37A2	Inducer	Nicotine polacrilex	Approved Drug	.	.	Nicotine polacrilex increases the expression of SLC37A2	.	.
DTD0323	SLC37A2	Inducer	Particulate Matter	Natural Product	.	.	Particulate Matter increases the expression of SLC37A2	.	.
DTD0323	SLC37A2	Inhibition	Pentanal	Chemical Compound	.	.	Pentanal inhibits the expression of SLC37A2	.	.
DTD0323	SLC37A2	Modulator	Phenobarbital	Approved Drug	.	.	Phenobarbital affects the expression of SLC37A2	.	.
DTD0323	SLC37A2	Inducer	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin increases the expression of SLC37A2	.	.
DTD0323	SLC37A2	Inhibition	Progesterone	Approved Drug	.	.	Progesterone inhibits the expression of SLC37A2	.	.
DTD0323	SLC37A2	Inducer	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin increases the expression of SLC37A2	.	.
DTD0323	SLC37A2	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC37A2	.	.
DTD0323	SLC37A2	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of SLC37A2	.	.
DTD0323	SLC37A2	Modulator	Valproic Acid	Approved Drug	.	.	Valproic Acid affects the expression of SLC37A2	.	.
DTD0323	SLC37A2	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of SLC37A2	.	.
DTD0324	SLC37A3	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of SLC37A3	.	.
DTD0324	SLC37A3	Inhibition	Dicrotophos	Pesticide/Insecticide	.	.	Dicrotophos inhibits the expression of SLC37A3	.	.
DTD0324	SLC37A3	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC37A3	.	.
DTD0324	SLC37A3	Inhibition	Dronabinol	Approved Drug	.	.	Dronabinol inhibits the expression of SLC37A3	.	.
DTD0324	SLC37A3	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC37A3	.	.
DTD0324	SLC37A3	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC37A3	.	.
DTD0325	SLC37A4	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC37A4	.	.
DTD0325	SLC37A4	Inhibition	Acrylamide	Acute Toxic Substance	.	.	Acrylamide inhibits the expression of SLC37A4	.	.
DTD0325	SLC37A4	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC37A4	.	.
DTD0325	SLC37A4	Inducer	Arsenic Trioxide	Approved Drug	.	.	Arsenic Trioxide increases the expression of SLC37A4	.	.
DTD0325	SLC37A4	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC37A4	.	.
DTD0325	SLC37A4	Modulator	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A affects the expression of SLC37A4	.	.
DTD0325	SLC37A4	Modulator	Carbamazepine	Approved Drug	.	.	Carbamazepine affects the expression of SLC37A4	.	.
DTD0325	SLC37A4	Inhibition	Chlorogenic acid	Investigative Drug	.	.	Chlorogenic acid inhibits the activity of SLC37A4	.	.
DTD0325	SLC37A4	Inducer	Cisplatin	Approved Drug	.	.	Cisplatin increases the expression of SLC37A4	.	.
DTD0325	SLC37A4	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC37A4	.	.
DTD0325	SLC37A4	Inhibition	Curcumin	Drug in Phase 3 Trial	.	.	Curcumin inhibits the expression of SLC37A4	.	.
DTD0325	SLC37A4	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC37A4	.	.
DTD0325	SLC37A4	Inducer	Dexamethasone	Approved Drug	.	.	Dexamethasone increases the expression of SLC37A4	.	.
DTD0325	SLC37A4	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the expression of SLC37A4	.	.
DTD0325	SLC37A4	Inhibition	GSK-J4	Patented Pharmaceutical Agent	.	.	GSK-J4 inhibits the expression of SLC37A4	.	.
DTD0325	SLC37A4	Inhibition	Ivermectin	Approved Drug	.	.	Ivermectin inhibits the expression of SLC37A4	.	.
DTD0325	SLC37A4	Inducer	Jinfukang	Traditional Medicine	.	.	Jinfukang increases the expression of SLC37A4	.	.
DTD0325	SLC37A4	Inhibition	K-7174	Patented Pharmaceutical Agent	.	.	K-7174 inhibits the expression of SLC37A4	.	.
DTD0325	SLC37A4	Inhibition	Methyleugenol	Natural Product	.	.	Methyleugenol inhibits the expression of SLC37A4	.	.
DTD0325	SLC37A4	Inhibition	Rosiglitazone	Approved Drug	.	.	Rosiglitazone inhibits the expression of SLC37A4	.	.
DTD0325	SLC37A4	Inducer	Temozolomide	Approved Drug	.	.	Temozolomide increases the expression of SLC37A4	.	.
DTD0325	SLC37A4	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC37A4	.	.
DTD0325	SLC37A4	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC37A4	.	.
DTD0325	SLC37A4	Inhibition	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate inhibits the expression of SLC37A4	.	.
DTD0325	SLC37A4	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of SLC37A4	.	.
DTD0325	SLC37A4	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC37A4	.	.
DTD0325	SLC37A4	Inducer	Zoledronic Acid	Approved Drug	.	.	Zoledronic Acid increases the expression of SLC37A4	.	.
DTD0326	SLC38A1	Modulator	[3H]Alanine	Investigative Drug	.	.	[3H]Alanine modulates the activity of SLC38A1	.	.
DTD0326	SLC38A1	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC38A1	.	.
DTD0326	SLC38A1	Inducer	Acrylamide	Acute Toxic Substance	.	.	Acrylamide increases the expression of SLC38A1	.	.
DTD0326	SLC38A1	Inducer	Arsenic Trioxide	Approved Drug	.	.	Arsenic Trioxide increases the expression of SLC38A1	.	.
DTD0326	SLC38A1	Inhibition	Atrazine	Herbicide	.	.	Atrazine inhibits the expression of SLC38A1	.	.
DTD0326	SLC38A1	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC38A1	.	.
DTD0326	SLC38A1	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC38A1	.	.
DTD0326	SLC38A1	Inducer	Chloropicrin	Acute Toxic Substance	.	.	Chloropicrin increases the expression of SLC38A1	.	.
DTD0326	SLC38A1	Inducer	Cisplatin	Approved Drug	.	.	Cisplatin increases the expression of SLC38A1	.	.
DTD0326	SLC38A1	Inducer	Copper Sulfate	Approved Drug	.	.	Copper Sulfate increases the expression of SLC38A1	.	.
DTD0326	SLC38A1	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of SLC38A1	.	.
DTD0326	SLC38A1	Inducer	Deguelin	Natural Product	.	.	Deguelin increases the expression of SLC38A1	.	.
DTD0326	SLC38A1	Inducer	Dihydrotestosterone	Drug in Phase 1 Trial	.	.	Dihydrotestosterone increases the expression of SLC38A1	.	.
DTD0326	SLC38A1	Inducer	Geldanamycin	Drug in Phase 1 Trial	.	.	Geldanamycin increases the expression of SLC38A1	.	.
DTD0326	SLC38A1	Inducer	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 increases the expression of SLC38A1	.	.
DTD0326	SLC38A1	Inhibition	Ivermectin	Approved Drug	.	.	Ivermectin inhibits the expression of SLC38A1	.	.
DTD0326	SLC38A1	Inhibition	Jinfukang	Traditional Medicine	.	.	Jinfukang inhibits the expression of SLC38A1	.	.
DTD0326	SLC38A1	Inducer	K-7174	Patented Pharmaceutical Agent	.	.	K-7174 increases the expression of SLC38A1	.	.
DTD0326	SLC38A1	Inducer	Nickel chloride	Acute Toxic Substance	.	.	Nickel chloride increases the expression of SLC38A1	.	.
DTD0326	SLC38A1	Inhibition	Oxaliplatin	Approved Drug	.	.	Oxaliplatin inhibits the expression of SLC38A1	.	.
DTD0326	SLC38A1	Inhibition	Perfluorooctane sulfonic acid	Health and Environmental Toxicant	.	.	Perfluorooctane sulfonic acid inhibits the expression of SLC38A1	.	.
DTD0326	SLC38A1	Inducer	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin increases the expression of SLC38A1	.	.
DTD0326	SLC38A1	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of SLC38A1	.	.
DTD0326	SLC38A1	Inducer	Temozolomide	Approved Drug	.	.	Temozolomide increases the expression of SLC38A1	.	.
DTD0326	SLC38A1	Inducer	Thapsigargin	Natural Product	.	.	Thapsigargin increases the expression of SLC38A1	.	.
DTD0326	SLC38A1	Inhibition	Thimerosal	Acute Toxic Substance	.	.	Thimerosal inhibits the expression of SLC38A1	.	.
DTD0326	SLC38A1	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC38A1	.	.
DTD0326	SLC38A1	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC38A1	.	.
DTD0326	SLC38A1	Modulator	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A affects the expression of SLC38A1	.	.
DTD0326	SLC38A1	Inducer	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate increases the expression of SLC38A1	.	.
DTD0326	SLC38A1	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC38A1	.	.
DTD0326	SLC38A1	Inhibition	Vorinostat	Approved Drug	.	.	Vorinostat inhibits the expression of SLC38A1	.	.
DTD0327	SLC38A10	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of SLC38A10	.	.
DTD0327	SLC38A10	Inhibition	Acrylamide	Acute Toxic Substance	.	.	Acrylamide inhibits the expression of SLC38A10	.	.
DTD0327	SLC38A10	Inhibition	Atrazine	Herbicide	.	.	Atrazine inhibits the expression of SLC38A10	.	.
DTD0327	SLC38A10	Inhibition	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A inhibits the expression of SLC38A10	.	.
DTD0327	SLC38A10	Inducer	Bisphenol B	Drug in Phase 2 Trial	.	.	Bisphenol B increases the expression of SLC38A10	.	.
DTD0327	SLC38A10	Inhibition	Cannabidiol	Approved Drug	.	.	Cannabidiol inhibits the expression of SLC38A10	.	.
DTD0327	SLC38A10	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC38A10	.	.
DTD0327	SLC38A10	Inhibition	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 inhibits the expression of SLC38A10	.	.
DTD0327	SLC38A10	Inhibition	Lead	Health and Environmental Toxicant	.	.	Lead inhibits the expression of SLC38A10	.	.
DTD0327	SLC38A10	Inducer	Manganese	Investigative Drug	.	.	Manganese increases the expression of SLC38A10	.	.
DTD0327	SLC38A10	Inducer	Manganese chloride	Approved Drug	.	.	Manganese chloride increases the expression of SLC38A10	.	.
DTD0327	SLC38A10	Modulator	Menadione	Approved Drug	.	.	Menadione affects the expression of SLC38A10	.	.
DTD0327	SLC38A10	Inhibition	Methotrexate	Approved Drug	.	.	Methotrexate inhibits the expression of SLC38A10	.	.
DTD0327	SLC38A10	Inducer	Milchsaure	Investigative Drug	.	.	Milchsaure increases the expression of SLC38A10	.	.
DTD0327	SLC38A10	Inducer	Phenylmercuric Acetate	Investigative Drug	.	.	Phenylmercuric Acetate increases the expression of SLC38A10	.	.
DTD0327	SLC38A10	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC38A10	.	.
DTD0327	SLC38A10	Inhibition	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate inhibits the expression of SLC38A10	.	.
DTD0327	SLC38A10	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC38A10	.	.
DTD0327	SLC38A10	Inducer	Zinc	Environmental toxicant	.	.	Zinc increases the expression of SLC38A10	.	.
DTD0328	SLC38A11	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC38A11	.	.
DTD0328	SLC38A11	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC38A11	.	.
DTD0328	SLC38A11	Inducer	Amiodarone	Approved Drug	.	.	Amiodarone increases the expression of SLC38A11	.	.
DTD0328	SLC38A11	Inhibition	Azathioprine	Approved Drug	.	.	Azathioprine inhibits the expression of SLC38A11	.	.
DTD0328	SLC38A11	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC38A11	.	.
DTD0328	SLC38A11	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC38A11	.	.
DTD0328	SLC38A11	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC38A11	.	.
DTD0328	SLC38A11	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the expression of SLC38A11	.	.
DTD0328	SLC38A11	Inhibition	Methyleugenol	Natural Product	.	.	Methyleugenol inhibits the expression of SLC38A11	.	.
DTD0328	SLC38A11	Inhibition	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin inhibits the expression of SLC38A11	.	.
DTD0328	SLC38A11	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of SLC38A11	.	.
DTD0328	SLC38A11	Inhibition	Vorinostat	Approved Drug	.	.	Vorinostat inhibits the expression of SLC38A11	.	.
DTD0329	SLC38A2	Modulator	[3H]Alanine	Investigative Drug	.	.	[3H]Alanine modulates the activity of SLC38A2	.	.
DTD0329	SLC38A2	Inducer	Acrylamide	Acute Toxic Substance	.	.	Acrylamide increases the expression of SLC38A2	.	.
DTD0329	SLC38A2	Inducer	Arsenic disulfide	Drug in Phase 3 Trial	.	.	Arsenic disulfide increases the expression of SLC38A2	.	.
DTD0329	SLC38A2	Modulator	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A affects the expression of SLC38A2	.	.
DTD0329	SLC38A2	Modulator	Chloropicrin	Acute Toxic Substance	.	.	Chloropicrin affects the expression of SLC38A2	.	.
DTD0329	SLC38A2	Inducer	Cisplatin	Approved Drug	.	.	Cisplatin increases the expression of SLC38A2	.	.
DTD0329	SLC38A2	Inducer	Copper Sulfate	Approved Drug	.	.	Copper Sulfate increases the expression of SLC38A2	.	.
DTD0329	SLC38A2	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC38A2	.	.
DTD0329	SLC38A2	Inducer	Dichloromethane	Health and Environmental Toxicant	.	.	Dichloromethane increases the expression of SLC38A2	.	.
DTD0329	SLC38A2	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC38A2	.	.
DTD0329	SLC38A2	Inducer	Ethyl benzene	Health and Environmental Toxicant	.	.	Ethyl benzene increases the expression of SLC38A2	.	.
DTD0329	SLC38A2	Inducer	Ethyl Methanesulfonate	Carcinogen	.	.	Ethyl Methanesulfonate increases the expression of SLC38A2	.	.
DTD0329	SLC38A2	Inducer	Formaldehyde	Acute Toxic Substance	.	.	Formaldehyde increases the expression of SLC38A2	.	.
DTD0329	SLC38A2	Inducer	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 increases the expression of SLC38A2	.	.
DTD0329	SLC38A2	Inhibition	Ivermectin	Approved Drug	.	.	Ivermectin inhibits the expression of SLC38A2	.	.
DTD0329	SLC38A2	Inhibition	Jinfukang	Traditional Medicine	.	.	Jinfukang inhibits the expression of SLC38A2	.	.
DTD0329	SLC38A2	Inducer	K-7174	Patented Pharmaceutical Agent	.	.	K-7174 increases the expression of SLC38A2	.	.
DTD0329	SLC38A2	Inducer	Leflunomide	Approved Drug	.	.	Leflunomide increases the expression of SLC38A2	.	.
DTD0329	SLC38A2	Inducer	Motexafin gadolinium	Drug in Phase 2 Trial	.	.	Motexafin gadolinium increases the expression of SLC38A2	.	.
DTD0329	SLC38A2	Modulator	Palmitic Acid	Drug in Phase 1 Trial	.	.	Palmitic Acid affects the expression of SLC38A2	.	.
DTD0329	SLC38A2	Inhibition	Perfluorooctane sulfonic acid	Health and Environmental Toxicant	.	.	Perfluorooctane sulfonic acid inhibits the expression of SLC38A2	.	.
DTD0329	SLC38A2	Inducer	Progesterone	Approved Drug	.	.	Progesterone increases the expression of SLC38A2	.	.
DTD0329	SLC38A2	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of SLC38A2	.	.
DTD0329	SLC38A2	Inducer	Raloxifene Hydrochloride	Approved Drug	.	.	Raloxifene Hydrochloride increases the expression of SLC38A2	.	.
DTD0329	SLC38A2	Inhibition	Rifampin	Approved Drug	.	.	Rifampin inhibits the expression of SLC38A2	.	.
DTD0329	SLC38A2	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC38A2	.	.
DTD0329	SLC38A2	Inducer	Sulindac	Approved Drug	.	.	Sulindac increases the expression of SLC38A2	.	.
DTD0329	SLC38A2	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of SLC38A2	.	.
DTD0329	SLC38A2	Inducer	Thapsigargin	Natural Product	.	.	Thapsigargin increases the expression of SLC38A2	.	.
DTD0329	SLC38A2	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC38A2	.	.
DTD0329	SLC38A2	Inducer	Toluene	Health and Environmental Toxicant	.	.	Toluene increases the expression of SLC38A2	.	.
DTD0329	SLC38A2	Inducer	Trichloroethylene	Drug in Phase 2 Trial	.	.	Trichloroethylene increases the expression of SLC38A2	.	.
DTD0329	SLC38A2	Inducer	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate increases the expression of SLC38A2	.	.
DTD0329	SLC38A2	Inducer	Urethane	Approved Drug	.	.	Urethane increases the expression of SLC38A2	.	.
DTD0329	SLC38A2	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC38A2	.	.
DTD0329	SLC38A2	Inhibition	Zidovudine	Approved Drug	.	.	Zidovudine inhibits the expression of SLC38A2	.	.
DTD0329	SLC38A2	Inducer	Zinc Acetate	Approved Drug	.	.	Zinc Acetate increases the expression of SLC38A2	.	.
DTD0330	SLC38A3	Modulator	[3H]Glutamine	Investigative Drug	.	.	[3H]Glutamine modulates the activity of SLC38A3	.	.
DTD0330	SLC38A3	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC38A3	.	.
DTD0330	SLC38A3	Inhibition	Acrylamide	Acute Toxic Substance	.	.	Acrylamide inhibits the expression of SLC38A3	.	.
DTD0330	SLC38A3	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC38A3	.	.
DTD0330	SLC38A3	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC38A3	.	.
DTD0330	SLC38A3	Modulator	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A affects the expression of SLC38A3	.	.
DTD0330	SLC38A3	Inducer	Carbamazepine	Approved Drug	.	.	Carbamazepine increases the expression of SLC38A3	.	.
DTD0330	SLC38A3	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the activity of SLC38A3	.	.
DTD0330	SLC38A3	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC38A3	.	.
DTD0330	SLC38A3	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC38A3	.	.
DTD0330	SLC38A3	Inducer	Dexamethasone	Approved Drug	.	.	Dexamethasone induces the activity of SLC38A3	.	.
DTD0330	SLC38A3	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC38A3	.	.
DTD0330	SLC38A3	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the expression of SLC38A3	.	.
DTD0330	SLC38A3	Inhibition	Methyleugenol	Natural Product	.	.	Methyleugenol inhibits the expression of SLC38A3	.	.
DTD0330	SLC38A3	Inhibition	Milchsaure	Investigative Drug	.	.	Milchsaure inhibits the expression of SLC38A3	.	.
DTD0330	SLC38A3	Inhibition	Paclitaxel	Approved Drug	.	.	Paclitaxel inhibits the activity of SLC38A3	.	.
DTD0330	SLC38A3	Inhibition	Propofol	Approved Drug	.	.	Propofol inhibits the expression of SLC38A3	.	.
DTD0330	SLC38A3	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of SLC38A3	.	.
DTD0330	SLC38A3	Inhibition	Rosiglitazone	Approved Drug	.	.	Rosiglitazone inhibits the expression of SLC38A3	.	.
DTD0330	SLC38A3	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC38A3	.	.
DTD0330	SLC38A3	Inhibition	Sulforafan	Drug in Phase 3 Trial	.	.	Sulforafan inhibits the expression of SLC38A3	.	.
DTD0330	SLC38A3	Inhibition	Sunitinib	Approved Drug	.	.	Sunitinib inhibits the expression of SLC38A3	.	.
DTD0330	SLC38A3	Inducer	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate increases the expression of SLC38A3	.	.
DTD0330	SLC38A3	Inhibition	Troglitazone	Approved Drug	.	.	Troglitazone inhibits the expression of SLC38A3	.	.
DTD0330	SLC38A3	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC38A3	.	.
DTD0330	SLC38A3	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of SLC38A3	.	.
DTD0331	SLC38A4	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of SLC38A4	.	.
DTD0331	SLC38A4	Modulator	[3H]Alanine	Investigative Drug	.	.	[3H]Alanine modulates the activity of SLC38A4	.	.
DTD0331	SLC38A4	Inducer	1-methyl-4-phenylpyridinium	Health and Environmental Toxicant	.	.	1-methyl-4-phenylpyridinium increases the expression of SLC38A4	.	.
DTD0331	SLC38A4	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC38A4	.	.
DTD0331	SLC38A4	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC38A4	.	.
DTD0331	SLC38A4	Inducer	Belinostat	Approved Drug	.	.	Belinostat increases the expression of SLC38A4	.	.
DTD0331	SLC38A4	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC38A4	.	.
DTD0331	SLC38A4	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC38A4	.	.
DTD0331	SLC38A4	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC38A4	.	.
DTD0331	SLC38A4	Inhibition	Dicrotophos	Pesticide/Insecticide	.	.	Dicrotophos inhibits the expression of SLC38A4	.	.
DTD0331	SLC38A4	Inducer	Dihydrotestosterone	Drug in Phase 1 Trial	.	.	Dihydrotestosterone increases the expression of SLC38A4	.	.
DTD0331	SLC38A4	Inhibition	Endosulfan	Pesticide/Insecticide	.	.	Endosulfan inhibits the expression of SLC38A4	.	.
DTD0331	SLC38A4	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the expression of SLC38A4	.	.
DTD0331	SLC38A4	Inducer	Folic Acid	Approved Drug	.	.	Folic Acid increases the expression of SLC38A4	.	.
DTD0331	SLC38A4	Inducer	Formaldehyde	Acute Toxic Substance	.	.	Formaldehyde increases the expression of SLC38A4	.	.
DTD0331	SLC38A4	Modulator	Glycine	Investigative Drug	.	.	[14C]Glycine modulates the activity of SLC38A4	.	.
DTD0331	SLC38A4	Inhibition	Kojic acid	Health and Environmental Toxicant	.	.	Kojic acid inhibits the expression of SLC38A4	.	.
DTD0331	SLC38A4	Inhibition	Methyleugenol	Natural Product	.	.	Methyleugenol inhibits the expression of SLC38A4	.	.
DTD0331	SLC38A4	Inducer	Pentanal	Chemical Compound	.	.	Pentanal increases the expression of SLC38A4	.	.
DTD0331	SLC38A4	Inhibition	Perfluorooctane sulfonic acid	Health and Environmental Toxicant	.	.	Perfluorooctane sulfonic acid inhibits the expression of SLC38A4	.	.
DTD0331	SLC38A4	Inhibition	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin inhibits the expression of SLC38A4	.	.
DTD0331	SLC38A4	Inhibition	Progesterone	Approved Drug	.	.	Progesterone inhibits the expression of SLC38A4	.	.
DTD0331	SLC38A4	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of SLC38A4	.	.
DTD0331	SLC38A4	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC38A4	.	.
DTD0331	SLC38A4	Modulator	Testosterone enanthate	Approved Drug	.	.	Testosterone enanthate affects the expression of SLC38A4	.	.
DTD0331	SLC38A4	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC38A4	.	.
DTD0331	SLC38A4	Inhibition	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A inhibits the expression of SLC38A4	.	.
DTD0331	SLC38A4	Inhibition	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan inhibits the expression of SLC38A4	.	.
DTD0331	SLC38A4	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of SLC38A4	.	.
DTD0331	SLC38A4	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC38A4	.	.
DTD0331	SLC38A4	Inhibition	Zidovudine	Approved Drug	.	.	Zidovudine inhibits the expression of SLC38A4	.	.
DTD0332	SLC38A5	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of SLC38A5	.	.
DTD0332	SLC38A5	Modulator	[14C]Histidine	Investigative Drug	.	.	[14C]Histidine modulates the activity of SLC38A5	.	.
DTD0332	SLC38A5	Modulator	[3H]Histidine	Investigative Drug	.	.	[3H]Histidine modulates the activity of SLC38A5	.	.
DTD0332	SLC38A5	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC38A5	.	.
DTD0332	SLC38A5	Inhibition	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A inhibits the expression of SLC38A5	.	.
DTD0332	SLC38A5	Inhibition	Dexamethasone	Approved Drug	.	.	Dexamethasone inhibits the expression of SLC38A5	.	.
DTD0332	SLC38A5	Inhibition	Ethyl Methanesulfonate	Carcinogen	.	.	Ethyl Methanesulfonate inhibits the expression of SLC38A5	.	.
DTD0332	SLC38A5	Inhibition	Formaldehyde	Acute Toxic Substance	.	.	Formaldehyde inhibits the expression of SLC38A5	.	.
DTD0332	SLC38A5	Inhibition	K-7174	Patented Pharmaceutical Agent	.	.	K-7174 inhibits the expression of SLC38A5	.	.
DTD0332	SLC38A5	Inducer	MS-275	Drug in Phase 2 Trial	.	.	MS-275 increases the expression of SLC38A5	.	.
DTD0332	SLC38A5	Inducer	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin increases the expression of SLC38A5	.	.
DTD0332	SLC38A5	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC38A5	.	.
DTD0332	SLC38A5	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC38A5	.	.
DTD0332	SLC38A5	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC38A5	.	.
DTD0332	SLC38A5	Inhibition	Zidovudine	Approved Drug	.	.	Zidovudine inhibits the expression of SLC38A5	.	.
DTD0333	SLC38A6	Inducer	1-methyl-4-phenylpyridinium	Health and Environmental Toxicant	.	.	1-methyl-4-phenylpyridinium increases the expression of SLC38A6	.	.
DTD0333	SLC38A6	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC38A6	.	.
DTD0333	SLC38A6	Inhibition	Aflatoxin M1	Mycotoxins	.	.	Aflatoxin M1 inhibits the expression of SLC38A6	.	.
DTD0333	SLC38A6	Inducer	Arsenic Trioxide	Approved Drug	.	.	Arsenic Trioxide increases the expression of SLC38A6	.	.
DTD0333	SLC38A6	Inducer	Belinostat	Approved Drug	.	.	Belinostat increases the expression of SLC38A6	.	.
DTD0333	SLC38A6	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of SLC38A6	.	.
DTD0333	SLC38A6	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC38A6	.	.
DTD0333	SLC38A6	Inducer	Bortezomib	Approved Drug	.	.	Bortezomib increases the expression of SLC38A6	.	.
DTD0333	SLC38A6	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the expression of SLC38A6	.	.
DTD0333	SLC38A6	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of SLC38A6	.	.
DTD0333	SLC38A6	Inhibition	Dicrotophos	Pesticide/Insecticide	.	.	Dicrotophos inhibits the expression of SLC38A6	.	.
DTD0333	SLC38A6	Inducer	Phenylmercuric Acetate	Investigative Drug	.	.	Phenylmercuric Acetate increases the expression of SLC38A6	.	.
DTD0333	SLC38A6	Modulator	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin affects the expression of SLC38A6	.	.
DTD0333	SLC38A6	Inhibition	Sodium bichromate	Carcinogen	.	.	Sodium bichromate inhibits the expression of SLC38A6	.	.
DTD0333	SLC38A6	Inducer	Sulforafan	Drug in Phase 3 Trial	.	.	Sulforafan increases the expression of SLC38A6	.	.
DTD0333	SLC38A6	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of SLC38A6	.	.
DTD0333	SLC38A6	Inhibition	Temozolomide	Approved Drug	.	.	Temozolomide inhibits the expression of SLC38A6	.	.
DTD0333	SLC38A6	Inhibition	Testosterone	Approved Drug	.	.	Testosterone inhibits the expression of SLC38A6	.	.
DTD0333	SLC38A6	Modulator	Testosterone enanthate	Approved Drug	.	.	Testosterone enanthate affects the expression of SLC38A6	.	.
DTD0333	SLC38A6	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC38A6	.	.
DTD0333	SLC38A6	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC38A6	.	.
DTD0333	SLC38A6	Inducer	Vorinostat	Approved Drug	.	.	Vorinostat increases the expression of SLC38A6	.	.
DTD0333	SLC38A6	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of SLC38A6	.	.
DTD0334	SLC38A7	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC38A7	.	.
DTD0334	SLC38A7	Inhibition	CD-437	Health and Environmental Toxicant	.	.	CD-437 inhibits the expression of SLC38A7	.	.
DTD0334	SLC38A7	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of SLC38A7	.	.
DTD0334	SLC38A7	Inducer	Dicrotophos	Pesticide/Insecticide	.	.	Dicrotophos increases the expression of SLC38A7	.	.
DTD0334	SLC38A7	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC38A7	.	.
DTD0334	SLC38A7	Inducer	Jinfukang	Traditional Medicine	.	.	Jinfukang increases the expression of SLC38A7	.	.
DTD0334	SLC38A7	Inducer	K-7174	Patented Pharmaceutical Agent	.	.	K-7174 increases the expression of SLC38A7	.	.
DTD0334	SLC38A7	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of SLC38A7	.	.
DTD0334	SLC38A7	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC38A7	.	.
DTD0334	SLC38A7	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC38A7	.	.
DTD0335	SLC38A8	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC38A8	.	.
DTD0335	SLC38A8	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the expression of SLC38A8	.	.
DTD0335	SLC38A8	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC38A8	.	.
DTD0336	SLC38A9	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC38A9	.	.
DTD0336	SLC38A9	Inhibition	Atrazine	Herbicide	.	.	Atrazine inhibits the expression of SLC38A9	.	.
DTD0336	SLC38A9	Inhibition	Clothianidin	Pesticide/Insecticide	.	.	Clothianidin inhibits the expression of SLC38A9	.	.
DTD0336	SLC38A9	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC38A9	.	.
DTD0336	SLC38A9	Inhibition	Dicrotophos	Pesticide/Insecticide	.	.	Dicrotophos inhibits the expression of SLC38A9	.	.
DTD0336	SLC38A9	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC38A9	.	.
DTD0336	SLC38A9	Inducer	Ethyl Methanesulfonate	Carcinogen	.	.	Ethyl Methanesulfonate increases the expression of SLC38A9	.	.
DTD0336	SLC38A9	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of SLC38A9	.	.
DTD0336	SLC38A9	Inhibition	Salinomycin	Acute Toxic Substance	.	.	Salinomycin inhibits the expression of SLC38A9	.	.
DTD0336	SLC38A9	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC38A9	.	.
DTD0336	SLC38A9	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of SLC38A9	.	.
DTD0336	SLC38A9	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC38A9	.	.
DTD0336	SLC38A9	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC38A9	.	.
DTD0337	SLC39A1	Inducer	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 increases the expression of SLC39A1	.	.
DTD0337	SLC39A1	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of SLC39A1	.	.
DTD0337	SLC39A1	Inhibition	Cadmium	Acute Toxic Substance	.	.	Cadmium inhibits the expression of SLC39A1	.	.
DTD0337	SLC39A1	Inhibition	Calcitriol	Approved Drug	.	.	Calcitriol inhibits the expression of SLC39A1	.	.
DTD0337	SLC39A1	Inducer	Epigallocatechin gallate	Drug in Phase 3 Trial	.	.	Epigallocatechin gallate increases the expression of SLC39A1	.	.
DTD0337	SLC39A1	Inducer	Grape Seed Proanthocyanidins	Plant Extract	.	.	Grape Seed Proanthocyanidins increases the expression of SLC39A1	.	.
DTD0337	SLC39A1	Inhibition	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 inhibits the expression of SLC39A1	.	.
DTD0337	SLC39A1	Inhibition	Ochratoxin A	Acute Toxic Substance	.	.	Ochratoxin A inhibits the expression of SLC39A1	.	.
DTD0337	SLC39A1	Inhibition	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin inhibits the expression of SLC39A1	.	.
DTD0337	SLC39A1	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC39A1	.	.
DTD0337	SLC39A1	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of SLC39A1	.	.
DTD0337	SLC39A1	Inducer	Vitamin E	Drug in Phase 3 Trial	.	.	Vitamin E increases the expression of SLC39A1	.	.
DTD0337	SLC39A1	Inhibition	Zinc	Environmental toxicant	.	.	Zinc inhibits the expression of SLC39A1	.	.
DTD0337	SLC39A1	Inhibition	Zinc Sulfate	Drug Marketed but not Approved by US FDA	.	.	Zinc Sulfate inhibits the expression of SLC39A1	.	.
DTD0338	SLC39A10	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of SLC39A10	.	.
DTD0338	SLC39A10	Inducer	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 increases the expression of SLC39A10	.	.
DTD0338	SLC39A10	Inhibition	Arsenic Trioxide	Approved Drug	.	.	Arsenic Trioxide inhibits the expression of SLC39A10	.	.
DTD0338	SLC39A10	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of SLC39A10	.	.
DTD0338	SLC39A10	Inhibition	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A inhibits the expression of SLC39A10	.	.
DTD0338	SLC39A10	Inhibition	Calcitriol	Approved Drug	.	.	Calcitriol inhibits the expression of SLC39A10	.	.
DTD0338	SLC39A10	Modulator	Carbamazepine	Approved Drug	.	.	Carbamazepine affects the expression of SLC39A10	.	.
DTD0338	SLC39A10	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the expression of SLC39A10	.	.
DTD0338	SLC39A10	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC39A10	.	.
DTD0338	SLC39A10	Inhibition	Dicrotophos	Pesticide/Insecticide	.	.	Dicrotophos inhibits the expression of SLC39A10	.	.
DTD0338	SLC39A10	Inducer	Dihydrotestosterone	Drug in Phase 1 Trial	.	.	Dihydrotestosterone increases the expression of SLC39A10	.	.
DTD0338	SLC39A10	Inducer	Doxorubicin	Approved Drug	.	.	Doxorubicin increases the expression of SLC39A10	.	.
DTD0338	SLC39A10	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the expression of SLC39A10	.	.
DTD0338	SLC39A10	Inhibition	Ethyl Methanesulfonate	Carcinogen	.	.	Ethyl Methanesulfonate inhibits the expression of SLC39A10	.	.
DTD0338	SLC39A10	Inducer	Gadodiamide	Approved Drug	.	.	Gadodiamide increases the expression of SLC39A10	.	.
DTD0338	SLC39A10	Inducer	Grape Seed Proanthocyanidins	Plant Extract	.	.	Grape Seed Proanthocyanidins increases the expression of SLC39A10	.	.
DTD0338	SLC39A10	Modulator	Hydrogen Peroxide	Approved Drug	.	.	Hydrogen Peroxide affects the expression of SLC39A10	.	.
DTD0338	SLC39A10	Inhibition	Ivermectin	Approved Drug	.	.	Ivermectin inhibits the expression of SLC39A10	.	.
DTD0338	SLC39A10	Inhibition	Jinfukang	Traditional Medicine	.	.	Jinfukang inhibits the expression of SLC39A10	.	.
DTD0338	SLC39A10	Modulator	Motexafin gadolinium	Drug in Phase 2 Trial	.	.	Motexafin gadolinium affects the expression of SLC39A10	.	.
DTD0338	SLC39A10	Inducer	NSC-689534	Patented Pharmaceutical Agent	.	.	NSC-689534 increases the expression of SLC39A10	.	.
DTD0338	SLC39A10	Inhibition	Perfluorooctane sulfonic acid	Health and Environmental Toxicant	.	.	Perfluorooctane sulfonic acid inhibits the expression of SLC39A10	.	.
DTD0338	SLC39A10	Inhibition	Phenylmercuric Acetate	Investigative Drug	.	.	Phenylmercuric Acetate inhibits the expression of SLC39A10	.	.
DTD0338	SLC39A10	Inducer	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin increases the expression of SLC39A10	.	.
DTD0338	SLC39A10	Inducer	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin increases the expression of SLC39A10	.	.
DTD0338	SLC39A10	Inhibition	Silver nanoparticle	Nanoparticle	.	.	Silver nanoparticle inhibits the expression of SLC39A10	.	.
DTD0338	SLC39A10	Inhibition	Temozolomide	Approved Drug	.	.	Temozolomide inhibits the expression of SLC39A10	.	.
DTD0338	SLC39A10	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC39A10	.	.
DTD0338	SLC39A10	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC39A10	.	.
DTD0338	SLC39A10	Inhibition	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate inhibits the expression of SLC39A10	.	.
DTD0338	SLC39A10	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC39A10	.	.
DTD0338	SLC39A10	Inhibition	Zidovudine	Approved Drug	.	.	Zidovudine inhibits the expression of SLC39A10	.	.
DTD0338	SLC39A10	Modulator	Zinc Acetate	Approved Drug	.	.	Zinc Acetate affects the expression of SLC39A10	.	.
DTD0338	SLC39A10	Inhibition	Zoledronic Acid	Approved Drug	.	.	Zoledronic Acid inhibits the expression of SLC39A10	.	.
DTD0339	SLC39A11	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC39A11	.	.
DTD0339	SLC39A11	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC39A11	.	.
DTD0339	SLC39A11	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC39A11	.	.
DTD0339	SLC39A11	Inhibition	Calcitriol	Approved Drug	.	.	Calcitriol inhibits the expression of SLC39A11	.	.
DTD0339	SLC39A11	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the expression of SLC39A11	.	.
DTD0339	SLC39A11	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC39A11	.	.
DTD0339	SLC39A11	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of SLC39A11	.	.
DTD0339	SLC39A11	Inhibition	Formaldehyde	Acute Toxic Substance	.	.	Formaldehyde inhibits the expression of SLC39A11	.	.
DTD0339	SLC39A11	Inhibition	Grape Seed Proanthocyanidins	Plant Extract	.	.	Grape Seed Proanthocyanidins inhibits the expression of SLC39A11	.	.
DTD0339	SLC39A11	Inducer	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 increases the expression of SLC39A11	.	.
DTD0339	SLC39A11	Inducer	Jinfukang	Traditional Medicine	.	.	Jinfukang increases the expression of SLC39A11	.	.
DTD0339	SLC39A11	Inhibition	Methyleugenol	Natural Product	.	.	Methyleugenol inhibits the expression of SLC39A11	.	.
DTD0339	SLC39A11	Inhibition	Milchsaure	Investigative Drug	.	.	Milchsaure inhibits the expression of SLC39A11	.	.
DTD0339	SLC39A11	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of SLC39A11	.	.
DTD0339	SLC39A11	Inducer	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite increases the expression of SLC39A11	.	.
DTD0339	SLC39A11	Inducer	Testosterone	Approved Drug	.	.	Testosterone increases the expression of SLC39A11	.	.
DTD0339	SLC39A11	Inducer	Thapsigargin	Natural Product	.	.	Thapsigargin increases the expression of SLC39A11	.	.
DTD0339	SLC39A11	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC39A11	.	.
DTD0339	SLC39A11	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC39A11	.	.
DTD0339	SLC39A11	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC39A11	.	.
DTD0341	SLC39A13	Inhibition	Acrylamide	Acute Toxic Substance	.	.	Acrylamide inhibits the expression of SLC39A13	.	.
DTD0341	SLC39A13	Inhibition	Arsenic Trioxide	Approved Drug	.	.	Arsenic Trioxide inhibits the expression of SLC39A13	.	.
DTD0341	SLC39A13	Inhibition	Calcitriol	Approved Drug	.	.	Calcitriol inhibits the expression of SLC39A13	.	.
DTD0341	SLC39A13	Modulator	Doxorubicin	Approved Drug	.	.	Doxorubicin affects the expression of SLC39A13	.	.
DTD0341	SLC39A13	Inducer	Grape Seed Proanthocyanidins	Plant Extract	.	.	Grape Seed Proanthocyanidins increases the expression of SLC39A13	.	.
DTD0341	SLC39A13	Inducer	Jinfukang	Traditional Medicine	.	.	Jinfukang increases the expression of SLC39A13	.	.
DTD0341	SLC39A13	Modulator	Menadione	Approved Drug	.	.	Menadione affects the expression of SLC39A13	.	.
DTD0341	SLC39A13	Inducer	Particulate Matter	Natural Product	.	.	Particulate Matter increases the expression of SLC39A13	.	.
DTD0341	SLC39A13	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC39A13	.	.
DTD0342	SLC39A14	Inducer	1-methyl-4-phenylpyridinium	Health and Environmental Toxicant	.	.	1-methyl-4-phenylpyridinium increases the expression of SLC39A14	.	.
DTD0342	SLC39A14	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC39A14	.	.
DTD0342	SLC39A14	Inducer	Acetylcysteine	Approved Drug	.	.	Acetylcysteine increases the expression of SLC39A14	.	.
DTD0342	SLC39A14	Inhibition	Calcitriol	Approved Drug	.	.	Calcitriol inhibits the expression of SLC39A14	.	.
DTD0342	SLC39A14	Inducer	Cannabidiol	Approved Drug	.	.	Cannabidiol increases the expression of SLC39A14	.	.
DTD0342	SLC39A14	Inducer	Cisplatin	Approved Drug	.	.	Cisplatin increases the expression of SLC39A14	.	.
DTD0342	SLC39A14	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC39A14	.	.
DTD0342	SLC39A14	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC39A14	.	.
DTD0342	SLC39A14	Inhibition	Dronabinol	Approved Drug	.	.	Dronabinol inhibits the expression of SLC39A14	.	.
DTD0342	SLC39A14	Inducer	Epigallocatechin gallate	Drug in Phase 3 Trial	.	.	Epigallocatechin gallate increases the expression of SLC39A14	.	.
DTD0342	SLC39A14	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC39A14	.	.
DTD0342	SLC39A14	Inhibition	Grape Seed Proanthocyanidins	Plant Extract	.	.	Grape Seed Proanthocyanidins inhibits the expression of SLC39A14	.	.
DTD0342	SLC39A14	Inducer	Isotretinoin	Approved Drug	.	.	Isotretinoin increases the expression of SLC39A14	.	.
DTD0342	SLC39A14	Modulator	Menadione	Approved Drug	.	.	Menadione affects the expression of SLC39A14	.	.
DTD0342	SLC39A14	Inducer	Motexafin gadolinium	Drug in Phase 2 Trial	.	.	Motexafin gadolinium increases the expression of SLC39A14	.	.
DTD0342	SLC39A14	Inducer	MS-275	Drug in Phase 2 Trial	.	.	MS-275 increases the expression of SLC39A14	.	.
DTD0342	SLC39A14	Inhibition	Particulate Matter	Natural Product	.	.	Particulate Matter inhibits the expression of SLC39A14	.	.
DTD0342	SLC39A14	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of SLC39A14	.	.
DTD0342	SLC39A14	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC39A14	.	.
DTD0342	SLC39A14	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of SLC39A14	.	.
DTD0342	SLC39A14	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC39A14	.	.
DTD0342	SLC39A14	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC39A14	.	.
DTD0342	SLC39A14	Inhibition	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan inhibits the expression of SLC39A14	.	.
DTD0342	SLC39A14	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC39A14	.	.
DTD0342	SLC39A14	Inhibition	Zidovudine	Approved Drug	.	.	Zidovudine inhibits the expression of SLC39A14	.	.
DTD0342	SLC39A14	Inducer	Zinc Acetate	Approved Drug	.	.	Zinc Acetate increases the expression of SLC39A14	.	.
DTD0343	SLC39A2	Inhibition	Calcitriol	Approved Drug	.	.	Calcitriol inhibits the expression of SLC39A2	.	.
DTD0343	SLC39A2	Modulator	Carbamazepine	Approved Drug	.	.	Carbamazepine affects the expression of SLC39A2	.	.
DTD0343	SLC39A2	Inhibition	Cytarabine	Approved Drug	.	.	Cytarabine inhibits the expression of SLC39A2	.	.
DTD0343	SLC39A2	Inhibition	Milchsaure	Investigative Drug	.	.	Milchsaure inhibits the expression of SLC39A2	.	.
DTD0343	SLC39A2	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC39A2	.	.
DTD0343	SLC39A2	Inducer	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan increases the expression of SLC39A2	.	.
DTD0343	SLC39A2	Inducer	Vitamin E	Drug in Phase 3 Trial	.	.	Vitamin E increases the expression of SLC39A2	.	.
DTD0343	SLC39A2	Inducer	Zinc chloride	Drug Marketed but not Approved by US FDA	.	.	Zinc chloride increases the expression of SLC39A2	.	.
DTD0344	SLC39A3	Inhibition	14-deoxy-11,12-didehydroandrographolide	Natural Product	.	.	14-deoxy-11,12-didehydroandrographolide inhibits the expression of SLC39A3	.	.
DTD0344	SLC39A3	Inhibition	Calcitriol	Approved Drug	.	.	Calcitriol inhibits the expression of SLC39A3	.	.
DTD0344	SLC39A3	Inducer	Dronabinol	Approved Drug	.	.	Dronabinol increases the expression of SLC39A3	.	.
DTD0344	SLC39A3	Inhibition	Grape Seed Proanthocyanidins	Plant Extract	.	.	Grape Seed Proanthocyanidins inhibits the expression of SLC39A3	.	.
DTD0344	SLC39A3	Inhibition	Plant Extracts	Plant Extract	.	.	Plant Extracts inhibits the expression of SLC39A3	.	.
DTD0344	SLC39A3	Inducer	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite increases the expression of SLC39A3	.	.
DTD0344	SLC39A3	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of SLC39A3	.	.
DTD0344	SLC39A3	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC39A3	.	.
DTD0344	SLC39A3	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC39A3	.	.
DTD0344	SLC39A3	Inhibition	Zinc	Environmental toxicant	.	.	Zinc inhibits the expression of SLC39A3	.	.
DTD0345	SLC39A4	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of SLC39A4	.	.
DTD0345	SLC39A4	Modulator	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A affects the expression of SLC39A4	.	.
DTD0345	SLC39A4	Inhibition	Calcitriol	Approved Drug	.	.	Calcitriol inhibits the expression of SLC39A4	.	.
DTD0345	SLC39A4	Inducer	Cisplatin	Approved Drug	.	.	Cisplatin increases the expression of SLC39A4	.	.
DTD0345	SLC39A4	Inducer	Coumestrol	Investigative Drug	.	.	Coumestrol increases the expression of SLC39A4	.	.
DTD0345	SLC39A4	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC39A4	.	.
DTD0345	SLC39A4	Inducer	Epigallocatechin gallate	Natural Product	.	.	(-)-Epigallocatechin-3-O-gallate induces the activity of SLC39A4	.	.
DTD0345	SLC39A4	Inhibition	Ethyl Methanesulfonate	Carcinogen	.	.	Ethyl Methanesulfonate inhibits the expression of SLC39A4	.	.
DTD0345	SLC39A4	Inhibition	Formaldehyde	Acute Toxic Substance	.	.	Formaldehyde inhibits the expression of SLC39A4	.	.
DTD0345	SLC39A4	Inducer	Grape Seed Proanthocyanidins	Plant Extract	.	.	Grape Seed Proanthocyanidins increases the expression of SLC39A4	.	.
DTD0345	SLC39A4	Inhibition	GSK-J4	Patented Pharmaceutical Agent	.	.	GSK-J4 inhibits the expression of SLC39A4	.	.
DTD0345	SLC39A4	Modulator	Hydrogen Peroxide	Approved Drug	.	.	Hydrogen Peroxide affects the expression of SLC39A4	.	.
DTD0345	SLC39A4	Inducer	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin increases the expression of SLC39A4	.	.
DTD0345	SLC39A4	Inhibition	Potassium perchlorate	Approved Drug	.	.	Potassium perchlorate inhibits the expression of SLC39A4	.	.
DTD0345	SLC39A4	Inducer	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin increases the expression of SLC39A4	.	.
DTD0345	SLC39A4	Inducer	Rotenone	Drug Marketed but not Approved by US FDA	.	.	Rotenone increases the expression of SLC39A4	.	.
DTD0345	SLC39A4	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC39A4	.	.
DTD0345	SLC39A4	Inhibition	Zinc	Environmental toxicant	.	.	Zinc inhibits the expression of SLC39A4	.	.
DTD0345	SLC39A4	Inhibition	Zinc chloride	Drug Marketed but not Approved by US FDA	.	.	Zinc chloride inhibits the expression of SLC39A4	.	.
DTD0346	SLC39A5	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of SLC39A5	.	.
DTD0346	SLC39A5	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC39A5	.	.
DTD0346	SLC39A5	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC39A5	.	.
DTD0346	SLC39A5	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC39A5	.	.
DTD0346	SLC39A5	Inhibition	Beta-naphthoflavone	Investigative Drug	.	.	Beta-naphthoflavone inhibits the expression of SLC39A5	.	.
DTD0346	SLC39A5	Modulator	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A affects the expression of SLC39A5	.	.
DTD0346	SLC39A5	Inhibition	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde inhibits the expression of SLC39A5	.	.
DTD0346	SLC39A5	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC39A5	.	.
DTD0346	SLC39A5	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC39A5	.	.
DTD0346	SLC39A5	Inhibition	Grape Seed Proanthocyanidins	Plant Extract	.	.	Grape Seed Proanthocyanidins inhibits the expression of SLC39A5	.	.
DTD0346	SLC39A5	Inhibition	Heptanal	Natural Product	.	.	Heptanal inhibits the expression of SLC39A5	.	.
DTD0346	SLC39A5	Inhibition	Methyleugenol	Natural Product	.	.	Methyleugenol inhibits the expression of SLC39A5	.	.
DTD0346	SLC39A5	Inhibition	Octanal	Investigative Drug	.	.	Octanal inhibits the expression of SLC39A5	.	.
DTD0346	SLC39A5	Inhibition	Pentanal	Chemical Compound	.	.	Pentanal inhibits the expression of SLC39A5	.	.
DTD0346	SLC39A5	Modulator	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin affects the expression of SLC39A5	.	.
DTD0346	SLC39A5	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC39A5	.	.
DTD0346	SLC39A5	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC39A5	.	.
DTD0346	SLC39A5	Inhibition	Zinc	Environmental toxicant	.	.	Zinc inhibits the expression of SLC39A5	.	.
DTD0347	SLC39A6	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of SLC39A6	.	.
DTD0347	SLC39A6	Inducer	Acrylamide	Acute Toxic Substance	.	.	Acrylamide increases the expression of SLC39A6	.	.
DTD0347	SLC39A6	Inhibition	Afimoxifene	Drug in Phase 3 Trial	.	.	Afimoxifene inhibits the expression of SLC39A6	.	.
DTD0347	SLC39A6	Inducer	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 increases the expression of SLC39A6	.	.
DTD0347	SLC39A6	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of SLC39A6	.	.
DTD0347	SLC39A6	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC39A6	.	.
DTD0347	SLC39A6	Inhibition	Calcitriol	Approved Drug	.	.	Calcitriol inhibits the expression of SLC39A6	.	.
DTD0347	SLC39A6	Inducer	Copper Sulfate	Approved Drug	.	.	Copper Sulfate increases the expression of SLC39A6	.	.
DTD0347	SLC39A6	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of SLC39A6	.	.
DTD0347	SLC39A6	Inhibition	Dicrotophos	Pesticide/Insecticide	.	.	Dicrotophos inhibits the expression of SLC39A6	.	.
DTD0347	SLC39A6	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC39A6	.	.
DTD0347	SLC39A6	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC39A6	.	.
DTD0347	SLC39A6	Inhibition	Fulvestrant	Approved Drug	.	.	Fulvestrant inhibits the expression of SLC39A6	.	.
DTD0347	SLC39A6	Inhibition	Gallium nitrate	Approved Drug	.	.	Gallium nitrate inhibits the expression of SLC39A6	.	.
DTD0347	SLC39A6	Inducer	Geldanamycin	Drug in Phase 1 Trial	.	.	Geldanamycin increases the expression of SLC39A6	.	.
DTD0347	SLC39A6	Inducer	Grape Seed Proanthocyanidins	Plant Extract	.	.	Grape Seed Proanthocyanidins increases the expression of SLC39A6	.	.
DTD0347	SLC39A6	Inducer	Nicotine polacrilex	Approved Drug	.	.	Nicotine polacrilex increases the expression of SLC39A6	.	.
DTD0347	SLC39A6	Inhibition	Ochratoxin A	Acute Toxic Substance	.	.	Ochratoxin A inhibits the expression of SLC39A6	.	.
DTD0347	SLC39A6	Inhibition	Panobinostat	Approved Drug	.	.	Panobinostat inhibits the expression of SLC39A6	.	.
DTD0347	SLC39A6	Inhibition	Raloxifene Hydrochloride	Approved Drug	.	.	Raloxifene Hydrochloride inhibits the expression of SLC39A6	.	.
DTD0347	SLC39A6	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC39A6	.	.
DTD0347	SLC39A6	Inducer	torcetrapib	Drug in Phase 3 Trial	.	.	torcetrapib increases the expression of SLC39A6	.	.
DTD0347	SLC39A6	Inhibition	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A inhibits the expression of SLC39A6	.	.
DTD0347	SLC39A6	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC39A6	.	.
DTD0348	SLC39A7	Inducer	Atrazine	Herbicide	.	.	Atrazine increases the expression of SLC39A7	.	.
DTD0348	SLC39A7	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC39A7	.	.
DTD0348	SLC39A7	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC39A7	.	.
DTD0348	SLC39A7	Inducer	Bisphenol B	Drug in Phase 2 Trial	.	.	Bisphenol B increases the expression of SLC39A7	.	.
DTD0348	SLC39A7	Inducer	Cannabidiol	Approved Drug	.	.	Cannabidiol increases the expression of SLC39A7	.	.
DTD0348	SLC39A7	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of SLC39A7	.	.
DTD0348	SLC39A7	Inducer	Dihydrotestosterone	Drug in Phase 1 Trial	.	.	Dihydrotestosterone increases the expression of SLC39A7	.	.
DTD0348	SLC39A7	Inhibition	Grape Seed Proanthocyanidins	Plant Extract	.	.	Grape Seed Proanthocyanidins inhibits the expression of SLC39A7	.	.
DTD0348	SLC39A7	Inhibition	NVS-ZP7-4	Investigative Drug	.	.	NVS-ZP7-4 inhibits the activity of SLC39A7	.	.
DTD0348	SLC39A7	Inhibition	Ochratoxin A	Acute Toxic Substance	.	.	Ochratoxin A inhibits the expression of SLC39A7	.	.
DTD0348	SLC39A7	Inducer	Selenium nanoparticles	Natural Product	.	.	Selenium nanoparticles increases the expression of SLC39A7	.	.
DTD0348	SLC39A7	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC39A7	.	.
DTD0348	SLC39A7	Modulator	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A affects the expression of SLC39A7	.	.
DTD0348	SLC39A7	Inhibition	Zinc	Environmental toxicant	.	.	Zinc inhibits the expression of SLC39A7	.	.
DTD0349	SLC39A8	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of SLC39A8	.	.
DTD0349	SLC39A8	Inhibition	Beta-naphthoflavone	Investigative Drug	.	.	Beta-naphthoflavone inhibits the expression of SLC39A8	.	.
DTD0349	SLC39A8	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC39A8	.	.
DTD0349	SLC39A8	Inhibition	Bisphenol B	Drug in Phase 2 Trial	.	.	Bisphenol B inhibits the expression of SLC39A8	.	.
DTD0349	SLC39A8	Inhibition	Cadmium	Acute Toxic Substance	.	.	Cadmium inhibits the expression of SLC39A8	.	.
DTD0349	SLC39A8	Inhibition	Calcitriol	Approved Drug	.	.	Calcitriol inhibits the expression of SLC39A8	.	.
DTD0349	SLC39A8	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC39A8	.	.
DTD0349	SLC39A8	Inducer	Coumestrol	Investigative Drug	.	.	Coumestrol increases the expression of SLC39A8	.	.
DTD0349	SLC39A8	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC39A8	.	.
DTD0349	SLC39A8	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC39A8	.	.
DTD0349	SLC39A8	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC39A8	.	.
DTD0349	SLC39A8	Inducer	Genistein	Drug in Phase 2 Trial	.	.	Genistein increases the expression of SLC39A8	.	.
DTD0349	SLC39A8	Inhibition	Isotretinoin	Approved Drug	.	.	Isotretinoin inhibits the expression of SLC39A8	.	.
DTD0349	SLC39A8	Inhibition	Jinfukang	Traditional Medicine	.	.	Jinfukang inhibits the expression of SLC39A8	.	.
DTD0349	SLC39A8	Inducer	Panobinostat	Approved Drug	.	.	Panobinostat increases the expression of SLC39A8	.	.
DTD0349	SLC39A8	Modulator	Phenobarbital	Approved Drug	.	.	Phenobarbital affects the expression of SLC39A8	.	.
DTD0349	SLC39A8	Inducer	Phenylmercuric Acetate	Investigative Drug	.	.	Phenylmercuric Acetate increases the expression of SLC39A8	.	.
DTD0349	SLC39A8	Inducer	Polychlorinated Biphenyls	Carcinogen	.	.	Polychlorinated Biphenyls increases the expression of SLC39A8	.	.
DTD0349	SLC39A8	Inhibition	Quercitrin	Natural Product	.	.	Quercitrin inhibits the expression of SLC39A8	.	.
DTD0349	SLC39A8	Inhibition	Silver nanoparticle	Nanoparticle	.	.	Silver nanoparticle inhibits the expression of SLC39A8	.	.
DTD0349	SLC39A8	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC39A8	.	.
DTD0349	SLC39A8	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of SLC39A8	.	.
DTD0349	SLC39A8	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC39A8	.	.
DTD0349	SLC39A8	Inducer	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A increases the expression of SLC39A8	.	.
DTD0349	SLC39A8	Inhibition	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan inhibits the expression of SLC39A8	.	.
DTD0349	SLC39A8	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC39A8	.	.
DTD0349	SLC39A8	Inducer	Vorinostat	Approved Drug	.	.	Vorinostat increases the expression of SLC39A8	.	.
DTD0349	SLC39A8	Inducer	Zoledronic Acid	Approved Drug	.	.	Zoledronic Acid increases the expression of SLC39A8	.	.
DTD0350	SLC39A9	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of SLC39A9	.	.
DTD0350	SLC39A9	Inhibition	Calcitriol	Approved Drug	.	.	Calcitriol inhibits the expression of SLC39A9	.	.
DTD0350	SLC39A9	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC39A9	.	.
DTD0350	SLC39A9	Inducer	Grape Seed Proanthocyanidins	Plant Extract	.	.	Grape Seed Proanthocyanidins increases the expression of SLC39A9	.	.
DTD0350	SLC39A9	Modulator	Hydrogen Peroxide	Approved Drug	.	.	Hydrogen Peroxide affects the expression of SLC39A9	.	.
DTD0350	SLC39A9	Inducer	K-7174	Patented Pharmaceutical Agent	.	.	K-7174 increases the expression of SLC39A9	.	.
DTD0350	SLC39A9	Inhibition	Milchsaure	Investigative Drug	.	.	Milchsaure inhibits the expression of SLC39A9	.	.
DTD0350	SLC39A9	Inducer	Motexafin gadolinium	Drug in Phase 2 Trial	.	.	Motexafin gadolinium increases the expression of SLC39A9	.	.
DTD0350	SLC39A9	Inhibition	Ochratoxin A	Acute Toxic Substance	.	.	Ochratoxin A inhibits the expression of SLC39A9	.	.
DTD0350	SLC39A9	Inhibition	Particulate Matter	Natural Product	.	.	Particulate Matter inhibits the expression of SLC39A9	.	.
DTD0350	SLC39A9	Inducer	Theophylline	Approved Drug	.	.	Theophylline increases the expression of SLC39A9	.	.
DTD0350	SLC39A9	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC39A9	.	.
DTD0350	SLC39A9	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of SLC39A9	.	.
DTD0350	SLC39A9	Inhibition	Zinc	Environmental toxicant	.	.	Zinc inhibits the expression of SLC39A9	.	.
DTD0350	SLC39A9	Inducer	Zinc Acetate	Approved Drug	.	.	Zinc Acetate increases the expression of SLC39A9	.	.
DTD0351	SLC3A1	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC3A1	.	.
DTD0351	SLC3A1	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC3A1	.	.
DTD0351	SLC3A1	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC3A1	.	.
DTD0351	SLC3A1	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC3A1	.	.
DTD0351	SLC3A1	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the expression of SLC3A1	.	.
DTD0351	SLC3A1	Inhibition	Ethinyl Estradiol	Approved Drug	.	.	Ethinyl Estradiol inhibits the expression of SLC3A1	.	.
DTD0351	SLC3A1	Modulator	Genistein	Drug in Phase 2 Trial	.	.	Genistein affects the expression of SLC3A1	.	.
DTD0351	SLC3A1	Inducer	Methyleugenol	Natural Product	.	.	Methyleugenol increases the expression of SLC3A1	.	.
DTD0351	SLC3A1	Inhibition	MS-275	Drug in Phase 2 Trial	.	.	MS-275 inhibits the expression of SLC3A1	.	.
DTD0351	SLC3A1	Inhibition	Phenobarbital	Approved Drug	.	.	Phenobarbital inhibits the expression of SLC3A1	.	.
DTD0351	SLC3A1	Inhibition	Phenylmercuric Acetate	Investigative Drug	.	.	Phenylmercuric Acetate inhibits the expression of SLC3A1	.	.
DTD0351	SLC3A1	Inducer	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin increases the expression of SLC3A1	.	.
DTD0351	SLC3A1	Inducer	Progesterone	Approved Drug	.	.	Progesterone increases the expression of SLC3A1	.	.
DTD0351	SLC3A1	Inhibition	Rifampin	Approved Drug	.	.	Rifampin inhibits the expression of SLC3A1	.	.
DTD0351	SLC3A1	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC3A1	.	.
DTD0351	SLC3A1	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC3A1	.	.
DTD0351	SLC3A1	Inhibition	Zoledronic Acid	Approved Drug	.	.	Zoledronic Acid inhibits the expression of SLC3A1	.	.
DTD0352	SLC3A2	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	1-methyl-4-phenylpyridinium	Health and Environmental Toxicant	.	.	1-methyl-4-phenylpyridinium increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Acrylamide	Acute Toxic Substance	.	.	Acrylamide increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Amiodarone	Approved Drug	.	.	Amiodarone increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inhibition	Andrographolide	Drug in Phase 2 Trial	.	.	Andrographolide inhibits the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Antimycin A	Acute Toxic Substance	.	.	Antimycin A increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Arsenic	Approved Drug	.	.	Arsenic increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Arsenic Trioxide	Approved Drug	.	.	Arsenic Trioxide increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Azathioprine	Approved Drug	.	.	Azathioprine increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inhibition	Azoxystrobin	Fungicide	.	.	Azoxystrobin inhibits the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Beta-naphthoflavone	Investigative Drug	.	.	Beta-naphthoflavone increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Bicalutamide	Approved Drug	.	.	Bicalutamide increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Bilirubin	Natural Product	.	.	Bilirubin increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inhibition	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A inhibits the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Bisphenol B	Drug in Phase 2 Trial	.	.	Bisphenol B increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Bisphenol F	Environmental toxicant	.	.	Bisphenol F increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Bosentan	Approved Drug	.	.	Bosentan increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Cadmium	Acute Toxic Substance	.	.	Cadmium increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Modulator	Carbamazepine	Approved Drug	.	.	Carbamazepine affects the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Celecoxib	Approved Drug	.	.	Celecoxib increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Cidofovir	Approved Drug	.	.	Cidofovir increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Cisplatin	Approved Drug	.	.	Cisplatin increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Modulator	Clodronic Acid	Drug Marketed but not Approved by US FDA	.	.	Clodronic Acid affects the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Clozapine	Approved Drug	.	.	Clozapine increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Coal Ash	Natural Product	.	.	Coal Ash increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Copper Sulfate	Approved Drug	.	.	Copper Sulfate increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Curcumin	Drug in Phase 3 Trial	.	.	Curcumin increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Cycloheximide	Acute Toxic Substance	.	.	Cycloheximide increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inhibition	Cyclophosphamide	Approved Drug	.	.	Cyclophosphamide inhibits the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Modulator	Decitabine	Approved Drug	.	.	Decitabine affects the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Deguelin	Natural Product	.	.	Deguelin increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inhibition	Dexamethasone	Approved Drug	.	.	Dexamethasone inhibits the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Diethylstilbestrol	Approved Drug	.	.	Diethylstilbestrol increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inhibition	Dronabinol	Approved Drug	.	.	Dronabinol inhibits the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Ethinyl Estradiol	Approved Drug	.	.	Ethinyl Estradiol increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Ethyl Methanesulfonate	Carcinogen	.	.	Ethyl Methanesulfonate increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Fenofibrate	Approved Drug	.	.	Fenofibrate increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Fenretinide	Drug in Phase 3 Trial	.	.	Fenretinide increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Fluorouracil	Approved Drug	.	.	Fluorouracil increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Formaldehyde	Acute Toxic Substance	.	.	Formaldehyde increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Gamolenic acid	Drug Marketed but not Approved by US FDA	.	.	Gamolenic acid increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Gedunin	Natural Product	.	.	Gedunin increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Genistein	Drug in Phase 2 Trial	.	.	Genistein increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	GSK-J4	Patented Pharmaceutical Agent	.	.	GSK-J4 increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Ibuprofen	Approved Drug	.	.	Ibuprofen increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Ifosfamide	Approved Drug	.	.	Ifosfamide increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Indomethacin	Approved Drug	.	.	Indomethacin increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inhibition	Ivermectin	Approved Drug	.	.	Ivermectin inhibits the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	K-7174	Patented Pharmaceutical Agent	.	.	K-7174 increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Leflunomide	Approved Drug	.	.	Leflunomide increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Lindane	Approved Drug	.	.	Lindane increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Lithium Chloride	Health and Environmental Toxicant	.	.	Lithium Chloride increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Methyleugenol	Natural Product	.	.	Methyleugenol increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Methylparaben	Natural Product	.	.	Methylparaben increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Motexafin gadolinium	Drug in Phase 2 Trial	.	.	Motexafin gadolinium increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	MS-275	Drug in Phase 2 Trial	.	.	MS-275 increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	NSC-305787	Investigative Drug	.	.	NSC-305787 increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	NSC-668394	Patented Pharmaceutical Agent	.	.	NSC-668394 increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Paraquat	Acute Toxic Substance	.	.	Paraquat increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Particulate Matter	Natural Product	.	.	Particulate Matter increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Perfluorooctane sulfonic acid	Health and Environmental Toxicant	.	.	Perfluorooctane sulfonic acid increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Phenobarbital	Approved Drug	.	.	Phenobarbital increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Phenylmercuric Acetate	Investigative Drug	.	.	Phenylmercuric Acetate increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inhibition	Piroxicam	Approved Drug	.	.	Piroxicam inhibits the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Raloxifene Hydrochloride	Approved Drug	.	.	Raloxifene Hydrochloride increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Rosiglitazone	Approved Drug	.	.	Rosiglitazone increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inhibition	Rotenone	Drug Marketed but not Approved by US FDA	.	.	Rotenone inhibits the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Selenium nanoparticles	Natural Product	.	.	Selenium nanoparticles increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Silver nanoparticle	Nanoparticle	.	.	Silver nanoparticle increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inhibition	Sulforafan	Drug in Phase 3 Trial	.	.	Sulforafan inhibits the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Sulindac	Approved Drug	.	.	Sulindac increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Sulindac sulfide	Drug in Phase 2 Trial	.	.	Sulindac sulfide increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Tamoxifen	Approved Drug	.	.	Tamoxifen increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Temozolomide	Approved Drug	.	.	Temozolomide increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Thapsigargin	Natural Product	.	.	Thapsigargin increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Tripterine	Drug in Preclinical Test	.	.	Tripterine increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Troglitazone	Approved Drug	.	.	Troglitazone increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Tungsten	Chemical Compound	.	.	Tungsten increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inducer	Zinc Acetate	Approved Drug	.	.	Zinc Acetate increases the expression of SLC3A2	.	.
DTD0352	SLC3A2	Inhibition	Zoledronic Acid	Approved Drug	.	.	Zoledronic Acid inhibits the expression of SLC3A2	.	.
DTD0353	SLC40A1	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC40A1	.	.
DTD0353	SLC40A1	Inducer	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 increases the expression of SLC40A1	.	.
DTD0353	SLC40A1	Inducer	Arsenic Trioxide	Approved Drug	.	.	Arsenic Trioxide increases the expression of SLC40A1	.	.
DTD0353	SLC40A1	Inducer	Azathioprine	Approved Drug	.	.	Azathioprine increases the expression of SLC40A1	.	.
DTD0353	SLC40A1	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of SLC40A1	.	.
DTD0353	SLC40A1	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC40A1	.	.
DTD0353	SLC40A1	Inducer	Chlorpyrifos	Acute Toxic Substance	.	.	Chlorpyrifos increases the expression of SLC40A1	.	.
DTD0353	SLC40A1	Inhibition	Copper	Approved Drug	.	.	Copper inhibits the expression of SLC40A1	.	.
DTD0353	SLC40A1	Inducer	Copper Sulfate	Approved Drug	.	.	Copper Sulfate increases the expression of SLC40A1	.	.
DTD0353	SLC40A1	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC40A1	.	.
DTD0353	SLC40A1	Inhibition	Cytarabine	Approved Drug	.	.	Cytarabine inhibits the expression of SLC40A1	.	.
DTD0353	SLC40A1	Inducer	Dasatinib	Approved Drug	.	.	Dasatinib increases the expression of SLC40A1	.	.
DTD0353	SLC40A1	Inducer	Dexamethasone	Approved Drug	.	.	Dexamethasone increases the expression of SLC40A1	.	.
DTD0353	SLC40A1	Inhibition	Dicrotophos	Pesticide/Insecticide	.	.	Dicrotophos inhibits the expression of SLC40A1	.	.
DTD0353	SLC40A1	Inducer	Dietary Carbohydrates	Natural Product	.	.	Dietary Carbohydrates increases the expression of SLC40A1	.	.
DTD0353	SLC40A1	Inducer	Diethylhexyl Phthalate	Health and Environmental Toxicant	.	.	Diethylhexyl Phthalate increases the expression of SLC40A1	.	.
DTD0353	SLC40A1	Inducer	Doxorubicin	Approved Drug	.	.	Doxorubicin increases the expression of SLC40A1	.	.
DTD0353	SLC40A1	Inducer	Erastin	Patented Pharmaceutical Agent	.	.	Erastin increases the expression of SLC40A1	.	.
DTD0353	SLC40A1	Inducer	Ethanol	Drug in Phase 2 Trial	.	.	Ethanol increases the expression of SLC40A1	.	.
DTD0353	SLC40A1	Modulator	Ethinyl Estradiol	Approved Drug	.	.	Ethinyl Estradiol affects the expression of SLC40A1	.	.
DTD0353	SLC40A1	Modulator	Folic Acid	Approved Drug	.	.	Folic Acid affects the expression of SLC40A1	.	.
DTD0353	SLC40A1	Inhibition	Gallium nitrate	Approved Drug	.	.	Gallium nitrate inhibits the expression of SLC40A1	.	.
DTD0353	SLC40A1	Modulator	LY2928057	Drug in Phase 1 Trial	.	.	LY2928057 modulates the activity of SLC40A1	.	.
DTD0353	SLC40A1	Inducer	Panobinostat	Approved Drug	.	.	Panobinostat increases the expression of SLC40A1	.	.
DTD0353	SLC40A1	Inhibition	Particulate Matter	Natural Product	.	.	Particulate Matter inhibits the expression of SLC40A1	.	.
DTD0353	SLC40A1	Inducer	Phenylmercuric Acetate	Investigative Drug	.	.	Phenylmercuric Acetate increases the expression of SLC40A1	.	.
DTD0353	SLC40A1	Modulator	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin affects the expression of SLC40A1	.	.
DTD0353	SLC40A1	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of SLC40A1	.	.
DTD0353	SLC40A1	Inducer	Silver nanoparticle	Nanoparticle	.	.	Silver nanoparticle increases the expression of SLC40A1	.	.
DTD0353	SLC40A1	Inducer	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite increases the expression of SLC40A1	.	.
DTD0353	SLC40A1	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC40A1	.	.
DTD0353	SLC40A1	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of SLC40A1	.	.
DTD0353	SLC40A1	Inducer	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A increases the expression of SLC40A1	.	.
DTD0353	SLC40A1	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC40A1	.	.
DTD0353	SLC40A1	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of SLC40A1	.	.
DTD0353	SLC40A1	Inducer	Zoledronic Acid	Approved Drug	.	.	Zoledronic Acid increases the expression of SLC40A1	.	.
DTD0354	SLC41A1	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of SLC41A1	.	.
DTD0354	SLC41A1	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of SLC41A1	.	.
DTD0354	SLC41A1	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC41A1	.	.
DTD0354	SLC41A1	Inducer	Calcitriol	Approved Drug	.	.	Calcitriol increases the expression of SLC41A1	.	.
DTD0354	SLC41A1	Inducer	Cisplatin	Approved Drug	.	.	Cisplatin increases the expression of SLC41A1	.	.
DTD0354	SLC41A1	Inducer	Dihydrotestosterone	Drug in Phase 1 Trial	.	.	Dihydrotestosterone increases the expression of SLC41A1	.	.
DTD0354	SLC41A1	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC41A1	.	.
DTD0354	SLC41A1	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC41A1	.	.
DTD0354	SLC41A1	Modulator	Lead	Health and Environmental Toxicant	.	.	Lead affects the expression of SLC41A1	.	.
DTD0354	SLC41A1	Inhibition	Milchsaure	Investigative Drug	.	.	Milchsaure inhibits the expression of SLC41A1	.	.
DTD0354	SLC41A1	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of SLC41A1	.	.
DTD0354	SLC41A1	Inhibition	Sunitinib	Approved Drug	.	.	Sunitinib inhibits the expression of SLC41A1	.	.
DTD0354	SLC41A1	Inducer	Testosterone	Approved Drug	.	.	Testosterone increases the expression of SLC41A1	.	.
DTD0354	SLC41A1	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC41A1	.	.
DTD0354	SLC41A1	Inhibition	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan inhibits the expression of SLC41A1	.	.
DTD0354	SLC41A1	Modulator	Valproic Acid	Approved Drug	.	.	Valproic Acid affects the expression of SLC41A1	.	.
DTD0355	SLC41A2	Inducer	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 increases the expression of SLC41A2	.	.
DTD0355	SLC41A2	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of SLC41A2	.	.
DTD0355	SLC41A2	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC41A2	.	.
DTD0355	SLC41A2	Inhibition	Aflatoxin M1	Mycotoxins	.	.	Aflatoxin M1 inhibits the expression of SLC41A2	.	.
DTD0355	SLC41A2	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC41A2	.	.
DTD0355	SLC41A2	Inducer	Calcitriol	Approved Drug	.	.	Calcitriol increases the expression of SLC41A2	.	.
DTD0355	SLC41A2	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of SLC41A2	.	.
DTD0355	SLC41A2	Modulator	DMU-212	Patented Pharmaceutical Agent	.	.	DMU-212 affects the expression of SLC41A2	.	.
DTD0355	SLC41A2	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC41A2	.	.
DTD0355	SLC41A2	Inhibition	Jinfukang	Traditional Medicine	.	.	Jinfukang inhibits the expression of SLC41A2	.	.
DTD0355	SLC41A2	Modulator	Lead	Health and Environmental Toxicant	.	.	Lead affects the expression of SLC41A2	.	.
DTD0355	SLC41A2	Inducer	MS-275	Drug in Phase 2 Trial	.	.	MS-275 increases the expression of SLC41A2	.	.
DTD0355	SLC41A2	Modulator	Phenobarbital	Approved Drug	.	.	Phenobarbital affects the expression of SLC41A2	.	.
DTD0355	SLC41A2	Inducer	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin increases the expression of SLC41A2	.	.
DTD0355	SLC41A2	Inducer	Progesterone	Approved Drug	.	.	Progesterone increases the expression of SLC41A2	.	.
DTD0355	SLC41A2	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of SLC41A2	.	.
DTD0355	SLC41A2	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC41A2	.	.
DTD0355	SLC41A2	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of SLC41A2	.	.
DTD0355	SLC41A2	Inducer	Testosterone	Approved Drug	.	.	Testosterone increases the expression of SLC41A2	.	.
DTD0355	SLC41A2	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of SLC41A2	.	.
DTD0355	SLC41A2	Inducer	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A increases the expression of SLC41A2	.	.
DTD0355	SLC41A2	Inducer	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate increases the expression of SLC41A2	.	.
DTD0355	SLC41A2	Inducer	Urethane	Approved Drug	.	.	Urethane increases the expression of SLC41A2	.	.
DTD0355	SLC41A2	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC41A2	.	.
DTD0356	SLC41A3	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of SLC41A3	.	.
DTD0356	SLC41A3	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC41A3	.	.
DTD0356	SLC41A3	Inhibition	Arsenic Trioxide	Approved Drug	.	.	Arsenic Trioxide inhibits the expression of SLC41A3	.	.
DTD0356	SLC41A3	Inhibition	Potassium perchlorate	Approved Drug	.	.	Potassium perchlorate inhibits the expression of SLC41A3	.	.
DTD0356	SLC41A3	Inhibition	Resveratrol	Drug in Phase 3 Trial	.	.	Resveratrol inhibits the expression of SLC41A3	.	.
DTD0356	SLC41A3	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of SLC41A3	.	.
DTD0356	SLC41A3	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC41A3	.	.
DTD0358	SLC42A2	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC42A2	.	.
DTD0358	SLC42A2	Modulator	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A affects the expression of SLC42A2	.	.
DTD0358	SLC42A2	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC42A2	.	.
DTD0358	SLC42A2	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC42A2	.	.
DTD0358	SLC42A2	Modulator	Hydrogen Peroxide	Approved Drug	.	.	Hydrogen Peroxide affects the expression of SLC42A2	.	.
DTD0358	SLC42A2	Inhibition	K-7174	Patented Pharmaceutical Agent	.	.	K-7174 inhibits the expression of SLC42A2	.	.
DTD0358	SLC42A2	Modulator	Menadione	Approved Drug	.	.	Menadione affects the expression of SLC42A2	.	.
DTD0358	SLC42A2	Inhibition	Methyleugenol	Natural Product	.	.	Methyleugenol inhibits the expression of SLC42A2	.	.
DTD0358	SLC42A2	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of SLC42A2	.	.
DTD0358	SLC42A2	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC42A2	.	.
DTD0358	SLC42A2	Inducer	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan increases the expression of SLC42A2	.	.
DTD0358	SLC42A2	Inhibition	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate inhibits the expression of SLC42A2	.	.
DTD0359	SLC42A3	Modulator	[14C]Methylamine	Investigative Drug	.	.	[14C]Methylamine modulates the activity of SLC42A3	.	.
DTD0359	SLC42A3	Inhibition	Acrylamide	Acute Toxic Substance	.	.	Acrylamide inhibits the expression of SLC42A3	.	.
DTD0359	SLC42A3	Inhibition	BRN-3548355	Investigative Drug	.	.	BRN-3548355 inhibits the expression of SLC42A3	.	.
DTD0359	SLC42A3	Inducer	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde increases the expression of SLC42A3	.	.
DTD0359	SLC42A3	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of SLC42A3	.	.
DTD0359	SLC42A3	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC42A3	.	.
DTD0359	SLC42A3	Inducer	Hydroquinone	Approved Drug	.	.	Hydroquinone increases the expression of SLC42A3	.	.
DTD0359	SLC42A3	Inducer	Jinfukang	Traditional Medicine	.	.	Jinfukang increases the expression of SLC42A3	.	.
DTD0359	SLC42A3	Inhibition	Milchsaure	Investigative Drug	.	.	Milchsaure inhibits the expression of SLC42A3	.	.
DTD0359	SLC42A3	Inducer	Particulate Matter	Natural Product	.	.	Particulate Matter increases the expression of SLC42A3	.	.
DTD0359	SLC42A3	Inducer	Pentanal	Chemical Compound	.	.	Pentanal increases the expression of SLC42A3	.	.
DTD0359	SLC42A3	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC42A3	.	.
DTD0359	SLC42A3	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC42A3	.	.
DTD0359	SLC42A3	Inducer	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate increases the expression of SLC42A3	.	.
DTD0360	SLC43A1	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of SLC43A1	.	.
DTD0360	SLC43A1	Inducer	2,3-dibromopropyl-2,4,6-tribromophenyl ether	Environmental toxicant	.	.	2,3-dibromopropyl-2,4,6-tribromophenyl ether increases the expression of SLC43A1	.	.
DTD0360	SLC43A1	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC43A1	.	.
DTD0360	SLC43A1	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC43A1	.	.
DTD0360	SLC43A1	Inducer	Arsenic Trioxide	Approved Drug	.	.	Arsenic Trioxide increases the expression of SLC43A1	.	.
DTD0360	SLC43A1	Inducer	Belinostat	Approved Drug	.	.	Belinostat increases the expression of SLC43A1	.	.
DTD0360	SLC43A1	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC43A1	.	.
DTD0360	SLC43A1	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC43A1	.	.
DTD0360	SLC43A1	Inducer	Calcitriol	Approved Drug	.	.	Calcitriol increases the expression of SLC43A1	.	.
DTD0360	SLC43A1	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the expression of SLC43A1	.	.
DTD0360	SLC43A1	Inhibition	Cyclophosphamide	Approved Drug	.	.	Cyclophosphamide inhibits the expression of SLC43A1	.	.
DTD0360	SLC43A1	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of SLC43A1	.	.
DTD0360	SLC43A1	Inducer	Dihydrotestosterone	Drug in Phase 1 Trial	.	.	Dihydrotestosterone increases the expression of SLC43A1	.	.
DTD0360	SLC43A1	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC43A1	.	.
DTD0360	SLC43A1	Inducer	Metribolone	Investigative Drug	.	.	Metribolone increases the expression of SLC43A1	.	.
DTD0360	SLC43A1	Inhibition	Mifepristone	Approved Drug	.	.	Mifepristone inhibits the expression of SLC43A1	.	.
DTD0360	SLC43A1	Inducer	Motexafin gadolinium	Drug in Phase 2 Trial	.	.	Motexafin gadolinium increases the expression of SLC43A1	.	.
DTD0360	SLC43A1	Inducer	MS-275	Drug in Phase 2 Trial	.	.	MS-275 increases the expression of SLC43A1	.	.
DTD0360	SLC43A1	Inhibition	Ochratoxin A	Acute Toxic Substance	.	.	Ochratoxin A inhibits the expression of SLC43A1	.	.
DTD0360	SLC43A1	Inducer	Panobinostat	Approved Drug	.	.	Panobinostat increases the expression of SLC43A1	.	.
DTD0360	SLC43A1	Inhibition	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin inhibits the expression of SLC43A1	.	.
DTD0360	SLC43A1	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC43A1	.	.
DTD0360	SLC43A1	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of SLC43A1	.	.
DTD0360	SLC43A1	Inhibition	Testosterone	Approved Drug	.	.	Testosterone inhibits the expression of SLC43A1	.	.
DTD0360	SLC43A1	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC43A1	.	.
DTD0360	SLC43A1	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC43A1	.	.
DTD0360	SLC43A1	Inducer	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A increases the expression of SLC43A1	.	.
DTD0360	SLC43A1	Inducer	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate increases the expression of SLC43A1	.	.
DTD0360	SLC43A1	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC43A1	.	.
DTD0360	SLC43A1	Inducer	Zinc Acetate	Approved Drug	.	.	Zinc Acetate increases the expression of SLC43A1	.	.
DTD0361	SLC43A2	Inducer	2,3-dibromopropyl-2,4,6-tribromophenyl ether	Environmental toxicant	.	.	2,3-dibromopropyl-2,4,6-tribromophenyl ether increases the expression of SLC43A2	.	.
DTD0361	SLC43A2	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC43A2	.	.
DTD0361	SLC43A2	Inducer	Acrylamide	Acute Toxic Substance	.	.	Acrylamide increases the expression of SLC43A2	.	.
DTD0361	SLC43A2	Inducer	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 increases the expression of SLC43A2	.	.
DTD0361	SLC43A2	Inhibition	Atrazine	Herbicide	.	.	Atrazine inhibits the expression of SLC43A2	.	.
DTD0361	SLC43A2	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of SLC43A2	.	.
DTD0361	SLC43A2	Inhibition	Beta-naphthoflavone	Investigative Drug	.	.	Beta-naphthoflavone inhibits the expression of SLC43A2	.	.
DTD0361	SLC43A2	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC43A2	.	.
DTD0361	SLC43A2	Inducer	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde increases the expression of SLC43A2	.	.
DTD0361	SLC43A2	Inducer	Cisplatin	Approved Drug	.	.	Cisplatin increases the expression of SLC43A2	.	.
DTD0361	SLC43A2	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC43A2	.	.
DTD0361	SLC43A2	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC43A2	.	.
DTD0361	SLC43A2	Inducer	Diethylhexyl Phthalate	Health and Environmental Toxicant	.	.	Diethylhexyl Phthalate increases the expression of SLC43A2	.	.
DTD0361	SLC43A2	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC43A2	.	.
DTD0361	SLC43A2	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the expression of SLC43A2	.	.
DTD0361	SLC43A2	Inducer	Ethanol	Drug in Phase 2 Trial	.	.	Ethanol increases the expression of SLC43A2	.	.
DTD0361	SLC43A2	Inducer	GSK-J4	Patented Pharmaceutical Agent	.	.	GSK-J4 increases the expression of SLC43A2	.	.
DTD0361	SLC43A2	Inducer	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 increases the expression of SLC43A2	.	.
DTD0361	SLC43A2	Inducer	Jinfukang	Traditional Medicine	.	.	Jinfukang increases the expression of SLC43A2	.	.
DTD0361	SLC43A2	Inducer	Leflunomide	Approved Drug	.	.	Leflunomide increases the expression of SLC43A2	.	.
DTD0361	SLC43A2	Inhibition	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin inhibits the expression of SLC43A2	.	.
DTD0361	SLC43A2	Inhibition	Sunitinib	Approved Drug	.	.	Sunitinib inhibits the expression of SLC43A2	.	.
DTD0361	SLC43A2	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC43A2	.	.
DTD0361	SLC43A2	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of SLC43A2	.	.
DTD0361	SLC43A2	Inducer	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate increases the expression of SLC43A2	.	.
DTD0361	SLC43A2	Inducer	Urethane	Approved Drug	.	.	Urethane increases the expression of SLC43A2	.	.
DTD0362	SLC43A3	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of SLC43A3	.	.
DTD0362	SLC43A3	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC43A3	.	.
DTD0362	SLC43A3	Inhibition	Acrylamide	Acute Toxic Substance	.	.	Acrylamide inhibits the expression of SLC43A3	.	.
DTD0362	SLC43A3	Inducer	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 increases the expression of SLC43A3	.	.
DTD0362	SLC43A3	Inhibition	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A inhibits the expression of SLC43A3	.	.
DTD0362	SLC43A3	Inhibition	Bortezomib	Approved Drug	.	.	Bortezomib inhibits the expression of SLC43A3	.	.
DTD0362	SLC43A3	Inducer	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde increases the expression of SLC43A3	.	.
DTD0362	SLC43A3	Inhibition	Calcitriol	Approved Drug	.	.	Calcitriol inhibits the expression of SLC43A3	.	.
DTD0362	SLC43A3	Inducer	Copper Sulfate	Approved Drug	.	.	Copper Sulfate increases the expression of SLC43A3	.	.
DTD0362	SLC43A3	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC43A3	.	.
DTD0362	SLC43A3	Inducer	Cytarabine	Approved Drug	.	.	Cytarabine increases the expression of SLC43A3	.	.
DTD0362	SLC43A3	Inducer	Decitabine	Approved Drug	.	.	Decitabine increases the expression of SLC43A3	.	.
DTD0362	SLC43A3	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC43A3	.	.
DTD0362	SLC43A3	Inhibition	Erlotinib	Approved Drug	.	.	Erlotinib inhibits the activity of SLC43A3	.	.
DTD0362	SLC43A3	Inhibition	Gefitinib	Approved Drug	.	.	Gefitinib inhibits the activity of SLC43A3	.	.
DTD0362	SLC43A3	Inhibition	Gemcitabine	Approved Drug	.	.	Gemcitabine inhibits the expression of SLC43A3	.	.
DTD0362	SLC43A3	Inducer	GSK-J4	Patented Pharmaceutical Agent	.	.	GSK-J4 increases the expression of SLC43A3	.	.
DTD0362	SLC43A3	Inhibition	Imatinib	Approved Drug	.	.	Imatinib inhibits the activity of SLC43A3	.	.
DTD0362	SLC43A3	Inhibition	Methylprednisolone	Approved Drug	.	.	Methylprednisolone inhibits the expression of SLC43A3	.	.
DTD0362	SLC43A3	Inducer	MS-275	Drug in Phase 2 Trial	.	.	MS-275 increases the expression of SLC43A3	.	.
DTD0362	SLC43A3	Inducer	Particulate Matter	Natural Product	.	.	Particulate Matter increases the expression of SLC43A3	.	.
DTD0362	SLC43A3	Inducer	Pentanal	Chemical Compound	.	.	Pentanal increases the expression of SLC43A3	.	.
DTD0362	SLC43A3	Inhibition	Prednisolone	Approved Drug	.	.	Prednisolone inhibits the expression of SLC43A3	.	.
DTD0362	SLC43A3	Modulator	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite affects the expression of SLC43A3	.	.
DTD0362	SLC43A3	Inhibition	Sorafenib	Approved Drug	.	.	Sorafenib inhibits the activity of SLC43A3	.	.
DTD0362	SLC43A3	Inhibition	Sunitinib	Approved Drug	.	.	Sunitinib inhibits the activity of SLC43A3	.	.
DTD0362	SLC43A3	Inhibition	Temozolomide	Approved Drug	.	.	Temozolomide inhibits the expression of SLC43A3	.	.
DTD0362	SLC43A3	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC43A3	.	.
DTD0362	SLC43A3	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC43A3	.	.
DTD0362	SLC43A3	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC43A3	.	.
DTD0362	SLC43A3	Inhibition	Vandetanib	Approved Drug	.	.	Vandetanib inhibits the activity of SLC43A3	.	.
DTD0363	SLC44A1	Inducer	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 increases the expression of SLC44A1	.	.
DTD0363	SLC44A1	Inhibition	Arsenic Trioxide	Approved Drug	.	.	Arsenic Trioxide inhibits the expression of SLC44A1	.	.
DTD0363	SLC44A1	Inducer	Atrazine	Herbicide	.	.	Atrazine increases the expression of SLC44A1	.	.
DTD0363	SLC44A1	Inhibition	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A inhibits the expression of SLC44A1	.	.
DTD0363	SLC44A1	Inhibition	Calcitriol	Approved Drug	.	.	Calcitriol inhibits the expression of SLC44A1	.	.
DTD0363	SLC44A1	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC44A1	.	.
DTD0363	SLC44A1	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC44A1	.	.
DTD0363	SLC44A1	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC44A1	.	.
DTD0363	SLC44A1	Inducer	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin increases the expression of SLC44A1	.	.
DTD0363	SLC44A1	Inhibition	Testosterone	Approved Drug	.	.	Testosterone inhibits the expression of SLC44A1	.	.
DTD0363	SLC44A1	Inducer	Tetrabromobisphenol A	Environmental toxicant	.	.	Tetrabromobisphenol A increases the expression of SLC44A1	.	.
DTD0363	SLC44A1	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of SLC44A1	.	.
DTD0363	SLC44A1	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC44A1	.	.
DTD0364	SLC44A2	Modulator	Arsenic	Approved Drug	.	.	Arsenic affects the expression of SLC44A2	.	.
DTD0364	SLC44A2	Inhibition	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A inhibits the expression of SLC44A2	.	.
DTD0364	SLC44A2	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC44A2	.	.
DTD0364	SLC44A2	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC44A2	.	.
DTD0364	SLC44A2	Modulator	Doxorubicin	Approved Drug	.	.	Doxorubicin affects the expression of SLC44A2	.	.
DTD0364	SLC44A2	Inducer	Ethanol	Approved Drug	.	.	Ethanol induces the activity of SLC44A2	.	.
DTD0364	SLC44A2	Inducer	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 increases the expression of SLC44A2	.	.
DTD0364	SLC44A2	Inducer	Jinfukang	Traditional Medicine	.	.	Jinfukang increases the expression of SLC44A2	.	.
DTD0364	SLC44A2	Inducer	Leflunomide	Approved Drug	.	.	Leflunomide increases the expression of SLC44A2	.	.
DTD0364	SLC44A2	Inducer	Methyleugenol	Natural Product	.	.	Methyleugenol increases the expression of SLC44A2	.	.
DTD0364	SLC44A2	Inhibition	Milchsaure	Investigative Drug	.	.	Milchsaure inhibits the expression of SLC44A2	.	.
DTD0364	SLC44A2	Inhibition	Resorcinol	Environmental toxicant	.	.	Resorcinol inhibits the expression of SLC44A2	.	.
DTD0364	SLC44A2	Inducer	Tetrabromobisphenol A	Environmental toxicant	.	.	Tetrabromobisphenol A increases the expression of SLC44A2	.	.
DTD0364	SLC44A2	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC44A2	.	.
DTD0364	SLC44A2	Inducer	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate increases the expression of SLC44A2	.	.
DTD0364	SLC44A2	Inducer	Urethane	Approved Drug	.	.	Urethane increases the expression of SLC44A2	.	.
DTD0364	SLC44A2	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC44A2	.	.
DTD0364	SLC44A2	Inhibition	Zoledronic Acid	Approved Drug	.	.	Zoledronic Acid inhibits the expression of SLC44A2	.	.
DTD0366	SLC44A4	Inhibition	Cadmium	Acute Toxic Substance	.	.	Cadmium inhibits the expression of SLC44A4	.	.
DTD0366	SLC44A4	Inducer	Calcitriol	Approved Drug	.	.	Calcitriol increases the expression of SLC44A4	.	.
DTD0366	SLC44A4	Inducer	Chloropicrin	Acute Toxic Substance	.	.	Chloropicrin increases the expression of SLC44A4	.	.
DTD0366	SLC44A4	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC44A4	.	.
DTD0366	SLC44A4	Modulator	Hydrogen Peroxide	Approved Drug	.	.	Hydrogen Peroxide affects the expression of SLC44A4	.	.
DTD0366	SLC44A4	Inducer	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 increases the expression of SLC44A4	.	.
DTD0366	SLC44A4	Modulator	Menadione	Approved Drug	.	.	Menadione affects the expression of SLC44A4	.	.
DTD0366	SLC44A4	Inducer	Selenium nanoparticles	Natural Product	.	.	Selenium nanoparticles increases the expression of SLC44A4	.	.
DTD0366	SLC44A4	Inducer	Testosterone	Approved Drug	.	.	Testosterone increases the expression of SLC44A4	.	.
DTD0366	SLC44A4	Modulator	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution affects the expression of SLC44A4	.	.
DTD0366	SLC44A4	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of SLC44A4	.	.
DTD0367	SLC44A5	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of SLC44A5	.	.
DTD0367	SLC44A5	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC44A5	.	.
DTD0367	SLC44A5	Inducer	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 increases the expression of SLC44A5	.	.
DTD0367	SLC44A5	Inhibition	Aflatoxin M1	Mycotoxins	.	.	Aflatoxin M1 inhibits the expression of SLC44A5	.	.
DTD0367	SLC44A5	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of SLC44A5	.	.
DTD0367	SLC44A5	Inducer	Calcitriol	Approved Drug	.	.	Calcitriol increases the expression of SLC44A5	.	.
DTD0367	SLC44A5	Inducer	Cisplatin	Approved Drug	.	.	Cisplatin increases the expression of SLC44A5	.	.
DTD0367	SLC44A5	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC44A5	.	.
DTD0367	SLC44A5	Inducer	Demecolcine	Drug Marketed but not Approved by US FDA	.	.	Demecolcine increases the expression of SLC44A5	.	.
DTD0367	SLC44A5	Modulator	Doxorubicin	Approved Drug	.	.	Doxorubicin affects the expression of SLC44A5	.	.
DTD0367	SLC44A5	Inducer	Ethyl Methanesulfonate	Carcinogen	.	.	Ethyl Methanesulfonate increases the expression of SLC44A5	.	.
DTD0367	SLC44A5	Inducer	Formaldehyde	Acute Toxic Substance	.	.	Formaldehyde increases the expression of SLC44A5	.	.
DTD0367	SLC44A5	Inhibition	Jinfukang	Traditional Medicine	.	.	Jinfukang inhibits the expression of SLC44A5	.	.
DTD0367	SLC44A5	Inhibition	Milchsaure	Investigative Drug	.	.	Milchsaure inhibits the expression of SLC44A5	.	.
DTD0367	SLC44A5	Inducer	Permethrin	Approved Drug	.	.	Permethrin increases the expression of SLC44A5	.	.
DTD0367	SLC44A5	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of SLC44A5	.	.
DTD0367	SLC44A5	Inhibition	Sunitinib	Approved Drug	.	.	Sunitinib inhibits the expression of SLC44A5	.	.
DTD0367	SLC44A5	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of SLC44A5	.	.
DTD0367	SLC44A5	Inducer	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A increases the expression of SLC44A5	.	.
DTD0367	SLC44A5	Inhibition	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate inhibits the expression of SLC44A5	.	.
DTD0367	SLC44A5	Modulator	Uranium	Acute Toxic Substance	.	.	Uranium affects the expression of SLC44A5	.	.
DTD0367	SLC44A5	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of SLC44A5	.	.
DTD0367	SLC44A5	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC44A5	.	.
DTD0367	SLC44A5	Inducer	Vincristine	Approved Drug	.	.	Vincristine increases the expression of SLC44A5	.	.
DTD0368	SLC45A1	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC45A1	.	.
DTD0368	SLC45A1	Inducer	Cadmium	Acute Toxic Substance	.	.	Cadmium increases the expression of SLC45A1	.	.
DTD0368	SLC45A1	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC45A1	.	.
DTD0368	SLC45A1	Inducer	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 increases the expression of SLC45A1	.	.
DTD0368	SLC45A1	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC45A1	.	.
DTD0368	SLC45A1	Modulator	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A affects the expression of SLC45A1	.	.
DTD0368	SLC45A1	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC45A1	.	.
DTD0369	SLC45A2	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC45A2	.	.
DTD0369	SLC45A2	Inducer	Calcitriol	Approved Drug	.	.	Calcitriol increases the expression of SLC45A2	.	.
DTD0369	SLC45A2	Inhibition	Clothianidin	Pesticide/Insecticide	.	.	Clothianidin inhibits the expression of SLC45A2	.	.
DTD0369	SLC45A2	Inducer	Colforsin	Drug in Phase 2 Trial	.	.	Colforsin increases the expression of SLC45A2	.	.
DTD0369	SLC45A2	Inhibition	Potassium perchlorate	Approved Drug	.	.	Potassium perchlorate inhibits the expression of SLC45A2	.	.
DTD0369	SLC45A2	Inhibition	Resveratrol	Drug in Phase 3 Trial	.	.	Resveratrol inhibits the expression of SLC45A2	.	.
DTD0369	SLC45A2	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC45A2	.	.
DTD0369	SLC45A2	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of SLC45A2	.	.
DTD0369	SLC45A2	Inducer	Testosterone	Approved Drug	.	.	Testosterone increases the expression of SLC45A2	.	.
DTD0370	SLC45A3	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of SLC45A3	.	.
DTD0370	SLC45A3	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC45A3	.	.
DTD0370	SLC45A3	Inducer	Atrazine	Herbicide	.	.	Atrazine increases the expression of SLC45A3	.	.
DTD0370	SLC45A3	Inducer	Dihydrotestosterone	Drug in Phase 1 Trial	.	.	Dihydrotestosterone increases the expression of SLC45A3	.	.
DTD0370	SLC45A3	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC45A3	.	.
DTD0370	SLC45A3	Inhibition	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 inhibits the expression of SLC45A3	.	.
DTD0370	SLC45A3	Modulator	Lead	Health and Environmental Toxicant	.	.	Lead affects the expression of SLC45A3	.	.
DTD0370	SLC45A3	Inducer	Metribolone	Investigative Drug	.	.	Metribolone increases the expression of SLC45A3	.	.
DTD0370	SLC45A3	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC45A3	.	.
DTD0370	SLC45A3	Modulator	Tretinoin	Approved Drug	.	.	Tretinoin affects the expression of SLC45A3	.	.
DTD0370	SLC45A3	Inducer	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan increases the expression of SLC45A3	.	.
DTD0370	SLC45A3	Inhibition	Zoledronic Acid	Approved Drug	.	.	Zoledronic Acid inhibits the expression of SLC45A3	.	.
DTD0371	SLC45A4	Modulator	Acetaminophen	Approved Drug	.	.	Acetaminophen affects the expression of SLC45A4	.	.
DTD0371	SLC45A4	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC45A4	.	.
DTD0371	SLC45A4	Inhibition	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde inhibits the expression of SLC45A4	.	.
DTD0371	SLC45A4	Inhibition	Folic Acid	Approved Drug	.	.	Folic Acid inhibits the expression of SLC45A4	.	.
DTD0371	SLC45A4	Inhibition	Particulate Matter	Natural Product	.	.	Particulate Matter inhibits the expression of SLC45A4	.	.
DTD0371	SLC45A4	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC45A4	.	.
DTD0371	SLC45A4	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC45A4	.	.
DTD0371	SLC45A4	Modulator	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A affects the expression of SLC45A4	.	.
DTD0371	SLC45A4	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC45A4	.	.
DTD0372	SLC46A1	Inducer	AM-251	Patented Pharmaceutical Agent	.	.	AM-251 increases the expression of SLC46A1	.	.
DTD0372	SLC46A1	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC46A1	.	.
DTD0372	SLC46A1	Inhibition	Bictegravir	Approved Drug	.	.	Bictegravir inhibits the activity of SLC46A1	.	.
DTD0372	SLC46A1	Inducer	Cadmium	Acute Toxic Substance	.	.	Cadmium increases the expression of SLC46A1	.	.
DTD0372	SLC46A1	Inducer	Calcitriol	Approved Drug	.	.	Calcitriol increases the expression of SLC46A1	.	.
DTD0372	SLC46A1	Inducer	Cisplatin	Approved Drug	.	.	Cisplatin increases the expression of SLC46A1	.	.
DTD0372	SLC46A1	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC46A1	.	.
DTD0372	SLC46A1	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC46A1	.	.
DTD0372	SLC46A1	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC46A1	.	.
DTD0372	SLC46A1	Inhibition	Dronabinol	Approved Drug	.	.	Dronabinol inhibits the expression of SLC46A1	.	.
DTD0372	SLC46A1	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC46A1	.	.
DTD0372	SLC46A1	Inducer	Ethyl Methanesulfonate	Carcinogen	.	.	Ethyl Methanesulfonate increases the expression of SLC46A1	.	.
DTD0372	SLC46A1	Modulator	Folic Acid	Approved Drug	.	.	Folic acid modulates the activity of SLC46A1	.	.
DTD0372	SLC46A1	Inducer	Formaldehyde	Acute Toxic Substance	.	.	Formaldehyde increases the expression of SLC46A1	.	.
DTD0372	SLC46A1	Modulator	Hydrogen Peroxide	Approved Drug	.	.	Hydrogen Peroxide affects the expression of SLC46A1	.	.
DTD0372	SLC46A1	Inhibition	Leucovorin	Approved Drug	.	.	Leucovorin inhibits the activity of SLC46A1	.	.
DTD0372	SLC46A1	Inhibition	Levomefolic acid	Approved Drug	.	.	Levomefolic acid inhibits the activity of SLC46A1	.	.
DTD0372	SLC46A1	Modulator	Methotrexate	Approved Drug	.	.	Methotrexate modulates the activity of SLC46A1	.	.
DTD0372	SLC46A1	Inducer	Phenylmercuric Acetate	Investigative Drug	.	.	Phenylmercuric Acetate increases the expression of SLC46A1	.	.
DTD0372	SLC46A1	Modulator	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin affects the expression of SLC46A1	.	.
DTD0372	SLC46A1	Inhibition	Pyrimethamine	Approved Drug	.	.	Pyrimethamine inhibits the activity of SLC46A1	.	.
DTD0372	SLC46A1	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC46A1	.	.
DTD0372	SLC46A1	Inhibition	Sulfasalazine	Approved Drug	.	.	Sulfasalazine inhibits the activity of SLC46A1	.	.
DTD0372	SLC46A1	Inhibition	Sunitinib	Approved Drug	.	.	Sunitinib inhibits the expression of SLC46A1	.	.
DTD0372	SLC46A1	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC46A1	.	.
DTD0372	SLC46A1	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of SLC46A1	.	.
DTD0372	SLC46A1	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC46A1	.	.
DTD0372	SLC46A1	Inducer	Vitamin D	Approved Drug	.	.	Vitamin D increases the expression of SLC46A1	.	.
DTD0373	SLC46A2	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of SLC46A2	.	.
DTD0373	SLC46A2	Inducer	Calcitriol	Approved Drug	.	.	Calcitriol increases the expression of SLC46A2	.	.
DTD0373	SLC46A2	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC46A2	.	.
DTD0373	SLC46A2	Inhibition	Medroxyprogesterone Acetate	Approved Drug	.	.	Medroxyprogesterone Acetate inhibits the expression of SLC46A2	.	.
DTD0373	SLC46A2	Inhibition	Milchsaure	Investigative Drug	.	.	Milchsaure inhibits the expression of SLC46A2	.	.
DTD0375	SLC48A1	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of SLC48A1	.	.
DTD0375	SLC48A1	Inhibition	Acrylamide	Acute Toxic Substance	.	.	Acrylamide inhibits the expression of SLC48A1	.	.
DTD0375	SLC48A1	Inducer	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 increases the expression of SLC48A1	.	.
DTD0375	SLC48A1	Inducer	Arsenic Trioxide	Approved Drug	.	.	Arsenic Trioxide increases the expression of SLC48A1	.	.
DTD0375	SLC48A1	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of SLC48A1	.	.
DTD0375	SLC48A1	Inducer	Beta-naphthoflavone	Investigative Drug	.	.	Beta-naphthoflavone increases the expression of SLC48A1	.	.
DTD0375	SLC48A1	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC48A1	.	.
DTD0375	SLC48A1	Modulator	Carbamazepine	Approved Drug	.	.	Carbamazepine affects the expression of SLC48A1	.	.
DTD0375	SLC48A1	Inducer	Cisplatin	Approved Drug	.	.	Cisplatin increases the expression of SLC48A1	.	.
DTD0375	SLC48A1	Inducer	Clothianidin	Pesticide/Insecticide	.	.	Clothianidin increases the expression of SLC48A1	.	.
DTD0375	SLC48A1	Inducer	Copper Sulfate	Approved Drug	.	.	Copper Sulfate increases the expression of SLC48A1	.	.
DTD0375	SLC48A1	Inducer	Curcumin	Drug in Phase 3 Trial	.	.	Curcumin increases the expression of SLC48A1	.	.
DTD0375	SLC48A1	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of SLC48A1	.	.
DTD0375	SLC48A1	Inducer	Dicrotophos	Pesticide/Insecticide	.	.	Dicrotophos increases the expression of SLC48A1	.	.
DTD0375	SLC48A1	Modulator	Fluorouracil	Approved Drug	.	.	Fluorouracil affects the expression of SLC48A1	.	.
DTD0375	SLC48A1	Inducer	Jinfukang	Traditional Medicine	.	.	Jinfukang increases the expression of SLC48A1	.	.
DTD0375	SLC48A1	Inhibition	Lead	Health and Environmental Toxicant	.	.	Lead inhibits the expression of SLC48A1	.	.
DTD0375	SLC48A1	Inducer	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite increases the expression of SLC48A1	.	.
DTD0375	SLC48A1	Inducer	Sulforafan	Drug in Phase 3 Trial	.	.	Sulforafan increases the expression of SLC48A1	.	.
DTD0375	SLC48A1	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of SLC48A1	.	.
DTD0375	SLC48A1	Inducer	Temozolomide	Approved Drug	.	.	Temozolomide increases the expression of SLC48A1	.	.
DTD0375	SLC48A1	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC48A1	.	.
DTD0375	SLC48A1	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of SLC48A1	.	.
DTD0375	SLC48A1	Inhibition	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate inhibits the expression of SLC48A1	.	.
DTD0375	SLC48A1	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of SLC48A1	.	.
DTD0375	SLC48A1	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC48A1	.	.
DTD0375	SLC48A1	Inducer	Zinc	Environmental toxicant	.	.	Zinc increases the expression of SLC48A1	.	.
DTD0375	SLC48A1	Inducer	Zinc chloride	Drug Marketed but not Approved by US FDA	.	.	Zinc chloride increases the expression of SLC48A1	.	.
DTD0376	SLC49A1	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC49A1	.	.
DTD0376	SLC49A1	Inhibition	Aflatoxin M1	Mycotoxins	.	.	Aflatoxin M1 inhibits the expression of SLC49A1	.	.
DTD0376	SLC49A1	Inducer	Atrazine	Herbicide	.	.	Atrazine increases the expression of SLC49A1	.	.
DTD0376	SLC49A1	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC49A1	.	.
DTD0376	SLC49A1	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC49A1	.	.
DTD0376	SLC49A1	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC49A1	.	.
DTD0376	SLC49A1	Inhibition	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 inhibits the expression of SLC49A1	.	.
DTD0376	SLC49A1	Inhibition	Jinfukang	Traditional Medicine	.	.	Jinfukang inhibits the expression of SLC49A1	.	.
DTD0376	SLC49A1	Modulator	Menadione	Approved Drug	.	.	Menadione affects the expression of SLC49A1	.	.
DTD0376	SLC49A1	Inducer	Milchsaure	Investigative Drug	.	.	Milchsaure increases the expression of SLC49A1	.	.
DTD0376	SLC49A1	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of SLC49A1	.	.
DTD0376	SLC49A1	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC49A1	.	.
DTD0376	SLC49A1	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC49A1	.	.
DTD0377	SLC49A2	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of SLC49A2	.	.
DTD0377	SLC49A2	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC49A2	.	.
DTD0377	SLC49A2	Modulator	Cidofovir	Approved Drug	.	.	Cidofovir affects the expression of SLC49A2	.	.
DTD0377	SLC49A2	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the expression of SLC49A2	.	.
DTD0377	SLC49A2	Inducer	Clodronic Acid	Drug Marketed but not Approved by US FDA	.	.	Clodronic Acid increases the expression of SLC49A2	.	.
DTD0377	SLC49A2	Inducer	Copper Sulfate	Approved Drug	.	.	Copper Sulfate increases the expression of SLC49A2	.	.
DTD0377	SLC49A2	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC49A2	.	.
DTD0377	SLC49A2	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC49A2	.	.
DTD0377	SLC49A2	Inhibition	Dronabinol	Approved Drug	.	.	Dronabinol inhibits the expression of SLC49A2	.	.
DTD0377	SLC49A2	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC49A2	.	.
DTD0377	SLC49A2	Inducer	Formaldehyde	Acute Toxic Substance	.	.	Formaldehyde increases the expression of SLC49A2	.	.
DTD0377	SLC49A2	Inducer	Gardiquimod	Drug in Preclinical Test	.	.	Gardiquimod increases the expression of SLC49A2	.	.
DTD0377	SLC49A2	Inducer	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 increases the expression of SLC49A2	.	.
DTD0377	SLC49A2	Inhibition	Ifosfamide	Approved Drug	.	.	Ifosfamide inhibits the expression of SLC49A2	.	.
DTD0377	SLC49A2	Inducer	Jinfukang	Traditional Medicine	.	.	Jinfukang increases the expression of SLC49A2	.	.
DTD0377	SLC49A2	Inducer	K-7174	Patented Pharmaceutical Agent	.	.	K-7174 increases the expression of SLC49A2	.	.
DTD0377	SLC49A2	Inducer	Perfluorooctane sulfonic acid	Health and Environmental Toxicant	.	.	Perfluorooctane sulfonic acid increases the expression of SLC49A2	.	.
DTD0377	SLC49A2	Inducer	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin increases the expression of SLC49A2	.	.
DTD0377	SLC49A2	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of SLC49A2	.	.
DTD0377	SLC49A2	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC49A2	.	.
DTD0377	SLC49A2	Inhibition	Sodium bichromate	Carcinogen	.	.	Sodium bichromate inhibits the expression of SLC49A2	.	.
DTD0377	SLC49A2	Inhibition	Sulforafan	Drug in Phase 3 Trial	.	.	Sulforafan inhibits the expression of SLC49A2	.	.
DTD0377	SLC49A2	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of SLC49A2	.	.
DTD0377	SLC49A2	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC49A2	.	.
DTD0377	SLC49A2	Inducer	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A increases the expression of SLC49A2	.	.
DTD0377	SLC49A2	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC49A2	.	.
DTD0377	SLC49A2	Inducer	Vorinostat	Approved Drug	.	.	Vorinostat increases the expression of SLC49A2	.	.
DTD0380	SLC4A1	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC4A1	.	.
DTD0380	SLC4A1	Inducer	Copper Sulfate	Approved Drug	.	.	Copper Sulfate increases the expression of SLC4A1	.	.
DTD0380	SLC4A1	Inducer	Diethylhexyl Phthalate	Health and Environmental Toxicant	.	.	Diethylhexyl Phthalate increases the expression of SLC4A1	.	.
DTD0380	SLC4A1	Inducer	Glucose	Investigative Drug	.	.	Glucose increases the expression of SLC4A1	.	.
DTD0380	SLC4A1	Inducer	Resveratrol	Drug in Phase 3 Trial	.	.	Resveratrol increases the expression of SLC4A1	.	.
DTD0380	SLC4A1	Inhibition	Tebuconazole	Fungicide	.	.	Tebuconazole inhibits the expression of SLC4A1	.	.
DTD0380	SLC4A1	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC4A1	.	.
DTD0381	SLC4A10	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of SLC4A10	.	.
DTD0381	SLC4A10	Inducer	Gardiquimod	Drug in Preclinical Test	.	.	Gardiquimod increases the expression of SLC4A10	.	.
DTD0381	SLC4A10	Inhibition	Manganese	Investigative Drug	.	.	Manganese inhibits the expression of SLC4A10	.	.
DTD0381	SLC4A10	Inhibition	Manganese chloride	Approved Drug	.	.	Manganese chloride inhibits the expression of SLC4A10	.	.
DTD0382	SLC4A11	Inducer	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 increases the expression of SLC4A11	.	.
DTD0382	SLC4A11	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of SLC4A11	.	.
DTD0382	SLC4A11	Inhibition	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A inhibits the expression of SLC4A11	.	.
DTD0382	SLC4A11	Inducer	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde increases the expression of SLC4A11	.	.
DTD0382	SLC4A11	Inducer	Calcitriol	Approved Drug	.	.	Calcitriol increases the expression of SLC4A11	.	.
DTD0382	SLC4A11	Inducer	Cisplatin	Approved Drug	.	.	Cisplatin increases the expression of SLC4A11	.	.
DTD0382	SLC4A11	Inducer	Doxorubicin	Approved Drug	.	.	Doxorubicin increases the expression of SLC4A11	.	.
DTD0382	SLC4A11	Inducer	Jinfukang	Traditional Medicine	.	.	Jinfukang increases the expression of SLC4A11	.	.
DTD0382	SLC4A11	Inducer	Methyleugenol	Natural Product	.	.	Methyleugenol increases the expression of SLC4A11	.	.
DTD0382	SLC4A11	Inducer	MS-275	Drug in Phase 2 Trial	.	.	MS-275 increases the expression of SLC4A11	.	.
DTD0382	SLC4A11	Inhibition	Phenylmercuric Acetate	Investigative Drug	.	.	Phenylmercuric Acetate inhibits the expression of SLC4A11	.	.
DTD0382	SLC4A11	Inhibition	Progesterone	Approved Drug	.	.	Progesterone inhibits the expression of SLC4A11	.	.
DTD0382	SLC4A11	Inducer	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin increases the expression of SLC4A11	.	.
DTD0382	SLC4A11	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC4A11	.	.
DTD0382	SLC4A11	Inducer	Testosterone	Approved Drug	.	.	Testosterone increases the expression of SLC4A11	.	.
DTD0382	SLC4A11	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC4A11	.	.
DTD0382	SLC4A11	Inducer	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A increases the expression of SLC4A11	.	.
DTD0382	SLC4A11	Inducer	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate increases the expression of SLC4A11	.	.
DTD0382	SLC4A11	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC4A11	.	.
DTD0382	SLC4A11	Inducer	Vorinostat	Approved Drug	.	.	Vorinostat increases the expression of SLC4A11	.	.
DTD0383	SLC4A2	Inducer	Cisplatin	Approved Drug	.	.	Cisplatin increases the expression of SLC4A2	.	.
DTD0383	SLC4A2	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC4A2	.	.
DTD0383	SLC4A2	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC4A2	.	.
DTD0383	SLC4A2	Inhibition	Folic Acid	Approved Drug	.	.	Folic Acid inhibits the expression of SLC4A2	.	.
DTD0383	SLC4A2	Inhibition	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 inhibits the expression of SLC4A2	.	.
DTD0383	SLC4A2	Inhibition	Ivermectin	Approved Drug	.	.	Ivermectin inhibits the expression of SLC4A2	.	.
DTD0383	SLC4A2	Inducer	Rifampicin	Approved Drug	.	.	Rifampicin induces the activity of SLC4A2	.	.
DTD0383	SLC4A2	Inhibition	Temozolomide	Approved Drug	.	.	Temozolomide inhibits the expression of SLC4A2	.	.
DTD0383	SLC4A2	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC4A2	.	.
DTD0383	SLC4A2	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC4A2	.	.
DTD0383	SLC4A2	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of SLC4A2	.	.
DTD0384	SLC4A3	Inhibition	Acrylamide	Acute Toxic Substance	.	.	Acrylamide inhibits the expression of SLC4A3	.	.
DTD0384	SLC4A3	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the expression of SLC4A3	.	.
DTD0384	SLC4A3	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC4A3	.	.
DTD0384	SLC4A3	Modulator	Doxorubicin	Approved Drug	.	.	Doxorubicin affects the expression of SLC4A3	.	.
DTD0384	SLC4A3	Inhibition	Folic Acid	Approved Drug	.	.	Folic Acid inhibits the expression of SLC4A3	.	.
DTD0384	SLC4A3	Inducer	Sasanquasaponin	Natural Product	.	.	Sasanquasaponin induces the activity of SLC4A3	.	.
DTD0385	SLC4A4	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of SLC4A4	.	.
DTD0385	SLC4A4	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC4A4	.	.
DTD0385	SLC4A4	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC4A4	.	.
DTD0385	SLC4A4	Inhibition	Aflatoxin M1	Mycotoxins	.	.	Aflatoxin M1 inhibits the expression of SLC4A4	.	.
DTD0385	SLC4A4	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC4A4	.	.
DTD0385	SLC4A4	Inhibition	Bicalutamide	Approved Drug	.	.	Bicalutamide inhibits the expression of SLC4A4	.	.
DTD0385	SLC4A4	Inhibition	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde inhibits the expression of SLC4A4	.	.
DTD0385	SLC4A4	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC4A4	.	.
DTD0385	SLC4A4	Inducer	Dihydrotestosterone	Drug in Phase 1 Trial	.	.	Dihydrotestosterone increases the expression of SLC4A4	.	.
DTD0385	SLC4A4	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC4A4	.	.
DTD0385	SLC4A4	Inducer	Geneticin	Patented Pharmaceutical Agent	.	.	Geneticin increases the expression of SLC4A4	.	.
DTD0385	SLC4A4	Inhibition	GSK-J4	Patented Pharmaceutical Agent	.	.	GSK-J4 inhibits the expression of SLC4A4	.	.
DTD0385	SLC4A4	Inhibition	Methyleugenol	Natural Product	.	.	Methyleugenol inhibits the expression of SLC4A4	.	.
DTD0385	SLC4A4	Inhibition	Particulate Matter	Natural Product	.	.	Particulate Matter inhibits the expression of SLC4A4	.	.
DTD0385	SLC4A4	Inhibition	Selenium nanoparticles	Natural Product	.	.	Selenium nanoparticles inhibits the expression of SLC4A4	.	.
DTD0385	SLC4A4	Inhibition	Temozolomide	Approved Drug	.	.	Temozolomide inhibits the expression of SLC4A4	.	.
DTD0385	SLC4A4	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC4A4	.	.
DTD0385	SLC4A4	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of SLC4A4	.	.
DTD0385	SLC4A4	Inducer	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A increases the expression of SLC4A4	.	.
DTD0385	SLC4A4	Inhibition	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan inhibits the expression of SLC4A4	.	.
DTD0385	SLC4A4	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC4A4	.	.
DTD0385	SLC4A4	Inhibition	Vitamin E	Drug in Phase 3 Trial	.	.	Vitamin E inhibits the expression of SLC4A4	.	.
DTD0385	SLC4A4	Inhibition	Zoledronic Acid	Approved Drug	.	.	Zoledronic Acid inhibits the expression of SLC4A4	.	.
DTD0386	SLC4A5	Inhibition	Acrylamide	Acute Toxic Substance	.	.	Acrylamide inhibits the expression of SLC4A5	.	.
DTD0386	SLC4A5	Inducer	Arsenic	Approved Drug	.	.	Arsenic increases the expression of SLC4A5	.	.
DTD0386	SLC4A5	Inducer	Clorgyline	Investigative Drug	.	.	Clorgyline increases the expression of SLC4A5	.	.
DTD0386	SLC4A5	Inducer	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 increases the expression of SLC4A5	.	.
DTD0386	SLC4A5	Inhibition	Malathion	Approved Drug	.	.	Malathion inhibits the expression of SLC4A5	.	.
DTD0386	SLC4A5	Inhibition	Methyleugenol	Natural Product	.	.	Methyleugenol inhibits the expression of SLC4A5	.	.
DTD0386	SLC4A5	Inhibition	Tenidap	Drug in Phase 3 Trial	.	.	Tenidap inhibits the activity of SLC4A5	.	.
DTD0387	SLC4A7	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of SLC4A7	.	.
DTD0387	SLC4A7	Modulator	AM-80	Drug in Phase 2/3 Trial	.	.	AM-80 affects the expression of SLC4A7	.	.
DTD0387	SLC4A7	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of SLC4A7	.	.
DTD0387	SLC4A7	Inducer	Calcitriol	Approved Drug	.	.	Calcitriol increases the expression of SLC4A7	.	.
DTD0387	SLC4A7	Modulator	Carbamazepine	Approved Drug	.	.	Carbamazepine affects the expression of SLC4A7	.	.
DTD0387	SLC4A7	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the expression of SLC4A7	.	.
DTD0387	SLC4A7	Inducer	Copper Sulfate	Approved Drug	.	.	Copper Sulfate increases the expression of SLC4A7	.	.
DTD0387	SLC4A7	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC4A7	.	.
DTD0387	SLC4A7	Inhibition	Demecolcine	Drug Marketed but not Approved by US FDA	.	.	Demecolcine inhibits the expression of SLC4A7	.	.
DTD0387	SLC4A7	Inducer	Deoxynivalenol	Mycotoxins	.	.	Deoxynivalenol increases the expression of SLC4A7	.	.
DTD0387	SLC4A7	Inducer	Dihydrotestosterone	Drug in Phase 1 Trial	.	.	Dihydrotestosterone increases the expression of SLC4A7	.	.
DTD0387	SLC4A7	Inducer	Dronabinol	Approved Drug	.	.	Dronabinol increases the expression of SLC4A7	.	.
DTD0387	SLC4A7	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC4A7	.	.
DTD0387	SLC4A7	Inhibition	Ethyl Methanesulfonate	Carcinogen	.	.	Ethyl Methanesulfonate inhibits the expression of SLC4A7	.	.
DTD0387	SLC4A7	Inhibition	Formaldehyde	Acute Toxic Substance	.	.	Formaldehyde inhibits the expression of SLC4A7	.	.
DTD0387	SLC4A7	Inhibition	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 inhibits the expression of SLC4A7	.	.
DTD0387	SLC4A7	Inhibition	Ivermectin	Approved Drug	.	.	Ivermectin inhibits the expression of SLC4A7	.	.
DTD0387	SLC4A7	Inhibition	Jinfukang	Traditional Medicine	.	.	Jinfukang inhibits the expression of SLC4A7	.	.
DTD0387	SLC4A7	Inducer	Leflunomide	Approved Drug	.	.	Leflunomide increases the expression of SLC4A7	.	.
DTD0387	SLC4A7	Inhibition	MS-275	Drug in Phase 2 Trial	.	.	MS-275 inhibits the expression of SLC4A7	.	.
DTD0387	SLC4A7	Inhibition	Nickel chloride	Acute Toxic Substance	.	.	Nickel chloride inhibits the expression of SLC4A7	.	.
DTD0387	SLC4A7	Inhibition	Particulate Matter	Natural Product	.	.	Particulate Matter inhibits the expression of SLC4A7	.	.
DTD0387	SLC4A7	Modulator	Polychlorinated Biphenyls	Carcinogen	.	.	Polychlorinated Biphenyls affects the expression of SLC4A7	.	.
DTD0387	SLC4A7	Inhibition	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin inhibits the expression of SLC4A7	.	.
DTD0387	SLC4A7	Inducer	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin increases the expression of SLC4A7	.	.
DTD0387	SLC4A7	Inhibition	Selenium nanoparticles	Natural Product	.	.	Selenium nanoparticles inhibits the expression of SLC4A7	.	.
DTD0387	SLC4A7	Inhibition	Silver nanoparticle	Nanoparticle	.	.	Silver nanoparticle inhibits the expression of SLC4A7	.	.
DTD0387	SLC4A7	Modulator	Testosterone enanthate	Approved Drug	.	.	Testosterone enanthate affects the expression of SLC4A7	.	.
DTD0387	SLC4A7	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC4A7	.	.
DTD0387	SLC4A7	Modulator	Tretinoin	Approved Drug	.	.	Tretinoin affects the expression of SLC4A7	.	.
DTD0387	SLC4A7	Inhibition	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A inhibits the expression of SLC4A7	.	.
DTD0387	SLC4A7	Inducer	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate increases the expression of SLC4A7	.	.
DTD0387	SLC4A7	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC4A7	.	.
DTD0387	SLC4A7	Inhibition	Vincristine	Approved Drug	.	.	Vincristine inhibits the expression of SLC4A7	.	.
DTD0387	SLC4A7	Inhibition	Vitamin E	Drug in Phase 3 Trial	.	.	Vitamin E inhibits the expression of SLC4A7	.	.
DTD0387	SLC4A7	Inhibition	Vorinostat	Approved Drug	.	.	Vorinostat inhibits the expression of SLC4A7	.	.
DTD0388	SLC4A8	Inducer	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 increases the expression of SLC4A8	.	.
DTD0388	SLC4A8	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC4A8	.	.
DTD0388	SLC4A8	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of SLC4A8	.	.
DTD0388	SLC4A8	Inhibition	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A inhibits the expression of SLC4A8	.	.
DTD0388	SLC4A8	Inducer	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde increases the expression of SLC4A8	.	.
DTD0388	SLC4A8	Inducer	Cisplatin	Approved Drug	.	.	Cisplatin increases the expression of SLC4A8	.	.
DTD0388	SLC4A8	Inhibition	Cytarabine	Approved Drug	.	.	Cytarabine inhibits the expression of SLC4A8	.	.
DTD0388	SLC4A8	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC4A8	.	.
DTD0388	SLC4A8	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC4A8	.	.
DTD0388	SLC4A8	Inhibition	GSK-J4	Patented Pharmaceutical Agent	.	.	GSK-J4 inhibits the expression of SLC4A8	.	.
DTD0388	SLC4A8	Inducer	Particulate Matter	Natural Product	.	.	Particulate Matter increases the expression of SLC4A8	.	.
DTD0388	SLC4A8	Inhibition	Phenylmercuric Acetate	Investigative Drug	.	.	Phenylmercuric Acetate inhibits the expression of SLC4A8	.	.
DTD0388	SLC4A8	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC4A8	.	.
DTD0388	SLC4A8	Inhibition	Sulforafan	Drug in Phase 3 Trial	.	.	Sulforafan inhibits the expression of SLC4A8	.	.
DTD0388	SLC4A8	Inhibition	Sunitinib	Approved Drug	.	.	Sunitinib inhibits the expression of SLC4A8	.	.
DTD0388	SLC4A8	Inducer	Tamoxifen	Approved Drug	.	.	Tamoxifen increases the expression of SLC4A8	.	.
DTD0388	SLC4A8	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC4A8	.	.
DTD0388	SLC4A8	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of SLC4A8	.	.
DTD0388	SLC4A8	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC4A8	.	.
DTD0390	SLC50A1	Inhibition	Acrylamide	Acute Toxic Substance	.	.	Acrylamide inhibits the expression of SLC50A1	.	.
DTD0390	SLC50A1	Inducer	Atrazine	Herbicide	.	.	Atrazine increases the expression of SLC50A1	.	.
DTD0390	SLC50A1	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC50A1	.	.
DTD0390	SLC50A1	Inducer	Cisplatin	Approved Drug	.	.	Cisplatin increases the expression of SLC50A1	.	.
DTD0390	SLC50A1	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC50A1	.	.
DTD0390	SLC50A1	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of SLC50A1	.	.
DTD0390	SLC50A1	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC50A1	.	.
DTD0390	SLC50A1	Inducer	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 increases the expression of SLC50A1	.	.
DTD0390	SLC50A1	Inhibition	Isotretinoin	Approved Drug	.	.	Isotretinoin inhibits the expression of SLC50A1	.	.
DTD0390	SLC50A1	Inducer	Jinfukang	Traditional Medicine	.	.	Jinfukang increases the expression of SLC50A1	.	.
DTD0390	SLC50A1	Inducer	Ochratoxin A	Acute Toxic Substance	.	.	Ochratoxin A increases the expression of SLC50A1	.	.
DTD0390	SLC50A1	Inducer	Particulate Matter	Natural Product	.	.	Particulate Matter increases the expression of SLC50A1	.	.
DTD0390	SLC50A1	Inducer	Thapsigargin	Natural Product	.	.	Thapsigargin increases the expression of SLC50A1	.	.
DTD0390	SLC50A1	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC50A1	.	.
DTD0390	SLC50A1	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC50A1	.	.
DTD0391	SLC51A	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC51A	.	.
DTD0391	SLC51A	Inducer	Acrylamide	Acute Toxic Substance	.	.	Acrylamide increases the expression of SLC51A	.	.
DTD0391	SLC51A	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC51A	.	.
DTD0391	SLC51A	Inducer	Amoxicillin	Approved Drug	.	.	Amoxicillin increases the expression of SLC51A	.	.
DTD0391	SLC51A	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC51A	.	.
DTD0391	SLC51A	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC51A	.	.
DTD0391	SLC51A	Inducer	Bosentan	Approved Drug	.	.	Bosentan increases the expression of SLC51A	.	.
DTD0391	SLC51A	Inducer	Budesonide	Approved Drug	.	.	Budesonide increases the expression of SLC51A	.	.
DTD0391	SLC51A	Inhibition	Calcitriol	Approved Drug	.	.	Calcitriol inhibits the expression of SLC51A	.	.
DTD0391	SLC51A	Inducer	Chenodeoxycholic acid	Approved Drug	.	.	Chenodeoxycholic acid increases the expression of SLC51A	.	.
DTD0391	SLC51A	Inducer	Cholic Acid	Approved Drug	.	.	Cholic Acid increases the expression of SLC51A	.	.
DTD0391	SLC51A	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC51A	.	.
DTD0391	SLC51A	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC51A	.	.
DTD0391	SLC51A	Inducer	Deoxycholic acid	Approved Drug	.	.	Deoxycholic acid increases the expression of SLC51A	.	.
DTD0391	SLC51A	Inhibition	Deoxynivalenol	Mycotoxins	.	.	Deoxynivalenol inhibits the expression of SLC51A	.	.
DTD0391	SLC51A	Modulator	Dexamethasone	Approved Drug	.	.	Dexamethasone affects the expression of SLC51A	.	.
DTD0391	SLC51A	Inhibition	Fidaxomicin	Approved Drug	.	.	Fidaxomicin inhibits the activity of SLC51A	.	.
DTD0391	SLC51A	Inducer	GW-4064	Patented Pharmaceutical Agent	.	.	GW-4064 increases the expression of SLC51A	.	.
DTD0391	SLC51A	Modulator	Hydrogen Peroxide	Approved Drug	.	.	Hydrogen Peroxide affects the expression of SLC51A	.	.
DTD0391	SLC51A	Inducer	Leflunomide	Approved Drug	.	.	Leflunomide increases the expression of SLC51A	.	.
DTD0391	SLC51A	Inducer	Lithocholic Acid	Investigative Drug	.	.	Lithocholic Acid increases the expression of SLC51A	.	.
DTD0391	SLC51A	Inducer	Methotrexate	Approved Drug	.	.	Methotrexate increases the expression of SLC51A	.	.
DTD0391	SLC51A	Inhibition	Methyleugenol	Natural Product	.	.	Methyleugenol inhibits the expression of SLC51A	.	.
DTD0391	SLC51A	Inducer	Obeticholic acid	Approved Drug	.	.	Obeticholic acid increases the expression of SLC51A	.	.
DTD0391	SLC51A	Inhibition	Oxyquinoline	Acute Toxic Substance	.	.	Oxyquinoline inhibits the expression of SLC51A	.	.
DTD0391	SLC51A	Inducer	Phenobarbital	Approved Drug	.	.	Phenobarbital increases the expression of SLC51A	.	.
DTD0391	SLC51A	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of SLC51A	.	.
DTD0391	SLC51A	Inducer	Rifampin	Approved Drug	.	.	Rifampin increases the expression of SLC51A	.	.
DTD0391	SLC51A	Inhibition	Ritonavir	Approved Drug	.	.	Ritonavir inhibits the expression of SLC51A	.	.
DTD0391	SLC51A	Inhibition	Rosiglitazone	Approved Drug	.	.	Rosiglitazone inhibits the expression of SLC51A	.	.
DTD0391	SLC51A	Inhibition	Sulforafan	Drug in Phase 3 Trial	.	.	Sulforafan inhibits the expression of SLC51A	.	.
DTD0391	SLC51A	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of SLC51A	.	.
DTD0391	SLC51A	Inhibition	Troglitazone	Approved Drug	.	.	Troglitazone inhibits the activity of SLC51A	.	.
DTD0391	SLC51A	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of SLC51A	.	.
DTD0391	SLC51A	Inducer	Ursodeoxycholic Acid	Approved Drug	.	.	Ursodeoxycholic Acid increases the expression of SLC51A	.	.
DTD0391	SLC51A	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC51A	.	.
DTD0392	SLC51B	Inducer	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 increases the expression of SLC51B	.	.
DTD0392	SLC51B	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC51B	.	.
DTD0392	SLC51B	Modulator	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A affects the expression of SLC51B	.	.
DTD0392	SLC51B	Inducer	Bosentan	Approved Drug	.	.	Bosentan increases the expression of SLC51B	.	.
DTD0392	SLC51B	Inducer	Budesonide	Approved Drug	.	.	Budesonide increases the expression of SLC51B	.	.
DTD0392	SLC51B	Inhibition	Calcitriol	Approved Drug	.	.	Calcitriol inhibits the expression of SLC51B	.	.
DTD0392	SLC51B	Inducer	Chenodeoxycholic acid	Approved Drug	.	.	Chenodeoxycholic acid increases the expression of SLC51B	.	.
DTD0392	SLC51B	Inducer	Cholic Acid	Approved Drug	.	.	Cholic Acid increases the expression of SLC51B	.	.
DTD0392	SLC51B	Inducer	Cisplatin	Approved Drug	.	.	Cisplatin increases the expression of SLC51B	.	.
DTD0392	SLC51B	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC51B	.	.
DTD0392	SLC51B	Inducer	Deoxycholic acid	Approved Drug	.	.	Deoxycholic acid increases the expression of SLC51B	.	.
DTD0392	SLC51B	Inducer	Dexamethasone	Approved Drug	.	.	Dexamethasone increases the expression of SLC51B	.	.
DTD0392	SLC51B	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC51B	.	.
DTD0392	SLC51B	Inhibition	Ethyl Methanesulfonate	Carcinogen	.	.	Ethyl Methanesulfonate inhibits the expression of SLC51B	.	.
DTD0392	SLC51B	Inhibition	Fidaxomicin	Approved Drug	.	.	Fidaxomicin inhibits the activity of SLC51B	.	.
DTD0392	SLC51B	Inducer	Fipronil	Acute Toxic Substance	.	.	Fipronil increases the expression of SLC51B	.	.
DTD0392	SLC51B	Inducer	GW-4064	Patented Pharmaceutical Agent	.	.	GW-4064 increases the expression of SLC51B	.	.
DTD0392	SLC51B	Modulator	Hydrogen Peroxide	Approved Drug	.	.	Hydrogen Peroxide affects the expression of SLC51B	.	.
DTD0392	SLC51B	Inducer	Jinfukang	Traditional Medicine	.	.	Jinfukang increases the expression of SLC51B	.	.
DTD0392	SLC51B	Inducer	Leflunomide	Approved Drug	.	.	Leflunomide increases the expression of SLC51B	.	.
DTD0392	SLC51B	Inducer	Liothyronine	Approved Drug	.	.	Liothyronine increases the expression of SLC51B	.	.
DTD0392	SLC51B	Inducer	Lithocholic Acid	Investigative Drug	.	.	Lithocholic Acid increases the expression of SLC51B	.	.
DTD0392	SLC51B	Inducer	Obeticholic acid	Approved Drug	.	.	Obeticholic acid increases the expression of SLC51B	.	.
DTD0392	SLC51B	Inducer	Pantothenate	Approved Drug	.	.	Pantothenate increases the expression of SLC51B	.	.
DTD0392	SLC51B	Inducer	Perfluorooctane sulfonic acid	Health and Environmental Toxicant	.	.	Perfluorooctane sulfonic acid increases the expression of SLC51B	.	.
DTD0392	SLC51B	Inducer	Phenobarbital	Approved Drug	.	.	Phenobarbital increases the expression of SLC51B	.	.
DTD0392	SLC51B	Inhibition	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin inhibits the expression of SLC51B	.	.
DTD0392	SLC51B	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of SLC51B	.	.
DTD0392	SLC51B	Inhibition	Resorcinol	Environmental toxicant	.	.	Resorcinol inhibits the expression of SLC51B	.	.
DTD0392	SLC51B	Inducer	Rifampin	Approved Drug	.	.	Rifampin increases the expression of SLC51B	.	.
DTD0392	SLC51B	Inducer	Rosiglitazone	Approved Drug	.	.	Rosiglitazone increases the expression of SLC51B	.	.
DTD0392	SLC51B	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC51B	.	.
DTD0392	SLC51B	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC51B	.	.
DTD0392	SLC51B	Inhibition	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan inhibits the expression of SLC51B	.	.
DTD0392	SLC51B	Inducer	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate increases the expression of SLC51B	.	.
DTD0392	SLC51B	Inducer	Ursodeoxycholic Acid	Approved Drug	.	.	Ursodeoxycholic Acid increases the expression of SLC51B	.	.
DTD0392	SLC51B	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC51B	.	.
DTD0393	SLC52A1	Inducer	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 increases the expression of SLC52A1	.	.
DTD0393	SLC52A1	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of SLC52A1	.	.
DTD0393	SLC52A1	Inducer	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde increases the expression of SLC52A1	.	.
DTD0393	SLC52A1	Inducer	Cisplatin	Approved Drug	.	.	Cisplatin increases the expression of SLC52A1	.	.
DTD0393	SLC52A1	Inhibition	Formaldehyde	Acute Toxic Substance	.	.	Formaldehyde inhibits the expression of SLC52A1	.	.
DTD0393	SLC52A1	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC52A1	.	.
DTD0393	SLC52A1	Inducer	Zinc	Environmental toxicant	.	.	Zinc increases the expression of SLC52A1	.	.
DTD0394	SLC52A2	Inhibition	4-Cyclohexyl-4-hydroxy-but-2-enoic acid	Investigative Drug	.	.	4-Cyclohexyl-4-hydroxy-but-2-enoic acid inhibits the activity of SLC52A2	.	.
DTD0394	SLC52A2	Inhibition	4-Hydroxy-3-methyl-but-2-enoic acid	Investigative Drug	.	.	4-Hydroxy-3-methyl-but-2-enoic acid inhibits the activity of SLC52A2	.	.
DTD0394	SLC52A2	Inhibition	4-Hydroxy-3-methyl-butyric acid	Investigative Drug	.	.	4-Hydroxy-3-methyl-butyric acid inhibits the activity of SLC52A2	.	.
DTD0394	SLC52A2	Inhibition	4-Hydroxy-4-phenyl-but-2-enoic acid	Investigative Drug	.	.	4-Hydroxy-4-phenyl-but-2-enoic acid inhibits the activity of SLC52A2	.	.
DTD0394	SLC52A2	Inhibition	4-Hydroxy-4-phenyl-butyric acid	Investigative Drug	.	.	4-Hydroxy-4-phenyl-butyric acid inhibits the activity of SLC52A2	.	.
DTD0394	SLC52A2	Inhibition	4-Hydroxy-but-2-enoate	Investigative Drug	.	.	4-Hydroxy-but-2-enoate inhibits the activity of SLC52A2	.	.
DTD0394	SLC52A2	Inhibition	4-Hydroxy-pent-2-enoic acid	Investigative Drug	.	.	4-Hydroxy-pent-2-enoic acid inhibits the activity of SLC52A2	.	.
DTD0394	SLC52A2	Inhibition	4-Hydroxy-pentanoic acid	Investigative Drug	.	.	4-Hydroxy-pentanoic acid inhibits the activity of SLC52A2	.	.
DTD0394	SLC52A2	Inhibition	5-Hydroxy-pentanoate	Investigative Drug	.	.	5-Hydroxy-pentanoate inhibits the activity of SLC52A2	.	.
DTD0394	SLC52A2	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of SLC52A2	.	.
DTD0394	SLC52A2	Inducer	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 increases the expression of SLC52A2	.	.
DTD0394	SLC52A2	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of SLC52A2	.	.
DTD0394	SLC52A2	Inhibition	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A inhibits the expression of SLC52A2	.	.
DTD0394	SLC52A2	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of SLC52A2	.	.
DTD0394	SLC52A2	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC52A2	.	.
DTD0394	SLC52A2	Inducer	Temozolomide	Approved Drug	.	.	Temozolomide increases the expression of SLC52A2	.	.
DTD0394	SLC52A2	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC52A2	.	.
DTD0394	SLC52A2	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC52A2	.	.
DTD0395	SLC52A3	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of SLC52A3	.	.
DTD0395	SLC52A3	Inducer	Atrazine	Herbicide	.	.	Atrazine increases the expression of SLC52A3	.	.
DTD0395	SLC52A3	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of SLC52A3	.	.
DTD0395	SLC52A3	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC52A3	.	.
DTD0395	SLC52A3	Inhibition	Milchsaure	Investigative Drug	.	.	Milchsaure inhibits the expression of SLC52A3	.	.
DTD0395	SLC52A3	Inducer	MS-275	Drug in Phase 2 Trial	.	.	MS-275 increases the expression of SLC52A3	.	.
DTD0395	SLC52A3	Inducer	Panobinostat	Approved Drug	.	.	Panobinostat increases the expression of SLC52A3	.	.
DTD0395	SLC52A3	Inducer	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite increases the expression of SLC52A3	.	.
DTD0395	SLC52A3	Inhibition	Testosterone	Approved Drug	.	.	Testosterone inhibits the expression of SLC52A3	.	.
DTD0395	SLC52A3	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC52A3	.	.
DTD0395	SLC52A3	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC52A3	.	.
DTD0400	SLC55A1	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC55A1	.	.
DTD0400	SLC55A1	Inhibition	Atrazine	Herbicide	.	.	Atrazine inhibits the expression of SLC55A1	.	.
DTD0400	SLC55A1	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC55A1	.	.
DTD0400	SLC55A1	Inducer	Bisphenol B	Drug in Phase 2 Trial	.	.	Bisphenol B increases the expression of SLC55A1	.	.
DTD0400	SLC55A1	Inducer	Bisphenol F	Environmental toxicant	.	.	Bisphenol F increases the expression of SLC55A1	.	.
DTD0400	SLC55A1	Inducer	Dicrotophos	Pesticide/Insecticide	.	.	Dicrotophos increases the expression of SLC55A1	.	.
DTD0400	SLC55A1	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC55A1	.	.
DTD0400	SLC55A1	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC55A1	.	.
DTD0400	SLC55A1	Modulator	Hydrogen Peroxide	Approved Drug	.	.	Hydrogen Peroxide affects the expression of SLC55A1	.	.
DTD0400	SLC55A1	Inhibition	Ivermectin	Approved Drug	.	.	Ivermectin inhibits the expression of SLC55A1	.	.
DTD0400	SLC55A1	Inducer	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite increases the expression of SLC55A1	.	.
DTD0400	SLC55A1	Inhibition	Tetrahydropalmatine	Drug in Phase 2 Trial	.	.	Tetrahydropalmatine inhibits the expression of SLC55A1	.	.
DTD0400	SLC55A1	Inhibition	Thapsigargin	Natural Product	.	.	Thapsigargin inhibits the expression of SLC55A1	.	.
DTD0400	SLC55A1	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC55A1	.	.
DTD0400	SLC55A1	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC55A1	.	.
DTD0400	SLC55A1	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC55A1	.	.
DTD0403	SLC56A1	Inducer	1-methyl-4-phenylpyridinium	Health and Environmental Toxicant	.	.	1-methyl-4-phenylpyridinium increases the expression of SLC56A1	.	.
DTD0403	SLC56A1	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC56A1	.	.
DTD0403	SLC56A1	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC56A1	.	.
DTD0403	SLC56A1	Inhibition	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A inhibits the expression of SLC56A1	.	.
DTD0403	SLC56A1	Inducer	Bisphenol B	Drug in Phase 2 Trial	.	.	Bisphenol B increases the expression of SLC56A1	.	.
DTD0403	SLC56A1	Inhibition	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde inhibits the expression of SLC56A1	.	.
DTD0403	SLC56A1	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC56A1	.	.
DTD0403	SLC56A1	Inhibition	Coumestrol	Investigative Drug	.	.	Coumestrol inhibits the expression of SLC56A1	.	.
DTD0403	SLC56A1	Inhibition	Curcumin	Drug in Phase 3 Trial	.	.	Curcumin inhibits the expression of SLC56A1	.	.
DTD0403	SLC56A1	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC56A1	.	.
DTD0403	SLC56A1	Inhibition	Formaldehyde	Acute Toxic Substance	.	.	Formaldehyde inhibits the expression of SLC56A1	.	.
DTD0403	SLC56A1	Inhibition	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 inhibits the expression of SLC56A1	.	.
DTD0403	SLC56A1	Inhibition	Ivermectin	Approved Drug	.	.	Ivermectin inhibits the expression of SLC56A1	.	.
DTD0403	SLC56A1	Inhibition	Rifampin	Approved Drug	.	.	Rifampin inhibits the expression of SLC56A1	.	.
DTD0403	SLC56A1	Inducer	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite increases the expression of SLC56A1	.	.
DTD0403	SLC56A1	Inducer	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A increases the expression of SLC56A1	.	.
DTD0403	SLC56A1	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC56A1	.	.
DTD0406	SLC56A4	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of SLC56A4	.	.
DTD0406	SLC56A4	Inhibition	14-deoxy-11,12-didehydroandrographolide	Natural Product	.	.	14-deoxy-11,12-didehydroandrographolide inhibits the expression of SLC56A4	.	.
DTD0406	SLC56A4	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC56A4	.	.
DTD0406	SLC56A4	Inhibition	Atrazine	Herbicide	.	.	Atrazine inhibits the expression of SLC56A4	.	.
DTD0406	SLC56A4	Modulator	Carbamazepine	Approved Drug	.	.	Carbamazepine affects the expression of SLC56A4	.	.
DTD0406	SLC56A4	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC56A4	.	.
DTD0406	SLC56A4	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC56A4	.	.
DTD0406	SLC56A4	Inhibition	Ethyl Methanesulfonate	Carcinogen	.	.	Ethyl Methanesulfonate inhibits the expression of SLC56A4	.	.
DTD0406	SLC56A4	Inhibition	Formaldehyde	Acute Toxic Substance	.	.	Formaldehyde inhibits the expression of SLC56A4	.	.
DTD0406	SLC56A4	Inhibition	Hydrogen Peroxide	Approved Drug	.	.	Hydrogen Peroxide inhibits the expression of SLC56A4	.	.
DTD0406	SLC56A4	Inducer	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 increases the expression of SLC56A4	.	.
DTD0406	SLC56A4	Inducer	Metribolone	Investigative Drug	.	.	Metribolone increases the expression of SLC56A4	.	.
DTD0406	SLC56A4	Inhibition	Plant Extracts	Plant Extract	.	.	Plant Extracts inhibits the expression of SLC56A4	.	.
DTD0406	SLC56A4	Inducer	Rotenone	Drug Marketed but not Approved by US FDA	.	.	Rotenone increases the expression of SLC56A4	.	.
DTD0406	SLC56A4	Inhibition	Thapsigargin	Natural Product	.	.	Thapsigargin inhibits the expression of SLC56A4	.	.
DTD0406	SLC56A4	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC56A4	.	.
DTD0406	SLC56A4	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of SLC56A4	.	.
DTD0406	SLC56A4	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC56A4	.	.
DTD0408	SLC57A1	Inhibition	Atrazine	Herbicide	.	.	Atrazine inhibits the expression of SLC57A1	.	.
DTD0408	SLC57A1	Inhibition	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A inhibits the expression of SLC57A1	.	.
DTD0408	SLC57A1	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC57A1	.	.
DTD0408	SLC57A1	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC57A1	.	.
DTD0408	SLC57A1	Inducer	Dronabinol	Approved Drug	.	.	Dronabinol increases the expression of SLC57A1	.	.
DTD0408	SLC57A1	Inducer	Leflunomide	Approved Drug	.	.	Leflunomide increases the expression of SLC57A1	.	.
DTD0408	SLC57A1	Inducer	Potassium perchlorate	Approved Drug	.	.	Potassium perchlorate increases the expression of SLC57A1	.	.
DTD0408	SLC57A1	Inhibition	Temozolomide	Approved Drug	.	.	Temozolomide inhibits the expression of SLC57A1	.	.
DTD0408	SLC57A1	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC57A1	.	.
DTD0408	SLC57A1	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC57A1	.	.
DTD0408	SLC57A1	Inhibition	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A inhibits the expression of SLC57A1	.	.
DTD0408	SLC57A1	Inducer	Urethane	Approved Drug	.	.	Urethane increases the expression of SLC57A1	.	.
DTD0408	SLC57A1	Modulator	Valproic Acid	Approved Drug	.	.	Valproic Acid affects the expression of SLC57A1	.	.
DTD0409	SLC57A2	Inducer	Acrylamide	Acute Toxic Substance	.	.	Acrylamide increases the expression of SLC57A2	.	.
DTD0409	SLC57A2	Inhibition	Atrazine	Herbicide	.	.	Atrazine inhibits the expression of SLC57A2	.	.
DTD0409	SLC57A2	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC57A2	.	.
DTD0409	SLC57A2	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC57A2	.	.
DTD0412	SLC57A5	Inducer	Arsenic Trioxide	Approved Drug	.	.	Arsenic Trioxide increases the expression of SLC57A5	.	.
DTD0412	SLC57A5	Inducer	Avobenzone	Approved Drug	.	.	Avobenzone increases the expression of SLC57A5	.	.
DTD0412	SLC57A5	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC57A5	.	.
DTD0412	SLC57A5	Inhibition	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde inhibits the expression of SLC57A5	.	.
DTD0412	SLC57A5	Inducer	Cisplatin	Approved Drug	.	.	Cisplatin increases the expression of SLC57A5	.	.
DTD0412	SLC57A5	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC57A5	.	.
DTD0412	SLC57A5	Inducer	Ethyl Methanesulfonate	Carcinogen	.	.	Ethyl Methanesulfonate increases the expression of SLC57A5	.	.
DTD0412	SLC57A5	Inhibition	Hydroquinone	Approved Drug	.	.	Hydroquinone inhibits the expression of SLC57A5	.	.
DTD0412	SLC57A5	Modulator	Lead	Health and Environmental Toxicant	.	.	Lead affects the expression of SLC57A5	.	.
DTD0412	SLC57A5	Inducer	MS-275	Drug in Phase 2 Trial	.	.	MS-275 increases the expression of SLC57A5	.	.
DTD0412	SLC57A5	Inhibition	Sunitinib	Approved Drug	.	.	Sunitinib inhibits the expression of SLC57A5	.	.
DTD0412	SLC57A5	Inhibition	Thimerosal	Acute Toxic Substance	.	.	Thimerosal inhibits the expression of SLC57A5	.	.
DTD0412	SLC57A5	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC57A5	.	.
DTD0412	SLC57A5	Inducer	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate increases the expression of SLC57A5	.	.
DTD0412	SLC57A5	Inducer	Urethane	Approved Drug	.	.	Urethane increases the expression of SLC57A5	.	.
DTD0412	SLC57A5	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC57A5	.	.
DTD0414	SLC58A1	Inducer	Bisphenol B	Drug in Phase 2 Trial	.	.	Bisphenol B increases the expression of SLC58A1	.	.
DTD0414	SLC58A1	Inducer	Bisphenol F	Environmental toxicant	.	.	Bisphenol F increases the expression of SLC58A1	.	.
DTD0414	SLC58A1	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of SLC58A1	.	.
DTD0414	SLC58A1	Inhibition	Dicrotophos	Pesticide/Insecticide	.	.	Dicrotophos inhibits the expression of SLC58A1	.	.
DTD0414	SLC58A1	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC58A1	.	.
DTD0414	SLC58A1	Inducer	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 increases the expression of SLC58A1	.	.
DTD0414	SLC58A1	Inhibition	Ivermectin	Approved Drug	.	.	Ivermectin inhibits the expression of SLC58A1	.	.
DTD0414	SLC58A1	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC58A1	.	.
DTD0414	SLC58A1	Inhibition	Temozolomide	Approved Drug	.	.	Temozolomide inhibits the expression of SLC58A1	.	.
DTD0414	SLC58A1	Modulator	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A affects the expression of SLC58A1	.	.
DTD0414	SLC58A1	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC58A1	.	.
DTD0414	SLC58A1	Inhibition	Vincristine	Approved Drug	.	.	Vincristine inhibits the expression of SLC58A1	.	.
DTD0414	SLC58A1	Inducer	Vorinostat	Approved Drug	.	.	Vorinostat increases the expression of SLC58A1	.	.
DTD0414	SLC58A1	Inducer	Zinc	Environmental toxicant	.	.	Zinc increases the expression of SLC58A1	.	.
DTD0415	SLC58A2	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of SLC58A2	.	.
DTD0415	SLC58A2	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC58A2	.	.
DTD0415	SLC58A2	Inducer	Amiodarone	Approved Drug	.	.	Amiodarone increases the expression of SLC58A2	.	.
DTD0415	SLC58A2	Inducer	Azathioprine	Approved Drug	.	.	Azathioprine increases the expression of SLC58A2	.	.
DTD0415	SLC58A2	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of SLC58A2	.	.
DTD0415	SLC58A2	Inducer	Copper Sulfate	Approved Drug	.	.	Copper Sulfate increases the expression of SLC58A2	.	.
DTD0415	SLC58A2	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC58A2	.	.
DTD0415	SLC58A2	Inhibition	Ivermectin	Approved Drug	.	.	Ivermectin inhibits the expression of SLC58A2	.	.
DTD0415	SLC58A2	Inducer	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin increases the expression of SLC58A2	.	.
DTD0415	SLC58A2	Inducer	Temozolomide	Approved Drug	.	.	Temozolomide increases the expression of SLC58A2	.	.
DTD0415	SLC58A2	Inducer	Theophylline	Approved Drug	.	.	Theophylline increases the expression of SLC58A2	.	.
DTD0415	SLC58A2	Inducer	Urethane	Approved Drug	.	.	Urethane increases the expression of SLC58A2	.	.
DTD0415	SLC58A2	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC58A2	.	.
DTD0416	SLC59A1	Inducer	1-methyl-4-phenylpyridinium	Health and Environmental Toxicant	.	.	1-methyl-4-phenylpyridinium increases the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inducer	Acrylamide	Acute Toxic Substance	.	.	Acrylamide increases the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inducer	Antimycin A	Acute Toxic Substance	.	.	Antimycin A increases the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inhibition	Azathioprine	Approved Drug	.	.	Azathioprine inhibits the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inducer	Azoxystrobin	Fungicide	.	.	Azoxystrobin increases the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inhibition	Benzatropine	Approved Drug	.	.	Benzatropine inhibits the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inducer	Beta-naphthoflavone	Investigative Drug	.	.	Beta-naphthoflavone increases the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inhibition	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A inhibits the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inducer	Bisphenol B	Drug in Phase 2 Trial	.	.	Bisphenol B increases the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inducer	Bisphenol F	Environmental toxicant	.	.	Bisphenol F increases the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inducer	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde increases the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inhibition	Chloropicrin	Acute Toxic Substance	.	.	Chloropicrin inhibits the expression of SLC59A1	.	.
DTD0416	SLC59A1	Modulator	Cidofovir	Approved Drug	.	.	Cidofovir affects the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inhibition	Clodronic Acid	Drug Marketed but not Approved by US FDA	.	.	Clodronic Acid inhibits the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inducer	Copper Sulfate	Approved Drug	.	.	Copper Sulfate increases the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inducer	Coumestrol	Investigative Drug	.	.	Coumestrol increases the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inducer	Deguelin	Natural Product	.	.	Deguelin increases the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inhibition	Deoxynivalenol	Mycotoxins	.	.	Deoxynivalenol inhibits the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inhibition	Dexamethasone	Approved Drug	.	.	Dexamethasone inhibits the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC59A1	.	.
DTD0416	SLC59A1	Modulator	Estradiol	Approved Drug	.	.	Estradiol affects the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inducer	Ethanol	Drug in Phase 2 Trial	.	.	Ethanol increases the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inducer	Fenofibrate	Approved Drug	.	.	Fenofibrate increases the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inhibition	Gold Sodium Thiomalate	Drug in Phase 1 Trial	.	.	Gold Sodium Thiomalate inhibits the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inducer	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 increases the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inducer	Ifosfamide	Approved Drug	.	.	Ifosfamide increases the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inducer	Isotretinoin	Approved Drug	.	.	Isotretinoin increases the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inhibition	Ivermectin	Approved Drug	.	.	Ivermectin inhibits the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inhibition	Lucanthone	Drug in Phase 2 Trial	.	.	Lucanthone inhibits the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inhibition	Methotrexate	Approved Drug	.	.	Methotrexate inhibits the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inhibition	Methylprednisolone	Approved Drug	.	.	Methylprednisolone inhibits the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inhibition	Metribolone	Investigative Drug	.	.	Metribolone inhibits the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inducer	Nicotine polacrilex	Approved Drug	.	.	Nicotine polacrilex increases the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inhibition	Ochratoxin A	Acute Toxic Substance	.	.	Ochratoxin A inhibits the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inhibition	Particulate Matter	Natural Product	.	.	Particulate Matter inhibits the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inducer	Perfluorooctane sulfonic acid	Health and Environmental Toxicant	.	.	Perfluorooctane sulfonic acid increases the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inhibition	Piroxicam	Approved Drug	.	.	Piroxicam inhibits the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inhibition	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin inhibits the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inhibition	Prednisolone	Approved Drug	.	.	Prednisolone inhibits the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inhibition	Rotenone	Drug Marketed but not Approved by US FDA	.	.	Rotenone inhibits the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inducer	Silver nanoparticle	Nanoparticle	.	.	Silver nanoparticle increases the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inducer	Sulforafan	Drug in Phase 3 Trial	.	.	Sulforafan increases the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inducer	Temozolomide	Approved Drug	.	.	Temozolomide increases the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inhibition	Tetrabromobisphenol A	Environmental toxicant	.	.	Tetrabromobisphenol A inhibits the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inducer	Thapsigargin	Natural Product	.	.	Thapsigargin increases the expression of SLC59A1	.	.
DTD0416	SLC59A1	Modulator	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution affects the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inducer	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan increases the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inducer	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate increases the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inducer	Troglitazone	Approved Drug	.	.	Troglitazone increases the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inhibition	Vitamin C	Approved Drug	.	.	Vitamin C inhibits the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inducer	Zinc	Environmental toxicant	.	.	Zinc increases the expression of SLC59A1	.	.
DTD0416	SLC59A1	Inhibition	Zoledronic Acid	Approved Drug	.	.	Zoledronic Acid inhibits the expression of SLC59A1	.	.
DTD0418	SLC5A1	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC5A1	.	.
DTD0418	SLC5A1	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC5A1	.	.
DTD0418	SLC5A1	Inducer	Caffeic acid	Health and Environmental Toxicant	.	.	Caffeic acid increases the expression of SLC5A1	.	.
DTD0418	SLC5A1	Inducer	Cannabidiol	Approved Drug	.	.	Cannabidiol increases the expression of SLC5A1	.	.
DTD0418	SLC5A1	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC5A1	.	.
DTD0418	SLC5A1	Inhibition	Ethanol	Drug in Phase 2 Trial	.	.	Ethanol inhibits the expression of SLC5A1	.	.
DTD0418	SLC5A1	Blocker	GSK1614235	Drug in Phase 1 Trial	.	.	GSK1614235 blocks the activity of SLC5A1	.	.
DTD0418	SLC5A1	Modulator	GSK1614235 + GSK2330672	Drug in Phase 1 Trial	.	.	GSK1614235 + GSK2330672 modulates the activity of SLC5A1	.	.
DTD0418	SLC5A1	Inducer	Hydroquinone	Approved Drug	.	.	Hydroquinone increases the expression of SLC5A1	.	.
DTD0418	SLC5A1	Inducer	Hyperoside	Natural Product	.	.	Hyperoside increases the expression of SLC5A1	.	.
DTD0418	SLC5A1	Inhibition	LIK-066	Drug in Phase 2 Trial	.	.	LIK-066 inhibits the activity of SLC5A1	.	.
DTD0418	SLC5A1	Modulator	LX-4211	Drug in Phase 3 Trial	.	.	LX-4211 modulates the activity of SLC5A1	.	.
DTD0418	SLC5A1	Inhibition	Methyleugenol	Natural Product	.	.	Methyleugenol inhibits the expression of SLC5A1	.	.
DTD0418	SLC5A1	Inhibition	Milchsaure	Investigative Drug	.	.	Milchsaure inhibits the expression of SLC5A1	.	.
DTD0418	SLC5A1	Inhibition	Ochratoxin A	Acute Toxic Substance	.	.	Ochratoxin A inhibits the expression of SLC5A1	.	.
DTD0418	SLC5A1	Inducer	Particulate Matter	Natural Product	.	.	Particulate Matter increases the expression of SLC5A1	.	.
DTD0418	SLC5A1	Inhibition	Phloretin	Investigative Drug	.	.	Phloretin inhibits the activity of SLC5A1	.	.
DTD0418	SLC5A1	Inhibition	Phlorizin	Investigative Drug	.	.	Phlorizin inhibits the activity of SLC5A1	.	.
DTD0418	SLC5A1	Inducer	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin increases the expression of SLC5A1	.	.
DTD0418	SLC5A1	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC5A1	.	.
DTD0418	SLC5A1	Inhibition	Sunitinib	Approved Drug	.	.	Sunitinib inhibits the expression of SLC5A1	.	.
DTD0418	SLC5A1	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC5A1	.	.
DTD0418	SLC5A1	Inhibition	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan inhibits the expression of SLC5A1	.	.
DTD0419	SLC5A10	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC5A10	.	.
DTD0419	SLC5A10	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC5A10	.	.
DTD0419	SLC5A10	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of SLC5A10	.	.
DTD0420	SLC5A11	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of SLC5A11	.	.
DTD0420	SLC5A11	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC5A11	.	.
DTD0420	SLC5A11	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of SLC5A11	.	.
DTD0420	SLC5A11	Inhibition	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A inhibits the expression of SLC5A11	.	.
DTD0420	SLC5A11	Inhibition	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde inhibits the expression of SLC5A11	.	.
DTD0420	SLC5A11	Inducer	Copper Sulfate	Approved Drug	.	.	Copper Sulfate increases the expression of SLC5A11	.	.
DTD0420	SLC5A11	Inducer	Methyleugenol	Natural Product	.	.	Methyleugenol increases the expression of SLC5A11	.	.
DTD0420	SLC5A11	Inhibition	Pentanal	Chemical Compound	.	.	Pentanal inhibits the expression of SLC5A11	.	.
DTD0420	SLC5A11	Inducer	Phenobarbital	Approved Drug	.	.	Phenobarbital increases the expression of SLC5A11	.	.
DTD0420	SLC5A11	Inducer	Rifampin	Approved Drug	.	.	Rifampin increases the expression of SLC5A11	.	.
DTD0420	SLC5A11	Inducer	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan increases the expression of SLC5A11	.	.
DTD0420	SLC5A11	Inhibition	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate inhibits the expression of SLC5A11	.	.
DTD0420	SLC5A11	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of SLC5A11	.	.
DTD0421	SLC5A12	Inducer	Arsenic Trioxide	Approved Drug	.	.	Arsenic Trioxide increases the expression of SLC5A12	.	.
DTD0421	SLC5A12	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC5A12	.	.
DTD0421	SLC5A12	Inhibition	Cadmium	Acute Toxic Substance	.	.	Cadmium inhibits the expression of SLC5A12	.	.
DTD0421	SLC5A12	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC5A12	.	.
DTD0421	SLC5A12	Inhibition	Cytarabine	Approved Drug	.	.	Cytarabine inhibits the expression of SLC5A12	.	.
DTD0421	SLC5A12	Inhibition	Diethylhexyl Phthalate	Health and Environmental Toxicant	.	.	Diethylhexyl Phthalate inhibits the expression of SLC5A12	.	.
DTD0421	SLC5A12	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC5A12	.	.
DTD0421	SLC5A12	Inducer	Folic Acid	Approved Drug	.	.	Folic Acid increases the expression of SLC5A12	.	.
DTD0421	SLC5A12	Modulator	Hydrogen Peroxide	Approved Drug	.	.	Hydrogen Peroxide affects the expression of SLC5A12	.	.
DTD0421	SLC5A12	Inhibition	Methyleugenol	Natural Product	.	.	Methyleugenol inhibits the expression of SLC5A12	.	.
DTD0421	SLC5A12	Inducer	Rifampin	Approved Drug	.	.	Rifampin increases the expression of SLC5A12	.	.
DTD0421	SLC5A12	Inducer	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A increases the expression of SLC5A12	.	.
DTD0421	SLC5A12	Inducer	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate increases the expression of SLC5A12	.	.
DTD0421	SLC5A12	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC5A12	.	.
DTD0421	SLC5A12	Inducer	Vorinostat	Approved Drug	.	.	Vorinostat increases the expression of SLC5A12	.	.
DTD0422	SLC5A2	Inducer	Atrazine	Herbicide	.	.	Atrazine increases the expression of SLC5A2	.	.
DTD0422	SLC5A2	Inhibition	Bexagliflozin	Drug in Phase 3 Trial	.	.	Bexagliflozin inhibits the activity of SLC5A2	.	.
DTD0422	SLC5A2	Inhibition	Canagliflozin	Approved Drug	.	.	Canagliflozin inhibits the activity of SLC5A2	.	.
DTD0422	SLC5A2	Inducer	Cannabidiol	Approved Drug	.	.	Cannabidiol increases the expression of SLC5A2	.	.
DTD0422	SLC5A2	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the expression of SLC5A2	.	.
DTD0422	SLC5A2	Inhibition	Ertugliflozin	Approved Drug	.	.	Ertugliflozin inhibits the activity of SLC5A2	.	.
DTD0422	SLC5A2	Inhibition	Formononetin	Investigative Drug	.	.	Formononetin inhibits the activity of SLC5A2	.	.
DTD0422	SLC5A2	Inhibition	Jinfukang	Traditional Medicine	.	.	Jinfukang inhibits the expression of SLC5A2	.	.
DTD0422	SLC5A2	Inhibition	Methyleugenol	Natural Product	.	.	Methyleugenol inhibits the expression of SLC5A2	.	.
DTD0422	SLC5A2	Inhibition	Pioglitazone	Approved Drug	.	.	Pioglitazone inhibits the activity of SLC5A2	.	.
DTD0422	SLC5A2	Modulator	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin affects the expression of SLC5A2	.	.
DTD0422	SLC5A2	Inhibition	Remogliflozin etabonate	Drug in Phase 1 Trial	.	.	Remogliflozin etabonate inhibits the activity of SLC5A2	.	.
DTD0422	SLC5A2	Inhibition	Sergliflozin A	Investigative Drug	.	.	Sergliflozin A inhibits the activity of SLC5A2	.	.
DTD0422	SLC5A2	Inhibition	Sophoraflavanone G	Investigative Drug	.	.	Sophoraflavanone G inhibits the activity of SLC5A2	.	.
DTD0422	SLC5A2	Inducer	Troglitazone	Approved Drug	.	.	Troglitazone induces the activity of SLC5A2	.	.
DTD0422	SLC5A2	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of SLC5A2	.	.
DTD0423	SLC5A3	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of SLC5A3	.	.
DTD0423	SLC5A3	Inducer	Acrylamide	Acute Toxic Substance	.	.	Acrylamide increases the expression of SLC5A3	.	.
DTD0423	SLC5A3	Inhibition	Aflatoxin M1	Mycotoxins	.	.	Aflatoxin M1 inhibits the expression of SLC5A3	.	.
DTD0423	SLC5A3	Inducer	Amiodarone	Approved Drug	.	.	Amiodarone increases the expression of SLC5A3	.	.
DTD0423	SLC5A3	Inducer	Avobenzone	Approved Drug	.	.	Avobenzone increases the expression of SLC5A3	.	.
DTD0423	SLC5A3	Inhibition	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A inhibits the expression of SLC5A3	.	.
DTD0423	SLC5A3	Inhibition	Cadmium	Acute Toxic Substance	.	.	Cadmium inhibits the expression of SLC5A3	.	.
DTD0423	SLC5A3	Inducer	Calcitriol	Approved Drug	.	.	Calcitriol increases the expression of SLC5A3	.	.
DTD0423	SLC5A3	Modulator	Carbamazepine	Approved Drug	.	.	Carbamazepine affects the expression of SLC5A3	.	.
DTD0423	SLC5A3	Inducer	Cisplatin	Approved Drug	.	.	Cisplatin increases the expression of SLC5A3	.	.
DTD0423	SLC5A3	Inducer	Coumestrol	Investigative Drug	.	.	Coumestrol increases the expression of SLC5A3	.	.
DTD0423	SLC5A3	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC5A3	.	.
DTD0423	SLC5A3	Inhibition	Dexamethasone	Approved Drug	.	.	Dexamethasone inhibits the expression of SLC5A3	.	.
DTD0423	SLC5A3	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC5A3	.	.
DTD0423	SLC5A3	Inducer	Ethanol	Drug in Phase 2 Trial	.	.	Ethanol increases the expression of SLC5A3	.	.
DTD0423	SLC5A3	Inducer	Hydrogen Peroxide	Approved Drug	.	.	Hydrogen Peroxide increases the expression of SLC5A3	.	.
DTD0423	SLC5A3	Inhibition	Hydroquinone	Approved Drug	.	.	Hydroquinone inhibits the expression of SLC5A3	.	.
DTD0423	SLC5A3	Inducer	Lithium Chloride	Health and Environmental Toxicant	.	.	Lithium Chloride increases the expression of SLC5A3	.	.
DTD0423	SLC5A3	Inhibition	Medroxyprogesterone Acetate	Approved Drug	.	.	Medroxyprogesterone Acetate inhibits the expression of SLC5A3	.	.
DTD0423	SLC5A3	Inducer	Phenylmercuric Acetate	Investigative Drug	.	.	Phenylmercuric Acetate increases the expression of SLC5A3	.	.
DTD0423	SLC5A3	Inducer	Piroxicam	Approved Drug	.	.	Piroxicam increases the expression of SLC5A3	.	.
DTD0423	SLC5A3	Modulator	Polychlorinated Biphenyls	Carcinogen	.	.	Polychlorinated Biphenyls affects the expression of SLC5A3	.	.
DTD0423	SLC5A3	Inhibition	Progesterone	Approved Drug	.	.	Progesterone inhibits the expression of SLC5A3	.	.
DTD0423	SLC5A3	Inducer	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin increases the expression of SLC5A3	.	.
DTD0423	SLC5A3	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of SLC5A3	.	.
DTD0423	SLC5A3	Inducer	Thimerosal	Acute Toxic Substance	.	.	Thimerosal increases the expression of SLC5A3	.	.
DTD0423	SLC5A3	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC5A3	.	.
DTD0423	SLC5A3	Inducer	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A increases the expression of SLC5A3	.	.
DTD0423	SLC5A3	Inducer	Urethane	Approved Drug	.	.	Urethane increases the expression of SLC5A3	.	.
DTD0423	SLC5A3	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC5A3	.	.
DTD0423	SLC5A3	Inhibition	Vorinostat	Approved Drug	.	.	Vorinostat inhibits the expression of SLC5A3	.	.
DTD0423	SLC5A3	Inhibition	Zidovudine	Approved Drug	.	.	Zidovudine inhibits the expression of SLC5A3	.	.
DTD0423	SLC5A3	Inhibition	Zoledronic Acid	Approved Drug	.	.	Zoledronic Acid inhibits the expression of SLC5A3	.	.
DTD0424	SLC5A4	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of SLC5A4	.	.
DTD0424	SLC5A4	Inhibition	Diethylhexyl Phthalate	Health and Environmental Toxicant	.	.	Diethylhexyl Phthalate inhibits the expression of SLC5A4	.	.
DTD0424	SLC5A4	Modulator	Remogli ozin-etabonate	Drug in Phase 2 Trial	.	.	Remogli ozin-etabonate modulates the activity of SLC5A4	.	.
DTD0424	SLC5A4	Blocker	Remogliflozin etabonate	Drug in Phase 2 Trial	.	.	Remogliflozin etabonate blocks the activity of SLC5A4	.	.
DTD0424	SLC5A4	Modulator	RG7201	Drug in Phase 3 Trial	.	.	RG7201 modulates the activity of SLC5A4	.	.
DTD0424	SLC5A4	Modulator	SaxaDapa FDC	Drug in Phase 3 Trial	.	.	SaxaDapa FDC modulates the activity of SLC5A4	.	.
DTD0425	SLC5A5	Inducer	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 increases the expression of SLC5A5	.	.
DTD0425	SLC5A5	Inducer	Alitretinoin	Approved Drug	.	.	Alitretinoin increases the expression of SLC5A5	.	.
DTD0425	SLC5A5	Inhibition	Amiodarone	Approved Drug	.	.	Amiodarone inhibits the expression of SLC5A5	.	.
DTD0425	SLC5A5	Inducer	Azacitidine	Approved Drug	.	.	Azacitidine increases the expression of SLC5A5	.	.
DTD0425	SLC5A5	Inducer	Butylbenzyl phthalate	Health and Environmental Toxicant	.	.	Butylbenzyl phthalate increases the expression of SLC5A5	.	.
DTD0425	SLC5A5	Inducer	Butyrate	Drug in Phase 1 Trial	.	.	Butyrate increases the expression of SLC5A5	.	.
DTD0425	SLC5A5	Inducer	Colforsin	Drug in Phase 2 Trial	.	.	Colforsin increases the expression of SLC5A5	.	.
DTD0425	SLC5A5	Inducer	Cycloheximide	Acute Toxic Substance	.	.	Cycloheximide increases the expression of SLC5A5	.	.
DTD0425	SLC5A5	Inducer	Decitabine	Approved Drug	.	.	Decitabine increases the expression of SLC5A5	.	.
DTD0425	SLC5A5	Inhibition	Dibutyl Phthalate	Health and Environmental Toxicant	.	.	Dibutyl Phthalate inhibits the expression of SLC5A5	.	.
DTD0425	SLC5A5	Inducer	Genistein	Drug in Phase 2 Trial	.	.	Genistein increases the expression of SLC5A5	.	.
DTD0425	SLC5A5	Inducer	Methimazole	Approved Drug	.	.	Methimazole increases the expression of SLC5A5	.	.
DTD0425	SLC5A5	Inhibition	Potassium perchlorate	Approved Drug	.	.	Potassium perchlorate inhibits the activity of SLC5A5	.	.
DTD0425	SLC5A5	Inducer	Propylthiouracil	Approved Drug	.	.	Propylthiouracil induces the activity of SLC5A5	.	.
DTD0425	SLC5A5	Modulator	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin affects the expression of SLC5A5	.	.
DTD0425	SLC5A5	Inducer	Resveratrol	Drug in Phase 3 Trial	.	.	Resveratrol increases the expression of SLC5A5	.	.
DTD0425	SLC5A5	Inducer	Tazarotene	Approved Drug	.	.	Tazarotene increases the expression of SLC5A5	.	.
DTD0425	SLC5A5	Inhibition	Tebuconazole	Fungicide	.	.	Tebuconazole inhibits the expression of SLC5A5	.	.
DTD0425	SLC5A5	Inducer	Theophylline	Approved Drug	.	.	Theophylline increases the expression of SLC5A5	.	.
DTD0425	SLC5A5	Modulator	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution affects the expression of SLC5A5	.	.
DTD0425	SLC5A5	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC5A5	.	.
DTD0425	SLC5A5	Inducer	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A increases the expression of SLC5A5	.	.
DTD0425	SLC5A5	Inducer	Troglitazone	Approved Drug	.	.	Troglitazone increases the expression of SLC5A5	.	.
DTD0425	SLC5A5	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC5A5	.	.
DTD0425	SLC5A5	Inducer	Vorinostat	Approved Drug	.	.	Vorinostat increases the expression of SLC5A5	.	.
DTD0426	SLC5A6	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of SLC5A6	.	.
DTD0426	SLC5A6	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of SLC5A6	.	.
DTD0426	SLC5A6	Inducer	Arsenic Trioxide	Approved Drug	.	.	Arsenic Trioxide increases the expression of SLC5A6	.	.
DTD0426	SLC5A6	Modulator	Biotin	Drug Marketed but not Approved by US FDA	.	.	Biotin affects the expression of SLC5A6	.	.
DTD0426	SLC5A6	Modulator	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A affects the expression of SLC5A6	.	.
DTD0426	SLC5A6	Inhibition	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde inhibits the expression of SLC5A6	.	.
DTD0426	SLC5A6	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC5A6	.	.
DTD0426	SLC5A6	Inducer	Dicrotophos	Pesticide/Insecticide	.	.	Dicrotophos increases the expression of SLC5A6	.	.
DTD0426	SLC5A6	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC5A6	.	.
DTD0426	SLC5A6	Modulator	Gabapentin enacarbil	Approved Drug	.	.	Gabapentin enacarbil modulates the activity of SLC5A6	.	.
DTD0426	SLC5A6	Inducer	Genistein	Drug in Phase 2 Trial	.	.	Genistein increases the expression of SLC5A6	.	.
DTD0426	SLC5A6	Modulator	Hydrogen Peroxide	Approved Drug	.	.	Hydrogen Peroxide affects the expression of SLC5A6	.	.
DTD0426	SLC5A6	Inhibition	Isotretinoin	Approved Drug	.	.	Isotretinoin inhibits the expression of SLC5A6	.	.
DTD0426	SLC5A6	Inhibition	K-7174	Patented Pharmaceutical Agent	.	.	K-7174 inhibits the expression of SLC5A6	.	.
DTD0426	SLC5A6	Inhibition	Perfluorooctane sulfonic acid	Health and Environmental Toxicant	.	.	Perfluorooctane sulfonic acid inhibits the expression of SLC5A6	.	.
DTD0426	SLC5A6	Inhibition	Phenylbutazone	Approved Drug	.	.	Phenylbutazone inhibits the activity of SLC5A6	.	.
DTD0426	SLC5A6	Modulator	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin affects the expression of SLC5A6	.	.
DTD0426	SLC5A6	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC5A6	.	.
DTD0426	SLC5A6	Modulator	Valproic Acid	Approved Drug	.	.	Valproic Acid affects the expression of SLC5A6	.	.
DTD0427	SLC5A7	Modulator	[3H]Hemicholinium-3	Investigative Drug	.	.	[3H]Hemicholinium-3 modulates the activity of SLC5A7	.	.
DTD0427	SLC5A7	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of SLC5A7	.	.
DTD0427	SLC5A7	Inhibition	Thimerosal	Acute Toxic Substance	.	.	Thimerosal inhibits the expression of SLC5A7	.	.
DTD0427	SLC5A7	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC5A7	.	.
DTD0427	SLC5A7	Inducer	Tretinoin	Approved Drug	.	.	Tretinoin increases the expression of SLC5A7	.	.
DTD0427	SLC5A7	Inducer	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan increases the expression of SLC5A7	.	.
DTD0427	SLC5A7	Modulator	Valproic Acid	Approved Drug	.	.	Valproic Acid affects the expression of SLC5A7	.	.
DTD0428	SLC5A8	Inhibition	Atrazine	Herbicide	.	.	Atrazine inhibits the expression of SLC5A8	.	.
DTD0428	SLC5A8	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of SLC5A8	.	.
DTD0428	SLC5A8	Modulator	Hydrogen Peroxide	Approved Drug	.	.	Hydrogen Peroxide affects the expression of SLC5A8	.	.
DTD0428	SLC5A8	Inhibition	Ibuprofen	Approved Drug	.	.	Ibuprofen inhibits the activity of SLC5A8	.	.
DTD0428	SLC5A8	Inducer	ICG-001	Patented Pharmaceutical Agent	.	.	ICG-001 increases the expression of SLC5A8	.	.
DTD0428	SLC5A8	Inhibition	Probenecid	Approved Drug	.	.	Probenecid inhibits the activity of SLC5A8	.	.
DTD0428	SLC5A8	Modulator	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution affects the expression of SLC5A8	.	.
DTD0429	SLC5A9	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC5A9	.	.
DTD0429	SLC5A9	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC5A9	.	.
DTD0429	SLC5A9	Inhibition	Azathioprine	Approved Drug	.	.	Azathioprine inhibits the expression of SLC5A9	.	.
DTD0429	SLC5A9	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC5A9	.	.
DTD0429	SLC5A9	Modulator	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A affects the expression of SLC5A9	.	.
DTD0429	SLC5A9	Inhibition	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde inhibits the expression of SLC5A9	.	.
DTD0429	SLC5A9	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC5A9	.	.
DTD0429	SLC5A9	Inhibition	Methyleugenol	Natural Product	.	.	Methyleugenol inhibits the expression of SLC5A9	.	.
DTD0429	SLC5A9	Inhibition	Pentanal	Chemical Compound	.	.	Pentanal inhibits the expression of SLC5A9	.	.
DTD0429	SLC5A9	Inhibition	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin inhibits the expression of SLC5A9	.	.
DTD0429	SLC5A9	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of SLC5A9	.	.
DTD0429	SLC5A9	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC5A9	.	.
DTD0429	SLC5A9	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC5A9	.	.
DTD0429	SLC5A9	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of SLC5A9	.	.
DTD0429	SLC5A9	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC5A9	.	.
DTD0433	SLC62A1	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC62A1	.	.
DTD0433	SLC62A1	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC62A1	.	.
DTD0433	SLC62A1	Inhibition	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde inhibits the expression of SLC62A1	.	.
DTD0433	SLC62A1	Inducer	Calcitriol	Approved Drug	.	.	Calcitriol increases the expression of SLC62A1	.	.
DTD0433	SLC62A1	Modulator	Carbamazepine	Approved Drug	.	.	Carbamazepine affects the expression of SLC62A1	.	.
DTD0433	SLC62A1	Inducer	Dasatinib	Approved Drug	.	.	Dasatinib increases the expression of SLC62A1	.	.
DTD0433	SLC62A1	Inducer	Dihydrotestosterone	Drug in Phase 1 Trial	.	.	Dihydrotestosterone increases the expression of SLC62A1	.	.
DTD0433	SLC62A1	Inducer	Doxorubicin	Approved Drug	.	.	Doxorubicin increases the expression of SLC62A1	.	.
DTD0433	SLC62A1	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC62A1	.	.
DTD0433	SLC62A1	Inducer	Methotrexate	Approved Drug	.	.	Methotrexate increases the expression of SLC62A1	.	.
DTD0433	SLC62A1	Inhibition	Milchsaure	Investigative Drug	.	.	Milchsaure inhibits the expression of SLC62A1	.	.
DTD0433	SLC62A1	Inducer	MS-275	Drug in Phase 2 Trial	.	.	MS-275 increases the expression of SLC62A1	.	.
DTD0433	SLC62A1	Inducer	Panobinostat	Approved Drug	.	.	Panobinostat increases the expression of SLC62A1	.	.
DTD0433	SLC62A1	Inducer	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin increases the expression of SLC62A1	.	.
DTD0433	SLC62A1	Inducer	Silver nanoparticle	Nanoparticle	.	.	Silver nanoparticle increases the expression of SLC62A1	.	.
DTD0433	SLC62A1	Inhibition	Sulforafan	Drug in Phase 3 Trial	.	.	Sulforafan inhibits the expression of SLC62A1	.	.
DTD0433	SLC62A1	Inducer	Testosterone	Approved Drug	.	.	Testosterone increases the expression of SLC62A1	.	.
DTD0433	SLC62A1	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC62A1	.	.
DTD0433	SLC62A1	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC62A1	.	.
DTD0433	SLC62A1	Inducer	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A increases the expression of SLC62A1	.	.
DTD0433	SLC62A1	Inhibition	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate inhibits the expression of SLC62A1	.	.
DTD0433	SLC62A1	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC62A1	.	.
DTD0433	SLC62A1	Inhibition	Vorinostat	Approved Drug	.	.	Vorinostat inhibits the expression of SLC62A1	.	.
DTD0435	SLC63A2	Inducer	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 increases the expression of SLC63A2	.	.
DTD0435	SLC63A2	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC63A2	.	.
DTD0435	SLC63A2	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC63A2	.	.
DTD0435	SLC63A2	Inducer	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde increases the expression of SLC63A2	.	.
DTD0435	SLC63A2	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC63A2	.	.
DTD0435	SLC63A2	Inducer	Diethylhexyl Phthalate	Health and Environmental Toxicant	.	.	Diethylhexyl Phthalate increases the expression of SLC63A2	.	.
DTD0435	SLC63A2	Inducer	Estradiol	Approved Drug	.	.	Estradiol increases the expression of SLC63A2	.	.
DTD0435	SLC63A2	Inducer	Fenofibrate	Approved Drug	.	.	Fenofibrate increases the expression of SLC63A2	.	.
DTD0435	SLC63A2	Inducer	GW-7647	Patented Pharmaceutical Agent	.	.	GW-7647 increases the expression of SLC63A2	.	.
DTD0435	SLC63A2	Inhibition	Methotrexate	Approved Drug	.	.	Methotrexate inhibits the expression of SLC63A2	.	.
DTD0435	SLC63A2	Inhibition	Methyleugenol	Natural Product	.	.	Methyleugenol inhibits the expression of SLC63A2	.	.
DTD0435	SLC63A2	Inhibition	Milchsaure	Investigative Drug	.	.	Milchsaure inhibits the expression of SLC63A2	.	.
DTD0435	SLC63A2	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC63A2	.	.
DTD0435	SLC63A2	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of SLC63A2	.	.
DTD0435	SLC63A2	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC63A2	.	.
DTD0435	SLC63A2	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC63A2	.	.
DTD0435	SLC63A2	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC63A2	.	.
DTD0439	SLC65A2	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the expression of SLC65A2	.	.
DTD0439	SLC65A2	Inducer	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 increases the expression of SLC65A2	.	.
DTD0439	SLC65A2	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC65A2	.	.
DTD0439	SLC65A2	Inducer	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde increases the expression of SLC65A2	.	.
DTD0439	SLC65A2	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC65A2	.	.
DTD0439	SLC65A2	Inducer	Dicrotophos	Pesticide/Insecticide	.	.	Dicrotophos increases the expression of SLC65A2	.	.
DTD0439	SLC65A2	Inhibition	Ezetimibe	Approved Drug	.	.	Ezetimibe inhibits the activity of SLC65A2	.	.
DTD0439	SLC65A2	Inhibition	Ezetimibe-glucuronide	Investigative Drug	.	.	Ezetimibe-glucuronide inhibits the activity of SLC65A2	.	.
DTD0439	SLC65A2	Inducer	Methotrexate	Approved Drug	.	.	Methotrexate increases the expression of SLC65A2	.	.
DTD0439	SLC65A2	Inhibition	Perfluorooctane sulfonic acid	Health and Environmental Toxicant	.	.	Perfluorooctane sulfonic acid inhibits the expression of SLC65A2	.	.
DTD0439	SLC65A2	Inhibition	Simvastatin	Approved Drug	.	.	Simvastatin inhibits the expression of SLC65A2	.	.
DTD0439	SLC65A2	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC65A2	.	.
DTD0439	SLC65A2	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC65A2	.	.
DTD0439	SLC65A2	Inducer	Zoledronic Acid	Approved Drug	.	.	Zoledronic Acid increases the expression of SLC65A2	.	.
DTD0440	SLC6A1	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC6A1	.	.
DTD0440	SLC6A1	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC6A1	.	.
DTD0440	SLC6A1	Modulator	Bosentan	Approved Drug	.	.	Bosentan affects the expression of SLC6A1	.	.
DTD0440	SLC6A1	Inhibition	Coal Ash	Natural Product	.	.	Coal Ash inhibits the expression of SLC6A1	.	.
DTD0440	SLC6A1	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC6A1	.	.
DTD0440	SLC6A1	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC6A1	.	.
DTD0440	SLC6A1	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the expression of SLC6A1	.	.
DTD0440	SLC6A1	Modulator	Lead	Health and Environmental Toxicant	.	.	Lead affects the expression of SLC6A1	.	.
DTD0440	SLC6A1	Inducer	MS-275	Drug in Phase 2 Trial	.	.	MS-275 increases the expression of SLC6A1	.	.
DTD0440	SLC6A1	Inhibition	Perfluorooctane sulfonic acid	Health and Environmental Toxicant	.	.	Perfluorooctane sulfonic acid inhibits the expression of SLC6A1	.	.
DTD0440	SLC6A1	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC6A1	.	.
DTD0440	SLC6A1	Inhibition	ST-1535	Investigative Drug	.	.	ST-1535 inhibits the activity of SLC6A1	.	.
DTD0440	SLC6A1	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC6A1	.	.
DTD0440	SLC6A1	Inhibition	Troglitazone	Approved Drug	.	.	Troglitazone inhibits the expression of SLC6A1	.	.
DTD0440	SLC6A1	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC6A1	.	.
DTD0443	SLC6A11	Blocker	Beta-alanine	Investigative Drug	.	.	Beta-alanine blocks the activity of SLC6A11	.	.
DTD0443	SLC6A11	Inhibition	Gamma-aminobutyric acid	Drug in Phase 2 Trial	.	.	Gamma-aminobutyric acid inhibits the activity of SLC6A11	.	.
DTD0443	SLC6A11	Modulator	Lead	Health and Environmental Toxicant	.	.	Lead affects the expression of SLC6A11	.	.
DTD0443	SLC6A11	Inhibition	Milchsaure	Investigative Drug	.	.	Milchsaure inhibits the expression of SLC6A11	.	.
DTD0443	SLC6A11	Inhibition	Phenylmercuric Acetate	Investigative Drug	.	.	Phenylmercuric Acetate inhibits the expression of SLC6A11	.	.
DTD0443	SLC6A11	Inducer	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin increases the expression of SLC6A11	.	.
DTD0443	SLC6A11	Inhibition	Progesterone	Approved Drug	.	.	Progesterone inhibits the expression of SLC6A11	.	.
DTD0443	SLC6A11	Inhibition	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin inhibits the expression of SLC6A11	.	.
DTD0443	SLC6A11	Inducer	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite increases the expression of SLC6A11	.	.
DTD0443	SLC6A11	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC6A11	.	.
DTD0443	SLC6A11	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC6A11	.	.
DTD0443	SLC6A11	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of SLC6A11	.	.
DTD0444	SLC6A12	Inhibition	(R)-EF-1520	Investigative Drug	.	.	(R)-EF-1520 inhibits the activity of SLC6A12	.	.
DTD0444	SLC6A12	Inhibition	(R/S) EF-1500	Investigative Drug	.	.	(R/S) EF-1500 inhibits the activity of SLC6A12	.	.
DTD0444	SLC6A12	Inhibition	(S)-EF-1520	Investigative Drug	.	.	(S)-EF-1520 inhibits the activity of SLC6A12	.	.
DTD0444	SLC6A12	Inducer	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 increases the expression of SLC6A12	.	.
DTD0444	SLC6A12	Inhibition	Arsenic Trioxide	Approved Drug	.	.	Arsenic Trioxide inhibits the expression of SLC6A12	.	.
DTD0444	SLC6A12	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC6A12	.	.
DTD0444	SLC6A12	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the expression of SLC6A12	.	.
DTD0444	SLC6A12	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC6A12	.	.
DTD0444	SLC6A12	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC6A12	.	.
DTD0444	SLC6A12	Inhibition	Dicrotophos	Pesticide/Insecticide	.	.	Dicrotophos inhibits the expression of SLC6A12	.	.
DTD0444	SLC6A12	Inhibition	Diethylhexyl Phthalate	Health and Environmental Toxicant	.	.	Diethylhexyl Phthalate inhibits the expression of SLC6A12	.	.
DTD0444	SLC6A12	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the expression of SLC6A12	.	.
DTD0444	SLC6A12	Inducer	Genistein	Drug in Phase 2 Trial	.	.	Genistein increases the expression of SLC6A12	.	.
DTD0444	SLC6A12	Inhibition	Jinfukang	Traditional Medicine	.	.	Jinfukang inhibits the expression of SLC6A12	.	.
DTD0444	SLC6A12	Inhibition	Leflunomide	Approved Drug	.	.	Leflunomide inhibits the expression of SLC6A12	.	.
DTD0444	SLC6A12	Inhibition	LU32-176B	Investigative Drug	.	.	LU32-176B inhibits the activity of SLC6A12	.	.
DTD0444	SLC6A12	Inhibition	NNC052090	Investigative Drug	.	.	NNC052090 inhibits the activity of SLC6A12	.	.
DTD0444	SLC6A12	Inducer	Quercetin	Drug in Phase 1 Trial	.	.	Quercetin increases the expression of SLC6A12	.	.
DTD0444	SLC6A12	Inducer	Rifampin	Approved Drug	.	.	Rifampin increases the expression of SLC6A12	.	.
DTD0444	SLC6A12	Inducer	Sodium Chloride	Chemical Compound	.	.	Sodium Chloride increases the expression of SLC6A12	.	.
DTD0444	SLC6A12	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC6A12	.	.
DTD0444	SLC6A12	Inducer	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan increases the expression of SLC6A12	.	.
DTD0444	SLC6A12	Inhibition	tris(1,3-dichloro-2-propyl)phosphate	Health and Environmental Toxicant	.	.	tris(1,3-dichloro-2-propyl)phosphate inhibits the expression of SLC6A12	.	.
DTD0444	SLC6A12	Inducer	Valproic Acid	Approved Drug	.	.	Valproic Acid increases the expression of SLC6A12	.	.
DTD0444	SLC6A12	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of SLC6A12	.	.
DTD0445	SLC6A13	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC6A13	.	.
DTD0445	SLC6A13	Modulator	Arsenic	Approved Drug	.	.	Arsenic affects the expression of SLC6A13	.	.
DTD0445	SLC6A13	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC6A13	.	.
DTD0445	SLC6A13	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the expression of SLC6A13	.	.
DTD0445	SLC6A13	Inducer	Ethyl Methanesulfonate	Carcinogen	.	.	Ethyl Methanesulfonate increases the expression of SLC6A13	.	.
DTD0445	SLC6A13	Inhibition	Jinfukang	Traditional Medicine	.	.	Jinfukang inhibits the expression of SLC6A13	.	.
DTD0445	SLC6A13	Inhibition	Methyleugenol	Natural Product	.	.	Methyleugenol inhibits the expression of SLC6A13	.	.
DTD0445	SLC6A13	Inhibition	Rotenone	Drug Marketed but not Approved by US FDA	.	.	Rotenone inhibits the expression of SLC6A13	.	.
DTD0445	SLC6A13	Inducer	Silver nanoparticle	Nanoparticle	.	.	Silver nanoparticle increases the expression of SLC6A13	.	.
DTD0445	SLC6A13	Inhibition	SNAP-5114	Investigative Drug	.	.	SNAP-5114 inhibits the activity of SLC6A13	.	.
DTD0445	SLC6A13	Inducer	Testosterone	Approved Drug	.	.	Testosterone increases the expression of SLC6A13	.	.
DTD0445	SLC6A13	Inducer	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution increases the expression of SLC6A13	.	.
DTD0445	SLC6A13	Inducer	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan increases the expression of SLC6A13	.	.
DTD0446	SLC6A14	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC6A14	.	.
DTD0446	SLC6A14	Inducer	Ampicillin	Approved Drug	.	.	Ampicillin increases the expression of SLC6A14	.	.
DTD0446	SLC6A14	Inhibition	Azathioprine	Approved Drug	.	.	Azathioprine inhibits the expression of SLC6A14	.	.
DTD0446	SLC6A14	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of SLC6A14	.	.
DTD0446	SLC6A14	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC6A14	.	.
DTD0446	SLC6A14	Inducer	Coumestrol	Investigative Drug	.	.	Coumestrol increases the expression of SLC6A14	.	.
DTD0446	SLC6A14	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC6A14	.	.
DTD0446	SLC6A14	Inhibition	Cyfluthrin	Pesticide/Insecticide	.	.	Cyfluthrin inhibits the expression of SLC6A14	.	.
DTD0446	SLC6A14	Inhibition	Dicrotophos	Pesticide/Insecticide	.	.	Dicrotophos inhibits the expression of SLC6A14	.	.
DTD0446	SLC6A14	Inducer	Diethylstilbestrol	Approved Drug	.	.	Diethylstilbestrol increases the expression of SLC6A14	.	.
DTD0446	SLC6A14	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC6A14	.	.
DTD0446	SLC6A14	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the expression of SLC6A14	.	.
DTD0446	SLC6A14	Inducer	Genistein	Drug in Phase 2 Trial	.	.	Genistein increases the expression of SLC6A14	.	.
DTD0446	SLC6A14	Inducer	GSK-J4	Patented Pharmaceutical Agent	.	.	GSK-J4 increases the expression of SLC6A14	.	.
DTD0446	SLC6A14	Modulator	Hydrogen Peroxide	Approved Drug	.	.	Hydrogen Peroxide affects the expression of SLC6A14	.	.
DTD0446	SLC6A14	Modulator	Menadione	Approved Drug	.	.	Menadione affects the expression of SLC6A14	.	.
DTD0446	SLC6A14	Inhibition	Milchsaure	Investigative Drug	.	.	Milchsaure inhibits the expression of SLC6A14	.	.
DTD0446	SLC6A14	Inducer	Polychlorinated Biphenyls	Carcinogen	.	.	Polychlorinated Biphenyls increases the expression of SLC6A14	.	.
DTD0446	SLC6A14	Inhibition	Polychlorinated dibenzodioxin	Environmental toxicant	.	.	Polychlorinated dibenzodioxin inhibits the expression of SLC6A14	.	.
DTD0446	SLC6A14	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC6A14	.	.
DTD0446	SLC6A14	Modulator	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution affects the expression of SLC6A14	.	.
DTD0446	SLC6A14	Inhibition	Urethane	Approved Drug	.	.	Urethane inhibits the expression of SLC6A14	.	.
DTD0446	SLC6A14	Inducer	Zeranol	Health and Environmental Toxicant	.	.	Zeranol increases the expression of SLC6A14	.	.
DTD0447	SLC6A15	Inducer	1-methyl-4-phenylpyridinium	Health and Environmental Toxicant	.	.	1-methyl-4-phenylpyridinium increases the expression of SLC6A15	.	.
DTD0447	SLC6A15	Inhibition	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A inhibits the expression of SLC6A15	.	.
DTD0447	SLC6A15	Inducer	Butyraldehyde	Health and Environmental Toxicant	.	.	Butyraldehyde increases the expression of SLC6A15	.	.
DTD0447	SLC6A15	Inhibition	Cisplatin	Approved Drug	.	.	Cisplatin inhibits the expression of SLC6A15	.	.
DTD0447	SLC6A15	Inhibition	PD-0325901	Drug in Phase 2 Trial	.	.	PD-0325901 inhibits the expression of SLC6A15	.	.
DTD0447	SLC6A15	Inducer	Pentanal	Chemical Compound	.	.	Pentanal increases the expression of SLC6A15	.	.
DTD0447	SLC6A15	Inhibition	Phenylmercuric Acetate	Investigative Drug	.	.	Phenylmercuric Acetate inhibits the expression of SLC6A15	.	.
DTD0447	SLC6A15	Inhibition	Piroxicam	Approved Drug	.	.	Piroxicam inhibits the expression of SLC6A15	.	.
DTD0447	SLC6A15	Inhibition	Sarin	Acute Toxic Substance	.	.	Sarin inhibits the expression of SLC6A15	.	.
DTD0447	SLC6A15	Inhibition	Temozolomide	Approved Drug	.	.	Temozolomide inhibits the expression of SLC6A15	.	.
DTD0447	SLC6A15	Inhibition	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution inhibits the expression of SLC6A15	.	.
DTD0447	SLC6A15	Inhibition	Tretinoin	Approved Drug	.	.	Tretinoin inhibits the expression of SLC6A15	.	.
DTD0447	SLC6A15	Inducer	Trichostatin A	Drug in Phase 1 Trial	.	.	Trichostatin A increases the expression of SLC6A15	.	.
DTD0447	SLC6A15	Inducer	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan increases the expression of SLC6A15	.	.
DTD0447	SLC6A15	Inhibition	Valproic Acid	Approved Drug	.	.	Valproic Acid inhibits the expression of SLC6A15	.	.
DTD0447	SLC6A15	Inducer	Vorinostat	Approved Drug	.	.	Vorinostat increases the expression of SLC6A15	.	.
DTD0449	SLC6A17	Inducer	1-methyl-4-phenylpyridinium	Health and Environmental Toxicant	.	.	1-methyl-4-phenylpyridinium increases the expression of SLC6A17	.	.
DTD0449	SLC6A17	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of SLC6A17	.	.
DTD0449	SLC6A17	Inhibition	Acrylamide	Acute Toxic Substance	.	.	Acrylamide inhibits the expression of SLC6A17	.	.
DTD0449	SLC6A17	Inducer	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene increases the expression of SLC6A17	.	.
DTD0449	SLC6A17	Inhibition	Doxorubicin	Approved Drug	.	.	Doxorubicin inhibits the expression of SLC6A17	.	.
DTD0449	SLC6A17	Inducer	Jinfukang	Traditional Medicine	.	.	Jinfukang increases the expression of SLC6A17	.	.
DTD0449	SLC6A17	Modulator	Lead	Health and Environmental Toxicant	.	.	Lead affects the expression of SLC6A17	.	.
DTD0449	SLC6A17	Inducer	Sunitinib	Approved Drug	.	.	Sunitinib increases the expression of SLC6A17	.	.
DTD0449	SLC6A17	Inhibition	Temozolomide	Approved Drug	.	.	Temozolomide inhibits the expression of SLC6A17	.	.
DTD0451	SLC6A19	Inhibition	Cinromide	Natural Product	.	.	Cinromide inhibits the activity of SLC6A19	.	.
DTD0451	SLC6A19	Inducer	Hydrogen Peroxide	Approved Drug	.	.	Hydrogen Peroxide increases the expression of SLC6A19	.	.
DTD0451	SLC6A19	Inducer	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan increases the expression of SLC6A19	.	.
DTD0452	SLC6A2	Modulator	1-methyl-4-phenylpyridinium	Health and Environmental Toxicant	.	.	1-methyl-4-phenylpyridinium affects the expression of SLC6A2	.	.
DTD0452	SLC6A2	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the activity of SLC6A2	.	.
DTD0452	SLC6A2	Inhibition	Amfepramone	Approved Drug	.	.	Amfepramone inhibits the activity of SLC6A2	.	.
DTD0452	SLC6A2	Inhibition	Amitifadine	Drug in Phase 3 Trial	.	.	Amitifadine inhibits the activity of SLC6A2	.	.
DTD0452	SLC6A2	Inhibition	Amitriptyline	Approved Drug	.	.	Amitriptyline inhibits the activity of SLC6A2	.	.
DTD0452	SLC6A2	Inhibition	Amoxapine	Approved Drug	.	.	Amoxapine inhibits the activity of SLC6A2	.	.
DTD0452	SLC6A2	Inducer	Antimycin A	Acute Toxic Substance	.	.	Antimycin A increases the expression of SLC6A2	.	.
DTD0452	SLC6A2	Inhibition	Atomoxetine	Approved Drug	.	.	Atomoxetine inhibits the activity of SLC6A2	.	.
DTD0452	SLC6A2	Inducer	Belinostat	Approved Drug	.	.	Belinostat increases the expression of SLC6A2	.	.
DTD0452	SLC6A2	Inhibition	BI 201335	Drug in Phase 3 Trial	.	.	BI 201335 inhibits the activity of SLC6A2	.	.
DTD0452	SLC6A2	Modulator	Bicifadine	Drug in Phase 3 Trial	.	.	Bicifadine modulates the activity of SLC6A2	.	.
DTD0452	SLC6A2	Inhibition	Bupropion + naltrexone	Drug in Phase 3 Trial	.	.	Bupropion + naltrexone inhibits the activity of SLC6A2	.	.
DTD0452	SLC6A2	Inducer	Carmustine	Approved Drug	.	.	Carmustine increases the expression of SLC6A2	.	.
DTD0452	SLC6A2	Inhibition	CCRIS-9277	Drug in Phase 1 Trial	.	.	CCRIS-9277 inhibits the activity of SLC6A2	.	.
DTD0452	SLC6A2	Inhibition	Clomipramine	Approved Drug	.	.	Clomipramine inhibits the activity of SLC6A2	.	.
DTD0452	SLC6A2	Inducer	Copper Sulfate	Approved Drug	.	.	Copper Sulfate increases the expression of SLC6A2	.	.
DTD0452	SLC6A2	Inhibition	Dasotraline	Drug in Phase 3 Trial	.	.	Dasotraline inhibits the activity of SLC6A2	.	.
DTD0452	SLC6A2	Inhibition	Desvenalfaxine succinate	Approved Drug	.	.	Desvenalfaxine succinate inhibits the activity of SLC6A2	.	.
DTD0452	SLC6A2	Inhibition	DOV 21947	Drug in Phase 2 Trial	.	.	DOV 21947 inhibits the activity of SLC6A2	.	.
DTD0452	SLC6A2	Inhibition	Haloperidol	Approved Drug	.	.	Haloperidol inhibits the activity of SLC6A2	.	.
DTD0452	SLC6A2	Inhibition	Hypericum	Drug in Phase 4 Trial	.	.	Hypericum inhibits the activity of SLC6A2	.	.
DTD0452	SLC6A2	Inhibition	Imipramine	Approved Drug	.	.	Imipramine inhibits the activity of SLC6A2	.	.
DTD0452	SLC6A2	Inhibition	Iobenguane I-123	Approved Drug	.	.	Iobenguane I-123 inhibits the activity of SLC6A2	.	.
DTD0452	SLC6A2	Inhibition	Lead	Health and Environmental Toxicant	.	.	Lead inhibits the expression of SLC6A2	.	.
DTD0452	SLC6A2	Modulator	Levomilnacipran	Approved Drug	.	.	Levomilnacipran modulates the activity of SLC6A2	.	.
DTD0452	SLC6A2	Inhibition	Maprotiline	Approved Drug	.	.	Maprotiline inhibits the activity of SLC6A2	.	.
DTD0452	SLC6A2	Inhibition	Milnacipran	Approved Drug	.	.	Milnacipran inhibits the activity of SLC6A2	.	.
DTD0452	SLC6A2	Inhibition	Nisoxetine	Investigative Drug	.	.	Nisoxetine inhibits the activity of SLC6A2	.	.
DTD0452	SLC6A2	Inhibition	Norepinephrine	Approved Drug	.	.	Norepinephrine inhibits the expression of SLC6A2	.	.
DTD0452	SLC6A2	Inhibition	Paroxetine	Approved Drug	.	.	Paroxetine inhibits the activity of SLC6A2	.	.
DTD0452	SLC6A2	Inhibition	Phenmetrazine	Approved Drug	.	.	Phenmetrazine inhibits the activity of SLC6A2	.	.
DTD0452	SLC6A2	Inhibition	Phentermine	Approved Drug	.	.	Phentermine inhibits the activity of SLC6A2	.	.
DTD0452	SLC6A2	Modulator	Roclatan	Drug in Phase 3 Trial	.	.	Roclatan modulates the activity of SLC6A2	.	.
DTD0452	SLC6A2	Inhibition	Selenium nanoparticles	Natural Product	.	.	Selenium nanoparticles inhibits the expression of SLC6A2	.	.
DTD0452	SLC6A2	Modulator	Sibutramine	Approved Drug	.	.	Sibutramine modulates the activity of SLC6A2	.	.
DTD0452	SLC6A2	Inhibition	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite inhibits the expression of SLC6A2	.	.
DTD0452	SLC6A2	Modulator	Suronacrine maleate	Drug in Phase 3 Trial	.	.	Suronacrine maleate modulates the activity of SLC6A2	.	.
DTD0452	SLC6A2	Modulator	Tapentadol	Approved Drug	.	.	Tapentadol modulates the activity of SLC6A2	.	.
DTD0452	SLC6A2	Inducer	Triclosan	Drug in Phase 3 Trial	.	.	Triclosan increases the expression of SLC6A2	.	.
DTD0452	SLC6A2	Inhibition	Trimipramine	Approved Drug	.	.	Trimipramine inhibits the activity of SLC6A2	.	.
DTD0452	SLC6A2	Inhibition	Vitamin E	Drug in Phase 3 Trial	.	.	Vitamin E inhibits the expression of SLC6A2	.	.
DTD0452	SLC6A2	Inducer	Vorinostat	Approved Drug	.	.	Vorinostat induces the activity of SLC6A2	.	.
DTD0452	SLC6A2	Inducer	Zidovudine	Approved Drug	.	.	Zidovudine increases the expression of SLC6A2	.	.
DTD0452	SLC6A2	Inducer	Zinc Sulfate	Drug Marketed but not Approved by US FDA	.	.	Zinc Sulfate increases the expression of SLC6A2	.	.
DTD0453	SLC6A20	Inhibition	(+)-JQ1	Drug in Preclinical Test	.	.	(+)-JQ1 inhibits the expression of SLC6A20	.	.
DTD0453	SLC6A20	Inducer	Acetaminophen	Approved Drug	.	.	Acetaminophen increases the expression of SLC6A20	.	.
DTD0453	SLC6A20	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC6A20	.	.
DTD0453	SLC6A20	Inducer	Beta-naphthoflavone	Investigative Drug	.	.	Beta-naphthoflavone increases the expression of SLC6A20	.	.
DTD0453	SLC6A20	Inducer	Cannabidiol	Approved Drug	.	.	Cannabidiol increases the expression of SLC6A20	.	.
DTD0453	SLC6A20	Inducer	Cyclosporine	Approved Drug	.	.	Cyclosporine increases the expression of SLC6A20	.	.
DTD0453	SLC6A20	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the expression of SLC6A20	.	.
DTD0453	SLC6A20	Modulator	Hydrogen Peroxide	Approved Drug	.	.	Hydrogen Peroxide affects the expression of SLC6A20	.	.
DTD0453	SLC6A20	Inhibition	Methyleugenol	Natural Product	.	.	Methyleugenol inhibits the expression of SLC6A20	.	.
DTD0453	SLC6A20	Inducer	Permethrin	Approved Drug	.	.	Permethrin increases the expression of SLC6A20	.	.
DTD0453	SLC6A20	Inducer	Rifampin	Approved Drug	.	.	Rifampin increases the expression of SLC6A20	.	.
DTD0453	SLC6A20	Inducer	Sodium arsenite	Drug in Phase 1 Trial	.	.	Sodium arsenite increases the expression of SLC6A20	.	.
DTD0453	SLC6A20	Modulator	Tobacco Smoke Pollution	Natural Product	.	.	Tobacco Smoke Pollution affects the expression of SLC6A20	.	.
DTD0453	SLC6A20	Inducer	Zoledronic Acid	Approved Drug	.	.	Zoledronic Acid increases the expression of SLC6A20	.	.
DTD0455	SLC6A3	Inhibition	1-methyl-4-phenylpyridinium	Health and Environmental Toxicant	.	.	1-methyl-4-phenylpyridinium inhibits the expression of SLC6A3	.	.
DTD0455	SLC6A3	Inhibition	Altropane	Approved Drug	.	.	Altropane inhibits the activity of SLC6A3	.	.
DTD0455	SLC6A3	Inducer	AM-2282	Drug in Preclinical Test	.	.	AM-2282 increases the activity of SLC6A3	.	.
DTD0455	SLC6A3	Inhibition	Amfetamine	Drug in Phase 2 Trial	.	.	Amfetamine inhibits the activity of SLC6A3	.	.
DTD0455	SLC6A3	Inhibition	Amitifadine	Drug in Phase 3 Trial	.	.	Amitifadine inhibits the activity of SLC6A3	.	.
DTD0455	SLC6A3	Inducer	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A increases the expression of SLC6A3	.	.
DTD0455	SLC6A3	Inducer	Butyrate	Drug in Phase 1 Trial	.	.	Butyrate increases the expression of SLC6A3	.	.
DTD0455	SLC6A3	Inducer	Calcitriol	Approved Drug	.	.	Calcitriol increases the expression of SLC6A3	.	.
DTD0455	SLC6A3	Modulator	Carbamazepine	Approved Drug	.	.	Carbamazepine affects the expression of SLC6A3	.	.
DTD0455	SLC6A3	Inhibition	Clomipramine	Approved Drug	.	.	Clomipramine inhibits the activity of SLC6A3	.	.
DTD0455	SLC6A3	Inhibition	Dasotraline	Drug in Phase 3 Trial	.	.	Dasotraline inhibits the activity of SLC6A3	.	.
DTD0455	SLC6A3	Modulator	Decamethrin	Pesticide/Insecticide	.	.	Decamethrin affects the activity of SLC6A3	.	.
DTD0455	SLC6A3	Inhibition	Deguelin	Natural Product	.	.	Deguelin inhibits the expression of SLC6A3	.	.
DTD0455	SLC6A3	Inducer	Dimethyl fumarate	Approved Drug	.	.	Dimethyl fumarate induces the activity of SLC6A3	.	.
DTD0455	SLC6A3	Inhibition	DOV 21947	Drug in Phase 2 Trial	.	.	DOV 21947 inhibits the activity of SLC6A3	.	.
DTD0455	SLC6A3	Inhibition	Haloperidol	Approved Drug	.	.	Haloperidol inhibits the activity of SLC6A3	.	.
DTD0455	SLC6A3	Modulator	Ioflupane I-123	Approved Drug	.	.	Ioflupane I-123 modulates the activity of SLC6A3	.	.
DTD0455	SLC6A3	Blocker	Methylphenidate	Approved Drug	.	.	Methylphenidate blocks the activity of SLC6A3	.	.
DTD0455	SLC6A3	Modulator	Modafinil	Approved Drug	.	.	Modafinil modulates the activity of SLC6A3	.	.
DTD0455	SLC6A3	Inhibition	Paroxetine	Approved Drug	.	.	Paroxetine inhibits the activity of SLC6A3	.	.
DTD0455	SLC6A3	Modulator	Permethrin	Approved Drug	.	.	Permethrin affects the activity of SLC6A3	.	.
DTD0455	SLC6A3	Inhibition	Rotenone	Drug Marketed but not Approved by US FDA	.	.	Rotenone inhibits the expression of SLC6A3	.	.
DTD0455	SLC6A3	Inducer	Testosterone	Approved Drug	.	.	Testosterone increases the expression of SLC6A3	.	.
DTD0455	SLC6A3	Inducer	Vorinostat	Approved Drug	.	.	Vorinostat increases the expression of SLC6A3	.	.
DTD0455	SLC6A3	Inhibition	Zinc	Environmental toxicant	.	.	Zinc inhibits the activity of SLC6A3	.	.
DTD0456	SLC6A4	Inhibition	Acetaminophen	Approved Drug	.	.	Acetaminophen inhibits the activity of SLC6A4	.	.
DTD0456	SLC6A4	Inhibition	Aflatoxin B1	Mycotoxins	.	.	Aflatoxin B1 inhibits the expression of SLC6A4	.	.
DTD0456	SLC6A4	Inhibition	Amfepramone	Approved Drug	.	.	Amfepramone inhibits the activity of SLC6A4	.	.
DTD0456	SLC6A4	Inhibition	Amitifadine	Drug in Phase 3 Trial	.	.	Amitifadine inhibits the activity of SLC6A4	.	.
DTD0456	SLC6A4	Inhibition	Amitriptyline	Approved Drug	.	.	Amitriptyline inhibits the activity of SLC6A4	.	.
DTD0456	SLC6A4	Inhibition	Benzo(a)pyrene	Carcinogen	.	.	Benzo(a)pyrene inhibits the expression of SLC6A4	.	.
DTD0456	SLC6A4	Modulator	Bicifadine	Drug in Phase 3 Trial	.	.	Bicifadine modulates the activity of SLC6A4	.	.
DTD0456	SLC6A4	Inhibition	Bisphenol A	Drug in Phase 2 Trial	.	.	Bisphenol A inhibits the expression of SLC6A4	.	.
DTD0456	SLC6A4	Inhibition	CCRIS-9277	Drug in Phase 1 Trial	.	.	CCRIS-9277 inhibits the expression of SLC6A4	.	.
DTD0456	SLC6A4	Modulator	Chlorphentermine	Approved Drug	.	.	Chlorphentermine modulates the activity of SLC6A4	.	.
DTD0456	SLC6A4	Modulator	Citalopram	Approved Drug	.	.	Citalopram modulates the activity of SLC6A4	.	.
DTD0456	SLC6A4	Inhibition	Clozapine	Approved Drug	.	.	Clozapine inhibits the activity of SLC6A4	.	.
DTD0456	SLC6A4	Inhibition	Copper Sulfate	Approved Drug	.	.	Copper Sulfate inhibits the expression of SLC6A4	.	.
DTD0456	SLC6A4	Inhibition	Cyclosporine	Approved Drug	.	.	Cyclosporine inhibits the expression of SLC6A4	.	.
DTD0456	SLC6A4	Inhibition	Dasotraline	Drug in Phase 3 Trial	.	.	Dasotraline inhibits the activity of SLC6A4	.	.
DTD0456	SLC6A4	Modulator	Desvenlafaxine	Approved Drug	.	.	Desvenlafaxine modulates the activity of SLC6A4	.	.
DTD0456	SLC6A4	Modulator	Dextromethorphan polistirex	Approved Drug	.	.	Dextromethorphan polistirex modulates the activity of SLC6A4	.	.
DTD0456	SLC6A4	Inhibition	Estradiol	Approved Drug	.	.	Estradiol inhibits the expression of SLC6A4	.	.
DTD0456	SLC6A4	Modulator	Fluoxetine	Approved Drug	.	.	Fluoxetine modulates the activity of SLC6A4	.	.
DTD0456	SLC6A4	Inhibition	Fluvoxamine	Approved Drug	.	.	Fluvoxamine inhibits the activity of SLC6A4	.	.
DTD0456	SLC6A4	Modulator	Fluvoxamine	Approved Drug	.	.	Fluvoxamine modulates the activity of SLC6A4	.	.
DTD0456	SLC6A4	Inhibition	Formaldehyde	Acute Toxic Substance	.	.	Formaldehyde inhibits the expression of SLC6A4	.	.
DTD0456	SLC6A4	Inhibition	Fumonisin B1	Mycotoxins	.	.	Fumonisin B1 inhibits the expression of SLC6A4	.	.
DTD0456	SLC6A4	Inhibition	Gabapentin	Approved Drug	.	.	Gabapentin inhibits the expression of SLC6A4	.	.
DTD0456	SLC6A4	Inhibition	Glyphosate	Environmental toxicant	.	.	Glyphosate inhibits the expression of SLC6A4	.	.
DTD0456	SLC6A4	Inducer	GSK-J4	Patented Pharmaceutical Agent	.	.	GSK-J4 increases the expression of SLC6A4	.	.
DTD0456	SLC6A4	Inhibition	Haloperidol	Approved Drug	.	.	Haloperidol inhibits the activity of SLC6A4	.	.
DTD0456	SLC6A4	Modulator	Hydrogen Peroxide	Approved Drug	.	.	Hydrogen Peroxide affects the expression of SLC6A4	.	.
DTD0456	SLC6A4	Inhibition	Hydroxyurea	Approved Drug	.	.	Hydroxyurea inhibits the expression of SLC6A4	.	.
DTD0456	SLC6A4	Inducer	Lamivudine	Approved Drug	.	.	Lamivudine increases the expression of SLC6A4	.	.
DTD0456	SLC6A4	Modulator	Levomilnacipran	Approved Drug	.	.	Levomiln